paper_link,paper_title,handle,message
http://medrxiv.org/cgi/content/short/2020.08.09.20170845,Predicting the future SARS-COV-2 reproductive rate.,@ctsinclair,#PrognosisScience #COVID19 #virology
http://medrxiv.org/cgi/content/short/2020.08.09.20170845,Predicting the future SARS-COV-2 reproductive rate.,@PandemicCovid20,Predicting the future SARS-COV-2 reproductive rate. https://t.co/8jD21pyu7P
http://medrxiv.org/cgi/content/short/2020.08.09.20170845,Predicting the future SARS-COV-2 reproductive rate.,@medrxivpreprint,Predicting the future SARS-COV-2 reproductive rate.  https://t.co/rJNXvYp8O4 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171207,The Link between Poverty and COVID-19 Case and Mortality Rates in Germany,@Kessy19721,Armut war in D bisher kein Risikofaktor an C19 zu versterben. Geringe Qualifikation schon. Was sagt uns das √ºber KH die Pleite gehen und Kinder ohne Bildung? Sind wir auf dem richtigen Weg? @Karl_Lauterbach @jensspahn @Grund_gesetzt
http://medrxiv.org/cgi/content/short/2020.08.09.20171207,The Link between Poverty and COVID-19 Case and Mortality Rates in Germany,@RiyazHanfi,"Very nice, but yesterday Germany reported maximum new cases, after firist outbreaks on 9th May."
http://medrxiv.org/cgi/content/short/2020.08.09.20171207,The Link between Poverty and COVID-19 Case and Mortality Rates in Germany,@PandemicCovid20,The Link between Poverty and #COVID19 Case and Mortality Rates in Germany https://t.co/3WoxGiBFWU
http://medrxiv.org/cgi/content/short/2020.08.09.20171207,The Link between Poverty and COVID-19 Case and Mortality Rates in Germany,@medrxivpreprint,The Link between Poverty and COVID-19 Case and Mortality Rates in Germany  https://t.co/8ZlYYmmJsq #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171264,Estimating the Impact of COVID-19 on the Individual Lifespan: A Conceptual Detour and an Empirical Shortcut,@CHOMES102,RT @medrxivpreprint: Estimating the Impact of COVID-19 on the Individual Lifespan:A Conceptual Detour and an Empirical Shortcut  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171264,Estimating the Impact of COVID-19 on the Individual Lifespan: A Conceptual Detour and an Empirical Shortcut,@medrxivpreprint,Estimating the Impact of COVID-19 on the Individual Lifespan:A Conceptual Detour and an Empirical Shortcut  https://t.co/TEj0U3s9zd #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20167247,Fine-tuned Forecasting Techniques for COVID-19 Prediction in India,@medrxivpreprint,Fine-tuned Forecasting Techniques for COVID-19 Prediction in India  https://t.co/ldyCSJPPBX #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171181,The impact of COVID-19 on Italy web users: a quantitative analysis of regional hygiene interest and emotional response,@medrxivpreprint,The impact of COVID-19 on Italy web users: a quantitative analysis of regional hygiene interest and emotional response  https://t.co/mkaLz5efj9 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@mjb0007,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Donaldverger,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@REB_JUNN,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@fireashdustlife,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Andromake000,RT @TorstenAkesson: Inte peer reviewed √§n: H√§lften av all smittspridning sker fr√•n personer som inte √§n har symtom. Analys fr√•n kontaktsp√•r‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@MikalJakubal,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@jenniecase,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@TorstenAkesson,Inte peer reviewed √§n: H√§lften av all smittspridning sker fr√•n personer som inte √§n har symtom. Analys fr√•n kontaktsp√•rning fr√•n 1‚Äô178 infekterade i Hunan. #COVID19   ‚Äù... with ~50% of transmission occurring in the pre-symptomatic phase. ‚Äù  https://t.co/CK
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@HoskoJane,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@blythecreek,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@kenmomd,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@QuoticIndepend1,RT @RATL2020: Social distancing is defined as staying 6 ft away from others for a total of 15 minutes. Kids are at school for 7 hours 2-5 d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@IKostenas,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@sanghyuk_shin,"New preprint by @SunKaiyuan @alexvespi and colleagues.  ""transmission risk between 1,178 SARS-CoV-2 infected individuals and their 15,648 close contacts based on detailed contact tracing data from Hunan, China."""
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@PassarelliAllan,RT @RATL2020: Social distancing is defined as staying 6 ft away from others for a total of 15 minutes. Kids are at school for 7 hours 2-5 d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@EdoGK6,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 https://t.co/an687sl7ym"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@kat_gris,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Navarp,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Cheechom,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@ShawnAdamsson,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Dnjairus,"2) La cercan√≠a con los contactos impacta el riesgo: el hogar fue el de mayor riesgo, luego los contactos en la familia extendida, luego el entorno comunitario: para ser efectivo, el distanciamiento social no puede tener fugas."
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@drmarkflowers,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@RileyBWarfield,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@ppiixx,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@1zzyzyx1,RT @RATL2020: Social distancing is defined as staying 6 ft away from others for a total of 15 minutes. Kids are at school for 7 hours 2-5 d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@KimDoss71,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@RATL2020,Social distancing is defined as staying 6 ft away from others for a total of 15 minutes. Kids are at school for 7 hours 2-5 days per week.
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@GailWaldby,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Cruellaisdevine,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@aino_kivela,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@Deb_B_Smith,"RT @AliNouriPhD: 2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@AliNouriPhD,"2)Closeness w/contacts impacts risk: household was highest risk, then contacts in extended family, then community setting: to be effective, social distancing can't be leaky.  Healthcare setting contacts posed lowest risk, suggesting there was adequate PPE"
http://medrxiv.org/cgi/content/short/2020.08.09.20171132,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2",@medrxivpreprint,"Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2  https://t.co/x6jweEObvU #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.26.20162008,COVID-19 mild cases determination from correlating COVID-line calls to reported cases,@medrxivpreprint,COVID-19 mild cases determination from   correlating COVID-line calls to reported cases  https://t.co/QcUjZ0FrmV #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@vignesh110991,RT @ahsanzileali: Pre-print of our meta-analysis on #COVID19 is available now: https://t.co/pxNG4V8Iex   Wonderful work of @vignesh110991 &‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@vignesh110991,"RT @WaqasHaque4: Worked with two dozen other MPH classmates and researchers, led by @vignesh110991 & mentored by @panagis21, to come up wit‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@vignesh110991,Extremely delighted that the pre-print version of our paper is out!  Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis https://t.co/C2EUx85DNs
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@zohaasghar16,RT @ahsanzileali: Pre-print of our meta-analysis on #COVID19 is available now: https://t.co/pxNG4V8Iex   Wonderful work of @vignesh110991 &‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@EvidenceRobot,"RT @WaqasHaque4: Worked with two dozen other MPH classmates and researchers, led by @vignesh110991 & mentored by @panagis21, to come up wit‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@WaqasHaque4,"Worked with two dozen other MPH classmates and researchers, led by @vignesh110991 & mentored by @panagis21, to come up with a COVID-19 meta-analysis! Many great lessons on teamwork and management along the way."
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@ahsanzileali,Pre-print of our meta-analysis on #COVID19 is available now: https://t.co/pxNG4V8Iex   Wonderful work of @vignesh110991 & others from @JohnsHopkinsSPH. Thanks to our mentor @panagis21.  Months of hard work came to fruition üôåüèº. #teamwork   Waiting for t
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@vignesh110991,RT @medrxivpreprint: Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Revi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@CHOMES102,RT @medrxivpreprint: Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Revi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@EvidenceRobot,RT @medrxivpreprint: Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Revi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20166868,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis,@medrxivpreprint,Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis  https://t.co/ydf5yhjXAI #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.08.20170746,ApharSeq: An Extraction-free Early-Pooling Protocol for Massively Multiplexed SARS-CoV-2 Detection,@medrxivpreprint,ApharSeq: An Extraction-free Early-Pooling Protocol for Massively Multiplexed SARS-CoV-2 Detection  https://t.co/EQp9UC4wKN #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20170803,COVID-19 Infection Among Healthcare Workers in a National Healthcare System: the Qatar Experience,@medrxivpreprint,COVID-19 Infection Among Healthcare Workers in a National Healthcare System: the Qatar Experience  https://t.co/amLP3oTyzO #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20154435,"Face masks release water vapour, but where does it go? An early observational study",@leoniedelt,Interesting!
http://medrxiv.org/cgi/content/short/2020.08.09.20154435,"Face masks release water vapour, but where does it go? An early observational study",@medrxivpreprint,"Face masks release water vapour, but where does it go? An early observational study  https://t.co/kmcRMcTrnT #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.07.20169441,Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing,@medrxivpreprint,Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing  https://t.co/SEDeziAYa3 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171041,"A city-level analysis of air pollution, climate and COVID-19 early spread during the Spanish lockdown",@medrxivpreprint,"A city-level analysis of air pollution, climate and COVID-19 early spread during the Spanish lockdown  https://t.co/czUITUdu2T #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.09.20171173,Effects of universal masking on Massachusetts healthcare workers' COVID-19 incidence,@medrxivpreprint,Effects of universal masking on Massachusetts healthcare workers' COVID-19 incidence  https://t.co/RSmcRe1aL2 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20170985,COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey,@medrxivpreprint,COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey  https://t.co/ZltkHx9aGF #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20170910,Acute Lung injury evolution in Covid-19,@epidatum,"Acute Lung injury evolution in #Covid_19  A morphologically distinct #Covid pattern was identified in the earlier stages, with prominent epithelial and endothelial cell abnormalities, differing strikingly from findings in classical diffuse alveolar damage"
http://medrxiv.org/cgi/content/short/2020.08.09.20170910,Acute Lung injury evolution in Covid-19,@benoit_durand,"RT @phil_w888: 791/  Italy (adult smoking rate was 23.7% in 2016)  Of 23 hospitalized patients who had a lung biopsy, zero were current smo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20170910,Acute Lung injury evolution in Covid-19,@phil_w888,"791/  Italy (adult smoking rate was 23.7% in 2016)  Of 23 hospitalized patients who had a lung biopsy, zero were current smokers & 2 were former smokers (8.7%)  Note: ""Mean duration of hospitalization was 29 days""  https://t.co/PoySxJ3h4b"
http://medrxiv.org/cgi/content/short/2020.08.09.20170910,Acute Lung injury evolution in Covid-19,@freurard,RT @Em23397: #apresJ20 #longCovid Acute Lung injury evolution in Covid-19 | medRxiv https://t.co/HiiYtP3yBP
http://medrxiv.org/cgi/content/short/2020.08.09.20170910,Acute Lung injury evolution in Covid-19,@Em23397,#apresJ20 #longCovid Acute Lung injury evolution in Covid-19 | medRxiv https://t.co/HiiYtP3yBP
http://medrxiv.org/cgi/content/short/2020.08.09.20170910,Acute Lung injury evolution in Covid-19,@medrxivpreprint,Acute Lung injury evolution in Covid-19  https://t.co/ZdOCNHRijy #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170373,Protocol for a Rapid Scoping Review of Evidence of Outdoor Transmission of COVID-19,@CHOMES102,RT @medrxivpreprint: Protocol for a Rapid Scoping Review of Evidence of Outdoor Transmission of COVID-19  https://t.co/LcxCjZQH7i #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170373,Protocol for a Rapid Scoping Review of Evidence of Outdoor Transmission of COVID-19,@tomwilliams1974,"RT @ProfMikeWeed: Protocol pre-print now also published on medrXiv  ""Rapid Scoping Review of Evidence of Incidents of #OutdoorTransmission‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170373,Protocol for a Rapid Scoping Review of Evidence of Outdoor Transmission of COVID-19,@ProfMikeWeed,"Protocol pre-print now also published on medrXiv  ""Rapid Scoping Review of Evidence of Incidents of #OutdoorTransmission of #COVID19""  Commissioned from @spear_News at @CanterburyCCUni by @parkrun. https://t.co/EHdjlBWG2V"
http://medrxiv.org/cgi/content/short/2020.08.07.20170373,Protocol for a Rapid Scoping Review of Evidence of Outdoor Transmission of COVID-19,@medrxivpreprint,Protocol for a Rapid Scoping Review of Evidence of Outdoor Transmission of COVID-19  https://t.co/LcxCjZQH7i #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@mapope60,RT @FArtigao: Eficacia del plasma de personas convalecientes en 35.200 pacientes ingresados con #COVID19 (52.3% en UCI). Menor mortalidad c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ElliTheelPhD,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@immuninfection,RT @FArtigao: Eficacia del plasma de personas convalecientes en 35.200 pacientes ingresados con #COVID19 (52.3% en UCI). Menor mortalidad c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@Sofiavi60344861,RT @FArtigao: Eficacia del plasma de personas convalecientes en 35.200 pacientes ingresados con #COVID19 (52.3% en UCI). Menor mortalidad c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@FArtigao,Eficacia del plasma de personas convalecientes en 35.200 pacientes ingresados con #COVID19 (52.3% en UCI). Menor mortalidad con la administraci√≥n precoz (<3 d√≠as del diagn√≥stico) y con concentraciones de anticuerpos IgG m√°s altas en el plasma. üëâhttps://
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@sboyd2575,RT @nbennett04: Previous safety data (20k pts) from this group showing low ADRs (<1%) and now clinical data from the Mayo plasma EAPüëá.
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@aliuho960,"RT @virusfantom: (1/n) Konvalesan plazma covid19 √∂l√ºmlerini azaltƒ±yor, yeni √ßƒ±kan bu √∂n-basƒ±ma g√∂re. Plazma alan 35bin hastanƒ±n %52‚Äôsi yoƒüu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@Immunojaculin,Promising preprint number 2!  #convalescentplasma therapy may reduce severity and help inform treatment for #COVID19 https://t.co/fPRHGx4XCt
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@efibaron,@carteblanchetv @DerekWatts @MNet @DStv https://t.co/Nf04ymgPrf
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@efibaron,@theSANBS https://t.co/Nf04ymgPrf
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@JimenaPrieto5,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@MSextonMD,EAP Efficacy Paper is out! @MayoAnesthesia @MayoClinic
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@JuanGRipoll1,RT @JuanGRipoll1: The efficacy data of the convalescent plasma use is now available! https://t.co/7Y3jozvoG6
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@KelseyOlson33,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@JudithaOtero,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ascorbicacid51,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@virusfantom,"(1/n) Konvalesan plazma covid19 √∂l√ºmlerini azaltƒ±yor, yeni √ßƒ±kan bu √∂n-basƒ±ma g√∂re. Plazma alan 35bin hastanƒ±n %52‚Äôsi yoƒüun bakƒ±mda, %28‚Äôi vantilat√∂re baƒülƒ± idi. Yedinci ve otuzuncu g√ºn √∂l√ºmlere bakƒ±ldƒ±. Sonu√ßlar i√ßin devam: https://t.co/IgAJuWLICZ"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@JuanGRipoll1,The efficacy data of the convalescent plasma use is now available!
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@avstmd,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@MadrigalMatute,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ABsteward,"Thanks for sharing, I had the same reaction, Not an RCT üòî"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@Tighnacoille,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@DrJPHenderson,"Big study of convalescent plasma includes new efficacy data identified through inherently randomized administration of units with varying titers in the early days of U.S. pandemic. Again, early administration appears critical! https://t.co/87IKrYlq0B"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@LMKingsley66,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@AB_IDPharmD,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@FranciscoMarty_,"RT @dr_michaelmarks: 35,322 missed opportunities. I will never understand this approach to assessing treatment efficacy."
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@IDstewardship,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@JCAlverdy,"Congrats to @DrMJoyner and @ACasadevall1. A strong scientific premise to apply convalescent plasma in a crisis situation. The foundation for efficacy has been established, now the approach can be refined. So exciting- more to come @LuciaMadariaga"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@WendyENThomas,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@DeepaDNanayakk1,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@kausikdatta22,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ACasadevall1,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@akkaufman,"RT @ASPphysician: Unfortunately, in my opinion, we are no further ahead in understanding the role of convalescent plasma.  A study of even‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@tckremmin,@JamesPeppers @TChramosta @GlennMackay12 https://t.co/b14lvW7xtl
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@Alexxdicunta,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@NateBahrMD,"RT @ASPphysician: Unfortunately, in my opinion, we are no further ahead in understanding the role of convalescent plasma.  A study of even‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ASPphysician,"Unfortunately, in my opinion, we are no further ahead in understanding the role of convalescent plasma.  A study of even 10K patients would have probably given us an answer.  I sure hope @CONCOR1Trial (which is seeking only 1200 participants) can give us a"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@gpollara,"RT @dr_michaelmarks: 35,322 missed opportunities. I will never understand this approach to assessing treatment efficacy. https://t.co/ZEpAy‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@MicrobLog_me_uk,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@dr_michaelmarks,"35,322 missed opportunities. I will never understand this approach to assessing treatment efficacy."
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@bjgzz,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@RobinFlynn20,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience https://t.co/JhvpkSbouC
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ChandyJohnLab,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@Dr_Bacillus,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@IDRoadrunner,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@AntifaDisabled,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@TomWalshMD13,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@PergamIC,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@prat1112001,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience   https://t.co/zJCNk26xBl
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@10minus6cosm,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@TamarAzikuri,RT @ShohamTxID: ‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ShohamTxID,‚Å¶@DrMJoyner‚Å©  ‚Å¶@ACasadevall1‚Å©  and team did it! Now let‚Äôs figure out how to move forward  https://t.co/KM4xmAUwdO
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@pash22,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@alfred_luk,Unfortunate this wasn‚Äôt a RCT with this many patients.
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@SajalTanna,"RT @GermHunterMD: üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mo‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ishan_bhupendra,"@drakchaurasia @DrSubhasree @Dharmen46587056  Preliminary results from convalescent plasma  35,322 patients  Not an RCT  But, lower mortality with earlier administration & higher antibody titre support possible efficacy . https://t.co/qL1yCecml6 https"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@nbennett04,Previous safety data (20k pts) from this group showing low ADRs (<1%) and now clinical data from the Mayo plasma EAPüëá.
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@GermHunterMD,"üî• Preliminary results from convalescent plasma Expanded Access Program üî•   35,322 patients üòØ  Not an RCT üòû  But, lower mortality with earlier administration & higher antibody titre support possible efficacy üßê  https://t.co/xwzz3mQ0qX https://t.co/Utquk"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@OncoAlert,"RT @Aiims1742: Preprint by @DrMJoyner @ACasadevall1 & colleagues (US Early Access Program #COVID19 Plasma consortium): After 3 months , >35‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@ayirpelle,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@MassatoHirai,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@AkshaySharmaMD,Convalescent plasma could reduce mortality if given early during #COVID19 and has high antibody levels ‚Å¶@MedArXiv‚Å© https://t.co/WEztDmSD2B
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@BenGewurz,"Promising results for convalescent plasma treatment. Earlier is better, as with the antiviral remdesivir. Would be interesting to see the result of antibody + rendesivir"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@outbreaksci,"Contribute a rapid review or request one for ""Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: ..."" (https://t.co/5U17E2VoGv). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.12.20169359) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@outbreaksci,New #COVID19 preprint: Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience https://t.co/5U17E2VoGv
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@_hoeman,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@drivandalism,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@rhinovir,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@HHH_Report,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@JamesonVoss,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@pegobry,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@toad_spotted,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@alexander_suh,"RT @GaetanBurgio: This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => r‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@GaetanBurgio,"This open labeled study evaluated the effect of convalescent plasma among 35,322 Hospitalized Patients with #COVID19 => reduction of mortality at 30 days post transfusion if administered early and high antibody level  https://t.co/N7CA6l8lPl https://t.c"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@tbold,RT @medrxivpreprint: Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@rmchavin,"8-12-2020:  Good news and bad news for convalescent plasma for COVID-19.  Yes, it does affect mortality but no, it will not be cheap and it must be given as early as possible.  I view it as good news for all vaccines much more than for convalescent plasma:"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@King_1831,"RT @mkcentral: #MayoClinic ""The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels pro‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@mkcentral,"#MayoClinic ""The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels provide signatures of efficacy for #convalescent #plasma in the treatment of hospitalized #COVID19"" #hope #treatment https://t.co/wf"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@Aiims1742,"Preprint by @DrMJoyner @ACasadevall1 & colleagues (US Early Access Program #COVID19 Plasma consortium): After 3 months , >35,000 patients have received convalescent plasma. Determinants of improved survival: -starting Rx within 3D of Dx - higher Ab"
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@akkaufman,RT @medrxivpreprint: Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.12.20169359,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience,@medrxivpreprint,Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience  https://t.co/7DTXtAs3mA #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@yorgomodis,RT @biorxivpreprint: Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2  https://t.co/UZDMX7GkGE #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2"" (https://t.co/itNRkyxnU0). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.12.247767) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2 https://t.co/itNRkyfMvq
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@msep0003,RT @biorxiv_micrbio: Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2  https://t.co/MPNtJNxbN6 #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@10_blue,RT @biorxivpreprint: Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2  https://t.co/UZDMX7GkGE #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@biorxiv_micrbio,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2  https://t.co/MPNtJNxbN6 #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.12.247767,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2,@biorxivpreprint,Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2  https://t.co/UZDMX7GkGE #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@NGR69575822,RT @thelonevirologi: TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/EJ0ozBjgF0
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@PaulTho50940982,RT @NG20194: @abledoc @__ice9 @SWICU_Rays  TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2  https://t.co/mBTXAjZTME
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Pseudovirus neutralization assay protocol download: https://t.co/Z9pyXg1Onl https://t"
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@epidatum,TRIM28 regulates #SARSCoV2 cell entry by targeting #ACE2  This study showed that knockdown of TRIM28 induces ACE2 expression and increases pseudotyped #SARS_CoV_2 cell entry of A549 cells and primary pulmonary alveolar epithelial cells (PAEpiCs).  https://
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@NG20194,@abledoc @__ice9 @SWICU_Rays  TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2  https://t.co/mBTXAjZTME
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@MassatoHirai,RT @outbreaksci: New #SARSCoV preprint: TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/yJn3eUSMR9
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@outbreaksci,New #SARSCoV preprint: TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/yJn3eUSMR9
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@outbreaksci,"Contribute a rapid review or request one for ""TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2"" (https://t.co/yJn3eUSMR9). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.12.247825) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@outbreaksci,New #COVID19 preprint: TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/yJn3eUSMR9
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@sangmotiani,RT @thelonevirologi: TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/EJ0ozBjgF0
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@10_blue,RT @biorxivpreprint: TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2  https://t.co/60bEIKVhNf #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@thelonevirologi,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/EJ0ozBjgF0
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@MLitbot,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2 https://t.co/UccXaIXsrZ
http://biorxiv.org/cgi/content/short/2020.08.12.247825,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2,@biorxivpreprint,TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2  https://t.co/60bEIKVhNf #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@uchida_kawasaki,RT @suzuki_takaya: „Å©„ÅÜ„ÅÑ„ÅÜÈ¢®„Å´Ëñ¨„Å´„Åß„Åç„Çã„ÅãÊÉ≥ÂÉè„Åå„Å§„Åã„Å™„ÅÑ„Åå„ÄÅÈù¢ÁôΩ„ÅÑÁô∫ÊÉ≥„ÄÇace2„Éä„Éé„Éë„Éº„ÉÜ„Ç£„ÇØ„É´„ÅÆ„Éá„Ç≥„Ç§„ÄÇ https://t.co/c26xUH0hz1
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@naomiattar,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@yesthatkarim,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@WiFi_NY,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@FribourgNancy,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Paleophile,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@epidatum,"Membrane Nanoparticles Derived from #ACE2-rich Cells Block #SARS_CoV_2 Nanomaterial contains 265.1ng mg-1 of ACE2 on surface and acts as a bait to trap #SARSCoV2 S1 in a dose-dependent manner, resulting in reduced recruitment of viral ligand to host cells"
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@YourDailyCurse,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@NwezeVictor,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@AlfonsoJGB,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@jawjahpeach,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@SparklesTopsy,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@EB71683020,"How did this study acquire ""human embryonic kidney-239T cell""?   Does bioRxiv support aborted fetus use in research?"
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@GHofmar,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@bruce_lambert,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@FranciesMary,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@MassatoHirai,RT @suzuki_takaya: „Å©„ÅÜ„ÅÑ„ÅÜÈ¢®„Å´Ëñ¨„Å´„Åß„Åç„Çã„ÅãÊÉ≥ÂÉè„Åå„Å§„Åã„Å™„ÅÑ„Åå„ÄÅÈù¢ÁôΩ„ÅÑÁô∫ÊÉ≥„ÄÇace2„Éä„Éé„Éë„Éº„ÉÜ„Ç£„ÇØ„É´„ÅÆ„Éá„Ç≥„Ç§„ÄÇ
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Leorange69,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@being_woman,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@MassatoHirai,RT @outbreaksci: New #SARSCoV preprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection https://t.co/gLb28d4‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@outbreaksci,"Contribute a rapid review or request one for ""Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection"" (https://t.co/gLb28d4adH). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.12.247338) at https://t.co/RnurTL3DyM @outbreaksci @PREreview"
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@outbreaksci,New #SARSCoV preprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection https://t.co/gLb28d4adH
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@husigisearch,RT @suzuki_takaya: „Å©„ÅÜ„ÅÑ„ÅÜÈ¢®„Å´Ëñ¨„Å´„Åß„Åç„Çã„ÅãÊÉ≥ÂÉè„Åå„Å§„Åã„Å™„ÅÑ„Åå„ÄÅÈù¢ÁôΩ„ÅÑÁô∫ÊÉ≥„ÄÇace2„Éä„Éé„Éë„Éº„ÉÜ„Ç£„ÇØ„É´„ÅÆ„Éá„Ç≥„Ç§„ÄÇ
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@GmEEwVRIkAzBNmf,RT @suzuki_takaya: „Å©„ÅÜ„ÅÑ„ÅÜÈ¢®„Å´Ëñ¨„Å´„Åß„Åç„Çã„ÅãÊÉ≥ÂÉè„Åå„Å§„Åã„Å™„ÅÑ„Åå„ÄÅÈù¢ÁôΩ„ÅÑÁô∫ÊÉ≥„ÄÇace2„Éä„Éé„Éë„Éº„ÉÜ„Ç£„ÇØ„É´„ÅÆ„Éá„Ç≥„Ç§„ÄÇ https://t.co/c26xUH0hz1
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@suzuki_takaya,„Å©„ÅÜ„ÅÑ„ÅÜÈ¢®„Å´Ëñ¨„Å´„Åß„Åç„Çã„ÅãÊÉ≥ÂÉè„Åå„Å§„Åã„Å™„ÅÑ„Åå„ÄÅÈù¢ÁôΩ„ÅÑÁô∫ÊÉ≥„ÄÇace2„Éä„Éé„Éë„Éº„ÉÜ„Ç£„ÇØ„É´„ÅÆ„Éá„Ç≥„Ç§„ÄÇ
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@EnrikeLopez,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Semoriil,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@nkemngo,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@chazmn78,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@VinothBabu_VR,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@ookk_aann,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@MileenKirkpatr3,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@NewYorksmooth,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@TheScottLove,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@haisgrig,https://t.co/CXfApPiV5z
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@SarahEn26458246,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@elebenty,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@drcameronjones,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection | bioRxiv https://t.co/3EiuuFOK7N
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@MorriganResists,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@elpearse,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@jennsalz,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Rajendr83556477,RT @biorxiv_micrbio: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/VCKKYWfgqq #biorxiv_micrb‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@drjimcox,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@KathleenChu5,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@redboybroken,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@ClauserLotus,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@leslieasheppard,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@BreakingHappy,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@CarolYMorrisse1,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@jmwallach,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Mrclant,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@NMblondewino,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@akkaufman,RT @Laurie_Garrett: Decoys https://t.co/u0QFLNuqau
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@marykmiller5,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@420since1968,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@TonyBurnetti,RT @biorxiv_micrbio: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/VCKKYWfgqq #biorxiv_micrb‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Bandislife2004,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@mugrogue,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@AriellePhoenix,RT @biorxivpreprint: Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Kathy08118773,RT @Laurie_Garrett: Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@Laurie_Garrett,Decoys
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@biorxiv_micrbio,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/VCKKYWfgqq #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.12.247338,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection,@biorxivpreprint,Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection  https://t.co/0QeMFx0feb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells"" (https://t.co/GagAdYtCr2).‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@outbreaksci,"Contribute a rapid review or request one for ""Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells"" (https://t.co/GagAdYtCr2). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.247320) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@outbreaksci,New #SARSCoV preprint: Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells https://t.co/GagAdYtCr2
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@10_blue,RT @biorxivpreprint: Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells  https://t.co/dJdr9zt5Kr #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@MLitbot,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells https://t.co/OUvaCmst2G
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@biorxiv_immuno,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells  https://t.co/lgm6LmwwaB #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.11.247320,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells,@biorxivpreprint,Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells  https://t.co/dJdr9zt5Kr #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@OliverActon3,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Michael91693258,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@carissalp14,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@countrsignal,RT @UWproteindesign: New collaborative preprint on our de novo designed COVID-19 nanoparticle vaccine. #proteindesign
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Char35x,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@aletortorici,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@baweletaisho,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Eomesodermin,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 https://t.co/bGaoWtEY8S #immunobot https://t.co/IKZAGPePWN
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@BrianGoldspiel,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@SunnySUppal,Very cool work for a #COVID19 vaccine by @veeslerlab Happy to see that Hydrogen deuterium exchange mass spec  was used by the Guttman and Lee labs for structure elucidation  @HdxMs #HDXMS
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@HaVanDang2712,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Dr_MattMcCallum,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@paul_v_thomas,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@gingraslab1,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@rickrecordist,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Eyesgack,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@FrankBioNano,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@DanLikeProteins,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@GHofmar,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@ajrferrari,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@grocklin,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@AndrewRouth,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@CyrilPedia,"RT @ImmunoFever: Beautiful work! ""These results highlight the utility of robust antigen display platforms for inducing potent neutralizing‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@MitosisLab,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@ImmunoFever,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@ImmunoFever,"Beautiful work! ""These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic."""
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@FranciesMary,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@ImmunoFever,RT @marija_backovic: ‚ÄúThe nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) RBD in a highly immunogenic array and induce‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@jbloom_lab,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@reidatcheson,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Elicitation of potent neutralizing antibody responses by designed protein nanoparticle v..."" (https://t.co/2VKfQ6wgcH). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.247395) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 https://t.co/2VKfQ6wgcH
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@_aparicioC,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Chloe_Lieng,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@biochemistries,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@khmelinskaia,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@marija_backovic,‚ÄúThe nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) RBD in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@mjcreid,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@igmrlm,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Shannon89558046,RT @DebraDuffy11: üß©üß©
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@reichowlab,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@eumathius,wow
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@joostsnijder,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@covid19_experts,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@tanyongzi,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@sofroniewn,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@MileenKirkpatr3,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@GBhardwaj8,RT @UWproteindesign: New collaborative preprint on our de novo designed COVID-19 nanoparticle vaccine. #proteindesign https://t.co/4CLtXLe0‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@stolidobranch,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@4KevinsSake,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@BurgettJeff,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@UWproteindesign,New collaborative preprint on our de novo designed COVID-19 nanoparticle vaccine. #proteindesign
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@ichaydon,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@REALITYofJNJ,RT @DebraDuffy11: üß©üß© https://t.co/lArfeYxBsb
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@DebraDuffy11,üß©üß©
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@KingLabIPD,RT @veeslerlab: We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@veeslerlab,We designed a #COVID19 vaccine multivalently displaying the SARS-CoV-2 receptor-binding domain which induces potent neutralizing antibodies! Fantastic collaboration with @KingLabIPD led by @coronalexington and Brooke Fiala.  https://t.co/4uVCIhnUn0
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@10_blue,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@redboybroken,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@JackBentonSr,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@joursansfin,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@hippyniki,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@jhvilas,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Esqueuezme,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@Laurie_Garrett,RT @biorxivpreprint: Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@biorxiv_immuno,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https://t.co/7pLJcAB26L #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.11.247395,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2,@biorxivpreprint,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2  https://t.co/ttmuT5LRKb #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20149286,The effect of public health policies in the transmission of COVID-19 for South American countries,@jlavileze,RT @medrxivpreprint: The effect of public health policies in the transmission of COVID-19 for South American countries  https://t.co/kcinM0‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20149286,The effect of public health policies in the transmission of COVID-19 for South American countries,@outbreaksci,"Contribute a rapid review or request one for ""The effect of public health policies in the transmission of COVID-19 for South America..."" (https://t.co/cCw4RBERqa). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20149286) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.09.20149286,The effect of public health policies in the transmission of COVID-19 for South American countries,@outbreaksci,New #COVID19 preprint: The effect of public health policies in the transmission of COVID-19 for South American countries https://t.co/cCw4RBERqa
http://medrxiv.org/cgi/content/short/2020.08.09.20149286,The effect of public health policies in the transmission of COVID-19 for South American countries,@CHOMES102,RT @medrxivpreprint: The effect of public health policies in the transmission of COVID-19 for South American countries  https://t.co/kcinM0‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20149286,The effect of public health policies in the transmission of COVID-19 for South American countries,@medrxivpreprint,The effect of public health policies in the transmission of COVID-19 for South American countries  https://t.co/kcinM0JTNJ #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@CFSciences,RT @biorxivpreprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/lzuYdpnwI7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@Astro_Erik,RT @biorxivpreprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/lzuYdpnwI7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@SciscoreReports,The paper ‚ÄúDiscovery of COVID-19 Inhibitors Targeting the SAR...‚Äù (https://t.co/RkKyH34HsJ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/SuHz1Qr4ws. We detected 2 key resources.
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@YuxingXia,RT @biorxivpreprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/lzuYdpnwI7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@emulenews,RT @biorxivpreprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/lzuYdpnwI7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@biochemistries,RT @biorxivpreprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/lzuYdpnwI7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@biorxiv_micrbio,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/ACozTDxtP5 #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@biorxivpreprint,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase  https://t.co/lzuYdpnwI7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@outbreaksci,New #SARSCoV preprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase https://t.co/nmcUdcGmaE
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@outbreaksci,"Contribute a rapid review or request one for ""Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase"" (https://t.co/nmcUdcGmaE). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.243246) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.09.243246,Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase,@outbreaksci,New #COVID19 preprint: Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase https://t.co/nmcUdcGmaE
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@Mari1usz,https://t.co/ZOHN0r1Yiu
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@sjingeo,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2 https://t.co/gD5QpJoCBa
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@Astro_Erik,RT @biorxivpreprint: Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2  https://t.co/yfmhELHu9l #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@SciscoreReports,The paper ‚ÄúWorldwide tracing of mutations and the evolutionar...‚Äù (https://t.co/ikSO80mMC2) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/aTGg0p5Jec. We detected 6 key resources.
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@aDNA_papers,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2 https://t.co/1vrzDX1PP9
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@Nwauka,RT @biorxivpreprint: Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2  https://t.co/yfmhELHu9l #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@msep0003,RT @biorxiv_micrbio: Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2  https://t.co/oVULWV4tyB #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@biorxivpreprint,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2  https://t.co/yfmhELHu9l #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@biorxiv_micrbio,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2  https://t.co/oVULWV4tyB #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2"" (https://t.co/4LcPdigkZS). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.242263) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.07.242263,Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2 https://t.co/4LcPdigkZS
http://medrxiv.org/cgi/content/short/2020.08.10.20171348,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia,@PandemicCovid20,Love during lockdown: findings from an online survey examining the impact of #COVID19 on the sexual practices of people living in Australia https://t.co/MvfowEEmDd
http://medrxiv.org/cgi/content/short/2020.08.10.20171348,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia,@drcameronjones,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia | medRxiv https://t.co/Ptds3E3yqW
http://medrxiv.org/cgi/content/short/2020.08.10.20171348,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia,@SciscoreReports,The paper ‚ÄúLove during lockdown: findings from an online surv...‚Äù (https://t.co/SGRkuRbvvT) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/q0DwH8gGmG. We detected 2 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171348,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia,@ethanjweiss,Also this paper is interesting...  https://t.co/Z47mZqcPvO
http://medrxiv.org/cgi/content/short/2020.08.10.20171348,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia,@OscarTengmark,Det finns s√• mycket forskning nu.
http://medrxiv.org/cgi/content/short/2020.08.10.20171348,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia,@medrxivpreprint,Love during lockdown: findings from an online survey examining the impact of COVID-19 on the sexual practices of people living in Australia  https://t.co/OPeIvDYAGE #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@thomasrohrer19,"@NYGovCuomo #NYCMayor Children will be a major transmission vector just like they are with HCoV. Denying that with ""no evidence ..."" will cost us dearly. They were not as affected in the Spring because of sheltering. With school openings that changes. http"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@MerryTea,RT @SarahGaneDSN: Interesting findings in this preliminary data on transmission of SARS-CoV-2 households.
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@outbreaksci,"Contribute a rapid review or request one for ""Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition..."" (https://t.co/C29OnpZlpw). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20169912) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@outbreaksci,New #SARSCoV preprint: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings https://t.co/C29OnpZlpw
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@thomasrohrer19,@ScottGottliebMD #Coronavirus #CDC #mtosterholm #CIDRAP Children get infected EASIER than adults: https://t.co/6T53vkk0BT
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@SarahGaneDSN,Interesting findings in this preliminary data on transmission of SARS-CoV-2 households.
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@wheelofchange,Italiaans studie over infectie bij kinderen ...   https://t.co/0YNQYw7jCO
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@1950sWomen,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@ChrisSylvain,RT @kamleshkhunti: Household transmission of SARS-CoV-2 high in both adults & children  https://t.co/pCYQ9ciXcu
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@Sanyeh1,So very worrying for parents
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@sanjyy_,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk https://t.co/WoWNVjP‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@brewdog1950,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@Dawkins1Freddie,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@DrSimonAshworth,"High level household transmission of #COVID19   The impact of returning schools will be significant, even if we haven‚Äôt quite proved it yet.  https://t.co/mKmJSWXKgJ"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@DrSimonAshworth,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@Carmichael_Rob,RT @kamleshkhunti: Household transmission of SARS-CoV-2 high in both adults & children  https://t.co/pCYQ9ciXcu
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@SallyFereday,"RT @surf4children: sorry to clearly highlight, if needed, that children easily get infected with #SARSCoV2 if exposed to the virus, as much‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@nuwandiss,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@AgnesAyton,RT @dombey: Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@DrAseemMalhotra,RT @kamleshkhunti: Household transmission of SARS-CoV-2 high in both adults & children  https://t.co/pCYQ9ciXcu
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@SaludHEALTHinfo,RT @kamleshkhunti: Household transmission of SARS-CoV-2 high in both adults & children  https://t.co/pCYQ9ciXcu
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@dombey,Seemingly a hugely important paper - if kids bring COVID back from school then the whole family is at risk
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@1Paulcoker,RT @kamleshkhunti: Household transmission of SARS-CoV-2 high in both adults & children  https://t.co/pCYQ9ciXcu
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@kamleshkhunti,Household transmission of SARS-CoV-2 high in both adults & children  https://t.co/pCYQ9ciXcu
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@SciscoreReports,The paper ‚ÄúSeroprevalence of anti-SARS-CoV-2 IgG antibodies i...‚Äù (https://t.co/nEwelzkEZj) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/8tpUHPGfSg. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@frauherkules,"RT @rabenfroh: Erwachsener Indexfall, im selben Haushalt lebende Kinder sind √§hnlich oft infiziert und (nicht) diagnostiziert wie weitere E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@rabenfroh,"Erwachsener Indexfall, im selben Haushalt lebende Kinder sind √§hnlich oft infiziert und (nicht) diagnostiziert wie weitere Erwachsene im selben Haushalt."
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@rabenfroh,Kinder stecken sich nach dieser Haushaltskontaktstudie mit erwachsenen Indexf√§llen √§hnlich oft an wie die erwachsenen Partner. Unterschied: Kinder werden scheinbar viel seltener diagnostiziert.
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@DasLebenIstSch7,#BildungAberSicher @BMFSFJ @BMBF_Bund @BMG_Bund Aktuelle Studie zu Infektionsbeteilugung von Kindern.
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@Robinwpb111,"RT @surf4children: sorry to clearly highlight, if needed, that children easily get infected with #SARSCoV2 if exposed to the virus, as much‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@apoorva_nyc,"RT @surf4children: sorry to clearly highlight, if needed, that children easily get infected with #SARSCoV2 if exposed to the virus, as much‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@surf4children,RT @medrxivpreprint: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: prelim‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@doroboehm,RT @medrxivpreprint: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: prelim‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@doroboehm,"RT @surf4children: sorry to clearly highlight, if needed, that children easily get infected with #SARSCoV2 if exposed to the virus, as much‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@surf4children,"sorry to clearly highlight, if needed, that children easily get infected with #SARSCoV2 if exposed to the virus, as much as adults. and pediatric #COVID19 is hugely undetected preprint: https://t.co/lhCfTP9Eix @apoorva_nyc @EricTopol @onisillos https://t.c"
http://medrxiv.org/cgi/content/short/2020.08.10.20169912,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings,@medrxivpreprint,Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings  https://t.co/ZKPaoXl2cI #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.11.20173005,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women,@outbreaksci,"Contribute a rapid review or request one for ""Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women"" (https://t.co/B9kZoPk3zW). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.20173005) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.11.20173005,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women,@outbreaksci,New #SARSCoV preprint: Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women https://t.co/B9kZoPk3zW
http://medrxiv.org/cgi/content/short/2020.08.11.20173005,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women,@SciscoreReports,The paper ‚ÄúHistopathology of Third Trimester Placenta from SA...‚Äù (https://t.co/j3pzxfLWrm) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/DOtJGpJ7jI. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.11.20173005,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women,@CentenoArocha,"""Las placentas de mujeres positivas al SARS-CoV-2 no muestran un patr√≥n patol√≥gico espec√≠fico. El embarazo complicado con COVID-19 durante el tercer trimestre no tiene un efecto demostrable sobre la estructura y patolog√≠a placentaria."""
http://medrxiv.org/cgi/content/short/2020.08.11.20173005,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women,@maureviv,The battle of the Titans! Freddy vs Jason!  The carnivore placenta vessels Versus the vessel-eating SARS-CoV-2!!!  üò± https://t.co/K2wqU8BySa
http://medrxiv.org/cgi/content/short/2020.08.11.20173005,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women,@medrxivpreprint,Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women  https://t.co/ydgK1XW6Nv #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@outbreaksci,"Contribute a rapid review or request one for ""High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-..."" (https://t.co/7zmPIMBIAO). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171942) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@outbreaksci,New #SARSCoV preprint: High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey https://t.co/7zmPIMBIAO
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@PandemicCovid20,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey https://t.co/9mla6dR7Iz
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@merrieclaire2,RT @CovidSerology: This is the third round of nationwide sampling and 1st round results from May found just over 1.4% of the population had‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@CovidSerology,"This is the third round of nationwide sampling and 1st round results from May found just over 1.4% of the population had antibodies. The study looked at IgG antibodies in over 33,205 participants spread across the 133 municipalities in Brazil 2/n https://t"
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@SciscoreReports,The paper ‚ÄúHigh prevalence of symptoms among Brazilian subjec...‚Äù (https://t.co/3d5WQtQSZm) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/U0adayJsz2. We detected 3 of 5 rigor criteria and 4 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171942,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey,@medrxivpreprint,High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey  https://t.co/0fAcUX0SqA #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@outbreaksci,"Contribute a rapid review or request one for ""Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die ..."" (https://t.co/ieoNrYB3hr). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171454) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@outbreaksci,New #SARSCoV preprint: Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out? https://t.co/ieoNrYB3hr
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@giridar100,RT @BhavKhatri: Can Sar-Cov-2 to die out without immunity? And how long would it take? I calculate exact extinction time distribution for s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@R0bMoon,RT @BhavKhatri: Can Sar-Cov-2 to die out without immunity? And how long would it take? I calculate exact extinction time distribution for s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@PandemicCovid20,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out? https://t.co/2kzaqJb4tt
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@jamimmunology,RT @BhavKhatri: Can Sar-Cov-2 to die out without immunity? And how long would it take? I calculate exact extinction time distribution for s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@BhavKhatri,"Can Sar-Cov-2 to die out without immunity? And how long would it take? I calculate exact extinction time distribution for simple stochastic SIR model. Conclusion: restrict R<0.5 this can happen in months, but if R is close to 1 it takes many many years!"
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@theOakMD,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out? https://t.co/ED5ff8Q9jp
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@SciscoreReports,The paper ‚ÄúStochastic extinction of epidemics: how long does...‚Äù (https://t.co/1q3p46Q76w) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/xG9CzsxDuB. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@Sandeepan1702,RT @pash22: Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out? https://t.co/7w0Yi24IqT via @BhavKha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@pash22,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out? https://t.co/7w0Yi24IqT via @BhavKhatri @giridar100
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@prat1112001,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?   https://t.co/9JpRipPqAs
http://medrxiv.org/cgi/content/short/2020.08.10.20171454,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?,@medrxivpreprint,Stochastic extinction of epidemics: how long does would it take for Sars-Cov-2 to die out?  https://t.co/eoP9RdUmbr #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171439,Extended SEIQR type model for COVID-19 epidemic and data analysis,@SciscoreReports,The paper ‚ÄúExtended SEIQR type model for COVID-19 epidemic an...‚Äù (https://t.co/PySg6lJz0g) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/K1IIVxgrGg. We detected 24 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20171439,Extended SEIQR type model for COVID-19 epidemic and data analysis,@medrxivpreprint,Extended SEIQR type model for COVID-19 epidemic and data analysis  https://t.co/4O495XzlK3 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@IGCGenomics,RT @medrxivpreprint: On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@R_milky_way,RT @medrxivpreprint: On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@gracehwang1970,"RT @outbreaksci: Contribute a rapid review or request one for ""On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@outbreaksci,"Contribute a rapid review or request one for ""On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence a..."" (https://t.co/6neqBTnc5J). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171884) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@outbreaksci,New #SARSCoV preprint: On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal https://t.co/6neqBTnc5J
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@MIglesiasCabal1,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@ines_cim,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@RicardoS_Ramiro,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@SciArt3D,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal | medRxiv https://t.co/QDGEvoCW9S
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@SciscoreReports,The paper ‚ÄúOn the track of the D839Y mutation in the SARS-CoV...‚Äù (https://t.co/CNUVnt3TRr) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/hA3nsBuave. We detected 4 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@FSantosAlex,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal       https://t.co/n5D2XCwR3n
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@antonioggsousa,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@MiguelCFPinto,RT @medrxivpreprint: On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@isidro_joana,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@_natachacouto_,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@MiguelCFPinto,RT @borges__vitor: Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really hap‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@borges__vitor,Our preprint paper about the highly frequent SARS-CoV-2 Spike Y839 variant in Portugal is now available. I am really happy to share some of the first results of this great collaborative study https://t.co/9VGtYjsHeC
http://medrxiv.org/cgi/content/short/2020.08.10.20171884,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal,@medrxivpreprint,On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in Portugal  https://t.co/fCBURSVTqt #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@jacobklaerke,"@IdaDonkin ‚ÄúAmong the total 668 seropositive participants, 433 (64.8%) had previously been tested for SARS-CoV-2 RNA, and 50.0% had a positive RT-PCR result. A total of 98% of individuals who had a previous positive viral RNA test were also found to be ser"
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@gracehwang1970,"RT @outbreaksci: Contribute a rapid review or request one for ""SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel ..."" (https://t.co/0PNM3WPbEk). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171850) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@outbreaksci,"New #SARSCoV preprint: SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region https://t.co/0PNM3WPbEk"
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@CHOMES102,"RT @medrxivpreprint: SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital servi‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@SciscoreReports,"The paper ‚ÄúSARS-CoV-2 seroprevalence survey among 18,000 heal...‚Äù (https://t.co/HJJH6WFwDK) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/JvuXFpvZPC. We detected 1 of 5 rigor criteria and 3 key resources"
http://medrxiv.org/cgi/content/short/2020.08.10.20171850,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region",@medrxivpreprint,"SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region  https://t.co/un0w1whBWf #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@MangioniG,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@hasterly,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@ciro,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@JChrisPires,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@CHOMES102,RT @joshuasweitz: Important evidence of nearly 10:1 ascertainment  bias in France earlier this year and more support that testing as mitiga‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@HartleyDM,RT @joshuasweitz: Important evidence of nearly 10:1 ascertainment  bias in France earlier this year and more support that testing as mitiga‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@svscarpino,RT @joshuasweitz: Important evidence of nearly 10:1 ascertainment  bias in France earlier this year and more support that testing as mitiga‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@davidlazer,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@mtizzoni,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@viralvideovlogs,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@thilogross,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@joshuasweitz,Important evidence of nearly 10:1 ascertainment  bias in France earlier this year and more support that testing as mitigation requires significantly more resources -> irrespective of symptom status.
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@svscarpino,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@jkbren,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@matteo_brainnet,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@eugeValdano,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@R3RT0,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@nauscopio,RT @vcolizza: 9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@vcolizza,9 out of 10 cases with symptoms were not detected in May-June in France. https://t.co/zpqjbibsfp Substantially more aggressive and efficient testing with easier access is required to act as a pandemic-fighting tool. #COVID19 #TestandTrace @Inserm https://t
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@SciscoreReports,The paper ‚ÄúUnderdetection of COVID-19 cases in France in the...‚Äù (https://t.co/HyhUcrks29) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/RasweZqtUw. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20171744,Underdetection of COVID-19 cases in France in the exit phase following lockdown,@medrxivpreprint,Underdetection of COVID-19 cases in France in the exit phase following lockdown  https://t.co/q0rmOjcaXp #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@DucksOnDucks,"$GILD justification for its egregious RDV pricing dismantled. Remember, no mortality benefit seen in RDV RCTs. A must read üëáüèæ  Will $GILD ever sponsor a dex +/- RDV RCT in severe covid pts? Dr. Bach says likely not even amid a RDV shortage (given the poten"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@Danderso13,RT @peterbachmd: Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp leng‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@rachelcohrs,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@DiStefano_MJ,RT @peterbachmd: Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp leng‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@jbkrell,RT @DavidP4AD: Important re: Remdesivir effectiveness & price. It was widely reported that Rem cut hosp stay by 4 days. Price set in part b‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@peterbachmd,RT @DavidP4AD: Important re: Remdesivir effectiveness & price. It was widely reported that Rem cut hosp stay by 4 days. Price set in part b‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@pharmacychecker,RT @DavidP4AD: Important re: Remdesivir effectiveness & price. It was widely reported that Rem cut hosp stay by 4 days. Price set in part b‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@ejb1893,RT @DavidP4AD: Important re: Remdesivir effectiveness & price. It was widely reported that Rem cut hosp stay by 4 days. Price set in part b‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@DavidP4AD,Important re: Remdesivir effectiveness & price. It was widely reported that Rem cut hosp stay by 4 days. Price set in part based on that metric. But it doesn't appear to be the case. And still no confirmed mortality benefit. @GileadSciences should redu
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@AnnRiordan6,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@mmadurga,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@RebeccaChandle1,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@CmdDasp,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@MorriganResists,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@christina_s_ho,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@pash22,@prat1112001 @d_s_thakur @giridar100 @das_seed https://t.co/HXceNDSwfb
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@a_kaltenboeck,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@_eleanorina,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@peterbachmd,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@AlexJohnLondon,"RT @walidgellad: If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their l‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@walidgellad,"If 36% of severe covid patients have hospital length of stay of 1-4 days, it will be hard for remdesivir to reduce their length of stay when it must be given for 5 days.   Interesting preprint data from a NYC cohort from the Spring. https://t.co/xqpmEEwYio"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@PamelaJohnsonMD,RT @peterbachmd: Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp leng‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@jonathanrockoff,RT @peterbachmd: Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp leng‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@rachelcohrs,RT @peterbachmd: Hospital length of stay for severe COVID-19: implications for Remdesivir's value. @walidgellad https://t.co/wsWKSbRQ4G
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@raj_mehta,RT @peterbachmd: Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp leng‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@AnilMakam,"Herein lies the rub - they can't be severely ill but have to be sick enough to need a long enough hospital course  With evidence for steroids in hospitalized patients on supplemental oxygen, it doesn't make sense to prescribe remdesivir alone & may not"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@VincentRK,RT @peterbachmd: Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp leng‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@peterbachmd,"Our paper (ty @medrxivpreprint): Remdesivir @GileadSciences pricing justification & plausibility of Rem reducing hosp length of stay by 4 days (LOS). While ACTT-1 study showed 4 day faster recovery for Rem (median 11 vs. 15 days), does that translate 1"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@SciscoreReports,The paper ‚ÄúHospital length of stay for severe COVID-19: impli...‚Äù (https://t.co/uSxgMCC3f1) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/1UOcYulrOB. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@rmchavin,"8-10-2020:  In a study just released today from Columbia University Medical Center, ""remdesivir treatment may not provide the length of stay reductions that Gilead relied on when [over]pricing their therapy:"" https://t.co/ZEMmihAgLz https://t.co/n5MKcpBNIs"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@phil_w888,115/  https://t.co/9fRWrtbmdQ
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@phil_w888,"786/  New York City, USA (adult smoking rate was 13.4% in 2017)  Of 1,643 patients hospitalized with severe C-19, 177 were smokers (10.8%*)  Notes:  current/ever not specified  *percentages in table don't correspond to numbers - discrepancy not explained"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@peterbachmd,Hospital length of stay for severe COVID-19: implications for Remdesivir's value. @walidgellad https://t.co/wsWKSbRQ4G
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@a_1_0_2,"""Hospital length of stay for severe COVID-19: implications for #Remdesivir's value""  https://t.co/HNQTNE2G3o"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@a_1_0_2,"""Hospital length of stay for severe COVID-19: implications for Remdesivir's value""  https://t.co/HNQTNE2G3o"
http://medrxiv.org/cgi/content/short/2020.08.10.20171637,Hospital length of stay for severe COVID-19: implications for Remdesivir's value,@medrxivpreprint,Hospital length of stay for severe COVID-19: implications for Remdesivir's value  https://t.co/Sl794cdbGE #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.11.20145458,Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19,@outbreaksci,"Contribute a rapid review or request one for ""Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19"" (https://t.co/enFbAoQxNS). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.20145458) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.11.20145458,Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19,@outbreaksci,New #SARSCoV preprint: Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19 https://t.co/enFbAoQxNS
http://medrxiv.org/cgi/content/short/2020.08.11.20145458,Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19,@SciscoreReports,The paper ‚ÄúOncologic Immunomodulatory Agents in Patients with...‚Äù (https://t.co/1jUKH58OPn) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/0eNBdX3pLw. We detected 1 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.11.20145458,Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19,@phil_w888,"787/  New York City, USA (adult smoking rate was 13.4% in 2017)  Of 820 cancer patients who developed C-19, 38.2% had a history of smoking  https://t.co/SDy92BVE9b  Note: overlaps with studies in tweets 329 & 683  https://t.co/Z0SvBDqLSJ https://t.co/"
http://medrxiv.org/cgi/content/short/2020.08.11.20145458,Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19,@medrxivpreprint,Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19  https://t.co/70TGUilqoP #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@Astro_Erik,RT @biorxivpreprint: Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test  https://t.co/MgnnuFo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@SciscoreReports,The paper ‚ÄúHuman Embryonic Stem Cell-derived Lung Organoids:...‚Äù (https://t.co/tvEE1NP0zf) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/ueuQCnDSzn. We detected 0 of 5 rigor criteria and 0 key resources.
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@biorxivpreprint,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test  https://t.co/MgnnuFo25R #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@biorxiv_micrbio,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test  https://t.co/Cy3sTD4Cli #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@outbreaksci,New #SARSCoV preprint: Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test https://t.co/uDD8U2IW8T
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@outbreaksci,"Contribute a rapid review or request one for ""Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and D..."" (https://t.co/uDD8U2IW8T). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.244350) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.10.244350,Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test,@outbreaksci,New #COVID19 preprint: Human Embryonic Stem Cell-derived Lung Organoids: a Model for SARS-CoV-2 Infection and Drug Test https://t.co/uDD8U2IW8T
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@outbreaksci,"Contribute a rapid review or request one for ""High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospec..."" (https://t.co/DnHxKaBUZI). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171413) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@outbreaksci,New #SARSCoV preprint: High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England https://t.co/DnHxKaBUZI
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@PINKYPIE41,RT @PandemicCovid20: High prevalence of SARS-CoV-2 antibodies in care homes affected by #COVID19; a prospective cohort study in England htt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@PandemicCovid20,High prevalence of SARS-CoV-2 antibodies in care homes affected by #COVID19; a prospective cohort study in England https://t.co/xFVz9VEhxv
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@CHOMES102,RT @medrxivpreprint: High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England  ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@SciscoreReports,The paper ‚ÄúHigh prevalence of SARS-CoV-2 antibodies in care h...‚Äù (https://t.co/yUwmnoBYR6) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/DzDHGnWuJt. We detected 0 of 6 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@stewak2,RT @12FreeBeer: Seroprevalence in 6 care homes in England: 81% of residents 75% of staff Levels ~5X-15X greater than general public. Serolo‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@12FreeBeer,Seroprevalence in 6 care homes in England: 81% of residents 75% of staff Levels ~5X-15X greater than general public. Serology studies only measure general public & don't include care homes. The results of this study reflect why these serology studies m
http://medrxiv.org/cgi/content/short/2020.08.10.20171413,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England,@medrxivpreprint,High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England  https://t.co/I3kOIa1zOE #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@outbreaksci,New #SARSCoV preprint: Low awareness of past SARS-CoV-2 infection in healthy adults https://t.co/Ghfwl8sMCs
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@outbreaksci,"Contribute a rapid review or request one for ""Low awareness of past SARS-CoV-2 infection in healthy adults"" (https://t.co/Ghfwl8bbdS). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171561) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@outbreaksci,New #COVID19 preprint: Low awareness of past SARS-CoV-2 infection in healthy adults https://t.co/Ghfwl8sMCs
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@PandemicCovid20,Low awareness of past SARS-CoV-2 infection in healthy adults https://t.co/m2LMBM390m
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@AntifaDisabled,"RT @chrishendel: ü§î  > ""Individuals donating plasma anywhere in the Netherlands were screened for total #SARSCoV2 antibodies.""  > ""48 percen‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@chrishendel,"ü§î  > ""Individuals donating plasma anywhere in the Netherlands were screened for total #SARSCoV2 antibodies.""  > ""48 percent of antibody-positive persons did not suspect having had #COVID19, in spite of most of them reporting symptoms.""  https://t.co/"
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@SciscoreReports,The paper ‚ÄúLow awareness of past SARS-CoV-2 infection in heal...‚Äù (https://t.co/4aVgu4o3Ah) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/xcI4cBZMZu. We detected 1 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@kyle_minogue,"Awareness of infection was low among individuals that tested positive for SARS-CoV-2 antibodies, even at the peak of the epidemic. https://t.co/gazmqjjAPK"
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@soltysik_rob,"Awareness of infection was low among individuals that tested positive for SARS-CoV-2 antibodies, even at the peak of the epidemic.  https://t.co/PNzYIjJxMx"
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@angelseti,RT @medrxivpreprint: Low awareness of past SARS-CoV-2 infection in healthy adults  https://t.co/vGYg3440j0 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171561,Low awareness of past SARS-CoV-2 infection in healthy adults,@medrxivpreprint,Low awareness of past SARS-CoV-2 infection in healthy adults  https://t.co/vGYg3440j0 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20170506,"A ""Tail"" of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL",@SciscoreReports,The paper ‚ÄúA &quot;Tail&quot; of Two Cities: Fatality-based M...‚Äù (https://t.co/vPL9ENSD8U) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/sBfTS5Qilm. We detected 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.10.20170506,"A ""Tail"" of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL",@medrxivpreprint,"A ""Tail"" of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL  https://t.co/5McjvQTCza #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@manavas21,RT @EnferEvidente: PPrint el caso del restaurante de Guangzhou El tipo de circulaci√≥n de aire en el interior de los locales parece centrar‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@NG20194,@apoorva_nyc
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@MassatoHirai,"RT @outbreaksci: New #SARSCoV preprint: The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces https://t.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@EnferEvidente,PPrint el caso del restaurante de Guangzhou El tipo de circulaci√≥n de aire en el interior de los locales parece centrar el riesgo de contagio de SARS-CoV-2 En este estudio utilizan el enfoque Langriano (ver por donde se desplaza un volumen) para mostrarlo
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@outbreaksci,"New #SARSCoV preprint: The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces https://t.co/v5FGZZqqPG"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@outbreaksci,"Contribute a rapid review or request one for ""The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces"" (https://t.co/v5FGZZqqPG). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.20173195) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@outbreaksci,"New #COVID19 preprint: The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces https://t.co/v5FGZZqqPG"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@jyoukeishibu,@AirborneKanki „Åì„Å°„Çâ„ÅØmedrxiv„Å´Êé≤Ëºâ„Åï„Çå„Å¶„ÇãÊúÄÊñ∞„ÅÆË´ñÊñá„Åß„Åô„ÄÇ„ÇÇ„ÅÜÂæ°Ë¶ß„Å´„Å™„Å£„Å¶„Çâ„Å£„Åó„ÇÉ„Çã„Åß„Åó„Çá„ÅÜ„ÅãÔºü https://t.co/b209MT4imX
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@PINKYPIE41,"RT @PandemicCovid20: The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces https://t.co/pOfwUEH1jw"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@PandemicCovid20,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces https://t.co/pOfwUEH1jw"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@GeorgeThampy,RT @drug_smolecules: I love these simulation models of particles coming out from #COVID19  Here is a model on the restaurant-acquired infec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@SciscoreReports,The paper ‚ÄúThe Build-Up of Droplet/Aerosols Carrying the SARS...‚Äù (https://t.co/7aDM4fted0) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/dlgBglIhhl. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@lifejoybiofun,RT @drug_smolecules: I love these simulation models of particles coming out from #COVID19  Here is a model on the restaurant-acquired infec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@drug_smolecules,I love these simulation models of particles coming out from #COVID19  Here is a model on the restaurant-acquired infections documented in China some months ago https://t.co/56ZSfn8zL4 https://t.co/LGs6HMAyGR
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@angelseti,"RT @medrxivpreprint: The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces  https://t.co/msjm8NpR6u #med‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@AntifaDisabled,"RT @medrxivpreprint: The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces  https://t.co/msjm8NpR6u #med‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20173195,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces",@medrxivpreprint,"The Build-Up of Droplet/Aerosols Carrying the SARS-CoV-2 Coronavirus, in Confined Spaces  https://t.co/msjm8NpR6u #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@EnferEvidente,PrePrint Impacto de las medidas no farmacologicas en la transmisi√≥n del SARS-CoV-2 en 130 pa√≠ses https://t.co/8RmgTQcZXA El cierre de escuelas y la restricci√≥n de movilidad muestran resultados s√≥lidos en todos los escenarios el resto son eficaces en determ
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@outbreaksci,New #SARSCoV preprint: The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories https://t.co/vihwr3rXMN
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@outbreaksci,"Contribute a rapid review or request one for ""The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 c..."" (https://t.co/vihwr3rXMN). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.20172643) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@outbreaksci,New #COVID19 preprint: The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories https://t.co/vihwr3rXMN
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@hazardscampaign,"https://t.co/Ig0Blqgf92  Next in line on with ‚Äòstrong evidence‚Äô of a related rate reduction comes workplace closure, income support and debt/contract relief."
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@PINKYPIE41,RT @PandemicCovid20: The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@PandemicCovid20,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories https://t.co/t0ocKURNq1
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@CHOMES102,RT @medrxivpreprint: The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@JamesonVoss,RT @medrxivpreprint: The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@HermanWerfhorst,"RT @rauscher_emily: ""The effectiveness of school closure and internal movement restrictions appears robust across different model specifica‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@SciscoreReports,The paper ‚ÄúThe impact of non-pharmaceutical interventions on...‚Äù (https://t.co/7tXizovXJ3) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/YXMOmD51TG. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@rauscher_emily,"""The effectiveness of school closure and internal movement restrictions appears robust across different model specifications""  https://t.co/pWtUNQ0Szj"
http://medrxiv.org/cgi/content/short/2020.08.11.20172643,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories,@medrxivpreprint,The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories  https://t.co/FbLDRQPD1h #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@nadanai263,"Cutting-edge stuff from @DrVivekThacker demonstrating how lung-on-chip devices can be used to probe #COVID19 pathogenesis with exquisite resolution, under sophisticated simulated physiological conditions. Check it out here! https://t.co/kZ20AM0v76"
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@gstanchev,I am sure @farid__jalali and @__ice9 would like this too...
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@SciscoreReports,The paper ‚ÄúRapid endothelialitis and vascular inflammation ch...‚Äù (https://t.co/SawSu3AZfk) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/e1bdTGhxjS. We detected 0 of 6 rigor criteria and 11 key resource
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@LucreSnooker,"interesting ""lung on a chip"" COVID-19 model suggests endothelial cells can get infected through direct contact with infected epithelial cells, in an ACE2-independent manner  https://t.co/zbo0Z8dZfP https://t.co/nF9tkCb7w3"
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@ambers876,@__ice9 is there anything that can be used to reverse/prevent this endothelial inflammation?   https://t.co/9cxm32UAkl
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@garmirsar,RT @DrVivekThacker: Excited to share our latest #preprint on #SARSCoV2 inefections of a model of the human alveolar space which recapitulat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@MLitbot,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model https://t.co/LT4zIEYqIL
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@CFSciences,RT @DrVivekThacker: Excited to share our latest #preprint on #SARSCoV2 inefections of a model of the human alveolar space which recapitulat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@MelanieHanneb,RT @DrVivekThacker: Excited to share our latest #preprint on #SARSCoV2 inefections of a model of the human alveolar space which recapitulat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@StefanBassler,RT @DrVivekThacker: Excited to share our latest #preprint on #SARSCoV2 inefections of a model of the human alveolar space which recapitulat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@DrVivekThacker,Excited to share our latest #preprint on #SARSCoV2 inefections of a model of the human alveolar space which recapitulates the vascular damage observed in clinical #COVID19 https://t.co/kbOQM8p89W
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@twistopherrobin,"""Rapid endothelialitis and vascular inflammation characterise SARSCoV-2 infection in a human lung-on-chip model"" by Vivek V. Thacker, Kunal Sharma, et al, Global Health Institute, Switzerland, August 10, 2020: https://t.co/wr8HlkqH2N"
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@outbreaksci,"Contribute a rapid review or request one for ""Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a h..."" (https://t.co/piKQBDyntz). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.243220) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.10.243220,Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model,@outbreaksci,New #SARSCoV preprint: Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model https://t.co/piKQBDyntz
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@Aquerales,"""The selection of reference genome and the search for the origin of SARS-CoV-2"" https://t.co/TARphhyjt4   <<The assembly obtained using RaTG13 as reference showed better statistics in total length and N50 than the assembly guided by SARS-CoV-2>&gt"
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@Aquerales,RT @SciscoreReports: The paper ‚ÄúThe selection of reference genome and the search f...‚Äù (https://t.co/OVpGka4WrW) has been reviewed by a set‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@SciscoreReports,The paper ‚ÄúThe selection of reference genome and the search f...‚Äù (https://t.co/OVpGka4WrW) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/gebgVF1PsQ. We detected 0 of 5 rigor criteria and 6 key resources
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@Real_Adam_B,"RT @TheSeeker268: ""The assembly obtained using RaTG13 as reference showed better statistics in total length and N50 than the assembly guide‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@NoWackyScience,RT @flavinkins: https://t.co/rxGBF37wV5
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@flavinkins,https://t.co/rxGBF37wV5
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@angoffinet,"RT @TheSeeker268: ""The assembly obtained using RaTG13 as reference showed better statistics in total length and N50 than the assembly guide‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@L_A_CruzRamirez,RT @biorxivpreprint: The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/M1a4lvwVsM #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@jsteward2930,RT @biorxiv_micrbio: The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/t2CfimYipB #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@biorxiv_micrbio,The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/t2CfimYipB #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@biorxivpreprint,The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/M1a4lvwVsM #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""The selection of reference genome and the search for the origin of SARS-CoV-2"" (https://t.co/No5IPxXF0C). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.245290) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: The selection of reference genome and the search for the origin of SARS-CoV-2 https://t.co/No5IPxXF0C
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@NoWackyScience,RT @TheSeeker268: The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/mKFnUJFhzq
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@Harvard2H,RT @TheSeeker268: The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/mKFnUJFhzq
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@LL97838288,ÂèÉËÄÉÂü∫Âõ†ÁµÑÊîπËÆäÁöÑÈÅ∏ÊìáÂíåSARS-CoV-2ÁöÑËµ∑Ê∫êÁöÑÊêúÁ¥¢
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@uacjess,RT @TheSeeker268: The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/mKFnUJFhzq
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@VenkyRamanujan,RT @TheSeeker268: The selection of reference genome and the search for the origin of SARS-CoV-2  https://t.co/mKFnUJFhzq
http://biorxiv.org/cgi/content/short/2020.08.10.245290,The selection of reference genome and the search for the origin of SARS-CoV-2,@TheSeeker268,"""The assembly obtained using RaTG13 as reference showed better statistics in total length and N50 than the assembly guided by SARS-CoV-2, indicating that RaTG13 maybe a better reference for assembling CoV in pangolin or other potential intermediate hosts."""
http://biorxiv.org/cgi/content/short/2020.08.11.242834,"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic",@epidatum,"AT-527 is a potent in vitro replication inhibitor of #SARSCoV2, the virus responsible for #COVID19 pandemic  A #Phase2 #clinicaltrial is currently ongoing to evaluate the safety and efficacy of AT-527 in COVID-19 patients. https://t.co/5YkpkyVR5s https://t"
http://biorxiv.org/cgi/content/short/2020.08.11.242834,"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic",@outbreaksci,"New #SARSCoV preprint: AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic https://t.co/VIUbZ7ILlo"
http://biorxiv.org/cgi/content/short/2020.08.11.242834,"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic",@biorxivpreprint,"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic  https://t.co/OZE61IaIti #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.11.242834,"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic",@outbreaksci,"Contribute a rapid review or request one for ""AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible f..."" (https://t.co/VIUbZ7ILlo). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.242834) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.11.242834,"AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic",@outbreaksci,"New #COVID19 preprint: AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic https://t.co/VIUbZ7ILlo"
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@outbreaksci,"Contribute a rapid review or request one for ""Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis"" (https://t.co/wW7GWxfr7B). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.243444) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@outbreaksci,New #SARSCoV preprint: Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis https://t.co/wW7GWxfr7B
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@helioRocha_,#bioRxiv   Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis    #bioinfo https://t.co/471UkzYZfY
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@SciscoreReports,The paper ‚ÄúIdentification of key genes in SARS-CoV-2 patients...‚Äù (https://t.co/YkNtRrvhWe) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/KLrrk17E7O. We detected 0 of 5 rigor criteria and 5 key resources
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@YuxingXia,RT @biorxivpreprint: Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis  https://t.co/1ob7siFFpn #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@biorxiv_bioinfo,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis  https://t.co/XEm6h3DMzI #biorxiv_bioinfo
http://biorxiv.org/cgi/content/short/2020.08.09.243444,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis,@biorxivpreprint,Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis  https://t.co/1ob7siFFpn #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@outbreaksci,"Contribute a rapid review or request one for ""A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions"" (https://t.co/q6y0j2lXYn). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.232520) at https://t.co/RnurTL3DyM @outbreaksci @PR"
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@outbreaksci,New #SARSCoV preprint: A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions https://t.co/q6y0j2lXYn
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@helioRocha_,#bioRxiv   A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions    #bioinfo https://t.co/0Vtg5AWIEV
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@SciscoreReports,The paper ‚ÄúA Comprehensive Classification of Coronaviruses an...‚Äù (https://t.co/dZTkekysHZ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/iBGiameCju. We detected 8 key resources.
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@PandemicCovid20,A Comprehensive Classification of #Coronaviruses and Inferred Cross-Host Transmissions https://t.co/zdmfVuixCc
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@hdeshmuk,RT @biorxiv_bioinfo: A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions  https://t.co/6GF7vX8JlV #biorxi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@biorxiv_bioinfo,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions  https://t.co/6GF7vX8JlV #biorxiv_bioinfo
http://biorxiv.org/cgi/content/short/2020.08.11.232520,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions,@biorxivpreprint,A Comprehensive Classification of Coronaviruses and Inferred Cross-Host Transmissions  https://t.co/QvZvHNvBjj #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@CFSciences,RT @cryoEM_Papers: Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/mqkskXXTKi
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@dillardluke1,RT @cryoEM_Papers: Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/mqkskXXTKi
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@SciscoreReports,The paper ‚ÄúCryo-EM Structures of the SARS-CoV-2 Endoribonucle...‚Äù (https://t.co/pFPHh9aFNp) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/80E0CI25q8. We detected 7 key resources.
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@bxv_biochem,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/RzYBOa8hUb
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@MartaUkleja,RT @cryoEM_Papers: Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/mqkskXXTKi
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@outbreaksci,New #SARSCoV preprint: Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/IcSyNGZ10x
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@cryoEM_Papers,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/mqkskXXTKi
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@outbreaksci,"Contribute a rapid review or request one for ""Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15"" (https://t.co/IcSyNGZ10x). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.244863) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@outbreaksci,New #COVID19 preprint: Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 https://t.co/IcSyNGZ10x
http://biorxiv.org/cgi/content/short/2020.08.11.244863,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15,@biorxivpreprint,Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15  https://t.co/PlvCodLctw #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172163,The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey,@uchida_kawasaki,The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey | medRxiv https://t.co/Y8jbiT03De „Ç™„Éº„Çπ„Éà„É©„É™„Ç¢„Å´‰Ωè„ÇÄ‰∫∫„ÅÆÁîüÊÆñ„Å´Èñ¢„Åô„ÇãÂÅ•Â∫∑„Å´ÂØæ„Åô„ÇãCOVID-19„ÅÆÂΩ±ÈüøÔºö„Ç™„É≥„É©„Ç§„É≥Ë™øÊüª„ÅÆÁµêÊûú
http://medrxiv.org/cgi/content/short/2020.08.10.20172163,The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey,@uchida_kawasaki,RT @medrxivpreprint: The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey  https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172163,The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey,@SciscoreReports,The paper ‚ÄúThe impact of COVID-19 on the reproductive health...‚Äù (https://t.co/V0yIeTvhWr) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/tN2CbU6JV8. We detected 2 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.10.20172163,The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey,@medrxivpreprint,The impact of COVID-19 on the reproductive health of people living in Australia: findings from an online survey  https://t.co/iiW5ozlqsI #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@UVMCompSci,"RT @uvmcomplexity: ""Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor comm‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@outbreaksci,"Contribute a rapid review or request one for ""Coordinated support for local action: A modeling study of strategies to facilitate beh..."" (https://t.co/csstXhk9H6). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.20172031) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@outbreaksci,New #SARSCoV preprint: Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression https://t.co/csstXhk9H6
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@CHOMES102,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@chpoletto,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@DynamicsSIAM,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@knkl33,"RT @uvmcomplexity: ""Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor comm‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@uvmcomplexity,"""Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression‚Äù  New preprint from faculty member @LHDnets w/@BMAlthouse & team  https://t.co"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@mc_shirty,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@uvmcomplexity,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@netsci15,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@svscarpino,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@LHDnets,"RT @BMAlthouse: New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@BMAlthouse,"New preprint out incorporating community engagement and behavior change with disease transmission, with Laura Skrip, Mosoka Fallah, @JamieBedson1, and @LHDnets! https://t.co/cNU5bg55Sc"
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@SciscoreReports,The paper ‚ÄúCoordinated support for local action: A modeling s...‚Äù (https://t.co/saDONxpnKM) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/w1pS3mGMND. We detected 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.11.20172031,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression,@medrxivpreprint,Coordinated support for local action: A modeling study of strategies to facilitate behavior adoption in urban poor communities of Liberia for sustained COVID-19 suppression  https://t.co/xHx2y0tg8u #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@MARYau_MCU_PH,"Insuffisant pour faire des guidelines, mais assez exhaustif d'un point de vue revue."
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@MassatoHirai,RT @outbreaksci: New #SARSCoV preprint: Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVI‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@EvidenceRobot,RT @outbreaksci: New #SARSCoV preprint: Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVI‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@outbreaksci,"Contribute a rapid review or request one for ""Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Out..."" (https://t.co/5BjcZZdv8r). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20172189) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@outbreaksci,New #SARSCoV preprint: Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis https://t.co/5BjcZZdv8r
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@outbreaksci,"Contribute a rapid review or request one for ""Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Out..."" (https://t.co/5BjcZZdv8r). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20172189) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@outbreaksci,New #COVID19 preprint: Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis https://t.co/5BjcZZdv8r
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@EvidenceRobot,RT @GeneticLifehack: This is a meta analysis of trial using JAK inhibitors or type I interferon in patients hospitalized with #covid19. The‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@GeneticLifehack,This is a meta analysis of trial using JAK inhibitors or type I interferon in patients hospitalized with #covid19. The results show that both are impressive at reducing mortality (~90% reduction).   https://t.co/lGl878FYQe
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@SciscoreReports,The paper ‚ÄúJanus Kinase-Inhibitor and Type I Interferon Abili...‚Äù (https://t.co/SKKgppnS54) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/AyEkrt1Ioj. We detected 0 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@EvidenceRobot,RT @medrxivpreprint: Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Sy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172189,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis,@medrxivpreprint,Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis  https://t.co/XlpuXK675b #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172155,EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL,@outbreaksci,"Contribute a rapid review or request one for ""EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL"" (https://t.co/PDjEPkgkIg). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20172155) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.10.20172155,EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL,@outbreaksci,New #COVID19 preprint: EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL https://t.co/PDjEPkgkIg
http://medrxiv.org/cgi/content/short/2020.08.10.20172155,EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL,@SciscoreReports,The paper ‚ÄúEPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENE...‚Äù (https://t.co/CzJChVsYDg) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/FGmBh5yghw. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20172155,EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL,@medrxivpreprint,EPIDEMIC ANALYSIS OF COVID-19 IN ALGERIA BY A GENERALIZED SEIR MODEL  https://t.co/0VMciB6Ov9 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.11.20172452,A diagnostic decision-making protocol combines a new-generation of serological assay and PCR to fully resolve ambiguity in COVID-19 diagnosis,@SciscoreReports,The paper ‚ÄúA diagnostic decision-making protocol combines a n...‚Äù (https://t.co/gdGC3aOBUe) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/ibNvGSzaxh. We detected 2 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.11.20172452,A diagnostic decision-making protocol combines a new-generation of serological assay and PCR to fully resolve ambiguity in COVID-19 diagnosis,@medrxivpreprint,A diagnostic decision-making protocol combines a new-generation of serological assay and PCR to fully resolve ambiguity in COVID-19 diagnosis  https://t.co/XQVLGYlU8r #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@SaurabhGayali,Rapid detection of SARS-Cov-2. Within 5 minutes.  https://t.co/vqs88R0UmV Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector https://t.co/0PAwGXLN39
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@ChenLabUofL,RT @ProfKope: @ULmicrofluidics and I have released a new preprint in collaboration with @aceabiosciences and the Center for Predictive Medi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@ProfKope,"RT @ULmicrofluidics: In collaboration with @aceabiosciences we detected COVID antibodies via electrochemical detection (label free, rapid,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@ULmicrofluidics,"In collaboration with @aceabiosciences we detected COVID antibodies via electrochemical detection (label free, rapid, and potentially high throughput) Preprint available! @UofLSpeedEng https://t.co/4yfuOkG6aO"
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@ProfKope,@ULmicrofluidics and I have released a new preprint in collaboration with @aceabiosciences and the Center for Predictive Medicine at @uofl describing our recent work on rapid detection of COVID-19 antibodies via electrochemical impedance sensing https://t.
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@SciscoreReports,The paper ‚ÄúRapid Detection of SARS-CoV-2 Antibodies Using Ele...‚Äù (https://t.co/dEeXj2Vy7B) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/oGvCZ0wGby. We detected 0 of 5 rigor criteria and 5 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171652,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector,@medrxivpreprint,Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector  https://t.co/ErqdhMYlKH #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@ninjablossom,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@carmelprzrz,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@schokomint,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@poteker_dimas,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@DrPieterPeach,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@nishaandany,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@georgentou1,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@linorberezin,RT @LynfaStroud: More important work from ID and resp colleagues @Sunnybrook @linorberezin @nishaandany @lunghealthcan et al.  Limits of su‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@_eleanorina,RT @DavidJuurlink: Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nisha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@DavidJuurlink,Self-reported dyspnea is a poor predictor of hypoxemia in outpatients with COVID-19. New preprint from colleagues @nishaandany et al. https://t.co/oNkecfWloR https://t.co/qL3YwIkfz4
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@nishaandany,RT @LynfaStroud: More important work from ID and resp colleagues @Sunnybrook @linorberezin @nishaandany @lunghealthcan et al.  Limits of su‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@LynfaStroud,More important work from ID and resp colleagues @Sunnybrook @linorberezin @nishaandany @lunghealthcan et al.  Limits of subjective measures of dyspnea in out-patient mgt of patients with COVID-19 -> need home O2 monitoring.   https://t.co/fnsvuICKsT
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@chrishendel,In need of peer-review and publication but an interesting paper posted in the preprint server today.  The Diagnostic Accuracy of Subjective #Dyspnea in Detecting #Hypoxemia Among Outpatients with #COVID19 https://t.co/1i5KJleA4B
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@SciscoreReports,The paper ‚ÄúThe Diagnostic Accuracy of Subjective Dyspnea in D...‚Äù (https://t.co/TNa4a69xE7) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/DaZQmLWcvI. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20172262,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19,@medrxivpreprint,The Diagnostic Accuracy of Subjective Dyspnea in Detecting Hypoxemia Among Outpatients with COVID-19  https://t.co/fYzxiag0JM #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@SORASTAR,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@uchida_kawasaki,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@kotoli33,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@finegan_wake,„Åæ„Å†Ë©≥„Åó„ÅèË™≠„Çì„Åß„ÅÑ„Åæ„Åõ„Çì„Åå„ÄÅÊ≠£„Åó„ÅÑÁµêÊûú„Åß„ÅÇ„Çå„Å∞„ÄÅ#COVID19 „ÅÆ‰∫àÈò≤„Å´„ÄÅ„ÅÇ„ÇãÊÑèÂë≥„Åß„ÅØ„ÉØ„ÇØ„ÉÅ„É≥„Çà„ÇäÂº∑Âäõ„Å™ÊîØÊè¥„Å´„Å™„Çã„Åã„ÇÇ„Åó„Çå„Åæ„Åõ„Çì„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@NorikaSaigawa,@kazukazu721 @tubame36741456 Êó•Êú¨ÂõΩÂÜÖ„Åß„ÇÇ„ÄÅBCG„ÉØ„ÇØ„ÉÅ„É≥Êé•Á®ÆÁéá„ÅÆÂú∞ÂüüÂ∑Æ„Å®ÊúâÁóÖÁéá„Å®„ÅÆÈñì„Å´Áõ∏Èñ¢„Åå„ÅÇ„Çã‰∫ã„ÅåÂÖ¨ÂàäÊ∏à„ÅøÊüªË™≠‰ªò„ÅçË´ñÊñá„Å®„Åó„Å¶Â†±Âëä„Åï„Çå„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ https://t.co/dKd1nWq6kk  „Åæ„Åü„ÄÅ„Åì„Å°„Çâ„ÅØÊú™ÊüªË™≠Ë´ñÊñá„Åß„Åô„ÅóÈÅé‰ø°„ÅØÁ¶ÅÁâ©„Åß„Åô„Åå„ÄÅËøΩÂä†Êé•Á®Æ„Å´„ÇÇÊÑüÊüìÊäëÂà∂ÂäπÊûú„Åå„ÅÇ„Çã„ÅÆ„Åß„ÅØ„Å™„ÅÑ„Åã„Å®„ÅÆÂ†±Âëä„ÇÇ„ÅÇ„Çã„Çà„ÅÜ„Åß„Åô„ÄÇ https://t.co/2Syvs2VO2m
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@takiba19690821,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@10kainu,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@dodo5519,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@tamamakeron,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@DbrWzKzHijSSpgz,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@honyoka,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@punk_cat_,"RT @kenmomd: Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/I‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@kerorrin,"RT @kenmomd: Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/I‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Okarin02419348,"RT @kenmomd: Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/I‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@55pikaichi,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@wyayoi,„Éû„Çπ„ÇØ„ÅÆÂæå„ÇçÂêë„ÅçË™øÊüª„Å®‰ºº„Å¶„ÅÑ„Å¶„ÄÅ„Åì„Çå„Å†„Åë„Åß„ÅÆÂà§Êñ≠„ÅØÈõ£„Åó„ÅÑ„ÄÇ‰ªªÊÑè=Â∏åÊúõËÄÖ„Å†„Å®„ÄÅÂ∏åÊúõËÄÖ„ÅØÊÑüÊüì‰∫àÈò≤„Å´Êó•È†É„Åã„ÇâÊ∞ó„Çí‰ªò„Åë„Å¶„ÅÑ„Çã(‰ΩôË£ï„ÅÆ„ÅÇ„Çã)ÈõÜÂõ£„Å†„Å£„Åü„Å®„Åã„ÄÅ„ÅÇ„ÇäÂæó„Çã„Åã„Çâ„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@20maaar14,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Totemo512,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@and_she_said,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Jabbath35280043,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@CordwainersCat,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@vostokintheair,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@72koyama,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@sabakunopencyan,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@uni_uni222,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Akikan11205193,"RT @kenmomd: Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/I‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@32zWPMgwFFgq2Yh,RT @AyakoMiyakawa: „ÉÑ„Éô„É´„ÇØ„É™„É≥ÂèçÂøú„ÄÅÊ§úÊüª„Åó„Å¶„Åø„Çà„ÅÜ„Åã„Å™„ÄÇ  BCG„ÅåË°®Âú®ÊÄßËÜÄËÉ±Áôå„ÅÆÊ≤ªÁôÇ„ÇÑÂÜçÁô∫‰∫àÈò≤„Å´ËâØ„ÅèÂäπ„Åè„ÅÆ„ÅØÂâç„Å´„ÇÇÂëü„Åç„Åæ„Åó„Åü„Åå„ÄÅ‰ΩúÁî®Ê©üÂ∫è„ÅØÂçä‰∏ñÁ¥Ä‰Ωø„Çè„Çå„Å¶„ÅÑ„Çã„ÅÆ„Å´„Åæ„Å†‰∏çÊòé„ÄÇ„Éü„Çπ„ÉÜ„É™„Ç¢„Çπ„Å™„ÉØ„ÇØ„ÉÅ„É≥„ÄÇ  „Åì„Çì„Å™Ë´ñÊñá„ÇÇÔºÅ  https://t.co/B91npn1‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@periodoespecial,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@fearless_TAISHO,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@goodfife1,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@sugichan55,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@ikotto,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@macchapahecat,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@arugos,„Åì„ÅÆÁµêÊûú„ÅØ‰∏ÄË¶ã„ÄÅÂº∑ÁÉà„Å†„Åå„ÄÅ‰∏ª„Å™ÂïèÈ°å„ÅØÔºìÁÇπ„ÄÇÁ¨¨1„Å´„ÄÅÊé•Á®Æ„Å®ÈùûÊé•Á®Æ„Å´Âä†„Åà„ÄÅ‰ª•Ââç„Å´Êé•Á®Æ„Åó„ÅüÁµåÊ≠¥„Åå„ÅÇ„Çå„Å∞„ÄÅ„Åù„Çå„ÇíËÄÉÊÖÆ„Åó„ÅüÂå∫ÂàÜ„ÅåÈÅ©Âàá„ÄÇÁ¨¨Ôºí„Å´„ÄÅÊÄßÂà•„ÄÅÂπ¥ÈΩ¢„ÄÅbmi„ÄÅÂü∫Á§éÁñæÊÇ£„ÅÆÊúâÁÑ°„ÄÅÊãÖÂΩì„Åó„Å¶„ÅÑ„ÇãËÅ∑Âãô„ÅÆ„É™„Çπ„ÇØ„Å™„Å©„Çí„Ç≥„É≥„Éà„É≠„Éº„É´„Åô„Åπ„Åç„Åì„Å®„ÄÇÁ¨¨Ôºì„Å´„ÄÅÊé•Á®Æ„ÅÆÂÜÖÁîüÊÄß„ÅÆÂïèÈ°å„ÄÇ„Åò„Å§„ÅØ„Åì„Çå„Åå„ÅÑ„Å°„Å∞„ÇìÂéÑ‰ªã„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@qinmu22,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@nobuyuki_nakata,"RT @kenmomd: Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/I‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@yukikaze056,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@gadgetm13019325,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@dandan1116,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@DanishIAS,"RT @StabellBenn: Not a randomised trial, potential for confounding, but still quite remarkable. There is already considerable support for a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@tbh5tbh,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@konta_kappa,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@araran100,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@MtTestudines,"RT @kenmomd: Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/I‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@kenmomd,"Effectiveness of booster BCG vaccination in preventing Covid-19 infection Iradj Amirlak et al. August 11, 2020. https://t.co/ILmnFasYsE"
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Nomuzou_mimic,„Éó„É¨„Éó„É™„É≥„Éà„Åß„ÅØ„ÅÇ„Çã„Åë„Å©„ÄÅBCGÊó¢Êé•Á®ÆËÄÖ„Å´‰∫åÂõûÁõÆ„ÅÆBCGÊé•Á®Æ„Çí„Åô„Çã„Å®COVID-19‰∫àÈò≤ÂäπÊûú„Åå„ÅÇ„Çä„Åù„ÅÜ„Å´Ë¶ã„Åà„Çã„ÄÇ ÁµêË´ñ„ÅØÊ≠£ÂºèË´ñÊñá„Å®Â§ßË¶èÊ®°Ë©¶È®ìÂæÖ„Å°„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@kuthumi215,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@bogidogu22,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@masaitomasa,ËøΩË©¶„ÄÅÁ∂öÂ†±„Å´Ê≥®ÁõÆ„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@aslan2626,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@iCeK1hYPhclsAFi,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@masaitomasa,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Q3QTV8SiVUhbwBN,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Pyotr1840,RT @influenzer3: „ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@SIGETU135,https://t.co/dp5wt7g0KU https://t.co/OyFkOtgV5z
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@influenzer3,„ÅÑ„Åö„Çå„Å´„Åó„Å¶„ÇÇ„ÄÅBCG„ÅÆ‰∫àÈò≤ÂäπÊûú„Å´„Å§„Åç„ÄÅÂ§ßË¶èÊ®°„Å™Ê§úË®º„ÇíË°å„ÅÜ„Åπ„Åç‰∫ã„ÇíÁ§∫ÂîÜ„Åô„ÇãÁµêÊûú„Åã„Å®„ÄÇ Effectiveness of booster BCG vaccination in preventing Covid-19 infection https://t.co/ucRvmTAmf5
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@tai_zf1,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@OMGitsGhastly,Some indications of better news to come regarding the prevention of #COVID19 even though it hasn't been 100% verified yet https://t.co/QWuwqlc1Hh
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@Atsu_4,RT @Liveandletkiss: Ë™§Ëß£„Åô„Çã‰∫∫„Åå„ÅÑ„Å™„ÅÑ„Å®„ÅÑ„ÅÑ„Çì„Å†„Åë„Å©„ÄÅ„ÄÅ  „É¨„Éù„Éº„Éà„Å´„Çà„Çã„Å®„Çπ„Çø„ÉÉ„Éï280Âêç‰∏≠71Âêç„Å´6ÊúàÊú´„Åæ„Åß„Å´BCGÊé•Á®Æ 71Âêç„ÄÄBCGÊé•Á®Æ  ÈôΩÊÄßÁéáÔºêÔºÖ 208Âêç ÈùûÊé•Á®Æ„ÄÄÈôΩÊÄßÁéá8.6ÔºÖ  „Åü„Å†„ÄÅ„Äé280ÂêçÂÖ®Âì°‰π≥ÂπºÂÖêÊúü„Å´BCGÊé•Á®Æ„Åó„Å¶„ÅÑ„Çã„Äè„ÅÆ„Åß„ÄÅ„ÄéÊó•Êú¨‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@ishihara,RT @Liveandletkiss: Ë™§Ëß£„Åô„Çã‰∫∫„Åå„ÅÑ„Å™„ÅÑ„Å®„ÅÑ„ÅÑ„Çì„Å†„Åë„Å©„ÄÅ„ÄÅ  „É¨„Éù„Éº„Éà„Å´„Çà„Çã„Å®„Çπ„Çø„ÉÉ„Éï280Âêç‰∏≠71Âêç„Å´6ÊúàÊú´„Åæ„Åß„Å´BCGÊé•Á®Æ 71Âêç„ÄÄBCGÊé•Á®Æ  ÈôΩÊÄßÁéáÔºêÔºÖ 208Âêç ÈùûÊé•Á®Æ„ÄÄÈôΩÊÄßÁéá8.6ÔºÖ  „Åü„Å†„ÄÅ„Äé280ÂêçÂÖ®Âì°‰π≥ÂπºÂÖêÊúü„Å´BCGÊé•Á®Æ„Åó„Å¶„ÅÑ„Çã„Äè„ÅÆ„Åß„ÄÅ„ÄéÊó•Êú¨‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@WeNeedSkyfall,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@namae29790755,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@soniar_yassy,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@LLigoNyjYmoyi46,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@kotarou_0608,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@QuimSegales,RT @PandemicCovid20: Effectiveness of booster BCG vaccination in preventing #Covid19 infection https://t.co/e5Oy6u9iE4
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@nipponishin,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@MxWwr,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@PRingholm,"Hva med litt p√•fyll av den gode gamle BCG vaksinen?   Fors√∏k p√• sykehus der noen ansatte fikk p√•fyll av BCG, andre ikke   Resultat:   0 % ble smittet av Covid-19 for de som fikk BCG spr√∏yta ‚Ä¶ mot 8,6 % for dem som ikke fikk gleden av n√•lestikket https://t."
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@PINKYPIE41,RT @PandemicCovid20: Effectiveness of booster BCG vaccination in preventing #Covid19 infection https://t.co/e5Oy6u9iE4
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@PandemicCovid20,Effectiveness of booster BCG vaccination in preventing #Covid19 infection https://t.co/e5Oy6u9iE4
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@mirurondesu,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@thuyoshi,RT @Liveandletkiss: Ë™§Ëß£„Åô„Çã‰∫∫„Åå„ÅÑ„Å™„ÅÑ„Å®„ÅÑ„ÅÑ„Çì„Å†„Åë„Å©„ÄÅ„ÄÅ  „É¨„Éù„Éº„Éà„Å´„Çà„Çã„Å®„Çπ„Çø„ÉÉ„Éï280Âêç‰∏≠71Âêç„Å´6ÊúàÊú´„Åæ„Åß„Å´BCGÊé•Á®Æ 71Âêç„ÄÄBCGÊé•Á®Æ  ÈôΩÊÄßÁéáÔºêÔºÖ 208Âêç ÈùûÊé•Á®Æ„ÄÄÈôΩÊÄßÁéá8.6ÔºÖ  „Åü„Å†„ÄÅ„Äé280ÂêçÂÖ®Âì°‰π≥ÂπºÂÖêÊúü„Å´BCGÊé•Á®Æ„Åó„Å¶„ÅÑ„Çã„Äè„ÅÆ„Åß„ÄÅ„ÄéÊó•Êú¨‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@a6m3dorian,RT @Dctr_K: UAE „ÅÆ Emirates International Hospital „ÅÆ„Çπ„Çø„ÉÉ„Éï„Åß„ÄÅ3 ÊúàÂàù„ÇÅ„Å´ BCG „ÅÆËøΩÂä†Êé•Á®Æ„Åó„Åü 71‰∫∫„Å®„Åó„Å™„Åã„Å£„Åü 209‰∫∫„Å®„ÅßÊØîËºÉ„ÄÇ6Êúà„ÅÆÁµÇ„Çè„Çä„Åæ„Åß„Å´ COVID-19 „Å´ÊÑüÊüì„Åó„ÅüËÄÖ„ÅØ„ÄÅÂâçËÄÖ„ÅØ„Çº„É≠„ÄÅÂæåËÄÖ„ÅØ 18‰∫∫ÔºàÊÑüÊüìÁéá‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@komachan9,RT @Dctr_K: ‚Äú71 subjects received the booster vaccination‚Ä¶209 subjects did not‚Ä¶The infection rate in the unvaccinated group was 8.6% versus‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@komachan9,RT @Dctr_K: UAE „ÅÆ Emirates International Hospital „ÅÆ„Çπ„Çø„ÉÉ„Éï„Åß„ÄÅ3 ÊúàÂàù„ÇÅ„Å´ BCG „ÅÆËøΩÂä†Êé•Á®Æ„Åó„Åü 71‰∫∫„Å®„Åó„Å™„Åã„Å£„Åü 209‰∫∫„Å®„ÅßÊØîËºÉ„ÄÇ6Êúà„ÅÆÁµÇ„Çè„Çä„Åæ„Åß„Å´ COVID-19 „Å´ÊÑüÊüì„Åó„ÅüËÄÖ„ÅØ„ÄÅÂâçËÄÖ„ÅØ„Çº„É≠„ÄÅÂæåËÄÖ„ÅØ 18‰∫∫ÔºàÊÑüÊüìÁéá‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@4CqcAXMrLvZ0yq5,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@c_tyo,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@pppkkkcccuuu,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@tmaeno,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@dr_metropolis,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@akane_kawahata,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@RBSonar,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@noma57,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@hawk318snow,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@e9gNnlalUHJPj4L,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@traderzms,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@ONEOKROCK_vv,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@LThorndike_2,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@kuma_kanpow,RT @AyakoMiyakawa: „ÉÑ„Éô„É´„ÇØ„É™„É≥ÂèçÂøú„ÄÅÊ§úÊüª„Åó„Å¶„Åø„Çà„ÅÜ„Åã„Å™„ÄÇ  BCG„ÅåË°®Âú®ÊÄßËÜÄËÉ±Áôå„ÅÆÊ≤ªÁôÇ„ÇÑÂÜçÁô∫‰∫àÈò≤„Å´ËâØ„ÅèÂäπ„Åè„ÅÆ„ÅØÂâç„Å´„ÇÇÂëü„Åç„Åæ„Åó„Åü„Åå„ÄÅ‰ΩúÁî®Ê©üÂ∫è„ÅØÂçä‰∏ñÁ¥Ä‰Ωø„Çè„Çå„Å¶„ÅÑ„Çã„ÅÆ„Å´„Åæ„Å†‰∏çÊòé„ÄÇ„Éü„Çπ„ÉÜ„É™„Ç¢„Çπ„Å™„ÉØ„ÇØ„ÉÅ„É≥„ÄÇ  „Åì„Çì„Å™Ë´ñÊñá„ÇÇÔºÅ  https://t.co/B91npn1‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@ju2_wa,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@hirotomito,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@sugi3_34,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@greifen,RT @kaz_ataka: BCGÊé•Á®Æ„ÅåÊú¨ÂΩì„Å´Âäπ„Åç„Åù„ÅÜ„Å®„ÅØ„ÄÅ„ÄÅ„ÄÇ‰ªñ„ÅÆ„Ç∞„É´„Éº„Éó„Å´„Çà„ÇãËøΩË©¶ÁöÑ„Å™ÁµêÊûú„ÅåË¶ã„Åü„ÅÑ„ÄÇ https://t.co/vi6CCuJQYf
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@ptrnoda135,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@wakao544,ÂÆâÂÆÖ„Åï„Çì„ÅÆ„ÉÑ„Ç§„Éº„Éà„Çà„Çä„ÇÑ„Åë„Å©„ÄÅ ‰∏°ËÖï„Å´„Å™„Åú„ÅãBCGË∑°„Åå„ÅÇ„ÇãÁßÅ„Çà„ÅÜ„ÇÑ„ÅèÂ†±„Çè„Çå„ÇãÊó•„Åå‚Ä¶ https://t.co/18EqRPQ1ty
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@f_tominaga,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@tsunaguJP,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@sennousarenu,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20172288,Effectiveness of booster BCG vaccination in preventing Covid-19 infection,@llljjj10758100,RT @j_sato: „Ç≠„Çø„ÉºÔºÅÔºÅ  UAE„ÅÆÁóÖÈô¢„ÄÅÂá∫ÁîüÊôÇ„Å´BCGÊé•Á®ÆÊ∏à„Åø„ÅÆÁóÖÈô¢„Çπ„Çø„ÉÉ„Éï280‰∫∫„ÅÆ„ÅÜ„Å°71‰∫∫„Å´ÂØæ„Åó„Å¶3Êúà‰∏äÊó¨„Å´BCG(Ê†™Á®Æ‰∏çÊòé)„ÇíËøΩÂä†Êé•Á®Æ„ÄÅ209‰∫∫„Å´„ÅØËøΩÂä†Êé•Á®Æ„Åó„Å™„Åã„Å£„ÅüÁµêÊûú  „ÄÄ„ÄÄ„ÄÄ„ÄÄ„ÄÄ‚Üì‚Üì‚Üì  BCGËøΩÂä†Êé•Á®Æ„ÅÇ„Çä71‰∫∫‚ÜíÊÑüÊüì0‰∫∫(ÊÑüÊüìÁéá0%) BCGËøΩÂä†Êé•Á®Æ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20163402,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China,@outbreaksci,"Contribute a rapid review or request one for ""A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline D..."" (https://t.co/Hnjrc4qWn4). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20163402) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20163402,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China,@outbreaksci,New #SARSCoV preprint: A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China https://t.co/Hnjrc4qWn4
http://medrxiv.org/cgi/content/short/2020.08.07.20163402,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China,@outbreaksci,"Contribute a rapid review or request one for ""A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline D..."" (https://t.co/Hnjrc4qWn4). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20163402) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20163402,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China,@outbreaksci,New #COVID19 preprint: A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China https://t.co/Hnjrc4qWn4
http://medrxiv.org/cgi/content/short/2020.08.07.20163402,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China,@SciscoreReports,The paper ‚ÄúA Large-Scale Clinical Validation Study Using nCap...‚Äù (https://t.co/2HM65kvYjd) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/UsY5IeTDL1. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20163402,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China,@medrxivpreprint,A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia in China  https://t.co/nhGapBMvJz #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@VCCLibrary,"RT @HealthTechWales: üìë The preprint of ‚ÄòThe effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@DewiPowell,"RT @HealthTechWales: üìë The preprint of ‚ÄòThe effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@HealthTechWales,"üìë The preprint of ‚ÄòThe effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis‚Äô is now available on @medrxivpreprint:   üîó https://t.co/xDeqTcNpNj"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@HealthTechWales,"üìë Mae fersiwn wedi‚Äôi ragargraffu o ‚ÄòThe effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis‚Äô ar gael nawr ar @medrxivpreprint:  üîó https://t.co/xDeqTcNpNj"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@EvidenceRobot,"RT @outbreaksci: New #SARSCoV preprint: The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@outbreaksci,"Contribute a rapid review or request one for ""The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies ..."" (https://t.co/nFDdFBLLfw). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171777) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@outbreaksci,"New #SARSCoV preprint: The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review https://t.co/nFDdFBLLfw"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@outbreaksci,"Contribute a rapid review or request one for ""The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies ..."" (https://t.co/nFDdFBLLfw). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20171777) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@outbreaksci,"New #COVID19 preprint: The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review https://t.co/nFDdFBLLfw"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@SciscoreReports,The paper ‚ÄúThe effectiveness of tests to detect the presence...‚Äù (https://t.co/i86VPCneM5) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/AOhjreM1VY. We detected 1 of 5 rigor criteria and 4 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@EvidenceRobot,"RT @medrxivpreprint: The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-1‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171777,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review",@medrxivpreprint,"The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review  https://t.co/93VHZHMD31 #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.11.20172478,Clustering of age standardised COVID-19 infection fatality ratios and death trajectories,@SciscoreReports,The paper ‚ÄúClustering of age standardised COVID-19 infection...‚Äù (https://t.co/22HL21biWj) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/uE8EqtklMA. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.11.20172478,Clustering of age standardised COVID-19 infection fatality ratios and death trajectories,@CHOMES102,RT @medrxivpreprint: Clustering of age standardised COVID-19 infection fatality ratios and death trajectories  https://t.co/4P9UTpRavR #med‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20172478,Clustering of age standardised COVID-19 infection fatality ratios and death trajectories,@per_petra,RT @medrxivpreprint: Clustering of age standardised COVID-19 infection fatality ratios and death trajectories  https://t.co/4P9UTpRavR #med‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.11.20172478,Clustering of age standardised COVID-19 infection fatality ratios and death trajectories,@medrxivpreprint,Clustering of age standardised COVID-19 infection fatality ratios and death trajectories  https://t.co/4P9UTpRavR #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.11.20172502,The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study protocol for a prospective observational trial,@outbreaksci,"Contribute a rapid review or request one for ""The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study pr..."" (https://t.co/nkllcKxxNo). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.11.20172502) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.11.20172502,The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study protocol for a prospective observational trial,@outbreaksci,New #SARSCoV preprint: The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study protocol for a prospective observational trial https://t.co/nkllcKxxNo
http://medrxiv.org/cgi/content/short/2020.08.11.20172502,The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study protocol for a prospective observational trial,@SciscoreReports,The paper ‚ÄúThe COVID-19 Early Detection in Doctors and Health...‚Äù (https://t.co/bv5xPYQZaG) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/hwVA4yFFhE. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.11.20172502,The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study protocol for a prospective observational trial,@medrxivpreprint,The COVID-19 Early Detection in Doctors and Healthcare Workers (CEDiD) Study: study protocol for a prospective observational trial  https://t.co/HUapkTBbpd #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@entrucada,RT @PandemicCovid20: Long-term exposure to air-pollution and #COVID19 mortality in England: a hierarchical spatial analysis https://t.co/Yr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@GercekSarsar,RT @PandemicCovid20: Long-term exposure to air-pollution and #COVID19 mortality in England: a hierarchical spatial analysis https://t.co/Yr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@PandemicCovid20,Long-term exposure to air-pollution and #COVID19 mortality in England: a hierarchical spatial analysis https://t.co/YrnzlUz3gu
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@Isegoria,RT @futurepundit: Air pollution is bad   Findings: We find a 0.5% (95% credible interval: -0.2%-1.2%) and 1.4% (-2.1%-5.1%) increase in COV‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@CharlieJRoscoe,RT @martablangiardo: Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@CharlieJRoscoe,"RT @konstantinoudis: We found a 0.5% (-0.2%, 1.2%) increase in #COVID19 mortality rate for every 1Œºg/m^3 increase in the averaged long-term‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@viralvideovlogs,RT @martablangiardo: Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@PaulNatsuo,RT @martablangiardo: Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@infrahumano,RT @martablangiardo: Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@dan_p_simpson,RT @martablangiardo: Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@AnastasiaNat57,"RT @konstantinoudis: We found a 0.5% (-0.2%, 1.2%) increase in #COVID19 mortality rate for every 1Œºg/m^3 increase in the averaged long-term‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@orrortega,RT @martablangiardo: Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@martablangiardo,Our high-resolution spatial model to investigate the relationship between long term air pollution exposure (NO2 and PM2.5) and COVID-19 mortality is available as preprint. #COVID19 #AirPollution @konstantinoudis @t_padellini
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@futurepundit,"Air pollution is bad   Findings: We find a 0.5% (95% credible interval: -0.2%-1.2%) and 1.4% (-2.1%-5.1%) increase in COVID-19 mortality rate for every 1Œºg/m3 increase in NO2 and PM2.5 respectively, after adjusting for confounding and spatial autocorrelati"
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@SciscoreReports,The paper ‚ÄúLong-term exposure to air-pollution and COVID-19 m...‚Äù (https://t.co/brXD3nzXjx) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/InRXNwGZtz. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@staub_bernice,"RT @konstantinoudis: We found a 0.5% (-0.2%, 1.2%) increase in #COVID19 mortality rate for every 1Œºg/m^3 increase in the averaged long-term‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@t_padellini,"üîÖüîÖProud to presentüîÖüîÖ  Long term air pollution exposure effect on #COVID19 mortality with the longest observation period (!) the finest spatial resolution (!!!) to date!   With @konstantinoudis, @martablangiardo (& great people not on twitter)"
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@konstantinoudis,"We found a 0.5% (-0.2%, 1.2%) increase in #COVID19 mortality rate for every 1Œºg/m^3 increase in the averaged long-term exposure to NO2. The effect of PM2.5 is more uncertain. #AirPollution @C_Althaus @nicolamlow @eggersnsf https://t.co/5nchGJhreE"
http://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,@medrxivpreprint,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis  https://t.co/emSiEKSrUM #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@BasienqaL,"RT @Kto72102356: pomimo niewielkiej liczby badanych pacjent√≥w, telmisartan ARB, lek przeciwnadci≈õnieniowy, podawany w du≈ºych dawkach, wykaz‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NG20194,@mvankerkhove @doctorsoumya @MoHFW_INDIA @drharshvardhan @DrHVoffice @DrMikeRyan @WHO @DrTedros
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@das_seed,"@NG20194 @SmitaKale13 @ICMRDELHI @AskDrShashank @pash22 @ProfBhargava @PremnathV6 May deserve chance for WHO solidarity trial, lets see.   Preliminary data is from an open-label randomized phase II clinical trial for evaluation of #telmisartan in COVID-19"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NG20194,@SmitaKale13 @ICMRDELHI @AskDrShashank @pash22 @das_seed @ProfBhargava @PremnathV6
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@__ice9,@ABsteward https://t.co/bj9w9vAFXc
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NG20194,@farid__jalali
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NG20194,@Dharmen46587056 @ishan_bhupendra
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NG20194,@abledoc @__ice9
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@EasyPeasy_3,"RT @__philipn__: First ARB RCT returns prelimary results w/ small # pts. ‚ÄúTelmisartan, a well-known inexpensive safe antihypertensive drug,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Kto72102356,"pomimo niewielkiej liczby badanych pacjent√≥w, telmisartan ARB, lek przeciwnadci≈õnieniowy, podawany w du≈ºych dawkach, wykazuje dzia≈Çanie przeciwzapalne i poprawƒô chorobowo≈õci u hospitalizowanych pacjent√≥w zaka≈ºonych SARS -CoV-2"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@julienpotet,"RT @__philipn__: First ARB RCT returns prelimary results w/ small # pts. ‚ÄúTelmisartan, a well-known inexpensive safe antihypertensive drug,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@gordonmturner,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Telmisartan for treatment of Covid-19 patients: an open randomized clinical‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@outbreaksci,"Contribute a rapid review or request one for ""Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Pre..."" (https://t.co/qrfZMI5Nhu). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20167205) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@outbreaksci,New #SARSCoV preprint: Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report. https://t.co/qrfZMI5Nhu
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@MassatoHirai,"RT @__philipn__: First ARB RCT returns prelimary results w/ small # pts. ‚ÄúTelmisartan, a well-known inexpensive safe antihypertensive drug,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Roshan_Karia,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@dronico,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@BaskettRalph,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@dronico,@BonellC
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@dronico,"RT @__philipn__: First ARB RCT returns prelimary results w/ small # pts. ‚ÄúTelmisartan, a well-known inexpensive safe antihypertensive drug,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@maureviv,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@MicrobLog_me_uk,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@BenNavarrete,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@ZeroCircle2,RT @fdzaraf: È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@dochawking,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Xcraft226,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Pekinno_okayu,RT @fdzaraf: È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@trsasa13,RT @fdzaraf: È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@ppaapp100,RT @fdzaraf: È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@rora_boceng,Ciyuus ni....remdesevir mahal tu kalah ma obat tu?
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@kiyun38580221,RT @fdzaraf: È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@qrPovpz8L33YIcW,RT @fdzaraf: È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NimaPatelShori,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@fdzaraf,È´òË°ÄÂúß„ÅÆÊ≤ªÁôÇ„Åß‰ΩøÁî®„Åï„Çå„ÇãÂÆâ‰æ°„ÅßÂÆâÂÖ®ÊÄß„ÅÆÈ´ò„ÅÑARB„ÄÅ #„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥ „ÇíÈ´òÁî®ÈáèÊäï‰∏é„Åó„Åü„Å®„Åì„Çç„ÄÅ#Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ ÊÑüÊüìÁóá„ÅÆÂÖ•Èô¢ÊÇ£ËÄÖ„Å´„Åä„ÅÑ„Å¶ÊäóÁÇéÁóá‰ΩúÁî®„Å®ÁΩπÊÇ£Áéá„ÅÆÊîπÂñÑ„ÅåË™ç„ÇÅ„Çâ„Åü„Çà„ÅÜ„Åß„Åô„ÄÇ  COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºö ÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫ÂåñËá®Â∫äË©¶È®ì.ÈÄüÂ†±. https://t.co/6CaGs83sCa
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@JeanmarcBenoit,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@CaetanoManfrini,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@neorevolt,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@__ice9,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@pash22,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@gstanchev,"RT @__philipn__: First ARB RCT returns prelimary results w/ small # pts. ‚ÄúTelmisartan, a well-known inexpensive safe antihypertensive drug,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@__philipn__,"First ARB RCT returns prelimary results w/ small # pts. ‚ÄúTelmisartan, a well-known inexpensive safe antihypertensive drug, administered in high doses, demonstrates anti-inflammatory effects and improved morbidity in hospitalized patients‚Äú. https://t.co/vfF"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@TheSportsJD,@richardursomd add another cheap drug to the list of potential COVID game changers.
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AyferAli5,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@zakkohane,"ACE-blocker trial @medrxivpreprint https://t.co/R8kQxSIzKY parallel group, randomized, two arm, open label: appears to reduce CRP, perhaps faster recover. No diff on ICU admission or mortality."
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@venkmurthy,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@ShelleyZieroth,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@mfkuepp,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@hswapnil,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AZLD501,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@GarCasey,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Gavin_White07,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@DrAntoniSerraT1,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@branemark1,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@joex92_,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@netoalmeidabjj,RT @Covid19Crusher: Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Covid19Crusher,Preliminary reading from small (n=78) randomized trial from Argentina shows anti-inflammatory benefit of generic antihypertensive telmisartan that enables 6 days faster hospital discharges. Remdesivir was at 4 days. No benefit on ICU admission or death. ht
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@ArdenBarry,"RT @Ricky_Turgeon: It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Ricky_Turgeon,"It looks like we have the (preliminary, preprint) results of our first RCT of renin-angiotensin blockers for the treatment of COVID-19. Some of my early thoughts 1/  https://t.co/htEMW2lonf"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Valueinvestor41,@__ice9  wasn't sure if this was on your follow list :) small rct
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@caroairiau,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@epidatum,#Telmisartan for treatment of #COVID19 patients: an open randomized clinical trial. Preliminary report  Analysis of time to discharge by Kaplan-Meier method showed that telmisartan treated patients had statistically significant lower time to discharge. htt
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@anahita70779373,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@KNRXRX,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@ajv67,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@louvetou,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@BertrandBio,@daltonprice386 Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report. https://t.co/pE4nooSedK
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AbdTahrani,RT @kamleshkhunti: ARB telmisartan in high doses demonstrates anti-inflammatory effects & reduced number of days hospitalised with #COVID-1‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Dawn100,RT @kamleshkhunti: ARB telmisartan in high doses demonstrates anti-inflammatory effects & reduced number of days hospitalised with #COVID-1‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Dopey_72F,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report ‚Äì medRxiv  https://t.co/yD5Ld7b6bb
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@VaqueroManu,RT @rubencotoh: Anda que como al final los ARA-II e IECA acaben formando parte del tratamiento...
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@NicolodeGroot,Another #tolicizumab null result. It seems to fade together with #hydroxychloroquine. Hopeful results from #leronlimab and cheap new kid on the block #telmisartan https://t.co/9IlQWvhg9A . BCG booster did well as prophylaxis in the Emirates.
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AmarPut,RT @kamleshkhunti: ARB telmisartan in high doses demonstrates anti-inflammatory effects & reduced number of days hospitalised with #COVID-1‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@drpatrickholmes,RT @kamleshkhunti: ARB telmisartan in high doses demonstrates anti-inflammatory effects & reduced number of days hospitalised with #COVID-1‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@kamleshkhunti,ARB telmisartan in high doses demonstrates anti-inflammatory effects & reduced number of days hospitalised with #COVID-19   Small Open label RCT  https://t.co/aaIZbob1jl https://t.co/5DqGGVF7Gm
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Alzhacker,COVID-19ÊÇ£ËÄÖ„Å´ÂØæ„Åô„Çã„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥„ÅÆÊ≤ªÁôÇÔºöÈùûÂÖ¨ÈñãÁÑ°‰ΩúÁÇ∫ÂåñËá®Â∫äË©¶È®ì„ÄÄÈÄüÂ†±  „ÉÜ„É´„Éü„Çµ„É´„Çø„É≥Êäï‰∏éÁæ§„Åß„ÅØÈÄÄÈô¢„Åæ„Åß„ÅÆÊúüÈñì„ÅåÁµ±Ë®àÂ≠¶ÁöÑ„Å´ÊúâÊÑè„Å´Áü≠Á∏Æ„Åï„Çå„ÅüÔºàÈÄÄÈô¢„Åæ„Åß„ÅÆÊúüÈñì‰∏≠Â§ÆÂÄ§„ÅØÂØæÁÖßÁæ§Ôºö15Êó•„ÄÅ„ÉÜ„É´„Éü„Çµ„É´„Çø„É≥Êäï‰∏éÁæ§Ôºö9Êó•Ôºâ„ÄÇ ICU„Å∏„ÅÆÂÖ•Èô¢„ÇÑÊ≠ª‰∫°„Å´„Å§„ÅÑ„Å¶„ÅØÂ∑Æ„ÅØË™ç„ÇÅ„Çâ„Çå„Å™„Åã„Å£„Åü„ÄÇ https://t.co/Z2uE7sS9LQ
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@khenmikhael,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@IDstewardship,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Rcaballeroc94,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@rmchavin,"8-4-2020:  In a clinical study released today from Argentina, ACE inhibitors & ARBs, Micardis (telmisartan) included, cause birth defects but are the healthiest, not only for lowering blood pressure, but also for surviving COVID-19: https://t.co/38xR4G"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Alergiacucuta1,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AllergyNet,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@mamenpreventiva,RT @rubencotoh: Anda que como al final los ARA-II e IECA acaben formando parte del tratamiento...
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@rubencotoh,Anda que como al final los ARA-II e IECA acaben formando parte del tratamiento...
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Israa54890595,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@TrubianoJason,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@SciscoreReports,The paper ‚ÄúTelmisartan for treatment of Covid-19 patients: an...‚Äù (https://t.co/dKmQoIJMVb) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/5I3tNSRo6l. We detected 2 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@drrongaldamez,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@SPILF_,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@galkabador,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AndyStringer,"Hmmm... interesting. So an ARB inhibitor (Telmisartan) may be beneficial (anti-inflammatory effects and improved morbidity) in treating #COVID19. Small study (n=78, 40 drug, 38 not), early days, but promising. #preprint https://t.co/d24kqrQMw0"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@kevinmb01,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@jquinteromd,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@AB_IDPharmD,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@Dr_J_Underwood,Interesting but too few to be true. Needs a bigger trial.
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@jaialv01,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@adolfo7777,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@pulmonology101,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@joursansfin,"RT @ABsteward: ‚õîPreprint‚õî Telmisartan ""80mg bid"" for treatment of #COVID19 patients: an open RCT. Preliminary Report 78 pts. Statistically‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167205,Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.,@josepmerid,#telmisartan
http://medrxiv.org/cgi/content/short/2020.08.10.20172361,Probability of elimination for COVID-19 in Aotearoa New Zealand,@SciscoreReports,The paper ‚ÄúProbability of elimination for COVID-19 in Aotearo...‚Äù (https://t.co/MwTPwShUbK) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/NJIlIP8AeQ. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20172361,Probability of elimination for COVID-19 in Aotearoa New Zealand,@medrxivpreprint,Probability of elimination for COVID-19 in Aotearoa New Zealand  https://t.co/EFPQj9OZUl #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@outbreaksci,"Contribute a rapid review or request one for ""Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa"" (https://t.co/aOeJl237vi). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20172049) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@outbreaksci,New #SARSCoV preprint: Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa https://t.co/aOeJl237vi
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@outbreaksci,"Contribute a rapid review or request one for ""Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa"" (https://t.co/aOeJl1Lw6I). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.20172049) at https://t.co/RnurTKM2ac @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@outbreaksci,New #COVID19 preprint: Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa https://t.co/aOeJl237vi
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@SciscoreReports,The paper ‚ÄúApplication of Optimal Control to Long Term Dynami...‚Äù (https://t.co/GE95nIX4HT) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/A17QRac2x6. We detected 6 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@William39684229,medrxiv viewer https://t.co/TKdQrPBdGD
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@William39684229,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa https://t.co/TYz9L39dI0
http://medrxiv.org/cgi/content/short/2020.08.10.20172049,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa,@medrxivpreprint,Application of Optimal Control to Long Term Dynamics of COVID-19 Disease in South Africa  https://t.co/EkIqmR0fw6 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171553,On the numbers of infected and deceased in the second Corona wave,@SciscoreReports,The paper ‚ÄúOn the numbers of infected and deceased in the sec...‚Äù (https://t.co/W5NLYiQXV2) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/bdTn85zNLg. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171553,On the numbers of infected and deceased in the second Corona wave,@medrxivpreprint,On the numbers of infected and deceased in the second Corona wave  https://t.co/QJDqLvFt0a #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20172320,Effective reproduction number for COVID-19 in Aotearoa New Zealand,@SciscoreReports,The paper ‚ÄúEffective reproduction number for COVID-19 in Aote...‚Äù (https://t.co/hho8bhPECj) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/FwMrL9BJla. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.10.20172320,Effective reproduction number for COVID-19 in Aotearoa New Zealand,@medrxivpreprint,Effective reproduction number for COVID-19 in Aotearoa New Zealand  https://t.co/d7iLrRXCra #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,@clifford0584,RT @andrewleedr: Early results from PRIEST Study - a multicenter observational cohort study of patients attending UK Emergency Departments.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,@andrewleedr,Early results from PRIEST Study - a multicenter observational cohort study of patients attending UK Emergency Departments.  Profile of ED attenders here: https://t.co/NQZCnDfdl4 @ScHARRSheffield  1/...
http://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,@Triagemonkey,"The PRIEST study of UK ED presentations of patients with COVID has released its preprint. Not peer-reviewed yet, but fascinating read - lots of important new findings. Well done to all the hospitals that contributed, and the whole study team.  https://t.co"
http://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,@SciscoreReports,The paper ‚ÄúCharacterisation of 22446 patients attending UK em...‚Äù (https://t.co/NU9O2UW8lJ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/7nfTfFauNC. We detected 2 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,@medrxivpreprint,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study  https://t.co/cCqxphymOw #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@karen_goudie,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@estelais,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@SDelprato,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@thakkar_samarth,RT @outbreaksci: New #COVID19 preprint: A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@thakkar_samarth,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@thakkar_samarth,RT @medrxivpreprint: A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@parthaskar,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@mmamas1973,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@_Smiorgan_,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@a_saratzis,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@drpatrickholmes,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@AnastasiaSMihai,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@AbdTahrani,RT @kamleshkhunti: Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@kamleshkhunti,Systematic Review of the Cardiovascular Manifestations & Outcomes of #COVID-19 https://t.co/dfTp1HropX @ProfKausikRay @AnastasiaSMihai https://t.co/tNHi6VbGTF
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@outbreaksci,"Contribute a rapid review or request one for ""A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting o..."" (https://t.co/TfAgoovjf0). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20171330) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@outbreaksci,New #COVID19 preprint: A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease https://t.co/TfAgoovjf0
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@DrShariff_M,RT @thakkar_samarth: Our pre-print featuring a systematic review on #cardiovascular manifestations and #outcomes due to #COVID19 #cardiotwi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@DrDeese99,@abhishek_mbbs @drmulpuru @thakkar_samarth Awesome work Sam! @MayoClinicCV @drpaulfriedman @DrTomEP
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@MJorge__JMB38,"RT @carioca_garota: @AlessandroLoio2 Dr. Alessandro, as recentes descobertas apontam para poss√≠vel envolvimento card√≠aco como sequela da co‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@DrKumar_A,RT @thakkar_samarth: Our pre-print featuring a systematic review on #cardiovascular manifestations and #outcomes due to #COVID19 #cardiotwi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@EvidenceRobot,RT @SciscoreReports: The paper ‚ÄúA Systematic Review of the Cardiovascular Manifest...‚Äù (https://t.co/osQusMyU5P) has been reviewed by a set‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@EvidenceRobot,RT @thakkar_samarth: Our pre-print featuring a systematic review on #cardiovascular manifestations and #outcomes due to #COVID19 #cardiotwi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@SciscoreReports,The paper ‚ÄúA Systematic Review of the Cardiovascular Manifest...‚Äù (https://t.co/osQusMyU5P) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Dk0Y9tKOsT. We detected 1 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@thakkar_samarth,Our pre-print featuring a systematic review on #cardiovascular manifestations and #outcomes due to #COVID19 #cardiotwitter #MedTwitter https://t.co/ygObraoAkM @DrDeese99 @DrKumar_A @DrShariff_M https://t.co/GAW4QbfVcn
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@schouschou65,RT @medrxivpreprint: A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@CHOMES102,RT @medrxivpreprint: A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@mariliacoutoesi,"RT @carioca_garota: QUEM TEM UMA SEQUELA CARD√çACA DA COVID, O QUE ACONTECER√Å SE USAR M√ÅSCARAS? POL√çTICOS QUE OBRIGAM TEM QUE TER ESSAS RESP‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@carioca_garota,"@AlessandroLoio2 Dr. Alessandro, as recentes descobertas apontam para poss√≠vel envolvimento card√≠aco como sequela da covid, em raz√£o de infec√ß√£o direta do mioc√°rdio e inflama√ß√£o sist√™mica. QUAIS SERIAM OS RISCOS do USO DE M√ÅSCARAS para pessoas com sequelas"
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@carioca_garota,"QUEM TEM UMA SEQUELA CARD√çACA DA COVID, O QUE ACONTECER√Å SE USAR M√ÅSCARAS? POL√çTICOS QUE OBRIGAM TEM QUE TER ESSAS RESPOSTAS!  ""principal hip√≥tese de envolvimento manifest. cardiovasculares √© por infec√ß√£o direta do mioc√°rdio e inflama√ß√£o sist√™mica(...)"" ht"
http://medrxiv.org/cgi/content/short/2020.08.09.20171330,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease,@medrxivpreprint,A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease  https://t.co/g8bYdvo16q #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@outbreaksci,"Contribute a rapid review or request one for ""Sensitivity, specificity and predictive values of molecular and serological tests for ..."" (https://t.co/FG2az6rHRA). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20171355) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@outbreaksci,"New #SARSCoV preprint: Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room. https://t.co/FG2az6rHRA"
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@outbreaksci,"Contribute a rapid review or request one for ""Sensitivity, specificity and predictive values of molecular and serological tests for ..."" (https://t.co/FG2az6rHRA). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20171355) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@outbreaksci,"New #COVID19 preprint: Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room. https://t.co/FG2az6rHRA"
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@Bill32967247,È†ëÂºµ„ÇåNZ!
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@Lilythiyotan,RT @hichachu: RT-PCRÊ§úÊüª„ÅÆÁ≤æÂ∫¶„ÅØÊßò„ÄÖ„ÄÇ COVID-19„ÅåÁñë„Çè„Çå„ÇãÁóá‰æã„Å´„ÅØË®∫Êñ≠Ê§úÊüª„ÅÆÁ≤æÂ∫¶„Åå‰∏çÂèØÊ¨†„ÄÇSARS-CoV-2ÊÑüÊüìÁóá„ÅÆË®∫Êñ≠„ÅÆ„Åü„ÇÅ„ÅÆÂàÜÂ≠êÊ§úÊüª„ÄÅË°ÄÊ∏ÖÂ≠¶ÁöÑÊ§úÊüª„ÅÆÊÑüÂ∫¶ÔºåÁâπÁï∞Â∫¶ÔºåÈôΩÊÄß„ÉªÈô∞ÊÄß‰∫àÊ∏¨ÂÄ§ÔºàPPV„Åä„Çà„Å≥NPVÔºâ„ÇíË©ï‰æ°„Åô„Çã„Åì„Å®„ÇíÁõÆÁöÑ„Å®„Åó„Åü„ÄÇÊàê‰∫∫ÊÇ£ËÄÖË®à 34‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@hichachu,RT-PCRÊ§úÊüª„ÅÆÁ≤æÂ∫¶„ÅØÊßò„ÄÖ„ÄÇ COVID-19„ÅåÁñë„Çè„Çå„ÇãÁóá‰æã„Å´„ÅØË®∫Êñ≠Ê§úÊüª„ÅÆÁ≤æÂ∫¶„Åå‰∏çÂèØÊ¨†„ÄÇSARS-CoV-2ÊÑüÊüìÁóá„ÅÆË®∫Êñ≠„ÅÆ„Åü„ÇÅ„ÅÆÂàÜÂ≠êÊ§úÊüª„ÄÅË°ÄÊ∏ÖÂ≠¶ÁöÑÊ§úÊüª„ÅÆÊÑüÂ∫¶ÔºåÁâπÁï∞Â∫¶ÔºåÈôΩÊÄß„ÉªÈô∞ÊÄß‰∫àÊ∏¨ÂÄ§ÔºàPPV„Åä„Çà„Å≥NPVÔºâ„ÇíË©ï‰æ°„Åô„Çã„Åì„Å®„ÇíÁõÆÁöÑ„Å®„Åó„Åü„ÄÇÊàê‰∫∫ÊÇ£ËÄÖË®à 346 ‰æã„ÇíÁôªÈå≤„ÄÇ6 Á®ÆÈ°û„ÅÆÈÅ∫‰ºùÂ≠êÊ®ôÁöÑ„ÇíÂê´„ÇÄ   https://t.co/ABnEuD79hg
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@SciscoreReports,"The paper ‚ÄúSensitivity, specificity and predictive values of...‚Äù (https://t.co/yTcugHWrRa) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/FltpyrCx9W. We detected 1 of 5 rigor criteria and 3 key resources."
http://medrxiv.org/cgi/content/short/2020.08.09.20171355,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.",@medrxivpreprint,"Sensitivity, specificity and predictive values of molecular and serological tests for COVID-19. A longitudinal study in emergency room.  https://t.co/P2493QBhXP #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@DVaninsberghe,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@outbreaksci,"Contribute a rapid review or request one for ""Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates"" (https://t.co/ZgtRG9zAac). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20170456) at https://t.co/RnurTL3DyM @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@outbreaksci,New #SARSCoV preprint: Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates https://t.co/ZgtRG9zAac
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@LTMorran,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@nicvega1,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@Alicia_Kraay,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@PrernaArora08,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@EpiPoopologist,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@dkenned11,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@brent_allman,My awesome colleagues in the @KoelleLab just wrote up a paper on SARS-CoV-2 vaccination modelling that you probably want to read! Nice work @MollyEFG and @ajsieben
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@MollyEFG,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@andreashandel,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@kbratnelson,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@B_Lopman,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@ajsieben,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@m_a_martin,"RT @KoelleLab: Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@KoelleLab,"Our latest article, on the importance of considering indirect vaccine benefits when evaluating SARS-CoV-2 vaccine candidates, is now up on MedRxiv. Led by @MollyEFG with @ajsieben, @kbratnelson, @Alicia_Kraay, @B_Lopman, and @andreashandel https://t.co/2kE"
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@SciscoreReports,The paper ‚ÄúConsidering indirect benefits is critical when eva...‚Äù (https://t.co/ZOS8toVTiN) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/b6hadpwK9J. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170456,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates,@medrxivpreprint,Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates  https://t.co/mIKyGxpCNx #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@Barmanns,RT @martiningi: We just published an extremely thorough longitudinal description on COVID-19 symptoms in Iceland https://t.co/KvV4uPoX6P ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@outbreaksci,"Contribute a rapid review or request one for ""The clinical spectrum of COVID-19: A population-based cohort study in Iceland"" (https://t.co/s3VulFesqa). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20171249) at https://t.co/RnurTL3DyM @outbreaksci @PRErevie"
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@outbreaksci,New #SARSCoV preprint: The clinical spectrum of COVID-19: A population-based cohort study in Iceland https://t.co/s3VulFesqa
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@SnArnar,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@eliaseythorsson,@Brief_19 @jeremyfaust You may find our preprint interesting. We prospectively followed a population-based sample of 1797 patients in Iceland. Of those asymptomatic at diagnosis 59% remained asymptomatic - the remaining 41% had symptoms after a median of 3
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@AgnarBjarnason,RT @martiningi: We just published an extremely thorough longitudinal description on COVID-19 symptoms in Iceland https://t.co/KvV4uPoX6P ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@eliaseythorsson,RT @califf001: The 2 graphics at the end are priceless.  This is the product of a coherent health system--a distant aspiration for the U.S.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@bgautijonsson,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@CitizenJoe76,RT @eliaseythorsson: @EricTopol @taraparkerpope @MikaGron @eleanor_lutz @nytgraphics This preprint may interest you. Here we show the sympt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@_eleanorina,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@outbreaksci,"Contribute a rapid review or request one for ""The clinical spectrum of COVID-19: A population-based cohort study in Iceland"" (https://t.co/s3VulFesqa). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20171249) at https://t.co/RnurTL3DyM @outbreaksci @PRErevie"
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@outbreaksci,New #COVID19 preprint: The clinical spectrum of COVID-19: A population-based cohort study in Iceland https://t.co/s3VulFesqa
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@thescratt,RT @bergthorh: Interesting and important #covid study from #iceland https://t.co/6ec7xRvXLq
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@Red_Nec,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@gfj1979,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@HelgasonDadi,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@DukeForge,RT @califf001: The 2 graphics at the end are priceless.  This is the product of a coherent health system--a distant aspiration for the U.S.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@BergssonMD,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@TLaskyPhD,RT @califf001: The 2 graphics at the end are priceless.  This is the product of a coherent health system--a distant aspiration for the U.S.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@bergthorh,Interesting and important #covid study from #iceland https://t.co/6ec7xRvXLq
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@thorirlong,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@felbalazard,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@califf001,The 2 graphics at the end are priceless.  This is the product of a coherent health system--a distant aspiration for the U.S.    . The clinical spectrum of COVID-19: A population-based cohort study in Iceland https://t.co/S5XEvVwhZu
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@eliaseythorsson,"@EricTopol @taraparkerpope @MikaGron @eleanor_lutz @nytgraphics This preprint may interest you. Here we show the symptom development among all Icelanders diagnosed with COVID-19. Prospectively collected data from a population-based sample, using repeated s"
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@JamiePrivratsky,RT @martiningi: We just published an extremely thorough longitudinal description on COVID-19 symptoms in Iceland https://t.co/KvV4uPoX6P ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@SaemundurMD,Longitudinal #COVID19 symptomatology in a nationwide screened cohort. This important and detailed data just published in preprint. Amazing work by @eliaseythorsson @runolfpa @martiningi @HildaLinnet @BjornssonHelgi @Doctorinkitchen and many more! Congrats!
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@ArnarGeirssonMD,RT @martiningi: We just published an extremely thorough longitudinal description on COVID-19 symptoms in Iceland https://t.co/KvV4uPoX6P ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@stefalfreds,RT @martiningi: We just published an extremely thorough longitudinal description on COVID-19 symptoms in Iceland https://t.co/KvV4uPoX6P ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@arnthorjon,The clinical spectrum of #COVID19: A population-based cohort study in #Iceland https://t.co/U40L0Cgawv
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@WildernessEAMed,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@HildaLinnet,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@eliaseythorsson,@WeinbergerDan I choose to 'publish it myself' https://t.co/IVIcMYlu1Q
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@HelgiKB,RT @eliaseythorsson: Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@eliaseythorsson,Have you ever wondered what proportion of patients with COVID-19 have specific symptoms when prospectively followed with repeated structured interviews in a population-based sample? Wonder no more! Our preprint is finally up.  https://t.co/IVIcMYlu1Q
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@martiningi,We just published an extremely thorough longitudinal description on COVID-19 symptoms in Iceland https://t.co/KvV4uPoX6P https://t.co/YOCgAgnamj
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@SciscoreReports,The paper ‚ÄúThe clinical spectrum of COVID-19: A population-ba...‚Äù (https://t.co/ngDQFILrl4) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/KeybnhmnEL. We detected 3 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.09.20171249,The clinical spectrum of COVID-19: A population-based cohort study in Iceland,@medrxivpreprint,The clinical spectrum of COVID-19: A population-based cohort study in Iceland  https://t.co/Gt2X4doy5v #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, infla‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@outbreaksci,"Contribute a rapid review or request one for ""Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory ma..."" (https://t.co/RSmgmqZkzg). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169060) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@outbreaksci,"New #SARSCoV preprint: Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature https://t.co/RSmgmqZkzg"
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@outbreaksci,"Contribute a rapid review or request one for ""Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory ma..."" (https://t.co/RSmgmqZkzg). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169060) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@outbreaksci,"New #COVID19 preprint: Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature https://t.co/RSmgmqZkzg"
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@SciscoreReports,The paper ‚ÄúTocilizumab in hospitalized patients with COVID-19...‚Äù (https://t.co/BVp1q3qSba) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/9JrnMBcjKQ. We detected 1 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@a_1_0_2,"#Tocilizumab did not improve outcomes in hospitalized patients with COVID-19.   ""#Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature""  https://t.co/o2TqvZ2rKK"
http://medrxiv.org/cgi/content/short/2020.08.05.20169060,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature",@medrxivpreprint,"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature  https://t.co/s2bjOcOynz #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@CHOMES102,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@DarthMods,"RT @phil_w888: 778/  UK (adult smoking rate was 14.7% in 2018)  Of 30,437 individuals with C-19, 7.7% were current smokers & 35% were forme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@hershko_vitz,‚Å¶üè≥Ô∏è‚Äçüåà‚Å© ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü: ◊î◊ê◊ù ◊ú◊†◊©◊ê◊ô HIV ◊ô◊© ◊°◊ô◊õ◊ï◊ô ◊í◊ë◊ï◊î ◊ô◊ï◊™◊® ◊ú◊û◊ï◊™ ◊û◊ß◊ï◊®◊ï◊†◊î?
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@EMutengesa,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@BARawitch,RT @Noams_Ark: ◊ò◊ô◊ï◊ò◊™ ◊û◊ó◊ß◊® ◊©◊§◊ï◊®◊°◊û◊î ◊ê◊™◊û◊ï◊ú ◊û◊®◊ê◊î ◊©◊ê◊†◊©◊ô◊ù ◊ó◊ô◊ï◊ë◊ô◊ô◊ù ◊ú-#HIV ◊©◊ê◊ï◊©◊§◊ñ◊ï ◊ë◊í◊ú◊ú #COVID19 ◊õ◊†◊®◊ê◊î ◊ë◊°◊ô◊õ◊ï◊ü ◊û◊ï◊í◊ë◊® ◊ú◊û◊ï◊™ ◊û◊î◊û◊ó◊ú◊î https://t.co/yuoRh2‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@Noams_Ark,"◊ò◊ô◊ï◊ò◊™ ◊û◊ó◊ß◊® ◊©◊§◊ï◊®◊°◊û◊î ◊ê◊™◊û◊ï◊ú ◊û◊®◊ê◊î ◊©◊ê◊†◊©◊ô◊ù ◊ó◊ô◊ï◊ë◊ô◊ô◊ù ◊ú-#HIV ◊©◊ê◊ï◊©◊§◊ñ◊ï ◊ë◊í◊ú◊ú #COVID19 ◊õ◊†◊®◊ê◊î ◊ë◊°◊ô◊õ◊ï◊ü ◊û◊ï◊í◊ë◊® ◊ú◊û◊ï◊™ ◊û◊î◊û◊ó◊ú◊î https://t.co/yuoRh2kEXY  ◊ë◊û◊ó◊ß◊® ◊¢◊ß◊ë◊ï ◊ú◊û◊©◊ö 28 ◊ô◊ï◊ù ◊ê◊ó◊® ◊ê◊†◊©◊ô◊ù ◊©◊ê◊ï◊©◊§◊ñ◊ï ◊ë◊í◊ú◊ú ◊ß◊ï◊®◊ï◊†◊î ◊ë◊û◊ß◊ï◊û◊ï◊™ ◊©◊ï◊†◊ô◊ù ◊ë◊ë◊®◊ô◊ò◊†◊ô◊î. ◊°◊ö ◊î◊õ◊ú ◊¢◊ß◊ë◊ï ◊ê◊ó◊®◊ô 47539 ◊ó◊ï◊ú◊ô◊ù, ◊û◊™◊ï◊õ◊ù 115 ◊î◊ô◊ï ◊ó◊ô◊ï◊ë◊ô"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@darrenabrown,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@MarisolVelaAmi,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@benoit_durand,"RT @phil_w888: 778/  UK (adult smoking rate was 14.7% in 2018)  Of 30,437 individuals with C-19, 7.7% were current smokers & 35% were forme‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@SaviAdikari,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@thenataliejane,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@tristanjbarber,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@Winser_NBueno,RT @Winser_NBueno: Este nuevo #preprint brinda m√°s informaci√≥n sobre los resultados en hospitalizaciones por #COVID19 de pacientes con VIH‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@Winser_NBueno,"Este nuevo #preprint brinda m√°s informaci√≥n sobre los resultados en hospitalizaciones por #COVID19 de pacientes con VIH positivo, frente a los negativos. Hallazgos muy interesantes. La mortalidad en el primer grupo fue mayor. @medrxivpreprint (1/3) https:/"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@ShahzadFaisalMD,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@mugecevik,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@LindaGailBekker,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study https://t.co/zSgtWjES55
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@drlaurajwaters,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@gpollara,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@carolinesabin,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@derekjsloan,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@CGangstamike2,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@BoyzMagazine,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@ImCristiReAn,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@Lupisky,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@antoniosolbe,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@chrisjoe01,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@Romancito40,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@tivalps,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@RALUGAZ,interesante estudio
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@bellyofashark3,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@_jgomez97,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@EduardoRosass,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@CDMX_VIH,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@vihvir,RT @BrendaCrabtreeR: #VIH y #COVID19  Interesantes datos del Reino Unido. https://t.co/shdz2wEqql
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@aquiboy19s,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@johnston_vj,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@FernieMachado,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@HarrisonBAustin,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@unvatoconvih,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@SciscoreReports,The paper ‚ÄúOutcomes of COVID-19 related hospitalisation among...‚Äù (https://t.co/SP86iUjNn4) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/rNqAQ6Zm7i. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@Stormydessert,"RT @dredgarbarragan: La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se e‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@dredgarbarragan,"La personas con VIH no deben sentirse protegidas del COVID-19 por tomar antirretrovirales. En este estudio en UK, se encontr√≥ posible >riesgo de mortalidad en personas hospitalizadas con #VIH y #COVID.üëáüèΩ"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@libokecha,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@JulioCZuniga1,RT @BrendaCrabtreeR: #VIH y #COVID19  Interesantes datos del Reino Unido. https://t.co/shdz2wEqql
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@GuineeTags,RT @BrendaCrabtreeR: #VIH y #COVID19  Interesantes datos del Reino Unido. https://t.co/shdz2wEqql
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@BrendaCrabtreeR,#VIH y #COVID19  Interesantes datos del Reino Unido. https://t.co/shdz2wEqql
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@sophiehkelly,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@chaseledin,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@BritishHIVAssoc,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@GvillaDr,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@phil_w888,113/  https://t.co/nxN6anpHZV
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@phil_w888,"778/  UK (adult smoking rate was 14.7% in 2018)  Of 30,437 individuals with C-19, 7.7% were current smokers & 35% were former smokers  https://t.co/yj1uZU9ryl  Note: some patients included in study in tweet 617  https://t.co/m5H1lV2jgf"
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@schrodingersbe1,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@farahmughal,RT @GerettiAnna: Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered q‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@GerettiAnna,Outcomes of Covid-19 hospitalisation in HIV-positive vs negative patients - interesting findings and some key unanswered questions ‚Å¶@drlaurajwaters‚Å© ‚Å¶@mugecevik‚Å© ‚Å¶‚Å¶@BritishHIVAssoc‚Å© ‚Å¶@HIViBase‚Å© ‚Å¶@carolinesabin‚Å© https://t.co/RG95XhCFOB
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@HarrisonBAustin,Outcomes of #COVID-19 related hospitalisation among people with #HIV in the @ISARIC1 @WHO Clinical Characterisation Protocol UK Protocol: prospective observational study  https://t.co/MkNbuSMaIb
http://medrxiv.org/cgi/content/short/2020.08.07.20170449,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study,@medrxivpreprint,Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study  https://t.co/ThSukVDXUf #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@outbreaksci,"Contribute a rapid review or request one for ""Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic."" (https://t.co/x2ClOoz7oO). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20167957) at https://t.co/RnurTL3DyM @outbreaksci @P"
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@outbreaksci,New #COVID19 preprint: Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic. https://t.co/x2ClOoz7oO
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@donkamion78,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic. https://t.co/e2IPjjKMiA
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@EnferEvidente,"PrePrint made in Extremadura E. Observacional basado en encuesta Uso de mascarilla y cefalea/migra√±a https://t.co/SLAywwnxGl  La aparici√≥n de cefalea ""nueva"" se relaciona con el uso de filtros respiratorios y con categor√≠as profesionales. https://t.co/tpZR"
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@DougYoung2009,A study from a university in Spain that involved a survey of 306 health care workers in a tertiary care hospital found that 51.6% of the workers reported developing a new headache associated with wearing a mask.  https://t.co/rD0WxY3QGO
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@SciscoreReports,The paper ‚ÄúMask-associated de novo headache in healthcare wor...‚Äù (https://t.co/E57PKv4mbX) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/eCJZhZSQXb. We detected 1 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@twellness,RT @medrxivpreprint: Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.  https://t.co/c7lRP5GYik #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20167957,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.,@medrxivpreprint,Mask-associated de novo headache in healthcare workers during the Covid-19 pandemic.  https://t.co/c7lRP5GYik #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170225,Population perspective comparing COVID-19 to all and common causes of death in seven European countries,@PINKYPIE41,RT @PandemicCovid20: Population perspective comparing #COVID19 to all and common causes of death in seven European countries https://t.co/D‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170225,Population perspective comparing COVID-19 to all and common causes of death in seven European countries,@PandemicCovid20,Population perspective comparing #COVID19 to all and common causes of death in seven European countries https://t.co/DLLxL3iGIP
http://medrxiv.org/cgi/content/short/2020.08.07.20170225,Population perspective comparing COVID-19 to all and common causes of death in seven European countries,@SciscoreReports,The paper ‚ÄúPopulation perspective comparing COVID-19 to all a...‚Äù (https://t.co/ElRW3XsA8C) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/zp0L0w126Q. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.07.20170225,Population perspective comparing COVID-19 to all and common causes of death in seven European countries,@medrxivpreprint,Population perspective comparing COVID-19 to all and common causes of death in seven European countries  https://t.co/yTf7WOnOBl #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170548,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic,@lotusgav,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic | medRxiv https://t.co/pzfiWBkFZM
http://medrxiv.org/cgi/content/short/2020.08.07.20170548,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic,@CovidWellbeing,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic https://t.co/BJUkNzBcOi #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.07.20170548,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic,@outbreaksci,"Contribute a rapid review or request one for ""Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic"" (https://t.co/XzAUFCtH11). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20170548) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.07.20170548,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic,@outbreaksci,New #COVID19 preprint: Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic https://t.co/XzAUFCtH11
http://medrxiv.org/cgi/content/short/2020.08.07.20170548,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic,@SciscoreReports,The paper ‚ÄúSocial Media Reveals Psychosocial Effects of the C...‚Äù (https://t.co/mVXfhFrNck) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/gmtddeeYXq. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.07.20170548,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic,@medrxivpreprint,Social Media Reveals Psychosocial Effects of the COVID-19 Pandemic  https://t.co/nvSCPeeaD3 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170183,COVID-19 mortality according to civilian records,@SciscoreReports,The paper ‚ÄúCOVID-19 mortality according to civilian records‚Äù (https://t.co/ze4QrRUOlQ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/xpV10hcrn7. We detected 0 of 5 rigor criteria and 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170183,COVID-19 mortality according to civilian records,@AmericoCunhaJr,The preprint of our paper that investigates the COVID-19 mortality in Brazil by means of civilian records.  medrxiv viewer https://t.co/P5Xxduvm2R
http://medrxiv.org/cgi/content/short/2020.08.07.20170183,COVID-19 mortality according to civilian records,@Thihaza02813773,RT @medrxivpreprint: COVID-19 mortality according to civilian records  https://t.co/OIhPD6vqxF #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170183,COVID-19 mortality according to civilian records,@medrxivpreprint,COVID-19 mortality according to civilian records  https://t.co/OIhPD6vqxF #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170555,Compound risks of hurricane evacuation amid the COVID-19 pandemic in the United States,@chrishendel,Prepare and hold tight.  Cascading Risks of #COVID19 Resurgence During an Active 2020 Atlantic Hurricane Season via @JAMA_current https://t.co/80RiZuHMRj  Compound risks of #hurricane evacuation amid the #COVID19Pandemic in the US via @medrxivpreprint  ht
http://medrxiv.org/cgi/content/short/2020.08.07.20170555,Compound risks of hurricane evacuation amid the COVID-19 pandemic in the United States,@SciscoreReports,The paper ‚ÄúCompound risks of hurricane evacuation amid the CO...‚Äù (https://t.co/6UG7J4gASr) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/lIkCPflwGb. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170555,Compound risks of hurricane evacuation amid the COVID-19 pandemic in the United States,@medrxivpreprint,Compound risks of hurricane evacuation amid the COVID-19 pandemic in the United States  https://t.co/vWIO9yQBDp #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@outbreaksci,"Contribute a rapid review or request one for ""Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching ..."" (https://t.co/zST7nbW5Sr). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20160275) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@outbreaksci,New #SARSCoV preprint: Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals https://t.co/zST7nbW5Sr
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@outbreaksci,"Contribute a rapid review or request one for ""Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching ..."" (https://t.co/zST7nbW5Sr). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20160275) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@outbreaksci,New #COVID19 preprint: Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals https://t.co/zST7nbW5Sr
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@SciscoreReports,The paper ‚ÄúSevere COVID-19 and Diabetes: A Retrospective Coho...‚Äù (https://t.co/X2U7i1P1Nt) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/gJXDnOrpTK. We detected 1 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@phil_w888,"774/  London, UK (adult smoking rate was 13.9% in 2018)  Of 484 hospitalized patients, 39% were current or ex-smokers  Odds of admission to ICU and/or death were not statistically significant  https://t.co/iFmOKeuUxw https://t.co/qXgapFELgB"
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@jsteward2930,RT @medrxivpreprint: Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals  https://t.co/T792mmma‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20160275,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals,@medrxivpreprint,Severe COVID-19 and Diabetes: A Retrospective Cohort Study from Three London Teaching Hospitals  https://t.co/T792mmmaKj #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170001,Switching from algorithm-based to universal admission screening for COVID-19 in hospital settings,@SciscoreReports,The paper ‚ÄúSwitching from algorithm-based to universal admiss...‚Äù (https://t.co/283pNleBVH) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/p5cwsTM3x1. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170001,Switching from algorithm-based to universal admission screening for COVID-19 in hospital settings,@See1Kc,RT @medrxivpreprint: Switching from algorithm-based to universal admission screening for COVID-19 in hospital settings  https://t.co/hT1EqX‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170001,Switching from algorithm-based to universal admission screening for COVID-19 in hospital settings,@medrxivpreprint,Switching from algorithm-based to universal admission screening for COVID-19 in hospital settings  https://t.co/hT1EqXSMj3 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170357,"An Observational Study of COVID-19 from A Large Healthcare System in Northern New Jersey: Diagnosis, Clinical Characteristics, and Outcomes",@CrCdK,"An Observational Study of COVID-19 from A Large Healthcare System in Northern New Jersey: Diagnosis, Clinical Characteristics, and Outcomes https://t.co/OX3Q8MAVlc"
http://medrxiv.org/cgi/content/short/2020.08.07.20170357,"An Observational Study of COVID-19 from A Large Healthcare System in Northern New Jersey: Diagnosis, Clinical Characteristics, and Outcomes",@SciscoreReports,The paper ‚ÄúAn Observational Study of COVID-19 from A Large He...‚Äù (https://t.co/oYSD42yELY) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/eue7Xcvg6I. We detected 1 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.07.20170357,"An Observational Study of COVID-19 from A Large Healthcare System in Northern New Jersey: Diagnosis, Clinical Characteristics, and Outcomes",@phil_w888,"775/  New Jersey, USA (adult smoking rate was 13.1% in 2019)  Of 679 hospitalized patients, 25.5% were former or current smokers  https://t.co/QQCUpIpmO9"
http://medrxiv.org/cgi/content/short/2020.08.07.20170357,"An Observational Study of COVID-19 from A Large Healthcare System in Northern New Jersey: Diagnosis, Clinical Characteristics, and Outcomes",@medrxivpreprint,"An Observational Study of COVID-19 from A Large Healthcare System in Northern New Jersey: Diagnosis, Clinical Characteristics, and Outcomes  https://t.co/d0CiaSBWVe #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@WholeLab,RT @cbauch1: Our model of the impact of student:educator ratios on COVID-19 outbreak size and student-days of closure is now on medRxiv: ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@cbauch1,"Our model of the impact of student:educator ratios on COVID-19 outbreak size and student-days of closure is now on medRxiv: https://t.co/FdyUwkboZL.  Joint work with Madhur Anand @globalecochange, Dillon Browne @WholeLab, and indefatigable PhD student Bren"
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@JacksonASmith,RT @WholeLab: Concerned about class sizes? Also like modeling (the statistical kind)? Our new preprint is for you! Check it out:   https://‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@DrCynthiaMB,RT @WholeLab: Concerned about class sizes? Also like modeling (the statistical kind)? Our new preprint is for you! Check it out:   https://‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@WholeLab,@reginegalanti Check out our preprint on back to school: https://t.co/mbCzgzD6R7
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@WholeLab,Concerned about class sizes? Also like modeling (the statistical kind)? Our new preprint is for you! Check it out:   https://t.co/mbCzgzD6R7 #school #COVID19 #teacher #classroom #SchoolReopening
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@SciscoreReports,The paper ‚ÄúModel-based projections for COVID-19 outbreak size...‚Äù (https://t.co/6nJN7X3OKV) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Dkjp3WkeEd. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170407,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools,@medrxivpreprint,Model-based projections for COVID-19 outbreak size and student-days lost to closure in Ontario childcare centres and primary schools  https://t.co/fQkv4ArV0Q #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@ruuunRich,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@rachomics,RT @alanmcn1: 80 clinical samples. That‚Äôs the data in this preprint. 80. No extensive testing of barcode cross over at high multiplexing. N‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@minouye271,RT @alanmcn1: 80 clinical samples. That‚Äôs the data in this preprint. 80. No extensive testing of barcode cross over at high multiplexing. N‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@emmahiacono,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@advanced_oxford,üëçüëè@nanopore
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@colindaven,"RT @Sisseljuul: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing htt‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@PgpMartin,"RT @Sisseljuul: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing htt‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@JHinkley24,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""LamPORE: rapid, accurate and highly scalable molecular screening for SARS-Co‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@DavidWorrall6,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@c_rands,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@outbreaksci,"Contribute a rapid review or request one for ""LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infect..."" (https://t.co/setmmTDiSW). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20161737) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@outbreaksci,"New #SARSCoV preprint: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing https://t.co/setmmTDiSW"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@markessexrivers,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@techno_row,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Jonno_Dales,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@MophDog,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@michael_s_scott,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@EllardSian,"RT @Sisseljuul: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing htt‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@RoryOB99,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@waynp,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@KenPenton,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@dcbcherrygate,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@nicknav1,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@G_Politic,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@AdrienLeger2,RT @ewanbirney: Breaking my twitter fast to retweet this! Great to see this coming out from the @nanopore team and I know the external vali‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@SarahBr59524756,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@MARKEYE,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@EDISON_Fungi,"RT @strnr: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection based on nanopore sequencing https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@drpaulitious,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@JohnBowyer6,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@FaisanFasaaa,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@jonnytheobald,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Mark_Farrington,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@kevinrw536,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@byboshir,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@francjwood,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@MMio76,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@timneigh,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@RobertBarton_,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@leemoss9,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@AfMediation,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@PhotoLawn,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@EENIMAC,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Chrisballingall,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Hummussy,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@makawlee,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@for_irony,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@BenedictRogers3,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Kiranyek,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@DrAlexLTurner,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@ArtsCombined,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@neil13666,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@tubafoon,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@RussWakefield86,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@james_bb,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@aphotogncworld,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@_LizToday,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@jacknannini,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@NorthForRory,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@MsGertie_,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@yo_segal,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@alexbuchanan,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@round_windows,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@two_30,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Fionadalton3,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@jonhgurr,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@SiNorthWales,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@side0180,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@tolkric,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@PogualPuss,RT @nanopore: We‚Äôre delighted to share this preprint describing the LamPORE method. The @nanopore team and external collaborators have been‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@PogualPuss,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@CondelynneLynne,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@lijinlinwhu,"RT @strnr: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection based on nanopore sequencing https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@rosetoot,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@markep_photo,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@jeffgreen73,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@VinaigretteGirl,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@jafellowsyates,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@jorallan,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@RMITBioinfo,RT @nanopore: We‚Äôre delighted to share this preprint describing the LamPORE method. The @nanopore team and external collaborators have been‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@HYHMD,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@Maw2Tu,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@TJesse62,"RT @Sisseljuul: LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing htt‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@SteveJonesnono1,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@maelysdervenn,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@MBRMark,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@staringatclouds,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@IzzetYenibayrak,RT @genperisi: Simdi #test ekosistemi degisecek. #SARSCoV2  Acaba TRde kullanilan test'in external validation datasini da bir gun gorur muy‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@chrisbu03352910,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@FSantosAlex,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing  https://t.co/cLzg8oZ4Kv"
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@bhrenton,Great work on this promising new sequencing method for Covid-19 tests!
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@HelenNadine2,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@crlsal0508,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@soundcube,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@mackemrich,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@duduschka,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@KevinADavies,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@RidingtheGoblin,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20161737,"LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing",@drnickmann,RT @AdamRutherford: Here is an academic (preprint) paper describing the methods in the DNA sequencing tech for one of the two companies tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170498,Management Strategies for People Experiencing Sheltered Homelessness during the COVID-19 Pandemic: Clinical Outcomes and Costs,@SciscoreReports,The paper ‚ÄúManagement Strategies for People Experiencing Shel...‚Äù (https://t.co/IJJXNch5rI) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/wIEJqpNqyS. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.07.20170498,Management Strategies for People Experiencing Sheltered Homelessness during the COVID-19 Pandemic: Clinical Outcomes and Costs,@medrxivpreprint,Management Strategies for People Experiencing Sheltered Homelessness during the COVID-19 Pandemic: Clinical Outcomes and Costs  https://t.co/GVQwPkqvhe #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.08.20170787,Comparative Clinical Outcomes and Mortality in Prisoner and Non-Prisoner Populations Hospitalized with COVID-19: A Cohort from Michigan,@SciscoreReports,The paper ‚ÄúComparative Clinical Outcomes and Mortality in Pri...‚Äù (https://t.co/UAkCJqbyyY) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/YrdEpg5uXd. We detected 2 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.08.20170787,Comparative Clinical Outcomes and Mortality in Prisoner and Non-Prisoner Populations Hospitalized with COVID-19: A Cohort from Michigan,@EdwardHubert4,"RT @phil_w888: 776/  Michigan, USA (adult smoking rate was 18.9% in 2019)  Of 96 prisoners hospitalized with C-19, 3 were active smokers (3‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.08.20170787,Comparative Clinical Outcomes and Mortality in Prisoner and Non-Prisoner Populations Hospitalized with COVID-19: A Cohort from Michigan,@phil_w888,"776/  Michigan, USA (adult smoking rate was 18.9% in 2019)  Of 96 prisoners hospitalized with C-19, 3 were active smokers (3.1%) & 74 were former smokers (77.1%)  Of 569 non-prisoners hospitalized with C-19, 25 were AS (4.4%) & 189 were FS (33.2%)"
http://medrxiv.org/cgi/content/short/2020.08.08.20170787,Comparative Clinical Outcomes and Mortality in Prisoner and Non-Prisoner Populations Hospitalized with COVID-19: A Cohort from Michigan,@medrxivpreprint,Comparative Clinical Outcomes and Mortality in Prisoner and Non-Prisoner Populations Hospitalized with COVID-19: A Cohort from Michigan  https://t.co/dMcsVfoKyU #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@outbreaksci,"Contribute a rapid review or request one for ""Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against CO..."" (https://t.co/qVN2k3KdBM). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20170258) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@outbreaksci,New #SARSCoV preprint: Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. https://t.co/qVN2k3KdBM
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@FanninStudio,"Check out our pre-print research paper to learn why the Brevitest team suggests salivary IgA antibody testing is not only feasible, but can play an essential role in testing for and developing vaccines against COVID-19. https://t.co/ouhWiGYh6z #Science #"
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@outbreaksci,"Contribute a rapid review or request one for ""Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against CO..."" (https://t.co/qVN2k3KdBM). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20170258) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@outbreaksci,New #influenza preprint: Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. https://t.co/qVN2k3KdBM
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@JamesonVoss,RT @medrxivpreprint: Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.  https://t.co/MVj06YCDwG‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@futurepundit,I want more and better biomarkers to predict how well one's body has responded to a vaccine. It would be great to know  how much risk was reduced by a vaccine.
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@gddamnbatmn,@BallouxFrancois What do you think about the potential of mucosal IgA antibodies? Could it be that some people generate mucosal antibodies but not picked up on serosurveys? I've just seen a few studies investigating it. Recently saw this preprint: https://
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@gddamnbatmn,Preprint: Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. https://t.co/aFMoVoz9YV
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@SciscoreReports,The paper ‚ÄúSalivary anti-SARS-CoV-2 IgA as an accessible biom...‚Äù (https://t.co/9YzVozv0Yu) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/b2sTc0apeQ. We detected 1 of 5 rigor criteria and 11 key resource
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@genperisi,RT @medrxivpreprint: Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.  https://t.co/MVj06YCDwG‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20170258,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.,@medrxivpreprint,Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.  https://t.co/MVj06YCDwG #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@outbreaksci,"Contribute a rapid review or request one for ""In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and ..."" (https://t.co/iOzRpjSBWf). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20170043) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@outbreaksci,"Updated #SARSCoV preprint: In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19 https://t.co/iOzRpjSBWf"
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@SciscoreReports,The paper ‚ÄúIn-depth Analysis of Laboratory Parameters Reveals...‚Äù (https://t.co/4ICIbgdzsD) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/4yz2mcezNL. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@vivischuch,"RT @CSBL1: In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@CostaMartinsAG,"RT @CSBL1: In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@CSBL1,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19 https://t.co/RbGMPnceAm"
http://medrxiv.org/cgi/content/short/2020.08.07.20170043,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19",@medrxivpreprint,"In-depth Analysis of Laboratory Parameters Reveals the Interplay Between Sex, Age and Systemic Inflammation in Individuals with COVID-19  https://t.co/BA1sTd7Glf #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bhrenton,A month? That's what the summer was for. Our preprint paper shows that most colleges are woefully unprepared for testing their populations regularly this fall. https://t.co/aHNUBgoYN8
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@outbreaksci,"Contribute a rapid review or request one for ""Markedly heterogeneous COVID-19 testing plans among US colleges and universities"" (https://t.co/T1cDXwM8bo). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.20171223) at https://t.co/RnurTL3DyM @outbreaksci @PREre"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@outbreaksci,New #SARSCoV preprint: Markedly heterogeneous COVID-19 testing plans among US colleges and universities https://t.co/T1cDXwM8bo
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@cchucklee,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@SeismOlliegist,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bonnithefox,"RT @ALUhawaii: Survey of over 500 U.S. college/uni fall testing plans. ""Only 27% of colleges are performing initial re-entry testing at lea‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@chanze47802655,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@twiwanicki,"RT @ALUhawaii: Survey of over 500 U.S. college/uni fall testing plans. ""Only 27% of colleges are performing initial re-entry testing at lea‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@SethLSanders,"RT @ALUhawaii: Survey of over 500 U.S. college/uni fall testing plans. ""Only 27% of colleges are performing initial re-entry testing at lea‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@ALUhawaii,"Survey of over 500 U.S. college/uni fall testing plans. ""Only 27% of colleges are performing initial re-entry testing at least for undergraduates, while an even smaller percentage, 20%, plan to test their communities regularly to some extent."" #OurRiskOurC"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@BugmanTim,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@ALUhawaii,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@USFGAU,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@abidhaque,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@myfairKT,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@diamataro_,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@SaltyCStar,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@RUGradsUnited,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@CAJUAgrads,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@glia_gal_aaa,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@LaplacesDaemon,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@dawnapari,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@SocialistsOfCIT,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@HaleyBauser,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@whitepeoplebad_,RT @CAHgrads: This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@CAHgrads,This damning study of over 500 campus reopening plans (by our very own @faythtan among others!) shows that @Caltech and other universities are prepared to sacrifice their workers' health on a massive scale. For that reason we join the X-campus demands for
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@glia_gal_aaa,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@YvesMulkers,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bobehayes,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@dajmeyer,"See also: @sinabooeshaghi, @faythtan, @bhrenton, @DrZackaryBerger & @lpachter, Markedly heterogeneous #COVID19 testing plans among US colleges & universities https://t.co/nEGOkTmYxe ""We highlight cases of divergence between testing plans and public"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jluton,RT @leonor_sierra: Comparison of college testing plans #UGA folks might be interested in this
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jluton,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@JackTheNeuroEng,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@TisdaleLab,Really fascinating thread. Great work.
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@hyphaltip,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bcwaite,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@HealeyParera,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@Greene_DM,"Oh, federalism"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@AlexWermerColan,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@Benjamin_AtmChm,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@rawreader,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@VinCannataro,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@mochi_masu_masu,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@nataleejo,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@szetoinsitu,RT @PhilippBayer: Every day I am more relieved that I did not listen to the 'you should do a postdoc in the US' advice: The uni might've ki‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jesse_kroll,"Important & depressing study on university reopening plans. As with so much in the US, considerations of health and safety are a strong function of how much $$ a given institution has."
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@yasmmeme,RT @SeismOlliegist: Students and faculty at @Caltech are doing really important work looking at hundreds of #COVID19 college reopening plan‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@caffeinatedkrys,RT @SeismOlliegist: Students and faculty at @Caltech are doing really important work looking at hundreds of #COVID19 college reopening plan‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@coey_elizabeth,Thread::::::::::::
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@RhodeIslandRT,"RT @futurepundit: How other colleges are following Harvard:  11 schools in Massachusetts, three in New York, two in Maine, one in Rhode Isl‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@futurepundit,"How other colleges are following Harvard:  11 schools in Massachusetts, three in New York, two in Maine, one in Rhode Island, and one in Connecticut are all contracting with the Broad Institute to perform their testing."
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@mwt2008,"RT @vfmcneill: ""Our findings reveal that 54% of universities are performing or facilitating some form of COVID-19 testing. Only 27% of coll‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@RandomUTFan,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@RS_McGee,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@big_data_kane,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@vfmcneill,"""Our findings reveal that 54% of universities are performing or facilitating some form of COVID-19 testing. Only 27% of colleges are performing initial re-entry testing at least for undergraduates, while ... 20%, plan to test their communities regularly..."
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@ayirpelle,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@ayirpelle,"RT @jhuber: ""...recent research has converged on the need for easily accessible, frequent testing for colleges to reopen safely."" #FFCE  Ou‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@SuhnyllaKler,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@cbazodi,"An impressive and timely look at #covid testing policies at US universities... Very grateful to be doing a ""#postdoc abroad"" in üá¶üá∫... Sending positive vibes to all my US colleagues getting ready to start what will likely be a crazy semester..."
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@Hypat1aYu,"RT @DrZackaryBerger: I second @lpachter's praise for the incredible work of these amazing students.   Of tertiary importance, but cool none‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@JChrisPires,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@minisciencegirl,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@sarah_reisman,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@Jared_Mamrot,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@arsuaga3,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@PergamIC,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@PhilippBayer,"Every day I am more relieved that I did not listen to the 'you should do a postdoc in the US' advice: The uni might've killed me, and not even cared about it."
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@stormyseas212,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jeremyvancleve,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@NaragonTom,RT @lpachter: I'm not going to lie. It has been painful while working on this to realize how poor my own institution's planning has been. S‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@watermicrobe,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@dgmacarthur,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bpasaniuc,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@leonor_sierra,Comparison of college testing plans #UGA folks might be interested in this
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@caffeinatedkrys,RT @dawnapari: Very thankful for this work and in particular for @faythtan who has also been on the front lines of the student battle for a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@JDon_chembio,"RT @jhuber: ""...recent research has converged on the need for easily accessible, frequent testing for colleges to reopen safely."" #FFCE  Ou‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jstonedotorg,"RT @jhuber: ""...recent research has converged on the need for easily accessible, frequent testing for colleges to reopen safely."" #FFCE  Ou‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bhrenton,"RT @jhuber: ... thoughtful analysis in preprint by @sinabooeshaghi, @faythtan, @bhrenton, @DrZackaryBerger & @lpachter. 2/2  https://t.co/5‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@lpachter,"RT @jhuber: ""...recent research has converged on the need for easily accessible, frequent testing for colleges to reopen safely."" #FFCE  Ou‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jhuber,"... thoughtful analysis in preprint by @sinabooeshaghi, @faythtan, @bhrenton, @DrZackaryBerger & @lpachter. 2/2  https://t.co/5ezYwZpJjE"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@jhuber,"""...recent research has converged on the need for easily accessible, frequent testing for colleges to reopen safely."" #FFCE  Out of 1,226 universities, ~2% so far have a coherent plan & chance of catching occurrences before they become outbreaks.  @Ope"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@windowseat,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@drkatylouiseday,RT @faythtan: University reopening plans should not read like PR statements. Reopening is a serious equity issue both between institutions‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@bhrenton,RT @chrishendel: üëèüëç @bhrenton @Middlebury et al.  Markedly heterogeneous #COVID19 testing plans among US colleges and universities via @med‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@LeftyMcentire,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@leahwrenn,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@curehiv1,RT @lpachter: I'm not going to lie. It has been painful while working on this to realize how poor my own institution's planning has been. S‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@pash22,"RT @bhrenton: Very grateful for the opportunity to work with this team (@lpachter, @sinabooeshaghi, @faythtan and @DrZackaryBerger, along w‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@chrishendel,üëèüëç @bhrenton @Middlebury et al.  Markedly heterogeneous #COVID19 testing plans among US colleges and universities via @medrxivpreprint today https://t.co/NQ9Vi1OvUV
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@DrZackaryBerger,"RT @bhrenton: Very grateful for the opportunity to work with this team (@lpachter, @sinabooeshaghi, @faythtan and @DrZackaryBerger, along w‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@lpachter,"RT @bhrenton: Very grateful for the opportunity to work with this team (@lpachter, @sinabooeshaghi, @faythtan and @DrZackaryBerger, along w‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@noawitheringly,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@noawitheringly,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@neurosenthali,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@hanhanhan_kim,"RT @lpachter: Seemingly chaotic and in some cases incoherent recently announced college reopening statements prompted @sinabooeshaghi, @fay‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@SciscoreReports,The paper ‚ÄúMarkedly heterogeneous COVID-19 testing plans amon...‚Äù (https://t.co/J5SVFcacbR) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/wZWvVc8OvS. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@UmAaup,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@UmAaup,Thread: need to add University of Miami to this database.
http://medrxiv.org/cgi/content/short/2020.08.09.20171223,Markedly heterogeneous COVID-19 testing plans among US colleges and universities,@dmcgilkathome,"RT @CT_Bergstrom: Just out, a report from @lpachter, @bhrenton, @faythtan, @sinabooeshaghi, and @DrZackaryBerger on the shitshow of this au‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169904,Model to Describe Fast Shutoff of CoVID-19 Pandemic Spread,@SciscoreReports,The paper ‚ÄúModel to Describe Fast Shutoff of CoVID-19 Pandemi...‚Äù (https://t.co/4RdUR6FFsC) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Uq3TJOQzKn. We detected 2 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20169904,Model to Describe Fast Shutoff of CoVID-19 Pandemic Spread,@medrxivpreprint,Model to Describe Fast Shutoff of CoVID-19 Pandemic Spread  https://t.co/12vKj2D3oR #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20170035,Quantifying threat from COVID-19 infection hazard in Primary Schools in England,@PandemicCovid20,Quantifying threat from #COVID19 infection hazard in Primary Schools in England https://t.co/sf0fxZ7tuX
http://medrxiv.org/cgi/content/short/2020.08.07.20170035,Quantifying threat from COVID-19 infection hazard in Primary Schools in England,@SciscoreReports,The paper ‚ÄúQuantifying threat from COVID-19 infection hazard...‚Äù (https://t.co/RcqAVLVmFF) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/1zw9COiqj8. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.07.20170035,Quantifying threat from COVID-19 infection hazard in Primary Schools in England,@medrxivpreprint,Quantifying threat from COVID-19 infection hazard in Primary Schools in England  https://t.co/9HzW3LiXoV #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@AmyBaxterMD,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial https://t.co/9bIqj0y8jC FANTASTIC news for a very inexpensive drug!! Surprised this isn't on the news."
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@marcmtk,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bryangrahn,"@P_F_Lherisson_ Haha.  Crazy, eh?  I'm just learning all of this too... Links here:    https://t.co/WvOl1RlSBU  ALSO, smaller data out of Greece and Brazil recently show possible efficacy:    https://t.co/tragX9JKQy https://t.co/r3WWuE4kVK"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@DiodoroCirino,"RT @mab_sp125: Apesar das limita√ß√µes pelo n pequeno, o rigor da metodologia cient√≠fica associados aos resultados positivos com signific√¢nci‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Mareeswj,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@simmian42,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@felipe_fcastro,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@omersharif9,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Plugplugly,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@RoshanaMN,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@MikroSundq,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BlackForext,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ImmunoFever,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@SJR78354712,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@CaesarSalad99,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@NewsAletheia,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@JeffSBennion,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@sclalmeida,"RT @renedroliveira: Trabalho realizado no HC de Ribeir√£o Preto, sobre colchicina para COVID-19. Em plataforma preprint. Aguardando revis√£o‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@semartin,"RT @Covid19Crusher: A third positive study on the benefits of colchicine, through a small (n=35) randomized, double-blinded, placebo-contro‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@MayooranShan,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Valtenio,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@DrAnimeshSingh,Sometimes we just need to use the old & cheap drugs :-)
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@fedemartinon,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@gstanchev,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@zzz_as_zzz,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Xcraft226,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@joex92_,"@docprimum @geekman15 @TroncheBiais @MrSam144 Pour la colchicine, on a d√©j√† 2 RCTs et une r√©trospective positive, et les r√©sultats interm√©diaires de colcorona encourageants. 1)https://t.co/R4rVdCPIEz 2)https://t.co/jRL1KFvTaQ 3)https://t.co/W7R5rrOoi8"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@gpollara,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@mason_042019,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@travelhealthdoc,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bardinidouglas,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@AVKarlsson,"RT @mab_sp125: Apesar das limita√ß√µes pelo n pequeno, o rigor da metodologia cient√≠fica associados aos resultados positivos com signific√¢nci‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@NG20194,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@AVKarlsson,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BertrandBio,"Basically any intervention works in Brazilian trials. At least this one is a double-blind RCT (n=38).  Beneficial effects of colchicine for moderate-severe #COVID19: interim analysis of a randomized, double-blinded, placebo controlled clinical trial https:"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@dvrachatis,Encouraging data for benefits #colchicine on #COVID add up. A small placebo-controlled #RCT from Brazil became available as pre-print a couple of days ago. This is the third study after GRECCO-19 (https://t.co/kM3L9xvQZ0) and the study from Italy (https://
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@HelioTelho,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial | medRxiv https://t.co/de4P5mgATi"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@__ice9,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@PInterim,"Top story: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial | medRxiv https://t.co/djtwGvNdKB, see more https://t.co/Y4GEqveFiL"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@NG20194,@sandhyafernez
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@uberrimaefidei1,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@farid__jalali,RT @__ice9: A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@6D6B6B,"RT @mab_sp125: Apesar das limita√ß√µes pelo n pequeno, o rigor da metodologia cient√≠fica associados aos resultados positivos com signific√¢nci‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@__ice9,"A recent smaller RCT for colchicine in hospitalized COVID-19 cases finds large reductions in need for supplemental oxygen and length of hospital stay for the colchicine group.  No deaths occurred in either group, so mortality effects cannot be assessed in"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@SotiriaGiotaki,"RT @Covid19Crusher: A third positive study on the benefits of colchicine, through a small (n=35) randomized, double-blinded, placebo-contro‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@wuest23,@AnnetteBruchfe1 Och det finns behandlings framg√•ng o b√§ttre routine? Australien: https://t.co/8YNTEmbdpt eller Detta √§r inte klar f√∂r puplikation men kan kanske vara en m√∂jlighet https://t.co/t2Yl7Hz4qL
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Invest_in_ME,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@RebeccaChandle1,RT @BrodinPetter: This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to seve‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BatResearch,A small but useful trial. In combination with other drugs this may be good.
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BrodinPetter,This makes sense! Strong Inflammasome activation is known and now - Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a RCT. Great job ‚Å¶@ZamboniLab‚Å© et al. https://t.co/38RXgRT0KF
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bhardwajutkarsh,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bryangrahn,RT @BrodskyIgor: Intriguing study by @usprp @ZamboniLab and colleagues - possible beneficial effect of colchicine for moderate-to-severe c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@nabeso,@nnago „ÅÑ„Åæ„ÅÆ„Å®„Åì„ÇçÂ∞èË¶èÊ®°RCTÔºë‰ª∂Ôºà„ÇÆ„É™„Ç∑„É£Ôºâ„ÄÅRCT‰∏≠ÈñìÂ†±ÂëäÔºà„Ç´„Éä„ÉÄ„ÄÅ„Éñ„É©„Ç∏„É´Ôºâ„Å£„Åß„Éù„Ç∏„ÉÜ„Ç£„Éñ„Å™„ÅÆ„Åß„Å†„ÅÑ„Å∂ÊúâÂäõ„Å™ÈÅ∏ÊäûËÇ¢„ÅÆ„Çà„ÅÜ„Å´ÊÄù„ÅÑ„Åæ„Åô„ÄÇ  https://t.co/94zBWQhEyV
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@MagooMito,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@JDAlbarnaz,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Deepika_Sharmad,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@becofx,"RT @AlessandroLoio2: ESTUDO RANDOMIZADO  Associa√ß√£o de Colchicina 0,5 mg VO 8/8h ao protocolo terap√™utico contra o covid diminui mortalidad‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@hannysalvarez,"RT @Pineda_shir: Tercer estudio sobre los beneficios de la colchicina, a trav√©s de un peque√±o (n= 35) ensayo aleatorio, doble ciego, contro‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@RodReimer,"RT @Covid19Crusher: A third positive study on the benefits of colchicine, through a small (n=35) randomized, double-blinded, placebo-contro‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@mtcosmo1,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@camilahcoelho,RT @BrodskyIgor: Intriguing study by @usprp @ZamboniLab and colleagues - possible beneficial effect of colchicine for moderate-to-severe c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@CaetanoManfrini,"RT @mab_sp125: Apesar das limita√ß√µes pelo n pequeno, o rigor da metodologia cient√≠fica associados aos resultados positivos com signific√¢nci‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@rmchavin,"8-6-2020:  In a clinical trial released today from Sao Paulo, Brazil, Colcrys (colchicine), which is slightly inferior to corticosteroids for treating gout, performed well against the cytokine storm of mid-stage & end-stage COVID-19 https://t.co/Ab77cx"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@mayer_barber,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@padopat1,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ezra_aksoy,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@NeuciMiatto,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@mab_sp125,@MRZGuara @RibeiroBrunov Sr? Para com isso! Rs Claro  https://t.co/S7Za9iBe4Z
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@alissonpantuza,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bryangrahn,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@misterchambo,RT @ryukidn: cc @misterchambo
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@danipini,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@renedroliveira,"Trabalho realizado no HC de Ribeir√£o Preto, sobre colchicina para COVID-19. Em plataforma preprint. Aguardando revis√£o por pares. https://t.co/IeiP5BwAbe"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@borgesks,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BockmannFlavio,Grande @ZamboniLab! Mais progressos cient√≠ficos alvissareiros no tratamento da COVID-19.
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@SunnyShinLab,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@grawoig,RT @wilsonmessias01: @grawoig New study  https://t.co/a0sVpKnmrL
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BrodskyIgor,Intriguing study by @usprp @ZamboniLab and colleagues - possible beneficial effect of colchicine for moderate-to-severe covid19? Old drug used to treat inflammatory disorders such as gout and FMF - blocks microtubule polymerization and inhibits nlrp3 infl
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@jaqsan1,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ryukidn,cc @misterchambo
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Pia_Hildegard,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@sclalmeida,"RT @mab_sp125: Apesar das limita√ß√µes pelo n pequeno, o rigor da metodologia cient√≠fica associados aos resultados positivos com signific√¢nci‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@AllergyNet,Colchicine for Covid keeps its head above water‚Ä¶just
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@RafaelPolidoro2,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@KevinWNg,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@BrodskyIgor,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@mvlourenco,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@LagaresNephtali,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ComeAgainVicky,"RT @mab_sp125: Apesar das limita√ß√µes pelo n pequeno, o rigor da metodologia cient√≠fica associados aos resultados positivos com signific√¢nci‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ojcius,"RT @ZamboniLab: It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine f‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Cadurevoltz,"RT @AlessandroLoio2: ESTUDO RANDOMIZADO  Associa√ß√£o de Colchicina 0,5 mg VO 8/8h ao protocolo terap√™utico contra o covid diminui mortalidad‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ZamboniLab,"It is online the results of our single-center randomized, double-blinded, placebo controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19 (1/n).  https://t.co/447Ym6TjsM"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@CecideSantos,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@CegoTwitteiro,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bitcoinman99,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@mariluciferraz,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@ev5te9am,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@jeffermanjj,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@bryangrahn,"Can't wait to see more results of this potential treatment @ZamboniLab  Seems promising!    Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial https://t.c"
http://medrxiv.org/cgi/content/short/2020.08.06.20169573,"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial",@Erika52621098,"RT @AiltonBenedito: Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@chrsclrksn,"Work from @Essex_CC , @PHE_uk on COVID19 prevalence in Essex care homes. Very proud of my girlfriend for her involvement in this vital work. https://t.co/8deWrPWdW0"
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@outbreaksci,"Contribute a rapid review or request one for ""Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom"" (https://t.co/jBy3ktkE9s). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20162859) at https://t.co/RnurTL3DyM @outbreaksci @P"
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@outbreaksci,New #SARSCoV preprint: Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom https://t.co/jBy3ktkE9s
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@PandemicCovid20,Whole Care Home Testing for #Covid19 in a Local Authority Area in the United Kingdom https://t.co/9cF6hqAGaU
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@AnnaStarling,RT @medrxivpreprint: Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom  https://t.co/tzYCQOsA0s #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@SciscoreReports,The paper ‚ÄúWhole Care Home Testing for Covid-19 in a Local Au...‚Äù (https://t.co/t1Vqf1sTMo) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/NtfSaf2UF4. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.06.20162859,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom,@medrxivpreprint,Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom  https://t.co/tzYCQOsA0s #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169839,"Expanding COVID-19 symptom screening to retail, restaurants, and schools by preserving privacy using relaxed digital signatures",@SciscoreReports,"The paper ‚ÄúExpanding COVID-19 symptom screening to retail, re...‚Äù (https://t.co/Yo4t9q07xO) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/y8ATNIkwl7. We detected 0 key resources."
http://medrxiv.org/cgi/content/short/2020.08.06.20169839,"Expanding COVID-19 symptom screening to retail, restaurants, and schools by preserving privacy using relaxed digital signatures",@medrxivpreprint,"Expanding COVID-19 symptom screening to retail, restaurants, and schools by preserving privacy using relaxed digital signatures  https://t.co/WPcrJiXeKE #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@LucianaBlancoV,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@masxonrisas,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@cugartegil,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@srecuenco,"RT @olimpia_ch_: Se tiene que seguir trabajando en el control de la Epizootia de rabia en  üê∂ al sur del Per√∫, reinventar las estrategias en‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@zerojuls,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@AnGeLaUyEn,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@claudiamaguina,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@SciscoreReports,The paper ‚ÄúThe impact of the COVID-19 pandemic on rabies reem...‚Äù (https://t.co/wZ3HcxI4Kb) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/WEkrO7qSv4. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@arenica2,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@vidayfuturope,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@JuanArriolaCol1,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@AyceNahomi,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@ricardocasney,RT @OneHealthUPCH: Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimien‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@olimpia_ch_,"Se tiene que seguir trabajando en el control de la Epizootia de rabia en  üê∂ al sur del Per√∫, reinventar las estrategias en tiempos de pandemia es el reto, de lo contrario @OneHealthUPCH muetra cual ser√≠a el impacto"
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@OneHealthUPCH,Nuevo #preprint de nuestro grupo: ‚ÄúEl impacto del #COVID19 en la rabia canina‚Äù.  ¬øC√≥mo afecta la pandemia al resurgimiento de la rabia en üê∂ üêï? La eliminaci√≥n de la rabia de üêï se basa en dos pilares principales... https://t.co/IzOo9sySzg https://t.co/gNjG9W
http://medrxiv.org/cgi/content/short/2020.08.06.20169581,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru",@medrxivpreprint,"The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru  https://t.co/JGErByjVfz #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Argenscore,RT @Argenscore: IMPACT OF THE COVID-19 PANDEMIC: TAVR AND SAVR IN UK  Disminuci√≥n significativa TAVR y RVA durante pandemia (mayor en elect‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@CGAM2016,RT @Argenscore: IMPACT OF THE COVID-19 PANDEMIC: TAVR AND SAVR IN UK  Disminuci√≥n significativa TAVR y RVA durante pandemia (mayor en elect‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@HAbedal,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Babar_Basir,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@mmamas1973,RT @Argenscore: IMPACT OF THE COVID-19 PANDEMIC: TAVR AND SAVR IN UK  Disminuci√≥n significativa TAVR y RVA durante pandemia (mayor en elect‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@SaDeRosa78,"There still much work to Do! One valve, one Life!"
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@jphsmart,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@AnastasiaSMihai,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@CalZole,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@drsophiebauer,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@SciscoreReports,The paper ‚ÄúIndirect Impact of the COVID-19 Pandemic on Activi...‚Äù (https://t.co/5NDdX0DT4X) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/COM7bqhHZd. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Argenscore,IMPACT OF THE COVID-19 PANDEMIC: TAVR AND SAVR IN UK  Disminuci√≥n significativa TAVR y RVA durante pandemia (mayor en electivos).   Estiman 2294 casos de estenosis a√≥rtica grave que no han recibido tratamiento c/estimaci√≥n de entre 46 y 321 muertes mientra
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@AnkurKalraMD,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@wordfinga,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@LynnGreigMiller,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@drandrewsharp,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@wayounihan,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Ortega_Paz,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@JayChance5,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@DocSavageTJU,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@JosipABorovac,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@CastlDalmunzie,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@cpgale3,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Kfarooqi,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@netrix_sky,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@HeartOTXHeartMD,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@BirkhoelzerS,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@adityadoc1,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@ShelleyZieroth,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@rajivxgulati,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Gerrythecynic,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@irisstylosa,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@SarasVallabhMD,Very important observations that will significantly impact our patients in 2020 and years to come. @emoryheart @emory_heart @EmoryHrtSuccess @EmoryCCRI
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@iamritu,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@proftomquinn,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@EmmaKealaher,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@jgloyo,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@TAVRBot,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@seonaidsnail,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@0Calamity,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@mmamas1973,RT @nishat76: Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@nishat76,Very worrying trend of increased mortality due to reduced TAVR & cardiac surgery for severe aortic stenosis during #covid19 pandemic- thanks to @mmamas1973 et al. for the prelim data
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@hvanspall,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@dataevan,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@Argenscore,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@purviparwani,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@rafavidalperez,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@proftomquinn,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@FemAnon1312,RT @mmamas1973: Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@mmamas1973,"Our analysis of UK TAVR and Cardiac surgery during #COVID19 led by @glen_martin1 https://t.co/xln6WWKYPG we estimate 2294 (95% CI 1872, 2716) cases of severe AS who have not received treatment, with between 46 and 321 deaths  while waiting for intervention"
http://medrxiv.org/cgi/content/short/2020.08.05.20168922,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England,@medrxivpreprint,Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England  https://t.co/Avs4k9ruSm #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@outbreaksci,"Contribute a rapid review or request one for ""Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and..."" (https://t.co/O4BuaULsyl). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20151027) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@outbreaksci,New #SARSCoV preprint: Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience https://t.co/O4BuaULsyl
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@lepeuvemartine,#raoult  derni√®re √©tude - sur HCQ patients d√©s√©quilibr√©s entre groupe trait√©  (65) et groupe controle TRES FAIBLE EN NOMBRE (20) AGE HCQ  48 ¬±18 contre 46 ¬±11  COMORBIDITES HCQ 66% contre 40 % SYMPTOMES HCQ 69% contre 15% c 'est sur c'est s√©rieux !!!! http
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@m_4_n_u_,RT @Covid19Crusher: Small (n=85) retrospective Saudi study claims to show the negative impact of hydroxychloroquine+/-azithromycin on viral‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@kksheld,RT @Covid19Crusher: Small (n=85) retrospective Saudi study claims to show the negative impact of hydroxychloroquine+/-azithromycin on viral‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@futurepundit,Conclusion: Hydroxychloroquine (HCQ) and azithromycin delay SARS-CoV-2 virus clearance In hospitalized patients with COVID-19 and it is correlated with older age. Larger studies are needed to confirm this finding.
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@SciscoreReports,The paper ‚ÄúTime to negative PCR from symptom onset in COVID-1...‚Äù (https://t.co/WpQElIHObj) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/5e4NH3iqbS. We detected 2 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@truthismaster,RT @Covid19Crusher: Small (n=85) retrospective Saudi study claims to show the negative impact of hydroxychloroquine+/-azithromycin on viral‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@Covid19Crusher,"Small (n=85) retrospective Saudi study claims to show the negative impact of hydroxychloroquine+/-azithromycin on viral clearance. The huge severity mismatch between the 2 arms is beyond statistical salvation, I'm afraid. https://t.co/NXsvmcPQ2H"
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@jawadjan123,RT @medrxivpreprint: Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world exp‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@sarfraz_saleemi,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience https://t.co/7dh3kISgOy
http://medrxiv.org/cgi/content/short/2020.08.05.20151027,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience,@medrxivpreprint,Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience  https://t.co/W3z0sQDWUe #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20160499,COVID-19 and Mental Health: A Study of its Impact on Students,@CovidWellbeing,COVID-19 and Mental Health: A Study of its Impact on Students https://t.co/oCVMYLMwzC #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.05.20160499,COVID-19 and Mental Health: A Study of its Impact on Students,@SciscoreReports,The paper ‚ÄúCOVID-19 and Mental Health: A Study of its Impact...‚Äù (https://t.co/O9LsgsSrVU) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/X5agf4CwZO. We detected 1 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.05.20160499,COVID-19 and Mental Health: A Study of its Impact on Students,@Marieaaow,#COVID_19 and #MentalHealth: A Study of its Impact on Students | medRxiv https://t.co/En9bbvxhX4
http://medrxiv.org/cgi/content/short/2020.08.05.20160499,COVID-19 and Mental Health: A Study of its Impact on Students,@medrxivpreprint,COVID-19 and Mental Health: A Study of its Impact on Students  https://t.co/Ltl5JEANM6 #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.242156,Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir,@biorxivpreprint,Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir  https://t.co/70TMeyM437 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.242156,Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir,@outbreaksci,New #SARSCoV preprint: Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir https://t.co/RVPgNx9p28
http://biorxiv.org/cgi/content/short/2020.08.07.242156,Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir,@outbreaksci,"Contribute a rapid review or request one for ""Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminate..."" (https://t.co/RVPgNx9p28). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.242156) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.07.242156,Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir,@outbreaksci,New #COVID19 preprint: Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir https://t.co/RVPgNx9p28
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@SciscoreReports,The paper ‚ÄúEbselen Reacts with SARS Coronavirus-2 Main Protea...‚Äù (https://t.co/SRwLNutr7x) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/pbH2CAo19X. We detected 1 of 6 rigor criteria and 0 key resources
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@GSharadaa,@__ice9
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@epidatum,"#Ebselen Reacts with #SARSCoV2 Main Protease Crystals  If #SARSCoV2 3CLpro is inhibited, the functional #virus proteins cannot form and virus cannot replicate and assemble. Diffraction power of 3CLpro crystals is effectively destroyed by Ebselen #COVID19 h"
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@HyphyNova,RT @biorxiv_biophys: Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals  https://t.co/wUd2ZSH0m5 #biorxiv_biophys
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@bxv_biophys,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals https://t.co/HJurzvtm4r
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@biorxiv_biophys,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals  https://t.co/wUd2ZSH0m5 #biorxiv_biophys
http://biorxiv.org/cgi/content/short/2020.08.10.244525,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals,@biorxivpreprint,Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals  https://t.co/faOIc9xdeb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@PaulKlauser,"RT @cole_bracken: Our #COVID work describing our strategy to make neutralizing VH multimers is on @biorxivpreprint. Simple but powerful, th‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@JieZhou55370495,"RT @realJimWells: In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@scientistamy,"RT @cole_bracken: Our #COVID work describing our strategy to make neutralizing VH multimers is on @biorxivpreprint. Simple but powerful, th‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@susanna_elledge,"RT @realJimWells: In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@MartinUCSF,"RT @realJimWells: In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@SportyReb,"RT @cole_bracken: Our #COVID work describing our strategy to make neutralizing VH multimers is on @biorxivpreprint. Simple but powerful, th‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@shionanlim,"RT @realJimWells: In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@ShawnMCostello,"RT @realJimWells: In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@SciscoreReports,The paper ‚ÄúBi-paratopic and multivalent human VH domains neut...‚Äù (https://t.co/Bpikf24OLy) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/aHjMJvroVf. We detected 1 of 6 rigor criteria and 5 key resources
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@helloanum,"RT @realJimWells: In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@cole_bracken,"Our #COVID work describing our strategy to make neutralizing VH multimers is on @biorxivpreprint. Simple but powerful, this multimerization approach can increase neutralization potency against SARS-CoV-2. Amazing work by all involved! https://t.co/bAk4do0g"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@realJimWells,"In our most recent #COVID19 @biorxivpreprint, in collaboration with the #QCRG Structural Biology Consortium, we generated multimers of VH domains that target the ACE2-binding interface of Spike and potently neutralize #SARSCoV2 by binding multiple RBDs. ht"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@epidatum,Bi-paratopic and multivalent human variable heavy domains neutralize #SARSCoV2 by targeting distinct epitopes within the #ACE2 binding interface of Spike #COVID19 https://t.co/wc77at32vx https://t.co/13wKvKdYp7
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@benjamin_n_bell,RT @cryoEM_Papers: Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 bindi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@cryoEM_Papers,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike https://t.co/oiTEZZR2wj
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@eng_papers,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike https://t.co/BNCNMFrnG7
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@biorxivpreprint,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike  https://t.co/IczY6mZXsq #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@outbreaksci,"Contribute a rapid review or request one for ""Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinc..."" (https://t.co/W1fTBthtbK). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.08.242511) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.08.242511,Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike,@outbreaksci,New #SARSCoV preprint: Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike https://t.co/W1fTBthtbK
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@tokan_tansel,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@nomadicwoman1,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@karaer007,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@AyselBilgin13,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@nihals10,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@serkanonair,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@fethiyesonmez23,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@nostrachelios,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Klao_75790609,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@dcelebi_,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@mrlbsr,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@vv_vv_34,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Kayatas,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@ikita661,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@calismailiskisi,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@SonicBubbleBoom,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@SonicBubbleBoom,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@baharumurtak,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@muuuurrrrrrraa1,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@yazsamki,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Drezilya1,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@yarhasret,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@FerhatO59,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@olayyerileydisi,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@zeynkafe,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@mugeerman,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@volkannevrim,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Emine32297438,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@SesSeda_B,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Gzdmir1,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@pearlyblackk,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@gulnurdc,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Aydin_aksy,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@NazKiz2,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@MartinUCSF,"RT @AashishManglik: We're excited to share a preprint from an incredible collaboration between our group, Peter Walter‚Äôs lab, the @QBI_UCSF‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@TuranTurkan,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Sakinetopkaya1,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@normamia4,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@OksayOksay,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@dulkusal,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@ibrahimsarul,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@MuratYAMAN3000,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@alpercuruk,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Bilgekaanguner,"RT @AashishManglik: We're excited to share a preprint from an incredible collaboration between our group, Peter Walter‚Äôs lab, the @QBI_UCSF‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@sbnmx,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@YZDMRGL,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@srhsfk,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@post_restant,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@rumeysaakkoc_,"Heycan verici bir √ßalƒ±≈üma , okumanƒ±zƒ± tavsiye ederim. Sars-Cov-2‚Äôye kar≈üƒ± antikor teknolojisinden bahsediyor.    An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation https://t.co/xCENHEi2hx"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Nihal71120787,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@gokayhazz,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@cs397,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@leylakayhank,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@BasakMagenta,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@NilayYazc,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@suleymanercin,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@70Serpill,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@aysearat1,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Demirhulyaa,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@IshanDeshpande,"Great work by an amazing team led by @AashishManglik, Peter Walter and Michael Schoof. Looking forward to a favorable outcome in clinical trials."
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@AlperKumral,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@drseraperdem,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Freedom1907,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@MehmetK42797742,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Tsieta06,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@KralLor77461504,Hƒ±m. 3 g√ºnd√ºr herkes neler neler buluyor b√∂yle..
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Day_Dreamer_133,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@joyfulearthtr,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@FMuftugil,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Penta1912,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@UgurTekin,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@ChoudharyLab,"RT @AashishManglik: We're excited to share a preprint from an incredible collaboration between our group, Peter Walter‚Äôs lab, the @QBI_UCSF‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@misSarkastik,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Hasanisim,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@fural22,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@sunasaygin1,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@nhrferreira,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@teomanf1,RT @allerjidoktoru: ≈ûu ana kadar √ßok etkili bir anti viral ila√ß tedavisi bulunamayan ve seneyede t√ºm korkutuculuƒüuyla hayatƒ±nƒ±zda olacak CO‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Semtbizim,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Sabarba10163771,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@FgN_ShN,RT @allerjidoktoru: ≈ûu ana kadar √ßok etkili bir anti viral ila√ß tedavisi bulunamayan ve seneyede t√ºm korkutuculuƒüuyla hayatƒ±nƒ±zda olacak CO‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@icodesins,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation  https://t.co/5H26Wd2qj2
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@isaaahishali1,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@denizgumuszade,Umarƒ±m doƒürudur.
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@automediaa,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@FevziYorulmaz9,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@OkanCelebi7,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Due_Orhan,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@mnurikaya,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@Day_Dreamer_133,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@mnlghtttt,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@muzeyyentna,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@aditya_24g,"RT @AashishManglik: We're excited to share a preprint from an incredible collaboration between our group, Peter Walter‚Äôs lab, the @QBI_UCSF‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@johngalttt,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@muzeyyentna,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@GencerKabaroglu,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@deryagibi2000,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@OOkutman,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@deadia35,"RT @DrGunerSonmez: G√ºzel bir haber. Covid 19‚Äôa neden olan #SARSCoV2 nin, h√ºcre giri≈ü kapƒ±sƒ± olan ACE resept√∂rlerine baƒülanmasƒ±nƒ± engelleyen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.08.238469,An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation,@gencertulu,RT @ghotamis: Kaliforniya Universitesinden √ßok heyecan verici bir √ßalƒ±≈üma SARS-CoV-2 vir√ºs√ºne kar≈üƒ± ileri derecede duyarlƒ±lƒ±k g√∂steren ve h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@SciscoreReports,The paper ‚ÄúThe interplay of SARS-CoV-2 evolution and constrai...‚Äù (https://t.co/5VSoGOiNpn) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/fBWNZMcBLP. We detected 4 key resources.
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@grace_V17,RT @biorxivpreprint: The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins  http‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@TonyBurnetti,RT @biorxiv_evobio: The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins  https‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@aglucaci,RT @biorxivpreprint: The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins  http‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@biorxiv_evobio,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins  https://t.co/Y42kLiOXVr #biorxiv_evobio
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@biorxivpreprint,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins  https://t.co/szRN9kTbfF #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@outbreaksci,"Contribute a rapid review or request one for ""The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and funct..."" (https://t.co/ViAa47Wqbr). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.244756) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.10.244756,The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins,@outbreaksci,New #SARSCoV preprint: The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins https://t.co/ViAa47Wqbr
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@zzz_as_zzz,RT @__ice9: The SARS-CoV-2 Nsp1 protein binds to host cell ribosomes and somehow causes them to preferentially synthesize viral proteins.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@JohnBeachTX,RT @__ice9: The SARS-CoV-2 Nsp1 protein binds to host cell ribosomes and somehow causes them to preferentially synthesize viral proteins.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@GSharadaa,RT @__ice9: The SARS-CoV-2 Nsp1 protein binds to host cell ribosomes and somehow causes them to preferentially synthesize viral proteins.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@__ice9,The SARS-CoV-2 Nsp1 protein binds to host cell ribosomes and somehow causes them to preferentially synthesize viral proteins.  Supposedly it has the largest post-entry effect on host cell viability of any of the viral proteins. https://t.co/1N61qWaZzo
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@zzz_as_zzz,RT @love_nihonsyu: („Éó„É¨„Éó„É™„É≥„Éà)Nsp1„ÅåÂÆø‰∏ª„ÅÆ„Çø„É≥„Éë„ÇØË≥™ÂêàÊàêÊ©üÊßã„Çí„Ç¶„Ç§„É´„ÇπÁî®„Å´Â§âÊõ¥„Åô„ÇãÂº∑Âäõ„Å™ÁóÖÂéüÊÄßÂõ†Â≠ê https://t.co/EKWL84l2Jd  28„Çø„É≥„Éë„ÇØË≥™„ÅÆ„ÅÜ„Å°„ÄÅNsp1„ÇíÁô∫Áèæ„Åï„Åõ„ÅüÁ¥∞ËÉû„ÅÆÁîüÂ≠òÁéá„ÅåËëó„Åó„Åè‰Ωé‰∏ã„ÄÇNsp1„ÅØ40S„É™„Éú„ÇΩ„Éº„É†„Çí„Çø„Éº‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@love_nihonsyu,(„Éó„É¨„Éó„É™„É≥„Éà)Nsp1„ÅåÂÆø‰∏ª„ÅÆ„Çø„É≥„Éë„ÇØË≥™ÂêàÊàêÊ©üÊßã„Çí„Ç¶„Ç§„É´„ÇπÁî®„Å´Â§âÊõ¥„Åô„ÇãÂº∑Âäõ„Å™ÁóÖÂéüÊÄßÂõ†Â≠ê https://t.co/EKWL84l2Jd  28„Çø„É≥„Éë„ÇØË≥™„ÅÆ„ÅÜ„Å°„ÄÅNsp1„ÇíÁô∫Áèæ„Åï„Åõ„ÅüÁ¥∞ËÉû„ÅÆÁîüÂ≠òÁéá„ÅåËëó„Åó„Åè‰Ωé‰∏ã„ÄÇNsp1„ÅØ40S„É™„Éú„ÇΩ„Éº„É†„Çí„Çø„Éº„Ç≤„ÉÉ„Éà„Å´„Åó„Å¶ÁøªË®≥„ÇíÈòªÂÆ≥„Åô„Çã„Åå„ÄÅ„Éí„ÉàÁ¥∞ËÉû„ÅÆ„Éà„É©„É≥„Çπ„ÇØ„É™„Éó„Éà„Éº„É†„ÇíÂ∫ÉÁØÑÂõ≤„Å´Â§âÂåñ„Åï„Åõ„Çã„ÄÇ
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@SciscoreReports,The paper ‚ÄúNonstructural protein 1 of SARS-CoV-2 is a potent...‚Äù (https://t.co/08x0pTUF5X) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/gHEbZtbh2N. We detected 19 key resources.
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@grace_V17,RT @biorxivpreprint: Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@outbreaksci,New #SARSCoV preprint: Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. https://t.co/82wLKALoxg
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@outbreaksci,"Contribute a rapid review or request one for ""Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host ..."" (https://t.co/82wLKALoxg). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.243451) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@outbreaksci,New #COVID19 preprint: Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. https://t.co/82wLKALoxg
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@cryoEM_Papers,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. https://t.co/UrelPsluai
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@jcooki1,Preprint
http://biorxiv.org/cgi/content/short/2020.08.09.243451,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA,@biorxivpreprint,Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA.  https://t.co/BmlvW9ACgy #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@Lab__Williams,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@OxytocinLau,"RT @MilySilvaM: Great study! #UofM, #CFI proud @OxytocinLau @MarielyAlvarezC"
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@OxytocinLau,RT @LangloisLab: Excited to have been apart of this study led by @tbold and in collaboration with @TheMenacheryLab. Assesses multiple ELISA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@MilySilvaM,"Great study! #UofM, #CFI proud @OxytocinLau @MarielyAlvarezC"
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from dono..."" (https://t.co/j3T5AvND9O). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.242271) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease https://t.co/j3T5AvND9O
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@ViralPseudotype,RT @LangloisLab: Excited to have been apart of this study led by @tbold and in collaboration with @TheMenacheryLab. Assesses multiple ELISA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@tfreedmanlab,Great work!
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@CFI_UMN,CFI teamwork!! What a great read! Thanks to all who worked tirelessly to make this study successful. üëèüëè#CFIproud
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@SciscoreReports,The paper ‚ÄúSARS-CoV-2 neutralization and serology testing of...‚Äù (https://t.co/U9B9VEwzkA) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/mgIDu2vxDC. We detected 2 of 6 rigor criteria and 4 key resources.
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@Winser_NBueno,#Preprint. Resultados de un estudio que analiz√≥ la actividad de neutralizaci√≥n del plasma convaleciente para #COVID19 de donantes con antecedentes de enfermedad no grave. https://t.co/ZU6TRpLSAq
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@psmitchej,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@priya_luthra,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@dalregu,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@FranciscoMarty_,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@ABaughnBaughn,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@dittmannlab,RT @LangloisLab: Excited to have been apart of this study led by @tbold and in collaboration with @TheMenacheryLab. Assesses multiple ELISA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@MatthewPCheng,Well done!
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@willmatchett,"New preprint! In some of my first work as a postdoc, I helped assess dozens of patient plasma samples for neutralizing antibodies titers for comparison to clinical serology tests."
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@AngryByChoice1,RT @LangloisLab: Excited to have been apart of this study led by @tbold and in collaboration with @TheMenacheryLab. Assesses multiple ELISA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@LangloisLab,Excited to have been apart of this study led by @tbold and in collaboration with @TheMenacheryLab. Assesses multiple ELISAs and virus neutralization to evaluate SARS-CoV-2 antibodies in outpatient convalescent plasma donors. https://t.co/6HwdQMCQOe
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@ThePerceptor,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@TheMenacheryLab,RT @tbold: Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@tbold,Results of our collaboration with ‚Å¶@LangloisLab‚Å© and ‚Å¶@TheMenacheryLab‚Å© to study neutralization activity of Covid convalescent plasma from donors with a history of non-severe disease. https://t.co/7lbjbjlY8g
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@biorxiv_immuno,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease  https://t.co/UJPrUrOvkG #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.07.242271,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease,@biorxivpreprint,SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease  https://t.co/b3QdfSBVnc #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@MultiGlyco,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@IBS_Grenoble,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@rreciom,RT @derafaeldelgado: DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@JulienMarcoux2,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@zzz_as_zzz,RT @glycopreprint: DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic a‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@glycopreprint,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist https://t.co/Enpo8dqHXE #glycotime
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@ChaoGlycoGao,"How many ways can SARS-CoV-2 interact with our cells and tissues? A recent work led by @fieschif and @derafaeldelgado confirmed CLRs may play a role in viral infection! This work, ours https://t.co/QODaUKyO1n and many others give an alternative innate immu"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@FinlayInstituto,"RT @FabrizioChiodo: Another elegant work supporting and extending our previous results: ""DC/L-SIGN recognition of spike glycoprotein promot‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@SciscoreReports,The paper ‚ÄúDC/L-SIGN recognition of spike glycoprotein promot...‚Äù (https://t.co/gl39Ls7oB2) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/UzRg2sOMkI. We detected 1 of 6 rigor criteria and 9 key resources
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@lola_folgueira,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@lola_folgueira,RT @derafaeldelgado: DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@Er_Goti,"RT @jjreinamartin: Fantastic work! Congrats to @fieschif, @derafaeldelgado, Anna Bernardi, Sara Sattin and all collaborators"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@mmergon1,RT @derafaeldelgado: DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@InnoglyA,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@Glyco_Alps,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@dunckerUAEM,RT @ElisaTelisa: DC/L-SIGN promote virus transfer to permissive ACE2+ cells. Brilliant work from @fieschif and colleagues üëèüëèüëèü•Çü•Çüçæ https://t.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@Angulo_Lab,RT @fieschif: A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@jjreinamartin,"Fantastic work! Congrats to @fieschif, @derafaeldelgado, Anna Bernardi, Sara Sattin and all collaborators"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@outbreaksci,"Contribute a rapid review or request one for ""DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can ..."" (https://t.co/41TRD1K9aD). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.242917) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@outbreaksci,New #SARSCoV preprint: DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist https://t.co/41TRD1K9aD
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@fieschif,A great collaboration with old friends @derafaeldelgado and anna bernardi  groupes but on new emergencies about the SARS-CoV-2 pandemic. A pleasure to work altogether. https://t.co/q69RABHTJ3
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@AVESA2016,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist https://t.co/cpqurATNOH
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@derafaeldelgado,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. Our contribution to understand the role of innate immunity CLRs in COVID-19 pathogenesis https://t.co/MJXkFWnJoq
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@dbudhadev2,"RT @FabrizioChiodo: Another elegant work supporting and extending our previous results: ""DC/L-SIGN recognition of spike glycoprotein promot‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@RPleass,"RT @FabrizioChiodo: Another elegant work supporting and extending our previous results: ""DC/L-SIGN recognition of spike glycoprotein promot‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@MolinaroTony,"RT @FabrizioChiodo: Another elegant work supporting and extending our previous results: ""DC/L-SIGN recognition of spike glycoprotein promot‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@CzerwinsMarcin,"RT @FabrizioChiodo: Another elegant work supporting and extending our previous results: ""DC/L-SIGN recognition of spike glycoprotein promot‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@ElisaTelisa,DC/L-SIGN promote virus transfer to permissive ACE2+ cells. Brilliant work from @fieschif and colleagues üëèüëèüëèü•Çü•Çüçæ https://t.co/BVn5HiJqk3
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@FabrizioChiodo,"Another elegant work supporting and extending our previous results: ""DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist"" #glycotime @derafaeldelgado @fieschif https://t.co/vfrpf"
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@biorxiv_immuno,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist  https://t.co/2yKk07vKPF #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.09.242917,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist,@biorxivpreprint,DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist  https://t.co/PaJAq7tufa #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.243717,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples",@SciscoreReports,"The paper ‚ÄúComparative analyses of SARS-CoV-2 binding (IgG, I...‚Äù (https://t.co/SLlzgOlvWp) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/VbQz7SoMGJ. We detected 27 key resources."
http://biorxiv.org/cgi/content/short/2020.08.10.243717,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples",@outbreaksci,"New #SARSCoV preprint: Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples https://t.co/M3sWp8kNNL"
http://biorxiv.org/cgi/content/short/2020.08.10.243717,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples",@outbreaksci,"Contribute a rapid review or request one for ""Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies f..."" (https://t.co/M3sWp8kNNL). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.243717) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.10.243717,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples",@outbreaksci,"New #COVID19 preprint: Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples https://t.co/M3sWp8kNNL"
http://biorxiv.org/cgi/content/short/2020.08.10.243717,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples",@biorxiv_immuno,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples  https://t.co/C70vCEbOSw #biorxiv_immuno"
http://biorxiv.org/cgi/content/short/2020.08.10.243717,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples",@biorxivpreprint,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples  https://t.co/y44CuKc9hs #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@mercy_rophina,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@RcBHOYAR,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@pvanheus,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SC_IGIB,Science from India on cover page in The Hindu - just overjoyed! Great work guys - proud moment @IGIBSocial and thanks @the_hindu @India_Alliance @IndiaBioscience @CSIR_IND
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@S_Bandyopadhyay,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@geopapu24,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@vinita_gowda,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@CSIR_IND,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SrashtiJAgrawal,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Samatha_Mathew,Front page of The Hindu! Probably have to start taking autographs from my labmates now üòÅ
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@MitraSiuli,A science news on the first page!
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@dishasharma2007,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Abhinav_Jain_19,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@oommen_john,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@IGIBSocial,"RT @vinodscaria: Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and ge‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@vinodscaria,"Coverage on the on the high-throughput , sensitive and scale-able next-generation sequencing approach for detection and genetic epidemiology of SARS-CoV-2 at @IGIBSocial   Read more on the reprint https://t.co/vKx4Ost7RN Read the full article here https://"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@sheetalgandotra,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Prahladseth,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SrashtiJAgrawal,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@theoneamit,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@PremasLifeSc,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@sumyanshu,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@yogeendra2020,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@mason_lab,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing on @illumina NGS machines https://t.co/DkAdH6n0FM
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@MissfitMoti,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@DAyyappaRaja1,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@ScienceBagels,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@vinodscaria,Apart from its utility as a confirmatory assay in inconclusive cases as described in https://t.co/vKx4Osbx0f by apex laboratories
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@ankitsabharwal9,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@LawlessKahlil,RT @SeqEasy: Promising data in the first report on COVID-Seq (BioRXiv): 752 clinical samples in duplicate (1536 total). Sensitivity = 97.53‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@kasturi60,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Samatha_Mathew,"RT @SridharSivasub3: Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SridharSivasub3,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SridharSivasub3,"Large scale detection, surveillance & genetic epidemiology of #SARSCoV2 holds key as we open up economic hubs & cities. #COVIDseq provides the way forward. Glad to undertake the first field testing of #COVIDseq at @IGIBSocial @CSIR_IND   @drharshva"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SC_IGIB,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@samirksil,RT @vinodscaria: Recent preprint on high throughput detection & genetic epidemiology of SARS-CoV-2 using #COVIDseq next generation sequenci‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@athos10025,RT @SeqEasy: Promising data in the first report on COVID-Seq (BioRXiv): 752 clinical samples in duplicate (1536 total). Sensitivity = 97.53‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SeqEasy,"Promising data in the first report on COVID-Seq (BioRXiv): 752 clinical samples in duplicate (1536 total). Sensitivity = 97.53% cf RT-PCR, 99% of viral genome in 495/676 positives, and COVIDSeq detected virus in 6 RT-PCR negative. https://t.co/0fefHtEMBa"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@VarmaKonala,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@medha_d,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@rsidd120,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@yogeendra2020,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@JayshankarDas3,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Vegaismyname,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@satyamtiwari97,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Sci_Lipi,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@shravrampalli,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@oommen_john,"RT @VidurMahajan1: @AnooBhu Then, more recently, this happened:  https://t.co/Mkc1e1hM4N  The first successful run of 1500 COVID RNA sequen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@adubharti,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing | bioRxiv https://t.co/tiPAWxApLr
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@VidurMahajan1,"@AnooBhu Then, more recently, this happened:  https://t.co/Mkc1e1hM4N  The first successful run of 1500 COVID RNA sequencing in the world"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@BioRxivCurator,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing https://t.co/H9XXn4umzr
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SundaramAchary1,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@_Ankit_Singla,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@_Ankit_Singla,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@_Ankit_Singla,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@oommen_john,@AnooBhu @NandiniNai https://t.co/tSkaUo0cRF
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Abhinav_Jain_19,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Abhinav_Jain_19,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Yenepoya_IIC,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@vinodscaria,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@VidurMahajan1,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@dishasharma2007,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@birendrabioinfo,"RT @IGIBSocial: Congratulations, Vinod, Sridhar and the large team that has been working on COVID genome sequencing during the pandemic..."
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@sandeepRCafee,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@vinita_gowda,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@PremasLifeSc,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Arushi_Batra28,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@atinsehgal,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@AnuragAgrawalMD,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@ayush_akd,@theRuchiChauhan
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Nikhil_Ratna,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@TataMemorial,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@DrManuSikarwar5,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@JaydevDas19,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@MitraSiuli,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@VickyMJ93,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@Samatha_Mathew,"RT @PrinSciAdvGoI: Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@PrinSciAdvGoI,"Kudos to the @IGIBSocial team. This is a scalable approach, with logistics of sample collection becoming addressable, and costs coming down with volume."
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@PrinSciAdvGoI,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@GVRayasam,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@kunalprats,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@satyaitrc,"RT @AnuragAgrawalMD: The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@AnuragAgrawalMD,"The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which could go down substantially. Invaluable strain cluster information for tracing clusters too  @CSIR_IND @kvijayraghavan @ProfBhargava https"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@AnuragAgrawalMD,"The future of NGS in pandemic preparedness. Higher throughout and greater accuracy at the same per sample cost, which could go down substantially. Invaluable strain cluster information for tracing clusters too  @CSIR_IND @kvijayraghavan @ProfBhargava https"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@msharmas,RT @VidurMahajan1: Super proud to have played a small role in this massive work by @vinodscaria and @SridharSivasub3   The world's first su‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@JatindraMohan13,RT @JayshankarDas3: Kudos to @soa_social team too https://t.co/wSFVCGsy78
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@yogeendra2020,RT @vinodscaria: Recent preprint on high throughput detection & genetic epidemiology of SARS-CoV-2 using #COVIDseq next generation sequenci‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@mkdivakar,"Finally, the preprint is here, for first successful real life experience of CovidSeq, from India. Great team work and wonderful collaboration."
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@drdevangm,COVID-Seq? Really?
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@PromPreprint,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing https://t.co/TDacfnRkDP
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@BiopapersC,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing https://t.co/dWPuQSKAgc
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@SciscoreReports,The paper ‚ÄúHigh throughput detection and genetic epidemiology...‚Äù (https://t.co/BOt13w61Mk) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/aYkVlbhtmg. We detected 1 of 5 rigor criteria and 8 key resources
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@JayshankarDas3,Kudos to @soa_social team too
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@bmd_sd,Concurrent diagnosis and viral sequence from a single test can drive both patient management and rapid public health response.  #covid19  #ngs
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@ZakirThomas,This @IGIBSocial study led by is the first report of the COVIDSeq approach for detection and genetic epidemiology of SARS-CoV-2.
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@RK_Premas,RT @VidurMahajan1: Super proud to have played a small role in this massive work by @vinodscaria and @SridharSivasub3   The world's first su‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@PhilFebboMD_CMO,"First BioRXiv report of COVID-Seq with 752 clinical samples in duplicate (1536 samples total). Sensitivity was 97.53% compared with RT-PCR, 99% of viral genome in 495/676 positives, and COVIDSeq detected virus in 6 RT-PCR negative. https://t.co/75BrgyxcuR"
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@virology_chitra,RT @vinodscaria: Recent preprint on high throughput detection & genetic epidemiology of SARS-CoV-2 using #COVIDseq next generation sequenci‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@sunilvats2004,"RT @IGIBSocial: Congratulations, Vinod, Sridhar and the large team that has been working on COVID genome sequencing during the pandemic..."
http://biorxiv.org/cgi/content/short/2020.08.10.242677,High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing,@anu_iris,"RT @IGIBSocial: Congratulations, Vinod, Sridhar and the large team that has been working on COVID genome sequencing during the pandemic..."
http://medrxiv.org/cgi/content/short/2020.08.02.20129767,A Classification Approach for Predicting COVID-19 Patient Survival Outcome with Machine Learning Techniques,@SciscoreReports,The paper ‚ÄúA Classification Approach for Predicting COVID-19...‚Äù (https://t.co/Tw3iHIcHIO) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/rNlZvO1qhP. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.02.20129767,A Classification Approach for Predicting COVID-19 Patient Survival Outcome with Machine Learning Techniques,@medrxivpreprint,A Classification Approach for Predicting COVID-19 Patient Survival Outcome with Machine Learning Techniques  https://t.co/oaWeDH95Qr #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@colindaven,Petabase-scale sequence alignment catalyses viral discovery https://t.co/vnp3k0Bflz
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@alphatauri2011,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@danlohrdev,"Serratus lives! So grateful to be a part of this, can‚Äôt wait to see what else is discovered üîé"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@bradyfcress,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@chtzeng,RT @RobertEdgarPhD: Petabase-scale sequence alignment catalyses discovery of novel viruses https://t.co/ddX86pCg30
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@agroppi,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@NovakovskyG,RT @tomeraltman: Our pre-print on searching all of the NCBI SRA to find novel coronaviruses is up on the bioRxiv. But also check out our ma‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@LilithElina,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@serghei_mangul,RT @tomeraltman: Our pre-print on searching all of the NCBI SRA to find novel coronaviruses is up on the bioRxiv. But also check out our ma‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@hayneswa,RT @tomeraltman: Our pre-print on searching all of the NCBI SRA to find novel coronaviruses is up on the bioRxiv. But also check out our ma‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ch_zimmer,RT @tomeraltman: Our pre-print on searching all of the NCBI SRA to find novel coronaviruses is up on the bioRxiv. But also check out our ma‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@tomeraltman,And here's the announcement tweet: https://t.co/r39UFgF3lP
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@claczny,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@tomeraltman,Our pre-print on searching all of the NCBI SRA to find novel coronaviruses is up on the bioRxiv. But also check out our main website at https://t.co/MHtQByGzND. @hackseq @RayanChikhi @akorobeynikov @RobertEdgarPhD @NovakovskyG
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@tomeraltman,"@lpachter @LabMutwil @bound_to_love We did something similar, searching all of SRA's RNA-Seq datasets for novel Coronaviruses. And it took far less than 250 days: https://t.co/r39UFgF3lP"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@GagalovaK,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@TheFirstNuomics,"""...cloud architecture, `Serratus`, tailored for petabase alignment...identified & assembled 1000s of CoV/CoV-like genomes & genome fragments ranging from known strains to putative novel genera.."" Petabase-scale sequence alignment catalyses viral d"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@simonepignotti,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@BioRxivCurator,Petabase-scale sequence alignment catalyses viral discovery https://t.co/aM2zh0DaJD
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@e_scaon,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ZaminIqbal,"@LabMutwil @lpachter @bound_to_love Sounds great! Not directly related, but maybe of interest and use (I'm not an author, just saw it) https://t.co/Iyg58R3eOm f"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@rohitdukemehta,RT @BallouxFrancois: An impressive piece of work mining 5.6 petabases of public sequencing data from 3.8M biological samples allowed for th‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Neda_TV,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@bloodSparasites,RT @bloodSparasites: Petabase-scale sequence alignment catalyses viral discovery https://t.co/OInS4Sm2tR @biorxivpreprint
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@YoannPageaud,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@BlasBenito,"RT @wormmaps: Serratus is a fascinating model for open science - an attempt to take an entire community of practice, dip into their collect‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@davidr_requena,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Yvan2935,"Amazing work! Beautiful demonstration of the ""good"" use of IT resources (infra/algo/communities) with ""open science by design"" approach... AMMMMMAAAAAAZZZZZZZZIINNNGGGGGGG"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@davidr_requena,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Rylobyte,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@C_morgan_lang,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@JenyaKopylova,"Many exciting achievements, great job!"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@C_morgan_lang,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@not__adi,when is usearch v12 gonna drop?
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ilnam_kang,RT @yokadzaki: Petabase-scale sequence alignment catalyses viral discovery https://t.co/L9ARuwGOdR
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@stephen_nayfach,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@TonyBurnetti,RT @PromPreprint: Petabase-scale sequence alignment catalyses viral discovery https://t.co/A2wQkHWykw
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@PromPreprint,Petabase-scale sequence alignment catalyses viral discovery https://t.co/A2wQkHWykw
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@mealser,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@NobregaFL,RT @yokadzaki: Petabase-scale sequence alignment catalyses viral discovery https://t.co/L9ARuwGOdR
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@BiopapersC,Petabase-scale sequence alignment catalyses viral discovery https://t.co/1t0jAqCFhX
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Seempleetoo,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@AlejandroFrank,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@BaBalogog,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@SebCarrere,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@gregory_annc,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@quangpmnguyen,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@SciscoreReports,The paper ‚ÄúPetabase-scale sequence alignment catalyses viral...‚Äù (https://t.co/4BulJY72aC) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/sGwRw5icIF. We detected 0 of 5 rigor criteria and 0 key resources.
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Paleophile,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@MicrobiomDigest,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@DGautheret,Wow.
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@caina89,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@vloux,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Dreamer0fships,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@WyWyWa,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@mikethemadbiol,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@lisancao,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@lalopangue,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@wormmaps,"Serratus is a fascinating model for open science - an attempt to take an entire community of practice, dip into their collective data, and come back out with new data we didn't even know we had. Looking forward to where they're going with this!"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@zevkronenberg,RT @RobertEdgarPhD: Petabase-scale sequence alignment catalyses discovery of novel viruses https://t.co/ddX86pCg30
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@OmicsOmicsBlog,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@thesteinegger,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@PatrikD,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@luizirber,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@simroux_virus,"RT @tomeraltman: I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slav‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@tomeraltman,"I'm proud to RT this project that I, along with an amazing international team of scrappy bioinformaticists, have been slaving away at for months. I headed up the viral genome annotation pipeline and repository submission. After working & home-schooling"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ZaminIqbal,"""From a screen of 3.8 million libraries... we report 11,120 assemblies, including sequences from 13 previously uncharacterised or unavailable CoV or CoV-like operational taxonomic units (OTUs), defined by clustering amino seq of the.. RdRp gene at 97% iden"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@IliaMinkin,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@victorlin_,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@pierre_marijon,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@NovakovskyG,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@FabianStaubach,RT @RobertEdgarPhD: Petabase-scale sequence alignment catalyses discovery of novel viruses https://t.co/ddX86pCg30
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ananth_k,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@RobertEdgarPhD,Petabase-scale sequence alignment catalyses discovery of novel viruses https://t.co/ddX86pCg30
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@downingtim1,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Eomesodermin,Petabase-scale sequence alignment catalyses viral discovery https://t.co/M5axQezdZ0 #immunobot https://t.co/LboxiHU69E
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@TonyBurnetti,RT @yokadzaki: Petabase-scale sequence alignment catalyses viral discovery https://t.co/L9ARuwGOdR
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@mcdonadt,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ChrispinChaguza,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@EBiederstedt,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@sminot,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@luizirber,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@underseaunicorn,RT @hackseq: Have you ever wanted to align literally _million_ sequencing libraries?   To find diverged coronaviruses in public sequencing‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@sergeynurk,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@vladsaveliev,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@abremges,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@krsahlin,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@shfo,"RT @KarelBrinda: ""...aligned 3,837,755 public...datasets against...pangenomes compr. all GenBank CoV records...+all non-retrov. RefSeq...ve‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@JeanManguy,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@Libardopez,RT @BallouxFrancois: An impressive piece of work mining 5.6 petabases of public sequencing data from 3.8M biological samples allowed for th‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ctitusbrown,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@nomad421,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@MartinDMuggli,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@HaveYouFoundOu1,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@BQPMalfoy,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@evogytis,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@edrybicki,RT @yokadzaki: Petabase-scale sequence alignment catalyses viral discovery https://t.co/L9ARuwGOdR
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@ayirpelle,"RT @RayanChikhi: We present Serratus, a petabase-scale alignment initiative to discover new (corona)viruses. Preprint: https://t.co/XhlU6PQ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@magicdmw,RT @BallouxFrancois: An impressive piece of work mining 5.6 petabases of public sequencing data from 3.8M biological samples allowed for th‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241729,Petabase-scale sequence alignment catalyses viral discovery,@burkhard_mstern,"RT @KarelBrinda: ""...aligned 3,837,755 public...datasets against...pangenomes compr. all GenBank CoV records...+all non-retrov. RefSeq...ve‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.10.244632,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site,@SciscoreReports,The paper ‚ÄúBioinformatic Analysis Reveals That Some Mutations...‚Äù (https://t.co/Y2F9aHdrqv) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/CeQ0zcbtqR. We detected 0 of 5 rigor criteria and 1 key resource.
http://biorxiv.org/cgi/content/short/2020.08.10.244632,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site,@outbreaksci,"Contribute a rapid review or request one for ""Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Da..."" (https://t.co/ZGNg7y3FKw). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.244632) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.10.244632,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site,@outbreaksci,New #SARSCoV preprint: Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site https://t.co/ZGNg7y3FKw
http://biorxiv.org/cgi/content/short/2020.08.10.244632,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site,@biorxiv_bioinfo,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site  https://t.co/8Urr6UWmbf #biorxiv_bioinfo
http://biorxiv.org/cgi/content/short/2020.08.10.244632,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site,@biorxivpreprint,Bioinformatic Analysis Reveals That Some Mutations May Affect On Both Spike Structure Damage and Ligand Binding Site  https://t.co/MCnK8JSFr7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@SciscoreReports,The paper ‚ÄúCharacterization of SARS-CoV-2 ORF6 deletion varia...‚Äù (https://t.co/P6eX4RfMJE) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/9lM5kstwEk. We detected 1 of 6 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@akkaufman,RT @outbreaksci: New #SARSCoV preprint: Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@outbreaksci,"Contribute a rapid review or request one for ""Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster d..."" (https://t.co/EQEugef0i7). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.241653) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@outbreaksci,"New #SARSCoV preprint: Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France https://t.co/EQEugef0i7"
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@paulcarald,RT @patorojassilva: @IMUSFQ @paulcarald
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@spiderspapers,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France https://t.co/VIV6Dn9JRZ"
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@patorojassilva,@IMUSFQ @paulcarald
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@10_blue,RT @biorxivpreprint: Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveill‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@Rajendr83556477,RT @biorxiv_micrbio: Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveill‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@biorxiv_micrbio,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France  https://t.co/vOaHWM2Tyi #biorxiv_micrbio"
http://biorxiv.org/cgi/content/short/2020.08.07.241653,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France",@biorxivpreprint,"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France  https://t.co/oWaJHfTTEE #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@SciscoreReports,The paper ‚ÄúK18-hACE2 Mice for Studies of COVID-19 Treatments...‚Äù (https://t.co/SdYak00azg) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/YIJRrFxU5Y. We detected 0 of 5 rigor criteria and 0 key resources.
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@LucreSnooker,"less silly data point from this paper (https://t.co/D3uruXPIWO): human convalescent plasma with 1:1,480 neutralizing titer protects hACE2-expressing mice from a lethal virus challenge when given a day before infection, but if given a day after infection, 3"
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@akkaufman,"RT @outbreaksci: Contribute a rapid review or request one for ""K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@outbreaksci,"Contribute a rapid review or request one for ""K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia"" (https://t.co/qyV14dGGYm). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.242073) at https://t.co/RnurTL3DyM @outbreaksci @PRE"
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@outbreaksci,New #SARSCoV preprint: K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia https://t.co/qyV14dGGYm
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@MattFrieman,RT @biorxiv_micrbio: K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia  https://t.co/CT3IfgntvO #biorxiv‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@Rajendr83556477,RT @biorxiv_micrbio: K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia  https://t.co/CT3IfgntvO #biorxiv‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@biorxiv_micrbio,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia  https://t.co/CT3IfgntvO #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.07.242073,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia,@biorxivpreprint,K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia  https://t.co/RhQ07n0bqI #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@NBADraft3,RT @TheSeeker268: Read the full paper here: https://t.co/jhPtf18dlg
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@_hoeman,RT @TheSeeker268: Read the full paper here: https://t.co/jhPtf18dlg
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@NoWackyScience,RT @TheSeeker268: Read the full paper here: https://t.co/jhPtf18dlg
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@luigi_warren,RT @TheSeeker268: Read the full paper here: https://t.co/jhPtf18dlg
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@TheSeeker268,Read the full paper here: https://t.co/jhPtf18dlg
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@Arachnoidea12,RT @Helmholtz_HZI: Eine neue Studie von Luka ƒåiƒçin-≈†ain mit @wwu_muenster untersucht die Evolution von #SARSCoV2. #preprint
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@Helmholtz_HZI,Eine neue Studie von Luka ƒåiƒçin-≈†ain mit @wwu_muenster untersucht die Evolution von #SARSCoV2. #preprint
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@SciscoreReports,The paper ‚ÄúSARS-CoV-2 Quasispecies Mediate Rapid Virus Evolut...‚Äù (https://t.co/vJuDivV8nU) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/H2sw06PvPq. We detected 11 key resources.
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation"" (https://t.co/vUYRqDwrAA). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.10.241414) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation https://t.co/vUYRqDwrAA
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@microbiomarisol,RT @biorxivpreprint: SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation  https://t.co/DBSl1Foefo #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@aglucaci,RT @biorxivpreprint: SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation  https://t.co/DBSl1Foefo #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@biorxiv_micrbio,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation  https://t.co/n2R9DvaHkZ #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.10.241414,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation,@biorxivpreprint,SARS-CoV-2 Quasispecies Mediate Rapid Virus Evolution and Adaptation  https://t.co/DBSl1Foefo #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@mikenov,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review | medRxiv https://t.co/t61ib1PVgx
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@alfonso_casi,SARS-CoV-2 y el papel de la transmisi√≥n orofecal: revisi√≥n sistem√°tica encuentra pruebas observacionales y mecanicistas que apoyan la hip√≥tesis de que el SARS-CoV-2 puede infectar y eliminarse del tracto gastrointestinal humano.  https://t.co/bPzEtSgCKT ht
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@EvidenceRobot,RT @Links_Medicus: [Preprint] Systematic review: SARS-CoV-2 and the role of orofecal transmission ‚Äì via @medrxivpreprint https://t.co/yv7M‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@Links_Medicus,[Preprint] Systematic review: SARS-CoV-2 and the role of orofecal transmission ‚Äì via @medrxivpreprint https://t.co/yv7Mw2LK4S
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review"" (https:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@EvidenceRobot,"RT @outbreaksci: Contribute a rapid review or request one for ""SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review"" (https:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@EvidenceRobot,RT @outbreaksci: New #SARSCoV preprint: SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review https://t.co/MyF9l1yUUg
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review"" (https://t.co/MyF9l1yUUg). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20168054) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review https://t.co/MyF9l1yUUg
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@arttzaddikim,RT @medrxivpreprint: SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review  https://t.co/V7vLXMBliR #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@FluScim,RT @SciArt3D: A tener en cuenta para la apertura de colegios con ni√±os que requieren que las maestras/os les limpien bien. Escuelas no son‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@SciArt3D,A tener en cuenta para la apertura de colegios con ni√±os que requieren que las maestras/os les limpien bien. Escuelas no son centros hospitalarios üëáüèªüëáüèªüëáüèªSARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review | medRxiv https://t.co/jp0OfANcbN
http://medrxiv.org/cgi/content/short/2020.08.04.20168054,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review,@medrxivpreprint,SARS-CoV-2 and the Role of Orofecal Transmission: Systematic Review  https://t.co/V7vLXMBliR #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@JOSEGRIVASNAAR,"RT @Aponte27C: Siete Nanoanticuepos muestran bloqueo de la interacci√≥n de variantes de SARS-CoV-2-RBD, murcielago-SL-CoV-WIV1-RBD and SARS-‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@len_unofficial,"""We showed that Nb11-59 expression could reach 20 g/L through fermentation using the yeast expression system, which means that it could be rapidly and widely used as a preventive or therapeutic molecule.""  https://t.co/AZQ1XJmSl6"
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@SciscoreReports,The paper ‚ÄúA potent neutralizing nanobody against SARS-CoV-2...‚Äù (https://t.co/P3aghH7KCj) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Y8e6M4w9u3. We detected 1 of 6 rigor criteria and 14 key resources
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@outbreaksci,"Contribute a rapid review or request one for ""A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential"" (https://t.co/PrLPzHjXGk). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.09.242867) at https://t.co/RnurTL3DyM @outbreaksci @PRErev"
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@outbreaksci,New #SARSCoV preprint: A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential https://t.co/PrLPzHjXGk
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@Aponte27C,"Siete Nanoanticuepos muestran bloqueo de la interacci√≥n de variantes de SARS-CoV-2-RBD, murcielago-SL-CoV-WIV1-RBD and SARS-CoV-1-RBD con la enzima convertidora de angiotensina 2 (ACE2). Su aplicaci√≥n inmedita puede ser por inhalaci√≥n... https://t.co/BQjkf"
http://biorxiv.org/cgi/content/short/2020.08.09.242867,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential,@biorxivpreprint,A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential  https://t.co/n4V44F40px #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@venceralcovid,RT @alfonso_casi: Inmunogenicidad y seguridad de una vacuna inactivada contra el SARS-CoV-2 (CoronaVac) en adultos sanos de 18 a 59 a√±os: e‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@alfonso_casi,Inmunogenicidad y seguridad de una vacuna inactivada contra el SARS-CoV-2 (CoronaVac) en adultos sanos de 18 a 59 a√±os: este ensayo cl√≠nico de fase 2 demuestra la seguridad e inmunogenicidad favorables respaldando la realizaci√≥n del ensayo de fase 3. https
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@ruliemaulana,"Ternyata udah ada jurnal hasil uji klinis fase-2 Sinovac (meski belum di-peer review). Keliatannya sih menjanjikan hasilnya.   Buzzer bumn mestinya bantu publikasi isi jurnal ini, jangan sibuk sama hestek.   link: https://t.co/4iYFu9ID4W https://t.co/PhZM5"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@sociotalker,iya....masih nunggu hasil peer-review kayaknya.
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@su_dody_,"@sociotalker Prof, Ini bkn publikasinya? Cm sepertinya blm d peer reviewed, sih...   https://t.co/QlMOcz0JmT"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@inoviolt,Still INOVIO is in pole position....
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Hall8Jack,RT @BertrandBio: Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@BertrandBio,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial #sinovac (no comparator other than pbo) https://t.co/71wk64rdk4"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@stolsgabriel,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@PandoradaMafao,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@bgg_nh,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@oblogdoprimo,"@oatila Mais informa√ß√µes, pelo menos da vacina chinesa da SINOVAC. Elas n√£o empolgaram tanto, mas nada que um complemento n√£o resolva, pelo que eu entendi. https://t.co/jZFUJErrpl"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@oblogdoprimo,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@MPedrasani,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@yngrid27,RT @Links_Medicus: [Preprint] Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: Report of t‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Links_Medicus,"[Preprint] Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: Report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial ‚Äì via @medrxivpreprint https://t.co/m1FtUBUcHj"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@MaltaMelissa,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@kevinpurcell,The SinoVac CoronaVac Phase 2 paper https://t.co/8lQA1XLS1x
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Yuji_Ono,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@arussolira1,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@docrodwong,SinoVac P2 results.  underwhelming for an inactivated whole virion vaccine.  nAbs were significantly lower than from convalescent patients assayed in the same lab.   https://t.co/uEUtOutY1Z https://t.co/ZZSujs1mNw
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@adiosiago,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@PabloAl71818691,$DVAX üò©üò©üò©üò©
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@BiaMaartins_,"Uma das minhas inspira√ß√µes na ci√™ncia, sempre com informa√ß√µes de qualidade explicadas de forma simples ‚ù§Ô∏è‚ù§Ô∏è"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@fkawakubo,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@RodrigotxA,"Not√≠cias da Sinovac, aposta de SP - Butantan!"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@stewak2,SinoVac interim report
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@sarro_f,"RT @alvaropereirajr: Don't believe the hype (leia antes as explica√ß√µes da Natalia, botando a bola no ch√£o)"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@EdgarKaizawa,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Alternativo,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@siiemak,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@ameliazein,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Marieaaow,Vaccine test #China The ethics committee of the #Jiangsu Provincial Center for Disease Control and Prevention Not peered! https://t.co/JrjMmNpAuI
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@lutl88,@florian_krammer https://t.co/udE2qexMk2
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@jamming_vibes,Parece que essa n√£o √© l√° muito boa n√£o
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@ayirpelle,RT @GaetanBurgio: Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + alum‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@caglcc13,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@onkoto3,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@LucianoCSantos,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@serinvisivel3,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@jon_beacham,RT @inoviolt: Inovio has better T cell response https://t.co/o53rj361KW
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Talitaduvanel,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@GregBorchers,RT @GaetanBurgio: Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + alum‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@RafaelRech14,"RT @alvaropereirajr: Don't believe the hype (leia antes as explica√ß√µes da Natalia, botando a bola no ch√£o)"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@ArnaldoJRibeiro,"RT @alvaropereirajr: Don't believe the hype (leia antes as explica√ß√µes da Natalia, botando a bola no ch√£o)"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@sofia19aimee,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@werner_fb,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@atomeseven,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@MassatoHirai,RT @outbreaksci: New #SARSCoV preprint: Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: R‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@turoneth,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@inoviolt,Inovio has better T cell response
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@outbreaksci,"Contribute a rapid review or request one for ""Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 1..."" (https://t.co/3cJ8swohwQ). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20161216) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@outbreaksci,"New #SARSCoV preprint: Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial https://t.co/3cJ8swohwQ"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@AkshaySharmaMD,RT @GaetanBurgio: Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + alum‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Fradbius,RT @GaetanBurgio: Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + alum‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@siddharthgpf,RT @GaetanBurgio: Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + alum‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@alexander_suh,RT @GaetanBurgio: Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + alum‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@GaetanBurgio,"Results on phase 2 trial (randomized double blind + placebo on 600 healthy adult) of #COVID19 whole virion vaccine + aluminium hydroxide as adjuvant (CoronaVac) => 2 doses elicit immunogenic response 28 d post immuno, no grade 3 incident => so far so"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@ClentScience,RT @medrxivpreprint: Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Random‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Eduardoigbrasil,"Balde de √°gua fria, eu tava com muita f√© nessa vacina"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@marizascolari,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@marciachocolate,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@MassatoHirai,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@sousasimoni,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@JuniaCajazeiro,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Apenas1De,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@raka_linda,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@CrfontesFontes,"RT @alvaropereirajr: Don't believe the hype (leia antes as explica√ß√µes da Natalia, botando a bola no ch√£o)"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@EverSoNN9,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@camposamd,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@caiopkabc,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@BioIven,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Lizzie76850554,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@saturnocasa2,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@binobiasutti,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@elsonfarias,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@jorgeponce2014,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@fernando__gama,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@dyctiostelium,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@pedrofbr0,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@gnarly_parker,Papers for phase 2 vaccine trials are coming it. Slowly getting there ü§û https://t.co/fDV6behqk5
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@tonyaraujo,üëáüèΩüëáüèΩüëáüèΩüëáüèΩüëáüèΩ
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@petrameeson,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@marilyngavrano1,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@deutschsamukka,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@MTackCVS,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@AnneRoCi,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@juangbromero,fio importante üëÄ
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@paulo_person,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@D4ntcar,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@alvaropereirajr,"Don't believe the hype (leia antes as explica√ß√µes da Natalia, botando a bola no ch√£o)"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@FitinhaR,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@BockmannFlavio,Resumo muito bem feito e claro. Como sempre. Leitura obrigat√≥ria. Obrigado @TaschnerNatalia .
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@Baba_Lilith,"RT @hildabast: 1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on plac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@flanaria,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@BatmanDarkBR,"RT @TaschnerNatalia: Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@OncoAlert,"RT @Aiims1742: Another day, another #SARSCoV2 vaccine preprint SinoVac (China), reporting ph2 data: - humoral immunity only, no T cell data‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@TaschnerNatalia,"Saiu finalmente uma publica√ß√£o (preprint) da Sinovac, resultados de fase 2. https://t.co/sUZTu44kMB"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@hildabast,"1st human data for an inactivated Covid-19 vaccine is out! Coronavac (by Sinovac) phase 2 data, for 480 people + 120 on placebo. Antibodies but not T-cells reported: 97% seroconversion 28 days after 2nd injection, but less for people over 50 ...  https://t"
http://medrxiv.org/cgi/content/short/2020.07.31.20161216,"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial",@spontonic,"Sinovac vaccine.....    weak responses, first blush.....   https://t.co/LdZFNXSGRb"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@taboella,My preprint is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/P0ZTkxBFPF
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@gsabrinus,This is ‚Äúgreat‚Äù news as I start my summer trapping! #fieldwork #micematter #staysafe
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@dvmphd2be,RT @CSU_MIP: Pre-print from #CSU researchers conclude that #DeerMice have the potential to serve as secondary #Reservoir #Hosts of #SARSCoV‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@SusanAShriner,RT @CSU_MIP: Pre-print from #CSU researchers conclude that #DeerMice have the potential to serve as secondary #Reservoir #Hosts of #SARSCoV‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@theresalaverty,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@CSU_MIP,Pre-print from #CSU researchers conclude that #DeerMice have the potential to serve as secondary #Reservoir #Hosts of #SARSCoV2 that could lead to periodic #COVID19 #Outbreaks in North America.  @EbelLaboratory @KadingLabCSU @GeissLaboratory @OlvePeersen
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@diego_amazonia,"RT @RolandKays: Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, b‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@lexibrownbats,F
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@khelgen,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@nyctomys,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@bryansmclean,"RT @KE_Stanchak: Meanwhile, Peromyscus says hi. https://t.co/CNvsuC0vUI   ""SARS-CoV-2 infection, neuropathogenesis and transmission among d‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@PLURplus,RT @KurianLab: Potential risk of establishing rodent reservoirs   https://t.co/dtWJSpiZro https://t.co/11GNlan6s2
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@nate_bickford,"RT @RolandKays: Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, b‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@JessicaKSchnell,"RT @RolandKays: Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, b‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@H_X_S,"RT @RolandKays: Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, b‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@The_Lagrangian,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@AlCambronne,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@GettingGophery,Ban mice 2020.
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@Samatha_Mathew,"RT @RolandKays: Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, b‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@DavidQuammen,"RT @RolandKays: Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, b‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@KE_Stanchak,"Meanwhile, Peromyscus says hi. https://t.co/CNvsuC0vUI   ""SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents"" https://t.co/jCLJHqqp8F"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@je_light,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ekesslerkc,@ksbioteachers
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@mfk_onehealth,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@akatora_senpai,To read later
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@RolandKays,"Great, probably our country‚Äôs most common mammal can catch COVID. Thankfully no obvious health consequences for the mice, but opens up a whole new ecological web of disease spread @DavidQuammen @mike_cove"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@RixeyMegan,"RT @n8_upham: Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they h‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@n8_upham,"Good news: North American deer mice ""are a suitable animal model for the study of SARS-CoV-2 pathogenesis""  Bad news: ""they have the potential to serve as secondary reservoir hosts that could lead to periodic outbreaks of COVID-19 in North America.""  https"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@SciscoreReports,"The paper ‚ÄúSARS-CoV-2 infection, neuropathogenesis and transm...‚Äù (https://t.co/0ptzfgZlNX) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/zPLY03os10. We detected 2 of 6 rigor criteria and 9 key resources"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@aivelo,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@overhannahlyze,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@batgirl_susan,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@neurosjk,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@IgorCarron,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@tpoi,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@DuckSwabber,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,We have 3 papers saying 2 types of mouse can be infected by Sarscov-2  Balb/c mouse (Spike N501Y) https://t.co/d756TIuurC  Deer Mice #1 No mutation info... https://t.co/io6h8utUEO #2  (Orf1 & Spike insert 216 KLRS=AAG CTG AGA AGT) https://t.co/bvEEPdUb
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@maxjfarrell,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@naomiattar,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ypoumay,"RT @angoffinet: ""Reverse zoonosis"", when COV2 passed from human to animals can jump back to human, is possible and should be scrutinized by‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@BiswapriyaMisra,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ToddEBear,"RT @angoffinet: ""Reverse zoonosis"", when COV2 passed from human to animals can jump back to human, is possible and should be scrutinized by‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@_hoeman,"RT @angoffinet: ""Reverse zoonosis"", when COV2 passed from human to animals can jump back to human, is possible and should be scrutinized by‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@angoffinet,"""Reverse zoonosis"", when COV2 passed from human to animals can jump back to human, is possible and should be scrutinized by veterinary labs all over world https://t.co/WcSn6NixFE https://t.co/Suee1z4RHB"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@KurianLab,Potential risk of establishing rodent reservoirs   https://t.co/dtWJSpiZro https://t.co/11GNlan6s2
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@CFGT_Edinburgh,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@dpmelters,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@EpiDoctor,RT @viralemergence: Congratulations to @annafagre on this fantastic new paper about spillback risk of SARS-CoV-2 into wild rodents!  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ruffssketches,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@MacacoSays,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@LyndonCoghill,https://t.co/ZBfMHNrIE4
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ThePedraLab,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ImmunoFever,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@janean_sharkey,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@interactivefly,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@wormmaps,RT @viralemergence: Congratulations to @annafagre on this fantastic new paper about spillback risk of SARS-CoV-2 into wild rodents!  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@viralemergence,Congratulations to @annafagre on this fantastic new paper about spillback risk of SARS-CoV-2 into wild rodents!  https://t.co/o7K8OhvVTI
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@JuergenLabermas,"RT @pollyp1: HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-C‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@pollyp1,"HEY HERE'S SOME MORE BAD NEWS 2 of 2 A second pre-print that documents that wild mice are infected but do not get sick ""SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents"" https:"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,RTÔºùÊüêÂáÜÊïôÊéà„ÅÆË´ñÊñá„ÅåÂá∫„Åæ„Åó„Åü„ÄÇ  „Éâ„Éñ„Éç„Ç∫„Éü„Å´„Å©„ÅÆÁ®ãÂ∫¶„ÅÆÊö¥Èú≤„ÅßÊÑüÊüì„Åó„ÄÅ„Å©„Çì„Å™Â§âÁï∞„Åå‰Ωï‰ª£ÁõÆ„ÅßÂÆöÁùÄ„Åó„ÄÅ„Åù„ÅÆÂ§âÁï∞„ÅåGISAID„Å´Êó¢„Å´Â≠òÂú®„Åô„Çã„ÅãÔºü„Å®„Åã„ÄÅDeer Mice„ÅÆÊßò„Å´Insert„Åå„ÅÇ„Å£„ÅüÂ†¥Âêà„Å´Ëµ∑Ê∫ê„ÇíÊòé„Çâ„Åã„Å´„Åô„Çã„Å®„Åã„ÇÇ„ÅÜÂ∞ë„ÅóÁ™Å„Å£Ëæº„Çì„ÅßÊ¨≤„Åó„Åã„Å£„Åü„Åß„Åô„Å≠„ÄÇ https://t.co/EQgGkdXKXs https://t.co/kHtESeCLLY
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@LousieTashi,"@nickmmark @DaveLeeERMD @JExpMed And another paper ""that deer mice are a suitable animal model for the study of SARS-CoV-2 pathogenesis, and that they have the potential to serve as secondary reservoir hosts that could lead to periodic outbreaks of COVID-1"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@Vasilakis_Lab,Great work!
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,@NYTScience Bats?  Check rodents. https://t.co/7qTasHhlq2 https://t.co/d756TIuurC https://t.co/9nSGv3CQhy
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,@HugoThorson @NYTScience Bats?  Check rodents. https://t.co/kHtESeCLLY https://t.co/d756TIuurC https://t.co/9nSGv3CQhy
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@urbanevol,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@DrTMaehr,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@GogoMarimoman,"RT @PromPreprint: SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@PromPreprint,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents https://t.co/yuBPTGIrJP"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@waywardsyintist,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ackarawita,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@lassancejm,RT @HuWantsToKnow: A 2nd preprint finding that deer mice are susceptible to SARS-CoV-2 and can transmit to one another under lab conditions‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@ldpsci,RT @DrBrianHBird: Great work by a great team! Congrats on broadening our understanding of potential rodent  hosts!
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@AbdulsatarBoch1,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents https://t.co/WFYc6rLMqg"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@sangmotiani,"RT @TheSeeker268: ""Collectively, this work has determined that deer mice are a suitable animal model for the study of SARS-CoV-2 pathogenes‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@virus_dog_lover,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents | bioRxiv https://t.co/Z4RkObjRQv"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@Virologica,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@DuckSwabber,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@rattus_mattus,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@AmandineGamble,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@GhersiBruno,Should we have the same precautions when doing rodent field work as we have for bats?üßê
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@OneHealthOHNO,RT @DrBrianHBird: Great work by a great team! Congrats on broadening our understanding of potential rodent  hosts! https://t.co/uD3snuX9zg
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@DrBrianHBird,Great work by a great team! Congrats on broadening our understanding of potential rodent  hosts!
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@Gfalbery,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@LisaHatha,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@mxwlj,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@EbelLaboratory,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@danjbecker,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@IsabelOtt,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@DrKrystleReagan,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@SincerelyCass11,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@jacksonprobably,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@AraniyF,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@dvmphd2be,RT @annafagre: Our pre-print describing infection & sustained natural transmission in deer mice is out üêÄ it's been an honor & privilege to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@HartsonLindsay,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@supernumbsoul,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,RT @zzz_as_zzz: „Åì„ÅÆÁ†îÁ©∂„Åß„ÅØ„ÄÅÈÅ∫‰ºùÂ≠ê„ÇÇË™ø„Åπ„Å¶„Åæ„Åô„Åå„ÄÅN501Y„ÅÆÂ§âÁï∞„Å´„Å§„ÅÑ„Å¶„ÅØË®ÄÂèä„Åó„Å¶„ÅÑ„Åæ„Åõ„Çì„ÄÇ  „Åù„Çå„Å®„ÅØÂà•„Å´„ÄÅ„Çπ„Éë„Ç§„ÇØ„ÅÆ216Áï™ÁõÆ„ÅÆÊâÄ„Å´KLRS„ÅÆËøΩÂä†„ÇíÁ¢∫Ë™ç„ÄÇ Âõ≥„ÅßÂàÜ„Åã„ÇãÊßò„Å´„ÄÅRBD„Å®„ÅØÈõ¢„Çå„ÅüÊâÄ„Å´„ÅÇ„ÇãÈÉ®‰Ωç„Åß„ÄÅÁ¥∞ËÉû‰æµÂÖ•„Å´„Å©„ÅÜÂΩ±Èüø„Åó„Å¶„ÅÑ„Çã„ÅÆ„Åã‰∏çÊòé„ÄÇ „Å©„Åì„Åã„Çâ„Åì„ÅÆ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,„Åì„ÅÆÁ†îÁ©∂„Åß„ÅØ„ÄÅÈÅ∫‰ºùÂ≠ê„ÇÇË™ø„Åπ„Å¶„Åæ„Åô„Åå„ÄÅN501Y„ÅÆÂ§âÁï∞„Å´„Å§„ÅÑ„Å¶„ÅØË®ÄÂèä„Åó„Å¶„ÅÑ„Åæ„Åõ„Çì„ÄÇ  „Åù„Çå„Å®„ÅØÂà•„Å´„ÄÅ„Çπ„Éë„Ç§„ÇØ„ÅÆ216Áï™ÁõÆ„ÅÆÊâÄ„Å´KLRS„ÅÆËøΩÂä†„ÇíÁ¢∫Ë™ç„ÄÇ Âõ≥„ÅßÂàÜ„Åã„ÇãÊßò„Å´„ÄÅRBD„Å®„ÅØÈõ¢„Çå„ÅüÊâÄ„Å´„ÅÇ„ÇãÈÉ®‰Ωç„Åß„ÄÅÁ¥∞ËÉû‰æµÂÖ•„Å´„Å©„ÅÜÂΩ±Èüø„Åó„Å¶„ÅÑ„Çã„ÅÆ„Åã‰∏çÊòé„ÄÇ „Å©„Åì„Åã„Çâ„Åì„ÅÆËøΩÂä†„ÅåÁ¥õ„ÇåËæº„Çì„Å†„ÅÆ„Åã„ÇÇ‰∏çÊòé„ÄÇ https://t.co/kHtESeCLLY https://t.co/5euOL0BAG5
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,RT @zzz_as_zzz: Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Åå„Éç„Ç∫„ÉüÊÑüÊüì„Åô„Çã„Å®„ÅÑ„ÅÜË´ñÊñá„ÅåÂá∫„Åæ„Åó„Åü„ÄÇ  „Åì„Çå„ÅØDeer Mice„Å®„ÅÑ„ÅÜÁ®ÆÈ°û„ÅÆ„Éç„Ç∫„Éü„ÄÇ ËÇ∫„ÇÑÈºª„ÄÅËÑ≥„Å´ÊÑüÊüì„Åó„Åü„ÅÆ„ÇíÁ¢∫Ë™ç„ÄÇ https://t.co/kHtESeCLLY  Deer Mice https://t.co/2e8oOi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@zzz_as_zzz,Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Åå„Éç„Ç∫„ÉüÊÑüÊüì„Åô„Çã„Å®„ÅÑ„ÅÜË´ñÊñá„ÅåÂá∫„Åæ„Åó„Åü„ÄÇ  „Åì„Çå„ÅØDeer Mice„Å®„ÅÑ„ÅÜÁ®ÆÈ°û„ÅÆ„Éç„Ç∫„Éü„ÄÇ ËÇ∫„ÇÑÈºª„ÄÅËÑ≥„Å´ÊÑüÊüì„Åó„Åü„ÅÆ„ÇíÁ¢∫Ë™ç„ÄÇ https://t.co/kHtESeCLLY  Deer Mice https://t.co/2e8oOi5cfN  „Éç„Ç∫„Éü„Åå„Ç¶„Ç§„É´„Çπ„ÅÆÂÆø‰∏ª„Å´„Å™„Çã„Å®„ÄÅ‰∫∫„Å∏„ÅÆÊÑüÊüì„ÇÑÊµÅË°å„ÅÆÂèØËÉΩÊÄß„ÅÇ„Çä„Å®„ÅÆ„Åì„Å®„ÄÇ  https://t.co/vtzDX93PQM https://t.co/g6SesDCHaY
http://biorxiv.org/cgi/content/short/2020.08.07.241810,"SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents",@anjbth,"RT @GeissLaboratory: Deer mice are able to be infected by SARS-CoV-2 without showing significant disease, suggesting they have the potentia‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@jb013b,"I am excited to share a great collaborative effort between three labs, with the Pinto and Richner lab #taylormade_labgrade  mRNA induced expression of human angiotensin converting enzyme 2 in mice for the study of the adaptive immune response to SARS-COV-2"
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@SciscoreReports,The paper ‚ÄúmRNA induced expression of human angiotensin-conve...‚Äù (https://t.co/i7ocSkrl87) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/LlJIv3r55I. We detected 1 of 6 rigor criteria and 6 key resources
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@bdkzhotsprings,RT @labgrade: New from the lab! Modeling #SARSCoV2 adaptive immune responses in mice using mRNA induced hACE2 expression in mice. Exciting‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@JonnyJenk,Look at some cool science a great mentor of mine is working on!
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@labgrade,New from the lab! Modeling #SARSCoV2 adaptive immune responses in mice using mRNA induced hACE2 expression in mice. Exciting to see T cell epitopes in spike and membrane! Studies like this will be critical for vaccine development to stop #COVID__19 https:/
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@Lokythor,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 https://t.co/EixdVLto9j https://t.co/Sl1aUE7gNM
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@outbreaksci,"Contribute a rapid review or request one for ""mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study o..."" (https://t.co/SQq4eO6vUW). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.241877) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@outbreaksci,New #SARSCoV preprint: mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 https://t.co/SQq4eO6vUW
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@MLitbot,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 https://t.co/nFGwtvIAGC
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@LabWaggoner,RT @biorxiv_immuno: mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@biorxiv_immuno,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe ...  https://t.co/61Smg6BwBf #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.07.241877,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2,@biorxivpreprint,mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2  https://t.co/wgnucplxhl #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.06.240796,"Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infection",@BertrandBio,"@JacobPlieth Cautious take here but you can also easily find paper saying the contrary (for COVID).  Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infectio"
http://biorxiv.org/cgi/content/short/2020.08.06.240796,"Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infection",@SciscoreReports,"The paper ‚ÄúExpression of ACE2, TMPRSS2 and CTSL in human airw...‚Äù (https://t.co/d6yivOf2b8) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/E2tAFwOsak. We detected 0 of 5 rigor criteria and 3 key resources"
http://biorxiv.org/cgi/content/short/2020.08.06.240796,"Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infection",@outbreaksci,"Contribute a rapid review or request one for ""Expression of ACE2, TMPRSS2, and CTSL in human airway epithelial cells under physiologic..."" (https://t.co/dxcvypr9ZF). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.240796) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.06.240796,"Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infection",@outbreaksci,"New #SARSCoV preprint: Expression of ACE2, TMPRSS2, and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV2 infection https://t.co/dxcvypr9ZF"
http://biorxiv.org/cgi/content/short/2020.08.06.240796,"Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infection",@FrancisBeaudry,"RT @biorxivpreprint: Expression of ACE2, TMPRSS2, and CTSL in human airway epithelial cells under physiological and pathological conditions‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240796,"Expression of ACE2, TMPRSS2 and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV-2 infection",@biorxivpreprint,"Expression of ACE2, TMPRSS2, and CTSL in human airway epithelial cells under physiological and pathological conditions: Implications for SARS-CoV2 infection  https://t.co/RnsXZvWvgq #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@Duke_of_neural,@drskyskull I just learned tonsil organoids were a thing and you can infect them with SARS-COV-2.  https://t.co/r097fUUHvX
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@SciscoreReports,The paper ‚ÄúGeneration of tonsil organoids as an ex vivo model...‚Äù (https://t.co/RdnY7iIoVu) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/2ClyeizxOa. We detected 0 of 5 rigor criteria and 0 key resources
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@biofreaks5,RT @drcameronjones: Breakthrough model system for drug screening. See: Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 in‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@Lokythor,Generation of tonsil organoids as an ex vivo model https://t.co/0GpE6cTjTK https://t.co/tahGq9a18z
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@outbreaksci,New #SARSCoV preprint: Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection https://t.co/Zu8OKA2VYI
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@outbreaksci,"Contribute a rapid review or request one for ""Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection"" (https://t.co/Zu8OKA2VYI). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.239574) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@outbreaksci,New #COVID19 preprint: Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection https://t.co/Zu8OKA2VYI
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@drcameronjones,Breakthrough model system for drug screening. See: Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection | bioRxiv https://t.co/fS6iNioG8H
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@msep0003,RT @biorxiv_micrbio: Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection  https://t.co/uO3i4spf5f #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@enerphyschem,RT @biorxivpreprint: Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection  https://t.co/5rHNq8GkYI #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@biorxiv_micrbio,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection  https://t.co/uO3i4spf5f #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.06.239574,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection,@biorxivpreprint,Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection  https://t.co/5rHNq8GkYI #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169870,BEHAVIORAL CHANGES DURING THE COVID-19 PANDEMIC: RESULTS OF A NATIONAL SURVEY IN SINGAPORE,@medrxivpreprint,BEHAVIORAL CHANGES DURING THE COVID-19 PANDEMIC: RESULTS OF A NATIONAL SURVEY IN SINGAPORE  https://t.co/gBGRc0IiaD #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169409,Public perceptions and preventive behaviours during the early phase of the COVID-19 pandemic: a comparative study between Hong Kong and the United Kingdom,@Samdeity,https://t.co/LIMsdBxgcC
http://medrxiv.org/cgi/content/short/2020.08.06.20169409,Public perceptions and preventive behaviours during the early phase of the COVID-19 pandemic: a comparative study between Hong Kong and the United Kingdom,@medrxivpreprint,Public perceptions and preventive behaviours during the early phase of the COVID-19 pandemic: a comparative study between Hong Kong and the United Kingdom  https://t.co/Wk4bHfmQC7 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@BRANCH_LAB_USC,RT @drkatiepage: #COVID19 is linked to reduced physical activity and high anxiety in children. Our @BRANCH_LAB_USC  team show children born‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@AlexisDefendis,RT @BRANCH_LAB_USC: Results from our #COVID19 study: children exposed to #gestationaldiabetes in utero (a risk factor for adverse psych. ou‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@jasminalves6,RT @drkatiepage: #COVID19 is linked to reduced physical activity and high anxiety in children. Our @BRANCH_LAB_USC  team show children born‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@BRANCH_LAB_USC,RT @BRANCH_LAB_USC: Results from our #COVID19 study: children exposed to #gestationaldiabetes in utero (a risk factor for adverse psych. ou‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@drkatiepage,#COVID19 is linked to reduced physical activity and high anxiety in children. Our @BRANCH_LAB_USC  team show children born to mothers with gestational diabetes have higher anxiety due in part to less #PhysicalActivity . https://t.co/manGzbzYC4 https://t.co
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@BRANCH_LAB_USC,"Results from our #COVID19 study: children exposed to #gestationaldiabetes in utero (a risk factor for adverse psych. outcomes) reported higher anxiety & lower physical activity during the pandemic, compared to unexposed children.  Check out our preprin"
http://medrxiv.org/cgi/content/short/2020.08.06.20169565,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes,@medrxivpreprint,Children's Anxiety and Physical Activity during COVID-19 in Relation to Prenatal Exposure to Gestational Diabetes  https://t.co/2G2UrUcDLS #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169813,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding,@Being_Medico,RT @drshalimar: Outcome of Conservative Therapy in #Covid_19 Patients Presenting with #Gastrointestinal #Bleeding #Cirrhosis #livertwitter‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169813,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding,@elhence_anshu,RT @drshalimar: Outcome of Conservative Therapy in #Covid_19 Patients Presenting with #Gastrointestinal #Bleeding #Cirrhosis #livertwitter‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169813,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding,@DrAnuraagJ,RT @drshalimar: Outcome of Conservative Therapy in #Covid_19 Patients Presenting with #Gastrointestinal #Bleeding #Cirrhosis #livertwitter‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169813,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding,@Sanchit30497977,RT @drshalimar: Outcome of Conservative Therapy in #Covid_19 Patients Presenting with #Gastrointestinal #Bleeding #Cirrhosis #livertwitter‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169813,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding,@drshalimar,Outcome of Conservative Therapy in #Covid_19 Patients Presenting with #Gastrointestinal #Bleeding #Cirrhosis #livertwitter https://t.co/uVbiDZcMYy
http://medrxiv.org/cgi/content/short/2020.08.06.20169813,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding,@medrxivpreprint,Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding  https://t.co/ADWAtJ2rpl #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Carmen16112218,RT @alonsosilva: @tm_todo Este es el tweet original: https://t.co/xyXdOvNOe8
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@DiseaseEcology,Two more age-specific IFRs are now available so 6 now exist+2 w/ all-cause estimates (Figs: log & not). *=Based on serology. Pastor (Spain): https://t.co/86rEG9Yq9U Ward (England): https://t.co/BGFHdd5gbL Other refs above (Note: 0's for young ages can'
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@uuaaai,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@yousun01,RT @yumifurusawa: „Äå„Å©„ÅÜÂàÜÊûê„Åó„Å¶„ÇÇ„Ç≥„É≠„Éä„Ç¶„Ç£„É´„Çπ„ÅØ„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Çà„Çä„ÇÇ‰∫∫„ÇíÂ§ö„ÅèÊ≠ª„Å´Ëá≥„Çâ„Åó„ÇÅ„Åæ„Åô„ÄÇ„Äç„Éè„Éº„É¥„Ç°„Éº„ÉâÂ§ßÂ≠¶„ÅÆMiguel Hern√°nÊïôÊéà„ÅÆÁ§∫„Åô„ÄÅË°ÄÊ∏ÖÊäó‰Ωì„ÅÆÂ§ßË¶èÊ®°Ë™øÊüª„Å´„Çà„ÇãÊÑüÊüìÊ≠ª‰∫°„É™„Çπ„ÇØ(IFR)„ÅÆÊ§úË®ºÁµêÊûú„ÄÇ„Ç≥„É≠„Éä„Ç¶„Ç£„É´„Çπ„ÅÆÂΩ±ÈüøÂäõ„Çí„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Åè„Çâ„ÅÑ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@shingokatou,RT @yumifurusawa: „Äå„Å©„ÅÜÂàÜÊûê„Åó„Å¶„ÇÇ„Ç≥„É≠„Éä„Ç¶„Ç£„É´„Çπ„ÅØ„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Çà„Çä„ÇÇ‰∫∫„ÇíÂ§ö„ÅèÊ≠ª„Å´Ëá≥„Çâ„Åó„ÇÅ„Åæ„Åô„ÄÇ„Äç„Éè„Éº„É¥„Ç°„Éº„ÉâÂ§ßÂ≠¶„ÅÆMiguel Hern√°nÊïôÊéà„ÅÆÁ§∫„Åô„ÄÅË°ÄÊ∏ÖÊäó‰Ωì„ÅÆÂ§ßË¶èÊ®°Ë™øÊüª„Å´„Çà„ÇãÊÑüÊüìÊ≠ª‰∫°„É™„Çπ„ÇØ(IFR)„ÅÆÊ§úË®ºÁµêÊûú„ÄÇ„Ç≥„É≠„Éä„Ç¶„Ç£„É´„Çπ„ÅÆÂΩ±ÈüøÂäõ„Çí„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Åè„Çâ„ÅÑ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@yumifurusawa,„Äå„Å©„ÅÜÂàÜÊûê„Åó„Å¶„ÇÇ„Ç≥„É≠„Éä„Ç¶„Ç£„É´„Çπ„ÅØ„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Çà„Çä„ÇÇ‰∫∫„ÇíÂ§ö„ÅèÊ≠ª„Å´Ëá≥„Çâ„Åó„ÇÅ„Åæ„Åô„ÄÇ„Äç„Éè„Éº„É¥„Ç°„Éº„ÉâÂ§ßÂ≠¶„ÅÆMiguel Hern√°nÊïôÊéà„ÅÆÁ§∫„Åô„ÄÅË°ÄÊ∏ÖÊäó‰Ωì„ÅÆÂ§ßË¶èÊ®°Ë™øÊüª„Å´„Çà„ÇãÊÑüÊüìÊ≠ª‰∫°„É™„Çπ„ÇØ(IFR)„ÅÆÊ§úË®ºÁµêÊûú„ÄÇ„Ç≥„É≠„Éä„Ç¶„Ç£„É´„Çπ„ÅÆÂΩ±ÈüøÂäõ„Çí„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Åè„Çâ„ÅÑ„ÅÆ„ÇÇ„ÅÆ„Å†„Å®Âº∑ÂºÅ„Åô„Çã‰∫∫„Åü„Å°„Å∏„ÅÆË≠¶Âëä„Å®„Å™„Å£„Å¶„ÅÑ„Åæ„Åô„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@zephyorg,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Chad_Cotti,"@ChrisCiancimino Bc its not the flu.  1) The Flu has IFR of 0.1%, COVID has an IFR of between 0.8% and 1% according to recent studies. So, its probably 8 to 10 times more deadly. https://t.co/TF2NlLu5r7."
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@maudefroberg,RT @ecapobianco: Important findings on the severity of #covid19.  ‚ÄúThe overall Infection Fatality Risk (IFR) ranges from 1.1% to 1.4% in me‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@AmarilleIan,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@iDeviceHelp_,„Ç≥„É≠„Éä„ÅØ„Åü„Å†„ÅÆ„Ç§„É≥„Éï„É´„Åß„ÅØ„Å™„ÅÑ ‰ªä„Åô„Åê‰ºëÊ†°„Å´„Åô„Åπ„Åç
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@iDeviceHelp_,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@gyobu2,„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Çà„Çä„ÄÅ„Ç≥„É≠„Éä„ÅÆÊñπ„ÅåÂúßÂÄíÁöÑ„Å´Âç±Èô∫„Å†„Çà„ÉºÔºÅ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@ACN_Veterinario,RT @Virusemergentes: Highly accurate estimation of IFR (infection fatality rate) in Spain based on nationwide seroprevalence study and exce‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@dodojenkins1,@youyanggu @spawnofKahn What accounts for the difference here   https://t.co/sCgRoDpthX
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@johanneszeller,"@weidenberger @reitschuster Einfach mal nachrechnen, was diese Zahlen auf die gesamte Bev√∂lkerung Deutschlands hochgerechnet bedeuten w√ºrden https://t.co/tqvQMRmttm"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@johanneszeller,"@KokospalmeBlog @nilsnto Niemand, der bei Verstand ist, kann eine Herdenimmunit√§t durch nat√ºrliche Durchseuchung der Bev√∂lkerung wollen. https://t.co/tqvQMRE4kU"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@CaveoLab,RT @RaquelYotti: The population-based seropidemiological study #ENECOVID  provides sex and age specific estimates of infection fatality ris‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@pasmo7298,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@SueSuegferguson,"RT @skathire: If you get COVID-19, what are your chances of dying?  Largest study yet of infection fatality rate (# deaths divided by #infe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@monicacmarta,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@zhihuachen,"RT @ScottGottliebMD: One of the largest studies to date of the Covid infection fatality rate (IFR not CFR). Overall, the IFR estimate was 0‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@RogerHilfiker,RT @C_Althaus: New seroprevalence-based estimates of the infection fatality ratio (IFR) in Spain (overall: 0.82%-1.07%) confirm our earlier‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@aolayink,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@nanashinomari,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@nanashinomari,„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆÊ≠ª‰∫°Áéá„ÅØ„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Çà„Çä„ÇÇ„ÅØ„Çã„Åã„Å´Â§ö„ÅÑ„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@MartinWaltherDD,@Herthaner02 @DaFeid @Nasirea1 H√§? Was? Wie alt ist diese Studie? Auch zu alt? https://t.co/gw6BrWzEaZ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Lluna02191138,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@MartinWaltherDD,@Herthaner02 @DaFeid @Nasirea1 Wollt ihr mich ver√§ppeln? Die IFR in den letzten 14 Tagen? Die Leute sterben in der Regel nach 3-4 Wochen! Hier gibt es korrekte Informationen. https://t.co/gw6BrWzEaZ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@CatArsenault,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@cincdefamilia,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@EsterRubio2,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@periodoespecial,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@johanneszeller,"@Martina__SchaLu @MartinWaltherDD @Darkwish1970 @tazgezwitscher Wie kommt es, dass Sie Herrn Miguel Hern√°n, der Professor f√ºr Biostatistik und Epidemiologie an der Harvard University ist, absprechen, die Lage beurteilen zu k√∂nnen? https://t.co/tqvQMRmttm"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@fusasippona,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Rsider,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@davidparron,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Jennicide,@MortoOnTech https://t.co/KNgr49Q9yK
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@BlackForext,"RT @skathire: If you get COVID-19, what are your chances of dying?  Largest study yet of infection fatality rate (# deaths divided by #infe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Naptown_G,Look at the IFR for under 50... minuscule #LetThemPlay
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@PolarBearby,@cinecristianm @Agroalcubo @latercera @conystipicic @matiasdelrio @edustekel No le√≠ste el art√≠culo de Nature? Niegas los datos? O este otro reci√©n publicado: https://t.co/PUtYIhRgof
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Ambroseglen,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@ircrc,@GeryWarner @kmcorby @jbouie @chrislhayes These authors studied one of the largest serodurveys in the world - Spain ‚Äî and found IFR of COVID-19 is about 10x the flu. They also studied excess death.  https://t.co/OAZotNHPXI
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@cdonatt,"SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study | medRxiv - The IFR increased sharply after age 50, ranging between 11.6% and 16.4% in men ‚â•80 years and between 4.6% and 6.5% in women ‚â•80 years. https://t.co/3Pyf23xoPO"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@necobone,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@DianvanderwalDr,"RT @skathire: If you get COVID-19, what are your chances of dying?  Largest study yet of infection fatality rate (# deaths divided by #infe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@BorisBarbour,@SethAbramson https://t.co/ukVb0rL5yd
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@skullkrusher95,@ScottGottliebMD https://t.co/Ufq7KtQklI  So-you know the difference between CFR and IFR yet you keep this misinformation up?
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@YogenKanthi,"RT @skathire: If you get COVID-19, what are your chances of dying?  Largest study yet of infection fatality rate (# deaths divided by #infe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@gli942,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@BeatrizPerezGom,@GidMK @federicolois @OYCar @CovidSerology @DiseaseEcology @MBittencourtMD @isabelrodbar @WesPegden @AdamJKucharski Spanish IFR  based on the national serosurvey https://t.co/PqYvsd4Tof
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@BeatrizPerezGom,@avtansh @xMohakGupta https://t.co/PqYvsd4Tof
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@forest10000,RT @C_Althaus: New seroprevalence-based estimates of the infection fatality ratio (IFR) in Spain (overall: 0.82%-1.07%) confirm our earlier‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@TJHisLaw,RT @C_Althaus: New seroprevalence-based estimates of the infection fatality ratio (IFR) in Spain (overall: 0.82%-1.07%) confirm our earlier‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@estherggeUAM,RT @RaquelYotti: The population-based seropidemiological study #ENECOVID  provides sex and age specific estimates of infection fatality ris‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@TJargstorff,@SHomburg @c_drosten @Karl_Lauterbach Woher haben die beiden die Behauptungen zur Sterberate? https://t.co/1b043QJi1o
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@sispona,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@macia_i,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@tomoyo_okumura,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@kevinpurcell,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@kevinpurcell,RT @C_Althaus: New seroprevalence-based estimates of the infection fatality ratio (IFR) in Spain (overall: 0.82%-1.07%) confirm our earlier‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@mmoliveras,RT @cescayora: 1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@alonsosilva,@tm_todo Este es el tweet original: https://t.co/xyXdOvNOe8
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@dodojenkins1,@BJLoVerde @mjbooth1 https://t.co/sCgRoDpthX
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@AlvaroMourenza,"Muy interesante este pre-print sobre la tasa de mortalidad del SARS-CoV-2 en Espa√±a, teniendo en cuenta muertes confirmadas y estimadas, comparadas con el estudio de seroprevalencia. https://t.co/SQpT8yF4oN"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@sebloom,RT @DougMasson: New study on Infection Fatality Risk (deaths divided by infections) (not yet peer-reviewed) - top line numbers between 1.1%‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@mjferreiro,RT @pmarsupia: Estos datos se han sacado gracias al gran estudio serol√≥gico que hizo Espa√±a.   Los estudios ser√≥logicos nos permiten estima‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@18Z73,RT @ernestorr: Estudios serol√≥gicos en Espa√±a indican los siguientes n√∫meros de mortalidad por COVID Total Hombres: 1.1%-1.4% Mujeres:  0.6‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@Carlos_alfamin,RT @pmarsupia: Estos datos se han sacado gracias al gran estudio serol√≥gico que hizo Espa√±a.   Los estudios ser√≥logicos nos permiten estima‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@supergirlmom3,RT @DougMasson: New study on Infection Fatality Risk (deaths divided by infections) (not yet peer-reviewed) - top line numbers between 1.1%‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@IndianaTalks,RT @DougMasson: New study on Infection Fatality Risk (deaths divided by infections) (not yet peer-reviewed) - top line numbers between 1.1%‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@cinnamochan,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@d33482348e0a460,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@IgnasiMeteo,RT @Virusemergentes: Highly accurate estimation of IFR (infection fatality rate) in Spain based on nationwide seroprevalence study and exce‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@cescayora,1‚É£ Els nens tamb√© s'infecten amb el SARS-CoV-2 malgrat la prevalen√ßa √©s lleugerament inferior que en adults.  2‚É£ Els s√≠mptomes s√≥n m√©s lleus i diferents dels dels adults. La mortalitat √©s pr√†cticament nul¬∑la. Hi ha diferents hip√≤tesis per explicar-ho.  htt
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@ttud1344429,RT @kemohure: „Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Å®Êñ∞Âûã„Ç≥„É≠„Éä„ÅÆËá¥ÂëΩÁéá„ÅÆÊØîËºÉ„Éá„Éº„Çø„ÄÇÂ∑Æ„ÅØÊ≠¥ÁÑ∂„Åß„Åô„Å≠„ÄÇ https://t.co/H1AXtx8hFs
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@lemon_drop22,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@kyasubaru_ani,RT @kemohure: „Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Å®Êñ∞Âûã„Ç≥„É≠„Éä„ÅÆËá¥ÂëΩÁéá„ÅÆÊØîËºÉ„Éá„Éº„Çø„ÄÇÂ∑Æ„ÅØÊ≠¥ÁÑ∂„Åß„Åô„Å≠„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@tohsekitetsu,RT @kemohure: „Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Å®Êñ∞Âûã„Ç≥„É≠„Éä„ÅÆËá¥ÂëΩÁéá„ÅÆÊØîËºÉ„Éá„Éº„Çø„ÄÇÂ∑Æ„ÅØÊ≠¥ÁÑ∂„Åß„Åô„Å≠„ÄÇ https://t.co/H1AXtx8hFs
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@kemohure,„Ç§„É≥„Éï„É´„Ç®„É≥„Ç∂„Å®Êñ∞Âûã„Ç≥„É≠„Éä„ÅÆËá¥ÂëΩÁéá„ÅÆÊØîËºÉ„Éá„Éº„Çø„ÄÇÂ∑Æ„ÅØÊ≠¥ÁÑ∂„Åß„Åô„Å≠„ÄÇ
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@kemohure,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@ich_rie,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@bokumamayo,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@ttxp_fctn7007,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@kenmomd,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@DougMasson,New study on Infection Fatality Risk (deaths divided by infections) (not yet peer-reviewed) - top line numbers between 1.1% and 1.4% in men and 0.58% to 0.77% in women. About 10x the rate for seasonal flu. https://t.co/ocq8Ol8Qlt
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@jazzlivesmatter,„Å©„ÅÖ„Éº„Çì  https://t.co/EPugvzMy6Y
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@suzuki_takaya,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@EvaBS14,RT @RaquelYotti: The population-based seropidemiological study #ENECOVID  provides sex and age specific estimates of infection fatality ris‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@TakBerdoi,"RT @skathire: If you get COVID-19, what are your chances of dying?  Largest study yet of infection fatality rate (# deaths divided by #infe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@eva_madrid_aris,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@VaccineWatch,"RT @skathire: If you get COVID-19, what are your chances of dying?  Largest study yet of infection fatality rate (# deaths divided by #infe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@artikeldienst,RT @epsilon3141: Neue Gro√üstudie: 0.83% IFR = Sterberate bezogen auf alle Infektionen (also auch asymptomatische).  => Durchseuchung bis He‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@MarcelHarmon1,"RT @j_g_allen: Critical to look at infection fatality rate (IFR) by age group   Big jumps in risk at 20, 50, and 70+  Key for risk decision‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@anafernandez78,RT @pmarsupia: Estos datos se han sacado gracias al gran estudio serol√≥gico que hizo Espa√±a.   Los estudios ser√≥logicos nos permiten estima‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@JacoboSilvaGuis,RT @RaquelYotti: The population-based seropidemiological study #ENECOVID  provides sex and age specific estimates of infection fatality ris‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@RalA19774067,RT @pmarsupia: Estos datos se han sacado gracias al gran estudio serol√≥gico que hizo Espa√±a.   Los estudios ser√≥logicos nos permiten estima‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@javig_asensio,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@SotilloJavi,RT @_Isra_Cruz: Assessing #SARSCoV2 Infection Fatality Risk in Spain using seroprevalence and excess mortality data  https://t.co/1tekO5YfD4
http://medrxiv.org/cgi/content/short/2020.08.06.20169722,SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study,@catanyasthings,RT @_MiguelHernan: Estimates of infection mortality risk (IFR) of #SARSCoV2 form largest serosurvey:  Overall Men: 1.1% to 1.4% Women: 0.58‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169656,Obtaining prevalence estimates of COVID-19: A model to inform decision-making,@biofreaks5,RT @DeRickNojkfMad: @HenriquezOsmar @SalaCnalSV @AsambleaSV @medrxivpreprint Ahora bien... Te comparto uno m√°s reciente. Esta enfermedad no‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169656,Obtaining prevalence estimates of COVID-19: A model to inform decision-making,@VengoViolento,"el derecho tambi√©n es ciencia, enterate, y de eso no sabes nada, miles de estudios hay sobre el covid, pero nuestra constituci√≥n solo es una leela a conciencia para no repetir sandeces como que la sala dice que no hay pandemia"
http://medrxiv.org/cgi/content/short/2020.08.06.20169656,Obtaining prevalence estimates of COVID-19: A model to inform decision-making,@DeRickNojkfMad,@VengoViolento @CLozada78 @HenriquezOsmar @SalaCnalSV @AsambleaSV Deja tu lenguaje peyorativo y despectivo. Lee informaci√≥n cient√≠fica y sal de la ignorancia https://t.co/233ZIgNHQy
http://medrxiv.org/cgi/content/short/2020.08.06.20169656,Obtaining prevalence estimates of COVID-19: A model to inform decision-making,@DeRickNojkfMad,"@HenriquezOsmar @SalaCnalSV @AsambleaSV @medrxivpreprint Ahora bien... Te comparto uno m√°s reciente. Esta enfermedad no es de √≠ndole financiera. Se necesits aprender c√≥mo funciona y pensar c√≥mo prevenirla, mitigarla, y luego erradicarla.  https://t.co/233Z"
http://medrxiv.org/cgi/content/short/2020.08.06.20169656,Obtaining prevalence estimates of COVID-19: A model to inform decision-making,@medrxivpreprint,Obtaining prevalence estimates of COVID-19: A model to inform decision-making  https://t.co/NzshAjxJRu #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20163840,Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020,@outbreaksci,"Contribute a rapid review or request one for ""Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020"" (https://t.co/Pfl47UL51K). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20163840) at https://t.co/RnurTL3DyM @outbreaksci @"
http://medrxiv.org/cgi/content/short/2020.08.07.20163840,Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020,@outbreaksci,New #SARSCoV preprint: Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020 https://t.co/Pfl47UttDa
http://medrxiv.org/cgi/content/short/2020.08.07.20163840,Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020,@EdidiFranck,RT @medrxivpreprint: Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020  https://t.co/B6VOu7kaLg #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20163840,Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020,@medrxivpreprint,Prevalence of SARS-CoV-2 among high-risk populations in Lom&eacute (Togo) in 2020  https://t.co/B6VOu7kaLg #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169557,A SEIR-like model with a time-dependent contagion factor describes the dynamics of the Covid-19 pandemic,@medrxivpreprint,A SEIR-like model with a time-dependent contagion factor describes the dynamics of the Covid-19 pandemic  https://t.co/SUHMu8Qu1m #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169664,Estimating the Changing Infection Rate of COVID-19 Using Bayesian Models of Mobility,@CHOMES102,"https://t.co/M8shQRirri Estimating the Changing Infection Rate of COVID-19 Using Bayesian Models of Mobility Luyang Liu, Sharad Vikram, Junpeng Lao, Xue Ben, Alexander D'Amour, Shawn O'Banion, Mark Sandler, Rif A. Saurous, Matthew D. Hoffman"
http://medrxiv.org/cgi/content/short/2020.08.06.20169664,Estimating the Changing Infection Rate of COVID-19 Using Bayesian Models of Mobility,@biofreaks5,RT @medrxivpreprint: Estimating the Changing Infection Rate of COVID-19 Using Bayesian Models of Mobility  https://t.co/MjTMIyJD0p #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169664,Estimating the Changing Infection Rate of COVID-19 Using Bayesian Models of Mobility,@medrxivpreprint,Estimating the Changing Infection Rate of COVID-19 Using Bayesian Models of Mobility  https://t.co/MjTMIyJD0p #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20169847,Pre-pandemic psychiatric disorders and risk of COVID-19: a cohort analysis in the UK Biobank,@CovidWellbeing,Pre-pandemic psychiatric disorders and risk of COVID-19: a cohort analysis in the UK Biobank https://t.co/JJi5Z6D2y3 #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.07.20169847,Pre-pandemic psychiatric disorders and risk of COVID-19: a cohort analysis in the UK Biobank,@drhalat,https://t.co/cH3zx35Gux
http://medrxiv.org/cgi/content/short/2020.08.07.20169847,Pre-pandemic psychiatric disorders and risk of COVID-19: a cohort analysis in the UK Biobank,@medrxivpreprint,Pre-pandemic psychiatric disorders and risk of COVID-19: a cohort analysis in the UK Biobank  https://t.co/pMVBYA3kIz #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@Justin_Remais,RT @medrxivpreprint: The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@ShelleyFacente,RT @JenniferR_Head: How do long-term school closures affect children's social networks? How effective were spring closures in the Bay Area?‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@Justin_Remais,RT @JenniferR_Head: How do long-term school closures affect children's social networks? How effective were spring closures in the Bay Area?‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@JenniferR_Head,"How do long-term school closures affect children's social networks? How effective were spring closures in the Bay Area? Which community/school interventions permit safe fall reopenings? Honored to have worked with @KristinAndrejko , @Justin_Remais & ot"
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@SSeguirem,Us convide a llegir almenys les p√†gines 26-30 d'aquest estudi: https://t.co/C241jxr1kT publicat avui per la Universitat de California #AixiNoTornem @AixiNoTornem @VicentMarza @STEPV_Iv @IntersindicalV @GVAeducacio @educaciongob
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@jm_links,"https://t.co/iuurFZadvE - The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis | medRxiv : New preprint, modelling COVID-19 transmission in Bay A"
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@jmason,"RT @KristinAndrejko: Our latest pre-print, ""The effect of school closures and reopening strategies on #COVID19 infection dynamics in the Sa‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@TAlexPerkins,"RT @KristinAndrejko: Our latest pre-print, ""The effect of school closures and reopening strategies on #COVID19 infection dynamics in the Sa‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@Justin_Remais,How many Bay Area cases were averted by spring school closures? @KristinAndrejko @JenniferR_Head and others investigate https://t.co/bB0kqwk7jF
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@Justin_Remais,New pre-print: What school protective measures might permit cautious reopening? Who benefits most from physical distancing measures? Which teachers & classrooms are most at risk? Exceptional work by @KristinAndrejko @JenniferR_Head provides answers
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@viralvideovlogs,"RT @KristinAndrejko: Our latest pre-print, ""The effect of school closures and reopening strategies on #COVID19 infection dynamics in the Sa‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@Pres_Hoover_II,"RT @KristinAndrejko: Our latest pre-print, ""The effect of school closures and reopening strategies on #COVID19 infection dynamics in the Sa‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169797,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis,@medrxivpreprint,The effect of school closures and reopening strategies on COVID-19 infection dynamics in the San Francisco Bay Area: a cross-sectional survey and modeling analysis  https://t.co/fakJsAdLIR #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@jolynhersch,RT @somacrat: New preprint: Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@Gareth_DFW,RT @somacrat: New preprint: Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@MayoOnTheBrain,RT @somacrat: New preprint: Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@somacrat,Here it is. https://t.co/s5ZBE9Sjhk
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@somacrat,"New preprint: Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.   https://t.co/BqBbpAIa7S"
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@kelene_k,"RT @zanfr: #COVID„Éº19 https://t.co/gT5wrf3gY0  donc il semble que charge virale, age et prise et charge rapide soient les facteurs les plus‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@75867966_Quinoa,"RT @zanfr: #COVID„Éº19 https://t.co/gT5wrf3gY0  donc il semble que charge virale, age et prise et charge rapide soient les facteurs les plus‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@marenrowold,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study. | medRxiv https://t.co/h0lDhfAc2F"
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@afao94,"RT @zanfr: #COVID„Éº19 https://t.co/gT5wrf3gY0  donc il semble que charge virale, age et prise et charge rapide soient les facteurs les plus‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@zanfr,"#COVID„Éº19 https://t.co/gT5wrf3gY0  donc il semble que charge virale, age et prise et charge rapide soient les facteurs les plus importants. donc masque et prophylaxie."
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@angelaferreirag,RT @medrxivpreprint: Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 day‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@HeManJespersen,¬´Thirty-day mortality rate in COVID-19 patients admitted to Swedish intensive care units is generally lower than previously reported.¬ª
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@HeManJespersen,RT @medrxivpreprint: Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 day‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169599,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.",@medrxivpreprint,"Characteristics and outcomes of patients admitted to Swedish intensive care units for COVID-19 during the first 60 days of the 2020 pandemic: a registry-based, multicenter, observational study.  https://t.co/iE0NYMV27d #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@Noams_Ark,"◊™◊ï◊¶◊ê◊î ◊ì◊ï◊û◊î ◊î◊™◊ß◊ë◊ú◊î ◊ë◊û◊ó◊ß◊® ◊©◊†◊¢◊®◊ö ◊ë◊ì◊®◊ï◊ù ◊ê◊§◊®◊ô◊ß◊î ◊ï◊ò◊ô◊ï◊ò◊î ◊©◊ú◊ï ◊§◊ï◊®◊°◊û◊î ◊ú◊§◊†◊ô ◊õ◊ó◊ï◊ì◊©. ◊î◊ï◊ê ◊û◊¶◊ê ◊©-HIV ◊ß◊©◊ï◊® ◊ú◊î◊õ◊§◊ú◊î, ◊õ◊û◊¢◊ò, ◊©◊ú ◊î◊°◊ô◊õ◊ï◊ü ◊ú◊û◊ï◊™ ◊û-COVID-19 https://t.co/HwSf9eih9y  ◊û◊ó◊ß◊® ◊ë◊®◊ô◊ò◊ô ◊†◊ï◊°◊£, ◊©◊ò◊ô◊ï◊ò◊î ◊©◊ú◊ï ◊§◊ï◊®◊°◊û◊î ◊ú◊§◊†◊ô ◊©◊ë◊ï◊¢, ◊û◊¶◊ê ◊í◊ù ◊î◊ï◊ê ◊ß◊©◊® ◊ë◊ô◊ü HIV ◊ú◊¢◊ú◊ô◊ô◊î ◊ë◊°◊ô◊õ◊ï◊ü ◊ú◊û◊ï◊™ ◊û◊ß◊ï◊®◊ï◊†◊î htt"
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@Winser_NBueno,"Y este √∫ltimo es otro que se llev√≥ a cabo en el Reino Unido - Primary Care OpenSAFELY. Aqu√≠ tambi√©n se asoci√≥ que la infecci√≥n por VIH (+) se relacion√≥, significativamente, de muerte por #COVID19. (3/3) @medrxivpreprint https://t.co/OtUihRuUmd"
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@YouCanFoolMost,"RT @Esteban09090: @GerettiAnna @drlaurajwaters @mugecevik @BritishHIVAssoc @HIViBase @carolinesabin Nice work  ‚Å¶@GerettiAnna, @drlaurajwate‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@Esteban09090,"@GerettiAnna @drlaurajwaters @mugecevik @BritishHIVAssoc @HIViBase @carolinesabin Nice work  ‚Å¶@GerettiAnna, @drlaurajwaters,  @mugecevik, ‚Å¶@BritishHIVAssoc, @HIViBase, ‚Å¶ @carolinesabin! Greater adjusted COVID-19 mortality in HIV+ persons! Similar results a"
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@uctcider,Very interesting to see similar hazard of HIV-associated COVID-19 death in the Western Cape and UK both using population cohorts. @bengoldacre @DarthCTR https://t.co/G1Dlmdtd5D https://t.co/btoDBJVnRQ
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@Aquerales,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.  https://t.co/pmFmm1YgBL #COVID19 #venezuela #chile #colombia #argentina #usa
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@EdidiFranck,RT @medrxivpreprint: HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death r‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,@medrxivpreprint,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform  https://t.co/MgkOakAa6F #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168476,Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays,@nonya_bidniss,RT @outbreaksci: New #SARSCoV preprint: Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168476,Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays,@outbreaksci,New #SARSCoV preprint: Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays https://t.co/QgWxDkrweH
http://medrxiv.org/cgi/content/short/2020.08.05.20168476,Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays,@outbreaksci,"Contribute a rapid review or request one for ""Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays"" (https://t.co/QgWxDkrweH). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168476) at https://t.co/RnurTL3DyM @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.08.05.20168476,Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays,@outbreaksci,New #COVID19 preprint: Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays https://t.co/QgWxDkrweH
http://medrxiv.org/cgi/content/short/2020.08.05.20168476,Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays,@medrxivpreprint,Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays  https://t.co/rmsB9hntTC #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@_tlr_,"RT @levitationpsych: ""...our data suggest that antibodies against the seasonal coronavirus 229E contribute to SCoV2 neutralization"" https:/‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@levitationpsych,"""...our data suggest that antibodies against the seasonal coronavirus 229E contribute to SCoV2 neutralization"" https://t.co/YXmWu3kyyP"
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@drafanysol,RT @medrxivpreprint: Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients  https://t.co/OVeqYSGkWV #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@drafanysol,@Juangs95 @Titiguesol_
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@marenrowold,CV 229E AK sch√ºtzen ggf teilweise? Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients | medRxiv https://t.co/rtVVLeUdo5
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@outbreaksci,"Contribute a rapid review or request one for ""Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients"" (https://t.co/TpL6LVq3Nm). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20169961) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@outbreaksci,New #SARSCoV preprint: Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients https://t.co/TpL6LVq3Nm
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@KrutikaKuppalli,RT @medrxivpreprint: Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients  https://t.co/OVeqYSGkWV #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20169961,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients,@medrxivpreprint,Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients  https://t.co/OVeqYSGkWV #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@IndianEwok,RT @rauch1jn: Check out our work profiling the asymptomatic COVID-19 infections in the SB community! https://t.co/b63T1BpR4M
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@maxzwilson,RT @rauch1jn: Check out our work profiling the asymptomatic COVID-19 infections in the SB community! https://t.co/b63T1BpR4M
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@rauch1jn,Check out our work profiling the asymptomatic COVID-19 infections in the SB community! https://t.co/b63T1BpR4M
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@RonniePageHarl1,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@kharlozzz2,RT @medrxivpreprint: CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@PPGA_UCSB,RT @medrxivpreprint: CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@cmv75638448,RT @IndianEwok: very empowered to have been a part of this. science isn‚Äôt dry and dusty‚Äîit‚Äôs real people w/their own stories collectively d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@m_grunberg,RT @sabrina_solley: We recently conducted a surveillance study using RT-qPCR and our CRISPR-based test CREST to study SARS-CoV-2 prevalence‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@surenna_p,RT @IndianEwok: very empowered to have been a part of this. science isn‚Äôt dry and dusty‚Äîit‚Äôs real people w/their own stories collectively d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@stefan_arrr,RT @medrxivpreprint: CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@Dplrblmctnght,RT @futurepundit: CRISPR works almost as well as  RT-qPCR at detecting asymptomatic SARS-COV-2. Lots of ways to scale up testing now availa‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@kathrynloudon,RT @IndianEwok: very empowered to have been a part of this. science isn‚Äôt dry and dusty‚Äîit‚Äôs real people w/their own stories collectively d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@futurepundit,CRISPR works almost as well as  RT-qPCR at detecting asymptomatic SARS-COV-2. Lots of ways to scale up testing now available. https://t.co/PkUmAvbTgW
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@outbreaksci,"Contribute a rapid review or request one for ""CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncove..."" (https://t.co/FVvyQgKZr6). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20169771) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@outbreaksci,New #SARSCoV preprint: CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population https://t.co/FVvyQgKZr6
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@franzappa2,RT @lab_arias: We are proud of this great collaboration with an amazing group of researchers and healthcare workers. @daa_lab @KosikLab @ma‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@catyaf1996,RT @IndianEwok: very empowered to have been a part of this. science isn‚Äôt dry and dusty‚Äîit‚Äôs real people w/their own stories collectively d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@yungsocialist,RT @sabrina_solley: We recently conducted a surveillance study using RT-qPCR and our CRISPR-based test CREST to study SARS-CoV-2 prevalence‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@mmang000,This was done at UCSB! The free and accessible COVID testing that they provided was a huge help to me üòä
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@nnielai,this study was done at UCSB!!
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@surenna_p,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@alexgoglia,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@Adriana9Ramirez,RT @lab_arias: We are proud of this great collaboration with an amazing group of researchers and healthcare workers. @daa_lab @KosikLab @ma‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@juliusbrennecke,RT @lab_arias: We are proud of this great collaboration with an amazing group of researchers and healthcare workers. @daa_lab @KosikLab @ma‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@IndianEwok,"very empowered to have been a part of this. science isn‚Äôt dry and dusty‚Äîit‚Äôs real people w/their own stories collectively driving towards creating a better future. This story will help inform our decisions of tomorrow, hopefully for the better. @sabrina_so"
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@maxzwilson,RT @lab_arias: We are proud of this great collaboration with an amazing group of researchers and healthcare workers. @daa_lab @KosikLab @ma‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@hitenmadhani,RT @lab_arias: We are proud of this great collaboration with an amazing group of researchers and healthcare workers. @daa_lab @KosikLab @ma‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@lab_arias,We are proud of this great collaboration with an amazing group of researchers and healthcare workers. @daa_lab @KosikLab @maxzwilson In summary... (1/3)
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@baxter_nj,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@Terdiv41,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@sabrina_solley,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@sabrina_solley,We recently conducted a surveillance study using RT-qPCR and our CRISPR-based test CREST to study SARS-CoV-2 prevalence in asymptomatic individuals in the UCSB community. Check out the results in medRxiv! @lab_arias @daa_lab @maxzwilson @KosikLab
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@daa_lab,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@Sara_Laila,RT @maxzwilson: Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@maxzwilson,Our CRISPR-based Covid surveillance study results are out: https://t.co/rhMkM8kPs6  We think we caught the leading edge of a wave of cases coming through the UCSB community.   Amazing work from an incredible team including @lab_arias @daa_lab @KosikLab lab
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@jriske,RT @medrxivpreprint: CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169771,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population,@medrxivpreprint,CRISPR-based and RT-qPCR surveillance of SARS-CoV-2 in asymptomatic individuals uncovers a shift in viral prevalence among a university population  https://t.co/eTdERilrYy #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@unclenate,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@torque2punto0,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@saramshika,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@brettvalle,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@segal_eran,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@JohnSam57668631,"RT @AmyBaxterMD: Wrong person, place and time: viral load and contact network predict SARS-CoV-2 transmission, super-spreading https://t.co‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AmyBaxterMD,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events https://t.co/kJ1B9ADQbm  ""nasal viral load below 10 5th RNA copies is unlikely to commonly result in transmission"" - why masks"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AmyBaxterMD,"Wrong person, place and time: viral load and contact network predict SARS-CoV-2 transmission, super-spreading https://t.co/kJ1B9ADQbm - another preprint lending credence to aerosol transmission, and the concept that decreasing viral load reduces transmissi"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@MonicaMalta7,"Wrong place, wrong time: Coronavirus ‚Äúsuperspreader‚Äù events are most likely during the 1‚Äì2 day period when a person is shedding the most virus, according to a modeling study that has not yet been peer reviewed.  üìù https://t.co/rBTwJgSFjh https://t.co/6xSl"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@pall336_2,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@ShatskihEvgeny,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@nisusmedical,RT @nisusmedical: A person infected with #COVID19 exposes more people within equivalent physical contact networks than a person infected wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Purdinola,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Camarlenco,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@michellemck0,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@NubiolaBr,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@gorka_orive,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@DRWUATSON_WJOPH,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@CotherHajat,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Dheeraj04427004,RT @AltamashGauhar: #NTAPOSTPONEJEE_NEET @DG_NTA @DrRPNishank @advocate_alakh @nidhiindiatv @ndtv  Sir ATLEAST STUDY THE RESEARCH BEFORE T‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AltamashGauhar,#NTAPOSTPONEJEE_NEET @DG_NTA @DrRPNishank @advocate_alakh @nidhiindiatv @ndtv  Sir ATLEAST STUDY THE RESEARCH BEFORE TAKING ANY DECISION.   1 ACT OF NEGLIGENCE CAN LEAD TO A HEALTH HAZARD ü•∂üò∞üò®üò•üòìüò™üò™
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@CMagendie,Interesting study on transmission dynamics of SARS-Cov2 https://t.co/NXnijjJ8g7
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Max1980kopylov,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Max1980kopylov,RT @JaninePaynter: Really interesting study of SARS-CoV-2 transmission characteristics plus comparison with flu
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@johncanet,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@economicsNZ,RT @JaninePaynter: Really interesting study of SARS-CoV-2 transmission characteristics plus comparison with flu https://t.co/c6RbixL9x9
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@jaragallardoFH,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@fdecharro,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@machobaronjose,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@gnuggat1,Very important practical implications if true. Read the referenced preprint summary.
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@srglnd,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@JaninePaynter,Really interesting study of SARS-CoV-2 transmission characteristics plus comparison with flu
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AntifaDisabled,RT @_dbrvs_: Here's a link to the paper: https://t.co/KNZyLH1GET
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AltamashGauhar,@11Petitioners @advocate_alakh @anubha1812 @nidhiindiatv @mtosterholm @neelkashkari @nytopinion A VERY SIGNIFICANT PIECE.  Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people.  RT-@EricTopol https://
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@ChrisLancashir3,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@laotzuvan,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@joaquinmencia,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@GGBengoechea,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@mgmglobal,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@MichelleBro1971,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@CarlHansenMD,80% of the problem comes from 10-20% of the populations. Crowds of fools shall be zapped.
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@noticianimal,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@CarlHansenMD,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@mejia_bf,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@jrblanco11,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@DrZouaghi,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@huubgelderblom,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@jboylan,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@anjbth,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@DanChenMDPhD,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@sminaev2015,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@usse1965,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@JYusuffmd,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@RiddhiKaul,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@shananalla,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@HlpJoseph,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@davenjoe76,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@jasl71,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@eldonredwards,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@drnic1,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AltamashGauhar,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@LuisTuqui,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@adair_from_ns,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@medical91,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@adskankster,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@ErinOfAlaska,Thread
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@chrishendel,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@jeannefisher17,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Fradbius,RT @centinel5051: Nuevo estudio (preprint): los eventos de supercontagio posiblemente se produzcan al coincidir que una persona est√° en el‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@MauricioMAS13,RT @FJEspinosa: Muy interesante art√≠culo para explicar porqu√© este virus es tan contagioso. https://t.co/8LDw6niOXJ
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AM04611,RT @FJEspinosa: Muy interesante art√≠culo para explicar porqu√© este virus es tan contagioso.
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@FJEspinosa,Muy interesante art√≠culo para explicar porqu√© este virus es tan contagioso.
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@_dbrvs_,Here's a link to the paper: https://t.co/KNZyLH1GET
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@SuhnyllaKler,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@dockarehealth,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@karendkelley,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@tomorrowdaworld,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@achmadhandoko,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@gooserrrrr,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@daniyal_asim,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@S_BikeProject,"‚ö†Ô∏èRecuerdan que les habl√°bamos de #SaludP√∫blica y #PrincipioDePareto  en √©sta semana‚ùì  Qu√© les parece √©ste hilo ajeno... ‚ùì  ‚òùüèªMera coin-cidencia, recuerden √©ste t√©rmino‚òùüèª  #UnaVidaContigo üò∑üíúüö¥‚Äç‚ôÄÔ∏èüö¥‚Äç‚ôÇÔ∏è"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@kmvnarayan14,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@DarkHorse1618,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@omnidelic,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@AuntSophie1,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@martiw65,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Fredros_Inc,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@gilson_kathleen,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@seonaidsnail,RT @MAM12CP: This is why courts make me extra cautious... https://t.co/dBpYB936uz
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@DaytonaII,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@andreacpowers,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@banueta,"RT @gorka_orive: La radiograf√≠a del quien, cuando y donde de los super-eventos de contagio se ilustra en esta infograf√≠a. Fuente: https://t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@MAM12CP,This is why courts make me extra cautious...
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@pkmonaghan,"So what would happen if we put a quarter million people in one place, many outdoors, with no masks, for ten days?"
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@Gretchen_Sae,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@CopperAceBoyd,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@shannonsie,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@GSRajahram,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@yodapoda,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169920,"Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events",@maharg101,RT @EricTopol: Superspreading follows the Pareto principle (80/20 rule); we know about venues but not why in certain people. I like this ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.07.20169987,Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts,@outbreaksci,New #SARSCoV preprint: Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts https://t.co/J9z0sh6Job
http://medrxiv.org/cgi/content/short/2020.08.07.20169987,Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts,@outbreaksci,"Contribute a rapid review or request one for ""Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts"" (https://t.co/J9z0sh6Job). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.07.20169987) at https://t.co/RnurTL3DyM @outbreaksci @PRErevi"
http://medrxiv.org/cgi/content/short/2020.08.07.20169987,Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts,@outbreaksci,New #COVID19 preprint: Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts https://t.co/J9z0sh6Job
http://medrxiv.org/cgi/content/short/2020.08.07.20169987,Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts,@medrxivpreprint,Performance of an automated anti-SARS-CoV-2 immunoassay in prepandemic cohorts  https://t.co/24jBjqyrtk #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@traceRoque,RT @serremiranda_c: Our most recent pre-print publication @medrxivpreprint on the performance of serological tests for #SARSCoV2 @icvs_umin‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@Vitor_Fer_,RT @serremiranda_c: Our most recent pre-print publication @medrxivpreprint on the performance of serological tests for #SARSCoV2 @icvs_umin‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@carolinbpereira,RT @serremiranda_c: Our most recent pre-print publication @medrxivpreprint on the performance of serological tests for #SARSCoV2 @icvs_umin‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@Palmira_zul,RT @serremiranda_c: Our most recent pre-print publication @medrxivpreprint on the performance of serological tests for #SARSCoV2 @icvs_umin‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@serremiranda_c,Our most recent pre-print publication @medrxivpreprint on the performance of serological tests for #SARSCoV2 @icvs_uminho @Med_UMinho (some of the co-authors @traceRoque @JoaoDoCanto2 @Palmira_zul)
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@gunkal,Yet another important study by the group of @Margari45449255 of the complexity of serological tests for SARS-CoV-2 and the clinical implications  https://t.co/pzIe125dcs
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@nonya_bidniss,RT @outbreaksci: New #SARSCoV preprint: Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@outbreaksci,New #SARSCoV preprint: Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients https://t.co/ZB5rR15nE3
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@outbreaksci,"Contribute a rapid review or request one for ""Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitaliz..."" (https://t.co/ZB5rR15nE3). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20168856) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@outbreaksci,New #COVID19 preprint: Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients https://t.co/ZB5rR15nE3
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@CHOMES102,RT @medrxivpreprint: Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168856,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients,@medrxivpreprint,Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients  https://t.co/oJwpjrmjb2 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@KarlPfleger,"7/8  But aging is an even bigger risk factor for C19 than low D, just less easily modified. That doesn't mean it's immutable. The world should realize biological age is different from time since birth. https://t.co/VRYb9AjJ7W shows bio age is the true age"
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@TeriMil28351407,RT @KejunY: Our recent work on #COVID19 and #aging is now available as a #medRxiv preprint! @xiashen @VadimGladyshev https://t.co/Hjz7hkET‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@patyverjan,RT @AgingBiology: Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19 https://t.co/4qjA7uPRU9
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@paulrhjtimmers,RT @KejunY: Our recent work on #COVID19 and #aging is now available as a #medRxiv preprint! @xiashen @VadimGladyshev https://t.co/Hjz7hkET‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@QuimSegales,RT @medrxivpreprint: Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19  https://t.co/zb9EmCp3zE #medRx‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@SocksScience,RT @AgingBiology: Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19 https://t.co/4qjA7uPRU9
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@KejunY,"@mkaeberlein Hi Matt, our preprint that just out today actually strongly supports your point! https://t.co/Hjz7hkETWa"
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@xiashen,RT @KejunY: Our recent work on #COVID19 and #aging is now available as a #medRxiv preprint! @xiashen @VadimGladyshev https://t.co/Hjz7hkET‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@Peachykeen80,RT @AgingBiology: Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19 https://t.co/4qjA7uPRU9
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@KejunY,RT @AgingBiology: Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19 https://t.co/4qjA7uPRU9
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@KejunY,Our recent work on #COVID19 and #aging is now available as a #medRxiv preprint! @xiashen @VadimGladyshev https://t.co/Hjz7hkETWa  We found evidence at both genetic and phenotypic level that suggests a causal link between aging and COVID-19. #genetics #MR
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@mike_lustgarten,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19   https://t.co/RLqlUKPaaX
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@AgingBiology,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19 https://t.co/4qjA7uPRU9
http://medrxiv.org/cgi/content/short/2020.08.06.20169854,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19,@medrxivpreprint,Genetic and Phenotypic Evidence for the Causal Relationship Between Aging and COVID-19  https://t.co/zb9EmCp3zE #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@futurepundit,@davidboxenhorn Here's an example of the many research reports coming out on easier SARS-CoV-2 testing.
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@HonkyTonkManJPN,RT @outbreaksci: New #SARSCoV preprint: Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Devic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@HonkyTonkManJPN,RT @futurepundit: Mobile PCR device can detect coronavirus in 20 minutes.
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@HonkyTonkManJPN,RT @medrxivpreprint: Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@HonkyTonkManJPN,RT @nojokenolife: „ÉÄ„Ç§„É¨„ÇØ„Éà
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@outbreaksci,New #SARSCoV preprint: Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction https://t.co/7rGglceRNe
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@outbreaksci,"Contribute a rapid review or request one for ""Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-T..."" (https://t.co/7rGglceRNe). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20168294) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@outbreaksci,New #COVID19 preprint: Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction https://t.co/7rGglceRNe
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@futurepundit,Mobile PCR device can detect coronavirus in 20 minutes.
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@nojokenolife,„ÉÄ„Ç§„É¨„ÇØ„Éà
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@nojokenolife,ÂâçÂá¶ÁêÜ‰∏çË¶Å
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@MassatoHirai,RT @medrxivpreprint: Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20168294,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction,@medrxivpreprint,Quickly And Simply Detection For Coronavirus Including SARS-CoV-2 On The Mobile Real-Time PCR Device And Without RNA Extraction  https://t.co/yi1qZAxxLh #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20164129,Associations between personal protective equipment and nursing staff stress during the COVID-19 pandemic,@CovidWellbeing,Associations between personal protective equipment and nursing staff stress during the COVID-19 pandemic https://t.co/DG5j9e5Snv #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.06.20164129,Associations between personal protective equipment and nursing staff stress during the COVID-19 pandemic,@medrxivpreprint,Associations between personal protective equipment and nursing staff stress during the COVID-19 pandemic  https://t.co/542TUJDmNd #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@bwclibrary,You can access the full article free at https://t.co/1eWDkUSdxa
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@InflamAge_UoB,"RT @unibirm_MDS: A study by Dr Graham Taylor, @helenmed, @BarneyUoB et al is the first to reveal that #Kawasaki disease and #PIMSTS are bot‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@ImmunologyUoB,"RT @unibirm_MDS: A study by Dr Graham Taylor, @helenmed, @BarneyUoB et al is the first to reveal that #Kawasaki disease and #PIMSTS are bot‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@WMPA_UK,"RT @unibirm_MDS: A study by Dr Graham Taylor, @helenmed, @BarneyUoB et al is the first to reveal that #Kawasaki disease and #PIMSTS are bot‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@WvSchaik,"RT @unibirm_MDS: A study by Dr Graham Taylor, @helenmed, @BarneyUoB et al is the first to reveal that #Kawasaki disease and #PIMSTS are bot‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@unibirm_MDS,"A study by Dr Graham Taylor, @helenmed, @BarneyUoB et al is the first to reveal that #Kawasaki disease and #PIMSTS are both characterised by profound changes in the numbers of monocytes and their genetic make-up: https://t.co/zTK7z7p73a Read the preprint:"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@simplycavero,@Enloyb https://t.co/c2gUySQDJL
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@SingleCellMedia,"RT @outbreaksci: Contribute a rapid review or request one for ""Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflamma‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@SingleCellMedia,RT @outbreaksci: New #SARSCoV preprint: Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@outbreaksci,"Contribute a rapid review or request one for ""Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multi..."" (https://t.co/Tjj3VN0rV7). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20164848) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@outbreaksci,New #SARSCoV preprint: Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS) https://t.co/Tjj3VN0rV7
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@SingleCellMedia,RT @medrxivpreprint: Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally assoc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@simplycavero,RT @medrxivpreprint: Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally assoc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@Chrisshanbova,RT @medrxivpreprint: Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally assoc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@jriske,RT @medrxivpreprint: Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally assoc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20164848,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS),@medrxivpreprint,Single-cell RNA-seq reveals profound monocyte changes in Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 infection (PIMS-TS)  https://t.co/yhRQ43vdwY #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20162883,"SARS-CoV-2 surveillance in decedents in a large, urban medical examiner's office",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 surveillance in decedents in a large, urban medical examiner's office"" (https://t.co/YC67Qfp0Ie). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20162883) at https://t.co/RnurTL3DyM @outbreaksci @PREre"
http://medrxiv.org/cgi/content/short/2020.08.03.20162883,"SARS-CoV-2 surveillance in decedents in a large, urban medical examiner's office",@outbreaksci,"New #SARSCoV preprint: SARS-CoV-2 surveillance in decedents in a large, urban medical examiner's office https://t.co/YC67Qfp0Ie"
http://medrxiv.org/cgi/content/short/2020.08.03.20162883,"SARS-CoV-2 surveillance in decedents in a large, urban medical examiner's office",@medrxivpreprint,"SARS-CoV-2 surveillance in decedents in a large, urban medical examiner's office  https://t.co/no8vFKgzvd #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@MartinOlalla_JM,@lipido Incluso dos art√≠culos https://t.co/FIIXHHqnI7
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@ElmerEdward1,RT @PandemicCovid20: Age disaggregation of crude excess deaths during the 2020 spring #COVID19 outbreak in Spain and Netherlands - https://‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@juanseapi,RT @MartinOlalla_JM: ‚ÄúAge disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands‚Äù is now a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@PolarBearby,RT @MartinOlalla_JM: ‚ÄúAge disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands‚Äù is now a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@MartinOlalla_JM,@_MiguelHernan @sanidadgob @SaludISCIII @RaquelYotti @BeatrizPerezGom Could you check this? https://t.co/8o5jKouTQI https://t.co/UdQZ7MWKWq
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@MartinOlalla_JM,Es curioso. Tambi√©n hoy ha aparecido en @medrxivpreprint un preprint del grupo de ENECOVID (Instituto de Salud Carlos III) sobre el IFR por grupos de edad. https://t.co/NCHxWjPJ3s
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@MartinOlalla_JM,‚ÄúAge disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands‚Äù is now available at @medrxivpreprint https://t.co/9hpatPgtIE IFR doubles in Spain ~ every five years of increase in age (40 yo on) https://t.co/0
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@PandemicCovid20,Age disaggregation of crude excess deaths during the 2020 spring #COVID19 outbreak in Spain and Netherlands - https://t.co/YoQmlQfuxM
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@CHOMES102,RT @medrxivpreprint: Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands  https://t‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169326,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands,@medrxivpreprint,Age disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain and Netherlands  https://t.co/yvfV7ktuZF #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@outbreaksci,New #SARSCoV preprint: The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission https://t.co/M5Ii1dwwvt
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@outbreaksci,"Contribute a rapid review or request one for ""The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne tr..."" (https://t.co/M5Ii1dwwvt). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20169433) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@outbreaksci,New #COVID19 preprint: The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission https://t.co/M5Ii1dwwvt
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@csloredoped,RT @medrxivpreprint: The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission  https://t.co/TUMOUGp‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@MassatoHirai,RT @medrxivpreprint: The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission  https://t.co/TUMOUGp‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@Jun_Sky_0610,RT @medrxivpreprint: The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission  https://t.co/TUMOUGp‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@simplycavero,RT @medrxivpreprint: The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission  https://t.co/TUMOUGp‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169433,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission,@medrxivpreprint,The SARS-COV-2 outbreak around the Amazon rainforest: the relevance of the airborne transmission  https://t.co/TUMOUGpLyo #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@OSDG_annotator,"#OSDG has linked this publication to the UN's #SustainableDevelopmentGoals, including #Goal3 - Good Health and Well-being.  ‚úÖ Try for yourself at https://t.co/s175UlEFSe  Thanks for contributing to #Agenda2030! https://t.co/PZiLqF9oH3"
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@SciscoreReports,The paper ‚ÄúAssociation of mental disorders with SARS-CoV-2 in...‚Äù (https://t.co/V7fvO8xBOd) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/JlSghSPKnI. We detected 1 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@nonya_bidniss,RT @outbreaksci: New #SARSCoV preprint: Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@outbreaksci,New #SARSCoV preprint: Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study https://t.co/TmojL19d9H
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@outbreaksci,"Contribute a rapid review or request one for ""Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: ..."" (https://t.co/TmojL19d9H). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169201) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@outbreaksci,New #COVID19 preprint: Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study https://t.co/TmojL19d9H
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@rmchavin,"8-5-2020:  In a South Korean study released today, schizophrenics were nearly twice as likely to die of COVID-19. Why? Schizophrenics have an average IQ that is about 20 to 30 points lower than normal people so they eat more sugar, salt, white starch, meat"
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@CovidWellbeing,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study https://t.co/0avaSD0RsG #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.05.20169201,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study,@medrxivpreprint,Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: a nationwide cohort study  https://t.co/OmR10EtJcO #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169250,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals,@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Pseudovirus neutralization assay protocol download: https://t.co/Z9pyXg1Onl https://t"
http://medrxiv.org/cgi/content/short/2020.08.06.20169250,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals,@ingentium_COVID,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals https://t.co/Txo6C0UGKB
http://medrxiv.org/cgi/content/short/2020.08.06.20169250,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals,@outbreaksci,"Contribute a rapid review or request one for ""Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 ..."" (https://t.co/380HeyKcQd). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20169250) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20169250,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals,@outbreaksci,New #SARSCoV preprint: Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals https://t.co/380HeyKcQd
http://medrxiv.org/cgi/content/short/2020.08.06.20169250,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals,@angelaferreirag,RT @medrxivpreprint: Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169250,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals,@medrxivpreprint,Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals  https://t.co/1x4ymPN80U #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167882,"Dynamic Analysis of Social Distancing Ratio, Isolation Rate and Transmission Coefficient in COVID-19 Epidemic for Many Countries by SIQR Model",@medrxivpreprint,"Dynamic Analysis of Social Distancing Ratio, Isolation Rate and Transmission Coefficient in COVID-19 Epidemic for Many Countries by SIQR Model  https://t.co/hPZ8IOcwzt #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@JohnSam57668631,RT @aswedensky: Aerosol Generation from Different Wind Instruments https://t.co/u6xITKh4D5
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@aswedensky,Aerosol Generation from Different Wind Instruments https://t.co/u6xITKh4D5
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@PandemicCovid20,Aerosol Generation from Different Wind Instruments https://t.co/hCiFa2uF41
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@AppalledBC,https://t.co/FD5sxxHBvJ @CanadasNAC @ShelleyConduct Something to think about for live concerts.
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@SamLipworth,"Whilst we await data from @Voicedoctor_uk study, here's a nice little piece from the US. Trumpet, bass trombone and oboe highest risk, some instruments dynamic dependent, others not.. https://t.co/FZeqfS5N3K"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@JhongflowImg,My preprint is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/Q7omhxJvbB
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@AbdulsatarBoch1,Aerosol Generation from Different Wind Instruments https://t.co/xYGAZe1NEX
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@Hammarstrand,RT @chrishendel: Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶†‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@Mekk,"Covidowa kandydatura do Ig Nobla ‚Äì klasyfikacja instrument√≥w muzycznych pod wzglƒôdem skali generacji aerozoli przy okazji grania na nich. Tuba jest OK ale trƒÖbka czy ob√≥j bardzo niedobre. Co wiƒôcej, technika gry ma wp≈Çyw na wynik! https://t.co/FntrxB98fl"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@vxel,O C19 wiemy wiƒôc ju≈º wszystko. üòÇ
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@RaquelMedialdea,"Interesting to see the concentration and size distribution of #aerosols generated from different musical instruments. Very relevant for #COVID19 mitigation strategies for various musical activities such as orchestras, concerts, music classes, bands, etc. h"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@ayirpelle,RT @chrishendel: Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶†‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@KarenRauen,RT @chrishendel: Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶†‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@Laeeth,"RT @futurepundit: Wind instruments vary for risk of virus transmission: we categorize the instruments into low (tuba), intermediate (piccol‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@pianobug,"This chart/study hasn't been through peer review yet so the info presented may be erroneous, but it's still very much of interest to musicians."
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@that_darn,Attention:  @NAfME  @CTMusicEd
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@AllergyNet,"It seems all wind instruments should wear masks, except, thankfully, the tuba"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@rmdash,"RT @futurepundit: Wind instruments vary for risk of virus transmission: we categorize the instruments into low (tuba), intermediate (piccol‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@lb_bklyn,"RT @futurepundit: Wind instruments vary for risk of virus transmission: we categorize the instruments into low (tuba), intermediate (piccol‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@mskathleenquinn,"RT @futurepundit: Wind instruments vary for risk of virus transmission: we categorize the instruments into low (tuba), intermediate (piccol‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@futurepundit,"Wind instruments vary for risk of virus transmission: we categorize the instruments into low (tuba), intermediate (piccolo, flute, bass clarinet, French horn, and clarinet) and high risk (trumpet, bass trombone, and oboe) levels based on a comparison of th"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@pevohr,Any bets on how soon tubas start trending?
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@craigmatsuda,RT @chrishendel: Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶†‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@painopolis,Band members beware:
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@berkeleyprc,RT @chrishendel: Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶†‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@cdanuloff,RT @chrishendel: Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶†‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@so_dendritic,I can't play any of these instruments but the data person in me finds this just fascinating.
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@Kathologist,RT @phil_w888: Preprint servers are full of fascinating studies. This one measured aerosol generation from musical instruments.  High risk:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@bhrenton,One of the best graphics I've ever seen in a scientific paper.
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@Pablo25852122,...
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@chrishendel,Aerosol Generation from Different Wind Instruments https://t.co/6BSEHzd8lJ  There's a chart you don't see every day üëá üìØüé∫ü¶† https://t.co/W13S0iJvdT
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@phil_w888,"Preprint servers are full of fascinating studies. This one measured aerosol generation from musical instruments.  High risk: trumpet, bass trombone, oboe  Intermediate: piccolo, flute, bass clarinet, French horn, clarinet  Low (appropriately): tuba  https:"
http://medrxiv.org/cgi/content/short/2020.08.03.20167833,Aerosol Generation from Different Wind Instruments,@medrxivpreprint,Aerosol Generation from Different Wind Instruments  https://t.co/k2X7BoTngX #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@DerekJo05756501,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@qwertyuiioasdg,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Victori93908916,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@rhinovir,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@10minus6cosm,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@_hoeman,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@kat_gris,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@kat_gris,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@gail_carson,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@RogueRifter,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@aHybridOriginal,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@TrueBlue4u2,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Qtan295,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@wimzkl,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@MichaelGIsonMD,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@MichaelGIsonMD,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@BaronianConsult,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Woodgirl1977,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@SandraLpezVergs,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Merz,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@moethomason,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@ic4rus1,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Anonymous_prodi,"Nuevo estudio sobre 34 personas con #COVID19 descubre que adquieren aproximadamente los mismos niveles de anticuerpos 3-4 meses despu√©s de la infecci√≥n, ya sea una enfermedad asintom√°tica, leve o grave https://t.co/LrIAzGJ7eP Muy peque√±o a√∫n el estudio"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@isabelrodbar,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@LaurieTMiller,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@fulop_dan,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Bigheadag,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Longshot137,"RT @_kickaha: Read the whole thread, because man, this is gonna get misreported.  tl;dr: Antibody levels drop over time, this is normal, un‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@arttzaddikim,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@DrUzmaSyed,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Dom77mu,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@PreetiNMalani,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Nancy59501057,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@PergamIC,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@stillbigo,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@InfectiousDz,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@RCScience,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@WilliamDLees,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@mkhatriDVM,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@kevinpurcell,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@GerlindeInaktiv,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@snowstormyou,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@JInterlandi,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@AmyTiemannPhD,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@clancynewyork,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@kpjpsp,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@AntifaDisabled,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Crof,RT @amymaxmen: New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infecti‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@amymaxmen,"New study on 34 people who had #COVID19 finds that they acquire about the same levels of antibodies 3-4 months after infection ‚Äî whether or not they have asymptomatic, mild or severe disease."
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@ravenlore,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@TimLaheyMD,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@barbrar47,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@AlexReverend,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@DrJeanneM,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@FactsMon,"RT @HelenChuMD: Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease c‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@olivermeixner,@SandraLpezVergs @xsaezll if you missed it
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@_kickaha,"Read the whole thread, because man, this is gonna get misreported.  tl;dr: Antibody levels drop over time, this is normal, unknown yet if they level off to a non-zero amount (i.e. some long-term immunity). If so, yay! If not, expect annual(ish) covid shot"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@HelenChuMD,"Happy to see this out. Important finding: at 3-4 months after infection, those with asymptomatic, mild and severe disease converge to a similar neutralizing antibody titer. Thanks to members of the HAARVI team and @jbloom_lab  for the hard work."
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@amadeusine,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@halvorz,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@memerman,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@HutchBasicSci,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@ernpossible,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@DanLikeProteins,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@ZichangXu,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@FOXTROT716,"RT @gingraslab1: Very nice study by @khdcrawford, @HelenChuMD and @jbloom_lab that looks at total and neutralizing antibody levels in patie‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@GreyWol27926578,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Magdoll,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@dbacsik,RT @khdcrawford: Very glad to have this project out the world. Thank you to @HelenChuMD (and everyone in her lab) for a great collaboration‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@EIEarIyBird,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@SydneyR56695845,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@honkiirheyv,@DeryaTR_ Hocam yeni bir √ßalƒ±≈üma yapƒ±lmƒ±≈ü. Kƒ±saca yorumda bulunabilir misiniz?  https://t.co/yb7b1GFnrA
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@jen_rathe,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@PSummers1986,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@AnMoLS42776977,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@NJTemperton,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@covid19_experts,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@handreahd,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@priya_luthra,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@tylernstarr,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@gingraslab1,"Very nice study by @khdcrawford, @HelenChuMD and @jbloom_lab that looks at total and neutralizing antibody levels in patients with COVID-19."
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@BrianRWasik,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@sahakris,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@drng,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@TheTafesseLab,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@svscarpino,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@outbreaksci,"Contribute a rapid review or request one for ""Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection"" (https://t.co/A1ZotDHp9x). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20169367) at https://t.co/RnurTL3DyM @outbreaksci @PREr"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@outbreaksci,New #SARSCoV preprint: Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection https://t.co/A1ZotDHp9x
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@felipe_melo,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@PatWilsonLab,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@ganbhag,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@rod_rahimi,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@SRsrivatsan,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@marija_backovic,"Interesting findings by @jbloom_lab including this important piece of the puzzle üëç ‚Äú.. patients w severe disease have higher initial neut titers, but (this is new) at later times the titers are similar across disease severity; IgG binding titers maintained"
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@spencer68,"Interesting thread on sarscov2 antibodies and how long they last.. Spoiler, they peak, then tail off but stick around.. Pretty typical for antibodies.."
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@PepperMarion,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@Zhang08T,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@jonmah_compbio,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@p_weidenbacher,Super interesting longitudinal study by the @jbloom_lab looking at durability of neutralizing titers to SARS-CoV-2 months after infection.
http://medrxiv.org/cgi/content/short/2020.08.06.20169367,Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection,@NirmalKumar1476,RT @jbloom_lab: Our new study led by @khdcrawford in collaboration with @HelenChuMD looks at the dynamics of neutralizing antibodies in the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169276,The implementation of a rapid sample preparation method for the detection of SARS-CoV-2 in a diagnostic laboratory in South Africa,@medrxivpreprint,The implementation of a rapid sample preparation method for the detection of SARS-CoV-2 in a diagnostic laboratory in South Africa  https://t.co/7Y4vEqwEs5 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@vida_abedi,#COVID19 & #Stroke: data from 17 countries. -> among the key findings: high number of young asymptomatic SARS-CoV-2 infections among stroke patients. Traditional vascular risk factors absent among large cohort of patients. ‚Å¶#teameffort https://t.co
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@MarkQuarter,RT @medrxivpreprint: SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group  https://t.co/65FoL‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@nonya_bidniss,RT @outbreaksci: New #SARSCoV preprint: SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke..."" (https://t.co/K2LUVZyOoq). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169169) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group https://t.co/K2LUVZyOoq
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@ChickenGate,RT @phil_w888: Dear activists masquerading as researchers at @TexasTech who claimed that smoking (and vaping) increases risk of having a Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@vida_abedi,RT @medrxivpreprint: SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group  https://t.co/65FoL‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@LanceChurchill,RT @phil_w888: Dear activists masquerading as researchers at @TexasTech who claimed that smoking (and vaping) increases risk of having a Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@phil_w888,"Dear activists masquerading as researchers at @TexasTech who claimed that smoking (and vaping) increases risk of having a Covid-19-related stroke:  Stick this in your pipe and smoke it.  Regards, Phil"
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@phil_w888,"754/  Earth (adult smoking rate was ~20% in 2015)  Of 423* patients in 17 countries with Covid-19 who had a subsequent stroke, 15.8% were smokers  Notes:  *Calculated from table 1 (could be 432 pts, S=15.5%)  not specified if current or ever  Continued  ht"
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@simplycavero,RT @medrxivpreprint: SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group  https://t.co/65FoL‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20169169,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group,@medrxivpreprint,SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group  https://t.co/65FoLG1GCS #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167593,"How to handle the deceased body of COVID-19: an insight from Indonesian muslim burial handlers knowledge, perception, and practice",@medrxivpreprint,"How to handle the deceased body of COVID-19: an insight from Indonesian muslim burial handlers knowledge, perception, and practice  https://t.co/b90mZdb7PX #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.29.20164558,Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia,@outbreaksci,"Contribute a rapid review or request one for ""Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients wit..."" (https://t.co/2VFYlzPBZp). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164558) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164558,Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia,@outbreaksci,New #SARSCoV preprint: Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia https://t.co/2VFYlzPBZp
http://medrxiv.org/cgi/content/short/2020.07.29.20164558,Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia,@medrxivpreprint,Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia  https://t.co/TGMX4xOi06 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20155804,Characterization of Israeli COVID-19 Outbreak Drivers and Forecasting Using a Versatile Web App,@ingentium_COVID,Characterization of Israeli COVID-19 Outbreak Drivers and Forecasting Using a Versatile Web App https://t.co/QIfv5zaiMt
http://medrxiv.org/cgi/content/short/2020.08.06.20155804,Characterization of Israeli COVID-19 Outbreak Drivers and Forecasting Using a Versatile Web App,@medrxivpreprint,Characterization of Israeli COVID-19 Outbreak Drivers and Forecasting Using a Versatile Web App  https://t.co/5zNA6tHyUY #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20169896,Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Incorporating Outdoor Temperature and School Re-Opening Effects,@outbreaksci,"Contribute a rapid review or request one for ""Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two P..."" (https://t.co/p2X1fZeoPf). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20169896) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20169896,Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Incorporating Outdoor Temperature and School Re-Opening Effects,@outbreaksci,New #SARSCoV preprint: Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Incorporating Outdoor Temperature and School Re-Opening Effects https://t.co/p2X1fZeoPf
http://medrxiv.org/cgi/content/short/2020.08.06.20169896,Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Incorporating Outdoor Temperature and School Re-Opening Effects,@j_orwellian,RT @medrxivpreprint: Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Inco‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20169896,Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Incorporating Outdoor Temperature and School Re-Opening Effects,@medrxivpreprint,Prediction of Covid-19 Infections Through December 2020 for 10 US States Using a Two Parameter Transmission Model Incorporating Outdoor Temperature and School Re-Opening Effects  https://t.co/RFEdUFOIiP #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@faradoost,RT @choxos: ÿØÿ± ÿß€åÿ±ÿßŸÜÿå ŸÖ€åÿ≤ÿßŸÜ ÿ≥ÿ±⁄Ü ÿØÿ± ŸÖŸàÿ±ÿØ ¬´ÿØŸÜÿØÿßŸÜ‚ÄåÿØÿ±ÿØ¬ª ÿØÿ± ÿØŸàÿ±Ÿá ŸÇÿ±ŸÜÿ∑€åŸÜŸá ÿØÿ± ŸÖŸÜÿßÿ∑ŸÇ ÿ®ÿß ÿØÿ±ÿ¨Ÿá ŸÖÿ≠ÿ±ŸàŸÖ€åÿ™ ÿ®ÿßŸÑÿßÿ™ÿ±ÿå ÿ®€åÿ¥‚Äåÿ™ÿ± ÿ®ŸàÿØ. https://t.co/VXjvew39y4
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@DavaghK,RT @choxos: ÿØÿ± ÿß€åÿ±ÿßŸÜÿå ŸÖ€åÿ≤ÿßŸÜ ÿ≥ÿ±⁄Ü ÿØÿ± ŸÖŸàÿ±ÿØ ¬´ÿØŸÜÿØÿßŸÜ‚ÄåÿØÿ±ÿØ¬ª ÿØÿ± ÿØŸàÿ±Ÿá ŸÇÿ±ŸÜÿ∑€åŸÜŸá ÿØÿ± ŸÖŸÜÿßÿ∑ŸÇ ÿ®ÿß ÿØÿ±ÿ¨Ÿá ŸÖÿ≠ÿ±ŸàŸÖ€åÿ™ ÿ®ÿßŸÑÿßÿ™ÿ±ÿå ÿ®€åÿ¥‚Äåÿ™ÿ± ÿ®ŸàÿØ. https://t.co/Yqit8gnPg8 ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@zhuanism,RT @choxos: ÿØÿ± ÿß€åÿ±ÿßŸÜÿå ŸÖ€åÿ≤ÿßŸÜ ÿ≥ÿ±⁄Ü ÿØÿ± ŸÖŸàÿ±ÿØ ¬´ÿØŸÜÿØÿßŸÜ‚ÄåÿØÿ±ÿØ¬ª ÿØÿ± ÿØŸàÿ±Ÿá ŸÇÿ±ŸÜÿ∑€åŸÜŸá ÿØÿ± ŸÖŸÜÿßÿ∑ŸÇ ÿ®ÿß ÿØÿ±ÿ¨Ÿá ŸÖÿ≠ÿ±ŸàŸÖ€åÿ™ ÿ®ÿßŸÑÿßÿ™ÿ±ÿå ÿ®€åÿ¥‚Äåÿ™ÿ± ÿ®ŸàÿØ. https://t.co/VXjvew39y4
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@choxos,ÿØÿ± ÿß€åÿ±ÿßŸÜÿå ŸÖ€åÿ≤ÿßŸÜ ÿ≥ÿ±⁄Ü ÿØÿ± ŸÖŸàÿ±ÿØ ¬´ÿØŸÜÿØÿßŸÜ‚ÄåÿØÿ±ÿØ¬ª ÿØÿ± ÿØŸàÿ±Ÿá ŸÇÿ±ŸÜÿ∑€åŸÜŸá ÿØÿ± ŸÖŸÜÿßÿ∑ŸÇ ÿ®ÿß ÿØÿ±ÿ¨Ÿá ŸÖÿ≠ÿ±ŸàŸÖ€åÿ™ ÿ®ÿßŸÑÿßÿ™ÿ±ÿå ÿ®€åÿ¥‚Äåÿ™ÿ± ÿ®ŸàÿØ. https://t.co/VXjvew39y4
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@ASofiMahmudi,RT @medrxivpreprint: The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran  http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@choxos,RT @medrxivpreprint: The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran  http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@bnschlz,https://t.co/vl3m33eEEr
http://medrxiv.org/cgi/content/short/2020.08.06.20160515,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran,@medrxivpreprint,The association between lockdown due to COVID-19 epidemic and searches for toothache using Google Trends in Iran  https://t.co/v2SaJhJFV9 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@outbreaksci,"Contribute a rapid review or request one for ""Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 in..."" (https://t.co/fXF7zBvTbc). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.20162446) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@outbreaksci,New #SARSCoV preprint: Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children https://t.co/fXF7zBvTbc
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@alfonso_casi,Cin√©tica del aclaramiento viral y producci√≥n de anticuerpos en grupos de edad en ni√±os infectados con SARS-CoV-2: La mayor√≠a present√≥ un per√≠odo prolongado de diseminaci√≥n viral tras la infecci√≥n. Se desconoce si esto se correlaciona con la infectividad...
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@BrCbHrR,RT @burakbaharmd: Our study on kinetics of viral clearance and antibody production in  kids diagnosed with COVID-19
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@burakbaharmd,Our study on kinetics of viral clearance and antibody production in  kids diagnosed with COVID-19
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@COVID_Papers,üìù Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children  medRxiv or bioRxiv https://t.co/DTXjn5Bqws #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@DrRiyamia,RT @medrxivpreprint: Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children  https://t.co/p6‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@akkaufman,RT @medrxivpreprint: Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children  https://t.co/p6‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.06.20162446,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children,@medrxivpreprint,Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children  https://t.co/p6AbKqhFNl #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.06.20148288,The Epidemiology Characteristics of Positive COVID-19 patients in a Caribbean Territory.,@rmchavin,"8-6-2020:  In a Caribbean study released today, 61.9% of the positive COVID-19 cases were females, 61.9% of whom had a travel history.  Of all positive cases, 44.9% coughed, only 37.1% had fever (temperature) https://t.co/1tTWawS54P https://t.co/DjM3Ia5L30"
http://medrxiv.org/cgi/content/short/2020.08.06.20148288,The Epidemiology Characteristics of Positive COVID-19 patients in a Caribbean Territory.,@COVID_Papers,üìù The Epidemiology Characteristics of Positive COVID-19 patients in a Caribbean Territory.  medRxiv or bioRxiv https://t.co/9BWzb9Z5bp #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.06.20148288,The Epidemiology Characteristics of Positive COVID-19 patients in a Caribbean Territory.,@medrxivpreprint,The Epidemiology Characteristics of Positive COVID-19 patients in a Caribbean Territory.  https://t.co/FUPMCrhDdN #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@CageBioInc,"RT @outbreaksci: New #SARSCoV preprint: A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic https:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@muveokte,RT @CageBioInc: Our Long-Lasting Sanitizing Skin Protectant (IonLAST) preprint is now online on #medRxiv! https://t.co/lQa0tEsT98 @CageBio‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@outbreaksci,"New #SARSCoV preprint: A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic https://t.co/jz1aVVFuBS"
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@outbreaksci,"Contribute a rapid review or request one for ""A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eu..."" (https://t.co/jz1aVVFuBS). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20161067) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@outbreaksci,"New #COVID19 preprint: A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic https://t.co/jz1aVVFuBS"
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@CageBioInc,RT @SMitragotri: The paper on the use of ionic liquid/deep eutectic CAGE for long-lasting hand sanitizer is out in @medrxivpreprint @CageBi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@Dharamdasani_V,RT @CageBioInc: Our Long-Lasting Sanitizing Skin Protectant (IonLAST) preprint is now online on #medRxiv! https://t.co/lQa0tEsT98 @CageBio‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@CageBioInc,"RT @COVID_Papers: üìù A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic  medRxiv or bioRxiv https:‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@CageBioInc,Our Long-Lasting Sanitizing Skin Protectant (IonLAST) preprint is now online on #medRxiv! https://t.co/lQa0tEsT98 @CageBioInc @covid19nz
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@SMitragotri,The paper on the use of ionic liquid/deep eutectic CAGE for long-lasting hand sanitizer is out in @medrxivpreprint @CageBioInc
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@COVID_Papers,"üìù A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic  medRxiv or bioRxiv https://t.co/t8BvwldpZp #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.08.04.20161067,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic",@medrxivpreprint,"A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic  https://t.co/0I4VPQAFdj #medRxiv"
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@SciscoreReports,The paper ‚ÄúStructural analysis of full-length SARS-CoV-2 spik...‚Äù (https://t.co/gywjeQvFTF) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/AkkZCcsK1n. We detected 4 key resources.
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@LukasCholeva,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. ùóîùòÇùòÅùóµùóºùóøùòÄ: Sandhya Bangaru, Gabriel Ozorowski, Hannah L Turner, Aleksandar Antanasijevic, Deli Huang, Xiaoning Wang, Jo... https://t.co/aGPJCYsFg5 https://"
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@TOWiU2,"""With structural, biophysical, and antigenic characterization now complete, evaluation in humans will provide the true proof-of-principle for this vaccine concept.""  $NVAX  https://t.co/lMEZasDJrv"
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@TOWiU2,"""Further, the tight clustering of the spikes in the nanoparticle formulation may lead to stronger immune responses over soluble trimers alone, consistent with other viral glycoprotein immunogens (HA and RSV F) (38, 39).""   $NVAX   https://t.co/lMEZasDJrv"
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@Hashemyaser4,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@menchant_liu,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@epidatum,Structural analysis of full-length #SARSCoV2 spike protein from an advanced #vaccine   Our studies reveal a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit compared to published spike ectodomain structures. ht
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@ElyseFischer7,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@jjmousa,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@Eva46653369,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@outbreaksci,New #SARSCoV preprint: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/pIYoOtKRI0
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@outbreaksci,"Contribute a rapid review or request one for ""Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine can..."" (https://t.co/pIYoOtKRI0). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.234674) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@outbreaksci,New #COVID19 preprint: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/pIYoOtKRI0
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@Jiaxing_Tan_,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@MalettaMax,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@MalettaMax,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@YasaWatanabe,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@CFSciences,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@jessica_rosarda,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@ProfPaulYoung,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@Ozlem__Dmr,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@nepalijamesbond,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@kaczmarski_joe,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@DanLikeProteins,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@zacharyberndsen,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@kamathdayanand,RT @biorxivpreprint: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate  https://t.co/yOiBzQmu1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@Paleophile,RT @biorxivpreprint: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate  https://t.co/yOiBzQmu1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@_ellecain,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@WardLab1,correct link here: https://t.co/3Ts57ZL8Gj
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@ElitzaTocheva,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@torusengoku,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@cryoET,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@marija_backovic,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@benjamin_n_bell,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@t2438,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@paul_v_thomas,RT @WardLab1: Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpre‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@WardLab1,Pretty pictures of #Covid_19 vaccine candidate NVX-CoV2373 from @Novavax in a study led by @Sandhyareddy88 now up @biorxivpreprint https://t.co/HcB34h4tTf https://t.co/ireATAve8o
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@dkumar02,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@paul_v_thomas,RT @cryoEM_Papers: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@cryoEM_Papers,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/4X6jKOhrzC
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@DrKynast,RT @biorxivpreprint: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate  https://t.co/yOiBzQmu1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@klausenhauser,"Interesting work, Spike in context of a vaccine formulation. Also observes linoleic acid from SF9 produced protein. Interesting multiple-Spike timer interactions too!"
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@glycopreprint,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate https://t.co/BJv5j8lwWd #glycotime
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@biorxiv_immuno,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate  https://t.co/oe1kS0of4d #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.06.234674,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,@biorxivpreprint,Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate  https://t.co/yOiBzQmu1F #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@JayChance12,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@SciscoreReports,The paper ‚ÄúStructure of papain-like protease from SARS-CoV-2...‚Äù (https://t.co/ufw1ix7yap) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/tdVvjpYgv8. We detected 0 of 5 rigor criteria and 0 key resources.
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@Ashok14851,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jerzy Osipiuk, Saara-Anne Azizi, Steve Dvorkin, Michael Endres, Robert Jedrzejczak, Krysten A. Jones, Soow... https://t.co/hoHBox5eby https://"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@coffeemoves,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@qualityisarul3,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@sp3intermediate,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@chem_chair,@SASnyderLab @UChiChemistry Welcome @SASnyderLab! ...and congratulations on your contribution to the new paper on PLpro from SARS-CoV-2!   https://t.co/zpJbCImgtX
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@BerkeleyBrett,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@SidDarthious,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@argonne,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@rmoellering14,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@LeGuo4,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@SciSteingard,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@UChicagoPSD,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@ChelseaAnorma,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@PhilippMGemmel,"RT @SASnyderLab: So glad to be a part of this project and collaboration.  The team did excellent work, and we hope that it will have an imp‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@SASnyderLab,"So glad to be a part of this project and collaboration.  The team did excellent work, and we hope that it will have an impact."
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@CBC_ChiBiomed,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@niu_group,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@KrishnanYamuna,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@isaleucine,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@outbreaksci,New #SARSCoV preprint: Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors https://t.co/hvyHRxxzCL
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@outbreaksci,"Contribute a rapid review or request one for ""Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent in..."" (https://t.co/hvyHRxxzCL). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.240192) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@outbreaksci,New #COVID19 preprint: Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors https://t.co/hvyHRxxzCL
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@Mfitzg79Mark,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@tao_bio,RT @biorxivpreprint: Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors  https://t.co/eZ6zUhD‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@PadminiPal,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@liulabtamu1,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@paulinarych,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@UChicagoBPHYS,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@ProtifiLlc,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@varun_gadkari,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@UChiChemistry,"RT @chembioBryan: Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the viru‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@chembioBryan,"Big congrats to a team effort between @UChicago @UChiChemistry and @argonne interrogating PLpro from SARS-CoV-2, the virus that causes COVID-19. This protein is a viable drug target for antiviral development, which could be accelerated by this work.   http"
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@KamounLab,RT @biorxivpreprint: Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors  https://t.co/eZ6zUhD‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.240192,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors,@biorxivpreprint,Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors  https://t.co/eZ6zUhDzc1 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@nanogenomic,@jjcouey I‚Äôve been talking about HCQ as an endosomal alkalyzing agent since February or March. Nice job being haughty though. Enjoy our preprint.   https://t.co/i1hh9eSP09
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@alainde96544302,"RT @FaustYin: J'ai besoin de bonnes nouvelles. En voil√† UNE... Ce preprint d√©montre que ""les peptides SARS-BLOCK ‚Ñ¢ sont de puissants inhibi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Whit_Writes,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DrSimonAshworth,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@nanogenomic,@Benioff Nice delivery system. I‚Äôm not as big of a fan of molecular approaches targeting the virus directly as this can interfere in antibody responses of the host organism.   Check out some of the rationale here:  https://t.co/qlVOB3CK1T
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@kraus_read,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@FaustYin,"J'ai besoin de bonnes nouvelles. En voil√† UNE... Ce preprint d√©montre que ""les peptides SARS-BLOCK ‚Ñ¢ sont de puissants inhibiteurs de l'infection qui emp√™chent ACE2 de se lier √† la prot√©ine de pointe du virus"". #apresj20 #LongCovid"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@TerryBurns_,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@nanogenomic,@JeffMaloney19 @Jason Check out the references in the discussion section   https://t.co/i1hh9eSP09
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@SciscoreReports,The paper ‚ÄúPeptide Antidotes to SARS-CoV-2 (COVID-19)‚Äù (https://t.co/Lj3T5A3bnW) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Gye9Jslexk. We detected 0 of 5 rigor criteria and 6 key resources.
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Illegalshift66,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@antibodies_ol,CR3022 from https://t.co/Y78eRHA6DJ (https://t.co/JPLaYFCdBA) was used to identify Peptide Antidotes to SARS-CoV-2 (COVID-19) https://t.co/UZzkzqLjKp
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@zuhalif_zeyneb,RT @epidatum: Peptide Antidotes to #SARSCoV2 (#COVID19)  SARS-BLOCK‚Ñ¢ peptides are able to potently and competitively inhibit SARS-CoV-2 S1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@AVKarlsson,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@AVKarlsson,RT @adamhamdy: 16. I hope this helps explain why SARS-BLOCK is such a promising solution to the #COVID19 pandemic. If you'd like to find ou‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@MarkWallaceGlos,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@St_Engineers,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@cestlavieinus,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@cestlavieinus,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Biaggi4NY,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@sambg93,RT @epidatum: Peptide Antidotes to #SARSCoV2 (#COVID19)  SARS-BLOCK‚Ñ¢ peptides are able to potently and competitively inhibit SARS-CoV-2 S1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@GaitondeSharada,RT @epidatum: Peptide Antidotes to #SARSCoV2 (#COVID19)  SARS-BLOCK‚Ñ¢ peptides are able to potently and competitively inhibit SARS-CoV-2 S1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@anonymouscaper,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: Peptide Antidotes to SARS-CoV-2 (COVID-19). ùóîùòÇùòÅùóµùóºùóøùòÄ: Andre Watson, Leonardo M.R. Ferreira, Peter Hwang, Jinbo Xu,‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@anonymouscaper,RT @epidatum: Peptide Antidotes to #SARSCoV2 (#COVID19)  SARS-BLOCK‚Ñ¢ peptides are able to potently and competitively inhibit SARS-CoV-2 S1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@nanogenomic,RT @epidatum: Peptide Antidotes to #SARSCoV2 (#COVID19)  SARS-BLOCK‚Ñ¢ peptides are able to potently and competitively inhibit SARS-CoV-2 S1‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@filipowi,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: Peptide Antidotes to SARS-CoV-2 (COVID-19). ùóîùòÇùòÅùóµùóºùóøùòÄ: Andre Watson, Leonardo M.R. Ferreira, Peter Hwang, Jinbo Xu,‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@nanogenomic,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: Peptide Antidotes to SARS-CoV-2 (COVID-19). ùóîùòÇùòÅùóµùóºùóøùòÄ: Andre Watson, Leonardo M.R. Ferreira, Peter Hwang, Jinbo Xu,‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@_RL_W,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@NikiMackayBooks,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@KeCheza,"RT @nanogenomic: The RBD, or receptor binding domain, is the part of the SARS-CoV-2 spike protein that binds to ACE2. Normally, spike prote‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@KeCheza,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@anonymouscaper,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@uncrossedtrader,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@HBCHoxton,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@michellemck0,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@juniordrblog,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@adamhamdy,@ProfWishart @lucyjohnston439 @nanogenomic Thanks. Results of lab studies can be found here.   https://t.co/hiT6bobcu7
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@ak2webd3,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@ak2webd3,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Wardog3624,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@CreateAccYour1,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@JmsOlvr,Here's hoping one these really works very well and we can go back to normal. https://t.co/fzB6NnC1E3
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@JoyKluver,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@KennyNewsNet,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@nanogenomic,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DudDesmondson,This is definitely exciting and seems promising! #SARS_CoV_2 #SARSCoV2 #covid19 #coronavirus
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@bookoholicme,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@anilbatchu,Peptide Antidotes to SARS-CoV-2 (COVID-19) https://t.co/eHp9iKZlVa
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Its effector cells: https://t.co/2hW8TKMBlv  Protocol: https://t.co/Z9pyXg1Onl https:/"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Its effector cells: https://t.co/2hW8TKMBlv  Protocol: https://t.co/Z9pyXg1Onl  https:"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@adamhamdy,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@fffeeerrr68,"@FatEmperor   bonjour,  que pensez vous de cette √©tude ?   https://t.co/pTImiuZefp"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Chamberchick2,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@AgEconomist,Peptide Antidotes to SARS-CoV-2 (COVID-19) | bioRxiv https://t.co/ulqDmaC5wO
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@MandaScott,This is really most inspiring... :)
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@MandaScott,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@jwcrawley,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Peptide Antidotes to SARS-CoV-2 (COVID-19). ùóîùòÇùòÅùóµùóºùóøùòÄ: Andre Watson, Leonardo M.R. Ferreira, Peter Hwang, Jinbo Xu, Robert Stroud https://t.co/ITP0KNJNwh https://t.co/LFjyl1mWNV"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@ak2webd3,RT @enhancerleo: We‚Äôve created #synthetic #peptide scaffolds that can act as #antidote and potentially as a #vaccine against COVID-19 SARS-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@ak2webd3,"RT @criccomini: I am newb, but this sounds like a big deal?"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@piccolofran,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@piccolofran,RT @adamhamdy: 16. I hope this helps explain why SARS-BLOCK is such a promising solution to the #COVID19 pandemic. If you'd like to find ou‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@EdwardDixon3,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@OWStarr,RT @adamhamdy: 16. I hope this helps explain why SARS-BLOCK is such a promising solution to the #COVID19 pandemic. If you'd like to find ou‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@dom,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@ejoep,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DanielleFong,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DanielleFong,RT @adamhamdy: 16. I hope this helps explain why SARS-BLOCK is such a promising solution to the #COVID19 pandemic. If you'd like to find ou‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@tommillar_uk,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@tortoiseneck,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@InfanteT4,RT @biorxivpreprint: Peptide Antidotes to SARS-CoV-2 (COVID-19)  https://t.co/NtNONHadRI #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@allsummerhoe2,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@enhancerleo,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@polarbearonbike,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DavidHHeadley,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@SarahRe16209029,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@LouBuchanan17,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@njsw1,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@threadhead25,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Chrissie_DSx,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DeeeDoc,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@NiSibeal,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@sdnpb_norman,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@seanhegarty,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@RoryStewartUK,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@MrKelly2u,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@uberrimaefidei1,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@FMConservatives,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@AOUBIO,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Damage_13,RT @adamhamdy: 16. I hope this helps explain why SARS-BLOCK is such a promising solution to the #COVID19 pandemic. If you'd like to find ou‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@d_vickery,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@daphne_parkin,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@MikeAMye,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@AmyMcLellan2,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DNimmersatt,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@NigelJGardner52,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@DerfelTheMighty,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@LabRatMtBiker,"RT @adamhamdy: 1. The @Ligandal antidote to #SARSCoV2 has been getting a lot of attention, but some people are having difficulty understand‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@Em_Lickspittle,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.238915,Peptide Antidotes to SARS-CoV-2 (COVID-19),@uberrimaefidei1,"RT @nanogenomic: Elated to share our preprint!!!  Peptide Antidotes to SARS-CoV-2 (COVID19).  In this study, we demonstrated that SARS-BLOC‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@SciscoreReports,The paper ‚ÄúComputational Hot-Spot Analysis of the SARS-CoV-2...‚Äù (https://t.co/kIyWRNSwmw) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Uz6Kd8yFVb. We detected 0 key resources.
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@AfSynchrotron,RT @BlackPhysicists: Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex https://t.co/qrc5VeUy35 #biop‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@BlackPhysicists,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex https://t.co/qrc5VeUy35 #biophysics https://t.co/6GctOzw4Dg
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@alexisroxario,RT @biorxiv_biophys: Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex  https://t.co/7eGbrt3f8T #bio‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@alexisroxario,RT @outbreaksci: New #SARSCoV preprint: Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex https://t.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@alexisroxario,"RT @outbreaksci: Contribute a rapid review or request one for ""Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain /‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex. ùóîùòÇùòÅùóµùóºùóøùòÄ: Pedro A. Rosario, Brian R McNaughton https://t.co/pvrFddOsto https://t.co/7J4qgR9FUD"
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@outbreaksci,"Contribute a rapid review or request one for ""Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex"" (https://t.co/S2RrBpbnBA). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.240333) at https://t.co/RnurTL3DyM @outbreaksci"
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@outbreaksci,New #SARSCoV preprint: Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex https://t.co/S2RrBpbnBA
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@biorxiv_biophys,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex  https://t.co/7eGbrt3f8T #biorxiv_biophys
http://biorxiv.org/cgi/content/short/2020.08.06.240333,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex,@biorxivpreprint,Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex  https://t.co/wLT2jfd3EI #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@SciscoreReports,The paper ‚ÄúIFN signaling and neutrophil degranulation transcr...‚Äù (https://t.co/bUEaQUtBOi) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/fubUmYccrZ. We detected 1 of 5 rigor criteria and 9 key resources
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@DrLBoominathan,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/37XDD9KTbj
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection. ùóîùòÇùòÅùóµùóºùóøùòÄ: Bruce A. Rosa, Mushtaq Ahmed, Dhiraj K. Singh, Jose Alberto Choreno-Parra, Journey Cole, Luis... https://t.co/lof2wmLioY https://"
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@deftronx,RT @KhaderShabaana: Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@DrQuinn4realz,RT @KhaderShabaana: Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@HTLVnet,RT @biorxiv_immuno: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection  https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@FanZhang_Jessie,RT @DeepakK40495575: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@MazDivangahi,RT @DeepakK40495575: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@DeepakK40495575,RT @KhaderShabaana: Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@txbiomed,RT @DeepakK40495575: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@Mushtaq73550530,RT @KhaderShabaana: Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@APC82236815,RT @DeepakK40495575: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@MysorekarLab,RT @KhaderShabaana: Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@SaraSuliman13,RT @DeepakK40495575: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@KhaderShabaana,https://t.co/S51mcM5Iiy
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@KhaderShabaana,https://t.co/S51mcM5Iiy
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@maxgabgut,RT @KhaderShabaana: Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@KhaderShabaana,"Outstanding collaboration with @DeepakK40495575 @Mak_Mitreva - key pathways upregulated in lungs of juvenile macaques compared to old macaques infected with SARS-CoV2 is Type I IFN and Notch signaling. Kudos to first co-authors Bruce Rosa, @Mushtaq73550530"
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@outbreaksci,New #SARSCoV preprint: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/AkACGVJ6Mk
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@outbreaksci,"Contribute a rapid review or request one for ""IFN signaling and neutrophil degranulation transcriptional signatures are induced during..."" (https://t.co/AkACGVJ6Mk). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.06.239798) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@outbreaksci,New #COVID19 preprint: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/AkACGVJ6Mk
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@deftronx,RT @DeepakK40495575: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@bxv_imm,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/iI6LDulfEQ
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@MLitbot,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/IJQyc2c6Dp
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@LabWaggoner,RT @biorxiv_immuno: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection  https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@leonardo_jesus9,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/FNaC0Khfo8 #biorxiv
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@DeepakK40495575,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection https://t.co/N7tT6xHhFR @txbiomed #snprc @NIH_ORIP @KhaderShabaana @Mak_Mitreva
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@FriendsOfPipe,RT @biorxivpreprint: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection  https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@EhecatlICU,RT @biorxivpreprint: IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection  https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@biorxiv_immuno,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection  https://t.co/WnfamvV6n9 #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.06.239798,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection,@biorxivpreprint,IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection  https://t.co/vMN83ihPun #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@SciscoreReports,The paper ‚ÄúPersistent bacterial coinfection of a COVID-19 pat...‚Äù (https://t.co/nCtjMMAuGj) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/hInLVPXh7C. We detected 1 of 5 rigor criteria and 1 key resource.
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@AnShiQi,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer https://t.co/tRYhbJoLiy
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer. ùóîùòÇùòÅùóµùóºùóøùòÄ: Zhao Cai, Yumei Liu, XiangKe Duan, Shuhong Han, Yuao Zhu, Yingdan Zhang, Ch... https://t.co/7n2qsorCmw https://"
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@EDurandINSERM,RT @biorxiv_micrbio: Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@WillRob_Rivii,RT @biorxivpreprint: Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@hbdchick,RT @biorxivpreprint: Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@FriendsOfPipe,RT @biorxivpreprint: Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@biorxiv_micrbio,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer  https://t.co/VJEcOtkb1B #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.05.238998,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer,@biorxivpreprint,Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer  https://t.co/lBZ18LewQd #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20167411,Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines. ùóîùòÇùòÅùóµùóºùóøùòÄ: Janet Alexis A. De los Santos, Leodoro J. Labrague https://t.co/XRH2KwO0f2 https://"
http://medrxiv.org/cgi/content/short/2020.08.05.20167411,Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines,@CovidWellbeing,Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines https://t.co/ihCLdgAtEM #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.05.20167411,Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines,@medrxivpreprint,Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines  https://t.co/19GAgObg6r #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169037,Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India. ùóîùòÇùòÅùóµùóºùóøùòÄ: Debnarayan Khatua, Debashree Guha, Samarjit Kar, Anupam De, Eshan Samanta https://t.co/fb6OiwYt7S https://t.co/YnrpmBJImJ"
http://medrxiv.org/cgi/content/short/2020.08.05.20169037,Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India,@outbreaksci,"Contribute a rapid review or request one for ""Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in..."" (https://t.co/cf1JnMubIO). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169037) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20169037,Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India,@outbreaksci,New #SARSCoV preprint: Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India https://t.co/cf1JnMubIO
http://medrxiv.org/cgi/content/short/2020.08.05.20169037,Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India,@medrxivpreprint,Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India  https://t.co/GImw1esaJQ #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20157768,Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration,@taufiquejoarder,RT @medrxivpreprint: Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration  https://t.co/UZ2IpIDZR‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20157768,Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration. ùóîùòÇùòÅùóµùóºùóøùòÄ: Taufique Joarder, Muhammad Nahian Bin Khaled, Shahaduz Zaman https://t.co/fHGnWTmT9G https://t.co/Arsntk6i6Y"
http://medrxiv.org/cgi/content/short/2020.08.05.20157768,Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration,@medrxivpreprint,Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration  https://t.co/UZ2IpIDZR6 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169094,U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19. ùóîùòÇùòÅùóµùóºùóøùòÄ: Luorongxin Yuan, Sherryn Sherryn, Peter Hu, Fenghao Chen https://t.co/8HHMXwmiR1 https://t.co/Tb5PNckSdS"
http://medrxiv.org/cgi/content/short/2020.08.05.20169094,U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19,@medrxivpreprint,U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19  https://t.co/TJWeS0pazD #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@PandemicCovid20,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic https://t.co/rWwHsm4wei
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@seriwreck,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic  https://t.co/Rdv1tU90Fg
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic. ùóîùòÇùòÅùóµùóºùóøùòÄ: Alfonso Landeros, Xiang Ji, Kenneth L. Lange, Timothy C. Stutz, Jason Xu, Mary E. Sehl, Janet S. Sinsheimer https://t.co/7nHJo9dAQM https://t.co/SupRqM82qh"
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@outbreaksci,"Contribute a rapid review or request one for ""An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic"" (https://t.co/YxvCmi6fDN). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169086) at https://t.co/RnurTL3DyM @outbreaksci @PREreview"
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@outbreaksci,New #SARSCoV preprint: An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic https://t.co/YxvCmi6fDN
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@DRTomlinsonEP,RT @medrxivpreprint: An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic  https://t.co/VKRN5AL3Bf #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20169086,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic,@medrxivpreprint,An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic  https://t.co/VKRN5AL3Bf #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@bryangrahn,"@P_F_Lherisson_ Haha.  Crazy, eh?  I'm just learning all of this too... Links here:    https://t.co/WvOl1RlSBU  ALSO, smaller data out of Greece and Brazil recently show possible efficacy:    https://t.co/tragX9JKQy https://t.co/r3WWuE4kVK"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@bryangrahn,@P_F_Lherisson_ https://t.co/WvOl1RlSBU
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@CrisBonorino,RT @sbi_imuno: Um estudo conduzido por pesquisadores da Faculdade de Medicina de Ribeir√£o Preto da Universidade de S√£o Paulo procura demons‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@sbi_imuno,Um estudo conduzido por pesquisadores da Faculdade de Medicina de Ribeir√£o Preto da Universidade de S√£o Paulo procura demonstrar o processo de ativa√ß√£o do inflamassoma em pacientes com #Covid19: https://t.co/qsNPJFKlLV #sbiimuno #ciencia #imunologia
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@bryangrahn,"@BiotechObserver @jctardif_mhi is stepping up!  4500 of 6000 already registered in a double blind RCT...  https://t.co/30sSsLGBaE https://t.co/63L9fP1kMQ  New preprint about what may be going on internally, and why a drug like colchicine might work:    ht"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@yopequienmash,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@ZamboniLab,"Mechanisms are still unknown, but in Gout colchicine inhibits tubulin polymerization and in turn activation of the NLRP3 inflammasome, which is important and higly active in severe cases of COVID-19* (6/n).  *Also in preprint: https://t.co/jEEC6red7m"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@bryangrahn,I'd love to get some expert opinion about: inflammasomes and colchicine.  I've read a LOT of covid papers.  This preprint seems key - and already a potential solution:    https://t.co/qzcG1xaAuQ https://t.co/30sSsLGBaE https://t.co/iCDJnEQyhn
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@bryangrahn,"@NYT_said_where @NYT_first_said Oddly enough, buried deep in this article, is that phrase you mention - and a KEY IDEA.  I'm not a dr, but this may be a core way this virus is killing - inflammasomes:    https://t.co/81YKPDJwii   Trials are underway using"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@AnaLuisaBarb,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@ezra_aksoy,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@mericien,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Inflammasome activation in COVID-19 patients. ùóîùòÇùòÅùóµùóºùóøùòÄ: Tamara S Rodrigues, Keyla SG Sa, Adriene Y Ishimoto, Amanda Becerra, Samuel Oliveira, Leticia Almeida, Augusto V Goncalves, Debora B Perucello, Warrison A And... https://t.co/CM1uSKvmx4 https://"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@JuliaB_fitness,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@HTLVnet,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@cica_dups,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@dipikanandi24,Very interesting read! Role of inflammasome in COVID-19.
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@felipe_fcastro,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@KarinaBortoluci,Amazing work from @ZamboniLab showing active NLRP3 in patients with #COVID19 and its correlation with poor outcome of the disease.
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@IforRWilliams,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@scholarcy,"When patients were separated according to the severity of the disease, researchers found that the levels of #Casp1p20 but not #IL„Éº18 were higher in patients with the severe form of #COVID„Éº19 https://t.co/UsMB6KJ8FG https://t.co/0WdKOoAek6"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@outbreaksci,"Contribute a rapid review or request one for ""Inflammasome activation in COVID-19 patients"" (https://t.co/c1pyrkxkH0). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168872) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@outbreaksci,New #SARSCoV preprint: Inflammasome activation in COVID-19 patients https://t.co/c1pyrkxkH0
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@ToshiAkima,"RT @GaetanBurgio: Interesting -> ""Inflammasome activation in #COVID-19 patients"" via NLRP3 and Caspase 1 canonical pathway. Looking at the‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@GaetanBurgio,"Interesting -> ""Inflammasome activation in #COVID-19 patients"" via NLRP3 and Caspase 1 canonical pathway. Looking at the data I agree NLRP3 is activated but IL1b, IL18 + Casp1p20 modest increase. Not convinced it is central as stated in the manuscript"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@CamilaC43108136,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@felipe_melo,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@VMcGilligan,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@OlivR06595334,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@Glo_loca,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@ttenev,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@zhang_liman,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@tnaderer,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@jeremymmunology,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@juan_sanar,Inflammasome activation in COVID-19 patients  #medRxiv @ZamboniLab @medrxivpreprint #ciencialatina https://t.co/51hoURhpsE https://t.co/i7gXVaya17
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@taabaman,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@TheAgingField,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@estercsabino,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@shames_lab,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@Deepika_Sharmad,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@SunnyShinLab,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@tamrodrigues1,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@phil_w888,"749/  Brazil (adult daily smoking rate was 15.4% in 2015)  Of 124 who tested positive, 26.6% had a history of smoking  https://t.co/NNm7y7ZrZu"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@LabWaggoner,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@VBriken,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@mbnetto2,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@kseniakrasileva,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@gvshrivastava,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@mayer_barber,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@_danielfox,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@JoseCar50418927,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@OpenDoorsGroup,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@thelonevirologi,Inflammasome activation in COVID-19 patients https://t.co/1vLKRB6w9w
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@Synth_Immune,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@DrGregMaguire,"Inflammasome in Covid-19: ""statistically significant differences when we compared obese with non-obese patients, as the levels of IL-18 were higher in patients with body mass index greater than 30."" BMI = 30 = obese"
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@MaverickNY,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@DrSalinasLab,RT @russellevance: Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@russellevance,Do inflammasomes cause severe COVID-19? Here is some intriguing new evidence from @ZamboniLab and colleagues. https://t.co/f5cMw8rKZJ
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@brunamaitan,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@bernardo647,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@JDAlbarnaz,RT @ZamboniLab: Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@ZamboniLab,Here's the #PrePrint of our manuscript reporting #Inflammasome activation in #COVID__19. #Nlrp3 inflammasome is active in patients and influences the clinical outcome of the disease. Thanks for many colleagues at #FMRP and #CRID for this collaboration.
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@Andrezadebem,Parab√©ns @ZamboniLab e a tantos outros pesquisadores brasileiros produzindo ci√™ncia de alta qualidade no contexto da Covid-19.
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@_Fabi_CZ,Great study from our neighbouring lab! Immuno rockstars ‚ú®
http://medrxiv.org/cgi/content/short/2020.08.05.20168872,Inflammasome activation in COVID-19 patients,@medrxivpreprint,Inflammasome activation in COVID-19 patients  https://t.co/sbb6aEFHnd #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@jcrdna1,Novavax: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine --> Robust T & B cell responses https://t.co/sSRGNEyM1e
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Entediado6,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@superultralulu,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@afsb2013,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@turoneth,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@rvmrs,@BizYago @TaschnerNatalia li r√°pido mas n√£o achei. talvez tu q sabe mais sobre consiga achar https://t.co/kFhCUDtqJS
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@andrebasbaum,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Tipassus,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@PradoPecci,"RT @TaschnerNatalia: e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@TaschnerNatalia,"e agora a fase 1 em humanos, que tamb√©m foi muito bem! https://t.co/YJgzFaogco"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@boylondon402,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@BrownGeary,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@MarewaGlover,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@JamesonVoss,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Zadz74,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@TalyaJW,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@travelhealthdoc,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@2marisa,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@stewak2,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@mzahalan,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@DarkWinter2020,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@rodberesford70,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@OleKitambi,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@squabalina,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@twitur_nancy,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Gimzatron,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@FrancoDespecho,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@DerekLo86006919,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@marksugruek,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@REB_JUNN,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@hopdegistonton,RT @volgademir: Ba≈üarƒ±lƒ± bir ba≈üka  covid 19 a≈üƒ± √ßalƒ±≈ümasƒ± g√∂rmek harika .A≈üama 1 klinik deney. ‚ÄºÔ∏è‚ÄºÔ∏è   Novovax (NVX-CoV2373) g√ºvenli g√∂r√ºn√º‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@jwgale,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@robyn_s_lee,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@NihalPia_zen,RT @volgademir: Ba≈üarƒ±lƒ± bir ba≈üka  covid 19 a≈üƒ± √ßalƒ±≈ümasƒ± g√∂rmek harika .A≈üama 1 klinik deney. ‚ÄºÔ∏è‚ÄºÔ∏è   Novovax (NVX-CoV2373) g√ºvenli g√∂r√ºn√º‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@tamamsatamammm,RT @volgademir: Ba≈üarƒ±lƒ± bir ba≈üka  covid 19 a≈üƒ± √ßalƒ±≈ümasƒ± g√∂rmek harika .A≈üama 1 klinik deney. ‚ÄºÔ∏è‚ÄºÔ∏è   Novovax (NVX-CoV2373) g√ºvenli g√∂r√ºn√º‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@pash22,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@TamTami00,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@MeganOCO,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@cmrherder,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Smience,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@ofindamola,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@bea_beattie,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@kylekirkup,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@BlakeGirardot,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@ricenbeanies,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@LindsayKempFan,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@alihejvani,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@SheilaGatensby,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@LaceyLaceyp,RT @BogochIsaac: Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@BogochIsaac,Great to see another successful #COVID19 vaccine Phase 1 clinical trial.   Novovax (NVX-CoV2373) appears safe & elicited an appropriate immune response in 106 people.  They also released a pre-print (below) right after the press release. Thank you.  ht
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@MassatoHirai,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Mekilla,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@mj_waldow,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@notdred,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@eliowa,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@NaudetFlorian,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@AnishPMahajan,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@cshperspectives,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@azaleakim,RT @jsross119: Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@NDevito1,Indeed
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@jsross119,"Delighted to see that Novavax's Tuesday afternoon press release on its vaccine trial was followed 2 days later by posting of the trial report as a preprint. Good for science, good for public and scientific scrutiny. https://t.co/8a8gl9JL8X"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. ùóîùòÇùòÅùóµùóºùóøùòÄ: Cheryl Keech, Gary Albert, Patricia Reed, Susan Neal, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, N... https://t.co/Ke9MGeRVL4 https://"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@das_seed,#COVID19 #Novavax. First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine.   Findings suggest vaccine may confer protection & support transition to efficacy evaluations to test this hypothesis. \1  https://t.co/2TQecGWZx9
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@bonnageur,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine https://t.co/IIjlwxaoio
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@_CamHanna,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. Great to see some subunit COVID-19 vaccines showing promise on both safety and efficacy. https://t.co/8NQWZ5Huj1
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@sambg93,RT @epidatum: First-in-Human Trial of a #SARSCoV2 Recombinant Spike Protein Nanoparticle #Vaccine (@Novavax )  NVX-CoV2373/Matrix-M1 was we‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@inoviolt,@DrakeJIRK @Pawn_E_Game @LuoshengPeng @SubhBandy @InovioPharma https://t.co/1o8k8jkpMa
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@a_1_0_2,"""First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine""  https://t.co/Na95iLtPPv"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@GaitondeSharada,@__ice9
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@GaitondeSharada,RT @epidatum: First-in-Human Trial of a #SARSCoV2 Recombinant Spike Protein Nanoparticle #Vaccine (@Novavax )  NVX-CoV2373/Matrix-M1 was we‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@shaghayeghharbi,"- Church et al  https://t.co/cTqxIbKkiT (read & reread ""enhanced disease and immunopathology"" & full length S protein may not be optimal) #preach   - Novavax https://t.co/RI1UfHLt9I recombinant nanoparticle vaccine constructed-> full length, wil"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Researchagain,RT @carlzimmer: Here is the preprint for the Novavax vaccine Phase I trial: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@epidatum,First-in-Human Trial of a #SARSCoV2 Recombinant Spike Protein Nanoparticle #Vaccine (@Novavax )  NVX-CoV2373/Matrix-M1 was well tolerated and elicited robust immune responses four-fold higher than the mean observed in #COVID19 convalescent serum https://t.
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Chaser521,RT @smallcappick: #MTPH NICE 1 https://t.co/dl1WTgyJSg
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@smallcappick,#MTPH NICE 1 https://t.co/dl1WTgyJSg
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@SinoVoices,RT @carlzimmer: Here is the preprint for the Novavax vaccine Phase I trial: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@carlzimmer,Here is the preprint for the Novavax vaccine Phase I trial: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine | medRxiv https://t.co/KSWYIBjDer
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@outbreaksci,"Contribute a rapid review or request one for ""First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine"" (https://t.co/DQSY7FRy4S). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168435) at https://t.co/RnurTL3DyM @outbreaksci @PR"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@outbreaksci,New #SARSCoV preprint: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine https://t.co/DQSY7FRy4S
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Spanishcountry,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine https://t.co/2ohK3De2HY
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@EmmaBiryabarema,RT @TomScriba: Another COVID-19 vaccine candidate that looks promising based on this preprint of First-in-Human Trial of a SARS CoV 2 Recom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@DustyOConnell,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@marknewlyn,RT @TomScriba: Another COVID-19 vaccine candidate that looks promising based on this preprint of First-in-Human Trial of a SARS CoV 2 Recom‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@PandemicCovid20,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine - https://t.co/McYlqkktRE
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@TomScriba,Another COVID-19 vaccine candidate that looks promising based on this preprint of First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine | medRxiv https://t.co/lUMmkKu4TE
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@Lin_ling_88,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine | medRxiv (8/6)  ‚ñ™Ô∏èPhase1 data from $NVAX #nano_particle SARS_CoV_2 #vaccine https://t.co/5hm1zbg4ls
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@hikariare0920,RT @medrxivpreprint: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine  https://t.co/x8lAvim8kg #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@iu22ie33,Preliminary data from Novavax.
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@JXantheW,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@maempitu,RT @Phwool: @iskander @MattFrieman @Novavax @JamesPLogue @StuartMWeston @rob_haupt @mcgrath_marisa the preprint is out! https://t.co/VYnVzb‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@biochembelle,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@OUCRU_CTU,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@AVHernandezDiaz,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@lotusgav,131 patients but it‚Äôs a good start
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@AdamHantman,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@MikeMadden,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@SamWangPhD,"RT @hildabast: Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@hildabast,"Novavax preprint, phase 1 trial of Covid-19 vaccine (NVX-CoV2373): 106 people, 2 injections (+ 25 placebo) https://t.co/QXGrVzQdCj If this holds up in big trials, tolerability/safety will be a major differentiator between vaccines: eg only 1 person had fev"
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@DRTomlinsonEP,RT @medrxivpreprint: First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine  https://t.co/x8lAvim8kg #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168435,First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine,@LondonAllergy,"RT @AllergyNet: Preprint Phase 1/2 Novavax nanoparticle SARS-CoV-2 vaccine trialled in Australia - well-tolerated, robust immune response h‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@OSDG_annotator,"#OSDG has linked this publication to the UN's #SustainableDevelopmentGoals, including #Goal3 - Good Health and Well-being.  ‚úÖ Try for yourself at https://t.co/Xj4KSY4LPv  Thanks for contributing to #Agenda2030! https://t.co/byGk05z18a"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@Scrubresearch,"RT @andrewpekosz: More COVID-19 collaborations between @JohnsHopkinsMMI , @HopkinsMedicine and @JHUAPL studying longterm #COVID19 shedding‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity. ùóîùòÇùòÅùóµùóºùóøùòÄ: Victoria Gniazdowski, C. Paul Morris, Shirlee Wohl, Thomas M... https://t.co/v4oR1qN4Mq https://"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@Michael91693258,"RT @andrewpekosz: More COVID-19 collaborations between @JohnsHopkinsMMI , @HopkinsMedicine and @JHUAPL studying longterm #COVID19 shedding‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@ovais_epilogue,"RT @andrewpekosz: More COVID-19 collaborations between @JohnsHopkinsMMI , @HopkinsMedicine and @JHUAPL studying longterm #COVID19 shedding‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@andrewpekosz,"More COVID-19 collaborations between @JohnsHopkinsMMI , @HopkinsMedicine and @JHUAPL studying longterm #COVID19 shedding of RNA and infectious virus  https://t.co/qn5AUN9LF1"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@outbreaksci,"Contribute a rapid review or request one for ""Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Mole..."" (https://t.co/H5qRliUsF7). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168963) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@outbreaksci,"New #SARSCoV preprint: Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity https://t.co/H5qRliUsF7"
http://medrxiv.org/cgi/content/short/2020.08.05.20168963,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity",@medrxivpreprint,"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity  https://t.co/6Qpt4WbHBq #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@adbelete,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@DrMFKearney,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@carlosmagis,"RT @DrJarlov: SARS-CoV-2 antibody assay sensitivity over time varies a lot, according to this preprint. Unfortunately lowest sensitivity la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@SJR78354712,"RT @DrJarlov: SARS-CoV-2 antibody assay sensitivity over time varies a lot, according to this preprint. Unfortunately lowest sensitivity la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@ForgeRat,"RT @DrJarlov: SARS-CoV-2 antibody assay sensitivity over time varies a lot, according to this preprint. Unfortunately lowest sensitivity la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@DrJarlov,@stats_q What are your thoughts on the long term sensitivity of the assay? This preprint looks pretty concerning. https://t.co/lZJiKgPSng https://t.co/Bf2mmtTRjN
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@jordan120,"RT @DrJarlov: SARS-CoV-2 antibody assay sensitivity over time varies a lot, according to this preprint. Unfortunately lowest sensitivity la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@DrJarlov,"SARS-CoV-2 antibody assay sensitivity over time varies a lot, according to this preprint. Unfortunately lowest sensitivity late after infection with the assay used by Italy and Spain (1 of 2) seroprevalence studies.   Have others done similar assessment?"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@kat_gris,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@VinayPathak,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@cbrenn22,Very interesting
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@brandano_laura,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@CalZole,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@poisondartfrog7,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@CVRHutchinson,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@Timothee_B,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@outbreaksci,"Contribute a rapid review or request one for ""Longitudinal analysis of clinical serology assay performance and neutralising antibody..."" (https://t.co/4RvguzKjtK). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20169128) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@outbreaksci,New #SARSCoV preprint: Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents https://t.co/4RvguzKjtK
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@HendryVictoria,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@CovidSerology,@ewinsberg @thehowie @hmkyale @rfsquared @szorowitz @notdred Your first statement is untrue and incorrect....A majority (>90%) of patients seroconvert after infection and we know antibody titres decline but remain detectable up to 4 months POS. https://
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@Sander_Lab,And another interesting #COVID19 serology study investigating change of overall antibody Titers and Neutralizing Titers over time https://t.co/vSPNx4Es0u
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@md_wentrejo,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@sangmotiani,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@FraukeMuecksch,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@ImmunoFever,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@marioph13,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@theodora_nyc,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@daisydew123,@DrBonnieHenry @DrEricDing
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@daisydew123,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@bealelab,"RT @PaulBieniasz: Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@PaulBieniasz,"Re: waning SARS-CoV-2 antibodies: Great collaboration with Helen Wise, Sara Jenks + NHS colleagues in Scotland. @FraukeMuecksch @theodora_nyc  Neutralizing titers decline ~45%/month in first ~3 months even when S-binding titers maintained   https://t.co/4v"
http://medrxiv.org/cgi/content/short/2020.08.05.20169128,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents,@medrxivpreprint,Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents  https://t.co/kML5yMqqHZ #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168351,Estimation of Effective Reproduction Number for COVID-19 in Bangladesh and its districts,@medrxivpreprint,Estimation of Effective Reproduction Number for COVID-19 in Bangladesh and its districts  https://t.co/mb5vBl73Z0 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@drcevdet,RT @Amipgiardia: Bu √∂zellikle √∂n√ºm√ºzdeki sonbahar ve kƒ±≈ü aylarƒ±nda i√ß mekanda aerosol ve damlacƒ±k konsantrasyonunun kontrol edilmesi gerekt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@ManPan45533575,@op1npo Steeds meer onderzoeken wijzen op besmetting via  aerosolen.   https://t.co/EgK3sqeHzu
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@kadturay,RT @Amipgiardia: Bu √∂zellikle √∂n√ºm√ºzdeki sonbahar ve kƒ±≈ü aylarƒ±nda i√ß mekanda aerosol ve damlacƒ±k konsantrasyonunun kontrol edilmesi gerekt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@gamzesisman,RT @Amipgiardia: Bu √∂zellikle √∂n√ºm√ºzdeki sonbahar ve kƒ±≈ü aylarƒ±nda i√ß mekanda aerosol ve damlacƒ±k konsantrasyonunun kontrol edilmesi gerekt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@ESKENEMROM,RT @Amipgiardia: Bu √∂zellikle √∂n√ºm√ºzdeki sonbahar ve kƒ±≈ü aylarƒ±nda i√ß mekanda aerosol ve damlacƒ±k konsantrasyonunun kontrol edilmesi gerekt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@reyhanerdem6,RT @Amipgiardia: Bu √∂zellikle √∂n√ºm√ºzdeki sonbahar ve kƒ±≈ü aylarƒ±nda i√ß mekanda aerosol ve damlacƒ±k konsantrasyonunun kontrol edilmesi gerekt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@Amipgiardia,"Bu √∂zellikle √∂n√ºm√ºzdeki sonbahar ve kƒ±≈ü aylarƒ±nda i√ß mekanda aerosol ve damlacƒ±k konsantrasyonunun kontrol edilmesi gerektiƒüi anlamƒ±na gelir.  Havalandƒ±rma, enfeksiy√∂z havanƒ±n odadan √ßƒ±kmasƒ±nƒ± veya hƒ±zla ve y√ºksek oranda seyreltilmesini saƒülar. https://t.c"
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@03kustom,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission https://t.co/RG5SgWDYnA
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@outbreaksci,New #SARSCoV preprint: Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission https://t.co/iD4not8JJC
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@outbreaksci,"Contribute a rapid review or request one for ""Extended lifetime of respiratory droplets in a turbulent vapour puff and its implicati..."" (https://t.co/iD4not8JJC). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20168468) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@outbreaksci,New #COVID19 preprint: Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission https://t.co/iD4not8JJC
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@TimothyBigelow5,Don't breath. Monsters are about!  Mask up. Please.
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@PandemicCovid20,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission - https://t.co/FrI78EG40h
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@jyoukeishibu,@AirborneKanki ÊúÄÊñ∞„ÅÆË´ñÊñá„Åß„Åô„ÄÇ https://t.co/4NtwDAvzSs
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@AhmadElhady0,RT @kareem_medhat: ÿ•ŸÑÿ®ÿ≥ ŸÉŸÖÿßŸÖÿ™ŸÉ ÿ®ÿßŸÑŸÑŸá ÿπŸÑŸäŸÉŸÉŸÉŸÉŸÉ
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@HaidyHesham30,RT @kareem_medhat: ÿ•ŸÑÿ®ÿ≥ ŸÉŸÖÿßŸÖÿ™ŸÉ ÿ®ÿßŸÑŸÑŸá ÿπŸÑŸäŸÉŸÉŸÉŸÉŸÉ https://t.co/Ecj5uHvvV2
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@kareem_medhat,ÿ•ŸÑÿ®ÿ≥ ŸÉŸÖÿßŸÖÿ™ŸÉ ÿ®ÿßŸÑŸÑŸá ÿπŸÑŸäŸÉŸÉŸÉŸÉŸÉ
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@medrxivpreprint,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission  https://t.co/ofpF2zZFJ5 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@prodreamer1,The time #COVID19 covid droplets remain in the air and the distance they travel is proportional to humidity. Time and distance are increased 30X for humidity of 50% and 150X for 90%.This may explain why certain states have experienced an explosion of cases
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@epi_twit,"RT @aliciaault: New study: respiratory droplets last longer, go further; same for aerosolized viral particles, esp in higher humidity. Says‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168468,Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission,@aliciaault,"New study: respiratory droplets last longer, go further; same for aerosolized viral particles, esp in higher humidity. Says #WHO estimates grossly inadequate. https://t.co/LqNwwrNPLN #COVID19 #epitwitter #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@medpedshosp,"RT @MRothbergMD: Back in May/June, we wondered how many #COVID19 patients knew where they contracted it. Turns out only 40%. Behaviors asso‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@MRothbergMD,"Back in May/June, we wondered how many #COVID19 patients knew where they contracted it. Turns out only 40%. Behaviors associated with new diagnoses included work outside the home and travel. Highlights the need for contact tracing.  https://t.co/7XEusihX3Z"
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@AZsnowstorm,This is beyond ridiculous.
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@AntifaDisabled,RT @PandemicCovid20: Social Behaviors Associated with a Positive #COVID19 Test Result - https://t.co/JoDma5Id1X
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@PandemicCovid20,Social Behaviors Associated with a Positive #COVID19 Test Result - https://t.co/JoDma5Id1X
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@Lollylulubes,RT @phil_w888: This is a fascinating study. Some results expected; some surprising. Wish I could see this with a bigger sample.  Social Beh‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@phil_w888,This is a fascinating study. Some results expected; some surprising. Wish I could see this with a bigger sample.  Social Behaviors Associated with a Positive COVID-19 Test Result  https://t.co/n54heE2YO3
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@CarlosNolascoMD,RT @medrxivpreprint: Social Behaviors Associated with a Positive COVID-19 Test Result  https://t.co/DHgK4Tg0NX #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168450,Social Behaviors Associated with a Positive COVID-19 Test Result,@medrxivpreprint,Social Behaviors Associated with a Positive COVID-19 Test Result  https://t.co/DHgK4Tg0NX #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@theboocock,"@benapeters @TonyMerriman2 Alternatively, one could scale the testing using NGS approaches, such as SwabSeq https://t.co/j6yj3qz9Dh.  Bit of investment needed but it doesn't suffer the same sensitivity issues that pooled testing has."
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@lpachter,Consider these two recent #SwabSeq preprints: https://t.co/1VllchDqfl https://t.co/F4u8TJ9kKp  Both were published with data as well as open source code and protocols making everything fully reproducible and usable.
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@abbyolena,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@weitinglin66,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing https://t.co/qWvc4ScOfB
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@csegerMD,"RT @NativeCACV: One more reason I‚Äôm proud to be a Bruin.  Great work team, thank you!"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@djwhelan,RT @BioscienceLA: Great work (https://t.co/FSYoKGgXH4) by @JoshSBloom @ArboledaVal @srikosuri @ZarEskinCompMed @jonathan_flint1 & @OctantBi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@BioscienceLA,Great work (https://t.co/FSYoKGgXH4) by @JoshSBloom @ArboledaVal @srikosuri @ZarEskinCompMed @jonathan_flint1 & @OctantBio team! üëèüèºüëèüèº& to immediately release under open covid license üôåüèºüëçüèº (https://t.co/hKFE3N1KlY)
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@lacks22,@INS_Peru @Minsa_Peru  Les refiero este nuevo metodo de detection del SARS-CoV2 para el rastreo y despistaje masivo a un bajo costo y rapido en comparacion con metedos como PCR o fluorescencia entre otros. Esto se adapta a las necesidades actualesüëá https:/
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@clintomics,This is great but hopefully we can move to simple at-home tests that the most vulnerable populations can use.
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@borauyar,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@gringene_bio,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@trevorwardill,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@meganamsu,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@PetrovADmitri,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@alexander_suh,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@kevinltweets,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@KerryMauck,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@gomezae_,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@JuhanaSiljander,"@lettipitko @Annu_Nakki Suomesta l√∂ytyy 70K sote-alan ty√∂ntekij√§√§ sote-sektorin ulkopuolelta; sielt√§ n√§ytteenottajia. Testit my√∂s kehittyy: sylkin√§ytteet, swab-seq etc.  Nyt jo ollut kuukausia aikaa varautua. Toki jos mit√§√§n ei (haluta) tehd√§, niin mik√§√§n"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@oligopain,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@punkrockscience,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@NeedhiBhalla,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@HarmitMalik,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@premal_shah,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@fernan_aguero,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@tangming2005,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@RichardMott7,RT @jonathan_flint1: Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing https://t.co/UPtYhKdStv  huge thanks f‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@zin_zah,RT @jukka_koskela: J√§lleen j√§rkipuhetta. Testikustannuksissa kuitenkin voisimme sukeltaa murto-osiin jos luvitus/tuet/kannusteet kunnossa k‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@ApeKanerva,RT @jukka_koskela: J√§lleen j√§rkipuhetta. Testikustannuksissa kuitenkin voisimme sukeltaa murto-osiin jos luvitus/tuet/kannusteet kunnossa k‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@anttivaris,RT @jukka_koskela: J√§lleen j√§rkipuhetta. Testikustannuksissa kuitenkin voisimme sukeltaa murto-osiin jos luvitus/tuet/kannusteet kunnossa k‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@NJdoc,RT @EricTopol: Opportunites galore. Action is what is missing. Saliva Direct https://t.co/AyDV72cwjV @NathanGrubaugh @YaleMed @YaleEMD A Be‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@MikkoAhtiainen,RT @jukka_koskela: J√§lleen j√§rkipuhetta. Testikustannuksissa kuitenkin voisimme sukeltaa murto-osiin jos luvitus/tuet/kannusteet kunnossa k‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@jukka_koskela,"J√§lleen j√§rkipuhetta. Testikustannuksissa kuitenkin voisimme sukeltaa murto-osiin jos luvitus/tuet/kannusteet kunnossa kehitt√§ville yksik√∂ille, olivat akateemisia tai eiv√§t. Yksi hyv√§ malli voisi olla Swab-Seq, 100% konkordanssi rtPCR kanssa: https://t.co/"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@ThePeoplesDr,RT @CannessonMaxime: Groundbreaking. @UCLAHealth @UCLAAnes @ZarEskinCompMed @CompMedUCLA @dgsomucla
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@theboocock,RT @JoshSBloom: We are serious about scaling up SARS-CoV-2 testing. Privileged to be working with such a talented and passionate team inclu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@DrSynbio,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@NativeCACV,"One more reason I‚Äôm proud to be a Bruin.  Great work team, thank you!"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@granex,RT @leonidkruglyak: Our preprint on NGS-based SARS-CoV-2 testing is up! https://t.co/SHN51RRVum  Work by an amazing team including @JoshSBl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@UCLAAnes,RT @CannessonMaxime: Groundbreaking. @UCLAHealth @UCLAAnes @ZarEskinCompMed @CompMedUCLA @dgsomucla
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@Rosy_Favicchio,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@d_a_keldsen,RT @leonidkruglyak: Our preprint on NGS-based SARS-CoV-2 testing is up! https://t.co/SHN51RRVum  Work by an amazing team including @JoshSBl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@CannessonMaxime,Groundbreaking. @UCLAHealth @UCLAAnes @ZarEskinCompMed @CompMedUCLA @dgsomucla
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@BiomeSankar,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@robertclab,"RT @lpachter: The #SwabSeq preprint, describing a method for high-throughput #covid19 diagnostic testing using next-generation sequencing b‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@Finnsense,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@egonwillighagen,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@ixenario,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@rfrsarmiento,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@P_J_Buckhaults,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@mjhegde,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@andy23tran,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@kbullaughey,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@KevinYauy,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@joshuawkho,"RT @lpachter: The #SwabSeq preprint, describing a method for high-throughput #covid19 diagnostic testing using next-generation sequencing b‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@deepvard,RT @EricTopol: Opportunites galore. Action is what is missing. Saliva Direct https://t.co/AyDV72cwjV @NathanGrubaugh @YaleMed @YaleEMD A Be‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@websun23,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@citrus_kyoto,RT @EricTopol: Opportunites galore. Action is what is missing. Saliva Direct https://t.co/AyDV72cwjV @NathanGrubaugh @YaleMed @YaleEMD A Be‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@segal_eran,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@segal_eran,"RT @lpachter: The #SwabSeq preprint, describing a method for high-throughput #covid19 diagnostic testing using next-generation sequencing b‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@seemaychou,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@Gonza10V,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@marimiya_clc,RT @jsantoyo: Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing. https://t.co/fU6nKqo7pp
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@marimiya_tky,RT @jsantoyo: Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing. https://t.co/fU6nKqo7pp
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@ojozenit,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@camera561,RT @miriamulu1: This is fantastic and could be a game changer! Bravo to Ulupreneur @srikosuri  @OctantBio
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@dilekopter,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing https://t.co/emZgp2G92F
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@LabOnTheCheap,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@timdewet,"This is cool, but I'm sorta struggling to see why it's more efficient than standard qRT-PCR on an extraction-free sample? It still requires an RT reaction and barcoding, and then has a slightly more complex readout?"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@futurepundit,RT @medrxivpreprint: Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing  https://t.co/dgjNvPEQx8 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@camiblinblin,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@rnomics,"Top #tweeted story in #bioinformatics: Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing | medRxiv https://t.co/RncmEnI7up, see more https://t.co/x4TiUjeQ4E"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@CarldeBoerPhD,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@MullinsLab,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@GabeOland,Excited for the possibilities that Next Generation Sequencing technology has for massively scaling up COVID testing! And proud to be part of this exceptional team! #UCLAHealth
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@PharmaDecisions,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@philippefroguel,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@arojass,@frankorestovic https://t.co/H18a8T8UIS
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@arthurostapenko,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@SimonettiFR,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@diegodidibi,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@karthikskamath,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@sanghyuk_shin,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@RanuDhillon,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@ekta_khurana,RT @leonidkruglyak: Our preprint on NGS-based SARS-CoV-2 testing is up! https://t.co/SHN51RRVum  Work by an amazing team including @JoshSBl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@nichetopia,"RT @jflier: SwabSeq looks to be a major COVID19 testing advance:‚Äù SwabSeq is simple, sensitive, flexible, rapidly scalable, inexpensive eno‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@nextgenseek,RT @leonidkruglyak: Our preprint on NGS-based SARS-CoV-2 testing is up! https://t.co/SHN51RRVum  Work by an amazing team including @JoshSBl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@skathire,RT @leonidkruglyak: Our preprint on NGS-based SARS-CoV-2 testing is up! https://t.co/SHN51RRVum  Work by an amazing team including @JoshSBl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@SeigoIzumo,"RT @jflier: SwabSeq looks to be a major COVID19 testing advance:‚Äù SwabSeq is simple, sensitive, flexible, rapidly scalable, inexpensive eno‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@PeterACarr,RT @srikosuri: Yay! #SwabSeq preprint online. SwabSeq is a cheap (~$5 in consumables) & scalable (10k/day w/o automation) method for purifi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@miggylol,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@jwbelmon,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@tuuliel,"@andreasblanco T√§t√§ ei voi kunnat tai edes yksitt√§iset labrat tehd√§, vaan tarvitaan THL:n vetoapua, panostusta ja tukea. Teknisi√§ haasteita on, mutta reagenssien suhteen ei pid√§ mietti√§ nykytestin vaatimuksia kun monet toimii ihan eri lailla. Esim: https:/"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@carrie_byington,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@MFAlvarez7,RT @leonidkruglyak: Our preprint on NGS-based SARS-CoV-2 testing is up! https://t.co/SHN51RRVum  Work by an amazing team including @JoshSBl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@CyrusMaher,"Pre-analytical best practices: samples are barcoded in tubes that can be placed directly in 96-well plates. From there, you can prep for RT-PCR in batch, then pool for sequencing. Per-well positive controls, buffer selection, and sequence length all affect"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@Vashishtrv,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@cavemanjohn,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@spaiglass,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@harishsbhat,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167874,Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing,@phylogenomics,"RT @atulbutte: SUPER work by @UCLA researchers & others on SwabSeq: multiplexed high-throughput #SARSCoV2 testing platform, uses next-gen s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@barrywyman2356,"RT @WillowWyse: A paper about ""cases"" that utterly fails to define a ""case"" üôÑ  https://t.co/VWsbrr8Xus"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@q_3verything,"RT @WillowWyse: A paper about ""cases"" that utterly fails to define a ""case"" üôÑ  https://t.co/VWsbrr8Xus"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@WillowWyse,"A paper about ""cases"" that utterly fails to define a ""case"" üôÑ  https://t.co/VWsbrr8Xus"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@PandemicCovid20,"Epidemiology of Reopening in the #COVID19 Pandemic in the United States, Europe and Asia https://t.co/b0RvjOqoTo"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@outbreaksci,"New #SARSCoV preprint: Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia https://t.co/Kvq597yj8K"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@outbreaksci,"Contribute a rapid review or request one for ""Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia"" (https://t.co/Kvq597yj8K). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168757) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@outbreaksci,"New #COVID19 preprint: Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia https://t.co/Kvq597yj8K"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@Bjornapoor,"RT @medrxivpreprint: Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia  https://t.co/1QF6EaBc96 #med‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168757,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia",@medrxivpreprint,"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia  https://t.co/1QF6EaBc96 #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@MiguelMolinaDH,RT @alfonso_casi: Sensibilidad de las pruebas moleculares del SARS-CoV-2 en la saliva respecto de hisopos nasofar√≠ngeos: La saliva podr√≠a c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@alfonso_casi,"Sensibilidad de las pruebas moleculares del SARS-CoV-2 en la saliva respecto de hisopos nasofar√≠ngeos: La saliva podr√≠a considerarse como m√©todo de muestreo alternativo respecto de los los hisopos nasofar√≠ngeos (sensibilidad 0,97). https://t.co/4lmbUmraCE"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@GeneQuan,"RT @jvdesomp: Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@RoelSterken,"RT @jvdesomp: Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@futurepundit,RT @medrxivpreprint: Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@naomiattar,"RT @jvdesomp: Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@kat_gris,"RT @jvdesomp: Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@outbreaksci,"Contribute a rapid review or request one for ""Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva c..."" (https://t.co/GaGGBsHe4T). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168716) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@outbreaksci,New #SARSCoV preprint: Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs https://t.co/GaGGBsHe4T
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@natelea2001,About testing SARS-CoV2 in saliva
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@JVerwilt,"RT @jvdesomp: Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@gertvanpeer,"RT @jvdesomp: Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@jvdesomp,"Literature indicates that SARS-CoV-2 testing on saliva is (almost) as good as on nasopharyngeal swabs, but our ongoing study suggest only good correspondence in mid to high viral load range https://t.co/MykwFewbaB"
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@yuezhang407,RT @medrxivpreprint: Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@BuglegsMcWalshy,RT @medrxivpreprint: Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@CHOMES102,RT @medrxivpreprint: Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168716,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs,@medrxivpreprint,Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs  https://t.co/zQfxenZAsp #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@alfonso_casi,"Mortalidad cl√≠nica en una gran cohorte de COVID-19: Casi el 50% d las muertes ocurrieron en un nivel d atenci√≥n fuera de la UCI, a pesar d ingresar en un entorno d atenci√≥n adecuado. Esto implica un deterioro repentino e inesperado del estado respiratorio."
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@luciaruggiero,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort #GPHO https://t.co/r594CWoAyl
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@equityhealthdev,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort #GPHO https://t.co/VZM6iDIIES
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@ghia1212,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort #GPHO https://t.co/DQKG1i5H5s
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@CofHEQ,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort #GPHO https://t.co/cEieOba2fA
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@CofHEQ,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort https://t.co/TAZFXd5JpE
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@ghia1212,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort https://t.co/TAZFXd5JpE
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@equityhealthdev,RT @GlobalPHObserv: Clinical #Mortality Review in a Large #COVID19 Cohort https://t.co/TAZFXd5JpE
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@GlobalPHObserv,Clinical #Mortality Review in a Large #COVID19 Cohort https://t.co/TAZFXd5JpE
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@outbreaksci,New #SARSCoV preprint: Clinical Mortality Review in a Large COVID-19 Cohort https://t.co/x6PcoO0Yh6
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@outbreaksci,"Contribute a rapid review or request one for ""Clinical Mortality Review in a Large COVID-19 Cohort"" (https://t.co/x6PcoO0Yh6). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168146) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@outbreaksci,New #COVID19 preprint: Clinical Mortality Review in a Large COVID-19 Cohort https://t.co/x6PcoO0Yh6
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@hswapnil,"RT @hildabast: Scary window into a New York hospital system March/April: 2,634 people who died of Covid-19. About half weren't in intensive‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@plurabellaties,"RT @hildabast: Scary window into a New York hospital system March/April: 2,634 people who died of Covid-19. About half weren't in intensive‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@RenegadeSci,"RT @hildabast: Scary window into a New York hospital system March/April: 2,634 people who died of Covid-19. About half weren't in intensive‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@inoviolt,"RT @hildabast: Scary window into a New York hospital system March/April: 2,634 people who died of Covid-19. About half weren't in intensive‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@hildabast,"Scary window into a New York hospital system March/April: 2,634 people who died of Covid-19. About half weren't in intensive care - they had a sudden unexpected crash. https://t.co/aZngwG5XXH (btw 4.3% were enrolled in clinical trials - apparently more lik"
http://medrxiv.org/cgi/content/short/2020.08.05.20168146,Clinical Mortality Review in a Large COVID-19 Cohort,@medrxivpreprint,Clinical Mortality Review in a Large COVID-19 Cohort  https://t.co/opZzNLWvf3 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@SAM4KV,RT @medrxivpreprint: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@Keshava_Datta,RT @medrxivpreprint: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@santosh4ever,RT @medrxivpreprint: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@kyle_minogue,An alternative to alleviate issues with current tests for COVID-19 the following test for Mayo Clinic could be easily implemented in Winnipeg. Since we already have these instruments and expertise in the city and province.  https://t.co/qmIaIl30Bf
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@outbreaksci,New #SARSCoV preprint: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens https://t.co/OvPnnHT6Yf
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@outbreaksci,"Contribute a rapid review or request one for ""Development of mass spectrometry-based targeted assay for direct detection of novel SA..."" (https://t.co/OvPnnHT6Yf). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168948) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@outbreaksci,New #COVID19 preprint: Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens https://t.co/OvPnnHT6Yf
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@Aiims1742,Mass spectrometry based targeted assay for direct detection of #SARSCoV2 antigen in clinical samples. By Akhilesh Pandey er al @MayoClinic https://t.co/MriVJNAFeD https://t.co/eN9Pj5cOme
http://medrxiv.org/cgi/content/short/2020.08.05.20168948,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens,@medrxivpreprint,Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens  https://t.co/BD7rUTlzhM #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168971,Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals,@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Pseudovirus neutralization assay protocol download: https://t.co/Z9pyXg1Onl https://t"
http://medrxiv.org/cgi/content/short/2020.08.05.20168971,Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals,@outbreaksci,"Contribute a rapid review or request one for ""Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Conva..."" (https://t.co/IOpSvtLsca). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168971) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168971,Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals,@outbreaksci,New #SARSCoV preprint: Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals https://t.co/IOpSvtLsca
http://medrxiv.org/cgi/content/short/2020.08.05.20168971,Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals,@medrxivpreprint,Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals  https://t.co/GtDRQJ9bkZ #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@DbrownRn08,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test https://t.co/4QJ1ssqb6B
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@outbreaksci,New #SARSCoV preprint: Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test https://t.co/enKwmuwyX9
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@outbreaksci,"Contribute a rapid review or request one for ""Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by ra..."" (https://t.co/enKwmuwyX9). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168815) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@outbreaksci,New #COVID19 preprint: Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test https://t.co/enKwmuwyX9
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@CHOMES102,RT @medrxivpreprint: Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test  https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@anonymous_leeks,RT @medrxivpreprint: Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test  https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168815,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test,@medrxivpreprint,Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test  https://t.co/QmFyBRL2wJ #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@HonourMcCann,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@drdalidali,This is fun -to follow the virus' fingerprints sorta speak.... We WILL find you lil sucker!!!üîç https://t.co/VWAj8z7Zl9
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@EvolvedBiofilm,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@MarvinBittner,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Tuwhera,"RT @theluqmanarian: As genome sequencing is utilised to help trace origins of Aotearoa's COVID-19 outbreak, check out this preprint as note‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@AUT_SC,"RT @theluqmanarian: As genome sequencing is utilised to help trace origins of Aotearoa's COVID-19 outbreak, check out this preprint as note‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@VirtuaProcessor,"RT @theluqmanarian: As genome sequencing is utilised to help trace origins of Aotearoa's COVID-19 outbreak, check out this preprint as note‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@theluqmanarian,"As genome sequencing is utilised to help trace origins of Aotearoa's COVID-19 outbreak, check out this preprint as noted by @SiouxsieW in the Spinoff.  Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand ht"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@stephen_streat,"@FoxyLustyGrover https://t.co/AR5UVLtn2i  Maybe this time- sorry about broken link in earlier (deleted) tweet   It might tell us ‚Äòprovenance‚Äô of the virus in the small AKL cluster, and hence where it came from ..."
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@andreajnz,RT @timnicholas: For those interested in the NZ sequencing from earlier infections this preprint is worth a read. https://t.co/7bCJ5R7EEf
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@sarabeee,RT @timnicholas: For those interested in the NZ sequencing from earlier infections this preprint is worth a read. https://t.co/7bCJ5R7EEf
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@7R4SM,RT @timnicholas: For those interested in the NZ sequencing from earlier infections this preprint is worth a read. https://t.co/7bCJ5R7EEf h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@timnicholas,@gtiso @LI_politico I don‚Äôt think it was that late.  https://t.co/7bCJ5R7EEf
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@timnicholas,For those interested in the NZ sequencing from earlier infections this preprint is worth a read. https://t.co/7bCJ5R7EEf
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@nigel_epilab_NZ,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@pingue7,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@opus135,@woopdedoo652 @diarmuid3003 @CaseyBriggs https://t.co/zjdWiX26iG only 11% of separate outbreaks actually infect more than one person before burning out on their own
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Aethylred,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Aethylred,"RT @ppgardne: Just in case anyone still disputes the value of a hard shutdown, followed by a very slow and cautious relaxation of restricti‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@EastDulwichMum,"RT @ppgardne: Just in case anyone still disputes the value of a hard shutdown, followed by a very slow and cautious relaxation of restricti‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@pierreroudier,"RT @ppgardne: Just in case anyone still disputes the value of a hard shutdown, followed by a very slow and cautious relaxation of restricti‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@drnickisaac,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@kevinpurcell,‚ÄúGenomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand‚Äù  https://t.co/dz8wCNMqyt
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@kevinpurcell,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@CampbellChrisB,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@AdamPalayew,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@BizGrowthGB,"RT @ppgardne: Just in case anyone still disputes the value of a hard shutdown, followed by a very slow and cautious relaxation of restricti‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@BauhiniaGenome,RT @KathyBelov: Great work Jemma and team. Very interesting that most NZ cases came from US not Asia or Australia!
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@KathyBelov,Great work Jemma and team. Very interesting that most NZ cases came from US not Asia or Australia!
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@mdsumner,"RT @ppgardne: Just in case anyone still disputes the value of a hard shutdown, followed by a very slow and cautious relaxation of restricti‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@rubenx,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@juanjogc,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@AntheaKatelaris,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@DominiqueVanpee,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@mrc7cam,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@DrDayaSharma,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@GlenWalker64,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@lgayosocouce,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Solutions_42,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@sejwatson,"@TuppyGloss @CT_Bergstrom would anyone want to go and study in the USA?  ""Most of the cases that resulted in a transmission lineage (in New Zealand) originated from North America""  https://t.co/5zK6FbF3mY"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@nikola1tesla,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@covid19_experts,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@emc_mcdonald,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@lizl_genealogy,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@econseptiles,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@rfitz77,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@lisalulutweets,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@B_Barbarian,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@below43,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Dimon_Lers,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@DerekRobinson2,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@DeniseBeale,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@SuhnyllaKler,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@DeniseBeale,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@MedOtaku,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@boback,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@nata_zamorano,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@bealelab,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Kutchinbird,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@tonymc39,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@aino_kivela,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Mondiablue,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@LAsskoul,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@LeeAnde81134144,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@HironoriFunabi1,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@looneytunes03,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@andreasosa_16,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@mejcb,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@mavsluys,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@mridulkthomas,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@lucy_carroll,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@jepekar,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@GreyWol27926578,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Leon_F_B,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@ael_yokan,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@4Kinesis,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@leilaluheshi,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@seth_edmunds,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@JoanRitchie11,"RT @ppgardne: Just in case anyone still disputes the value of a hard shutdown, followed by a very slow and cautious relaxation of restricti‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@AdelAHamdeh,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Toetterbeck,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Bozaster,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@uchida_kawasaki,"RT @kenmomd: NZÈñ¢ÈÄ£„ÅÆË´ñÊñá ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@SnorreEikeland,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@caglarbakcay,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@BorowiecKathrin,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@bearlymade_it,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@MorriganResists,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@Furious_mico,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@microtago,Amazing work Jemma Geoghegan
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@microtago,RT @Jemma_Geoghegan: Genomics of COVID-19 in Aotearoa - great to work with the whole team @Joepdl @sciolato @MathStorey @fabiokmendes @sebd‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@mwalimurural,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@HallHomesweeths,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@dauskasim,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@OldeNaturalist,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@lizditz,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@carloshotta,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@tp_1024,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@kakape,"RT @AdamJKucharski: ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.05.20168930,Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand,@kouske616,"RT @kenmomd: NZÈñ¢ÈÄ£„ÅÆË´ñÊñá ""Despite the small size of the New Zealand outbreak, there were 277 separate introductions of the virus out of the 649‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.200691,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets,@SciscoreReports,The paper ‚ÄúPredicted Cellular Immunity Population Coverage Ga...‚Äù (https://t.co/NuK8f8hJ9s) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/18T9L7MpH2. We detected 1 key resource.
http://biorxiv.org/cgi/content/short/2020.08.04.200691,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets. ùóîùòÇùòÅùóµùóºùóøùòÄ: Ge Liu, Brandon Carter, David K. Gifford https://t.co/OGgaEUvk2h https://t.co/0EZX9FNSlY"
http://biorxiv.org/cgi/content/short/2020.08.04.200691,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets,@outbreaksci,"Contribute a rapid review or request one for ""Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and..."" (https://t.co/8lPeDgOAoP). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.200691) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.04.200691,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets,@outbreaksci,New #SARSCoV preprint: Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets https://t.co/8lPeDgOAoP
http://biorxiv.org/cgi/content/short/2020.08.04.200691,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets,@biorxiv_immuno,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets  https://t.co/BjadznQgPw #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.04.200691,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets,@biorxivpreprint,Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets  https://t.co/yEYNvNk5Fu #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168617,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)",@futurepundit,The contrast between the number of research preprints on how to lower testing costs versus the low volume of testing in USA continues to be stark. The knowledge is there to make testing so much better.
http://medrxiv.org/cgi/content/short/2020.08.04.20168617,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)",@mariobarata6,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with‚Ä¶ https://t.co/6xvAZg7NLW"
http://medrxiv.org/cgi/content/short/2020.08.04.20168617,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)",@outbreaksci,"Contribute a rapid review or request one for ""Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybr..."" (https://t.co/PcXXy90zWL). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20168617) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20168617,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)",@outbreaksci,"New #SARSCoV preprint: Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP) https://t.co/PcXXy90zWL"
http://medrxiv.org/cgi/content/short/2020.08.04.20168617,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)",@davsrodrigues,"Estudo alem√£o, de ontem: https://t.co/yvLJU7SWmV  reclamam validade do teste r√°pido frente a PCR-RT,  10 min, ~1‚Ç¨ quero ver replica√ß√£o disto. Se n√£o tiver os falsos positivos que os anteriores tinham podem ser √∫teis"
http://medrxiv.org/cgi/content/short/2020.08.04.20168617,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)",@medrxivpreprint,"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)  https://t.co/g4GNjiW52o #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.05.20168682,The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody,@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Pseudovirus neutralization assay protocol download: https://t.co/Z9pyXg1Onl https://t"
http://medrxiv.org/cgi/content/short/2020.08.05.20168682,The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody,@outbreaksci,"Contribute a rapid review or request one for ""The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemok..."" (https://t.co/XmAesm1hbC). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168682) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168682,The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody,@outbreaksci,New #SARSCoV preprint: The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody https://t.co
http://medrxiv.org/cgi/content/short/2020.08.05.20168682,The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody,@medrxivpreprint,The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody  https://t.co/4SVXaSwxW4 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@antoniovis1,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@fett1111,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@thomasmmr,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@COSseaton,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@KatonaFa,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@donkamion78,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@newsanceandgg,#LivingHistory
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@newsanceandgg,"RT @CristinaDragani: A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@CristinaDragani,"A Brazilian study reported that #COVID19 patients who, for unknown reasons, experience a massive #viral load are those at the highest risk of #death. https://t.co/6PNUBFp6C9 #Health #coronavirus #pandemic #SARSCoV2 https://t.co/Ljae1YxOVF"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@klingerfaiko,"RT @rmchavin: 8-4-2020:  In a scientific study released today from Sao Paulo, Brazil, higher viral loads were directly correlated with seve‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@klingerfaiko,"RT @epidatum: Is Higher Viral Load in #SARSCoV2 Associated With #COVID19 Death?  A Ct value of <25 (472/875) indicated a high viral load, w‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@epidatum,"Is Higher Viral Load in #SARSCoV2 Associated With #COVID19 Death?  A Ct value of <25 (472/875) indicated a high viral load, which was independently associated with mortality (OR: 0,34; 95% CI: 0,217 to 0,533; p < 0.0001).  https://t.co/3mECXIR1Xr htt"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@outbreaksci,Updated #SARSCoV preprint: Is Higher Viral Load in SARS-CoV-2 Associated With Death? https://t.co/VwJJcTHBn7
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@outbreaksci,"Contribute a rapid review or request one for ""Is Higher Viral Load in SARS-CoV-2 Associated With Death?"" (https://t.co/VwJJcTHBn7). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20164061) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@outbreaksci,Updated #COVID19 preprint: Is Higher Viral Load in SARS-CoV-2 Associated With Death? https://t.co/VwJJcTHBn7
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@Heel_Gewoon,Admission #SARS_CoV_2 viral load is an important surrogate biomarker of infectivity and is independently associated with mortality among patients hospitalized with #COVID__19. https://t.co/qrtpcecNX7
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@Heel_Gewoon,Is Higher Viral Load in #SARS_CoV_2 Associated With Death?  https://t.co/qrtpcecNX7
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@CarlosNolascoMD,RT @medrxivpreprint: Is Higher Viral Load in SARS-CoV-2 Associated With Death?  https://t.co/xV5yMbW9jS #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@rmchavin,"8-4-2020:  In a scientific study released today from Sao Paulo, Brazil, higher viral loads were directly correlated with severe complications and death in COVID-19.  This would indicate that both mask wearing and favipiravir would diminish disease severity"
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@medrxivpreprint,Is Higher Viral Load in SARS-CoV-2 Associated With Death?  https://t.co/xV5yMbW9jS #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@fvguima,RT @victorpassa: Um dos orgulhinhos dessa reta final da resid√™ncia em meio a pandemia ‚ù§Ô∏è  https://t.co/Ow6I2Rtbng
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@gabrieltcuba,Ahhhhhh <3
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@victorpassa,Um dos orgulhinhos dessa reta final da resid√™ncia em meio a pandemia ‚ù§Ô∏è  https://t.co/Ow6I2Rtbng
http://medrxiv.org/cgi/content/short/2020.08.04.20164061,Is Higher Viral Load in SARS-CoV-2 Associated With Death?,@klingerfaiko,Is Higher Viral Load in SARS-CoV-2 Associated With Death? https://t.co/Gg8xrfx7EJ
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YalePediatrics,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YaleCRC,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@OSDG_annotator,"#OSDG has linked this publication to the UN's #SustainableDevelopmentGoals, including #Goal3 - Good Health and Well-being, #Goal11 - Sustainable Cities and Communities.  ‚úÖ Try for yourself at https://t.co/JwFpZHZajo  Thanks for contributing to #Agenda2030!"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@MarkQuarter,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@shiwani_mahajan,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@tejasavsehrawat,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@willnanken,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@louvetou,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@KrutikaKuppalli,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@hmkyale,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@emilyallia,A friendly minder for students returning to campus
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YaleAlumni,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@monitor_PH,RT @YaleSPH: New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YaleSPH,New study shows most people in CT don't have antibodies against SARS-CoV-2. That means we all need to stay vigilant to prevent a resurgence of COVID-19.   Keep your space. Wear your mask. Wash your hands.  @hmkyale @YaleMed @QuestDX @Gallup @jacksonlab htt
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@DaisySMassey,RT @shiwani_mahajan: Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@tejasavsehrawat,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@tejasavsehrawat,RT @shiwani_mahajan: Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@gandhisk,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@KatyjennM,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@jacksonlab,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@SuveenAngraal,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@NeilSehgal,"In a large #COVID19 prevalence study in Connecticut, authors found that most people do not have detectable levels of antibodies against SARS-CoV-2, and while many have engaged in risk mitigating behaviors there is a need for continued adherence to them.  h"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@outbreaksci,"New #SARSCoV preprint: Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study https://t.co/3r25MS7nWt"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@outbreaksci,"Contribute a rapid review or request one for ""Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticu..."" (https://t.co/3r25MS7nWt). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20168203) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@outbreaksci,"New #COVID19 preprint: Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study https://t.co/3r25MS7nWt"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@AndThoracic,RT @shiwani_mahajan: Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@ElleMandell,"@federicolois take a look at this study out of CT - also very low. Yet, they absolutely had some of the highest level of infection and fatalities in the country. https://t.co/hC716omEHG"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@AVHernandezDiaz,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@Donaldverger,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@AtomsksSanakan,"28/  Connecticut (see part 26/) 4.0% https://t.co/45HSqWnTAu  More Rhode Island info (see part 26/): https://t.co/T4LFXk14Be (slide 6)  May/June update: NYS, 1.2% NYC, 1.0% https://t.co/sJ4gW8u6GB  [https://t.co/FPmw5nJI4I]  Ferguson et al., Imperial (May)"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@Biomaven,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@damseldem,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@RuthMontgomery1,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@RaviParikhMD,"‚Å¶‚Å¶@YaleMed‚Å© study   Shows that only about 3.1% of ppl in CT have antibodies to #COVID19.  This shows despite decreased hospitalizations in some states, we need to continue #masks, #distancing, and avoiding large crowds. #MedTwitter https://t.co/7RXCD8yY93"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@Poitras_Colin,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@aakriti_15,RT @shiwani_mahajan: Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@willnanken,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@byultokkie,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@SarahEOlson2009,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@JCavallo972,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@CesarCaraballoC,RT @shiwani_mahajan: Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@NellMLuo,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YaleSPH,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@shiwani_mahajan,"RT @khurramn1: congrats @shiwani_mahajan @hmkyale   so much to learn for other states, large metropolitan areas  #Houston @ushahmd @Houston‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YaleSPH,RT @shiwani_mahajan: Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@khurramn1,"congrats @shiwani_mahajan @hmkyale   so much to learn for other states, large metropolitan areas  #Houston @ushahmd @HoustonChron"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@shiwani_mahajan,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@shiwani_mahajan,Our statewide seroprevalence study out on @medrxivpreprint now! We found that most people in Connecticut do not have detectable antibodies against SARS-CoV-2. Read below for details and check out the full paper here:  https://t.co/RWmSllcPx0 @YaleMed @Yale
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@DrJHarlan,"""We can quibble about meaning of antibodies‚Ä¶ but low prevalence in Connecticut suggests most population is still susceptible."" Great @gallup partnership with @YaleMed @QuestDX and @jacksonlab learning more about #COVID prevalence in CT. #research"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@BrooklynBiome,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@methodsmanmd,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@GailWaldby,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@SherryBannon4,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@YaleMed,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@JCDarnestown,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@craigmatsuda,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@JacksonR08,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@hmkyale,"@ewinsberg @QuestDX @Gallup @jacksonlab @CTDPH @CDCgov @medrxivpreprint @YaleMed We did our best to assess the performance of these tests‚Ä¶ though not able to exactly answer the question you are posing. We were most, by the way, within 2 months of infection"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@NetworkSomelier,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@JustTheFacts37,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@mcdormom,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@SKaliamurthy,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@politikaterina,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@InfectiousDz,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@mlezukowski,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@AEndersWalsh,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@queerlycontent,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@Polit_eurOpines,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@Polit_eurOpines,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@hmkyale,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@sbc111,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@stephenslayter,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@reidatcheson,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@cshperspectives,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@ctdata,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@amanda_dettmer,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@awyllie13,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@TheGOV17,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@notdred,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@dchen333,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@Anthropic,"RT @thehowie: BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@thehowie,"BREAKING: ""These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-CoV-2. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents, to prevent resurgence of C"
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@sbc111,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@NathanGrubaugh,RT @hmkyale: Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpre‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168203,"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study",@hmkyale,Our new seroprevalence study in Connecticut done w/ @QuestDX @Gallup @jacksonlab & support from @CTDPH @CDCgov now @medrxivpreprint; bottom line‚Ä¶small percentage of people in CT have evidence of antibodies & many engaged in mitigation activities. @
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@JingBioinfor,RT @fabiokmendes: Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynami‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@jimenez_cinthy,"RT @jimenez_cinthy: An early version of our paper is out!. Here, we recovered the phylodynamic inference of the COVID-19 outbreak in New Ze‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@Warsywarsy,"RT @futurepundit: Taiwan, New Zealand, Australia, Iceland: Our reconstruction of COVID-19's phylogenetic history indicated that this diseas‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@MonarchCorner,"RT @futurepundit: Taiwan, New Zealand, Australia, Iceland: Our reconstruction of COVID-19's phylogenetic history indicated that this diseas‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@futurepundit,"Taiwan, New Zealand, Australia, Iceland: Our reconstruction of COVID-19's phylogenetic history indicated that this disease was introduced many times into each island, and that introductions slowed down markedly when the borders closed."
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@brunoasm,RT @fabiokmendes: Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynami‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@outbreaksci,New #SARSCoV preprint: Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations https://t.co/gnfd89me4I
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@outbreaksci,"Contribute a rapid review or request one for ""Phylodynamics reveals the role of human travel and contact tracing in controlling COVI..."" (https://t.co/gnfd89me4I). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20168518) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@outbreaksci,New #COVID19 preprint: Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations https://t.co/gnfd89me4I
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@jimenez_cinthy,"An early version of our paper is out!. Here, we recovered the phylodynamic inference of the COVID-19 outbreak in New Zealand. The rapid real-time assessment of viral genomic data can complement health surveillance strategies. I`m so happy to have been part"
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@jimenez_cinthy,RT @fabiokmendes: Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynami‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@jmarshallnz,RT @phydyn: Happy to have two preprints out today looking at #COVID19 in Aotearoa/NZ using viral genomes.  The lead authors of the first ar‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@phydyn,RT @phydyn: Happy to have two preprints out today looking at #COVID19 in Aotearoa/NZ using viral genomes.  The lead authors of the first ar‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@MitovVenelin,RT @fabiokmendes: Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynami‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@lutulentstreams,RT @phydyn: Happy to have two preprints out today looking at #COVID19 in Aotearoa/NZ using viral genomes.  The lead authors of the first ar‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@fabiokmendes,RT @phydyn: Happy to have two preprints out today looking at #COVID19 in Aotearoa/NZ using viral genomes.  The lead authors of the first ar‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@phydyn,Happy to have two preprints out today looking at #COVID19 in Aotearoa/NZ using viral genomes.  The lead authors of the first are Jordan Douglas and F√°bio Mendes @fabiokmendes (hire him!) https://t.co/d7JQQhUBe3.  A little üßµabout both papers follows... http
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@phydyn,RT @fabiokmendes: Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynami‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@nicfelm,RT @fabiokmendes: Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynami‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@fabiokmendes,"Happy to share this early version of our scientific contribution to characterizing COVID-19. We looked at the phylodynamics of the pandemic in four islands, and how it responded to human travel: https://t.co/KMZcF5eKZG"
http://medrxiv.org/cgi/content/short/2020.08.04.20168518,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations,@medrxivpreprint,Phylodynamics reveals the role of human travel and contact tracing in controlling COVID-19 in four island nations  https://t.co/QiN7PYgWOW #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@libertates,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@cosasqueoigo,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@_JeanLeon,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@argie84,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@awgreen,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@desipsmith,Cool !
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@lenidot,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@chuckjugo,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@realGuyShalev,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@rutgervanbergem,Symptom onset to test time is underrated in containment
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@Ben35846532,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@rubin,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@tylercowen,RT @OfirReich: What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@OfirReich,"This paper is possible thanks to many people! @realGuyShalev, Tom Kalvari, @AviadReich, @davidmanheim, Dean Foster & more.  Here's the paper again: https://t.co/LoiC5hFPxe Still a preprint, all comments are welcome!  11/11"
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@OfirReich,What determines the success of #COVID19 #TestAndTrace?  Our SEIR on a graph says: (i) Symptom Onset to Test Time (& to self-isolation) (ii) Share of Contacts Traced  Less important: (iii) Test & Trace Time: test turnaround & contact tracing tim
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@CHOMES102,RT @medrxivpreprint: COVID-19 Test & Trace Success Determinants: Modeling On A Network  https://t.co/efuJCMl643 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168799,COVID-19 Test & Trace Success Determinants: Modeling On A Network,@medrxivpreprint,COVID-19 Test & Trace Success Determinants: Modeling On A Network  https://t.co/efuJCMl643 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168195,"Mathematical Analysis, Model and Prediction of COVID-19 Data",@medrxivpreprint,"Mathematical Analysis, Model and Prediction of COVID-19 Data  https://t.co/Rh2q700W5e #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.05.20168674,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country,@outbreaksci,"Contribute a rapid review or request one for ""Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned f..."" (https://t.co/NbILTIb3dZ). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168674) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168674,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country,@outbreaksci,New #COVID19 preprint: Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country https://t.co/NbILTIb3dZ
http://medrxiv.org/cgi/content/short/2020.08.05.20168674,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country,@brf_bd,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country https://t.co/fbK7Wuz4i5
http://medrxiv.org/cgi/content/short/2020.08.05.20168674,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country,@Siam_01,"Our paper is now online in medrxiv. Title: "" Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country"" #COVID19 #Bangladesh #HighRisk https://t.co/MIRyKhQci4"
http://medrxiv.org/cgi/content/short/2020.08.05.20168674,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country,@medrxivpreprint,Insights into the first wave of the COVID-19 pandemic in Bangladesh: Lessons learned from a high-risk country  https://t.co/3fKjqY0Kkp #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168880,Discontinuity of the deadly infection rate for the COVID-19 pandemia due to lockdown measures,@CHOMES102,RT @medrxivpreprint: Discontinuity of the deadly infection rate for the COVID-19 pandemia due to lockdown measures  https://t.co/G72wIwuKIr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168880,Discontinuity of the deadly infection rate for the COVID-19 pandemia due to lockdown measures,@TheFireTracker2,RT @medrxivpreprint: Discontinuity of the deadly infection rate for the COVID-19 pandemia due to lockdown measures  https://t.co/G72wIwuKIr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.05.20168880,Discontinuity of the deadly infection rate for the COVID-19 pandemia due to lockdown measures,@medrxivpreprint,Discontinuity of the deadly infection rate for the COVID-19 pandemia due to lockdown measures  https://t.co/G72wIwuKIr #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168443,Inhomogeneous mixing and asynchronic transmission between local outbreaks account for the spread of COVID-19 epidemics,@CHOMES102,RT @medrxivpreprint: Inhomogeneous mixing and asynchronic transmission between local outbreaks account for the spread of COVID-19 epidemics‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168443,Inhomogeneous mixing and asynchronic transmission between local outbreaks account for the spread of COVID-19 epidemics,@medrxivpreprint,Inhomogeneous mixing and asynchronic transmission between local outbreaks account for the spread of COVID-19 epidemics  https://t.co/TMcjRi6Pn4 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168344,Performing Qualitative Mask Fit Testing without a Commercial Kit: Fit Testing Which can be Performed at Home and at Work,@SciscoreReports,The paper ‚ÄúPerforming Qualitative Mask Fit Testing without a...‚Äù (https://t.co/K8PB3rPN7m) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/DkP0ch6jxZ. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.04.20168344,Performing Qualitative Mask Fit Testing without a Commercial Kit: Fit Testing Which can be Performed at Home and at Work,@medrxivpreprint,Performing Qualitative Mask Fit Testing without a Commercial Kit: Fit Testing Which can be Performed at Home and at Work  https://t.co/XNACyW2hv9 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168781,"Groundbreaking predictions about COVID-19 pandemic duration, number of infected and dead: A novel mathematical approach never used in epidemiology",@medrxivpreprint,"Groundbreaking predictions about COVID-19 pandemic duration, number of infected and dead: A novel mathematical approach never used in epidemiology  https://t.co/Mohjfl0bCe #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@NelzaVianna,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@paras_0707,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@HereshAmini,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@poojatya,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@PDez90,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@ufn00,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@alldominguez,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@francescadomin8,just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the states in all US https://t.co/qQm1RF6bAF led by   @poojatya
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@JuliaGBrody,Info about air pollution during COVID lockdowns can guide regional strategies for clean air after.
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@TBenmarhnia,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@futurepundit,NO2 dropped by a fifth. This gives us an idea of how much electric vehicles will improve air quality.
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@SergioIbarraEs1,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@rjmori,RT @francescadomin8: just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@francescadomin8,just posted!  Counterfactual time series analysis to estimate changes in NO2 and PM25 during the lockdown for all the states in all US https://t.co/hGcXjiVeWG led by @poojatyagi5
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@SciscoreReports,The paper ‚ÄúShort-term change in air pollution following the C...‚Äù (https://t.co/nuzeUBfbMM) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/n7zsyjhlwa. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.04.20168237,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States,@medrxivpreprint,Short-term change in air pollution following the COVID-19 state of emergency: A national analysis for the United States  https://t.co/1XrDfBHiQp #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@mauhernandez80,Felicidades por la validaci√≥n de esta herramienta para medir la inseguridad alimentaria en tiempos de #COVID @pablogaitan @Mvilar213 @GracielaTeruel1 @rperezescamilla
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@zepecaos,RT @equide_ibero: üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during th‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@pablogaitan,RT @equide_ibero: ‚ö†Ô∏èDos ideas que pueden desprenderse:  1‚É£ La ELCSA telef√≥nica es una escala v√°lida y confiable para medir inseguridad alim‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@pablogaitan,RT @equide_ibero: üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during th‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@Mvilar213,RT @equide_ibero: üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during th‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@rperezescamilla,RT @equide_ibero: üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during th‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@AlfredoNarvaez,RT @equide_ibero: üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during th‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@equide_ibero,"‚ö†Ô∏èDos ideas que pueden desprenderse:  1‚É£ La ELCSA telef√≥nica es una escala v√°lida y confiable para medir inseguridad alimentaria.   Su uso puede ser viable cuando se necesitan sistemas de monitoreo r√°pidos, baratos y de calidad  2‚É£ La inseguridad alimentar"
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@palomaparda,RT @equide_ibero: üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during th‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@equide_ibero,üî•Nuevo art√≠culo acad√©micoüî•  ü¶†Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico  üó£Ô∏è Pablo Gaitan üó£Ô∏è Mireya Vilar üó£Ô∏è Graciela Teruel üó£Ô∏è Rafael Perez-Escamilla  üîóhttps://t.co/2x58DvKmVd h
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@tshamah1,RT @rperezescamilla: @equide @YaleSPH study demonstrates strong validity of ELCSA scale for frequent phone tracking of household food insec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@medrxivpreprint,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico  https://t.co/cglgjhWTLO #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@Pacto1aInfancia,RT @rperezescamilla: @equide @YaleSPH study demonstrates strong validity of ELCSA scale for frequent phone tracking of household food insec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@lilation,RT @rperezescamilla: @equide @YaleSPH study demonstrates strong validity of ELCSA scale for frequent phone tracking of household food insec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@pablogaitan,RT @rperezescamilla: @equide @YaleSPH study demonstrates strong validity of ELCSA scale for frequent phone tracking of household food insec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@Mvilar213,RT @rperezescamilla: @equide @YaleSPH study demonstrates strong validity of ELCSA scale for frequent phone tracking of household food insec‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167650,Measurement lessons of a repeated cross-sectional household food insecurity survey during the COVID-19 pandemic in Mexico,@rperezescamilla,@equide @YaleSPH study demonstrates strong validity of ELCSA scale for frequent phone tracking of household food insecurity during COVID-19 pandemic in Mexico. https://t.co/63fmMQuMfu @UNICEFMexico @1CINyS @tshamah1 @Pacto1aInfancia @FAOMexico @Mvilar213 @
http://medrxiv.org/cgi/content/short/2020.08.04.20154203,Safety of hot and cold site admissions within a high volume urology department in the United Kingdom at the peak of the COVID-19 pandemic,@DRTomlinsonEP,"I‚Äôm jealous. At the height of the UK pandemic, these London Urologists were able to obtain SARS-CoV-2 PCR within 72 hours of elective surgery+with patients required to self-isolate for 14d pre-op. Sensible IP&C or startlingly ahead of the curve: anyone"
http://medrxiv.org/cgi/content/short/2020.08.04.20154203,Safety of hot and cold site admissions within a high volume urology department in the United Kingdom at the peak of the COVID-19 pandemic,@medrxivpreprint,Safety of hot and cold site admissions within a high volume urology department in the United Kingdom at the peak of the COVID-19 pandemic  https://t.co/vvOFW6zFkA #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@GidMK,"RT @carissa_bon: @GidMK Our survey analysis found clustering within rumours too, roughly linked to prevention, management and cure. It is a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@carissa_bon,"@GidMK Our survey analysis found clustering within rumours too, roughly linked to prevention, management and cure. It is arguable whether some of these are truly myths, e.g. we should have asked about UV more specifically, but the preprint is here: https:/"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@DrToddWo,RT @ThomsonAngus: Excellent study. We need to generate these kinds of insights in all countries.
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@naveenthacker,RT @ThomsonAngus: Excellent study. We need to generate these kinds of insights in all countries.
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@phlu,RT @ThomsonAngus: Excellent study. We need to generate these kinds of insights in all countries.
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@cathimon,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@MelissaSweetDr,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@louvetou,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@sylvaindelouvee,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@ThomsonAngus,Excellent study. We need to generate these kinds of insights in all countries.
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@gmopundit,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@JulieLeask,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@CSHeartResearch,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@debbie_fearon,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@MarieBashirInst,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@julieayre32,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@KaraTStarbuck,"RT @CaulfieldTim: ""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@margymaclibrary,"RT @CaulfieldTim: ""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@carissa_bon,"@haydnjones84 @HealthLitLab Hi, that's a fair point that age and gender weren't the only associations with misinformation, but the editor framed it this way because they had already covered language and education in other articles. The full results cover t"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@HealthLitLab,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@viralvideovlogs,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@brooke_nickel,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@TessaCopp,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@ValeryRidde,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@PicklesKristen,"RT @CaulfieldTim: ""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@seyeabimbola,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@carissa_bon,RT @PicklesKristen: Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLit‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@PicklesKristen,Our new preprint looking at agreement with #COVID19  misinformation in Aus community https://t.co/bKPtlY5lZ3 @HealthLitLab
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@carissa_bon,Full results here led by @PicklesKristen : https://t.co/lhypsWxzhb
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@carissa_bon,RT @pash22: COVID-19: Beliefs in misinformation in the Australian community https://t.co/UjuJfwNL4Y via @PicklesKristen et al
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@StobKent1,"RT @CaulfieldTim: ""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@pash22,COVID-19: Beliefs in misinformation in the Australian community https://t.co/UjuJfwNL4Y via @PicklesKristen et al
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@ameliazein,"RT @CaulfieldTim: ""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@De_Duck_Music,◊ú◊ê ◊û◊§◊™◊ô◊¢ ◊ë◊õ◊ú◊ú: ◊§◊ó◊ï◊™ ◊ê◊û◊ï◊ü ◊ë◊û◊û◊°◊ì (◊î◊û◊ì◊¢◊ô/◊û◊û◊©◊ú◊™◊ô) ◊ï◊ê◊ï◊®◊ô◊ô◊†◊ï◊™ ◊™◊ß◊©◊ï◊®◊™◊ô◊™ (◊û◊ì◊ô◊î ◊ú◊ô◊ò◊®◊°◊ô) ◊í◊ï◊®◊®◊ô◊ù ◊ê◊û◊ï◊†◊î ◊ë◊û◊ô◊°◊ê◊ô◊†◊§◊ï◊®◊¶◊ô◊î ◊ï◊û◊ô◊™◊ï◊°◊ô◊ù ◊¢◊ú ◊ß◊ï◊®◊ï◊†◊î. (◊û◊ê◊û◊® ◊ú◊§◊†◊ô ◊ë◊ô◊ß◊ï◊®◊™ ◊¢◊û◊ô◊™◊ô◊ù: https://t.co/o98I7gEso2 )
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@CicelyMcWilliam,"RT @CaulfieldTim: ""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@CaulfieldTim,"""#COVID19: Beliefs in #misinformation in the Australian community"" https://t.co/weBHJdxyjd by @PicklesKristen, et al. #infodemic   < institutional trust + < media literacy = > support for myths  Interesting preprint highlighting importance of trus"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@zkabir17,COVID-19: Beliefs in misinformation in the Australian community https://t.co/jhrpPd9DrM
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@jamiekwood,@jeffandersontv This paper seems to be saying the government are the ones with ‚Äúall the truth‚Äù a and every divergent view or study becomes ‚Äúmisinformation‚Äù.    https://t.co/AsIn85DA3t
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@ben42578824,"RT @phil_w888: 'Researchers': Any opinion which isn't in lockstep with ours is misinformation.  Examples of 'misinformation beliefs':  ""Her‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@phil_w888,"'Researchers': Any opinion which isn't in lockstep with ours is misinformation.  Examples of 'misinformation beliefs':  ""Herd immunity would be beneficial for COVID-19 and this fact is covered up""  ""The government restrictions are stronger than is needed"""
http://medrxiv.org/cgi/content/short/2020.08.04.20168583,COVID-19: Beliefs in misinformation in the Australian community,@medrxivpreprint,COVID-19: Beliefs in misinformation in the Australian community  https://t.co/TtcNRt7UM7 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168187,An improved methodology for estimating the prevalence of SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: An improved methodology for estimating the prevalence of SARS-CoV-2 https://t.co/Qvfau1fzqv
http://medrxiv.org/cgi/content/short/2020.08.04.20168187,An improved methodology for estimating the prevalence of SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""An improved methodology for estimating the prevalence of SARS-CoV-2"" (https://t.co/Qvfau1fzqv). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20168187) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.04.20168187,An improved methodology for estimating the prevalence of SARS-CoV-2,@outbreaksci,New #COVID19 preprint: An improved methodology for estimating the prevalence of SARS-CoV-2 https://t.co/Qvfau1fzqv
http://medrxiv.org/cgi/content/short/2020.08.04.20168187,An improved methodology for estimating the prevalence of SARS-CoV-2,@medrxivpreprint,An improved methodology for estimating the prevalence of SARS-CoV-2  https://t.co/ieN30efKmm #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.05.20168666,Paediatric Attendances and Acuity in the Emergency Department during the COVID-19 Pandemic,@outbreaksci,"Contribute a rapid review or request one for ""Paediatric Attendances and Acuity in the Emergency Department during the COVID-19 Pand..."" (https://t.co/KShRUuyb2F). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.20168666) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.05.20168666,Paediatric Attendances and Acuity in the Emergency Department during the COVID-19 Pandemic,@outbreaksci,New #SARSCoV preprint: Paediatric Attendances and Acuity in the Emergency Department during the COVID-19 Pandemic https://t.co/KShRUuyb2F
http://medrxiv.org/cgi/content/short/2020.08.05.20168666,Paediatric Attendances and Acuity in the Emergency Department during the COVID-19 Pandemic,@medrxivpreprint,Paediatric Attendances and Acuity in the Emergency Department during the COVID-19 Pandemic  https://t.co/0wr0GRwSNb #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@SciscoreReports,The paper ‚ÄúIFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage p...‚Äù (https://t.co/CIcHhnRzx4) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/MS5LfY5xvo. We detected 1 key resource.
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@jrmears8,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@simplycavero,@Enloyb https://t.co/nUq8EAbKp4
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation. ùóîùòÇùòÅùóµùóºùóøùòÄ: Lorien Shakib, Sara Shanaj, Aparna Nathan, - Accelerating Medicines Part... https://t.co/vSdY99aJwO https://"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@jbeynor,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@mariaGTAC,RT @FanZhang_Jessie: Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and oth‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@asgari_samira,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@aparnanathan,RT @FanZhang_Jessie: Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and oth‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@broadinstitute,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@Donlinlab,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@yluo86,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@s_keshavjee,RT @megan_b_murray: Very cool analysis from Soumya Raychaudhuri and colleagues.
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@AHelenaJonsson1,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@AHelenaJonsson1,RT @FanZhang_Jessie: Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and oth‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@Rosenchild,RT @biorxiv_genomic: IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@elisabetta1412,RT @FanZhang_Jessie: Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and oth‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@GHResearchCore,RT @megan_b_murray: Very cool analysis from Soumya Raychaudhuri and colleagues.
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@SingleCellMedia,RT @FanZhang_Jessie: Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and oth‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@megan_b_murray,Very cool analysis from Soumya Raychaudhuri and colleagues.
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@kaz_yos,RT @FanZhang_Jessie: Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and oth‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@FanZhang_Jessie,"Happy to share our recent work of IFN-Œ≥ and TNF-Œ± driven CXCL10+ CCL2+ macrophage phenotype in severe COVID-19 and other inflammatory diseases by meta-analyzing >300,000 single cell profiles!"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@sjiafoundation,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@afvallejop,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@KragstrupTW,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@joycebkang,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@jarora_inde,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@SingleCellMedia,"RT @soumya_boston: Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflam‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@soumya_boston,"Our latest  with @FanZhang_Jessie and @Donlinlab. Analysis of public single cell data from severe #COVID, 5 other inflammatory diseases, and ex vivo blood derived macrophages identified an  IFN-Œ≥ and TNF-Œ± driven  CXCL10+ CCL2+ macrophage phenotype https:/"
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@sloanlewis,RT @biorxivpreprint: IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@ageofthephage,RT @biorxivpreprint: IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@pooledseq,bioArXiv_ IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation https://t.co/GgDbha2ueP
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@MitochondriaNe1,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation https://t.co/bnFIQ9zzZY
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@simplycavero,RT @biorxivpreprint: IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@biorxiv_genomic,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation  https://t.co/FMZsmV2HDR #biorxiv_genomic
http://biorxiv.org/cgi/content/short/2020.08.05.238360,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation,@biorxivpreprint,IFN-Œ≥ and TNF-Œ± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation  https://t.co/i6EdhaIgpB #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.237313,Dynamics of the COVID -19 Related Publications,@SciscoreReports,The paper ‚ÄúDynamics of the COVID -19 Related Publications‚Äù (https://t.co/Xoz8Z6uCyA) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/H29UDJppD4. We detected 1 of 5 rigor criteria and 1 key resource.
http://biorxiv.org/cgi/content/short/2020.08.05.237313,Dynamics of the COVID -19 Related Publications,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Dynamics of the COVID -19 Related Publications. ùóîùòÇùòÅùóµùóºùóøùòÄ: Biplab Sarkar, Anusheel Munshi, Bhaswar Ghosh, Tharmarnadar Ganesh, Arjunan Manikandan, Subhra Singhdha Biswal, Tanweer Sahid, Rajagopalan B, Sinjini Sengup... https://t.co/eWwehwN6XU https://"
http://biorxiv.org/cgi/content/short/2020.08.05.237313,Dynamics of the COVID -19 Related Publications,@Science_comedu,Dynamics of the COVID -19 Related Publications   https://t.co/GemdTIQWJD
http://biorxiv.org/cgi/content/short/2020.08.05.237313,Dynamics of the COVID -19 Related Publications,@biorxivpreprint,Dynamics of the COVID -19 Related Publications  https://t.co/yGVYnCrqFt #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@YuZhu4,RT @bio_clouseau: Pre-print for $PTCT DHODH inhibitor PTC299 https://t.co/sFqZqXOJBE $IMUX
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@lonondon,RT @bio_clouseau: Pre-print for $PTCT DHODH inhibitor PTC299 https://t.co/sFqZqXOJBE $IMUX
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@MogulAzam,RT @bio_clouseau: Pre-print for $PTCT DHODH inhibitor PTC299 https://t.co/sFqZqXOJBE $IMUX
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@Hall8Jack,RT @bio_clouseau: Pre-print for $PTCT DHODH inhibitor PTC299 https://t.co/sFqZqXOJBE $IMUX
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@semodough,RT @bio_clouseau: Pre-print for $PTCT DHODH inhibitor PTC299 https://t.co/sFqZqXOJBE $IMUX
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@bio_clouseau,Pre-print for $PTCT DHODH inhibitor PTC299 https://t.co/sFqZqXOJBE $IMUX
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jeremy Luban, Rachel Sattler, Elke Muhlberger, Jason D. Graci, Liangxian Cao, Marla Weetall, C... https://t.co/kUOcj5ifjB https://"
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@Becourt20,RT @PandemicCovid20: The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines - https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@rmchavin,"8-5-2020:  Good news from New Jersey's PTC Therapeutics for their DHODH inhibitor, PTC299, in ""tissue culture models"" against SARS-CoV-2, Ebola, and many other RNA viruses: https://t.co/bYSPYY9SrR https://t.co/c08aU0DXIk https://t.co/Lt8kt5qiU6 https://t.c"
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@SciscoreReports,The paper ‚ÄúThe DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Repl...‚Äù (https://t.co/tGzRLseCcG) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/3rY9r4DNl6. We detected 0 of 6 rigor criteria and 25 key resource
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@GODZILLASLAYS65,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines | bioRxiv https://t.co/giPrsG9Bf3
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@outbreaksci,New #SARSCoV preprint: The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines https://t.co/q3Wd4NcTH4
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@outbreaksci,New #COVID19 preprint: The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines https://t.co/q3Wd4NcTH4
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@outbreaksci,"Contribute a rapid review or request one for ""The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of In..."" (https://t.co/q3Wd4NcTH4). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.238394) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@outbreaksci,New #Ebola preprint: The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines https://t.co/q3Wd4NcTH4
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@ElmerEdward1,RT @PandemicCovid20: The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines - https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238394,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines,@PandemicCovid20,The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines - https://t.co/1OIx9EMQPd
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@SciscoreReports,The paper ‚ÄúAnalysis of the potential impact of genomic varian...‚Äù (https://t.co/YXWORdl7Ha) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/ODFYeyoH3o. We detected 0 of 5 rigor criteria and 2 key resources
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@ankitsabharwal9,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays. ùóîùòÇùòÅùóµùóºùóøùòÄ: Abhinav Jain, Mercy Rophina, Saurabh Mahajan, Bhavya Balaji Krishnan, Manasa Sharma, S... https://t.co/3toBEkuFMA https://"
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@SrashtiJAgrawal,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@vinodscaria,@RajeevJayadevan @Abhinav_Jain_19 @mercy_rophina @Samatha_Mathew @SridharSivasub3 @IGIBSocial @CSIR_IND @IndiaDST @serbonline @COVID19centre @CovidOpen Please feel free to share the paper https://t.co/VRGqesrWjy or the summary link
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@Rosenchild,RT @biorxiv_genomic: Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@bxv_genomics,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays https://t.co/ITlGUpIEMW
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@GODZILLASLAYS65,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays | bioRxiv https://t.co/lZ1j5tGR0m
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@virology_chitra,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@outbreaksci,New #SARSCoV preprint: Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays https://t.co/wpqhiGxjrM
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@outbreaksci,"Contribute a rapid review or request one for ""Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on..."" (https://t.co/wpqhiGxjrM). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.238618) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@outbreaksci,New #COVID19 preprint: Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays https://t.co/wpqhiGxjrM
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@RodriguesCalvin,RT @userSaurabh: A very small contribution to Covid research. Thanks @vinodscaria for the opportunity. Current and ex-undergrads from @sjcb‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@Pratima_India,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@rk_boyapati,RT @userSaurabh: A very small contribution to Covid research. Thanks @vinodscaria for the opportunity. Current and ex-undergrads from @sjcb‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@SeqComplete,"Top story: Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays | bioRxiv https://t.co/Sfz2USQOm5, see more https://t.co/TycLla79wi"
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@RK_Premas,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@bani_jolly,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@sumayrasultanji,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@SreyaMandal,RT @userSaurabh: A very small contribution to Covid research. Thanks @vinodscaria for the opportunity. Current and ex-undergrads from @sjcb‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@manasa298,RT @userSaurabh: A very small contribution to Covid research. Thanks @vinodscaria for the opportunity. Current and ex-undergrads from @sjcb‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@userSaurabh,A very small contribution to Covid research. Thanks @vinodscaria for the opportunity. Current and ex-undergrads from @sjcbengaluru scanned Covid papers for many days and collected data for this. @manasa298 Bhavya @Teresa1652 @SreyaMandal @sumayrasultanji
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@Abhinav_Jain_19,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@Samatha_Mathew,RT @Abhinav_Jain_19: Excited to share a preprint from our lab on potential impact of #Genomic #variants on the molecular diagnostic assays‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@manasa298,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@gyanranjan2197,RT @Abhinav_Jain_19: Excited to share a preprint from our lab on potential impact of #Genomic #variants on the molecular diagnostic assays‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@S_Bandyopadhyay,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@mercy_rophina,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@DNAed_tech,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@IGIBSocial,RT @vinodscaria: Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https:/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@Samatha_Mathew,Latest pre-print-short comm- from VS-SSB group @IGIBSocial to map Indian SARS-Cov-2 variants to RT-PCR primers/probes from kits across the globe. Genome and variation analysis by @Abhinav_Jain_19 @mercy_rophina   PS: I am on a COVID preprint after all üòÖ Th
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@mercy_rophina,RT @Abhinav_Jain_19: Excited to share a preprint from our lab on potential impact of #Genomic #variants on the molecular diagnostic assays‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@vinodscaria,Fresh preprint on the potential impact of genomic variants in SARS-CoV-2 from India on molecular diagnostic assays https://t.co/gfQuvjVEDh #CSIRfightsCOVID19 #COVID19India #SARSCoV2 #Genomics https://t.co/tqMObR2cjf
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@Abhinav_Jain_19,Excited to share a preprint from our lab on potential impact of #Genomic #variants on the molecular diagnostic assays in #SARSCoV2 #NextGenerationSequencing @vinodscaria @SridharSivasub3 @mercy_rophina @Samatha_Mathew. Please RT and share in your network.
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@biorxiv_genomic,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays  https://t.co/EawLWItvZJ #biorxiv_genomic
http://biorxiv.org/cgi/content/short/2020.08.05.238618,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays,@biorxivpreprint,Analysis of the potential impact of genomic variants in SARS-CoV-2 genomes from India on molecular diagnostic assays  https://t.co/UIheoUWHKB #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@SciscoreReports,The paper ‚ÄúIdentification of SARS-CoV-2 recombinant genomes‚Äù (https://t.co/gXKMT1JuV9) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/BsE9T6ygtI. We detected 4 key resources.
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@NassMeryl,"Of course they are occurring.  They always do. This is a nothingburger, intended only to scare you without any data, from our friends at Emory aka CDC"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@BillyBostickson,Sooner or Later... COVID-19 Genomics: Emory University Research Warns Emerging Recombinant SARS-CoV-2 Strains Already Occurring  via @THAILANDMEDICA1 (a great resource) https://t.co/acoy5IpngI  Paper: https://t.co/wNNuDA4LRE
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@Acrea9,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Identification of SARS-CoV-2 recombinant genomes. ùóîùòÇùòÅùóµùóºùóøùòÄ: David VanInsberghe, Andrew S Neish, Anice C Lowen, Katia Koelle https://t.co/Vs8Ta1CWEF https://t.co/aVFxMi6zHk"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@AkramChishti2,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@PhyDyn_Papers,"Identification of SARS-CoV-2 recombinant genomes David VanInsberghe @DVaninsberghe, Andrew S Neish, Anice C Lowen @anice_lowen, Katia Koelle @KoelleLab https://t.co/xwKS69NbsB"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@CeriFielding,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@biofadialnaji,RT @anice_lowen: Was great to contribute to this effort led by @DVaninsberghe and in collaboration with @KoelleLab! The work identifies rec‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@EIEarIyBird,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@EIEarIyBird,RT @anice_lowen: Was great to contribute to this effort led by @DVaninsberghe and in collaboration with @KoelleLab! The work identifies rec‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@sindiso_n,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@PeterWoolf6,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@DuckSwabber,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@BortzGroup,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@AndrewW66619812,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@DiseaseEcology,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@thesciencebae,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@shyogenes,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@shyogenes,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@JustinLessler,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@BenManOfWald,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@abrussel86,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@science_tay,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@CIDIDteam,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@anice_lowen,Was great to contribute to this effort led by @DVaninsberghe and in collaboration with @KoelleLab! The work identifies recombination among circulating SARS-CoV-2 variants.
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@SternLab,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@fatiaysh,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@ajsieben,"RT @KoelleLab: Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISA‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@CienciaBKRJ,RT @DVaninsberghe: I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recom‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@KoelleLab,"Our latest work on SARs-CoV-2, this time a highly collaborative project looking at recombinant genomes identified from @GISAID sequences. See Dave's thread on key findings below."
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@DVaninsberghe,I'm excited to share the results of a collaboration with the @KoelleLab and @anice_lowen on identifying SARS-CoV-2 recombinant genomes. I appreciate all of the support and feedback from everyone that made this project come together! https://t.co/adpp1ANyYP
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@FribourgNancy,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@GODZILLASLAYS65,Identification of SARS-CoV-2 recombinant genomes | bioRxiv https://t.co/k8HeYEekAR
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@hiiika9,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@DeylDjama,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@S3GIT9,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@outbreaksci,"Contribute a rapid review or request one for ""Identification of SARS-CoV-2 recombinant genomes"" (https://t.co/jyrnZrfUos). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.238386) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@outbreaksci,New #SARSCoV preprint: Identification of SARS-CoV-2 recombinant genomes https://t.co/jyrnZrfUos
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@houkifuji,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@BashEya,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@TheAbhijitDN,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@sarchan_mama,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@jimenez_cinthy,RT @biorxiv_evobio: Identification of SARS-CoV-2 recombinant genomes  https://t.co/M2DZnbj7Vj #biorxiv_evobio
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@Vallecillo_AJ,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@fakeDespommier,RT @biorxiv_evobio: Identification of SARS-CoV-2 recombinant genomes  https://t.co/M2DZnbj7Vj #biorxiv_evobio
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@JOAT2020JAN,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@fuku6,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@kanabun_029,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@takavet1,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@EIEarIyBird,RT @biorxiv_evobio: Identification of SARS-CoV-2 recombinant genomes  https://t.co/M2DZnbj7Vj #biorxiv_evobio
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@deanprocter,RT @biorxivpreprint: Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@biorxiv_evobio,Identification of SARS-CoV-2 recombinant genomes  https://t.co/M2DZnbj7Vj #biorxiv_evobio
http://biorxiv.org/cgi/content/short/2020.08.05.238386,Identification of SARS-CoV-2 recombinant genomes,@biorxivpreprint,Identification of SARS-CoV-2 recombinant genomes  https://t.co/lY9q91pykL #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NUFeinbergMed,"RT @NUCATSInstitute: With support from @NUCATSInstitute in the form of a rapid response grant, a team of @NorthwesternMed researchers syste‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,"RT @NUCATSInstitute: With support from @NUCATSInstitute in the form of a rapid response grant, a team of @NorthwesternMed researchers syste‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@CLIC_CTSA,"RT @NUCATSInstitute: With support from @NUCATSInstitute in the form of a rapid response grant, a team of @NorthwesternMed researchers syste‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RidgeLabNU,"RT @NUCATSInstitute: With support from @NUCATSInstitute in the form of a rapid response grant, a team of @NorthwesternMed researchers syste‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NUCATSInstitute,"With support from @NUCATSInstitute in the form of a rapid response grant, a team of @NorthwesternMed researchers systematically profiled 86 patients with severe #COVID19 and 252 patients with severe pneumonia caused by other respiratory pathogens ‚Äî https:/"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@loreleilutin1,RT @BlaiseScalpa: Pas reveiw√©.. mais cette analyse de lavages broncho-alv√©olaires semble expliquer pas mal des constats empiriques que nous‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@MichaelGIsonMD,RT @NU_IntMed: Great to see more than 100 of our PCCM colleagues as co-authors on this recent SCRIPT study.  Congratulations to all! https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@ClaireS33425114,RT @Miray_Ambu: Another great publication on aScope 4 Broncho being used for BAL procedures in COVID-19 patients.  Alveolitis in severe SAR‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@dusud_kiki,RT @BlaiseScalpa: Pas reveiw√©.. mais cette analyse de lavages broncho-alv√©olaires semble expliquer pas mal des constats empiriques que nous‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@BlaiseScalpa,Pas reveiw√©.. mais cette analyse de lavages broncho-alv√©olaires semble expliquer pas mal des constats empiriques que nous avons fait ces derniers mois sur la #Covid. üëâüèΩ physiopathologie üëâüèΩ disparit√© de sympt√¥mes en fonction de l‚Äô√¢ge  Merci @MARYau_MCU_PH
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Guillaume_RACLE,"RT @MARYau_MCU_PH: Covid19 et ifn. Voie IFN I bloqu√©e, mais voie IFN II pr√©sente et favorise l'alveolite (preprint). Le concept d'un epithe‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@MARYau_MCU_PH,"Covid19 et ifn. Voie IFN I bloqu√©e, mais voie IFN II pr√©sente et favorise l'alveolite (preprint). Le concept d'un epithelium/pneumocyte incapable de d√©fendre en inn√©e, suivi d'un rattrapage excessif par les leucocytes se tient. https://t.co/nO7t5gKrdE"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NU_IntMed,Great to see more than 100 of our PCCM colleagues as co-authors on this recent SCRIPT study.  Congratulations to all! https://t.co/LwQsQoeOyx
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Ambu_UK,RT @Miray_Ambu: Another great publication on aScope 4 Broncho being used for BAL procedures in COVID-19 patients.  Alveolitis in severe SAR‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Miray_Ambu,Another great publication on aScope 4 Broncho being used for BAL procedures in COVID-19 patients.  Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells https://t.co/RQsUwzalcS #aS
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@lrasmus,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RidgeLabNU,RT @NMPulmCritCare: @NorthwesternMed physicians & pulmonary scientists examined hundreds of bronchoalveolar lavage fluid samples from patie‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,RT @NMPulmCritCare: @NorthwesternMed physicians & pulmonary scientists examined hundreds of bronchoalveolar lavage fluid samples from patie‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NUCATSInstitute,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NMPulmCritCare,@NorthwesternMed physicians & pulmonary scientists examined hundreds of bronchoalveolar lavage fluid samples from patients with #COVID19 and severe pneumonia by other respiratory pathogens. Read the article here to see the results: https://t.co/koY3dyD
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@mwupce,RT @RidgeLabNU: Thanks and congratulations to everyone involved in the SCRIPT study! Check out the latest preprint: Alveolitis in severe SA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@jmd5120,RT @RidgeLabNU: Thanks and congratulations to everyone involved in the SCRIPT study! Check out the latest preprint: Alveolitis in severe SA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@sangmotiani,RT @CyrilPedia: 'We collected bronchoalveolar lavage fluid samples from 86 patients with SARS-CoV-2-induced respiratory failure and 252 pat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@JKropski,RT @RidgeLabNU: Thanks and congratulations to everyone involved in the SCRIPT study! Check out the latest preprint: Alveolitis in severe SA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells. ùóîùòÇùòÅùóµùóºùóøùòÄ: Rogan A Grant, Luisa Morales-Nebreda, Nikolay S Markov, Suchitra Swaminat... https://t.co/8z3uAtc785 https://"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,RT @RidgeLabNU: Thanks and congratulations to everyone involved in the SCRIPT study! Check out the latest preprint: Alveolitis in severe SA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RidgeLabNU,Thanks and congratulations to everyone involved in the SCRIPT study! Check out the latest preprint: Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells https://t.co/p1X8dBeqWK
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@ScottBudinger,RT @AnkitBharatMD: Congratulations to our world-class Pulmonary investigators  for characterizing transcriptional changes in #COVID__19 and‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,RT @AnkitBharatMD: Congratulations to our world-class Pulmonary investigators  for characterizing transcriptional changes in #COVID__19 and‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Eomesodermin,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells https://t.co/2u8uvFoRNg #immunobot https://t.co/Kqdp60bRfk
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@salwa_lin,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Daltmann10,RT @CyrilPedia: 'We collected bronchoalveolar lavage fluid samples from 86 patients with SARS-CoV-2-induced respiratory failure and 252 pat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@amadlau,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,"RT @NMPulmCritCare: This is a GREAT thread from Scott Budinger, MD @ScottBudinger, detailing the findings and methodology of his latest NU‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RafaelPolidoro2,I'll find the time to place those manuscripts together with our model one day. Hopefully after my lab meeting. =)  #scicomm
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@emilyethornton,RT @CyrilPedia: 'We collected bronchoalveolar lavage fluid samples from 86 patients with SARS-CoV-2-induced respiratory failure and 252 pat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@EBartom,RT @bsinger007: Thrilled to share this collaborative work! @luisamnMD from the #SingerLab is a co-first author on this project from the #SC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@afsb2013,RT @CyrilPedia: 'We collected bronchoalveolar lavage fluid samples from 86 patients with SARS-CoV-2-induced respiratory failure and 252 pat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@robhynds,RT @CyrilPedia: 'We collected bronchoalveolar lavage fluid samples from 86 patients with SARS-CoV-2-induced respiratory failure and 252 pat‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@CyrilPedia,'We collected bronchoalveolar lavage fluid samples from 86 patients with SARS-CoV-2-induced respiratory failure and 252 patients with known or suspected pneumonia from other pathogens and subjected them to flow cytometry and bulk transcriptomic profiling'
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@wanderlostlass,I work with super smart people!
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NMPulmCritCare,"This is a GREAT thread from Scott Budinger, MD @ScottBudinger, detailing the findings and methodology of his latest NU SCRIPT study."
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@NMPulmCritCare,RT @AnkitBharatMD: Congratulations to our world-class Pulmonary investigators  for characterizing transcriptional changes in #COVID__19 and‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Colin_E_Evans,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@ManuelTorresAc2,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@jskim8223,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,"RT @RoganAGrant: Delighted to share my first first-author publication of my PhD, currently available as a bioRxiv preprint! This was a high‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@EBartom,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,"RT @EBartom: Super excited for this preprint! The SCRIPT study has been studying pneumonia outcomes in patients for years now, profiling mi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RobertMTighe1,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@jeremyhirota,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@lww95779173,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Shiloh_EC,"RT @RoganAGrant: Delighted to share my first first-author publication of my PhD, currently available as a bioRxiv preprint! This was a high‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@DelaCruzYaleMed,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@SciscoreReports,The paper ‚ÄúAlveolitis in severe SARS-CoV-2 pneumonia is drive...‚Äù (https://t.co/BL4oBKmqTp) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/864Gyksiky. We detected 2 of 5 rigor criteria and 12 key resource
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@jonas_schupp,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@jonas_schupp,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@EBartom,"Super excited for this preprint! The SCRIPT study has been studying pneumonia outcomes in patients for years now, profiling microbiome, host cell transcriptome, clinical outcome, etc.  When the pandemic started, data collection and analysis continued, and"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@SingleCellMedia,RT @AnkitBharatMD: Congratulations to our world-class Pulmonary investigators  for characterizing transcriptional changes in #COVID__19 and‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@MohammadLotfol1,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@MattWFoster,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@S007Elena,RT @AnkitBharatMD: Congratulations to our world-class Pulmonary investigators  for characterizing transcriptional changes in #COVID__19 and‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@AnkitBharatMD,Congratulations to our world-class Pulmonary investigators  for characterizing transcriptional changes in #COVID__19 and other pneumonias at single cell level revealing novel insights into lung pathobiology. @NMPulmCritCare https://t.co/AVA8799KSK
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@MarcSala_MD,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@SchillerLab,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@pnanny,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,"RT @Misharin_lab: New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Misharin_lab,Read the preprint https://t.co/apM8jubl4E and explore the data online https://t.co/P8p7HAl7kv (and if you need to see more ‚Äì download it from GEO and reproduce using the code from GitHub)
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@Misharin_lab,"New preprint from our group! Work from the NU SCRIPT consortium led by Rich Wunderink, with Ben Singer @bsinger007, Scott Budinger @ScottBudinger. Really enjoyed working on analysis with Rogan, Luisa, and Nick @RoganAGrant @luisamnMD @system001273866 - equ"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RidgeLabNU,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@system001273866,"I'm grateful and honoured to participate in this amazing feat of team work with great scientists, clinicians and mentors. Special shout-out to fellow first authors @RoganAGrant and @luisamnMD thank you üß°"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RoganAGrant,Pre-print: https://t.co/xqi55FuCnl Interactive data: https://t.co/JNSPu4uuXs Code: https://t.co/Xk56IJ3Hgo
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RoganAGrant,"Delighted to share my first first-author publication of my PhD, currently available as a bioRxiv preprint! This was a highly collaborative project with co-first authors @luisamnMD and @system001273866, as well as many talented clinical, informatics, and ex"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@CatGaoHow,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@RamyaGurunathan,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@thorplab,RT @ScottBudinger: We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneum‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bsinger007,"Thrilled to share this collaborative work! @luisamnMD from the #SingerLab is a co-first author on this project from the #SCRIPT Systems Biology Center @NMPulmCritCare . I am honored to be a part of this team working on mechanisms of severe viral pneumonia,"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@ScottBudinger,"We are excited to share the first manuscript from the NU SCRIPT study funded by @NIAIDNews on patients with severe pneumonia, including patients with severe COVID-19. https://t.co/5r5UrISFo8 https://t.co/TKZH8TK587"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@outbreaksci,New #SARSCoV preprint: Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells https://t.co/oJ3O4rYju3
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@outbreaksci,"Contribute a rapid review or request one for ""Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between ..."" (https://t.co/oJ3O4rYju3). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.238188) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@outbreaksci,New #COVID19 preprint: Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells https://t.co/oJ3O4rYju3
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@bxv_imm,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells https://t.co/B0cD4XDoEV
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@phil_w888,"736/  Chicago, USA (adult smoking rate was 16.8% in 2018)  Of 50 patients with SARS-CoV-2-induced pneumonia and respiratory failure requiring mechanical ventilation, zero were current smokers & 12 were past smokers (24%)  https://t.co/iWWVnsKgrn"
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@DrJuanCadavid,RT @biorxivpreprint: Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@eatinParis,RT @biorxivpreprint: Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@biorxiv_immuno,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells  https://t.co/9gw3c9uGwE #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.05.238188,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells,@biorxivpreprint,Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells  https://t.co/uroB2YhsYx #bioRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167643,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies,@GODZILLASLAYS65,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies | medRxiv https://t.co/1b8NpMfrT0
http://medrxiv.org/cgi/content/short/2020.08.04.20167643,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies,@outbreaksci,"Contribute a rapid review or request one for ""Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 ..."" (https://t.co/zApYR3VtKP). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20167643) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.04.20167643,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies,@outbreaksci,New #SARSCoV preprint: Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies https://t.co/zApYR3VtKP
http://medrxiv.org/cgi/content/short/2020.08.04.20167643,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies,@IanMedical,RT @medrxivpreprint: Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies  https://t.co/NWVDGoO‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167643,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies,@medrxivpreprint,Comparative Evaluation of Three Serologic Assays for the Identification of SARS-CoV-2 Antibodies  https://t.co/NWVDGoOlc8 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@TheDanWoods,"There's likely to be underdiagnosing of Covid deaths, and the seroprevalence data might be unrepresentative, but this still looks bonkers.  https://t.co/onvsKGech7"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@TheDanWoods,"The paper hasn't been through peer review yet, but if true these are huge numbers.  196 million people live in Nigeria and they've reported 950 deaths: a population fatality rate of 0.0005%, or 1 in 200,000.  https://t.co/onvsKGech7"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@TheDanWoods,A study in Niger State in Nigeria seems to have found that 25%(!) now have Covid antibodies. This implies that the virus has already largely swept through the population.   https://t.co/onvsKGech7
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@wartortle1989,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@MosheKeller,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@UnintendedCons5,@PlausibleUse @M7AMI @fredct @3KidsareaBlessi @NateSilver538 https://t.co/Na3j796L1N
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@EuphoniusNuts,@MrChelseaBlue @LeanderAlphabet https://t.co/0qnqiDT8og https://t.co/DNZLwSGPja https://t.co/zuBe1dKlo6 https://t.co/rlbzFpJb4A https://t.co/KeUG6XLeNu https://t.co/X0yCUgTNY2 https://t.co/rWA4at0wew https://t.co/cPVi4Lcsuo https://t.co/3jqxmRPi1c https://
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Ulloa2919,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@AdamForTrump,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@PSpinabella,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@meatjb1,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Kimberl32278503,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@chibaz101,RT @Diqsen: Our research team carried out a pilot study on the spread of coronavirus disease in Niger State and we found some interesting r‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@tomntempe,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@mwmjenard,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Fashion_Whit,üò±üò±
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Fashion_Whit,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@profpepper,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@VERBAL_CHANCLA,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@GodzillaFeet,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@g17891,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@harpersoo,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@princesseffel,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@chad_guertin,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@mgallagher465,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@MoniqAR,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Nynaeve5,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Charles85315641,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@ANobles21,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@LakerGMC,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@ilovespring1111,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@JSlate__,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@DerrickByford,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@2Chenery,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@turpinator929,"RT @12FreeBeer: 19% seroprevalence in general population (non-health care workers) in Niger State, Nigeria at end of June.  ~750,000 infect‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@catspath,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@garl02,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@DenZzar,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@jazzlifer,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@MarvinMartian0,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@ClydeMcK,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@AzannasirNasir,RT @Diqsen: Our research team carried out a pilot study on the spread of coronavirus disease in Niger State and we found some interesting r‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Grateful_Haroon,RT @Diqsen: Our research team carried out a pilot study on the spread of coronavirus disease in Niger State and we found some interesting r‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@yoakumgirl923,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Diqsen,Our research team carried out a pilot study on the spread of coronavirus disease in Niger State and we found some interesting results.   Seroprevalence of COVID-19 in Niger State https://t.co/eazAVhiQYj
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@ben1970arnold,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@abatizs,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@HaydenPresley,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@margare44233427,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Michael95494331,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@NewNormality20,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@7counting,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@KevinQuirk9,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@sick_silent,Im done with #lockdown im done with #socialdistancing #imdonewiththebs
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@CorruptionDC,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@donkamion78,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@dheathfield90,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@HiawathaCat,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@PlebianScot,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@cantika17024242,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@itsapurplelife,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@drsethallen,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@0Praying,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@JAMS45226427,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@cchant00,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@RandalMitchell,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@topkubob,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@ScottCa23802997,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@GooN849,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@HealthiestH,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@jennife19289969,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@RigMatthew,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Kylecar45148724,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@JGaltxxx,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@bakker_eileen,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@jessa_ana,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@momofalupusteen,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@JennyGo19112761,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@BrandonSwisher1,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@GrayGod8,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@GrantC1313,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@DdTexaneagle,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Mikemg34,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@imissdogstango,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@ieatcerealtoo,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@hamblin_jared,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@RebeccPlum,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@Pops01988132,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@UfedojoM,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@trishie818,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@be_the_press,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@JoeFreedomLove,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@To_Be_Benji,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@cooperanddiane,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@McGrubbert,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@cabville,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@VLabarum,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@5280Zl1,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@waynesonnichsen,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20168112,Seroprevalence of COVID-19 in Niger State,@JuanJosGuzmn10,"RT @aginnt: A new seroprevalence study in Nigeria finds +25% + a critique of lockdowns  ""Since this study recorded high COVID asymptomatic‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@SciscoreReports,The paper ‚ÄúAnalysis of single nucleotide polymorphisms betwee...‚Äù (https://t.co/KL19RS4Q8u) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/UvGQox21xZ. We detected 0 of 5 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage. ùóîùòÇùòÅùóµùóºùóøùòÄ: Suruchi Gupta, Ravail Singh, Prosenjit Paul https://t.co/xu67d6qS9R https://t.co/ISI19SnQTU"
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@TakAcd1217,RT @biorxiv_genomic: Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage  https://t.co/QSev‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@bxv_genomics,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage https://t.co/iBvE6gd1GS
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@jimenez_cinthy,RT @biorxiv_genomic: Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage  https://t.co/QSev‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@thparietallobe,RT @biorxivpreprint: Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage  https://t.co/hke6‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@jsteward2930,RT @biorxiv_genomic: Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage  https://t.co/QSev‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@biorxiv_genomic,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage  https://t.co/QSevgT8ng2 #biorxiv_genomic
http://biorxiv.org/cgi/content/short/2020.08.05.237404,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage,@biorxivpreprint,Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage  https://t.co/hke6kUPFwz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@SciscoreReports,The paper ‚ÄúEvolutionary dynamics of SARS-CoV-2 nucleocapsid p...‚Äù (https://t.co/fxV4PfGEvf) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/5csUhu6mD4. We detected 0 of 5 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences. ùóîùòÇùòÅùóµùóºùóøùòÄ: M. Shaminur Rahman, M. Rafiul Islam, A. S. M. Rubayet Ul Alam, Israt Islam, M. Nazmul Hoque, Salma Akter, Md. Miz... https://t.co/PXKBrpImtr https://"
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@outbreaksci,New #SARSCoV preprint: Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences https://t.co/80WWZEAafJ
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@outbreaksci,"Contribute a rapid review or request one for ""Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences"" (https://t.co/80WWZEAafJ). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.237339) at https://t.co/RnurTL3DyM @outbreaksci"
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@outbreaksci,New #COVID19 preprint: Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences https://t.co/80WWZEAafJ
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@simplycavero,RT @biorxivpreprint: Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences  https://t.co/IqN4g4KENZ #bi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@jimenez_cinthy,RT @biorxiv_evobio: Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences  https://t.co/zO9MZopbZl #bio‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@biorxiv_evobio,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences  https://t.co/zO9MZopbZl #biorxiv_evobio
http://biorxiv.org/cgi/content/short/2020.08.05.237339,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences,@biorxivpreprint,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein (N protein) and its consequences  https://t.co/IqN4g4KENZ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@SciscoreReports,The paper ‚ÄúRapid GMP-compliant expansion of SARS-CoV-2-specif...‚Äù (https://t.co/m9SBRlQvNr) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/BWnRQMQJjm. We detected 1 of 5 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19. ùóîùòÇùòÅùóµùóºùóøùòÄ: Rachel S Cooper, Alasdair R Fraser, Linda Smith, Paul Burgoyne, St... https://t.co/83Ws5gZdLj https://"
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@outbreaksci,"Contribute a rapid review or request one for ""Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors fo..."" (https://t.co/MgXO0aJvuW). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.237867) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@outbreaksci,New #SARSCoV preprint: Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19 https://t.co/MgXO0aJvuW
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@Bubblechuck,RT @biorxiv_immuno: Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell the‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@LucreSnooker,"in a different t-cell study (which doesn‚Äôt initially expand the cells with extended peptide stimulation) it‚Äôs striking that healthy donors show no responses to the spike, nucleoprotein, or membrane peptides checked https://t.co/IHztTZ9vFo https://t.co/cnSR"
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@atorbo,An interesting approach
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@mjwsim,RT @biorxiv_immuno: Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell the‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@APC82236815,RT @biorxiv_immuno: Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell the‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@LabWaggoner,RT @biorxiv_immuno: Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell the‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@biorxiv_immuno,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19  https://t.co/wyRBTbncmc #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.08.05.237867,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19,@biorxivpreprint,Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19  https://t.co/mgCSOQrwd1 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@SciscoreReports,The paper ‚ÄúCamostat mesylate inhibits SARS-CoV-2 activation b...‚Äù (https://t.co/uMYMCP14As) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/egSnzyhsIU. We detected 9 key resources.
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@IvermectinS,RT @LbyMads: New paper shows camostat and the metabolite GBPA inhibits TMPRSS2 /-13 /-11 which are involver in SARS-CoV-2 cell entry. #camo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@LbyMads,New paper shows camostat and the metabolite GBPA inhibits TMPRSS2 /-13 /-11 which are involver in SARS-CoV-2 cell entry. #camoco19 #aukdk #lundbeckfonden #aarhusuni
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@GYZhang2,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. ùóîùòÇùòÅùóµùóºùóøùòÄ: Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith, Nadine Krueger, Lamb... https://t.co/GzWDgWfgmJ https://"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@overseasdem,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@marrrkyyy,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@sangmotiani,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@yaw_shin,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@marija_backovic,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@PavlosMsaouel,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@ayirpelle,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@ne02012,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@MogulAzam,"RT @ImranSHaque: Can we all now stop calling TMPRSS2 ""necessary""? It's _sufficient_, but plenty of proteases will equally do the job. Our d‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@ZaniaStamataki,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@JulieMarieWolf,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@OmicsOmicsBlog,"RT @ImranSHaque: Can we all now stop calling TMPRSS2 ""necessary""? It's _sufficient_, but plenty of proteases will equally do the job. Our d‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@nouspoetikos,@__ice9
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@LucreSnooker,from https://t.co/9eHTj6zb3j
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@JasonWilliamsNY,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@cispt2,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@rod_rahimi,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@joans,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@ImranSHaque,"Can we all now stop calling TMPRSS2 ""necessary""? It's _sufficient_, but plenty of proteases will equally do the job. Our data has shown cathepsins do just fine, and @JSheltzer's team here broaden the diversity of serine proteases that will permit SARS-CoV-"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@houndcl,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@KevinWNg,"RT @JSheltzer: Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@JSheltzer,"Our new preprint on #COVID19 with Stefan P√∂hlmann, Markus Hoffman, and @joans is up. We show that proteases other than TMPRSS2 are capable of promoting SARS-CoV-2 uptake, but camostat (and its active metabolite) can still inhibit their activity.  https://t"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@smnlssn,"RT @FrankNoeBerlin: Follow-up on SARS-CoV-2 cell entry inhibition by blocking TMPRSS2: The metabolic product of the drug camostat, GBPA, al‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@FrankNoeBerlin,"Follow-up on SARS-CoV-2 cell entry inhibition by blocking TMPRSS2: The metabolic product of the drug camostat, GBPA, also blocks cell entry and binds to TMPRSS2, but weaker than camostat. Led by M Hoffmann,S P√∂hlmann, @tmhmpl,@smnlssn,cc:@cispt2 #COVID19"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@MassatoHirai,RT @outbreaksci: New #SARSCoV preprint: Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GB‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@outbreaksci,New #SARSCoV preprint: Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity https://t.co/BMF3DyBhhK
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@outbreaksci,"Contribute a rapid review or request one for ""Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its me..."" (https://t.co/BMF3DyBhhK). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.05.237651) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@outbreaksci,New #COVID19 preprint: Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity https://t.co/BMF3DyBhhK
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@rmchavin,"8-5-2020:  Good news from the Leibniz Institute for Primate Research in G√∂ttingen, Germany for the Japanese pancreatitis drug, camostat, for early COVID-19: https://t.co/DJAnk4FfRN https://t.co/gTGVwwsw7j https://t.co/XFE5ukm1jt https://t.co/soLPqeSJRt htt"
http://biorxiv.org/cgi/content/short/2020.08.05.237651,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity,@biorxivpreprint,Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity  https://t.co/dNwtVQ1kCr #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@ayush_akd,@snbkol
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Host metabolic reprogramming in response to SARS-Cov-2 infection. ùóîùòÇùòÅùóµùóºùóøùòÄ: S T R Moolamalla, Ruchi Chauhan, U Deva Priyakumar, P K Vinod https://t.co/EEi3Jr6K9A https://t.co/C1RfhofP99"
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@SciscoreReports,The paper ‚ÄúHost metabolic reprogramming in response to SARS-C...‚Äù (https://t.co/rqvtcPH2ve) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/D77OR7gCsw. We detected 0 of 5 rigor criteria and 4 key resources
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@doctorinigo,Host metabolic reprogramming in response to SARS-Cov-2 infection https://t.co/pYn74cQpAB
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@iriyagupta,RT @theRuchiChauhan: How does SARS-CoV-2 hijack our metabolism? What is the underlying pathogenesis of COVID19? Excited to share the latest‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@ian_hoffecker,Host metabolic reprogramming in response to SARS-Cov-2 infection https://t.co/kc2zBF78nh
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@Brunorm84,Host metabolic reprogramming in response to SARS-Cov-2 infection @biorxivpreprint https://t.co/q1SdhqOHIE
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@anekoplato,RT @theRuchiChauhan: How does SARS-CoV-2 hijack our metabolism? What is the underlying pathogenesis of COVID19? Excited to share the latest‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@abhinavdhere,Another contribution from IIIT-H towards battling this pandemic. Interesting work.
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@AkundiP,@SerumInstIndia @velumania #COVID19 #research
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@outbreaksci,"Contribute a rapid review or request one for ""Host metabolic reprogramming in response to SARS-Cov-2 infection"" (https://t.co/GPWNnVL2wL). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.232645) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@outbreaksci,New #SARSCoV preprint: Host metabolic reprogramming in response to SARS-Cov-2 infection https://t.co/GPWNnVL2wL
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@ayush_akd,@ICMRDELHI @docurvishukla @ArvinderSoin @drharshvardhan @ccmb_csir @bic_ccmb
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@theRuchiChauhan,"Our analysis revealed host-dependent dysregulation of glycolysis, mitochondrial metabolism, amino acid metabolism, glutathione metabolism, polyamine synthesis, and lipid metabolism.  Visit: https://t.co/957Zvw78Nj"
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@theRuchiChauhan,"How does SARS-CoV-2 hijack our metabolism? What is the underlying pathogenesis of COVID19? Excited to share the latest work from our group at CCNSB, @iiit_hyderabad:   https://t.co/957Zvw78Nj #coronavirus #COVID19India #COVID19 #IndiaFightsCorona"
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@helioRocha_,#bioRxiv   Host metabolic reprogramming in response to SARS-Cov-2 infection    #bioinfo https://t.co/J7VuZVefjs
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@Saiteja_reddy,"Our group's work at @iiit_hyderabad CCNSB, ""Host metabolic reprogramming in response to SARS-CoV-2 infection"" is now available on bioRxiv.  https://t.co/2tjLb0Lv1D #COVID19 #COVID19India #Bioinformatics #SARS_CoV_2"
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@Jessica61620980,RT @biorxivpreprint: Host metabolic reprogramming in response to SARS-Cov-2 infection  https://t.co/OYQZqVzSuh #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@carynjrogers,RT @biorxivpreprint: Host metabolic reprogramming in response to SARS-Cov-2 infection  https://t.co/OYQZqVzSuh #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@biorxiv_bioinfo,Host metabolic reprogramming in response to SARS-Cov-2 infection  https://t.co/TqlCvQiUGr #biorxiv_bioinfo
http://biorxiv.org/cgi/content/short/2020.08.02.232645,Host metabolic reprogramming in response to SARS-Cov-2 infection,@biorxivpreprint,Host metabolic reprogramming in response to SARS-Cov-2 infection  https://t.co/OYQZqVzSuh #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@PandemicCovid20,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale https://t.co/vQ5M4sAZVC
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@TaunRey,"@ThoBaSwe @AndreasPrucha @SHomburg @c_drosten @Karl_Lauterbach @HaraldofW Unterschied gemacht haben zwischen der Situation die wir jetzt in DE haben, und Zust√§nden wie wir sie in Italien hatten. Das sind aber alles theoretische √úberlegungen mit echt d√ºnner"
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@PIPSQC,RT @medrxivpreprint: Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale  https://t.co/XJixba2fMy #m‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@outbreaksci,"Contribute a rapid review or request one for ""Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global s..."" (https://t.co/gtQTEurKTm). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164939) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@outbreaksci,New #SARSCoV preprint: Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale https://t.co/gtQTEurKTm
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@m7m5ea,RT @medrxivpreprint: Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale  https://t.co/XJixba2fMy #m‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@CHOMES102,RT @medrxivpreprint: Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale  https://t.co/XJixba2fMy #m‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164939,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale,@medrxivpreprint,Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale  https://t.co/XJixba2fMy #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay"" (https://t.co‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@TrollRater,AL AGUA PATOS #COVID19
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@outbreaksci,Updated #SARSCoV preprint: Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay https://t.co/a1SlSFAZmc
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@outbreaksci,"Contribute a rapid review or request one for ""Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay"" (https://t.co/a1SlSFAZmc). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.235549) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@outbreaksci,Updated #COVID19 preprint: Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay https://t.co/a1SlSFAZmc
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@NACREspirale,RT @MARYau_MCU_PH: #Covid19 et #nacl hypertonique. En lien avec un tweet o√π je lancait l'id√©e d'un placebo sympa (plus que l'hcq).  Content‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@MARYau_MCU_PH,#Covid19 et #nacl hypertonique. En lien avec un tweet o√π je lancait l'id√©e d'un placebo sympa (plus que l'hcq).  Content de voir que √ßa marche in vitro. Dommage aucun rct pr√©vu dessus. https://t.co/IisXFw4oZa
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@SciscoreReports,The paper ‚ÄúHypertonic saline solution inhibits SARS-CoV-2 in...‚Äù (https://t.co/wJvdiBEv2x) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/hednJ0mvRd. We detected 0 of 6 rigor criteria and 7 key resources.
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@a_1_0_2,"""Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay""  https://t.co/WbzyFz6nkc"
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@1913undweiter,SARSCOV2  https://t.co/hEoMKFSBYy
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@outbreaksci,New #SARSCoV preprint: Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay https://t.co/a1SlSFAZmc
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@outbreaksci,"Contribute a rapid review or request one for ""Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay"" (https://t.co/a1SlSFAZmc). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.235549) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@outbreaksci,New #COVID19 preprint: Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay https://t.co/a1SlSFAZmc
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@jazzorion,I hate it here
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@jazzorion,RT @upulie: Guys really   Really https://t.co/hb5nUiQeo9
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@arndt_eric,RT @upulie: Guys really   Really
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@SacriliciousM,Cue the idiots injecting themselves with 3% saline solution
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@Brian00406663,@__ice9 @NicolodeGroot So 1.5% saline solution can help against Covid?
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@NotHF,RT @upulie: Guys really   Really https://t.co/hb5nUiQeo9
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@paddybts,RT @upulie: Guys really   Really https://t.co/hb5nUiQeo9
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@upulie,Guys really   Really
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@biorxiv_micrbio,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay  https://t.co/YqvOP7XySf #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.04.235549,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay,@biorxivpreprint,Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay  https://t.co/FxeFACt1xa #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@ayirpelle,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@KiWookKim816,Illumina vs Nanopore on SARS-CoV-2 amplicon WGS: what's our verdict? https://t.co/mT0bB87XKr
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@PromPreprint,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/4bZWk0zEdV
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@BioRxivCurator,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/kyUIp1gbIC
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@SciscoreReports,The paper ‚ÄúAnalytical validity of nanopore sequencing for rap...‚Äù (https://t.co/4Wj7afg4KY) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/yP62G9b8d5. We detected 0 of 5 rigor criteria and 4 key resources
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@Rosenchild,RT @biorxiv_genomic: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/gaqDpn6ncn #biorxiv_geno‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@chelysheva_i,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@joyeuph,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@EikeSteinig,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@IAnalyzeGenomes,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@kinghorngenomes,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@danielkein,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@Ghadavirol,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@hao_li12,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@erezaterez,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@SeqComplete,"#nanopores Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis | bioRxiv https://t.co/oM3dPD7JmK, see more https://t.co/QGcZ4oAz3B"
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@soulhomestudio1,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@surt_lab,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@huntr_seekr,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@_Tim_Chalmers,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@10minus6cosm,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@pablotsukayama,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@Psy_Fer_,RT @bxv_genomics: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/vivSofP2hI
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@laulam94,RT @bxv_genomics: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/vivSofP2hI
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@jsantoyo,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis. https://t.co/Lk1f5dGWkG
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@Vironaut1,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@OmicsOmicsBlog,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@giocarpi,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@outbreaksci,New #SARSCoV preprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/hWYpv4nQk6
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@BortzGroup,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@outbreaksci,"Contribute a rapid review or request one for ""Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis"" (https://t.co/hWYpv4nQk6). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.236893) at https://t.co/RnurTL3DyM @outbreaksci @PRErevie"
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@outbreaksci,New #COVID19 preprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/hWYpv4nQk6
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@bioinformer,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@AlexKneubehl,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@olga_francino,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@marimiya_clc,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@marimiya_tky,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@colindaven,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@jes_adams5,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@PhyDyn_Papers,"Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis Rowena A Bull, Thiruni Adikari, Jillian M Hammond, Igor Stevanovski, James M Ferguson, Alicia G Beukers, Zin Naing, Malinna Yeang, Andrey Verich, Hasindu Gamaarachichi et al ht"
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@vidya_ss,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@ogrecio,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@gringene_bio,RT @bxv_genomics: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/vivSofP2hI
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@cantika17024242,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@jseden1,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@janetteedson,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@realLedgerwatch,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@genomematt,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@VascoElbrecht,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@jil_hammond,RT @biorxivpreprint: Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@ION_BRU,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@nanopore,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@whitefoxsc,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@Amandatron89,RT @Psy_Fer_: Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 m‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@Psy_Fer_,"Want to know how well @nanopore does with #COVID sequencing?  We performed viral WGS with ONT and Illumina platforms on 157 matched SARS-CoV-2-positive patient specimens and synthetic RNA controls, enabling rigorous evaluation of analytical performance"
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@bxv_genomics,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis https://t.co/vivSofP2hI
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@biorxiv_genomic,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/gaqDpn6ncn #biorxiv_genomic
http://biorxiv.org/cgi/content/short/2020.08.04.236893,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis,@biorxivpreprint,Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis  https://t.co/jyiz5wjC5w #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@SciscoreReports,The paper ‚ÄúLead compounds for the development of SARS-CoV-2 3...‚Äù (https://t.co/PSHhsY2mii) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/RoBDU30iKC. We detected 2 of 6 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@outbreaksci,"Contribute a rapid review or request one for ""Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors"" (https://t.co/3byPlU7Hmk). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.235291) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@outbreaksci,New #SARSCoV preprint: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors https://t.co/3byPlU7Hmk
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@CFSciences,RT @biorxivpreprint: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/cK47oqauBD #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@THebertMcGill,RT @biorxivpreprint: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/cK47oqauBD #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@alfobioq,RT @biorxivpreprint: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/cK47oqauBD #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@scientistamy,RT @biorxivpreprint: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/cK47oqauBD #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@ShorterLab,RT @biorxivpreprint: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/cK47oqauBD #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@biorxiv_micrbio,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/SryDPSNZub #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.03.235291,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors,@biorxivpreprint,Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors  https://t.co/cK47oqauBD #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@SciscoreReports,The paper ‚ÄúCold-adapted live attenuated SARS-CoV-2 vaccine co...‚Äù (https://t.co/1PoBSlcwKM) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/ZXpm3o1XGt. We detected 2 of 6 rigor criteria and 20 key resource
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@chunjp,Áîü„ÉØ„ÇØ„ÉÅ„É≥„Å£„Å¶Âº±ÊØíÊ†™„Å£„Å¶Ë®Ä„ÅÜ„Åë„Å©„ÄÅ„Åù„Çì„Å™„ÅÆ„Å©„ÅÜ„ÇÑ„Å£„Å¶‰Ωú„Çã„Çì„Å†Ôºü „Åü„Åæ„Åü„ÅæÂ∏Ç‰∏≠„ÅßË¶ã„Å§„Åã„Å£„Åü„ÅÆ„ÇíÂèñ„Å£„Å¶„Åè„Çã„ÅÆÔºü „Å®„ÅãÁñëÂïè„Å´ÊÄù„Å£„Å¶„Åü„Çâ„ÄÅ‰ΩéÊ∏©È¶¥Âåñ„ÉØ„ÇØ„ÉÅ„É≥„ÅÆ‰ªïÁµÑ„Åø„ÇíÁü•„Å£„Å¶„Äå„Å™„Çã„Åª„Å©ÔΩû„Äç„Å£„Å¶„Å™„Å£„Åü„ÄÇ „Åì„Çì„Å™ÊôÇÈñì„Åß‰Ωú„Çå„Çã„Çì„Åã‚Ä¶‚Ä¶ https://t.co/JYAzrICY7Z
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@PromPreprint,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection https://t.co/Q27CXdRaKw
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@SmitsLab,RT @biorxiv_micrbio: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@Saul94_20,RT @Nick_atanelov: First data on live attenuated #SARSCoV2 vaccine candidate from South Korea.   https://t.co/qd4FNCsycu
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@epidatum,Cold-adapted live attenuated #SARSCoV2 #vaccine completely protects human #ACE2 transgenic mice from SARS-CoV-2 infection This #COVID19  vaccine can be potentially administered to humans through nasal spray.  https://t.co/7Kg9jtG9kP https://t.co/aNJhB4lmNH
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@neodocjdg,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection #COVID19 https://t.co/xUAyaRWYWq
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@AmandaShouting,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection https://t.co/nmRv4hMDWm
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@Masoor_Alam,RT @thelonevirologi: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@cybxrsxd,https://t.co/6IYcTtV2DW
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@NicoleD70375006,RT @thelonevirologi: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@Nick_atanelov,First data on live attenuated #SARSCoV2 vaccine candidate from South Korea.   https://t.co/qd4FNCsycu
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@KennethTimmis,RT @thelonevirologi: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@NGR69575822,RT @thelonevirologi: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@mjcreid,RT @thelonevirologi: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@thelonevirologi,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection https://t.co/oZvnOKIA29
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@outbreaksci,New #SARSCoV preprint: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection https://t.co/jkuxDirMp6
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@outbreaksci,"Contribute a rapid review or request one for ""Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgeni..."" (https://t.co/jkuxDirMp6). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.235689) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@outbreaksci,New #COVID19 preprint: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection https://t.co/jkuxDirMp6
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@NGR69575822,RT @biorxiv_micrbio: Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infecti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@biorxiv_micrbio,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection  https://t.co/UWzLESfA9D #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.04.235689,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection,@biorxivpreprint,Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection  https://t.co/clkmVeXtgn #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@SciscoreReports,The paper ‚ÄúSARS-CoV-2 genome analysis of strains in Pakistan...‚Äù (https://t.co/rmiAjpuedd) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/DqGh57goPe. We detected 0 of 5 rigor criteria and 7 key resources.
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@JennyTenaa,"RT @glycopreprint: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic https:/‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@Rosenchild,"RT @biorxiv_genomic: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic  http‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@zzz_as_zzz,"RT @glycopreprint: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic https:/‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@glycopreprint,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic https://t.co/MgsgksQZTy #glycotime"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@AdNaR80,RT @asghar_n: SARS-CoV-2 genome analysis of strains in Pakistan
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@RomaisaRaza1,"RT @GhanchiNajia: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic¬†https://‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@FyezahJehan,"RT @GhanchiNajia: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic¬†https://‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at t..."" (https://t.co/JseehBz0hJ). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.234153) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@outbreaksci,"New #SARSCoV preprint: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic https://t.co/JseehBz0hJ"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@PhyDyn_Papers,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic Najia Ghanchi, Masood, Nasir, Khan, Abidi, Shahid, Mahmood, Kanji, Razzak, Ansar, Islam, Mohammad B Dharejo, Zahra Hasan, Rumina Hasan https://"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@WaqasuddinK,"RT @biorxivpreprint: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic  http‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@WaqasuddinK,"RT @GhanchiNajia: SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic¬†https://‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@WaqasuddinK,RT @GhanchiNajia: Our preprint on SARS-CoV 2 is out @WaqasuddinK @asghar_n @Kiran_I_Masood @AKUGlobal @drsyedasad @AdilHaiderMD
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@asghar_n,SARS-CoV-2 genome analysis of strains in Pakistan
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@GhanchiNajia,Our preprint on SARS-CoV 2 is out @WaqasuddinK @asghar_n @Kiran_I_Masood @AKUGlobal @drsyedasad @AdilHaiderMD
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@GhanchiNajia,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic¬†https://t.co/VLEbhNf5fS¬†#bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@pooledseq,"bioArXiv_ SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic https://t.co/XQjcn6lZSc"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@MitochondriaNe1,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic https://t.co/i7iKCvRGOT"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@biorxiv_genomic,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic  https://t.co/NN8bGWC2MD #biorxiv_genomic"
http://biorxiv.org/cgi/content/short/2020.08.04.234153,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic",@biorxivpreprint,"SARS-CoV-2 genome analysis of strains in Pakistan reveals GH, S and L clade strains at the start of the pandemic  https://t.co/aXYJJdVQVX #bioRxiv"
http://medrxiv.org/cgi/content/short/2020.07.30.20149567,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,@outbreaksci,New #SARSCoV preprint: Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing. https://t.co/fpTZ8bk7jP
http://medrxiv.org/cgi/content/short/2020.07.30.20149567,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,@outbreaksci,"Contribute a rapid review or request one for ""Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from..."" (https://t.co/fpTZ8bk7jP). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20149567) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20149567,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,@outbreaksci,New #COVID19 preprint: Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing. https://t.co/fpTZ8bk7jP
http://medrxiv.org/cgi/content/short/2020.07.30.20149567,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,@thartman2u,RT @medrxivpreprint: Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20149567,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,@ajv67,RT @medrxivpreprint: Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20149567,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.,@medrxivpreprint,Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing.  https://t.co/XUkcH3QTvJ #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@AnnaFogdellHahn,RT @Doc_Cunningham: The preprint can be read here: https://t.co/pYbERPjpp8
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@tompollak,RT @Doc_Cunningham: The preprint can be read here: https://t.co/pYbERPjpp8 https://t.co/o4rpIXNx1G
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@ImmunopsychSwe,RT @medrxivpreprint: Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19  https://t‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@Meir_Rubin,"◊§◊®◊°◊ï◊ù ◊û◊ß◊ì◊ô◊ù ◊û◊©◊ë◊ì◊ô◊î: ◊í◊ë◊® ◊ë◊®◊ô◊ê ◊ë◊ü 40 ◊†◊ì◊ë◊ß ◊ë◊ß◊ï◊®◊ï◊†◊î, ◊ï◊õ◊¢◊™ ◊ë◊û◊¶◊ë ◊ß◊ò◊ò◊ï◊†◊ô ◊ó◊û◊ï◊®.  ◊®◊ô◊í◊ï◊©, ◊§◊¢◊ú◊™◊†◊ï◊™ ◊ô◊™◊®, ◊™◊†◊ï◊¢◊™◊ô◊ï◊™ ◊ó◊ñ◊®◊™◊ô◊™, ◊ï◊™◊ï◊ß◊§◊†◊ï◊™; ◊ê◊ï ◊ú◊î◊ô◊§◊ö, ◊ô◊®◊ô◊ì◊î ◊ß◊ô◊¶◊ï◊†◊ô◊™ ◊ë◊™◊í◊ï◊ë◊™◊ô◊ï◊™, ◊¢◊¶◊ô◊®◊™ ◊§◊¢◊ô◊ú◊ï◊™, ◊î◊™◊ê◊ë◊†◊ï◊™ ◊ï◊ß◊§◊ô◊ê◊™ ◊î◊í◊ï◊£ ◊ë◊™◊†◊ï◊ó◊î ◊†◊ï◊ß◊©◊î ◊û◊°◊ï◊ô◊û◊™ ◊ú◊ê◊ï◊®◊ö ◊©◊¢◊ï◊™, ◊ï◊¢◊®◊§◊ï◊ú¬†◊ó◊ï◊©◊ô◊ù. #◊ê◊ú_◊™◊ì◊ë◊ß◊ï.   https://"
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@johanvirhammar,RT @medrxivpreprint: Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19  https://t‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@Doc_Cunningham,@BrodinPetter Interesting idea. There was no involvement from other organs and no sign of hyper inflammation could it still be MIS-C? Here is the preprint: https://t.co/6yxs09eA9J
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@edvingranlund,RT @medrxivpreprint: Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19  https://t‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@EdCara4,RT @medrxivpreprint: Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19  https://t‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@Doc_Cunningham,The preprint can be read here: https://t.co/pYbERPjpp8
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@deirdresm,@edyong209 To your weirder pandemic point:  Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with #Covid19 https://t.co/1F0q18El84  I‚Äôm glad they figured out how to help him because that sounds scary AF not jus
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@outbreaksci,"Contribute a rapid review or request one for ""Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male ..."" (https://t.co/Idj4y22BjR). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.23.20160770) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@outbreaksci,New #SARSCoV preprint: Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19 https://t.co/Idj4y22BjR
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@deirdresm,"#Covid19 says: I have a new trick, let me show you it!  Autoimmune encephalitis (It tricking you into attacking the outer lining of your brain.) presenting as acute malignant catatonia with autonomic instability.  The guy lost a freaking literal month.  ht"
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@COVID_Papers,üìù Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19  medRxiv or bioRxiv https://t.co/3YY0vGlyRl #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.23.20160770,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19,@medrxivpreprint,Autoimmune Encephalitis Presenting with Acute Excited Catatonia in a 40-Year-Old Male Patient with Covid-19  https://t.co/3DCIrSPcus #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166678,Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach,@ArtsySci,"Pilot stud suggests therapeu pot Aprepitant. Pats w/comb ther Aprepitant/Dex recovd earlier &showd improvd clin outcomes, labs &reducd C-react prot. May b more effective in severe 2 critical pats havn respir difs. Inflam reducd by Neurokinin 1 Rece"
http://medrxiv.org/cgi/content/short/2020.08.01.20166678,Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach,@MehboobRiffat,Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach https://t.co/9NSMQYs6FD
http://medrxiv.org/cgi/content/short/2020.08.01.20166678,Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach,@rmchavin,"8-1-2020:  In a scientific study released today from Lahore, Pakistan, the anti-nausea drug, Emend (aprepitant), plus dexamethasone outperformed dexamethasone alone for treating mid-stage & end-stage COVID-19 https://t.co/z5O3t1StyT https://t.co/a9EjpJ"
http://medrxiv.org/cgi/content/short/2020.08.01.20166678,Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach,@medrxivpreprint,Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach  https://t.co/gV97agdyg2 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@SorenSchifter,Nedenst√•ende systematiske review i preprint belyser nogle af problemerne med rt-PCR tests. Se ogs√• link til tidligere Tweet. https://t.co/iOzx6MB0aG https://t.co/enTV5wvFAN #dkpol #dkmedier #sundpol #coronadk #COVID19dk
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@ENDBSLFOREVER,RT @Donna_In_Heaven: Tall Tales & nothing new  Do NOT #MaskUpWA #TwistedScience Who benefits? Viral cultures to validate infection?  How a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@petermbenglish,We still don't  know enough about how positive PCR test results for Covid-19 relate to infectiousness. https://t.co/UAdwriefhf  And I have not seen good data on the specificity of these tests.
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Andrea63591011,RT @Donna_In_Heaven: Tall Tales & nothing new  Do NOT #MaskUpWA #TwistedScience Who benefits? Viral cultures to validate infection?  How a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Donna_In_Heaven,RT @Donna_In_Heaven: Tall Tales & nothing new  Do NOT #MaskUpWA #TwistedScience Who benefits? Viral cultures to validate infection?  How a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Donna_In_Heaven,"Tall Tales & nothing new  Do NOT #MaskUpWA #TwistedScience Who benefits? Viral cultures to validate infection?  How about the infected never get sick folks & why told to #MaskUp https://t.co/nBQnYaju8p  Preprint August 4, 2020 https://t.co/IOyttm"
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@altershot_tv,Kultury wirusowe do oceny zaka≈∫no≈õci COVID-19. Systematyczny przeglƒÖd. Oxford CEBM https://t.co/wKP6icuNAO https://t.co/troMFdEuay
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@BrandonSwisher1,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Andrea63591011,RT @Donna_In_Heaven: Tall Tales & nothing new  Do NOT #MaskUpWA #TwistedScience Who benefits? Viral cultures to validate infection?  How a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Donna_In_Heaven,"Tall Tales & nothing new  Do NOT #MaskUpWA #TwistedScience Who benefits? Viral cultures to validate infection?  How about the infected never get sick folks & why told to #MaskUp https://t.co/1Zu3TJuf6N  Preprint August 4, 2020 https://t.co/nvWUPW"
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Anumaya8,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@YabraDo,"BOOOM! Test rt-PCR to obecnie z≈Çoty standard w wykrywaniu infekcji, a tymczasem okazuje siƒô ≈ºe niekoniecznie tak jest.. https://t.co/dTn3R6AMhI"
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@leoniedelt,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Ephesians6__12,"Carl, this is fake news @CovidMillion will be pay you $1MILLION USD if you can prove C19 has made one person in the world sick.."
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@ArchibaldHeath1,"@Ephesians6__12 @alexkx3 The folks at Oxford CEBM appear to trust that SARS-CoV-2 has been successfully cultured, as per references in this paper. That's not direct proof but they've been trustworthy in orther things. https://t.co/LfumAwvdfq"
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@MctagueNicole,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@SteveG06322664,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@esgosu,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@immunity_co,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@markwilcox_ism,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@London_Lady,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@AbiChippindale,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@temennuconsult,RT @carlheneghan: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@carlheneghan,Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/WcpnbqBC6T
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@marta_amilibia,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Stormydessert,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@SkrJaScorpio,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@JulianLopezOwen,RT @PROMEDICOS: Lo dicho tantas veces. Tomar tantas decisiones con la incertidumbre de los PCR de Covid
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@outbreaksci,"Contribute a rapid review or request one for ""Viral cultures for COVID-19 infectivity assessment. Systematic review"" (https://t.co/ocIRXwv9GV). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20167932) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@outbreaksci,New #SARSCoV preprint: Viral cultures for COVID-19 infectivity assessment. Systematic review https://t.co/ocIRXwv9GV
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@mtmonicaMimi,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@xmartinezjara,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@PROMEDICOS,Lo dicho tantas veces. Tomar tantas decisiones con la incertidumbre de los PCR de Covid
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@PauMatalap,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@Alicia82mad,RT @EnferEvidente: PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realiza‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@EnferEvidente,PRE-PRINT Una de las cuestiones m√°s inquietantes sobre el SARS-CoV-2 es que a√∫n no tenemos criterios claros para realizar cultivos que identifiquen virus viables (no olvidar que la PCR detecta fragmentos ARN) esta RS nos pone ante esa incertidumbre #TLG ht
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@EvidenceRobot,RT @SciArt3D: Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/6tzOo9iq20
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@SciArt3D,Viral cultures for COVID-19 infectivity assessment. Systematic review | medRxiv https://t.co/6tzOo9iq20
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@EdidiFranck,RT @medrxivpreprint: Viral cultures for COVID-19 infectivity assessment. Systematic review  https://t.co/alWtP0paia #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@COVID_Papers,üìù Viral cultures for COVID-19 infectivity assessment. Systematic review  medRxiv or bioRxiv https://t.co/GqN35MeX1p #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.04.20167932,Viral cultures for COVID-19 infectivity assessment. Systematic review,@medrxivpreprint,Viral cultures for COVID-19 infectivity assessment. Systematic review  https://t.co/alWtP0paia #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@candelassastre,"RT @edrybicki: @florian_krammer @medicagoinc @leaf_expression  You see, Florian: first we make your reagents in plants, then your vaccines.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@Bastaway,RT @virusmonologues: medrxiv viewer https://t.co/QtaXrohAuD  Our paper setting up a SARS-CoV-2 ELISA using plant proteins is out as a pre-p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@HsiaoMarvin,RT @virusmonologues: medrxiv viewer https://t.co/QtaXrohAuD  Our paper setting up a SARS-CoV-2 ELISA using plant proteins is out as a pre-p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@CIDRI_Africa,"Wendy Burgers will be characterising cross-reactive and durable immunity to SARS-CoV-2, & there's even a preprint up about her team's in-house ELISA already @medrxivpreprint https://t.co/iAfbCc4VHJ https://t.co/RPhDchlTbQ"
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients"" (https://t.co/e5iD3Wkmut). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.04.20167940) at https://t.co/RnurTL3DyM @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients https://t.co/e5iD3Wkmut
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@virusmonologues,"RT @edrybicki: @florian_krammer @medicagoinc @leaf_expression  You see, Florian: first we make your reagents in plants, then your vaccines.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@edrybicki,"@florian_krammer @medicagoinc @leaf_expression  You see, Florian: first we make your reagents in plants, then your vaccines...üòÑ"
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@edrybicki,#GoingGreen Well done!!
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@GamaBee,RT @medrxivpreprint: SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients  https://t.co/Tr6fUYg3pk #medRx‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@TomScriba,RT @virusmonologues: medrxiv viewer https://t.co/QtaXrohAuD  Our paper setting up a SARS-CoV-2 ELISA using plant proteins is out as a pre-p‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@virusmonologues,medrxiv viewer https://t.co/QtaXrohAuD  Our paper setting up a SARS-CoV-2 ELISA using plant proteins is out as a pre-print!  @edrybicki @capebiopharms @EmmanuelMargol1 @HsiaoMarvin @LindaGailBekker  @TomScriba
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@COVID_Papers,üìù SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients  medRxiv or bioRxiv https://t.co/pqfo6juEqM #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.04.20167940,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients,@medrxivpreprint,SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients  https://t.co/Tr6fUYg3pk #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.04.20168039,The impact of the COVID-19 lockdown on maternal mental health and coping in the UK: Data from the COVID-19 New Mum Study,@MomBaby_Study,"RT @newmumstudy: Lastly, you can read the pre-print results here:   https://t.co/5zMt0lBb41  #COVID19NewMumStudy"
http://medrxiv.org/cgi/content/short/2020.08.04.20168039,The impact of the COVID-19 lockdown on maternal mental health and coping in the UK: Data from the COVID-19 New Mum Study,@newmumstudy,"Lastly, you can read the pre-print results here:   https://t.co/5zMt0lBb41  #COVID19NewMumStudy"
http://medrxiv.org/cgi/content/short/2020.08.04.20168039,The impact of the COVID-19 lockdown on maternal mental health and coping in the UK: Data from the COVID-19 New Mum Study,@COVID_Papers,üìù The impact of the COVID-19 lockdown on maternal mental health and coping in the UK: Data from the COVID-19 New Mum Study  medRxiv or bioRxiv https://t.co/yFMATiSHFf #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.04.20168039,The impact of the COVID-19 lockdown on maternal mental health and coping in the UK: Data from the COVID-19 New Mum Study,@medrxivpreprint,The impact of the COVID-19 lockdown on maternal mental health and coping in the UK: Data from the COVID-19 New Mum Study  https://t.co/SNVqOnCNe2 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166967,Impacts of people's learning behavior in fighting the COVID-19 epidemic,@outbreaksci,"Contribute a rapid review or request one for ""Impacts of people's learning behavior in fighting the COVID-19 epidemic"" (https://t.co/k5gSlCSjA5). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166967) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.02.20166967,Impacts of people's learning behavior in fighting the COVID-19 epidemic,@outbreaksci,New #COVID19 preprint: Impacts of people's learning behavior in fighting the COVID-19 epidemic https://t.co/k5gSlCSjA5
http://medrxiv.org/cgi/content/short/2020.08.02.20166967,Impacts of people's learning behavior in fighting the COVID-19 epidemic,@medrxivpreprint,Impacts of people's learning behavior in fighting the COVID-19 epidemic  https://t.co/o39nst51tS #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@DrMFKearney,@CapoferriAdam
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@bicidiario,RT @alexvespi: ‚ÄòEvaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity‚Äô   https://t.co/5x7mwH1vIi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@HelenGavaghan,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@tsetiady,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@kagningemmanuel,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@BallouxFrancois,@SixandLaura You're most welcome. We've just rerun the analyses on ~50k genomes and our conclusions remain unchanged (updated figure 1 below). There is also another paper that deals with the same question and reaches somewhat ambiguous conclusions: https:/
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@netsci15,RT @alexvespi: ‚ÄòEvaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity‚Äô   https://t.co/5x7mwH1vIi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@kevinpurcell,"‚ÄúDespite the availability of a very large data set, well represented by both Spike 614 variants, not all approaches showed a conclusive signal of higher transmission rate for 614G‚Äù"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@SBSatEd,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@noawitheringly,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@CoronaHeadsUp,"#Coronavirus #Mutation #Mortality  ""We do not find any indication that patients infected with the Spike 614G variant have higher #COVID19 mortality, but younger patients have slightly increased odds of 614G carriage.""  https://t.co/MMjkQSEpwV"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@BallouxFrancois,"@Mathew94379832 @Flagg_ould School openings need to be though out very carefully, and all measures that are not overly damaging to children should be considered. The D614G mutation story is a bit of a hoax. See e.g. https://t.co/fgp2cSpcu1 or https://t.co/"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ChrispinChaguza,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Marieaaow,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity | medRxiv Notice: Preprint not peered https://t.co/9gsxLY8kvk
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@DoubleEagle49,RT @alexvespi: ‚ÄòEvaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity‚Äô   https://t.co/5x7mwH1vIi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Marieaaow,https://t.co/9gsxLY8kvk https://t.co/HLfr4KUS1Z
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@luciaruggiero,RT @GlobalPHObserv: Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity https://t.co/9Ui3AGaHly
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@KIMPY123,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@LadyJusticeGA,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@IFB_Bioinfo,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@barricko_bama,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@NoWackyScience,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@NJdoc,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Helen504,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@BallouxFrancois,@zanfr @Dineshh_Nepal https://t.co/fgp2cSpcu1
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@iamnotcordelia,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@culturalfatwa,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Saramrey,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@DarrenSmithdx,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@mrc7cam,"@BallouxFrancois @inazone240 @deb_cohen @leoniedelt Indeed, and studies like this one below are only possible because of the co-operation in isolating and sequencing viral isolates from many individual sources. https://t.co/EEmnj9diKB"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@WL_Hamilton,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Herbsistah,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@healthcare4safe,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@cariadmevans,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@QuimSegales,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MOFV,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@deepvard,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Ophelia93836578,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@fizaibty,RT @chriskc_Lee: COVID-19: How fast D614G has become dominant SARS-CoV-2 strain globally. Spreads easier but with no increase in disease se‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MikroSundq,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ironorehopper,"Top story: Science & Research Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity | medRxiv https://t.co/T3RaryqQcN, see more https://t.co/RGUABS93Wx"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@geng_mf,RT @chriskc_Lee: COVID-19: How fast D614G has become dominant SARS-CoV-2 strain globally. Spreads easier but with no increase in disease se‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@VinayPathak,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Planck_Epoch,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@betzhallo,RT @alexvespi: ‚ÄòEvaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity‚Äô   https://t.co/5x7mwH1vIi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MattLabor,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@jkellyca,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@AyinAzirinee,RT @chriskc_Lee: COVID-19: How fast D614G has become dominant SARS-CoV-2 strain globally. Spreads easier but with no increase in disease se‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@BiteOfAMosquito,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@CovidLabs,RT @alexvespi: ‚ÄòEvaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity‚Äô   https://t.co/5x7mwH1vIi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@RapidCovidLabs,RT @alexvespi: ‚ÄòEvaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity‚Äô   https://t.co/5x7mwH1vIi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@marioph13,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@TrevorLithgow,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@jansen_marnix,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@motte_17,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Wardog3624,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@isham55,RT @chriskc_Lee: COVID-19: How fast D614G has become dominant SARS-CoV-2 strain globally. Spreads easier but with no increase in disease se‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@CuestaLozano,RT @GlobalPHObserv: Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity https://t.co/9Ui3AGaHly
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@arenica2,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MonaSmitte,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@AmyHFitzpatrick,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@CollignonPeter,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@minouye271,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@colour171207,"RT @MarionKoopmans: With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MarionKoopmans,"With increasing availability of data, phylodynamic analysis of SARS COV 2 variants does suggest selective advantage for D614G spike mutation, given increased clustersize in UK. No difference in virulence observed. Animal infection experiments needed https:"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@CofHEQ,RT @GlobalPHObserv: Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity https://t.co/9Ui3AGaHly
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ghia1212,RT @GlobalPHObserv: Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity https://t.co/9Ui3AGaHly
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@equityhealthdev,RT @GlobalPHObserv: Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity https://t.co/9Ui3AGaHly
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MJ_Humphries,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@RommieAmaro,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@kat_gris,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@pablotsukayama,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@tom_paine1737,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@timp0,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@PharmaDecisions,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@kuukkeli5,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@MRCClimb,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@AlexanderTM507,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@mgmglobal,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@mikethemadbiol,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@EmmanuelNaouri,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@radfugee,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@Ryan_Lanham,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@GlobalPHObserv,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity https://t.co/9Ui3AGaHly
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@TanyaKlassen,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@RomainM45081967,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ewanbirney,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@cispt2,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@joyce_macri,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@JayneBarnard1,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@YYCist,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ForgeRat,"@MoriartyLab @COVIDtrialsON @community_sos @COVID_19_Canada @COVID19Tracking  New spike protein increases rate of transmission significantly.   Appears ""Doug"" may increase transmission by younger people.  How appropriate!ü§∑‚Äç‚ôÄÔ∏èü§∑‚Äç‚ôÇÔ∏è #onted #onpoli #Doug19"
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@n8_upham,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ForgeRat,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@ForgeRat,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@andrewflood,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@x3nome,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@LelaBella11,RT @TheCGPS: 04Aug20 @covidgenomicsuk update: 32701 of 69358 global SARS-CoV-2 genomes. Screenshot shows distribution of D614G mutation and‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@BarbaraSakai1,RT @EricTopol: Remember all the buzz a month ago about the new mutation of #SARSCoV2 (D->G) in the spike protein (that is now the dominant‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166082,Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity,@LonelyJoeParker,RT @arambaut: The preprint of our analysis of Spike D614G (Doug) in the context of the @CovidGenomicsUK genome sequences is out: https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@CovidWellbeing,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study https://t.co/bWm10vTUA7 #mentalhealth
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@tweetingturkey,"RT @QueerantineS: If you want to read more about the findings from the first paper, you can here: https://t.co/4HjgJVEVyP.üè≥Ô∏è‚Äç‚ößÔ∏èüè≥Ô∏è‚Äçüåàüëç 4/4"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@andrewdhking,RT @DylanKneale: You can read more about the first findings in the preprint  co-authored with the brilliant @inequalccsr: https://t.co/DBst‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@RMBlaber56,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study https://t.co/ggXnC8MmCV
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@outbreaksci,"Contribute a rapid review or request one for ""The mental health and experiences of discrimination of LGBTQ+ people during the COVID-..."" (https://t.co/44Oi1JmF1p). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20167403) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@outbreaksci,New #COVID19 preprint: The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study https://t.co/44Oi1JmF1p
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@sussexlgbtplus,"RT @QueerantineS: If you want to read more about the findings from the first paper, you can here: https://t.co/4HjgJVEVyP.üè≥Ô∏è‚Äç‚ößÔ∏èüè≥Ô∏è‚Äçüåàüëç 4/4"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@lizzietweeter,"RT @inequalccsr: Full findings published in @medrxivpreprint (preprint) 17% reported discrimination incl verbal harassment (8.7%), exclusio‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@DylanKneale,You can read more about the first findings in the preprint  co-authored with the brilliant @inequalccsr: https://t.co/DBstKrnTl2 2/4
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@EvidSynthTeam,"RT @QueerantineS: If you want to read more about the findings from the first paper, you can here: https://t.co/4HjgJVEVyP.üè≥Ô∏è‚Äç‚ößÔ∏èüè≥Ô∏è‚Äçüåàüëç 4/4"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@QueerantineS,"If you want to read more about the findings from the first paper, you can here: https://t.co/4HjgJVEVyP.üè≥Ô∏è‚Äç‚ößÔ∏èüè≥Ô∏è‚Äçüåàüëç 4/4"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@inequalccsr,"Full findings published in @medrxivpreprint (preprint) 17% reported discrimination incl verbal harassment (8.7%), exclusion from events or activities (5.6%) & involuntary disclosure of LGBTQ+ identity (3.5%) 2/5  https://t.co/BEZAMXl7GG"
http://medrxiv.org/cgi/content/short/2020.08.03.20167403,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study,@medrxivpreprint,The mental health and experiences of discrimination of LGBTQ+ people during the COVID-19 pandemic: Initial findings from the Queerantine Study  https://t.co/NrXmwr9n94 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167262,Altitude as a protective factor from COVID-19,@IBMB_CSIC,"üìëAltitude as a protective factor from COVID-19 Timothy M Thomson, Fresia Casas, Harold Andre Guerrero, R√≥mulo Figueroa-Mujica, Francisco C Villafuerte, Claudia Machicado medRxiv 2020.08.03.20167262; doi: https://t.co/fnQ6BB3Qul  @CayetanoHeredia"
http://medrxiv.org/cgi/content/short/2020.08.03.20167262,Altitude as a protective factor from COVID-19,@IBMB_CSIC,üìëAltitude as a protective factor from COVID-19  [This article is a preprint and has not been certified by peer review] üîóhttps://t.co/3ZCFPbywmf
http://medrxiv.org/cgi/content/short/2020.08.03.20167262,Altitude as a protective factor from COVID-19,@editavinnitsky,https://t.co/xocRJuzFBV
http://medrxiv.org/cgi/content/short/2020.08.03.20167262,Altitude as a protective factor from COVID-19,@rmchavin,"8-3-2020:  High altitude areas are substantially protective against COVID-19 because (1)wide open spaces, (2)people move around less, keep themselves covered, & are more fit, (3)the virus moves around less because the air is thinner & hit by cosmic"
http://medrxiv.org/cgi/content/short/2020.08.03.20167262,Altitude as a protective factor from COVID-19,@BCNThomson,Chronic adaptation to #altitude as a protective factor from #COVID19. https://t.co/dDLUs2orc8
http://medrxiv.org/cgi/content/short/2020.08.03.20167262,Altitude as a protective factor from COVID-19,@medrxivpreprint,Altitude as a protective factor from COVID-19  https://t.co/cnuTg7AwO2 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@Klau_995,RT @ricpuglisi: @CCKKI @antoniogolfari @udogumpel @pellegrino_fra @Cr1st14nM3s14n0 Qui il nostro lavoro su dati relativi al San Raffaele.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@ricpuglisi,RT @ricpuglisi: @CCKKI @antoniogolfari @udogumpel @pellegrino_fra @Cr1st14nM3s14n0 Qui il nostro lavoro su dati relativi al San Raffaele.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@ricpuglisi,@CCKKI @antoniogolfari @udogumpel @pellegrino_fra @Cr1st14nM3s14n0 Qui il nostro lavoro su dati relativi al San Raffaele.   https://t.co/BiGkL8ERrg  Qui un lavoro -sempre su dati individuali ma molto pi√π ampi- sull'andamento in Florida.   Che conferma l'an
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@InkenPadberg,@AndreasShrugged @tazgezwitscher Siehe hier: https://t.co/jm7gEwo9bE https://t.co/r7prXZdSv9 https://t.co/m0Lr7OQ7AF (2/4)
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@SRAnesthesiaICU,RT @ricpuglisi: Here is the link to the PDF: https://t.co/4bz5xzNY5c  PS: Thanks to Jeff Harris for citing our paper as a first example of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@giovannilandoni,RT @ricpuglisi: Here is the link to the PDF: https://t.co/4bz5xzNY5c  PS: Thanks to Jeff Harris for citing our paper as a first example of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@ildelfinogiulio,RT @ricpuglisi: Qui potete trovare il PDF del pre-print. https://t.co/4bz5xzNY5c  Ringraziamo Jeff Harris per avere citato il nostro paper‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@stegian67,RT @ricpuglisi: Qui potete trovare il PDF del pre-print. https://t.co/4bz5xzNY5c  Ringraziamo Jeff Harris per avere citato il nostro paper‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@ricpuglisi,Qui potete trovare il PDF del pre-print. https://t.co/4bz5xzNY5c  Ringraziamo Jeff Harris per avere citato il nostro paper sulla mortalit√† al San Raffaele come primo studio con dati individuali (e piccola scala) su andamento temporale della mortalit√†.   ht
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@Gauro5,RT @ricpuglisi: Here is the link to the PDF: https://t.co/4bz5xzNY5c  PS: Thanks to Jeff Harris for citing our paper as a first example of‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@ricpuglisi,"Here is the link to the PDF: https://t.co/4bz5xzNY5c  PS: Thanks to Jeff Harris for citing our paper as a first example of small-scale, individual-level longitudinal analysis of mortality rates for #COVID19. https://t.co/BiGkL8ERrg"
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@zuhalif_zeyneb,RT @medrxivpreprint: COVID-19 Case Mortality Rates Continue to Decline in Florida  https://t.co/UkhP7po3P1 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@ricpuglisi,RT @medrxivpreprint: COVID-19 Case Mortality Rates Continue to Decline in Florida  https://t.co/UkhP7po3P1 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@HenkPoley,@BallouxFrancois @ChGefaell @zorinaq For example: https://t.co/d2fN6btQVG
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@AndyfromTucson,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@akkaufman,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@aimhg,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@InkenPadberg,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@MagnetsOh,Preprint Link:  https://t.co/6jSEgZ9AOH
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@MagnetsOh,"Huge CFR gains in FL per new preprint by @jeffeconomist getting scant attention.  From better treatment not more testing.  - Over 3 months CFR's fell *62%* for 60-69, *52%* for 70-79, and *34%* for 80+ - Note 90% of FL deaths are 60+. - @CohoKelly @AVG_Jos"
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@CV2gether,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@RexDouglass,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@SJR78354712,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@tsetiady,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@tajarvarghese,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@RAFALOCA1,@MMmarco0 Molto difficile da chiudere il discorso quando i numeri in moltissime parti del mondo dicono il contrario e smentiscono il piu‚Äô grande immunologo italiano.  https://t.co/qYJi9uKEFI
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@stevenmosher,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@lipsticklibre,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@HallieSnowman,RT @zorinaq: A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to ha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@zorinaq,A data gold mine for COVID-19 analysis is the FDOH line list (half a million cases!): https://t.co/in2MuH8GYF  I am hapy to have just stumbled upon a preprint analyzing it: https://t.co/yQOBXYZEfN  They find Case Fatality Ratios dropping (left). Similar to
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@RAFALOCA1,@agorarai @WRicciardi Non e‚Äô quello che dicono i dati in tutto il mondo. https://t.co/qYJi9uKEFI
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@RAFALOCA1,@azangrillo Studio della Florida https://t.co/qYJi9uKEFI
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@RAFALOCA1,"RT @JasonSalemi: 1/ CASE-FATALITY IN FLORIDA  Colleague sent me a pre-print server paper titled ""COVID-19 Case Mortality Rates Continue to‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@nosmhnmh,"RT @JasonSalemi: 1/ CASE-FATALITY IN FLORIDA  Colleague sent me a pre-print server paper titled ""COVID-19 Case Mortality Rates Continue to‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@JasonSalemi,"1/ CASE-FATALITY IN FLORIDA  Colleague sent me a pre-print server paper titled ""COVID-19 Case Mortality Rates Continue to Decline in Florida""  Group cases into 4 cohorts based on 4 case-line files. Tries to use similar f/u windows.  Link is below:  https:/"
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@Eyecatcher_Pro,https://t.co/HaDWVRzP68
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@RephreshedMind,@aginnt According to this study done in FL the CFR continues to decline even for older age ranges.   https://t.co/Nh1NYqfv9v
http://medrxiv.org/cgi/content/short/2020.08.03.20167338,COVID-19 Case Mortality Rates Continue to Decline in Florida,@medrxivpreprint,COVID-19 Case Mortality Rates Continue to Decline in Florida  https://t.co/UkhP7po3P1 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@alej0078,"RT @drhuerta: Importante estudio demuestra que EL AIRE DE HABITACIONES CERRADAS, en donde han estado personas infectadas, contiene part√≠cul‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@PazRivas_,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@rawoxi,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@simonsdlj,"RT @doctormacias: Por fin, se ha podido cultivar el virus SARS-CoV-2 de aerosoles de habitaciones con pacientes, incluso a m√°s de 5 metros.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@natepaschall,"If aerosolization is what this study demonstrates (14 feet away!), then we should expect a much higher attack rate with this in indoor settings. https://t.co/pNTOfwqFIR"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@DorothySunday,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Finacodina23,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@DamarymodestO,"RT @doctormacias: Por fin, se ha podido cultivar el virus SARS-CoV-2 de aerosoles de habitaciones con pacientes, incluso a m√°s de 5 metros.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@maozumbado,"RT @leochacon: ""Nuestros hallazgos revelan que el SARS-CoV-2 viable puede estar presente en aerosoles generados por un paciente en una habi‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@albet777,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@JoseLuisortiz56,"RT @doctormacias: Por fin, se ha podido cultivar el virus SARS-CoV-2 de aerosoles de habitaciones con pacientes, incluso a m√°s de 5 metros.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Eugnia30966115,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@ManzanillaMiel5,RT @EnfermeroNinja: ¬øAlguien tiene m√°s informaci√≥n acerca de esto?   https://t.co/9k3gBaCcUS
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@olgatresserras,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@PsuRgsSuDC8RNT9,RT @carpe_diem0820: Â†±Âëä„ÅåÊüªË™≠„Åï„Çå„Å¶„ÅÑ„Å™„ÅÑ„Éó„É¨„Éó„É™„É≥„Éà„Åß„ÅÇ„Çã„Åì„Å®„Å®„ÄÅÂüπÈ§äÊ§úÊüª„ÅßÂ¢óÊÆñËÉΩ„Åå„ÅÇ„Çã„Ç¶„Ç§„É´„Çπ„ÅåÂêåÂÆö„Åß„Åç„Çã„Åì„Å®„Åå„ÄÅÂÆüÈöõ„Å´‰∫∫„Å∏„ÅÆÊÑüÊüìÊÄß„Åå„Å©„ÅÆÁ®ãÂ∫¶„ÅÇ„Çã„Åì„Å®„ÇíÊÑèÂë≥„Åô„Çã„ÅÆ„Åã(„ÅÇ„Çã„Åã„Å©„ÅÜ„Åã„ÇíÂê´„ÇÅ„Å¶)„Å´„Å§„ÅÑ„Å¶„ÅØ‰∏çÊòé„Åß„ÅÇ„Çã„Åì„Å®„Å´„ÅØÊ≥®ÊÑè„ÅåÂøÖË¶Å„Å®ÊÄù„ÅÑ„Åæ„Åô„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@rarzatek,"RT @doctormacias: Por fin, se ha podido cultivar el virus SARS-CoV-2 de aerosoles de habitaciones con pacientes, incluso a m√°s de 5 metros.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@DoctorWerner44,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@thinkcatalonia,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@martaatram_sr,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@JulietteSeverin,RT @Jopinie: PREPRINT: Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients https://t.co/px6Jugb95U
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@TradiCatholic,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@SeguimCatalunya,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Tamborras,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@4Ferran,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@OrcasRevenge,@thehill https://t.co/RDJdBqlxOz
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@BuffaloParkDad,@markpoloncarz @NYGovCuomo https://t.co/AVaxvsW5yR Covid transmissible up to 15 feet via Aerosol. Most school re-opening plans are based around surface cleaning and 6 feet of distance.
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@VdeRuben,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Giantsgrrrl,"RT @linseymarr: If this isn't a smoking gun, then I don't know what is. Successful isolation (cytopathic effect) of SARS-CoV-2 in aerosols‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@silviaggsgg,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Allenhardage,RT @NARNfan: Patients with respiratory manifestations of COVID-19 produce aerosols in the absence of aerosol-generating procedures that con‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Allenhardage,RT @NARNfan: i.e. masks are bullshit
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@cracia2,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@dronico,Slowly but surely... https://t.co/WvHPTkSrq1
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Cristin13909817,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@WireStar1,RT @yaneerbaryam: How far should you distance from people who might be sick?  Material was collected from room air  Result: Viable virus in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@NARNfan,i.e. masks are bullshit
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@NARNfan,"Patients with respiratory manifestations of COVID-19 produce aerosols in the absence of aerosol-generating procedures that contain viable SARS-CoV-2, and these aerosols may serve as a source of transmission of the virus. https://t.co/P7bNKD4Lbs"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@iveaaru,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Manel_go,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Karme00,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@EduardCarreras5,Si es porta masquereta tindria que ser suficient...Evidentment aixo no es posible als bars i restaurants.
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@sarriix,"RT @gmnzgerard: S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@CareyLauren64,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@UbiBest,"It has been confirmed that aerosols can carry the COVID-19 virus, further demonstrating the need for masks. Teach your patients about these findings with constant digital engagement!  @NYTHealth @nytimes @orlandosentinel @COVID19Tracking @NPRHealth   https"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@gmnzgerard,"S√≥n suficients els 2m de dist√†ncia?  Es troben part√≠cules viables de COVID entre 2 i 4,8m dels pacients.  L'article complet: https://t.co/uRNjlwjgWS"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Khaled71262641,"Seg√∫n https://t.co/ckpepyvubY ocupamos casi 7.805.000.000 (@Worldometers ), el 8% de los 510 millones de Km2 del planeta . Necesitando cada un zona de 28 m2(c√≠rculos de 6 m de di√°metro) : con 430 planetas podr√≠amos caber, no en una d√©cima parte ü§î"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@bff007,RT @doctormacias: Este pre-print pudiera ser uno de los estudios m√°s importantes de la pandemia covid-19. Investigadores en Florida logran‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@genekel27182073,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Dan_Donovan_17,@ABC New Study shows Covid-19 can spread by aerosol particles that are smaller than masks can stop.  Neck Gaitors and Bandanas work almost as bad if not worse than no masks. https://t.co/9oy44cvUk5
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@twitmarianacerv,ay basta! qu√© se hace?
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Jotabe63b,RT @1000genes: Demuestran que el coronavirus es infeccioso a partir de aire de hospital de personas infectadas por COVID-19.  La v√≠a a√©rea‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@drcraigfleisher,RT @CatedraInt: Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients | medRxiv https://t.co/dtWPNtdJAK
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@laextrania,"Sg este articulo (preprint, sujeto a revisi√≥n) la distancia de dos metros es poco eficaz. A√∫n a 5 metros, en espacios cerrados, el virus de Covid Sars2 sigue teniendo poder de contagio https://t.co/S1t3NaWiR0"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@AlethaCartwrig1,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@QwestarCapital,https://t.co/x1tCTqnTUU
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@MaGnOLiA_S,"RT @doctormacias: Por fin, se ha podido cultivar el virus SARS-CoV-2 de aerosoles de habitaciones con pacientes, incluso a m√°s de 5 metros.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Dan_Donovan_17,@FridaGhitis @JoeBiden @KamalaHarris Why aren't Democrats pushing for more N95 masks to be made that actually protect people?  https://t.co/9oy44cvUk5
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@humbertoschwab,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients | medRxiv ! Kunnen we dit ook even wetenschappelijk  ‚Äúweg disselen‚Äù! 5m binnen nog gevaarlijk via aerosols! #mauricedehond https://t.co/sY6ypNSqIm
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@DonaldWelsh16,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Dan_Donovan_17,@SusanStone110 @FridaGhitis @JoeBiden @KamalaHarris Medical study says that Covid-19 spreads via aerosol which is smaller than most masks can block.  https://t.co/9oy44cvUk5
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@RODRIGORRC72,RT @AnalystSantiago: De confirmarse lo que cita este estudio mal escenario para el curso acad√©mico.   Viable SARS-CoV-2 in the air of a hos‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@imRadu,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@TallTXTenor,RT @Lucas_Bolivian: New pre-print on viable SARS-CoV-2 in aerosols (with observed CPE and TCID50s done in Vero E6 cells) by Lednicky et al:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@isabelRamon6,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@McginnElaine,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@FERNANDOMEXIC0,RT @doctormacias: Este pre-print pudiera ser uno de los estudios m√°s importantes de la pandemia covid-19. Investigadores en Florida logran‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@AnalystSantiago,De confirmarse lo que cita este estudio mal escenario para el curso acad√©mico.   Viable SARS-CoV-2 in the air of a hospital room with #Covid_19 patients.   üëâüèª Viable virus was isolated from air samples collected 2 to 4.8m away from the patients. ü§î https://
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@OscarGuerraN,"RT @Chertorivski: Gracias, @doctormacias, un pretexto menos para los que no quer√≠an afirmar nada ""sin pruebas de laboratorio""."
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@JB_546,RT @Links_Medicus: [Preprint] Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients ‚Äì via @medrxivpreprint https://t.co/6‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Blessed0912,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Links_Medicus,[Preprint] Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients ‚Äì via @medrxivpreprint https://t.co/6T5IForGS9  Commentary: https://t.co/LNJjYdIrd3
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@DexterHouseCAT,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@Regiiiia,"@unna_chilanga Y luego con estas novedades, menos  https://t.co/Uk3ILylahq"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@ParentingFFutur,"RT @Dlf_Forschung: Forschende aus den USA liefern einen Beweis, dass das #Coronavirus auch √ºber die Luft √ºbertragen wird. Das und mehr in d‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@sebasnogueres,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@monjejuli,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@betaniajrc,@HLGatell https://t.co/01hIOclfCD
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@betaniajrc,@Abadmargarito_2 @HLGatell https://t.co/01hIOclfCD
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@ccarman602,"RT @Laurie_Garrett: Think you can make your office, school or theater ""safe"" from #SARSCoV2 ? Here, a hospital had top-of-the-line HEPA fil‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@juanfherrero,"RT @Chertorivski: Gracias, @doctormacias, un pretexto menos para los que no quer√≠an afirmar nada ""sin pruebas de laboratorio"". https://t.co‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@canal_salud,"RT @micronauta: La distancia m√≠nima entre personas, hasta que no haya desaparecido la pandemia de #SARSCoV2 / #COVID19, deber√≠a ser >2.4m.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@suewang,"RT @micronauta: La distancia m√≠nima entre personas, hasta que no haya desaparecido la pandemia de #SARSCoV2 / #COVID19, deber√≠a ser >2.4m.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@LeftCoastLeftst,6 feet really isn‚Äôt enough in many situations.
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@micronauta,"La distancia m√≠nima entre personas, hasta que no haya desaparecido la pandemia de #SARSCoV2 / #COVID19, deber√≠a ser >2.4m. https://t.co/uMMCVmpBJJ"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@betsyni,"RT @doctormacias: Por fin, se ha podido cultivar el virus SARS-CoV-2 de aerosoles de habitaciones con pacientes, incluso a m√°s de 5 metros.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@betsyni,"RT @Chertorivski: Gracias, @doctormacias, un pretexto menos para los que no quer√≠an afirmar nada ""sin pruebas de laboratorio""."
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@CatedraInt,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients | medRxiv https://t.co/dtWPNtdJAK
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@AnalystSantiago,Viable SARS-CoV-2 in the air of a hospital room with #Covid_19 patients.   üëâüèª Viable virus was isolated from air samples collected 2 to 4.8m away from the patients. ü§î https://t.co/Ocj0MI3Gfb
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@miquelescola,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@LorenYeg,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@EudaimoniaLever,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@PDKhov,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@misterchambo,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@RicGator,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@THarderr,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@ems56rn,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@JodyRLaPorte,RT @AlexBerenson: Strong evidence here #SARSCoV2 can be transmitted via aerosols (essentially this means through tiny virus particles in ro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@lilipet3,"RT @_AlexArenas: Troben virus flotant a l'aire d'un hospital, s'obre la porta a una extraordin√†ria complicaci√≥ ...   https://t.co/LgEcN4d3E‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@pstanos,https://t.co/HJtcXYxTmj
http://medrxiv.org/cgi/content/short/2020.08.03.20167395,Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients,@OrcasRevenge,@GovRicketts .@NEGOP .@Jean_Stothert .@MayorLeirion .@NebraskaDems .@LNKhealth .@JournalStarNews .@OWHnews .@1011_News .@Channel8ABC .@FOX42KPTM .@KETV .@WOWT6News .@3NewsNowOmaha .@BillSchammert .@JenniferNOrtega .@RodFowlerKLKN .@pdturman .@NEStateColleg
http://medrxiv.org/cgi/content/short/2020.08.01.20166470,"Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia",@outbreaksci,"New #SARSCoV preprint: Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia https://t.co/jOrIHMhsnc"
http://medrxiv.org/cgi/content/short/2020.08.01.20166470,"Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia",@outbreaksci,"Contribute a rapid review or request one for ""Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia"" (https://t.co/jOrIHMhsnc). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166470) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.01.20166470,"Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia",@outbreaksci,"New #COVID19 preprint: Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia https://t.co/jOrIHMhsnc"
http://medrxiv.org/cgi/content/short/2020.08.03.20167254,Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdowns,@outbreaksci,"Contribute a rapid review or request one for ""Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Count..."" (https://t.co/oXgJyWnEMC). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20167254) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20167254,Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdowns,@outbreaksci,Updated #COVID19 preprint: Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdowns https://t.co/oXgJyWnEMC
http://medrxiv.org/cgi/content/short/2020.08.03.20167254,Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdowns,@outbreaksci,"Contribute a rapid review or request one for ""Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Count..."" (https://t.co/oXgJyWnEMC). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20167254) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20167254,Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdowns,@outbreaksci,New #COVID19 preprint: Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdown https://t.co/oXgJyWnEMC
http://medrxiv.org/cgi/content/short/2020.08.03.20167254,Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdowns,@medrxivpreprint,Review of Forecasting Models for Coronavirus (COVID-19) Pandemic in India during Country-wise Lockdown  https://t.co/zr64ntv8eY #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@ManjariMGautam,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@19Oyekola,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@JamieSharp21,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@shuniecov,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@nijbhala,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@ben_humberstone,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@Jenny_Edwards,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@poojaliverpool,@Obasi_TropMed
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@scelee1,Risk attenuation after correcting for geography and deprivation.
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@docwas,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@Dawn100,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@ShahzadFaisalMD,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@AskDrShashank,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@drpatrickholmes,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@AbdTahrani,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@squilkie6,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@AliRacaniere,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@ClareHambling,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@amibanerjee1,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@PerseusPotter1,RT @kamleshkhunti: Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely att‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@kamleshkhunti,Our preprint publication led by @Vnafilyan show differences in COVID-19 mortality between ethnic groups were largely attenuated by geographical & socio-economic factors - tho some residual risk remained  The hazards ‚¨áÔ∏è after lockdown for all ethnic gro
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@ElmerEdward1,RT @PandemicCovid20: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated #COVID19 mortality: a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@_alexfowler,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@DrNaeemAhmed,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@Vnafilyan,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@SamECatperson,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@_the_lbb,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@kamleshkhunti,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@xandvt,RT @amibanerjee1: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a ret‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@amibanerjee1,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records @Vnafilyan @ben_humberstone @kamleshkhunti https://t.co/dG4RxgML5h
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@PandemicCovid20,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated #COVID19 mortality: a retrospective cohort study linking Census and death records - https://t.co/yrCLRKszQ0
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@SciscoreReports,The paper ‚ÄúEthnic minority groups in England and Wales - fact...‚Äù (https://t.co/Q81obPwdq1) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/FFRHJ6z8Jx. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@outbreaksci,"Contribute a rapid review or request one for ""Ethnic minority groups in England and Wales - factors affecting the size and timing of..."" (https://t.co/vr5yh7SNan). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20167122) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,@outbreaksci,New #COVID19 preprint: Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records https://t.co/vr5yh7SNan
http://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study,@PeterKilmarx,Patient-facing #Healthcareworkers and their household members at increased risk for #COVID19 https://t.co/uY5YNYBIRE
http://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study,@outbreaksci,"Contribute a rapid review or request one for ""Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their ..."" (https://t.co/ljjRKOEe7K). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20164897) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study,@outbreaksci,New #COVID19 preprint: Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study https://t.co/ljjRKOEe7K
http://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study,@rmchavin,"8-3-2020:  In a scientific study released today from Scotland, ""Healthcare workers and their households contribute one-sixth of all hospitalized COVID-19 cases:"" https://t.co/W86z3TgkkD https://t.co/k9ndk5il9P"
http://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study,@ajtweet,"‚Ä¶patient facing healthc workers & hshlds, est abs risk COVID hospt‚Äôn <0.5% but >1% in older men w comorbidity. Concl: Healthc workers & hshlds contrib 1/6 of hospitalised cases. Patient facing healthc workers & hshlds 3x & 2x incr ris"
http://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households: a nationwide linkage cohort study,@medrxivpreprint,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households:a nationwide linkage cohort study  https://t.co/LkWGsEfaCU #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20164137,"A Comprehensive Analysis of COVID-19 Transmission and Fatality Rates at the County level in the United States considering Socio-Demographics, Health Indicators, Mobility Trends and Health Care Infrastructure Attributes",@Nothing73144852,RT @medrxivpreprint: A Comprehensive Analysis of COVID-19 Transmission and Fatality Rates at the County level in the United States consider‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20164137,"A Comprehensive Analysis of COVID-19 Transmission and Fatality Rates at the County level in the United States considering Socio-Demographics, Health Indicators, Mobility Trends and Health Care Infrastructure Attributes",@medrxivpreprint,"A Comprehensive Analysis of COVID-19 Transmission and Fatality Rates at the County level in the United States considering Socio-Demographics, Health Indicators, Mobility Trends and Health Care Infrastructure Attributes  https://t.co/edm4hnBdkc #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.03.20167304,Correlation between daily infections and fatality rate due to Covid-19 in Germany,@medrxivpreprint,Correlation between daily infections and fatality rate due to Covid-19 in Germany  https://t.co/ptcLqQWgb6 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@ScienceShared,RT @ScienceShared: @Selinarajan @mastweiler8 @raven58008 @IanBradbury17 @deb_cohen @martinmckee @chrischirp @carlheneghan @AllysonPollock @‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@chrischirp,RT @ScienceShared: @Selinarajan @mastweiler8 @raven58008 @IanBradbury17 @deb_cohen @martinmckee @chrischirp @carlheneghan @AllysonPollock @‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@LarissaBlum1991,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@IlchevLazar,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@mjnmlm,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@ScienceShared,@Selinarajan @mastweiler8 @raven58008 @IanBradbury17 @deb_cohen @martinmckee @chrischirp @carlheneghan @AllysonPollock @PHE_uk @WHO Saliva tests üëç  Study the other day showed viral RNA stable in saliva in a normal eppendorf for days.   Plus I know also fro
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@kevinpurcell,RT @Aiims1742: More good stuff on #SARSCoV2 testing from @awyllie13 @NathanGrubaugh @VirusesImmunity et al: ‚ÄúWe found RNA in saliva from in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@revolution_fr,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@VZufferey,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Umu999_0YOtJHCt,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@satohkouichi,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@C_TanaCoCo,ËâØ„ÅÑÁü•„Çâ„Åõ„Å®ÊÇ™„ÅÑÁü•„Çâ„ÅõÔºà„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÅÆ„ÅßÊ≥®ÊÑèÔºâ  ËâØ„ÅÑÁü•„Çâ„Åõ„ÅØ„ÄÅÂîæÊ∂≤„Åß„ÅÆPCRÊ§úÊüª„Åå„Çà„ÇäÂÆâ‰æ°„Å´„Å™„Çã„Åã„ÇÇ„Åó„Çå„Åæ„Åõ„Çì  ÊÇ™„ÅÑÁü•„Çâ„Åõ„ÅØ„ÄÅÂîæÊ∂≤‰∏≠„ÅÆ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅåÈùûÂ∏∏„Å´ÂÆâÂÆöÊÄß„ÅåÈ´ò„ÅÑ„Å®„ÅÑ„ÅÜ„Åì„Å®„Åß„Åô„ÄÄ  https://t.co/En5SVEda8x  ÂîæÊ∂≤‰∏≠„Åß„ÅØÂáçÁµê„Åó„Å¶„ÇÇÂ∏∏Ê∏©„Åß„ÇÇ30‚ÑÉ„Åß„ÇÇÈï∑ÊúüÂÆâÂÆö„Å£„Å¶‚Ä¶ÊÉ≥ÂÉè„ÅÆÊñú„ÇÅ‰∏ä„Åô„Åé‚Ä¶ https://t.co/cYtUFjOga0
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@vaneay,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@baldricman,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Biomaven,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@FLAHAULT,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Shareresearcher,RT @AlistairEdwar10: Good news for the Avacta #avct saliva test. https://t.co/9D3KG3NMGb
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Vicktor1111,RT @AlistairEdwar10: Good news for the Avacta #avct saliva test. https://t.co/9D3KG3NMGb
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Titus_VIII,RT @Aiims1742: More good stuff on #SARSCoV2 testing from @awyllie13 @NathanGrubaugh @VirusesImmunity et al: ‚ÄúWe found RNA in saliva from in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@codax07,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@AlistairEdwar10,Good news for the Avacta #avct saliva test.
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@MorriganResists,RT @Aiims1742: More good stuff on #SARSCoV2 testing from @awyllie13 @NathanGrubaugh @VirusesImmunity et al: ‚ÄúWe found RNA in saliva from in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@CSCIColumbia,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@VirusesImmunity,RT @Aiims1742: More good stuff on #SARSCoV2 testing from @awyllie13 @NathanGrubaugh @VirusesImmunity et al: ‚ÄúWe found RNA in saliva from in‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@ElmerEdward1,RT @PandemicCovid20: Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices - https://t.co/mW2y‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Kabix,"RT @IsabelOtt: In case y‚Äôall are curious about my day job, we have a new paper out showing that simple lab plastic tubes work great for sal‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@almostlikethat,"RT @IsabelOtt: In case y‚Äôall are curious about my day job, we have a new paper out showing that simple lab plastic tubes work great for sal‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@orbofborbs,"RT @IsabelOtt: In case y‚Äôall are curious about my day job, we have a new paper out showing that simple lab plastic tubes work great for sal‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@omen_syria,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@24mobius42,ü§î
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@futurepundit,But we still have the US FDA in the way.
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@RomainM45081967,RT @stephaniekays: Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices https://t.co/dtDq9ZJM‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@stephaniekays,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices https://t.co/dtDq9ZJMGY
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@cloudydays1971,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@KNRXRX,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@PORKYANON,RT @PandemicCovid20: Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices - https://t.co/mW2y‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@lkelemen13,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@PandemicCovid20,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices - https://t.co/mW2yY61TIL
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@MicrobLog_me_uk,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@CovidSenseBloke,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@gstewtwo,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@jaywang06138467,RT @PaulaMarttila: Prepare for #COVID19 #SecondWave with affordable mass testing that allows allocate testing funds into increased tracing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@awyllie13,RT @PaulaMarttila: Prepare for #COVID19 #SecondWave with affordable mass testing that allows allocate testing funds into increased tracing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@PaulaMarttila,Prepare for #COVID19 #SecondWave with affordable mass testing that allows allocate testing funds into increased tracing capacity. Pls read entire thread. #COVID19SWEDEN #Covid19sverige #coronavirus #koronafi #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@GailCKal,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@NinaScience,@MaaritLeinonen @eroonkoronasta @thlbr @KirsiVarhila @T_Puumalainen https://t.co/D3fvypX0Oz
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@sjames_65,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Le_Van_Tan,RT @EsteeTorok: Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices https://t.co/bWkYqat1Ku
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@dkathunt,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@RachelHeckert,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@NinaScience,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@deborah_c,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@ppjvpp,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@coralnerd,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@atariq__,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@pollyresists,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@CarolLei4,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@GinnyTuman,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@camcneill,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@zLochnerMonster,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Eduardo75562848,RT @pmarsupia: El ARN del virus parece estable a temperatura ambiente en la saliva.  Este resultado es buen√≠simo si se desarrollan tests de‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@SarrisW,"This is a very good thing. TL;DR, saliva tests for Covid-19 have been proven to work really well and be inexpensive!"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@olga_francino,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@CollignonPeter,RT @Maikel_Boot: Q: Why bother using expensive ‚Äúpreservatives‚Äù if you can use regular tubes to collect saliva samples for Covid-19 tests? S‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@KathrynSalmon,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@ariesadrift,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@JillAnn1721,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Asiczwave,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@UomoPena,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@_Liz_Kitteh_,Well crap.
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@JoForDCCC,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@JoForDCCC,@SpeakerPelosi @RepAdamSchiff @ProjectLincoln @JoeBiden
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@side1track1,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@prpeep,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@jjfeds,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@KarenSalitis,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@CSP92204993,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@boylondon402,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@chemdocmommy,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@eliowa,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@KimRNcali,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@PalmettoVice,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@MorriganResists,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Pegster99,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Elizabe83931161,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@crtorrent,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@10minus6cosm,RT @awyllie13: The take home: expensive collection devices are prohibitive to mass testing efforts. Simple saliva collection frees testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@HahnTHEman,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@MotherFulkerson,Ever willing to latch onto potentially good news in the current environment...
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@REALmillerfinch,Read thread on why saliva stability is important to #coronavirus testing üëá
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@AntifaDisabled,"RT @IsabelOtt: In case y‚Äôall are curious about my day job, we have a new paper out showing that simple lab plastic tubes work great for sal‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@jsgjames,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@PsychoRooks,"No wonder it lives so long on hard surfaces.  This also means that kids going to school should be wearing rubber gloves and eye protection, right? Is everyone still washing their hands when they're wearing masks? How many kids will do both regularly?  Anyh"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@redboybroken,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@BBusBus,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@rkadis,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Schoollluminati,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@Nuculurrabitt,"RT @apoorva_nyc: Why don't we have more saliva tests yet?   Here's more evidence, from @awyllie13 and others, that viral RNA is stable in s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@ayirpelle,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165233,Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices,@kristenwarner,RT @hmkyale: New imp @medrxivpreprint by @awylie13 @IsabelOtt and team showing 'SARS-CoV-2 RNA in saliva from infected individuals stable a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@EEksD,https://t.co/t506F3DR5d
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@DanielleFong,RT @PRussW1: The TLDR inferences I took from this study: 1)Quick thoughts. T cell exhaustion a real concern as T cell count declines with d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@EEksD,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes https://t.co/t506F3DR5d"
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@outbreaksci,"New #SARSCoV preprint: Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes https://t.co/WJaDyYsEVi"
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@outbreaksci,"Contribute a rapid review or request one for ""Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, p..."" (https://t.co/WJaDyYsEVi). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166587) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@outbreaksci,"New #COVID19 preprint: Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes https://t.co/WJaDyYsEVi"
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@RicardLopez123,RT @PRussW1: The TLDR inferences I took from this study: 1)Quick thoughts. T cell exhaustion a real concern as T cell count declines with d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@nanogenomic,RT @PRussW1: The TLDR inferences I took from this study: 1)Quick thoughts. T cell exhaustion a real concern as T cell count declines with d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@PRussW1,"The TLDR inferences I took from this study: 1)Quick thoughts. T cell exhaustion a real concern as T cell count declines with duration; 2) Dramatically reduced B cell count, which may be what is driving weak antibody response. /1  https://t.co/WLIG217IQ8"
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@jsteward2930,"RT @medrxivpreprint: Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and ha‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166587,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes",@medrxivpreprint,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and half-dead lymphocytes  https://t.co/S8tmGXCfam #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Pseudovirus neutralization assay protocol download: https://t.co/Z9pyXg1Onl https://t"
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Its effector cells: https://t.co/2hW8TKMBlv  Protocol: https://t.co/Z9pyXg1Onl  https:"
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@rajdeoraosu,RT @YountLabOSU: Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-lu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@EugeneOltz,RT @YountLabOSU: Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-lu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@sciencesalesrep,RT @shanluliu: Excited to share our work on SARS-CoV-2 neutralizing antibodies using secreted gLuc or secreted Nano-luc lentiviral pseudoty‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@IDIatOSU,Check out the latest work from Dr. Shan-Lu Liu and his team on SARS-CoV-2 antibody testing. Dr. Liu is a co-director of IDI's Viruses and Emerging Pathogens Program.
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@outbreaksci,"Contribute a rapid review or request one for ""Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care worke..."" (https://t.co/oFdGWoVhml). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166819) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@outbreaksci,"New #SARSCoV preprint: Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay https://t.co/oFdGWoVhml"
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@lijinlinwhu,RT @shanluliu: Excited to share our work on SARS-CoV-2 neutralizing antibodies using secreted gLuc or secreted Nano-luc lentiviral pseudoty‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@JingyouYu,A big shoutout for @shanluliu lab gLuc and Nano-luc pseudovirus system!
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@fakeDespommier,RT @YountLabOSU: Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-lu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@VirologistVal,RT @YountLabOSU: Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-lu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@XuZhou1984,Congratulations to @shanluliu! High throughout platform for screening neutralizing antibodies for SARS-CoV-2!
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@shanluliu,Excited to share our work on SARS-CoV-2 neutralizing antibodies using secreted gLuc or secreted Nano-luc lentiviral pseudotypes: ICU patients > non-ICU patients > COVID-19 blood donors > Health care workers. https://t.co/X687mS102h https://t.co/Ny
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@ImmunoFever,RT @YountLabOSU: Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-lu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@memerman,RT @YountLabOSU: Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-lu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166819,"Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay",@YountLabOSU,Excited to share this CoV-2 Ab neutralization study from OSU led by @shanluliu.  Many points of interest: secreted nano-luciferase pseudoparticle assay; C9 tag on Spike C-term increased pseudoparticle titer;... https://t.co/do520GrpLS
http://medrxiv.org/cgi/content/short/2020.08.03.20167098,Waves of COVID-19 pandemic. Detection and SIR simulations,@COVID_Papers,üìù Waves of COVID-19 pandemic. Detection and SIR simulations  medRxiv or bioRxiv https://t.co/1IJUkvhrfO #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.03.20167098,Waves of COVID-19 pandemic. Detection and SIR simulations,@medrxivpreprint,Waves of COVID-19 pandemic. Detection and SIR simulations  https://t.co/Fg5GozcgM3 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166041,Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing,@SidewalkSciGuy,"Pretty cool news, my sister is second author on this preprint (not yet peer reviewed) article on COVID out of Johns Hopkins:  https://t.co/0fYn3q4BBc"
http://medrxiv.org/cgi/content/short/2020.07.31.20166041,Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing,@drummondscico,"RT @outbreaksci: Contribute a rapid review or request one for ""Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166041,Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing,@outbreaksci,"Contribute a rapid review or request one for ""Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing"" (https://t.co/wNih2bBnf0). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20166041) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.07.31.20166041,Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing,@outbreaksci,New #SARSCoV preprint: Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing https://t.co/wNih2bBnf0
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@DavidRaichlen,"RT @YKlimentidis: Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study https://t.co/igE7JKk3pN"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@YKlimentidis,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study https://t.co/igE7JKk3pN"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@charo_79,"RT @EnferEvidente: Actividad f√≠sica, IMC y #COVID19 Estudio observacional sobre datos de un biobanco y datos de AF subjetivos y objetivos.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@EnferEvidente,"Actividad f√≠sica, IMC y #COVID19 Estudio observacional sobre datos de un biobanco y datos de AF subjetivos y objetivos. Parece positivo aconsejar y facilitar la realizaci√≥n de ejercicios a la poblaci√≥n a√∫n en momentos de limitaci√≥n de movilidad #TLG https:"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@outbreaksci,"Contribute a rapid review or request one for ""Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study"" (https://t.co/Vpsue2Qofh). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166405) at https://t.co/RnurTL3DyM @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@outbreaksci,"New #COVID19 preprint: Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study https://t.co/Vpsue2Qofh"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@Roshan_Karia,"RT @medrxivpreprint: Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study  https://t.co/oWOYtXFeq8 #medR‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",@medrxivpreprint,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study  https://t.co/oWOYtXFeq8 #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@Distinct_Words,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population https://t.co/hp7p8kMXYO
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@outbreaksci,"Contribute a rapid review or request one for ""Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID..."" (https://t.co/g0s8WX2q5M). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20165589) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@outbreaksci,New #SARSCoV preprint: Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population https://t.co/g0s8WX2q5M
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@acet0125,RT @medrxivpreprint: Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@WilVoitus,"RT @vrsimility: @MichaelRosenYes Interesting pre-print on phased reopening of schools in S Korea (and yes, they wore masks in class). https‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@vrsimility,"@MichaelRosenYes Interesting pre-print on phased reopening of schools in S Korea (and yes, they wore masks in class). https://t.co/Bq1TPLXtTn"
http://medrxiv.org/cgi/content/short/2020.08.03.20165589,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population,@medrxivpreprint,Stepwise School Opening Online and Off-line and an Impact on the Epidemiology of COVID-19 in the Pediatric Population  https://t.co/LFVE8ZRnbk #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166876,SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms,@futurepundit,Fading seropositivity: those who ... experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more
http://medrxiv.org/cgi/content/short/2020.08.02.20166876,SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms"" (https://t.co/soWQygdGgK). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166876) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.02.20166876,SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms https://t.co/soWQygdGgK
http://medrxiv.org/cgi/content/short/2020.08.02.20166876,SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms,@csloredoped,RT @medrxivpreprint: SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms  https://t.co/Nq6ix5Gnsi #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166876,SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms,@medrxivpreprint,SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms  https://t.co/Nq6ix5Gnsi #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20163733,"Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet",@outbreaksci,"Contribute a rapid review or request one for ""Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clini..."" (https://t.co/qx5m5Ktet6). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20163733) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20163733,"Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet",@outbreaksci,"New #influenza preprint: Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet https://t.co/qx5m5Ktet6"
http://medrxiv.org/cgi/content/short/2020.08.01.20163733,"Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet",@COVID_Papers,"üìù Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet  medRxiv or bioRxiv https://t.co/2pVPS9hhh3 #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.08.01.20163733,"Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet",@medrxivpreprint,"Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet  https://t.co/zn7nbhFVg7 #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.03.20167007,Severity Assessment and Progression Prediction of COVID-19 Patients based on the LesionEncoder Framework and Chest CT,@COVID_Papers,üìù Severity Assessment and Progression Prediction of COVID-19 Patients based on the LesionEncoder Framework and Chest CT  medRxiv or bioRxiv https://t.co/8khn8VIYMA #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.03.20167007,Severity Assessment and Progression Prediction of COVID-19 Patients based on the LesionEncoder Framework and Chest CT,@medrxivpreprint,Severity Assessment and Progression Prediction of COVID-19 Patients based on the LesionEncoder Framework and Chest CT  https://t.co/WpA3SCouYY #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166785,The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System,@outbreaksci,New #SARSCoV preprint: The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System https://t.co/vgDjggLKs7
http://medrxiv.org/cgi/content/short/2020.08.02.20166785,The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System,@outbreaksci,"Contribute a rapid review or request one for ""The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System"" (https://t.co/vgDjggLKs7). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166785) at https://t.co/RnurTL3DyM @outbreaksci @PREreview"
http://medrxiv.org/cgi/content/short/2020.08.02.20166785,The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System,@outbreaksci,New #COVID19 preprint: The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System https://t.co/vgDjggLKs7
http://medrxiv.org/cgi/content/short/2020.08.02.20166785,The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System,@medrxivpreprint,The Lebanese Cohort for COVID-19; A Challenge for the ABO Blood Group System  https://t.co/BPwvD0TVBq #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@ERawshan,RT @syedarehaq: Really proud to be a part of this crucial work on clinical trial leadership on #COVID19  and gender imbalance  Thank you @m‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@Michael91693258,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@GlobalHealthMGH,RT @IDDocJen: I got the chance of a lifetime from the amazing @mugecevik and the great @PaulSaxMD ...  To participate in this important res‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@LouBuchanan17,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@MaynoothNest,Hope I‚Äôm not wrecking your head tagging you in stuff like this but thought it would be of interest üòÅ @CCriadoPerez
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@Laconic_doc,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@docanthea,RT @SMDequalities: Our @Athena_SWAN Chair @profchloeorkin shares her paper showing gender disparities in authorship are exacerbated during‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@madre_del_ano,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@savoy__truffle,"RT @profchloeorkin: In this paper **pre-print** , we examined the gender of clinical trial leadership during #COVID and compared two other‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@damianaswan,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@mugecevik,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@IDDocJen,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@GermHunterMD,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@womeninGH,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@DancyGeorgia,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@EricMeyerowitz,"RT @mugecevik: In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate pr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@DancyGeorgia,RT @RoopaDhatt: DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 relate‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@mugecevik,RT @RoopaDhatt: DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 relate‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@mugecevik,"In this preprint, we demonstrate that despite women accounting for 70% of the global health workforce, a disproportionate proportion of COVID-19 related clinical studies are led by principal investigators who were predicted to be men. https://t.co/hyjcwVcH"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@Ammer_B,@ZusterMerel @ronwichgers @TwitViv @Wim_Schellekens @MinVWS @bosmana @XanderKoolman @ginnymooy @pesla @bslagter @mzelst @edwinveldhuizen Lees deze maar eens. Is een echt probleem. Gaat over clinical trial leadership in public health: https://t.co/GtqBiWtxy
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@profchloeorkin,RT @IDDocJen: I got the chance of a lifetime from the amazing @mugecevik and the great @PaulSaxMD ...  To participate in this important res‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@medicalwomenuk,RT @SMDequalities: Our @Athena_SWAN Chair @profchloeorkin shares her paper showing gender disparities in authorship are exacerbated during‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@SMDequalities,Our @Athena_SWAN Chair @profchloeorkin shares her paper showing gender disparities in authorship are exacerbated during COVID especially in terms of clinical trial lead authorship @NeenaModi1 @CNagpaul
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@medicalwomenuk,"RT @profchloeorkin: In this paper **pre-print** , we examined the gender of clinical trial leadership during #COVID and compared two other‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@DipeshGopal,"RT @profchloeorkin: In this paper **pre-print** , we examined the gender of clinical trial leadership during #COVID and compared two other‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@Gender_COVID19,RT @RoopaDhatt: Women researchers go above and beyond to prove the gender gap in clinical trial leadership.   ‚ÄúWe demonstrate that less tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@khamland1,RT @RoopaDhatt: DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 relate‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@annvkeeling,RT @RoopaDhatt: DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 relate‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@PortaSong,RT @KrutikaKuppalli: Honored to be involved with this important article showing that despite opportunities in a new field gender disparitie‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@HealthFinInst,RT @IDDocJen: I got the chance of a lifetime from the amazing @mugecevik and the great @PaulSaxMD ...  To participate in this important res‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@IDDocJen,I got the chance of a lifetime from the amazing @mugecevik and the great @PaulSaxMD ...  To participate in this important research on #WomenInMedicine in the age of #COVID19:   https://t.co/Ai98X9gaPI  Thanks to @KrutikaKuppalli @profchloeorkin @maiamajumd
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@syedarehaq,Here is the link to the preprint: https://t.co/J1hydzeskW
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@syedarehaq,Really proud to be a part of this crucial work on clinical trial leadership on #COVID19  and gender imbalance  Thank you @mugecevik @maiamajumder @profchloeorkin @KrutikaKuppalli @IDDocJen @PaulSaxMD for making this paper happen. It was great learning expe
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@mAryalbelloso,RT @RoopaDhatt: Women researchers go above and beyond to prove the gender gap in clinical trial leadership.   ‚ÄúWe demonstrate that less tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@DrJudyStone,RT @KrutikaKuppalli: Thanks @RoopaDhatt for amplifying this very important work. We need to improve gender disparities in clinical trial le‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@womeninGH,RT @RoopaDhatt: DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 relate‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@KrutikaKuppalli,Thanks @RoopaDhatt for amplifying this very important work. We need to improve gender disparities in clinical trial leadership for #COVID19   Thanks to the amazing team I had the privilege to work with @mugecevik @syedarehaq @PaulSaxMD @maiamajumder @profc
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@astle_barbara,RT @RoopaDhatt: DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 relate‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@RoopaDhatt,DYK: There is a gender gap clinical trial leadership and it matters.  ‚ÄúWe demonstrate that less than 1/3 of #COVID19 related clinical trials are led by principal investigators who [are] üö∫ ‚Äù   @mugecevik @KrutikaKuppalli @maiamajumder and more https://t.co/
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@RosemaryJMorgan,RT @RoopaDhatt: Women researchers go above and beyond to prove the gender gap in clinical trial leadership.   ‚ÄúWe demonstrate that less tha‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@KrutikaKuppalli,@BhadeliaMD Perhaps you should quote our paper to the NIH https://t.co/bWTI8Bbliw
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@RoopaDhatt,Women researchers go above and beyond to prove the gender gap in clinical trial leadership.   ‚ÄúWe demonstrate that less than 1/3 of #COVID19 related clinical trials are led by principal investigators who [are] üö∫ ‚Äù   @mugecevik @KrutikaKuppalli https://t.c
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@KevinEscandonMD,RT @KrutikaKuppalli: Honored to be involved with this important article showing that despite opportunities in a new field gender disparitie‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@KrutikaKuppalli,Honored to be involved with this important article showing that despite opportunities in a new field gender disparities persist during #COVID19. <1/3 of #COVID19 related clinical trials are led by women PI's. We must identify and address these barriers.
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@RosemaryJMorgan,RT @medrxivpreprint: Gender disparities in international COVID-19 clinical trial leadership  https://t.co/kSJRKpogsD #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166751,Gender disparities in international COVID-19 clinical trial leadership,@medrxivpreprint,Gender disparities in international COVID-19 clinical trial leadership  https://t.co/kSJRKpogsD #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20166983,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.,@ElmerEdward1,RT @PandemicCovid20: Application of Social Vulnerability Index to Identify High- risk Population of Contracting #COVID19 Infection: a state‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20166983,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.,@PandemicCovid20,Application of Social Vulnerability Index to Identify High- risk Population of Contracting #COVID19 Infection: a state-level study. - https://t.co/lL3RN99RAN
http://medrxiv.org/cgi/content/short/2020.08.03.20166983,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.,@SciscoreReports,The paper ‚ÄúApplication of Social Vulnerability Index to Ident...‚Äù (https://t.co/UJ0iihsRNx) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/k9PPMQmlJt. We detected 0 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.03.20166983,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.,@chrishendel,Application of Social Vulnerability Index to Identify High- risk Population of Contracting #COVID19 Infection: a state-level study. https://t.co/Zhst1VBjHe
http://medrxiv.org/cgi/content/short/2020.08.03.20166983,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.,@medrxivpreprint,Application of Social Vulnerability Index to Identify High- risk Population of Contracting COVID-19 Infection: a state-level study.  https://t.co/lmMrR9Zbdu #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166157,"High prevalence of food insecurity, the adverse impact of COVID-19 in Brazilian favela",@PandemicCovid20,"High prevalence of food insecurity, the adverse impact of #COVID19 in Brazilian favela - https://t.co/As0RwCJ3kE"
http://medrxiv.org/cgi/content/short/2020.07.31.20166157,"High prevalence of food insecurity, the adverse impact of COVID-19 in Brazilian favela",@COVID_Papers,"üìù High prevalence of food insecurity, the adverse impact of COVID-19 in Brazilian favela  medRxiv or bioRxiv https://t.co/pJgOqOApK5 #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.31.20166157,"High prevalence of food insecurity, the adverse impact of COVID-19 in Brazilian favela",@medrxivpreprint,"High prevalence of food insecurity, the adverse impact of COVID-19 in Brazilian favela  https://t.co/vQ9yNzkAgD #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.01.20162115,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics,@SciscoreReports,The paper ‚ÄúA Study on Survival Scenario of COVID-19 patients...‚Äù (https://t.co/mAAKDa0RUC) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/hiSOIZCm0I. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.01.20162115,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics,@SampurnaKundu,RT @medrxivpreprint: A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20162115,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics,@SampurnaKundu,RT @COVID_Papers: üìù A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20162115,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics,@COVID_Papers,üìù A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics  medRxiv or bioRxiv https://t.co/Bkkc5pwz6f #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.01.20162115,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics,@medrxivpreprint,A Study on Survival Scenario of COVID-19 patients in India: An Application of Survival Analysis on patient demographics  https://t.co/FNwM7TwnLp #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@SciscoreReports,The paper ‚ÄúSooner than you think: a very early affective reac...‚Äù (https://t.co/XLESmxJvAK) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Q3V2lL1f3W. We detected 2 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@victorcarrascal,"RT @ManesF: ""M√°s r√°pido de lo pensado: reacci√≥n emocional temprana a la pandemia de COVID-19 y a la cuarentena en Argentina"". https://t.co/‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@ChumpiCarmen,"RT @ManesF: ""M√°s r√°pido de lo pensado: reacci√≥n emocional temprana a la pandemia de COVID-19 y a la cuarentena en Argentina"". https://t.co/‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@ManesF,"""M√°s r√°pido de lo pensado: reacci√≥n emocional temprana a la pandemia de COVID-19 y a la cuarentena en Argentina"". https://t.co/yMgXyUocAz"
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@JustLoliAP,RT @adrianself: Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina https://t.co/mg‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@adrianself,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina https://t.co/mg9KUxNcDe   Wow!  Our first pre-print about very early effects of #COVID__19 #pandemic and quarantine in #Argentina is out! @INECOArg
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@COVID_Papers,üìù Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina  medRxiv or bioRxiv https://t.co/XkUXcJY1De #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20166272,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina,@medrxivpreprint,Sooner than you think: a very early affective reaction to the COVID-19 pandemic and quarantine in Argentina  https://t.co/hmfdDCCpQg #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167361,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature,@outbreaksci,"Contribute a rapid review or request one for ""Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-..."" (https://t.co/yJ2K1xhiHb). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20167361) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20167361,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature,@outbreaksci,New #SARSCoV preprint: Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature https://t.co/yJ2K1xhiHb
http://medrxiv.org/cgi/content/short/2020.08.03.20167361,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature,@viralvideovlogs,RT @COVID_Papers: üìù Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167361,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature,@COVID_Papers,üìù Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature  medRxiv or bioRxiv https://t.co/Y46gMh81ms #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.03.20167361,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature,@medrxivpreprint,Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature  https://t.co/I5zRK6TGyv #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@Patrick_Gerland,RT @StephaneVerguet: Our #medrxivpreprint paper discusses impact on #COVID19 mortality of self-imposed behavior change and government regul‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@helleringer143,RT @StephaneVerguet: Our #medrxivpreprint paper discusses impact on #COVID19 mortality of self-imposed behavior change and government regul‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@StephaneVerguet,"Our #medrxivpreprint paper discusses impact on #COVID19 mortality of self-imposed behavior change and government regulations across 13 countries @julianjamison Jacob Spitz, Don Bundy, and Dean Jamison https://t.co/fygS3kuEoW https://t.co/74Yvtcw2Z4"
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@ElmerEdward1,RT @PandemicCovid20: Comparing the impact on #COVID19 mortality of self-imposed behavior change and of government regulations across 13 cou‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@PandemicCovid20,Comparing the impact on #COVID19 mortality of self-imposed behavior change and of government regulations across 13 countries - https://t.co/Mf3f4wL0yp
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@alfonso_casi,Comparaci√≥n del impacto en la mortalidad de COVID-19 del cambio de comportamiento autoimpuesto y de las regulaciones gubernamentales en 13 pa√≠ses europeos: los efectos de ambas alternativas son del mismo orden de magnitud. https://t.co/qbd44xfQ19 https://t
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@outbreaksci,"Contribute a rapid review or request one for ""Comparing the impact on COVID-19 mortality of self-imposed behavior change and of gove..."" (https://t.co/AaJ2Jykk3k). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166793) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@outbreaksci,New #COVID19 preprint: Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries https://t.co/AaJ2Jykk3k
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@gsgs2,"13 EU-Countries : mobility reduction before measures:-9%COVID,  closures:-14% best : intercity travel restriction, events cancelled, closing workplaces almost useless : closing schools, stay-at-home-orders,"
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@COVID_Papers,üìù Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries  medRxiv or bioRxiv https://t.co/kEazA19YXm #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.02.20166793,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries,@medrxivpreprint,Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries  https://t.co/uS43jIbmsD #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@SarahTom123,RT @TheBottomDoc: Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@anjan_dhar6,"Attending for endoscopy is safe for staff and patients in UK. Zero cases : 6200 procedures. Time to swab, scope and stop Covid cancer collateral damage. https://t.co/w91goo0iJY @CDDFTNHS @BritSocGastro"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@EasleyDoesIt53,Important study! #GITwitter
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@EasleyDoesIt53,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@Mfletch69,@SouthTees
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@anjan_dhar6,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@shwankarim1984,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@TavakoliParis,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom | medRxiv https://t.co/OBuQTTEGmM
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@CorlessLynsey,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@BritSocGastro,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@BritSocGastro,RT @GastronautIan: Congrats to @IBDdoc for leading and driving this study and @BottProf @ThoufeeqMo #JamesEast.  We‚Äôre learning more about‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@martinswadley,RT @TheBottomDoc: Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@cynthiamich,RT @TheBottomDoc: Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@sasbanerjee,RT @TheBottomDoc: Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@BhrutE,RT @TheBottomDoc: Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@SergioCoda3,RT @TheBottomDoc: Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@VishCPatel,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@DiagmedHCare,A great study by @IBDdoc and others showing reassuring data supporting swabbing: 3/2611 (0.11%) asymptomatic patients testing positive for SARS-CoV-2 on swab testing pre-endoscopy. No cases of COVID-19 were documented after endoscopy in patients/staff üëá ht
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@TheBottomDoc,Reassuring data supporting swabbing in UK:  Only 3/2611 (0.11%) asymptomatic patients tested positive for SARS-CoV-2 pre-endoscopy. No cases of COVID-19 in any centre after endoscopy in either patients or staff (7 and 14 day phone follow-up).  https://t.co
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@jacqbin,@Paul_Tisi this is the study
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@almu_inch,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@SiwanTG,RT @GastronautIan: Congrats to @IBDdoc for leading and driving this study and @BottProf @ThoufeeqMo #JamesEast.  We‚Äôre learning more about‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@LauraJNeilson,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@Arvind_venks,Great effort and reassuring data @BritSocGastro
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@CholestasisDoc,Massive effort by @IBDdoc and @KingsCollegeLon for leading this important study. Well done
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@shraddha_gulati,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@emadelomar,RT @GastronautIan: Congrats to @IBDdoc for leading and driving this study and @BottProf @ThoufeeqMo #JamesEast.  We‚Äôre learning more about‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@iosifbeintaris,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@charlie_lees,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@karenlamsgen,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@rachelcooney7,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@outbreaksci,"Contribute a rapid review or request one for ""A multi-centre prospective study of COVID-19 transmission following outpatient Gastroi..."" (https://t.co/xqJ1ciw6Fu). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166736) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@outbreaksci,New #SARSCoV preprint: A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom https://t.co/xqJ1ciw6Fu
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@AngadDhillon,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@Uk_BowelDoc,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@NEndoscopy,Great study and proud to have contributed
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@rogprudham,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@gastrosid,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@DisneyBen,Great work Bu
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@Dr_E_Walker,"This is great news, very good to hear!"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@jacqbin,Thank you - this will give reassurance to many.
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@GastronautIan,Congrats to @IBDdoc for leading and driving this study and @BottProf @ThoufeeqMo #JamesEast.  We‚Äôre learning more about this infection every day. Multiple components to keeping patients & staff safe. Next steps?  Safely building ‚¨ÜÔ∏è Endoscopy capacity ‚úÖ
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@PolychronisP,"RT @IBDdoc: Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@UKGastroDr,Proud that @KGHEndoscopy is one of the contributing centres to this study
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@IBDdoc,"Our study through a fantastic collaborative of 18 UK centres,  n=6208 @GastronautIan @BottProf and *many* others  Zero cases of #COVID19 after outpt #endoscopy in pts/staff. Support for SCOTS criteria and pre-endo testing to create COVID-minimised pathways"
http://medrxiv.org/cgi/content/short/2020.08.02.20166736,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom,@medrxivpreprint,A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom  https://t.co/OjuL9PV7LE #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167197,Spreading of COVID-19 in Italy as the spreading of a wave packet,@COVID_Papers,üìù Spreading of COVID-19 in Italy as the spreading of a wave packet  medRxiv or bioRxiv https://t.co/tiAoENOo3W #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.03.20167197,Spreading of COVID-19 in Italy as the spreading of a wave packet,@medrxivpreprint,Spreading of COVID-19 in Italy as the spreading of a wave packet  https://t.co/ELspPZJjIs #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@Mahamsaleem88,"RT @BIPS_Bremen: Our doctoral student Furqan Ahmed has been involved in an interesting #SARSCoV2 modelling study, currently out for comment‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@LSCDiPH,"RT @BIPS_Bremen: Our doctoral student Furqan Ahmed has been involved in an interesting #SARSCoV2 modelling study, currently out for comment‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@BIPS_Bremen,"Our doctoral student Furqan Ahmed has been involved in an interesting #SARSCoV2 modelling study, currently out for comments and submitted for peer-review. Hajo Zeeb (@girafium) also contributed. Feedback is welcome:  https://t.co/DOm74kuMsz"
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@JavedMu17043209,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries https://t.co/pdBFFuKFNc @FurqanKabir @ahmedfurqan100
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@WaqasuddinK,RT @KabirFurqan: https://t.co/ua21AvMenJ
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@KabirFurqan,https://t.co/ua21AvMenJ
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@zensaleem,RT @medrxivpreprint: Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  https://t.co/J‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@Salmankuird,A timely quantitative analysis of Covid-19. Must read!
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@Salmankuird,RT @medrxivpreprint: Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  https://t.co/J‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@Mahamsaleem88,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries https://t.co/5WBKNL17Do
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@ahmedfurqan100,RT @medrxivpreprint: Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  https://t.co/J‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@Mahamsaleem88,RT @medrxivpreprint: Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  https://t.co/J‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@CHOMES102,RT @medrxivpreprint: Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  https://t.co/J‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@COVID_Papers,üìù Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  medRxiv or bioRxiv https://t.co/CAFN4ymLcA #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.03.20167189,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries,@medrxivpreprint,Evaluating Data-Driven Forecasting Methods for Predicting SARS-CoV2 Cases: Evidence From 173 Countries  https://t.co/J8Mbk3UvVm #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167692,"COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020",@Ren48057460,@raoult_didier https://t.co/ZqIaBm3thm
http://medrxiv.org/cgi/content/short/2020.08.03.20167692,"COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020",@Vinnie22b,RT @COVID_Papers: üìù COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first tw‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167692,"COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020",@COVID_Papers,"üìù COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020  medRxiv or bioRxiv https://t.co/qHAmQuo86f #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.08.03.20167692,"COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020",@medrxivpreprint,"COVID-19 pandemic in Djibouti: epidemiology and the response strategy followed to contain the virus during the first two months, 17 March to 16 May 2020  https://t.co/fNNL5d1zey #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.01.20166330,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,@SciscoreReports,The paper ‚ÄúRespiratory viral infections by Non-influenza viru...‚Äù (https://t.co/XDag4i8shh) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/EltpMpOd58. We detected 2 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.08.01.20166330,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,@outbreaksci,"Contribute a rapid review or request one for ""Respiratory viral infections by Non-influenza viruses are associated with more adverse..."" (https://t.co/IgPKgjhmpE). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166330) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20166330,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,@outbreaksci,New #influenza preprint: Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study. https://t.co/IgPKgjhmpE
http://medrxiv.org/cgi/content/short/2020.08.01.20166330,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,@COVID_Papers,üìù Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.  medRxiv or bioRxiv https://t.co/uf7vb2faJ3 #COVID19 #COVID19Paper
http://medrxiv.org/cgi/content/short/2020.08.01.20166330,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,@xainab_Umair,RT @medrxivpreprint: Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients wi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166330,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.,@medrxivpreprint,Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.  https://t.co/q1BVcWSD1O #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166538,Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.,@outbreaksci,"Contribute a rapid review or request one for ""Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction a..."" (https://t.co/JXOmubays4). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166538) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20166538,Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.,@outbreaksci,New #SARSCoV preprint: Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification. https://t.co/JXOmubays4
http://medrxiv.org/cgi/content/short/2020.08.01.20166538,Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.,@medrxivpreprint,Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.  https://t.co/OGVXEpeDpc #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166447,On the temporal spreading of the SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""On the temporal spreading of the SARS-CoV-2"" (https://t.co/znXpeksfsz). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166447) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.01.20166447,On the temporal spreading of the SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: On the temporal spreading of the SARS-CoV-2 https://t.co/znXpeksfsz
http://medrxiv.org/cgi/content/short/2020.08.01.20166447,On the temporal spreading of the SARS-CoV-2,@CHOMES102,RT @medrxivpreprint: On the temporal spreading of the SARS-CoV-2  https://t.co/AhV80GloOK #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166447,On the temporal spreading of the SARS-CoV-2,@medrxivpreprint,On the temporal spreading of the SARS-CoV-2  https://t.co/AhV80GloOK #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166397,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage",@futurepundit,The shortage of nasopharyngeal swabs need not be a bottleneck for SARS-CoV-2 testing since alternative sampling methods work well.
http://medrxiv.org/cgi/content/short/2020.08.01.20166397,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage",@outbreaksci,"New #SARSCoV preprint: Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage https://t.co/p5SbXE7fnS"
http://medrxiv.org/cgi/content/short/2020.08.01.20166397,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage",@outbreaksci,"Contribute a rapid review or request one for ""Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2..."" (https://t.co/p5SbXE7fnS). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166397) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20166397,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage",@outbreaksci,"New #COVID19 preprint: Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage https://t.co/p5SbXE7fnS"
http://medrxiv.org/cgi/content/short/2020.08.01.20166397,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage",@medrxivpreprint,"Sensitivity of nasopharyngeal, oropharyngeal and nasal washes specimens for SARS-CoV-2 detection in the setting of sampling device shortage  https://t.co/53X4kpyY4t #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@GEGENCovidioten,"RT @MSchmutzkind: @Karl_Lauterbach Sie werden ja sicher wieder f√ºr die japanische Clusterstrategie werben. Ich bef√ºrchte jedoch, dass diese‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Pedinska,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@JariSaramaki,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@RemainRevoke,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@FrenchAHA,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@yellow_earth,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Esqueuezme,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@KavukcuNurtac,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Hansalotte1,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@jesusricofe,RT @SEIMC_: Algunas estrategias de #rastreo pueden incrementar significativamente (hasta el doble) el n√∫mero de contactos positivos. Este h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@vbintx,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@karendkelley,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@EcoLogicalNet,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@JeremyKonyndyk,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@dccc_phd,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@pathogenomenick,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@MichaelPaulEdw1,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@FanchetAldo,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AFernandes78,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AKTC3,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@ZaminIqbal,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@EuphoricEuler,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@kat_gris,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@per_petra,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@redboybroken,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@ClaireJStandley,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@RachelHeckert,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@phylogenomics,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@RobACooper,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@DFisman,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@yatevasamejorar,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@vbintx,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@marthajadams,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@StefanSerban,RT @BillHanage: This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@BillHanage,This is a fantastically interesting and relevant preprint on the importance of backward contact tracing - identifying the source of an case as well as anyone they might have transmitted to. Bravo @cmmid_lshtm https://t.co/Bs5Icdj7IE
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Claudia68067469,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@winteressme,RT @nobody_indepth: Adam KucharskiÍ∑∏Î£πÏùò ÏµúÍ∑º OverdispersionÍ≥º backward tracingÏóê ÎåÄÌïú Î™®Îç∏ ÎÖºÎ¨∏ÏùÑ ÏùΩÏóàÎã§. Ïù¥Îü∞ ÏßÄÏãùÏÉùÏÇ∞Ïù¥ ÌïúÍµ≠ÏóêÏÑúÎèÑ Ïù¥Î§ÑÏ°åÏúºÎ©¥ Ï¢ãÍ≤†Îã§. ÌïúÍµ≠Ïñ∏Î°† ÎÇòÎ¶Ñ Í¥ÄÏã¨ÏûàÍ≤å Î≥¥ÎäîÎç∞ ÎÑàÎ¨¥ Í∏∞Ï¥àÏ≤¥‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@kam3266,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@seawiz2,COVID Best Prectices
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AbraarKaran,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@MoSchaefer66,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@John_Bailey,"RT @rvenkayya: I hadn't understood the role of ""backward tracing"" in the Japanese and Korean cluster-busting strategies, but it makes perfe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@TENTUCOYA,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@MSchmutzkind,"@Karl_Lauterbach Sie werden ja sicher wieder f√ºr die japanische Clusterstrategie werben. Ich bef√ºrchte jedoch, dass diese mit retrospektiver Suche gleichgesetzt wird. Tats√§chlich ist das Tracing in Japan aber sowohl prospektiv als auch retrospektiv. https:"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@gabls,RT @SEIMC_: Algunas estrategias de #rastreo pueden incrementar significativamente (hasta el doble) el n√∫mero de contactos positivos. Este h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Ye_Yelopa,RT @isabelrodbar: Sobre la estrategia de rastreo retrospectivo de Jap√≥n y por qu√© podr√≠a ser eficiente y complementar al rastreo prospectiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@vvelanos,"RT @kikollan: Muy interesante esto sobre rastreo de clusters (backward/forward tracing), y un tema del que hablamos creo que poco en Espa√±a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@marian_onieva,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@rvenkayya,"I hadn't understood the role of ""backward tracing"" in the Japanese and Korean cluster-busting strategies, but it makes perfect sense and should be added to our toolkit in the US when we get transmission low enough to do contact tracing for suppression."
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@lgcrowes,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@strongblast,RT @nobody_indepth: Adam KucharskiÍ∑∏Î£πÏùò ÏµúÍ∑º OverdispersionÍ≥º backward tracingÏóê ÎåÄÌïú Î™®Îç∏ ÎÖºÎ¨∏ÏùÑ ÏùΩÏóàÎã§. Ïù¥Îü∞ ÏßÄÏãùÏÉùÏÇ∞Ïù¥ ÌïúÍµ≠ÏóêÏÑúÎèÑ Ïù¥Î§ÑÏ°åÏúºÎ©¥ Ï¢ãÍ≤†Îã§. ÌïúÍµ≠Ïñ∏Î°† ÎÇòÎ¶Ñ Í¥ÄÏã¨ÏûàÍ≤å Î≥¥ÎäîÎç∞ ÎÑàÎ¨¥ Í∏∞Ï¥àÏ≤¥‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@nobody_indepth,Adam KucharskiÍ∑∏Î£πÏùò ÏµúÍ∑º OverdispersionÍ≥º backward tracingÏóê ÎåÄÌïú Î™®Îç∏ ÎÖºÎ¨∏ÏùÑ ÏùΩÏóàÎã§. Ïù¥Îü∞ ÏßÄÏãùÏÉùÏÇ∞Ïù¥ ÌïúÍµ≠ÏóêÏÑúÎèÑ Ïù¥Î§ÑÏ°åÏúºÎ©¥ Ï¢ãÍ≤†Îã§. ÌïúÍµ≠Ïñ∏Î°† ÎÇòÎ¶Ñ Í¥ÄÏã¨ÏûàÍ≤å Î≥¥ÎäîÎç∞ ÎÑàÎ¨¥ Í∏∞Ï¥àÏ≤¥Î†•Ïù¥ Ïó¨Îü¨ Ï∏°Î©¥ÏóêÏÑú Î∂ÄÏã§ÌïòÎã§.. https://t.co/i7brhNjSMm
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@HollyBlomberg,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@davidto302,RT @isabelrodbar: Sobre la estrategia de rastreo retrospectivo de Jap√≥n y por qu√© podr√≠a ser eficiente y complementar al rastreo prospectiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@nataliamataON,"RT @kikollan: Muy interesante esto sobre rastreo de clusters (backward/forward tracing), y un tema del que hablamos creo que poco en Espa√±a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AnnaGar22274534,"RT @lipido: Jap√≥n traza contactos tambi√©n hacia atr√°s, no s√≥lo hacia adelante. No s√≥lo investiga a qui√©n pudiste contagiar t√∫ (adelante), s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@miqme,RT @SEIMC_: Algunas estrategias de #rastreo pueden incrementar significativamente (hasta el doble) el n√∫mero de contactos positivos. Este h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Tambopaxi,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@EstebanOrtizMD,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Mh5fjg,RT @SEIMC_: Algunas estrategias de #rastreo pueden incrementar significativamente (hasta el doble) el n√∫mero de contactos positivos. Este h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@c_groetzner,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Wer_Ich_Bin,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Zentenario1,RT @SEIMC_: Algunas estrategias de #rastreo pueden incrementar significativamente (hasta el doble) el n√∫mero de contactos positivos. Este h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Zentenario1,RT @vbaosv: @_miriku_ Habl√°bamos el otro d√≠a de esto.
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@vbaosv,@_miriku_ Habl√°bamos el otro d√≠a de esto.
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@SEIMC_,Algunas estrategias de #rastreo pueden incrementar significativamente (hasta el doble) el n√∫mero de contactos positivos. Este hilo trata de explicarlo  https://t.co/haQsFvmW73 #Covid_19
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@felly500,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@andrewleedr,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@FluScim,"A ver si lo entiendo: puedes ver los contactos directos de tu caso... y luego, posiblemente con otro equipo, ¬øa los contactos comunes de los contactos directos? ¬øTriangular para ver los epicentros? Por favor que alguien me lo confirme. Dice que 2x mejor. ¬ø"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AdelinaCoHe,"RT @EdMHill: The number of onward transmissions of SARS-CoV-2 is highly variable. A preprint by @_akiraendo, @sbfnk, @AdamJKucharski et al‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@josefineb7,F√ºr ich der erste n√ºtzliche Politiker: @Karl_Lauterbach
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@EnrikeLopez,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@EnrikeLopez,"RT @kikollan: Muy interesante esto sobre rastreo de clusters (backward/forward tracing), y un tema del que hablamos creo que poco en Espa√±a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Mar_Leza_Salord,"RT @1000genes: En Jap√≥n, para detectar supercontagiadores y fuentes comunes de contagio, rastrean en retrospectiva y no solamente a los con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@CoViDVincitAmor,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Telasa2,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@medienbotschaft,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Domecevallos92,Rastreo prospectivo y rastreo retrospectivo üëÄ
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AkiOno67,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Alifmaksoura,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@panteon_college,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@tharwan,"RT @friiyo: Wahrscheinlich gibt's in Japan einen Arzt und Politiker, der dort den deutschen Weg preist.  https://t.co/NygQpJ2jIN https://t.‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@AngelikaGabor,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@ibnkafka,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@ricardoq0101,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@alfredfischer17,You can have lockdown without lockdown with this strategy.   #COVID19 #COVID #coronavirus #SARSCoV2 #pandemic #virology #epidemiology #sciencetwitter   Strategy from Japan here to read.  https://t.co/UMjICfdMDt
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@mariavhaperen,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Blauer_Sauser,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@saba0078,RT @flurry: ÂæåÂêë„Åç„ÅÆÊé•Ëß¶ËÄÖË™øÊüª„Å®„Å™„ÄÇKucharski„ÅÆ„ÉÅ„Éº„É†„Åß„Éï„Ç°„Éº„Çπ„Éà„Ç™„Éº„Çµ„Éº„ÅØÊó•Êú¨‰∫∫„ÅÆ„Åã„Åü„ÅÆ„Çà„ÅÜ„Å†„ÄÇ Ôºû  Implication of backward contact tracing in the presence of overdispersed tra‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@FabulousSunshi3,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@LudwigOssiander,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@solsilvanazb,RT @isabelrodbar: Sobre la estrategia de rastreo retrospectivo de Jap√≥n y por qu√© podr√≠a ser eficiente y complementar al rastreo prospectiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Leonislionheart,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@felicitas_pat,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@BADMOSQUAD,"Also viele arbeiten, wenige profitieren... mega Idee"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Chri_Sanders,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@FritzQuincke,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@Michael10415865,"RT @Karl_Lauterbach: (1) F√ºr jeden, der sich mit der von @c_drosten und auch von mir vorgeschlagenen retrospektiven japanischen Clusterstra‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@twremcat,RT @flurry: ÂæåÂêë„Åç„ÅÆÊé•Ëß¶ËÄÖË™øÊüª„Å®„Å™„ÄÇKucharski„ÅÆ„ÉÅ„Éº„É†„Åß„Éï„Ç°„Éº„Çπ„Éà„Ç™„Éº„Çµ„Éº„ÅØÊó•Êú¨‰∫∫„ÅÆ„Åã„Åü„ÅÆ„Çà„ÅÜ„Å†„ÄÇ Ôºû  Implication of backward contact tracing in the presence of overdispersed tra‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166595,Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak,@p_koehler,RT @AdamJKucharski: A key feature of response in Japan (https://t.co/mE7c0u7GUA) and Korea (https://t.co/QDv8nXMiD6) has been cluster inves‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166546,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity,@outbreaksci,"Contribute a rapid review or request one for ""Analytical and clinical performances of five immunoassays for the detection of SARS-Co..."" (https://t.co/tNlJwXnwDF). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166546) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20166546,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity,@outbreaksci,New #SARSCoV preprint: Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity https://t.co/tNlJwXnwDF
http://medrxiv.org/cgi/content/short/2020.08.01.20166546,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity,@medrxivpreprint,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity  https://t.co/USLdJVSYsk #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167056,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China,@drdrtsai,RT @harlingg: New preprint showing post #Covid19 lockdown social interaction in China: a slight bounceback but still much ‚¨áÔ∏èpre-Covid. Even‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.03.20167056,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China,@harlingg,"New preprint showing post #Covid19 lockdown social interaction in China: a slight bounceback but still much ‚¨áÔ∏èpre-Covid. Even w/o enforcement, contact patterns have changed medium (long?) term  Led by Juanjuan Zhang w/ @marcoajelli @alexvespi ++  https://t"
http://medrxiv.org/cgi/content/short/2020.08.03.20167056,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China,@outbreaksci,"Contribute a rapid review or request one for ""The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmis..."" (https://t.co/6mrWR8XBEl). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.20167056) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.03.20167056,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China,@outbreaksci,New #SARSCoV preprint: The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China https://t.co/6mrWR8XBEl
http://medrxiv.org/cgi/content/short/2020.08.03.20167056,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China,@medrxivpreprint,The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China  https://t.co/udfQwRaOQF #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166256,Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan,@outbreaksci,"Contribute a rapid review or request one for ""Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the..."" (https://t.co/XYv1TmrCSy). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166256) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.02.20166256,Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan,@outbreaksci,New #SARSCoV preprint: Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan https://t.co/XYv1TmrCSy
http://medrxiv.org/cgi/content/short/2020.08.02.20166256,Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan,@phil_w888,"712/  Japan (adult smoking rate was 18.2% in 2016)  Of 130 patients, 46.9% had a history of smoking  Of 32 with severe cases, 56.3% had a history of smoking  https://t.co/QvmsxD7D1S"
http://medrxiv.org/cgi/content/short/2020.08.02.20166256,Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan,@medrxivpreprint,Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan  https://t.co/KeFCStQBQD #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.03.20167320,Retrospective SARS-CoV-2 Real-Time PCR Testing of Stored Bronchoalveolar Lavage Samples from February 2020,@gerdosi,@WillowWyse @FatEmperor @RossjournoClark @carlheneghan RT-PCR false positives (at 1-2 %) are lower than false negatives. This is not a political question. Some claim that false positives are at least 20 %. Where are those positives in restrospective studie
http://medrxiv.org/cgi/content/short/2020.08.03.20167320,Retrospective SARS-CoV-2 Real-Time PCR Testing of Stored Bronchoalveolar Lavage Samples from February 2020,@gerdosi,"@LibertadCami @daniellevitt22 @FatEmperor I‚Äôm wondering how restrospective sample analyses can yield zero positives if false positive rate of the RT-PCR  method is at least 20 %? Out of 34 samples that should be 7 positives or more, shouldn‚Äôt it? https://t"
http://medrxiv.org/cgi/content/short/2020.08.03.20167320,Retrospective SARS-CoV-2 Real-Time PCR Testing of Stored Bronchoalveolar Lavage Samples from February 2020,@SciscoreReports,The paper ‚ÄúRetrospective SARS-CoV-2 Real-Time PCR Testing of...‚Äù (https://t.co/YDM1XNLep3) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/0BlunV5hZJ. We detected 1 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.03.20167320,Retrospective SARS-CoV-2 Real-Time PCR Testing of Stored Bronchoalveolar Lavage Samples from February 2020,@medrxivpreprint,Retrospective SARS-CoV-2 Real-Time PCR Testing of Stored Bronchoalveolar Lavage Samples from February 2020  https://t.co/Bw0xEQmo0t #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166371,Outcome of COVID-19 with co-existing surgical emergencies in children: our initial experiences and recommendations,@COVID_Papers,üìù Outcome of COVID-19 with co-existing surgical emergencies in children: our initial experiences and recommendations  medRxiv or bioRxiv https://t.co/UL6t6xZkDl #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.01.20166371,Outcome of COVID-19 with co-existing surgical emergencies in children: our initial experiences and recommendations,@medrxivpreprint,Outcome of COVID-19 with co-existing surgical emergencies in children: our initial experiences and recommendations  https://t.co/hEII8gxTZg #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166710,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,@futurepundit,The longer you delay getting infected the better the treatments will get.
http://medrxiv.org/cgi/content/short/2020.08.02.20166710,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,@MedicalScitech,üí°@zaiapresidente: ¬´Banca del sangue dei malati #COVID19 guariti¬ª. Curati i primi 12 pazienti (7 maggio 2020) https://t.co/hw9buvwVOf https://t.co/I25MSkk6LS https://t.co/7kvZmhTiuW
http://medrxiv.org/cgi/content/short/2020.08.02.20166710,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,@MedicalScitech,"üíØEffectiveness of #ConvalescentPlasma for Treatment of #COVID19 Patients ¬ª https://t.co/H92YoboFBZ Viral NAA test of most patients with COVID-19 who received #CP transfusion turned negative on the 2nd to 8th days after transfusion, shorter than that of cri"
http://medrxiv.org/cgi/content/short/2020.08.02.20166710,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,@Mourad86824575,Convalescent plasma has been shown effective in shortening the time to RTPCR test turning negative and lowering inflammatory markers (CRP and others). https://t.co/vVZhIQbQHH
http://medrxiv.org/cgi/content/short/2020.08.02.20166710,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,@COVID_Papers,üìù Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients  medRxiv or bioRxiv https://t.co/GKrvVzYBUF #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.02.20166710,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients,@medrxivpreprint,Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients  https://t.co/q23CBvxPSd #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@ElmerEdward1,RT @PandemicCovid20: Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19 - https://t.co/bVkLlYoUNQ
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@LaTavernaCabo,@doctormacias @YouTube Es este: https://t.co/l6yAR37ymN
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@stefan_arrr,RT @medrxivpreprint: Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19  https://t.co/SRVrPxgo72 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@futurepundit,They say:  Experimental results demonstrate that the filtration efficacy of cloth masks with either a light or heavy starch can approach the performance of much costlier masks.
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@Georgiemutt,RT @PandemicCovid20: Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19 - https://t.co/bVkLlYoUNQ
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@RonChusid,RT @PandemicCovid20: Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19 - https://t.co/bVkLlYoUNQ
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@LaTavernaCabo,RT @PandemicCovid20: Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19 - https://t.co/bVkLlYoUNQ
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@PandemicCovid20,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19 - https://t.co/bVkLlYoUNQ
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@alfonso_casi,Mejora de bajo coste de la filtraci√≥n de la mascarilla para prevenir la transmisi√≥n de COVID-19: La eficacia de filtraci√≥n de las mascarillas de tela con almid√≥n pueden aproximarse al rendimiento de las mascarillas mucho m√°s costosas. https://t.co/Q7YagH02
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@SciscoreReports,The paper ‚ÄúLow-Cost Enhancement of Facial Mask Filtration to...‚Äù (https://t.co/TkGYwKMrpt) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/LxGnkR891c. We detected 1 key resource.
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@MedicalScitech,üíØLow-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of #COVID19 ¬ª https://t.co/gNt3EwQPYV Experimental results demonstrate that the filtration efficacy of #clothmasks with either a light or heavy starch can approach the performance of m
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@COVID_Papers,üìù Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19  medRxiv or bioRxiv https://t.co/4CQPb5btVb #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.01.20166637,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19,@medrxivpreprint,Low-Cost Enhancement of Facial Mask Filtration to Prevent Transmission of COVID-19  https://t.co/SRVrPxgo72 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20160077,Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study,@SciscoreReports,The paper ‚ÄúImpact of COVID-19 mitigation measures on the inci...‚Äù (https://t.co/H7CduyOBHm) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/G1FkwcixeU. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.08.01.20160077,Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study,@VWVJaddoe,COVID-19 mitigation measures and lower incidence of preterm birth in the Netherlands. ‚Å¶@JasperBeen‚Å© @IKMReiss‚Å© ‚Å¶@ErasmusMC‚Å© https://t.co/ISB9N57bxI
http://medrxiv.org/cgi/content/short/2020.08.01.20160077,Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study,@COVID_Papers,üìù Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study  medRxiv or bioRxiv https://t.co/5hCCqo8Jl4 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.08.01.20160077,Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study,@medrxivpreprint,Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study  https://t.co/by46VOs6Wm #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20143016,The characteristics of multi-source mobility datasets and how they reveal the luxury nature of social distancing in the U.S. during the COVID-19 pandemic,@medrxivpreprint,The characteristics of multi-source mobility datasets and how they reveal the luxury nature of social distancing in the U.S. during the COVID-19 pandemic  https://t.co/a9napuKHvI #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@ivantzv,Una verg√ºenza que  @SSalud_mx  todav√≠a cuestione el uso de mascarillas. Ac√° üëá un meta-estudio de RCTs. Resultado: Las mascarillas disminuyeron las infecciones en TODOS los estudios durante el seguimiento m√°ximo !!! √ösenla amigos üò∑ #COVID19 https://t.co/Vx
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@vrsimility,@StephenBDugmore @daniellevitt22 https://t.co/NbXzqE5BCF
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@ElmerEdward1,RT @PandemicCovid20: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials - https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@vrsimility,@ClarkeMicah @ret_ward https://t.co/vcqtofFeLy
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@HPegliasco,RT @PandemicCovid20: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials - https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CookaName,@Laurie_Garrett https://t.co/mocN0BpSjW
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@c4lidor3,RT @PandemicCovid20: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials - https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@AntiAgify,RT @PandemicCovid20: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials - https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CookaName,@joncoopertweets https://t.co/mocN0BpSjW
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CookaName,@nytimes https://t.co/mocN0BpSjW
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CookaName,@DirkSchwenk https://t.co/mocN0BpSjW
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CookaName,@RepJeffries https://t.co/mocN0BpSjW
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@StacyMatson333,RT @PandemicCovid20: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials - https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CookaName,https://t.co/mocN0BpSjW
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@PandemicCovid20,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials - https://t.co/qHpwRwHWZv
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@Nela_Polanska,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@JPrzystajko,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@FluScim,RT @SciArt3D: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials | medRxiv https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@PIPSQC,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@KrzysztofLanda,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@t_macher,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@karolpoznanski,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@mgrMilos,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@kris_skorupski,RT @Kto72102356: Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@Kto72102356,"Maski na twarz chroniƒÖ populacje przed infekcjami i nie stanowiƒÖ znaczƒÖcego zagro≈ºenia dla u≈ºytkownik√≥w. Nale≈ºy przedstawiƒá zalecenia i jasnƒÖ komunikacjƒô na temat zalet masek na twarz, aby ograniczyƒá liczbƒô COVID-19 i innych infekcji dr√≥g oddechowych.   ht"
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@nextgenseek,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@eroonkoronasta,"RT @outbreaksci: Contribute a rapid review or request one for ""Face masks prevent transmission of respiratory diseases: a meta-analysis of‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@outbreaksci,New #SARSCoV preprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials https://t.co/Zn1qgEDrKn
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@outbreaksci,"Contribute a rapid review or request one for ""Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized..."" (https://t.co/Zn1qgEDrKn). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20166116) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@outbreaksci,New #COVID19 preprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials https://t.co/Zn1qgEDrKn
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@BarreiroDr,RT @alfonso_casi: Las mascarillas evitan la transmisi√≥n de enfermedades respiratorias. De acuerdo a este metan√°lisis de ensayos controlados‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@alfonso_casi,"Las mascarillas evitan la transmisi√≥n de enfermedades respiratorias. De acuerdo a este metan√°lisis de ensayos controlados aleatorios, las mascarillas protegen a la poblaci√≥n de las infecciones y no representan un riesgo significativo para los usuarios. htt"
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@ajv67,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@CHOMES102,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@vrsimility,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@SciArt3D,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials | medRxiv https://t.co/sRmQjy0B59
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@AngelAzpeitia,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@gk_murray,RT @medrxivpreprint: Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@SvjatoslavG,"""Our results show that face masks protect populations from infections and do not pose a significant risk to users. Recommendations and clear communication concerning the benefits of face masks should be provided to limit the number of COVID-19 and other re"
http://medrxiv.org/cgi/content/short/2020.07.31.20166116,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials,@medrxivpreprint,Face masks prevent transmission of respiratory diseases: a meta-analysis of randomized controlled trials  https://t.co/IarZE0X7XA #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166348,Containing the Spread of Infectious Disease on College Campuses,@Lupo72301428,RT @medrxivpreprint: Containing the Spread of Infectious Disease on College Campuses  https://t.co/T3zAZKoWft #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166348,Containing the Spread of Infectious Disease on College Campuses,@medrxivpreprint,Containing the Spread of Infectious Disease on College Campuses  https://t.co/T3zAZKoWft #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@arnthorjon,"@mverbora This paper estimates median R0 = 5,8. Which means heard immunity achieved at ca 1 - 1/5,8 = 82,7%. https://t.co/CIyJuw1L2a"
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@ElmerEdward1,RT @PandemicCovid20: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@HPegliasco,RT @PandemicCovid20: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@AlexiaP03759306,RT @SmartFlightInfo: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@ke_lab,RT @medrxivpreprint: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@unique_anonym,RT @PandemicCovid20: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@kerkozer,RT @PandemicCovid20: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@PandemicCovid20,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination - https://t.co/31xUnWsKhp
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@AeroMedicine,RT @SmartFlightInfo: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@SciscoreReports,The paper ‚ÄúEstimating the reproductive number R0 of SARS-CoV-...‚Äù (https://t.co/RivKdBsHY8) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/5CmOTMSk0v. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@thomas_dava,RT @CarlosdelRio7: Estimating the R0 of #SARSCoV2 in the US and eight European countries and implications for vaccination | ‚Å¶@medrxivprepri‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@SmartFlightInfo,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. #SARSCoV2 #coronavirus #COVID19 #pandemic #vaccines https://t.co/JDGe8CTdHe
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@Dr_Tomubb,RT @CarlosdelRio7: Estimating the R0 of #SARSCoV2 in the US and eight European countries and implications for vaccination | ‚Å¶@medrxivprepri‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@DancyGeorgia,RT @CarlosdelRio7: Estimating the R0 of #SARSCoV2 in the US and eight European countries and implications for vaccination | ‚Å¶@medrxivprepri‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@CarlosdelRio7,"Estimating the R0 of #SARSCoV2 in the US and eight European countries and implications for vaccination | ‚Å¶@medrxivpreprint‚Å© Herd immunity threshold estimated ~ 73-84%, which would require mass vaccination campaigns multiple times a year.  https://t.co/Seut"
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@outbreaksci,"Contribute a rapid review or request one for ""Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight Eur..."" (https://t.co/8X5yLrnkIZ). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20166298) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@outbreaksci,New #SARSCoV preprint: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination https://t.co/8X5yLrnkIZ
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@Mourad86824575,Reproductive number R0 for #COVID19 in the US and eight EU countries.  https://t.co/BdmbstBH6L
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@Lupo72301428,RT @medrxivpreprint: Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166298,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination,@medrxivpreprint,Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination  https://t.co/N3L3DqNyaE #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@salcoleaf,"Tiempo de incubaci√≥n del s√≠ndrome respiratorio agudo severo X Covid: esta revisi√≥n sistem√°tica estima, para percentil 97,5, 19,2 d√≠as (IC 95%: 17,4-21,4), + all√° d los 14 d√≠as actualmente sugeridos d cuarentena.E preimpresi√≥n pendiente de revisi√≥n x pares"
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@alfonso_casi,"El per√≠odo de incubaci√≥n del s√≠ndrome respiratorio agudo severo Coronavirus 2: esta revisi√≥n sistem√°tica estima, para el percentil 97,5, 19,2 d√≠as (IC 95%: 17,4-21,4), m√°s all√° de los 14 d√≠as actualmente sugeridos para el per√≠odo de cuarentena. https://t.c"
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@SciscoreReports,The paper ‚ÄúThe Incubation Period of Severe Acute Respiratory...‚Äù (https://t.co/Xi5r19XR3T) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/gLRQzPsU3t. We detected 0 of 5 rigor criteria and 0 key resources.
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@EvidenceRobot,RT @outbreaksci: New #COVID19 preprint: The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@outbreaksci,"Contribute a rapid review or request one for ""The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic ..."" (https://t.co/LaeY8uxvtF). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20164335) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@outbreaksci,New #COVID19 preprint: The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review https://t.co/LaeY8uxvtF
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@MedicalScitech,"üí°The inclusion of #ASYMPTOMATIC and #presymptomatic patients, as well as cases with incubation periods exceeding 14 days, led to an estimation of 97.5th percentile with 19.2 days (95% CI: 17.4-21.4) beyond the currently suggested 14-day quarantine period."
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@MedicalScitech,"The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review ¬ª https://t.co/3wETVpdyrh Appeal to prolong the quarantine duration, especially for areas that have insufficient testing resources, to protect susceptible populati"
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@kumasanhome,RT @medrxivpreprint: The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review  https://t.co/IvJv23nzQt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@ajv67,RT @medrxivpreprint: The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review  https://t.co/IvJv23nzQt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@CHOMES102,RT @medrxivpreprint: The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review  https://t.co/IvJv23nzQt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@SvjatoslavG,"@Maggie_DeBlock ""... led to our estimation of 97.5th percentile with 19.2 days.., beyond the currently suggested 14-day quarantine period. Therefore, we appeal to prolong the quarantine duration, especially for areas that have insufficient testing resource"
http://medrxiv.org/cgi/content/short/2020.08.01.20164335,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review,@medrxivpreprint,The Incubation Period of Severe Acute Respiratory Syndrome Coronavirus 2:A Systematic Review  https://t.co/IvJv23nzQt #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20165142,A variational model for computing the effective reproduction number of SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""A variational model for computing the effective reproduction number of SARS-CoV-2"" (https://t.co/Vw0kbGndWh). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20165142) at https://t.co/RnurTL3DyM @outbreaksci @PREr"
http://medrxiv.org/cgi/content/short/2020.08.01.20165142,A variational model for computing the effective reproduction number of SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: A variational model for computing the effective reproduction number of SARS-CoV-2 https://t.co/Vw0kbGndWh
http://medrxiv.org/cgi/content/short/2020.08.01.20165142,A variational model for computing the effective reproduction number of SARS-CoV-2,@medrxivpreprint,A variational model for computing the effective reproduction number of SARS-CoV-2  https://t.co/IZoedcNeIx #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.02.20166504,Epidemiological characteristics of SARS-COV-2 in Myanmar,@KyawMTun,Epidemiological characteristics of SARS-CoV-2 in Myanmar https://t.co/98ZWuvg1u6
http://medrxiv.org/cgi/content/short/2020.08.02.20166504,Epidemiological characteristics of SARS-COV-2 in Myanmar,@KyawMTun,RT @outbreaksci: New #COVID19 preprint: Epidemiological characteristics of SARS-COV-2 in Myanmar https://t.co/Y7EWPE5JAI
http://medrxiv.org/cgi/content/short/2020.08.02.20166504,Epidemiological characteristics of SARS-COV-2 in Myanmar,@outbreaksci,New #SARSCoV preprint: Epidemiological characteristics of SARS-COV-2 in Myanmar https://t.co/Y7EWPE5JAI
http://medrxiv.org/cgi/content/short/2020.08.02.20166504,Epidemiological characteristics of SARS-COV-2 in Myanmar,@outbreaksci,"Contribute a rapid review or request one for ""Epidemiological characteristics of SARS-COV-2 in Myanmar"" (https://t.co/Y7EWPE5JAI). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.20166504) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.08.02.20166504,Epidemiological characteristics of SARS-COV-2 in Myanmar,@outbreaksci,New #COVID19 preprint: Epidemiological characteristics of SARS-COV-2 in Myanmar https://t.co/Y7EWPE5JAI
http://medrxiv.org/cgi/content/short/2020.08.02.20166504,Epidemiological characteristics of SARS-COV-2 in Myanmar,@medrxivpreprint,Epidemiological characteristics of SARS-COV-2 in Myanmar  https://t.co/qOcRV5Yjl4 #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@peymvn,"RT @ASofiMahmudi: In this infosurveillance study, we found out that online searches for ‚Äútoothache‚Äù have increased during #COVID19 lockdown‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@ASofiMahmudi,RT @peymvn: My first collaboration with a great team of dentistry researchers.
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@peymvn,My first collaboration with a great team of dentistry researchers.
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@choxos,"RT @ASofiMahmudi: In this infosurveillance study, we found out that online searches for ‚Äútoothache‚Äù have increased during #COVID19 lockdown‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@ASofiMahmudi,"In this infosurveillance study, we found out that online searches for ‚Äútoothache‚Äù have increased during #COVID19 lockdowns compared to the similar periods in the past four years."
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@ASofiMahmudi,RT @medrxivpreprint: The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@SpireSec,Can't decide if these guys are hilarious or the joke's on them...
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@choxos,RT @medrxivpreprint: The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends  https://t.co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20157065,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends,@medrxivpreprint,The association between COVID-19-imposed lockdowns and online searches for toothache using Google Trends  https://t.co/zko5SF3ZHI #medRxiv
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@_stah,@youyanggu @alchemytoday @Fyodor32768 @Aintropy @EricTopol @Noahpinion @florian_krammer Didn't find his original - it is a different preprint with the same result - he has commentary in his thread. https://t.co/q0p8egzing
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@rkdoctr,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@amaury,"@couleurkf Bon bein je le retrouve plus :|   j'ai juste sauv√© un papier qui √©tait li√©, y'en avait un autre... :/   https://t.co/56GB6vPOEF"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@kevinpurcell,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@nbcc_ltri,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Erth53,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@EIEarIyBird,RT @jbloom_lab: ... titers in months following recovery and (in our reading) they all come to pretty much conclusions described above. See‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@lala_anela,"@bonerkuwanger @GregFromBallard @DanielleMuscato @kroger There are many studies, you can find them, here is one. https://t.co/5JlR1NGt6a"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jbloom_lab,"@gingraslab1 @khdcrawford @HelenChuMD Same to you on your recent study (https://t.co/oCLXNUSBxs). We liked it, and your study made us more confident in the IgG versus IgA results we saw, since your comparison showing greater IgG than IgA durability was a l"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@drng,RT @jbloom_lab: ... titers in months following recovery and (in our reading) they all come to pretty much conclusions described above. See‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@arttzaddikim,RT @jbloom_lab: ... titers in months following recovery and (in our reading) they all come to pretty much conclusions described above. See‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@ImmunoFever,RT @jbloom_lab: ... titers in months following recovery and (in our reading) they all come to pretty much conclusions described above. See‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jbloom_lab,... titers in months following recovery and (in our reading) they all come to pretty much conclusions described above. See also: (9/9) https://t.co/ng3SskJCij https://t.co/reKdO0EuNW https://t.co/oCLXNUSBxs https://t.co/PN04MKhKgx https://t.co/aLzz6ZF7MO h
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@KathyDMcCoy,RT @JenGommerman: Thank you Florian!
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@IchBinDynamis,RT @Virologist13: ÿ≠ÿ∂Ÿàÿ± ÿ¢ŸÜÿ™€å ÿ®ÿßÿØ€å ÿØÿ± ÿ≠ŸÅÿ±Ÿá ÿØŸáÿßŸÜ€å ŸÖŸÖ⁄©ŸÜŸá ÿØÿ± ÿ≥€åÿ± ÿ®€åŸÖÿßÿ±€å ⁄©ÿ±ŸàŸÜÿß ŸÖŸáŸÖ ÿ®ÿßÿ¥Ÿá(ÿ®ÿß ÿ™Ÿàÿ¨Ÿá ÿ®Ÿá ÿ™⁄©ÿ´€åÿ± ÿßŸàŸÑ€åŸá Ÿà€åÿ±Ÿàÿ≥ ÿØÿ± ⁄ØŸÑŸà Ÿà ÿ®€åŸÜ€å) ŸÖ€åÿ≤ÿßŸÜ ÿ¢ŸÜÿ™€å‚Äåÿ®ÿß‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@BO3dsmcadQRIirG,RT @Virologist13: ÿ≠ÿ∂Ÿàÿ± ÿ¢ŸÜÿ™€å ÿ®ÿßÿØ€å ÿØÿ± ÿ≠ŸÅÿ±Ÿá ÿØŸáÿßŸÜ€å ŸÖŸÖ⁄©ŸÜŸá ÿØÿ± ÿ≥€åÿ± ÿ®€åŸÖÿßÿ±€å ⁄©ÿ±ŸàŸÜÿß ŸÖŸáŸÖ ÿ®ÿßÿ¥Ÿá(ÿ®ÿß ÿ™Ÿàÿ¨Ÿá ÿ®Ÿá ÿ™⁄©ÿ´€åÿ± ÿßŸàŸÑ€åŸá Ÿà€åÿ±Ÿàÿ≥ ÿØÿ± ⁄ØŸÑŸà Ÿà ÿ®€åŸÜ€å) ŸÖ€åÿ≤ÿßŸÜ ÿ¢ŸÜÿ™€å‚Äåÿ®ÿß‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@KatarinaJenko,"RT @rjerala: Kanadski znanstveniki poroƒçajo, da so protitelesa IgG proti proteinu S in RBD, s katerim se virus pritrdi na celice, ostala st‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@SciscoreReports,The paper ‚ÄúEvidence for sustained mucosal and systemic antibo...‚Äù (https://t.co/9aUz1dLFiB) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Iz8WOWOgGl. We detected 1 of 6 rigor criteria and 21 key resource
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@NGR69575822,RT @thelonevirologi: Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@masseyranch,RT @erin_VMD: #epitwitter
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@epi_twit,RT @erin_VMD: #epitwitter https://t.co/dVpNPtKH3n
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@YaneValdezT,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@erin_VMD,#epitwitter
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@RamagliaV,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@RamagliaV,RT @JenGommerman: This thread below...@gingraslab has described this study perfectly. So great working with her team and that of the other‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@suzecresswell,"RT @Infiltraiter: @jwadders40 @ProfKarolSikora No reinfections to date, which is consistent with emerging studies eg https://t.co/l7eYbHdc0‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@NyakwarArowo,Another interesting insightful preprint:   Anti-Cov-2 antibodies peak levels detected at 16-30 days post-symptomatic onset..these were stable for slightly over 100 days... https://t.co/PHqLbXCEhj
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@mjcreid,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@neil_bodie,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Ji_young_Youn,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@tanvirahman,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Furry_Fairy,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@sdelagrave,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@LizSzabo,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@mac_fionn,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@PicornavirusB,RT @thelonevirologi: Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@RhonaRaskin,"""Importantly, IgG responses in saliva and serum were correlated, suggesting that antibodies in the saliva may serve as a surrogate measure of systemic immunity."""
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@leslieasheppard,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@MAMdayIndayOut,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@F1cyclist,RT @JenGommerman: Thank you Florian!
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@BankoFranci,"RT @rjerala: Kanadski znanstveniki poroƒçajo, da so protitelesa IgG proti proteinu S in RBD, s katerim se virus pritrdi na celice, ostala st‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Laeeth,RT @Barton_options: pretty encouraging results from UToronto on COVID19 IgG/IgA antibody longevity.   Looks like 80% of the people includin‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@breakliquid,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@virology_chitra,RT @thelonevirologi: Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@EpelmanLab,RT @JenGommerman: Thank you Florian! https://t.co/QAWm5qGJ9X
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@vlah58,"RT @rjerala: Kanadski znanstveniki poroƒçajo, da so protitelesa IgG proti proteinu S in RBD, s katerim se virus pritrdi na celice, ostala st‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@simonpeyda,"TL;DR ""anti-CoV-2 IgA antibodies (Ab) rapidly decayed, IgG Ab remained relatively stable up to 115 days PSO in both biofluids. Importantly, IgG responses in saliva and serum were correlated, suggesting that Ab in the saliva may serve as a surrogate measure"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@mariouneinparis,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Michael91693258,RT @thelonevirologi: Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@milenaac,RT @thelonevirologi: Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@DrMFKearney,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@starfouine,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jbloom_lab,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@QuimSegales,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@JaberiSaja,RT @AntibioticDoc: Antibody levels: remember that decline doesn‚Äôt mean people ‚Äúlose immunity‚Äù per se.  Memory B cell and CTL response may h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Inmuno_UB,RT @mafranco123: https://t.co/GgyO9jjrkz  Olga Luc√≠a Rojas Coautora de importante art√≠culo de inmunidad  de la mucosa a SARS-CoV-2
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Winser_NBueno,"Respuestas sostenidas de anticuerpos mucosos y sist√©micos a ant√≠genos de #SARSCoV2 en pacientes con COVID-19. Ensayos para determinar igA e igG contra la prote√≠na del pico del virus y su dominio (RBD). En @medrxivpreprint, trabajo muy bien hecho. https://t"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@HansAcha,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@stewak2,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@davecoghlan,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@JuanMAnayaC,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@nataliadg,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@PharmactDE,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Bubblechuck,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@BJ_Dyakov,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@wootangcreates,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@InnatOss,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@microbe_to,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@BendingLab,More evidence for sustained IgG responses (up to 115 days) in covid-19 patients. Interestingly levels in saliva and serum correlate https://t.co/B8BkRKnewG
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@seth_edmunds,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@BendingLab,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@fred_mg,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@evolv67,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@mejia_bf,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jbkrell,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jokerstanley1,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@gabydel,RT @mafranco123: https://t.co/GgyO9jjrkz  Olga Luc√≠a Rojas Coautora de importante art√≠culo de inmunidad  de la mucosa a SARS-CoV-2
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jwgale,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Decentarian,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Michael37823933,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients https://t.co/wlHn8DzMmI
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Garzon_Hoy,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@AMAinsight,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@jorgegomezmarin,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@ignacio47566084,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@angepalencia,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@ZulmaCucunuba,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@outbreaksci,"Contribute a rapid review or request one for ""Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens ..."" (https://t.co/n1jMhROd72). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166553) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@outbreaksci,New #SARSCoV preprint: Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients https://t.co/n1jMhROd72
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@inmunoacoi,RT @mafranco123: https://t.co/GgyO9jjrkz  Olga Luc√≠a Rojas Coautora de importante art√≠culo de inmunidad  de la mucosa a SARS-CoV-2
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@GeneticaPUJ,RT @mafranco123: https://t.co/GgyO9jjrkz  Olga Luc√≠a Rojas Coautora de importante art√≠culo de inmunidad  de la mucosa a SARS-CoV-2
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@UofTPRiME,"RT @gingraslab1: Our manuscript with @JenGommerman, Allison McGeer and many colleagues describing mucosal and systemic antibody responses t‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@iic_a,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@ProfPaulYoung,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@a_husby,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Infiltraiter,"@jwadders40 @ProfKarolSikora No reinfections to date, which is consistent with emerging studies eg https://t.co/l7eYbHdc0h at least 115days here plus positive news from mucosal detection"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@embalaza,"RT @rjerala: Kanadski znanstveniki poroƒçajo, da so protitelesa IgG proti proteinu S in RBD, s katerim se virus pritrdi na celice, ostala st‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@Sarita1110,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@immunoJo,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@eladgil,"RT @florian_krammer: Another outstanding preprint on antibody longevity for SARS-CoV-2, this time from Toronto from the @JenGommerman and @‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.08.01.20166553,Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients,@InfoZdravstvena,"RT @rjerala: Kanadski znanstveniki poroƒçajo, da so protitelesa IgG proti proteinu S in RBD, s katerim se virus pritrdi na celice, ostala st‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@MillieFiore,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@Richard_Linear,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@wigmore_hall,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@kieranjones123,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@andrewteale,Now we need something like this for woodwind https://t.co/OuFL4N3Mwu
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@cohnkaren,RT @jljcolorado: @ShellyMBoulder
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@SiccoVanHoegee,RT @jljcolorado: @ShellyMBoulder https://t.co/dz7THB36Pk
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@jljcolorado,@ShellyMBoulder
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@SiccoVanHoegee,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@StegsHorn,This follows on from the research from Brass Bands England. Both to still be peer reviewed but looking very positive. https://t.co/8HuuSzN1kF Can you make one for French horns that we can put our hand through? @brasspasstv
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@majorii,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@ECPrice222,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@Babby_Gee,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@dahlhaus,Ïã§Ï†ú ÎÖºÎ¨∏: https://t.co/Cxibm0dGYx
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@6MilesTall,ü¶†üé∫  Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19 | medRxiv https://t.co/gj1jUnIp1F
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@rosemary,Brass players ‚Äî >>
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@CamJazzChoir,RT @M_Castelletti: A set of investigations into the release of respiratory aerosols by brass instruments @BrassBandsEng @medrxivpreprint  R‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@FulhamSO,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@CumbriaMusicHub,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@KlockworksKate,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@PlymouthMEH,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@ModalMusic,RT @M_Castelletti: A set of investigations into the release of respiratory aerosols by brass instruments @BrassBandsEng @medrxivpreprint  R‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@XtopherCalvert,RT @LdnGMC: Interesting report by @BrassBandsEng  - we look forward to reading more on the study into singing and hope for more guidance fr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@LdnGMC,Interesting report by @BrassBandsEng  - we look forward to reading more on the study into singing and hope for more guidance from @OliverDowden & @DCMS soon.
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@hori_euph,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@paulfishermusic,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@UKKandF,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@M_Castelletti,A set of investigations into the release of respiratory aerosols by brass instruments @BrassBandsEng @medrxivpreprint  Results showed that fewer particles were produced when playing (singing?) than when breathing alone   https://t.co/m8TvTS3GW6 https://t.
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@AnthonyReimer,"More #windband research, this time from @BrassBandsEng. There‚Äôs definite good news here. #COVID19 https://t.co/Hj6nC7kUb9"
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@2mogs,@Musicisclassy Interesting reading!!
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@___just___me,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@CrostonBen,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@brass_and,"At last, some promising news"
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@amershamband,RT @medrxivpreprint: Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@amershamband,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@rachelhmarriott,@pwbrassband üé∫
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@alextootskenyon,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@JohnSam57668631,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@FemmesFortissi1,RT @BrassBandsEng: We've been working on some research on aerosol particles released by brass. Results = less particles released than singi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@BrassBandsEng,"We've been working on some research on aerosol particles released by brass. Results = less particles released than singing, using a cover can significantly reduce the release further. Press release at https://t.co/8L7VUYeaqG  or  https://t.co/bH3gcfBf5F fo"
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@BrassBandsEng,RT @medrxivpreprint: Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@BrassBandsEng,RT @COVID_Papers: üìù Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Cov‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@COVID_Papers,üìù Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19  medRxiv or bioRxiv https://t.co/N2uVARg912 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20165837,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19,@medrxivpreprint,Investigation into the Release of Respiratory Aerosols by Brass Instruments and Mitigation Measures with Respect to Covid-19  https://t.co/1vej5ruuit #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165019,A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae,@outbreaksci,"Contribute a rapid review or request one for ""A throughput serological Western blot system using whole virus lysate for the concomit..."" (https://t.co/giwJQqRN8L). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165019) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165019,A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae,@outbreaksci,New #SARSCoV preprint: A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae https://t.co/giwJQqRN8L
http://medrxiv.org/cgi/content/short/2020.07.31.20165019,A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae,@medrxivpreprint,A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae  https://t.co/FtRL3mJPDH #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166249,"Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India",@outbreaksci,"Contribute a rapid review or request one for ""Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with ..."" (https://t.co/H4q06pxjsx). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20166249) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20166249,"Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India",@outbreaksci,"New #SARSCoV preprint: Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India https://t.co/H4q06pxjsx"
http://medrxiv.org/cgi/content/short/2020.07.31.20166249,"Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India",@medrxivpreprint,"Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India  https://t.co/ceo99vN2tB #medRxiv"
http://medrxiv.org/cgi/content/short/2020.08.01.20166173,Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation,@outbreaksci,"Contribute a rapid review or request one for ""Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation"" (https://t.co/EYoNgfM9sh). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.20166173) at https://t.co/RnurTL3DyM @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.08.01.20166173,Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation,@outbreaksci,New #SARSCoV preprint: Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation https://t.co/EYoNgfM9sh
http://medrxiv.org/cgi/content/short/2020.08.01.20166173,Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation,@medrxivpreprint,Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation  https://t.co/aKvNsEBTA8 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Awarding_Women,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@ElmerEdward1,RT @PandemicCovid20: Land Use Change and #Coronavirus Emergence Risk - https://t.co/G9cue4IeGP
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@SmithFellows,"RT @PeterDaszak: 2nd, a preprint from @dtsh2 on likely reasons why conditions in S. China are seemingly so compatible for origins of novel‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@dtsh2,"RT @PeterDaszak: 2nd, a preprint from @dtsh2 on likely reasons why conditions in S. China are seemingly so compatible for origins of novel‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Toetterbeck,"RT @PeterDaszak: 2nd, a preprint from @dtsh2 on likely reasons why conditions in S. China are seemingly so compatible for origins of novel‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Dvrmvet,"RT @PeterDaszak: 2nd, a preprint from @dtsh2 on likely reasons why conditions in S. China are seemingly so compatible for origins of novel‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@PeterDaszak,"2nd, a preprint from @dtsh2 on likely reasons why conditions in S. China are seemingly so compatible for origins of novel diseases (clue - expanding interface of wildlife, human interactions)  https://t.co/4DoYOkjEBb"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@PandemicCovid20,Land Use Change and #Coronavirus Emergence Risk - https://t.co/G9cue4IeGP
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@CillaWehi,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Jussi_T_Eronen,RT @thomaslilley77: Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease. https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@PaulaPrist,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Filosganga,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@VeronikaNLaine,RT @thomaslilley77: Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease.
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@VTwort,RT @thomaslilley77: Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease.
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@halkka,RT @thomaslilley77: Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease.
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@dr_sajith,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@LeaBerrang,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@BatResearch,@FOXTROT716 delayed release I guess - https://t.co/G38efKKmgI
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@BatResearch,Preprint: Land Use Change and Coronavirus Emergence Risk. https://t.co/DaM6SkmrGF #landuse #COV #zoonosis #emergence
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@MuyRe,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@MCRULLI1,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@calhi415,This one had to be read at once. Great work from our colleagues Hayman et al. highlighting very well what many of us have been saying... humans and their activities are quickly changing Ecosystem dynamics that affect pathogen transmission. ü§ìüëådon't blame th
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@otusposti,RT @thomaslilley77: Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease. https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Marrunen,RT @thomaslilley77: Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease.
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@DiseaseEcology,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@friendorfomite,haven't checked this out yet put I plan to! Forest fragmentation and human behavior influence our world greatly #onehealth
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@nikolasgalli,"Take a look at our study on how #COVID19 is connected to land use change in China, and which other areas may be at spillover risk in the future. https://t.co/9sPqa0ENCQ"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@jacoker2,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@AjitKarna,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@thomaslilley77,Super-interesting preprint on how human encroachment of the habitat of wild animals can promote zoonotic disease.
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@KRdland,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@Toetterbeck,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@jaywang06138467,https://t.co/i958EeGthJ Here is another paper hypothesizing climate change pushed the bats' invasion. https://t.co/gMI2t57wm4
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@sneweyy,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@green5347,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@liberiachimps,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@LubanLab,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@COVID19digest1,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@COVID19digest1,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@mstandaert,RT @PeterDaszak: Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@PeterDaszak,"Important paper from @dtsh2's group. Shows w/ crystal clarity that horseshoe bat reservoirs of SARS-related CoVs are under intense pressure from human popn. encroachment, land use change, livestock expansion in S. China. Yet more evidence on why COVID emer"
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@ticks7,Like Kyasanur?
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@gallagher_grant,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@EpiDoctor,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@cc_martell,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@DuckSwabber,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@jw132,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@maroshcka,RT @medrxivpreprint: Land Use Change and Coronavirus Emergence Risk  https://t.co/B2iFJuqPaV #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@cl_faust,RT @dtsh2: Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@COVID_Papers,üìù Land Use Change and Coronavirus Emergence Risk  medRxiv or bioRxiv https://t.co/yQiKZIP8Mb #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@dtsh2,Land Use Change and Coronavirus Emergence Risk - our new work looking at the nexus of land use change around SARSr-CoV bat hosts in Asia & what might tip some locations into being high risk locations in the future https://t.co/cqF9Ouy63j (feedback welc
http://medrxiv.org/cgi/content/short/2020.07.31.20166090,Land Use Change and Coronavirus Emergence Risk,@medrxivpreprint,Land Use Change and Coronavirus Emergence Risk  https://t.co/B2iFJuqPaV #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@ElmerEdward1,"RT @PandemicCovid20: Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of #COVID19 - https://t.co/XM‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@PandemicCovid20,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of #COVID19 - https://t.co/XMuhUCC997"
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@DGalbadage,"RT @DrBMPetersonPhD: #NEW #PREPRINT #ALERT from our group.  #Delayed #Interventions, Low #Compliance, and #Health #Disparities Amplified th‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@DrBMPetersonPhD,"#NEW #PREPRINT #ALERT from our group.  #Delayed #Interventions, Low #Compliance, and #Health #Disparities Amplified the Early Spread of #COVID19 https://t.co/WHK7XVonz3 @DGalbadage @CAPublicHealth @lapublichealth @CDPHE @ColoradoSPH @biolau"
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@COVID_Papers,"üìù Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19  medRxiv or bioRxiv https://t.co/5euUZpLdSf #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@AngelAzpeitia,"RT @medrxivpreprint: Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19  https://t.co/Gbq‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165654,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19",@medrxivpreprint,"Delayed Interventions, Low Compliance, and Health Disparities Amplified the Early Spread of COVID-19  https://t.co/GbqLWTcGHx #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.31.20166264,Risk stratification as a tool to rationalize quarantine among health care workers exposed to COVID-19 cases ‚àí Evidence from a tertiary healthcare centre in India,@COVID_Papers,üìù Risk stratification as a tool to rationalize quarantine among health care workers exposed to COVID-19 cases - Evidence from a tertiary healthcare centre in India  medRxiv or bioRxiv https://t.co/dLC7DEp42T #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20166264,Risk stratification as a tool to rationalize quarantine among health care workers exposed to COVID-19 cases ‚àí Evidence from a tertiary healthcare centre in India,@medrxivpreprint,Risk stratification as a tool to rationalize quarantine among health care workers exposed to COVID-19 cases - Evidence from a tertiary healthcare centre in India  https://t.co/LjmUIHKjam #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@phil_w888,103a/  https://t.co/MiaqImqICI
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@phil_w888,"709a/  ""...in this study...smoking was not found to be a risk factor for severity outcomes""  Note: *number error in Table 3. Also in text (lines 167 & 168)  https://t.co/WdhvSCKudo"
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@luciaruggiero,RT @medrxivpreprint: Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities dist‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@equityhealthdev,RT @medrxivpreprint: Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities dist‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@ghia1212,RT @medrxivpreprint: Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities dist‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@CofHEQ,RT @medrxivpreprint: Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities dist‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@GlobalPHObserv,RT @medrxivpreprint: Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities dist‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165480,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort,@medrxivpreprint,Clinical course and severity outcome indicators among COVID 19 hospitalized patients in relation to comorbidities distribution Mexican cohort  https://t.co/guQ49xQPjf #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@MarkQuarter,RT @outbreaksci: New #COVID19 preprint: A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected loc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@SciscoreReports,The paper ‚ÄúA longitudinal survey for genome-based identificat...‚Äù (https://t.co/MhtDPGYioV) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/QLY0g1WPHC. We detected 0 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@outbreaksci,"New #SARSCoV preprint: A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy https://t.co/tNGGiF9W4M"
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@outbreaksci,"Contribute a rapid review or request one for ""A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in..."" (https://t.co/tNGGiF9W4M). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165126) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@outbreaksci,"New #COVID19 preprint: A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy https://t.co/tNGGiF9W4M"
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@adnan_a_malik,"Driving force for smart lockdown in Pakistan  A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy #covid19 https://"
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@adnan_a_malik,Results of rigorous team work in last month ‚úåüèº
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@OxonAndrew,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy https://t.co/Ajk5jxbbBq https://t.co/QPr2KC0BxX"
http://medrxiv.org/cgi/content/short/2020.07.31.20165126,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy",@medrxivpreprint,"A longitudinal survey for genome-based identification of SARS-CoV-2 in sewage water in selected lockdown areas of Lahore city, Pakistan; a potential approach for future smart lockdown strategy  https://t.co/g7n2RAr0AZ #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@SciscoreReports,The paper ‚ÄúThe COVID-19 Consequences of College Class Continu...‚Äù (https://t.co/ljeni8vowk) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/OU5YHpcDPy. We detected 1 key resource.
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@Danny_Malagon3,RT @BewickLab: The paper describing methods for our online app is now available on medRxiv (so now you know what we really did)! https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@ReptileRhett,RT @BewickLab: The paper describing methods for our online app is now available on medRxiv (so now you know what we really did)! https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@luciaruggiero,RT @medrxivpreprint: The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@equityhealthdev,RT @medrxivpreprint: The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@ghia1212,RT @medrxivpreprint: The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@BewickLab,The paper describing methods for our online app is now available on medRxiv (so now you know what we really did)! https://t.co/ypI8ZEUovj  Find the app at: https://t.co/UPcFow5xF8 Please share!  And stay safe out there!!!
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@CofHEQ,RT @medrxivpreprint: The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@GlobalPHObserv,RT @medrxivpreprint: The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with E‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165761,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus,@medrxivpreprint,The COVID-19 Consequences of College Class Continuity Calculator: A Tool to Provide Students and Administrators with Estimated Risks of Returning to Campus  https://t.co/2XT19wFF9M #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@outbreaksci,Updated #SARSCoV preprint: SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers https://t.co/GFudq3XzKn
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers"" (https://t.co/GFudq3XzKn). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20166066) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@outbreaksci,Updated #COVID19 preprint: SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers https://t.co/GFudq3XzKn
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@rtdemmer,The manuscript is on MedRxiv while under peer review: https://t.co/mAcF1qTg9w
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@ElmerEdward1,RT @PandemicCovid20: SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers - https://t.co/3agMOCsx3t
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@Miti_Vigliero,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers https://t.co/egL9iwaInf
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@PandemicCovid20,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers - https://t.co/3agMOCsx3t
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@outbreaksci,Updated #SARSCoV preprint: SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers https://t.co/GFudq3XzKn
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers"" (https://t.co/GFudq3XzKn). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20166066) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@outbreaksci,Updated #COVID19 preprint: SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers https://t.co/GFudq3XzKn
http://medrxiv.org/cgi/content/short/2020.07.31.20166066,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers,@medrxivpreprint,SARS-CoV-2 Infection Among Symptom-Free Healthcare Workers  https://t.co/EZnroVdGwS #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20166025,Analytical Model of COVID-19 for lifting non-pharmaceutical interventions,@ElmerEdward1,RT @PandemicCovid20: Analytical Model of #COVID19 for lifting non-pharmaceutical interventions - https://t.co/DqcrDs081p
http://medrxiv.org/cgi/content/short/2020.07.31.20166025,Analytical Model of COVID-19 for lifting non-pharmaceutical interventions,@PandemicCovid20,Analytical Model of #COVID19 for lifting non-pharmaceutical interventions - https://t.co/DqcrDs081p
http://medrxiv.org/cgi/content/short/2020.07.31.20166025,Analytical Model of COVID-19 for lifting non-pharmaceutical interventions,@medrxivpreprint,Analytical Model of COVID-19 for lifting non-pharmaceutical interventions  https://t.co/ZHE7h8NXkZ #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@WWredmond4,"RT @ChilesResearch: New report from our @LabPiening and team on #genomic sequencing of #COVID19 in Oregon, with potential utilization for o‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@InspirationArch,"RT @ChilesResearch: New report from our @LabPiening and team on #genomic sequencing of #COVID19 in Oregon, with potential utilization for o‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@SAliabadiMD,"RT @ChilesResearch: New report from our @LabPiening and team on #genomic sequencing of #COVID19 in Oregon, with potential utilization for o‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@rbryanbell,"RT @ChilesResearch: New report from our @LabPiening and team on #genomic sequencing of #COVID19 in Oregon, with potential utilization for o‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@lifeinpdx,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@ChilesResearch,"New report from our @LabPiening and team on #genomic sequencing of #COVID19 in Oregon, with potential utilization for outbreak tracing and acute disease prediction. Read the preprint article ‚ñ∂Ô∏è https://t.co/1YBog0B48Z @medrxivpreprint @alexadowdell @carl"
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@outbreaksci,"Contribute a rapid review or request one for ""Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon"" (https://t.co/uCmp4xY6eI). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20160069) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@outbreaksci,New #SARSCoV preprint: Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon https://t.co/uCmp4xY6eI
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@DNAed_tech,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@InspirationArch,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@JayChance12,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@rbryanbell,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@WWredmond4,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@WalterUrba,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@Campbel22146672,RT @LabPiening: Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@LabPiening,Our new preprint article is live! A genomic survey of SARS-CoV-2 in Oregon. @carlobifulco @WalterUrba @OmicsAutomation #Covid_19 #Genomics #PDX
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@phil_w888,710a/  7 ventilated: CS=1 (14.3%) & FS=3 (42.9%)  Note: possible overlap with tweets 12 & 443  https://t.co/BmfSDohq5q https://t.co/Z9ZZPpX8AL https://t.co/JGG7TOAnn6
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@COVID_Papers,üìù Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon  medRxiv or bioRxiv https://t.co/JlHNfNo4m2 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20160069,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon,@medrxivpreprint,Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon  https://t.co/OEzbtPpf2X #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@prashbio,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets https://t.co/5y4TSHLxpl
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@TheSandlings,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@garryweil,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@snagger_ca,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@styrohome,"RT @vegsource: Real life tests, not models and speculation based on fake tests, would show H2O in a sneeze quickly evaporates, leaving any‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@obradam,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@Anawsantos,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@vegsource,"Real life tests, not models and speculation based on fake tests, would show H2O in a sneeze quickly evaporates, leaving any virus behind which is then a dust that escapes into public space with exhale. Buncha negligent homicidal maniacs in employ of vaccin"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@DarthPharmacist,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@welsh_seb,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@DonaldWelsh16,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@Brandon777gr,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@lauracarter_dr,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@ish_michelle,"""The single layer cotton mask was not able to protect as we observed stain on the face itself."""
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@SiponenMatti,"RT @gerdosi: Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@gerdosi,"Confirming previous evidence, this mask development test highlights that regular cloth masks are useless, while surgical masks vary in efficacy of retaining small particles. N95 is of course effective. No data on extended use or on cleaning/replacement. ht"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@ElmerEdward1,RT @PandemicCovid20: Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@Miti_Vigliero,RT @PandemicCovid20: Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@PandemicCovid20,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets - https://t.co/AnddGcRDVV
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@alfonso_casi,Protecci√≥n de las mascarillas caseras vs quir√∫rgicas de triple capa: una mascarilla con dos capas de algod√≥n y una capa impermeable polipropileno recubierto con poliuretano parece tan eficaz como las quir√∫rgicas. https://t.co/zX557NIgDt https://t.co/Qifnuf
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@outbreaksci,"Contribute a rapid review or request one for ""Making cotton face masks extra-protective by use of impervious cloth as the front laye..."" (https://t.co/ZJApKxPTG0). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165563) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@outbreaksci,New #SARSCoV preprint: Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets https://t.co/ZJApKxPTG0
http://medrxiv.org/cgi/content/short/2020.07.30.20165563,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets,@medrxivpreprint,Making cotton face masks extra-protective by use of impervious cloth as the front layer to restrict flow of aerosols and droplets  https://t.co/kdew4Ej4vw #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@kungfucol,@TraceyStreet @BBCNews https://t.co/9rUyhVgkny
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ChenGenomics,RT @kyleserikawa: Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@mwmjenard,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@HansWur77874781,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@QwestarCapital,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@findrootcause,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@over_711,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ProfessorPants2,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ybitda,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@LenferUS,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@shekinah1313,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ShifanAhmedMV,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@KageinMidsomer,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@barkandforest,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@SierraDante,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@temennuconsult,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@FutureBuffalo,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@RAFALOCA1,@Cartabellotta https://t.co/INdzgqhW2l
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@RAFALOCA1,@fabotind @Cartabellotta https://t.co/wYL2cELxf2
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@dharmabuilt,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@DentonRobert,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@vaccinescience,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Pseudonym45,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@StevenJ56038726,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@drsethallen,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@RawRaider357,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@mallond4,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@outbreaksci,"Contribute a rapid review or request one for ""Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individu..."" (https://t.co/B3t7eWD8L0). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165647) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@outbreaksci,Updated #SARSCoV preprint: Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels https://t.co/B3t7eWD8L0
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@DocDonnieH,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@liberty_addict,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@NewNormality20,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ptrhydn,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@javierguevara,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ArneLarsen7,@dockaurG
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@RicksFreeSpeech,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@michael_cowen,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@BChinatti,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@FredNurf,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@PaulTraining,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@19Mookie76,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@mfkoerschner,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Bassbluff,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@yann_uk,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ABell2019,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@SteveG06322664,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@DarrenBellreads,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@DonCorl04820121,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@sorrelmysweet,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@hoover1919,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@mvianin,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@biveselov,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@doug_no1,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@tickitiboo,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@kconnell13,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@prasangika57348,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@donkamion78,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@duckford10,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Pollemann1,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@jadenozzz,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@entrophix,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@cryptopacked,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@CharlotteNilse8,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ShivamGusain20,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@continu_um,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@arditgjokola1,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Tat_Loo,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@princesseffel,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@rtaggart,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@rugbyrhino16,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@OnePokerMind,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@BeverlyA1984,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@cabville,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Dnz779,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@StephenPLundy,@WillowWyse @tnewtondunn https://t.co/od7xVW5TRq
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@patrick_layton,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@EpigenomeHacker,#COVID19 #immunology #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@StephenPLundy,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@daridor,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@daridor,@Omer0Man https://t.co/Tnp9gHrQ3E
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@WSunlover,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@MarkReady47,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@hotasatoaster,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@ocmommy8675309,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@PerrineBridge,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@EuliaBounn,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@HealthFreedomLA,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Amanda05597148,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@thatgirlmo,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@9PVk6cD9YiwzmKb,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@mdvrdrmn,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@NotGoingAway14,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@jacobmbuck,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@kprigel,"But that doesn‚Äôt fit with the media narrative that lack of antibodies means no herd immunity ever, despite the fact that they can‚Äôt find reinfection examples among the millions of cases in the world. Quit spouting off #science that so clearly disagrees wit"
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@TimTravis2,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@HumphreyPT,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@DrTinazli,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@PlumRemson,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@jb_handley,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165647,Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels,@Tagg13,RT @daniellevitt22: T-cell immunity lasts longer (decades for SARS) than antibody immunity...  ‚ÄúSubjects show lasting memory T-cell populat‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@TropMedOxford,RT @lakshmanoharan: Clinical characterisation studies are essential from the start of a pandemic - what did we learn in the first few month‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@louise_sigfrid,RT @lakshmanoharan: Clinical characterisation studies are essential from the start of a pandemic - what did we learn in the first few month‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@gerdosi,"@Rattus_Lamia @OZmandia @ptrtwtr @FatEmperor You can find ‚Äúlots more weird stuff‚Äù in other viral infections that are not tackled at mucosal barriers. What really matters is typical manifestation in the majority of people. This is an Oxford group, the paper"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@carlynharris,"RT @louise_sigfrid: Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@PGoggolidou,"RT @louise_sigfrid: Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@helloitsandres,"RT @p_openshaw: 'Clinicians should remain vigilant to the possibility of covid-19 in patients presenting without fever, cough and dyspnoea,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@helloitsandres,"RT @louise_sigfrid: Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@mylittlebaklava,WHO is working on this @_katusche
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@per_petra,"RT @louise_sigfrid: Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@lakshmanoharan,"RT @p_openshaw: 'Clinicians should remain vigilant to the possibility of covid-19 in patients presenting without fever, cough and dyspnoea,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@lakshmanoharan,"RT @louise_sigfrid: Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@lakshmanoharan,Clinical characterisation studies are essential from the start of a pandemic - what did we learn in the first few months of #COVID19? @ISARIC1 https://t.co/NuV9u67Bwr
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@JonathanKBall,"RT @p_openshaw: 'Clinicians should remain vigilant to the possibility of covid-19 in patients presenting without fever, cough and dyspnoea,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@louise_sigfrid,"RT @p_openshaw: 'Clinicians should remain vigilant to the possibility of covid-19 in patients presenting without fever, cough and dyspnoea,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@broberg_e,"RT @louise_sigfrid: Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@p_openshaw,"'Clinicians should remain vigilant to the possibility of covid-19 in patients presenting without fever, cough and dyspnoea, particularly in older adults'"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@louise_sigfrid,"Early Clinical #COVID19 studies indicated that it is a multisystem illness, but wide variation in reporting did not consistently reflect this  = need for timely standardised data collection for #emerging #epidemics #pandemics @ISARIC1 https://t.co/MMwye0W"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@outbreaksci,"Contribute a rapid review or request one for ""Early clinical characteristics of Covid-19: scoping review"" (https://t.co/6Ryx5kMjTY). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165738) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@outbreaksci,New #COVID19 preprint: Early clinical characteristics of Covid-19: scoping review https://t.co/6Ryx5kMjTY
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@ajv67,RT @medrxivpreprint: Early clinical characteristics of Covid-19: scoping review  https://t.co/wGg8ZroDGa #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165738,Early clinical characteristics of Covid-19: scoping review,@medrxivpreprint,Early clinical characteristics of Covid-19: scoping review  https://t.co/wGg8ZroDGa #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20163055,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers"" (https://t.co/XR6bCD2zUk). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20163055) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.31.20163055,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers https://t.co/XR6bCD2zUk
http://medrxiv.org/cgi/content/short/2020.07.31.20163055,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers,@phil_w888,11/  https://t.co/xxb2UXm24I
http://medrxiv.org/cgi/content/short/2020.07.31.20163055,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers,@phil_w888,"711/  Los Angeles County, USA (adult smoking rate was 11% in 2015-17)  Of 6,062 health care workers tested for antibodies, 102 were current smokers (1.7%) & 87 were current vapers (1.4%)  Of 212 who tested positive, CS=3 (1.4%) & CV=4 (1.9%)  https"
http://medrxiv.org/cgi/content/short/2020.07.31.20163055,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers,@medrxivpreprint,SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers  https://t.co/WvhN0dGF7O #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165720,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial",@outbreaksci,"New #SARSCoV preprint: Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial https://t.co/Gp6ukiVdvH"
http://medrxiv.org/cgi/content/short/2020.07.31.20165720,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial",@outbreaksci,"Contribute a rapid review or request one for ""Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-1..."" (https://t.co/Gp6ukiVdvH). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165720) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165720,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial",@outbreaksci,"New #COVID19 preprint: Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial https://t.co/Gp6ukiVdvH"
http://medrxiv.org/cgi/content/short/2020.07.31.20165720,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial",@medrxivpreprint,"Evaluation of Convalescent Plasma versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial  https://t.co/MO7UIvSHlK #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.31.20165704,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,@outbreaksci,"Contribute a rapid review or request one for ""R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using ..."" (https://t.co/FzzCEgRWKH). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165704) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165704,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,@outbreaksci,New #SARSCoV preprint: R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes https://t.co/FzzCEgRWKH
http://medrxiv.org/cgi/content/short/2020.07.31.20165704,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,@MedicalScitech,"üí°More importantly, One-step RT-qPCR kit successfully detected #COVID19 in clinical samples of broad viral titers with similar reliability and selectivity as that of the Invitrogen SuperScript III Platinum One-step RT-qPCR and TaqPath 1-Step RT-qPCR kits. h"
http://medrxiv.org/cgi/content/short/2020.07.31.20165704,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,@MedicalScitech,"üîùR3T (Rapid Research Response Team) One-step RT-qPCR kit for #COVID19 diagnostic using in-house enzymes ¬ª https://t.co/dVIdKZpFAN A simple, economical, and powerful one-step RT-qPCR patent-free-based kit reliably detects as low as 10 copies of the syntheti"
http://medrxiv.org/cgi/content/short/2020.07.31.20165704,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,@qkhan91,RT @medrxivpreprint: R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes  https://t.co/w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165704,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes,@medrxivpreprint,R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes  https://t.co/wTo24XKq7S #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@amadorgj,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@rkartagena,"El art√≠culo completo, versi√≥n pre-print, est√° aqu√≠ https://t.co/j1F3yQ4K1B"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@LuisBulaSilva,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@MariaMi76344609,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Tito15_,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Lorenatv507,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@marjavi_09,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@TilciaYi,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@KristelitaG24,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@solnitin,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@victor0693,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Lore16_NR,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@gilbertomartez,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@josleonardog,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@negrita73bn,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@negrita73bn,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@rodoepifanio,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@juan21mjua,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@YWilliamsPma,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@rubiidelcarmen,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@InmunologiaDe,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@jorgeriera20,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@mijail_09,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@bryanjavier_08,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@dra_aherrera,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@davvyid,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@xgen2506,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@kjr5n2009,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@phasmasapientia,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@TiareYoselin,Lean esto! S√öPER IMPORTANTEüëåüèª
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@ReyinaRK,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Cleo_FC,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Anelson831,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Cs737H,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@amadorgj,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@frankup9,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@jcortiz89,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@DamairaLucia,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Dgpleyda1,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Jeka84,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@nats_vega,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@LuiyithMagallon,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Enerol96,Muy Crack üëèüèºüëèüèº
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@GRiquelme05,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@g_moschos,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@dmrmay,"RT @JeanCarrPaul: Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Ne‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Krystel19P,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@JeanCarrPaul,"Nuestros estudiantes de medicina de la UP, haciendo un an√°lisis del manuscrito. Aplaudo el entusiasmo y la iniciativa. Necesitamos m√°s gente evaluando y hablando con evidencia. Necesitamos m√°s #m√©dicos y #cient√≠ficos @CienciaPTY @arebollon"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@mariavictoriamn,RT @manuel_ro25: Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@manuel_ro25,Hoy ha estado circulando un extracto de este art√≠culo pre-print en La Prensa y ha causado mucha controversia y comentarios de toda clase. Este art√≠culo el cual pueden encontrar en: https://t.co/NoAMYCHTEa https://t.co/69fN7hzZG9
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@AymasAqui,"RT @DrNESTORSOSA2: Nuevamente felicidades a todos los autores. Voy a leer el ""paper"" con calma y disfrutarlo. Me pondr√© el su√©ter del Gorga‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@DoctorPanama,"Comparto estudio de la epidemia de SARS-CoV-2 en Panama  Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. https://t.co/kGhoXrtx4G"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@luzmila71,"RT @DrNESTORSOSA2: Nuevamente felicidades a todos los autores. Voy a leer el ""paper"" con calma y disfrutarlo. Me pondr√© el su√©ter del Gorga‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@StephaniMirand,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@avielmar,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@RAGittensI,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@negrita73bn,"RT @DrNESTORSOSA2: Nuevamente felicidades a todos los autores. Voy a leer el ""paper"" con calma y disfrutarlo. Me pondr√© el su√©ter del Gorga‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@pbarrerap5,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Milthonrod,"RT @DrNESTORSOSA2: Nuevamente felicidades a todos los autores. Voy a leer el ""paper"" con calma y disfrutarlo. Me pondr√© el su√©ter del Gorga‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@DrNESTORSOSA2,"Nuevamente felicidades a todos los autores. Voy a leer el ""paper"" con calma y disfrutarlo. Me pondr√© el su√©ter del Gorgas mientras lo leo para sentirlo m√°s. Pa'lante!"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@GrisellEspinosa,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@SHERLYGP,"RT @medrxivpreprint: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.  https://t.co/1qQ2ZrAqBB #m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@LudgardisConce1,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Milva77493608,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@fetitoc,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@IngRaulMorTeran,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@cuidemosapanama,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@lupitaquirosa,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@surse,"RT @KwPulso: Con confinamiento, se mitiga  la escasez de camas y m√©dicos. Pero eso trae hambre, tolerada hasta que ya no m√°s.  Hastiada, la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@GiovannaSC26,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@yaminacover,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@xsaezll,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@virgbeatriz,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@GigiPorcel,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@RobertoEisen,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@arobleschiari,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@arobleschiari,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@DrREpifanio,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@drajanice,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@CEVAXIN_PTY,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@CEVAXIN_PTY,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@metalarte09,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@JorgeRubenO,"RT @medrxivpreprint: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.  https://t.co/1qQ2ZrAqBB #m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@luishenriquez02,"RT @medrxivpreprint: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.  https://t.co/1qQ2ZrAqBB #m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@negrita73bn,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@SusanaDeLeonMD,"RT @medrxivpreprint: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.  https://t.co/1qQ2ZrAqBB #m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@djriveraros,"RT @KwPulso: Con confinamiento, se mitiga  la escasez de camas y m√©dicos. Pero eso trae hambre, tolerada hasta que ya no m√°s.  Hastiada, la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@pbarrerap5,"RT @KwPulso: Con confinamiento, se mitiga  la escasez de camas y m√©dicos. Pero eso trae hambre, tolerada hasta que ya no m√°s.  Hastiada, la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@507ptyfl,"RT @KwPulso: Con confinamiento, se mitiga  la escasez de camas y m√©dicos. Pero eso trae hambre, tolerada hasta que ya no m√°s.  Hastiada, la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@JorgeRubenO,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@JorgeRubenO,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@AlexisDixonRod1,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@FernandoCorreaJ,"RT @KwPulso: Con confinamiento, se mitiga  la escasez de camas y m√©dicos. Pero eso trae hambre, tolerada hasta que ya no m√°s.  Hastiada, la‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@DaniloePanama,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@bmpf21,"RT @DrJulioSandoval: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicac‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@myurologia,RT @InstitutoGorgas: Compartimos con ustedes el pre-print que describe las 5 primeras semanas de epidemia del #COVID19 en Panam√° felicidade‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@DrJulioSandoval,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama. | medRxiv Primeras publicaciones internacionales de colegas paname√±os!  https://t.co/9uh84CNYpV"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@KwPulso,"Con confinamiento, se mitiga  la escasez de camas y m√©dicos. Pero eso trae hambre, tolerada hasta que ya no m√°s.  Hastiada, la gente saldr√°.   ¬øHay alternativa? : Trazar casos usando Apps y cercos s√≥lo en pueblos clave.   Detallesüëáüèª https://t.co/KmkCn4FEE8"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@Svetlana923,"RT @medrxivpreprint: Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.  https://t.co/1qQ2ZrAqBB #m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20160929,"Early transmission dynamics, spread, and genomic characterization of SARS-CoV-2 in Panama.",@rotzencratz,RT @arebollon: As√≠ fue la epidemia de #COVID en Panam√°. Hecho por amigos y maestros del patio
http://medrxiv.org/cgi/content/short/2020.07.30.20165266,"How does public knowledge, attitudes, and behaviors correlate in relation to COVID-19? A community-based cross-sectional study in Nepal",@COVID_Papers,"üìù How does public knowledge, attitudes, and behaviors correlate in relation to COVID-19? A community-based cross-sectional study in Nepal  medRxiv or bioRxiv https://t.co/Vyn7HotqHh #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.30.20165266,"How does public knowledge, attitudes, and behaviors correlate in relation to COVID-19? A community-based cross-sectional study in Nepal",@medrxivpreprint,"How does public knowledge, attitudes, and behaviors correlate in relation to COVID-19? A community-based cross-sectional study in Nepal  https://t.co/X1Uwjf9qbI #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.30.20165571,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques,@CovidWellbeing,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques https://t.co/3FjzxKzjAW #mentalhealth
http://medrxiv.org/cgi/content/short/2020.07.30.20165571,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques,@AmandeepJutla,RT @medrxivpreprint: An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165571,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques,@COVID_Papers,üìù An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques  medRxiv or bioRxiv https://t.co/H8268SGjTp #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165571,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques,@medrxivpreprint,An Exploration of Impact of COVID 19 on mental health -Analysis of tweets using Natural Language Processing techniques  https://t.co/XlUYTEWgBr #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165662,Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective,@outbreaksci,"Contribute a rapid review or request one for ""Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective"" (https://t.co/rqUbcFR3wT). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165662) at https://t.co/RnurTL3DyM @outbreaksci @PRErevie"
http://medrxiv.org/cgi/content/short/2020.07.31.20165662,Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective,@outbreaksci,New #SARSCoV preprint: Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective https://t.co/rqUbcFR3wT
http://medrxiv.org/cgi/content/short/2020.07.31.20165662,Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective,@COVID_Papers,üìù Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective  medRxiv or bioRxiv https://t.co/VqGSiwTAwz #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20165662,Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective,@medrxivpreprint,Optimal lockdown strategies for SARS-CoV2 mitigation--- an Indian perspective  https://t.co/slsjn7d5pE #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@outbreaksci,"Contribute a rapid review or request one for ""Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations point..."" (https://t.co/frH51kSCsO). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165696) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@outbreaksci,New #SARSCoV preprint: Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis. https://t.co/frH51kSCsO
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@debe,"@phil_w888 @giovannilandoni There is an interesting preprint, out just today, on the association between several variables including hygiene and GDP, and covid mortality: https://t.co/jDsNtFkc9N  You know my pet theory: lower GDP, more smokers, less refine"
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@eraycollins,RT @RichardLehman1: Interesting idea that early and prolonged exposure to squalor protects against death from covid-19. Suspect not. More l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@colbycosh,RT @RichardLehman1: Interesting idea that early and prolonged exposure to squalor protects against death from covid-19. Suspect not. More l‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@RichardLehman1,Interesting idea that early and prolonged exposure to squalor protects against death from covid-19. Suspect not. More likely due to youth dominance in popln + inadequate recording?
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@DrLindaDykes,RT @medrxivpreprint: Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.  ht‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165696,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.,@medrxivpreprint,Paradoxical Case Fatality Rate dichotomy of Covid-19 among rich and poor nations points to the hygiene hypothesis.  https://t.co/RdxKO46RXD #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.26.20156380,The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers,@SciscoreReports,The paper ‚ÄúThe Impact of COVID-19 on Medical Practice: A Nati...‚Äù (https://t.co/3LKLrVHiAQ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/duSgybDqSZ. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.26.20156380,The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers,@COVID_Papers,üìù The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers  medRxiv or bioRxiv https://t.co/cibaAHmCJZ #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.26.20156380,The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers,@medrxivpreprint,The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers  https://t.co/sQ402STCJa #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.28.20157974,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery,@outbreaksci,New #SARSCoV preprint: Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery https://t.co/LpHB4vtWCt
http://medrxiv.org/cgi/content/short/2020.07.28.20157974,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery,@outbreaksci,"Contribute a rapid review or request one for ""Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery"" (https://t.co/LpHB4vtWCt). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.28.20157974) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.07.28.20157974,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery,@outbreaksci,New #COVID19 preprint: Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery https://t.co/LpHB4vtWCt
http://medrxiv.org/cgi/content/short/2020.07.28.20157974,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery,@COVID_Papers,üìù Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery  medRxiv or bioRxiv https://t.co/BWceJWnVdd #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.28.20157974,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery,@medrxivpreprint,Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery  https://t.co/LIXkP31ACp #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@CordwainersCat,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@outbreaksci,"Contribute a rapid review or request one for ""AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase ..."" (https://t.co/g1pV2r0C0A). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.26.20154724) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@outbreaksci,Updated #SARSCoV preprint: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://t.co/g1pV2r0C0A
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ppaaddmmiinniiy,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@aslan2626,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@gooochin,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://t.co/WZDuULnLjt
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@gooochin,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@shin_ymmt,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ItouToshi,RT @chaosbalance_: @hanakotomari „Ç¢„Éì„Ç¨„É≥„ÅÆ„Ç∏„Çß„Éç„É™„ÉÉ„ÇØ„ÅßÂ§ß„Åç„Å™ÂâØ‰ΩúÁî®„ÅØ„Çâ„Å™„Åè„ÄÅÂäπÊûú„Åå„ÅÇ„Å£„Åü„Å®Ë´ñÊñá„ÅßÁô∫Ë°®„Åï„Çå„Å¶„ÅÑ„Åæ„Åô„ÇàÔºÅ  https://t.co/riyp1llEOP
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ibaibabaibai,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@meltypot,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Cuetie2,RT @kharaguchi: https://t.co/1w64j0pFbg „ÄåAVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@TakaoYOSHIDA6,RT @kharaguchi: https://t.co/1w64j0pFbg „ÄåAVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@J75614042,RT @hichachu: @KamiMasahiro https://t.co/XoK9VTD6oE Preprint„ÅåÂÖ¨Èñã„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇ #„Ç¢„Éì„Ç¨„É≥
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ysaito8015,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@hudietwn3,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kadumi28,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@SisterMaas_ver2,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@uchida_kawasaki,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@murakami_taro1,RT @kharaguchi: https://t.co/1w64j0pFbg „ÄåAVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@goodfife1,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ikotto,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@BDkRDA7IBeHip7O,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@tt2253,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@myfavoritescene,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@FMK03,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@nVTULGfVb4QaPcX,RT @kharaguchi: https://t.co/1w64j0pFbg „ÄåAVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@cUt55giiq3PrApj,RT @kharaguchi: https://t.co/1w64j0pFbg „ÄåAVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kharaguchi,https://t.co/1w64j0pFbg „ÄåAVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial„Äç
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@gannbattemasenn,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kickxxx2,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@CarlakaruraRami,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@SORASTAR,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@fearless_TAISHO,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kotabifutatabi,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@uni_uni222,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@torusengoku,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@uenomiyuu,RT @takiba19690821: ÊÄù„ÅÑ„ÅÆÂ§ñ„ÄÅÂ∞èË¶èÊ®°„Å™Ë©¶È®ì„ÄÇ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Totemo512,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@hichachu,RT @hichachu: @KamiMasahiro https://t.co/XoK9VTD6oE Preprint„ÅåÂÖ¨Èñã„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇ #„Ç¢„Éì„Ç¨„É≥
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@hichachu,@KamiMasahiro https://t.co/XoK9VTD6oE Preprint„ÅåÂÖ¨Èñã„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇ #„Ç¢„Éì„Ç¨„É≥
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@8beichan,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@seapollo,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@araran100,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@takiba19690821,ÊÄù„ÅÑ„ÅÆÂ§ñ„ÄÅÂ∞èË¶èÊ®°„Å™Ë©¶È®ì„ÄÇ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@periodoespecial,RT @influenzer3: ‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https:/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@influenzer3,‚óè„É≠„Ç∑„Ç¢„Åß„ÅÆfavipiravir„ÅÆÁ¨¨II/IIIÁõ∏Ë©¶È®ì ‚Üí„Éó„É¨„Éó„É™„É≥„Éà„Åß„Åô„ÄÇ „É≠„Ç∑„Ç¢„Åß„ÅØgeneric„Å®„Åó„Å¶AVIFAVIR„Å®„ÅÑ„ÅÜÂêçÂâç„ÅÆ„Çà„ÅÜ„Åß„Åô„ÄÇ Ë´ñÊñá„Åå„Ç∑„É≥„Éó„É´„Åô„Åé„Çã„ÅÆ„Åß„ÄÅ„Åó„Å£„Åã„Çä„Å®„Åó„Åü„Ç∏„É£„Éº„Éä„É´„Å´Êé≤Ëºâ„Åï„Çå„Çã„Åã„ÇÑ„ÇÑË¨é„ÅÆÂá∫Êù•„ÄÇ https://t.co/KkfgNOpbjn
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kokoiroaoku,#Êñ∞Âûã„Ç≥„É≠„Éä„ÄÄ#defle„ÄÄ#MMT „ÄÄ#ÂÆâÂÄçÊîøÊ®©„ÇíÂÆà„Çç„ÅÜ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@GibsonLPS,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@shuwawa5,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://t.co/FFUx1TS36U
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@wcGdl9Nw3fmzqJr,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial | medRxiv https://t.co/KXAByUcnsK
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@adwt1298,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kaze50s,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kokoiroaoku,#Êñ∞Âûã„Ç≥„É≠„Éä„ÄÄ#defle„ÄÄ#MMT „ÄÄ#ÂÆâÂÄçÊîøÊ®©„ÇíÂÆà„Çç„ÅÜ https://t.co/jOzthxtFqV ‚Üë„Åì„Çå„ÇíË¶ã„Çã„Å®„É≠„Ç∑„Ç¢„Åß„ÅØ„ÄÅ7ÊúàÂæåÂçä„Åã„ÇâÊÄ•ÈÄü„Å´Ê≠ª‰∫°ËÄÖÂ¢óÂä†Áéá„ÅåÊ∏õ„Å£„Å¶„ÅÑ„Åæ„Åô„ÄÇ „Åä„Åù„Çâ„Åè6Êúà„Åã„ÇâÂßã„Åæ„Å£„Åü„Ç¢„Éì„Ç¨„É≥Êäï‰∏é„ÅÆÁµêÊûú„ÅÆÂèØËÉΩÊÄß„Åå„ÅÇ„Çä„Åæ„Åô„ÄÇ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@yossiy1494,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kokoiroaoku,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@kokoiroaoku,#Êñ∞Âûã„Ç≥„É≠„Éä„ÄÄ#defle„ÄÄ#MMT „ÄÄ#ÂÆâÂÄçÊîøÊ®©„ÇíÂÆà„Çç„ÅÜ Êó•Êú¨„Åß„ÅØÊâøË™ç„Åß„Åç„Å™„ÅÑÊîøÊ≤ªÁöÑÁêÜÁî±„Åå„ÅÇ„Çä„Åù„ÅÜ„Å†„Åã„Çâ„ÄÅÂõΩÊ∞ë„ÅåÂ§ßÂ£∞„Çí‰∏ä„Åí„Å™„Åë„Çå„Å∞„ÅÑ„Åë„Åæ„Åõ„Çì„ÄÇ ÂåªÂ∏´„ÅÆÊñπ„ÇÇ„Åó„Å£„Åã„ÇäË¶ÅÊ±Ç„Åó„Å¶„Åè„Å†„Åï„ÅÑ„ÄÇ „Ç¢„Éì„Ç¨„É≥Á∑äÊÄ•ÊâøË™ç„Çí„Åß„ÅôÔºÅ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Cst3q2,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@tomokazutomokaz,Êó•Êú¨„Åß„ÅØÁô∫Áóá„Åô„Çã‰∫∫„ÅØ„Åª„Å®„Çì„Å©„ÅÑ„Å™„ÅÑ„ÅÆ„Åß„Ç¢„Éì„Ç¨„É≥„ÅØ„ÅÑ„Çâ„Å™„Åè„Å™„Å£„Å¶„Åó„Åæ„ÅÑ„Åæ„Åó„Åü„Å≠„ÄÇ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@TKDOMO,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ItouToshi,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@drnrkw,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@s09211953,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@myoga33,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Devine99code,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ninjabroo,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ninjabroo,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@w3LUe3ZomAAhrec,ÂéöÂä¥ÁúÅ„ÇÑÂ∞èÊ±†„Çø„Éå„Ç≠„ÅåÊñ∞„Ç≥„É≠ÊÑüÊüìËÄÖÊï∞ÊçèÈÄ†„ÅßÊÉÖÂ†±Âº±ËÄÖ„ÅÆÊÅêÊÄñ„ÇíÁÖΩ„Çã‰∏ÄÊñπ„ÄÅÂÜ∑Èùô„Å™„É≠„Ç∑„Ç¢‰∫∫„ÅØ„Ç¢„Éì„Ç¨„É≥ÂæåÁô∫Ëñ¨„ÅÆËá®Â∫äÁµêÊûú„Çí„Åó„Å£„Åã„Çä„Å®Âá∫„Åó„Å¶„Åæ„Åô„ÄÇ„Çπ„Éë„Çπ„Ç£-„Éêüíï  #„Ç¢„Éì„Ç¨„É≥Êú™ÊâøË™ç„Å´ÊäóË≠∞üí¢ #„ÉØ„ÇØ„ÉÅ„É≥Âº∑Âà∂ÂèçÂØæ #VitaminD #„Éä„Ç¨„É¨-„ÇπÂÖ•„Çä„ÉØ„ÇØ„ÉÅ„É≥Êà¶Áï•Ë®±„Åï„Å™„ÅÑ #„Éû„Çπ„Ç¥„Éü‰ªï‰∫ã„Åõ„Çà #Âæ°Áî®Â≠¶ËÄÖË¶Å„Çâ„Å™„ÅÑ #„É™„ÉÅ„É£„Ç≥„Ç∑
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@w3LUe3ZomAAhrec,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@black7b5544,@morningshow_tv https://t.co/naLqtSnWZg „Ç¢„Éì„Ç¨„É≥Êäï‰∏éÁæ§ 62.5%„ÄÅÂØæÁÖßÁæ§ 30%
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@gZcVrTf8oDQihqL,RT @aichikyu369: „Ç¢„Éì„Ç¨„É≥„Çí„Åæ„Å®„ÇÇ„Å´‰Ωø„Åà„Å∞„ÄÅÊñ∞Âûã„Ç≥„É≠„ÉäÊÇ£ËÄÖ„ÅÆ6Ââ≤‰ª•‰∏ä„Åå4Êó•„Åß„Å™„Åä„Çã„ÄÇ https://t.co/hrA9kHqiZF
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@yutan_1961,pivotal stage„Åß„ÅØ„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÊ∂àÂ§±„Åæ„Åß„ÅÆÊó•Êï∞„Å®Ëá®Â∫äÁóáÁä∂„ÅÆÊîπÂñÑ„ÅÆ‰∏°Êñπ„ÇíË¶ã„Å¶„Åæ„Åô„Å≠„ÄÇÂ∞ëÊï∞‰æã„Åß„Åô„Åå„ÄÅPCRÈô∞ÊÄß„Åæ„Åß„ÅÆÊó•Êï∞„ÇíÁü≠Á∏Æ„Åó„Å¶„ÅÑ„Çã„Çà„ÅÜ„Åß„Åô„Å≠„ÄÇ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Jun_Sky_0610,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@tomsly2,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@tomsly2,„É™„Ç¢„É´ÔºöÊÉÖÂ†±Êèê‰æõË™†„Å´„ÅÇ„Çä„Åå„Å®„ÅÜ„Åî„Åñ„ÅÑ„Åæ„Åô„ÄÇ
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@sqbhv,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@ppmx94,RT @nekonekoz: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@crystal69237174,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@nekonekoz,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://t.co/MSbaKw5bxj
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@lialialia666,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@momodaisuki27,ÊäïÁ®øÊ¨ÑÊ≥®ÁõÆ„Éº „Äê‰∏≠Á®ãÂ∫¶„ÅÆCOVID-19ÊÇ£ËÄÖ„ÅÆÊ≤ªÁôÇ„ÅÆÁÇ∫„ÅÆAVIFAVIR:P2/P3‰ªñÊñΩË®≠ÁÑ°‰ΩúÁÇ∫ÂåñËá®Â∫äË©¶È®ì„ÅÆ‰∏≠ÈñìÁµêÊûú„Äë Èú≤‰øùÂÅ•ÁúÅ„ÅØAVIFAVIR„ÅÆËøÖÈÄü„Å™Ë≤©Â£≤ÊâøË™ç„Çí‰ªò‰∏é P2/P3Ëá®Â∫äË©¶È®ì„ÅÆ„Éë„Ç§„É≠„ÉÉ„ÉàÊÆµÈöé„Åß4Êó•‰ª•ÂÜÖ„Å´ÊÇ£ËÄÖ„ÅÆ62.5%„ÅßSARS-CoV-2„Ç¶„Ç£„É´„Çπ„ÅÆ„ÇØ„É™„Ç¢„É©„É≥„Çπ„ÇíÂèØËÉΩ„Å´„ÅóÂÆâÂÖ®ÊÄß„ÅßË™çÂÆπÊÄß„ÅåÈ´ò„Åã„Å£„Åü https://t.co/ZWWvaRiJjs
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@OutOfTheDarkAge,"@SlickRockWeb @IdeaGov @carrybeyond @ushadrons @ValdisKrebs Indirect evidence that hydroxychloroquine is used in Russia. Study was on ""Favipiravir for moderate+ cases"" and 75% of soc was hcq. July 27th- recent. Favipiravir approved for moderate+.   https:/"
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Khazarjude,"#Favipiravir enabled #SARSCoV2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.   Interim Results of a Phase II/III MRCT (Aug 5, 2020)  https://t.co/oZSKRlPPvt #COVID19 #coronavirus #avifavir #avigan #hydroxychloroquin"
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@Dalex61331717,RT @rmchavin: 7-26-2020:  Russia released the preliminary results for their Phase 2/3 clinical trial of Avifavir (improved quality favipira‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@sawame753,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@chaosbalance_,@hanakotomari „Ç¢„Éì„Ç¨„É≥„ÅÆ„Ç∏„Çß„Éç„É™„ÉÉ„ÇØ„ÅßÂ§ß„Åç„Å™ÂâØ‰ΩúÁî®„ÅØ„Çâ„Å™„Åè„ÄÅÂäπÊûú„Åå„ÅÇ„Å£„Åü„Å®Ë´ñÊñá„ÅßÁô∫Ë°®„Åï„Çå„Å¶„ÅÑ„Åæ„Åô„ÇàÔºÅ  https://t.co/riyp1llEOP
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@gZcVrTf8oDQihqL,RT @hichachu: AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@black7b5544,@morningshow_tv https://t.co/naLqtSnWZg
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@DrSamPappas,RT @Covid19Crusher: The preprint of the interim reading of a small (n=60) Russian phase 2/3 randomized trial of favipiravir is out. It sugg‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@hichachu,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial #„Ç¢„Éì„Ç¨„É≥„ÄÄ#Favipiravir  „É≠„Ç∑„Ç¢„ÅÆÊ≤ªÈ®ì„ÅÆ‰∏≠ÈñìÂ†±Âëä SARS-CoV-2„ÅÆÊéíÈô§ Day5  „Ç¢„Éì„Ç¨„É≥Êäï‰∏éÁæ§ 62.5%„ÄÅÂØæÁÖßÁæ§ 30% (P=0.018) ÊúâÊÑèÂ∑Æ„ÅÇ„Çä https://t.co/aomJesKzqO
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@tamariver_y,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@setsu_rava,RT @tbtrqGnWbwDO5ml: „É≠„Ç∑„Ç¢„ÅÆ„Ç¢„Éì„Ç¨„É≥„ÅÆÂæåÁô∫Ëñ¨„ÅÆP2„ÅÆËá®Â∫äÁµêÊûú„ÅåÂá∫„Åü„ÄÇ„Ç¢„Éì„Ç¨„É≥„ÅÆÂäπÊûú„ÅåÁ¢∫Ë™ç„Åß„Åç„Åü„Å®Â†±Âëä„Åï„Çå„Å¶„ÅÑ„Çã„ÄÇËªΩÁóá„ÅÆÂ†¥Âêà„Å†„Å®4Êó•‰ª•ÂÜÖ„ÅßÂ§ö„Åè„ÅÆÊÇ£ËÄÖ„ÅåÈô∞ÊÄß„Å´„Å™„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊõ¥„Å´ÂâØ‰ΩúÁî®„Å´Èñ¢„Åó„Å¶„ÅØÂïèÈ°åË¶ñ„Åô„ÇãÁä∂Ê≥Å„Åß„ÅØ„Å™„Åã„Å£„Åü„Çâ„Åó„ÅÑ„ÄÇÊó•Êú¨„Åß„ÇÇÊó©„Åè„Ç¢„Éì„Ç¨„É≥„ÇíËß£Á¶Å„Åó„Å¶„ÇÇ„Çâ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@sagleyos,RT @Covid19Crusher: The preprint of the interim reading of a small (n=60) Russian phase 2/3 randomized trial of favipiravir is out. It sugg‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@somescientist1,„Ç¢„Éì„Ç¨„É≥„ÄÄ„É≠„Ç∑„Ç¢Á†îÁ©∂ËÄÖË´ñÊñá  https://t.co/vnFVCkcTLU
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@drnrkw,RT @chaosbalance_: „É≠„Ç∑„Ç¢„Åã„ÇâË´ñÊñá„ÅåÂá∫„Åæ„Åó„Åü„Å≠„ÄÇ „Ç¢„Éì„Ç¨„É≥„ÅÆ„Ç∏„Çß„Éç„É™„ÉÉ„ÇØ„Çí‰ΩøÁî®„Åó„ÄÅÁâπ„Å´Â§ß„Åç„Å™ÂâØ‰ΩúÁî®„ÇÇ„Å™„ÅèÊúâÁî®„Åß„ÅÇ„Å£„Åü„Å®„ÄÅ„ÄÅ„ÄÅ  https://t.co/riyp1llEOP
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@drnrkw,RT @Covid19Crusher: The preprint of the interim reading of a small (n=60) Russian phase 2/3 randomized trial of favipiravir is out. It sugg‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@chaosbalance_,„É≠„Ç∑„Ç¢„Åã„ÇâË´ñÊñá„ÅåÂá∫„Åæ„Åó„Åü„Å≠„ÄÇ „Ç¢„Éì„Ç¨„É≥„ÅÆ„Ç∏„Çß„Éç„É™„ÉÉ„ÇØ„Çí‰ΩøÁî®„Åó„ÄÅÁâπ„Å´Â§ß„Åç„Å™ÂâØ‰ΩúÁî®„ÇÇ„Å™„ÅèÊúâÁî®„Åß„ÅÇ„Å£„Åü„Å®„ÄÅ„ÄÅ„ÄÅ  https://t.co/riyp1llEOP
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@aitablog,RT @rmchavin: 7-26-2020:  Russia released the preliminary results for their Phase 2/3 clinical trial of Avifavir (improved quality favipira‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@uberrimaefidei1,RT @Covid19Crusher: The preprint of the interim reading of a small (n=60) Russian phase 2/3 randomized trial of favipiravir is out. It sugg‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20154724,AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial,@SciscoreReports,The paper ‚ÄúAVIFAVIR for Treatment of Patients with Moderate C...‚Äù (https://t.co/NbY6s52xNm) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/3uz3yxS0S2. We detected 3 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@NicolodeGroot,@weare_spartan @drsimonegold With Azm: https://t.co/HKpMWqCVeM With zinc: https://t.co/6fFyC1m2dK and (see supplementary material) https://t.co/ZOvYaF0ESS All early at normal doses
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@8chantruth,RT @JeffLatham7: @danicamckellar @methodsmanmd @WaterlandDPT @janae72103520 @JenLucPiquant Results from one randomized trial includes zinc.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@JeffLatham7,@danicamckellar @methodsmanmd @WaterlandDPT @janae72103520 @JenLucPiquant Results from one randomized trial includes zinc. https://t.co/RSFovgAu6c
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@bartholomewtali,"@ErnieHoffmeist1 @robertodiaspoa @ScottAdamsSays Italy used HCQ from day one.  It was was one of the few ways that China thought was effective early on, and Italy borrowed from that.  Zn is somewhat effective, but adding HCQ to that doesn't make it any mor"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@NicolodeGroot,@algascoigne @AmeshAA Except for a few big pharma executives most people want something simple and fast to work. This is a study with zinc and vitD: https://t.co/6fFyC1m2dK  It looks like the vitD is efficient enough to get the zinc in the cells.
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@michaelj20201,@thiagolinmar @sou_eumesma https://t.co/I8kxxmlFy1
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@NicolodeGroot,"@gvandervoet @kakketoe @telegraaf Dit is de enige studie waarvan ik weet: https://t.co/6fFyC1m2dK zink/vitC/vitD met en zonder #HCQ. Geen verschil, het zou best eens kunnen dat vitD al genoeg doet om de zink in de cellen te brengen."
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@bartholomewtali,@phreatomagnetic @ScottAdamsSays HCQ+Zn is no better than just Zn  https://t.co/iH6IUYGN0f
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@michaelj20201,@flppreis @Anononimo8 @CarlosACDelfino @GauchaGremist4 @DanielMaiaMello https://t.co/I8kxxmlFy1 este(ainda est√° sendo analisando mas √© bom vc ler tamb√©m)
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@JeremyAnso,"@lebon80 @stordunbeag @Samuel_Mondy @LoLoWarn Cet RCT r√©cent aussi, sur des formes l√©g√®res (avec du zinc) sans effet : https://t.co/KiAgiuFq98  Apr√®s je conc√®de qu'il y a peut-√™tre un effet immunomodulateur avec l'HCQ mais le b√©n√©fice semble mineur, et par"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@SciscoreReports,The paper ‚ÄúClearing the fog: Is HCQ effective in reducing COV...‚Äù (https://t.co/mzOx1YFNNl) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/GkzS6BCyK0. We detected 2 of 5 rigor criteria and 2 key resources
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@aarkay_i,RT @OlgaG58726484: No reason to check for PCR negativity. PCR can be positive up to 90 days despite of full recovery/ non contagiosity.  Pl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@ProfitJim,"@Theostecum @mjanec143 @Ek7_PRN There is no proof of that.. Another RCT, were they gave Zinc, Vit C, Vit D to the control group and added HCQ to the other group.. No improvement when adding HCQ..  https://t.co/2pkqFc44p8"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@bartholomewtali,@jbo5112 @Matt44888 @spencerstang @ScottAdamsSays There is a preprint of a double-blind study that compared HCQ+Zn vs. Zn.  No difference.  https://t.co/iH6IUYGN0f
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@yettithaoj,RT @OlgaG58726484: No reason to check for PCR negativity. PCR can be positive up to 90 days despite of full recovery/ non contagiosity.  Pl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@amareshskumar,RT @OlgaG58726484: No reason to check for PCR negativity. PCR can be positive up to 90 days despite of full recovery/ non contagiosity.  Pl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@OlgaG58726484,"No reason to check for PCR negativity. PCR can be positive up to 90 days despite of full recovery/ non contagiosity.  Plus this study is very weak statistically, a lot of biases."
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Sibahle_Ntando,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@ABsteward,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@worldfflyer,@tortu05079620 @KregineSimon @louisjulia220 @MartineWonner @Laissonslespre1 Une de plus ! https://t.co/bZ4Swrw2hN
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@thierrysouccar,"Hydroxychloroquine : nvelle √©tude randomis√©e contr√¥l√©e sur 500 patients avec forme l√©g√®re de la maladie.Pas de diminution du risque de progression vers une forme plus s√©v√®re. Pas + de n√©gativit√© cons√©cutive des test PCR √† 7 et 14 jours Preprint, open label"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@b8b6ea4b037141f,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@ProOpenmind2020,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Jeanyor,@kameleon59000 @tradefutur @complotissss @silvano_trotta @Alexis_Cossette et pourquoi pas https://t.co/wnfOwEMNhR
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Jeanyor,@kameleon59000 @tradefutur @complotissss @silvano_trotta @Alexis_Cossette un autre ici https://t.co/wnfOwEMNhR
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@davidashprice,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@FrLecardonnel,"RT @a_1_0_2: Coucou ‚Å¶@raoult_didier‚Å© ‚Å¶@IHU_Marseille‚Å© ‚Å¶@YanisJGR‚Å© üòò  M√™me les pakistanais vous d√©savouent !  ""Clearing the fog: Is HCQ effe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@bartholomewtali,@spencerstang @Public_Service1 @K9fanboy @jade_shm @Acosta Clinical trial of HCQ with zinc.  https://t.co/iH6IUYGN0f  Conclusion: Addition of HCQ to standard of care treatment in Mild COVID-19 neither prevents disease progression nor is it significantly as
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@khaipharm,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@ABarVent,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@BadNewsForTrump,"RT @rmchavin: 7-30-2020:  In a clinical trial released today from Rawalpindi, Pakistan, bad news for the Trump-touted malaria drug, hydroxy‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@rmchavin,"7-30-2020:  In a clinical trial released today from Rawalpindi, Pakistan, bad news for the Trump-touted malaria drug, hydroxychloroquine, for treating the early stages of COVID-19: https://t.co/1eSCkrH6yg https://t.co/B4xL3RKPuj https://t.co/fXtGurUonR htt"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@joey_sugar,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@NicolodeGroot,"@jangajentaan De laatste, geen Azm maar wel zink:https://t.co/6fFyC1m2dK"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@NicolodeGroot,"And another #HCQ trial with zinc. no effect. No RCT, control group made up of patients not suited for HCQ: https://t.co/6fFyC1m2dK"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@cd_land,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Tonio_Logique,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Holydragjohn,@CDiscute @Skandaya @nathanpsmad @basquinoz @Nael_Infinite @raoult_didier @dr_l_alexandre @Inserm @WHO On va attendre que celle l√† soit peer-reviewed d√©j√† et √©couter leurs arguments absurdes. Apr√®s le communiqu√© de Yale qui ridiculise le chercheur qui a fa
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@AnnehLyon,@amelie_for_you https://t.co/i7SXrQqR7o pourquoi tous les pays du monde ont test√© l‚ÄôHCQ et montrent que √ßa marche... c‚Äôest s√ªrement pour lui nuire ! üôÑ
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@juganon64,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@MusicalElo,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@DCTannoudji,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@RogerTelefunk,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Cwildoc2,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@thomas02q,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@toine512,"RT @Le___Doc: #hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Le___Doc,"#hydroxychroloquine  √áa marche pas, √©pisode 356... spoiler.   ""Addition of HCQ to standard of care treatment in Mild COVID-19 neither prevents disease progression nor is it significantly associated with successive PCR negativity on day 7 and 14"" https://t."
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Vitalityyyyyy,RT @Damkyan_Omega: Un RCT en preprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@monteynard,RT @Damkyan_Omega: Un RCT en preprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@DrJoaquinID,HCQ with or without Zinc FAILED #IDTwitter #evidencebased
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@DgCostagliola,RT @Damkyan_Omega: Un RCT en preprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Fargosaison1,RT @Damkyan_Omega: Un RCT en preprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Samuel_Mondy,RT @Damkyan_Omega: Un RCT en preprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Damkyan_Omega,Un RCT en preprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial  Avec du Zinc  https://t.co/7SaQUlowds
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@stuartbuck1,@vekerchberger @piyushyadav928 @Qthemusic9 @gummibear737 @nebre8ed @AtomsksSanakan Yet another null RCT is now available:   https://t.co/roXrAxafcs
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@raoult_didier C‚Äôest bizarre. D√®s que c‚Äôest randomis√©, ta bouillabaisse ne fonctionne nulle part dans le monde. Ici au Pakistan.  ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@soncharm,"RT @LucreSnooker: ¬°¬°zinc alert!! 500-person randomized open-label trial in Pakistan compares HCQ + ""standard of care"" to ""standard of care""‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Roshan_Karia,"RT @LucreSnooker: ¬°¬°zinc alert!! 500-person randomized open-label trial in Pakistan compares HCQ + ""standard of care"" to ""standard of care""‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@leonorperianez,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@LucreSnooker,"¬°¬°zinc alert!! 500-person randomized open-label trial in Pakistan compares HCQ + ""standard of care"" to ""standard of care"" alone, but SOC includes ¬°¬°zinc!! (dose unclear), vitamin C, and vitamin D. pts are young (median 34yo), w/mild cases https://t.co/YeUp"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@BleibtreuAlexa1,J‚Äôaime pas trop les pr√©-print  En esp√©rant qu‚Äôil soit v√©rifi√© lors de la publication....https://t.co/JBn7vOsDlI
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@AB_IDPharmD,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@ProlongingCovid ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@LezatDarcourt @Barbusceptique Tenez. Le frais du jour ! ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@AnnehLyon,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@nandom_bitrus,RT @ABsteward: ‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mil‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@DrRomainBrunel,https://t.co/1tIIGFTBFy
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@Fargosaison1,"RT @a_1_0_2: Coucou ‚Å¶@raoult_didier‚Å© ‚Å¶@IHU_Marseille‚Å© ‚Å¶@YanisJGR‚Å© üòò  M√™me les pakistanais vous d√©savouent !  ""Clearing the fog: Is HCQ effe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@rsvmike,"RT @a_1_0_2: Coucou ‚Å¶@raoult_didier‚Å© ‚Å¶@IHU_Marseille‚Å© ‚Å¶@YanisJGR‚Å© üòò  M√™me les pakistanais vous d√©savouent !  ""Clearing the fog: Is HCQ effe‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@ABsteward,‚ú¥Ô∏èPreprint ‚ú¥Ô∏è wWith Zinc or without HCQ FAILED  Clearing the fog RCT üáµüá∞ Addition of HCQ to standard of care treatment in Mild #COVID19 neither prevents disease progression nor is it significantly associated with successive PCR negativity on day 7 and 14. h
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@drsimonegold @djefair @JamesTodaroMD ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@raoult_didier Les pakistanais ne sont pas d‚Äôaccord ! ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@raoult_didier Bizarre. D√®s que c‚Äôest randomis√©, ta bouillabaisse perd toute efficacit√©. ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"@raoult_didier La bouillabaisse ne marche pas non plus au Pakistan ! ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@a_1_0_2,"Coucou ‚Å¶@raoult_didier‚Å© ‚Å¶@IHU_Marseille‚Å© ‚Å¶@YanisJGR‚Å© üòò  M√™me les pakistanais vous d√©savouent !  ""Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial""  https://t.co/5kemm1EOcL"
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@sultan_majoka,RT @medrxivpreprint: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial  https://t.co/zd8KI‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@COVID_Papers,üìù Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial  medRxiv or bioRxiv https://t.co/VqXFyCe1aq #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165365,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial,@medrxivpreprint,Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial  https://t.co/zd8KIXOIxO #medRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@SciscoreReports,The paper ‚ÄúSimilarity between mutation spectra in hypermutate...‚Äù (https://t.co/Igx7Lfe1Fq) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/nltvEX3RPU. We detected 2 key resources.
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@RoufDr,RT @DmitryYeast: Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@outbreaksci,"Contribute a rapid review or request one for ""Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS..."" (https://t.co/HnuShKwsVW). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234005) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@outbreaksci,New #SARSCoV preprint: Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic https://t.co/HnuShKwsVW
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@SainiNatalie,Our work on the mutation spectra of #SARSCoV2 is on biorxiv!  https://t.co/NZbCKSgIdk
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@prokuninaolsson,It got to be done! Best when done by experts such as @DmitryYeast and his team! Congrats!
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@BethOsia,RT @DmitryYeast: Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@SurteesJennifer,RT @DmitryYeast: Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@LucasArgueso,RT @DmitryYeast: Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@sebastianw,RT @DmitryYeast: Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@DmitryYeast,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic https://t.co/UrkiQ28I0k  Trails rubella work https://t.co/tyjthxpCjF.   Looking forward to comments @gaddyg @san
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@biorxiv_genetic,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the ...  https://t.co/1oiqvlPmrL #biorxiv_genetic
http://biorxiv.org/cgi/content/short/2020.08.03.234005,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic,@biorxivpreprint,Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic  https://t.co/SkrwJaikhm #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@OliverActon3,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@FrankBioNano,"This is a week old, but who cares it's  still pretty awesome!!! De novo designed peptide inhibitors of SARS-CoV-2"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@SoleumAlpha,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Rechenkraft_net,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@outbreaksci,"Contribute a rapid review or request one for ""De novo design of picomolar SARS-CoV-2 miniprotein inhibitors"" (https://t.co/rqkJlhJfr1). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234914) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@outbreaksci,Updated #SARSCoV preprint: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/rqkJlhJfr1
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@CovidSalon,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/Wzi1iB5DuD https://t.co/yplFqKW7pj
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@jkmontclare,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Belencabello29,RT @BioquimiU: Protein engineering to fight the coronavirus ü¶†
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@miriamvaldayo_,RT @BioquimiU: Protein engineering to fight the coronavirus ü¶†
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@BioquimiU,Protein engineering to fight the coronavirus ü¶†
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@vyy_sf,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@TwistBioscience,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@sidcelery,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@RobZitterbart,RT @PomplunSeb: Great work by @UWproteindesign David Baker.
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ZhalehGhaemi,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@CarlySchissel,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@PomplunSeb,Great work by @UWproteindesign David Baker.
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Vanderr18,RT @germangfeler: Inhibidores de SARS-CoV-2 dise√±ados por computadora.   Que viva la bioinform√°tica üòç https://t.co/0Q8oH9AfgT
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@EddValera,RT @germangfeler: Inhibidores de SARS-CoV-2 dise√±ados por computadora.   Que viva la bioinform√°tica üòç
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@florbenitez_7,RT @germangfeler: Inhibidores de SARS-CoV-2 dise√±ados por computadora.   Que viva la bioinform√°tica üòç https://t.co/0Q8oH9AfgT
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@PetrovichGuido,RT @mellases: Computational design of hyperstable miniproteins (~60 aa) which bind specifically to SARS-CoV with high affinity. And CryoEM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Nico_Stocchi,RT @germangfeler: Inhibidores de SARS-CoV-2 dise√±ados por computadora.   Que viva la bioinform√°tica üòç https://t.co/0Q8oH9AfgT
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@PatrickJosephB,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@germangfeler,Inhibidores de SARS-CoV-2 dise√±ados por computadora.   Que viva la bioinform√°tica üòç
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@lucamakinen,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@BanerjeeLab_UB,"David Baker's group reporting ""the power of computational protein design for rapidly generating potential therapeutic candidates against pandemic threats."".   https://t.co/9tZPkP9XFw"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@shozeb_haider,This is what computational predictions are capable of. Amazing work by David Baker  & Co. https://t.co/tTT4o23vk3
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Vegaismyname,RT @druselabs1: https://t.co/OuEXcHq30d De novo design of picomolar SARS-CoV-2 miniprotein inhibitors by David Baker Longxing Cao (et al.)‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@masha_niv,RT @FrankNoeBerlin: This is incredible
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@CisnerosRes,#compchem
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@HelliwellJohn,RT @druselabs1: https://t.co/OuEXcHq30d De novo design of picomolar SARS-CoV-2 miniprotein inhibitors by David Baker Longxing Cao (et al.)‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@FeixiongCheng,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@SoleCelej,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@SuperSciJew,RT @Craggs_Lab: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors - David Baker and #Rosetta really pull it out of the bag here‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Hermanslab,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ProfSyK,A study of which shows the power of in silico molecular design - really cool.
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@fedextasis,@emmaiarussi para vos
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Craggs_Lab,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors - David Baker and #Rosetta really pull it out of the bag here‚§µÔ∏è https://t.co/6B7spdFGUu
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@vnzloy,"""De novo design of picomolar SARS-CoV-2 miniprotein inhibitors David Baker et al. bioRxiv. posted 3 August 2020, 10.1101/2020.08.03.234914 https://t.co/XWX7AAVVSs"" https://t.co/mpuiuPfJdZ"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@deepgradient,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ManRat26,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@druselabs1,https://t.co/OuEXcHq30d De novo design of picomolar SARS-CoV-2 miniprotein inhibitors by David Baker Longxing Cao (et al.) Michael Diamond David Veesler  saturation mutagenesis libraries  a small number of closely related 91 sequences  LCB1-LCB8 https://t.
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@chemeslab,Designed SARSCoV-2 RBD inhibitors
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@NikoMcCarty,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@MhkoScience,This is truly amazing. I just wonder who will produce it and how fast this could reach the market. https://t.co/0p1wmDz69q
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@JaviMedChem,"Wow, an impressive work https://t.co/blV1cDArMM"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ikalvet,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@pablitoarantes,RT @mdpoleto: Excellent read!   https://t.co/posXAzZyj0
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@mdpoleto,Excellent read!   https://t.co/posXAzZyj0
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Jonnygfrazer,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/rKpm9JBARs
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@MingqingCai,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Jamie_Rossjohn,"RT @JoelPMackay: The Baker lab has, not surprisingly, turned their protein design skills to COVID-19. Sub-nM inhibitors - shows how far ROS‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@eugenevalkov,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors | bioRxiv https://t.co/hW14vyKshX
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@JoelPMackay,"The Baker lab has, not surprisingly, turned their protein design skills to COVID-19. Sub-nM inhibitors - shows how far ROSETTA has come. It's been amazing to see it evolve over the years. https://t.co/flpMMapB7J"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@SynBioGrant,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@capdevilalab,RT @mellases: Computational design of hyperstable miniproteins (~60 aa) which bind specifically to SARS-CoV with high affinity. And CryoEM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@BeneschResearch,RT @BobSchiffrin: https://t.co/gj7miB5euR
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@vignesh_k757,Wow.
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@BrausenManuel,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@jsteward2930,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@JamesLingford,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@GonzaParra_,"""The structural bioinformatics field is in the past.."".. The structure bioinformatics field: ""De novo design of picomolar SARS-CoV-2 miniprotein inhibitors"" üò±üñ§. Amazing David Baker! https://t.co/CiUcn40z1q"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@PromPreprint,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/DN4OPhcEub
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Eyesgack,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@countrsignal,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@YoungjunPark11,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Rosario_Strano,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@RoryCHenderson,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/xUg5HAYpet
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@golobor,RT @FrankNoeBerlin: This is incredible
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ArantesLab,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@joostsnijder,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Rob_Field_Lab,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@BobSchiffrin,https://t.co/gj7miB5euR
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@__Suggie__,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Mizimmer90,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@coronalexington,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@MichaelVLeVine,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@AdrianMulholla1,Beautiful and very impressive work.
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@dalvarezpaggi,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@opehache,RT @cryoEM_Papers: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/P5puPxDFcl
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@PPMC_UAB,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@GBhardwaj8,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@RommieAmaro,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@DanLikeProteins,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@FrankNoeBerlin,This is incredible
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Char35x,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@tir0__,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@KotaroTsuboyama,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ChemKritzer,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. ùóîùòÇùòÅùóµùóºùóøùòÄ: David Baker, Longxing Cao, Inna Goreshnik, Brian Coventry, James Brett Case, Lauren Miller, Lisa Kozodoy, Rita E. Chen, Lauren Carter, Alexan... https://t.co/tI0xvYrgnI https://"
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ElizabethKenkel,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@UWMolES,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@veeslerlab,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@mellases,Computational design of hyperstable miniproteins (~60 aa) which bind specifically to SARS-CoV with high affinity. And CryoEM structures of the complexes.ü§©ü§Ø
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@ajrferrari,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@Lauren06Miller,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@grocklin,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@NogiMemes,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234914,De novo design of picomolar SARS-CoV-2 miniprotein inhibitors,@vasil_katerina,RT @UWproteindesign: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors https://t.co/mJWbrL5guH | @biorxivpreprint https://t.co/‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@outbreaksci,"Contribute a rapid review or request one for ""PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outb..."" (https://t.co/4Gugcr2QTh). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.233718) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@outbreaksci,Updated #SARSCoV preprint: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak https://t.co/4Gugcr2QTh
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@PhyDyn_Papers,"PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak Arindam Maitra, Raghav, Dalal, Ali, Molin Paynter, Paul, Biswas, Ghosh, Jani, Chinnaswamy, Pati, Sahu, Mitra, Kumar Bhat, Mayor, Sarin et al https://t.co/pwUcMqWpU"
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@Rosenchild,RT @biorxiv_genomic: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  https://t.co/TtSf1w58Jk‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak. ùóîùòÇùòÅùóµùóºùóøùòÄ: Arindam Maitra, Sunil Raghav, Ashwin Dalal, Farhan Ali, Vanessa Molin Paynter, Dhiraj Paul, Nidhan K Biswas, A... https://t.co/rv11lioVPe https://"
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@outbreaksci,"Contribute a rapid review or request one for ""PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outb..."" (https://t.co/4Gugcr2QTh). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.233718) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@outbreaksci,New #SARSCoV preprint: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak https://t.co/4Gugcr2QTh
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@nogodbutarceus,"Finally, a govt sponsored research work is being made public"
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@TavoGLC,RT @biorxivpreprint: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  https://t.co/EBPBN7kr7i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@Naresh_hanchate,RT @biorxivpreprint: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  https://t.co/EBPBN7kr7i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@COVID_Papers,üìù PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  medRxiv or bioRxiv https://t.co/hGBkKJvpib #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@jsteward2930,RT @biorxiv_genomic: PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  https://t.co/TtSf1w58Jk‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@biorxiv_genomic,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  https://t.co/TtSf1w58Jk #biorxiv_genomic
http://biorxiv.org/cgi/content/short/2020.08.03.233718,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak,@biorxivpreprint,PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak  https://t.co/EBPBN7kr7i #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@Sheng_Zhang_,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@outbreaksci,"Contribute a rapid review or request one for ""Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease"" (https://t.co/19v5DIj1gO). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234872) at https://t.co/RnurTL3DyM @outbreaksci @PRE"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@outbreaksci,Updated #SARSCoV preprint: Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease https://t.co/19v5DIj1gO
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@harbari,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@CMTParrocha,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@MGordonJoyce,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@NowickGroup,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@moveonlyforward,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@Kenzibit,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@QuantumG,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@DrSeeboth,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@KittySn52889207,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@anjbth,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@Angela_Biochem,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@Cosmicpixle,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@khanimambobar,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@jessdarkcyde,"RT @DelthiaRicks: Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@DelthiaRicks,"Scientists get 'initial hit' in #COVID19-specific drug. James Nowick, professor of chemistry at UC Irvine has developed a ring-shaped molecule called a macrocycle designed to gum up the machinery of the virus by blocking an enzyme essential to replication"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@lissathechemist,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@chelseajones873,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@impofthediverse,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@Vy_Dong_Group,More reasons to love cyclic peptides from our friends and collaborators in the @NowickGroup
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@CMTParrocha,"RT @MajKrumberger: The first pre-print from our group, and the first manuscript I got to contribute a little bit to. Give it a read if you'‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@chang_c_liu,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@G_Guagli,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@UCIChemistry,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease. ùóîùòÇùòÅùóµùóºùóøùòÄ: Adam G Kreutzer, Maj Krumberger, Chelsea Marie T Parrocha, Michael A Morris, Gretchen Guaglianone, James S Nowick https://t.co/ZsQrpncRf8 https://t.co/63H"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@rachelwmartin,A cyclic peptide inhibitor for the SARS-CoV-2 main protease from our collaborators in the Nowick lab!
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@lissathechemist,"RT @MajKrumberger: The first pre-print from our group, and the first manuscript I got to contribute a little bit to. Give it a read if you'‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@SamdinTuan,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@MajKrumberger,"The first pre-print from our group, and the first manuscript I got to contribute a little bit to. Give it a read if you're interested in SARS-CoV-2 antivirals and want to see our take on it. Since this is a new area of research for us we'd love some feedba"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@morris_m_chem,RT @NowickGroup: Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@NowickGroup,Our first pre-print is now out on @biorxivpreprint. Antivirals are something we just recently got interested in and are looking forward to any and all feedback on our manuscript. https://t.co/pFBBhPU0tS
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@outbreaksci,"Contribute a rapid review or request one for ""Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease"" (https://t.co/19v5DIj1gO). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234872) at https://t.co/RnurTL3DyM @outbreaksci @PRE"
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@outbreaksci,New #SARSCoV preprint: Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease https://t.co/19v5DIj1gO
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@bxv_biochem,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease https://t.co/7ESJeSFR9t
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@COVID_Papers,üìù Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease  medRxiv or bioRxiv https://t.co/uFIDCTNovO #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.03.234872,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease,@biorxivpreprint,Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease  https://t.co/P19jZMvddj #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outbreaksci,Updated #SARSCoV preprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/CDJCLI2iId
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""De novo design of ACE2 protein decoys to neutralize SARS-CoV-2"" (https://t.co/CDJCLI2iId). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.231340) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outbreaksci,Updated #COVID19 preprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/CDJCLI2iId
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@Kotomo1020,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@areli_moran,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/Ukcf1jBEp2
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@omi_UT,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@CameronSparr,RT @n_codina: At @neoleukin we have designed de novo protein decoys that block #SARSCoV2 from entering and infecting the cells - by mimicki‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@rkakamilan,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@val_spiteri,RT @n_codina: At @neoleukin we have designed de novo protein decoys that block #SARSCoV2 from entering and infecting the cells - by mimicki‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outyoshipon,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@drMSupervia,Exciting news! @neoleukin designed a de novo protein that blocks #SARSCoV2 from entering and infecting the cells. They #research team did an incredible job in <10w !! Congrats for the rapid #pandemic response! Proud of my friend Luis Blancas üîù #COVID19
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@dreycey,"Wow.  This was an exciting read. A decoy for SARS-CoV-2, dubbed CTC-445, was designed using a computational, selection, and directed evolution pipeline (starting with hACE2). The authors at @neoleukin did an incredible job here. Make sure to read this! üëè h"
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@reinaworld_,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@msparrpdx,RT @n_codina: At @neoleukin we have designed de novo protein decoys that block #SARSCoV2 from entering and infecting the cells - by mimicki‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@takigawamizuki,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@ayanosatoh,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@Ag_smith,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@n_codina,"At @neoleukin we have designed de novo protein decoys that block #SARSCoV2 from entering and infecting the cells - by mimicking the binding interface of its receptor, so it won't be able to mutate to escape! ü¶†üôÖ‚Äç‚ôÄÔ∏èüíä Check them out here: https://t.co/hob6x2w"
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2. ùóîùòÇùòÅùóµùóºùóøùòÄ: Thomas William Linsky, Renan Vergara, Nuria Codina, Jorgen W Nelson, Matthew J Walker, Wen Su, Tien-Ying Hsiang, Katharina Esser-Nobis, Kevi... https://t.co/GNejAfZcrx https://"
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@shintaro_minami,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@CovidLabs,RT @nelsondl: Very proud of my son Jorgen‚Äôs hard work to develop a SARS-CoV2 (and CoV1!) decoy protein! It shows potent and specific viral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@RapidCovidLabs,RT @nelsondl: Very proud of my son Jorgen‚Äôs hard work to develop a SARS-CoV2 (and CoV1!) decoy protein! It shows potent and specific viral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@helloanum,"in addition, https://t.co/9BBBjCXBxM Crazy-tight de novo binders from the Baker lab  https://t.co/2cZBupyHqc Impressively stable mini-proteins"
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@tomoeit0524,RT @biorxivpreprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2  https://t.co/q8Z4S5Ihp7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@mubear36,RT @nelsondl: Very proud of my son Jorgen‚Äôs hard work to develop a SARS-CoV2 (and CoV1!) decoy protein! It shows potent and specific viral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@AzaiJude,RT @nelsondl: Very proud of my son Jorgen‚Äôs hard work to develop a SARS-CoV2 (and CoV1!) decoy protein! It shows potent and specific viral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@nelsondl,RT @tlinsky00: Preprint is out! Our research team has designed new proteins unlike any found in nature that prevent the #SARSCoV2 virus fro‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@genperisi,RT @nelsondl: Very proud of my son Jorgen‚Äôs hard work to develop a SARS-CoV2 (and CoV1!) decoy protein! It shows potent and specific viral‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@nelsondl,Very proud of my son Jorgen‚Äôs hard work to develop a SARS-CoV2 (and CoV1!) decoy protein! It shows potent and specific viral neutralization with low nanomolar affinity. Congrats to all at @neoleukin for the rapid pandemic response! Read all about it: https
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@rinrin3306,„Éá„Ç≥„Ç§„Åã„Äú„Å™„Çã„Åª„Å© De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/HtOjzpgL9X
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@takatoh1,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@skm58,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@0090bb,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@0090bb,RT @biorxivpreprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2  https://t.co/q8Z4S5Ihp7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@ByOcchi,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@kira_kira_world,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@chemicl_t,RT @sanbon_exe: Neoleukin Therapeutics„ÅßÊê∫„Çè„Å£„ÅüÁ†îÁ©∂„ÅåbioRxiv„Å´ÂÖ¨Èñã„Åï„Çå„Åæ„Åó„ÅüÔºÅ Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ‰æµÂÖ•Âè£„Å´„Å™„Å£„Å¶„Çã„Éí„Éà„ÅÆËÜú„Çø„É≥„Éë„ÇØË≥™„ÅÆ‰∏ÄÈÉ®„Çí‰Ωø„Å£„Å¶È†ë‰∏à„Å™„Çø„É≥„Éë„ÇØË≥™„ÇíÊñ∞„Åó„Åè‰Ωú„Å£„Åü„Çâ„ÄÅÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„Å´„Åè„Å£„Å§„ÅÑ„Å¶ÊÑüÊüì„ÇíÈò≤„Åí„Çì„Åò„ÇÉ„Å≠ÔºÅ‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/CDJCLI2iId
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""De novo design of ACE2 protein decoys to neutralize SARS-CoV-2"" (https://t.co/CDJCLI2iId). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.231340) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@outbreaksci,New #COVID19 preprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/CDJCLI2iId
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@HA_official1111,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@ddd_ppp_story,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@hir0pon_2,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@noriheese,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@Plura36,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@n0rr,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@piyota0,RT @ryotaiino: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/4JARSbj5pW
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@piyota0,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@ShunsukeTAGAMI,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@ryotaiino,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/4JARSbj5pW
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@Ag_smith,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@skm58,RT @shintaro_minami: ‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@shintaro_minami,‰ºöÁ§æ„Åã„Çâ„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÈñ¢ÈÄ£„ÅÆ‰∫∫Âè£„Çø„É≥„Éë„ÇØË≥™Ôºà„Éí„Éà„ÅÆËÜúÈñ¢ÈÄ£„Çø„É≥„Éë„ÇØË≥™„Å´‰ºº„Åõ„ÅüÂΩ¢Áä∂„ÅßÂõÆ„Å´„Å™„Å£„Å¶„ÄÅ„Ç¶„Ç§„É´„Çπ„ÅÆÁ¥∞ËÉûÂÜÖ„Å∏„ÅÆ‰æµÂÖ•„ÇíÈòªÂÆ≥„Åô„ÇãÔºâ„ÅÆ„Éá„Ç∂„Ç§„É≥Ë´ñÊñá„Åå„Éë„Éñ„É™„ÉÉ„Ç∑„É•„Åï„Çå„Åæ„Åó„Åü„ÄÇ  https://t.co/dMaHLAPLTp
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@tlinsky00,Preprint is out! Our research team has designed new proteins unlike any found in nature that prevent the #SARSCoV2 virus from entering cells. Proud to be part of the amazing @neoleukin team! #COVID19 #coronavirus
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@skm58,„Çè„Åü„Åó„ÅÆ„Åõ„ÅÑ„ÅßÂ≠¶‰Ωç„ÅåÂç±„Å∂„Åæ„Çå„Å¶„ÇãÂæåËº©„Åï„Çì„ÄÅ„Åä„ÇÅ„Åß„Å®„ÅÜ„Åî„Åñ„ÅÑ„Åæ„Åô
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@bxv_biochem,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 https://t.co/EEMzRpExac
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@DrgDrshyaViveka,RT @biorxivpreprint: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2  https://t.co/q8Z4S5Ihp7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.231340,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2,@biorxivpreprint,De novo design of ACE2 protein decoys to neutralize SARS-CoV-2  https://t.co/q8Z4S5Ihp7 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@outbreaksci,"Contribute a rapid review or request one for ""Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfa..."" (https://t.co/NlpjjmBZpa). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234716) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@outbreaksci,Updated #SARSCoV preprint: Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design https://t.co/NlpjjmBZpa
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design. ùóîùòÇùòÅùóµùóºùóøùòÄ: Monica Rosas-Lemus, George Minasov, Ludmilla ... https://t.co/kb56hh4oUY https://"
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@outbreaksci,"Contribute a rapid review or request one for ""Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfa..."" (https://t.co/NlpjjmBZpa). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234716) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@outbreaksci,New #SARSCoV preprint: Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design https://t.co/NlpjjmBZpa
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@rabc92_,RT @ribosome_papers: bioRxiv:  Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals ne‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@jsteward2930,RT @ribosome_papers: bioRxiv:  Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals ne‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@ribosome_papers,bioRxiv:  Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design https://t.co/qKyL6bIJZG
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@COVID_Papers,üìù Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design  medRxiv or bioRxiv https://t.co/DSL1U4DinT #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@biorxiv_micrbio,Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for ...  https://t.co/V026w6ZrIm #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.03.234716,Structure of SARS-CoV-2 2‚Ä≤-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design,@biorxivpreprint,Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design  https://t.co/mCHWfiS1ML #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@outbreaksci,Updated #SARSCoV preprint: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity https://t.co/OMzc390I4d
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@outbreaksci,"Contribute a rapid review or request one for ""Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediat..."" (https://t.co/OMzc390I4d). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.233536) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@outbreaksci,Updated #COVID19 preprint: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity https://t.co/OMzc390I4d
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@Shafiq70090570,RT @glycopreprint: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity https://t.co/OFhob‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@glycopreprint,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity https://t.co/OFhobLYOwZ #glycotime
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@MCB_Illinois,RT @tomcaniels: Great work by the Wilson lab and @wchnicholas @vanGilsLab to characterize one of our cross-neutralizing SARS-CoV-2 antibodi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. ùóîùòÇùòÅùóµùóºùóøùòÄ: Hejun Liu, Nicholas C. Wu, Meng Yuan, Sandhya Bangaru, Jonathan L. Torres, Tom G. Caniels, Jelle van ... https://t.co/oMXTVZyQLL https://"
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@dirkeggink,RT @tomcaniels: Great work by the Wilson lab and @wchnicholas @vanGilsLab to characterize one of our cross-neutralizing SARS-CoV-2 antibodi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@YasaWatanabe,RT @tomcaniels: Great work by the Wilson lab and @wchnicholas @vanGilsLab to characterize one of our cross-neutralizing SARS-CoV-2 antibodi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@wchnicholas,RT @tomcaniels: Great work by the Wilson lab and @wchnicholas @vanGilsLab to characterize one of our cross-neutralizing SARS-CoV-2 antibodi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@tomcaniels,Great work by the Wilson lab and @wchnicholas @vanGilsLab to characterize one of our cross-neutralizing SARS-CoV-2 antibodies with high-res crystallography #antibodies #COVID19
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@outbreaksci,New #SARSCoV preprint: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity https://t.co/OMzc390I4d
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@outbreaksci,"Contribute a rapid review or request one for ""Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediat..."" (https://t.co/OMzc390I4d). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.233536) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@outbreaksci,New #COVID19 preprint: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity https://t.co/OMzc390I4d
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@imaginarybar,"‚ÄúThese findings, along with structural and functional rationale for the epitope conservation, provide a blueprint for development of more universal SARS-like coronavirus vaccines and therapies.‚Äù"
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@COVID_Papers,üìù Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity  medRxiv or bioRxiv https://t.co/4syJC3OR7F #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@biorxiv_micrbio,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity  https://t.co/3xTl0YG7Mg #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.02.233536,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity,@biorxivpreprint,Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity  https://t.co/Tr2Pasp8nW #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@MarkQuarter,RT @GreningerLab: New preprint from our lab on SARS-CoV-2 ORF6 and its shutdown of nucleocytoplasmic trafficking via nuclear pore interacti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@MarkQuarter,RT @outbreaksci: Updated #SARSCoV preprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98 h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and ..."" (https://t.co/AyAm7BI5ek). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234559) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@outbreaksci,Updated #SARSCoV preprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98 https://t.co/AyAm7BI5ek
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@SGinossarLab,RT @GreningerLab: New preprint from our lab on SARS-CoV-2 ORF6 and its shutdown of nucleocytoplasmic trafficking via nuclear pore interacti‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@GreningerLab,New preprint from our lab on SARS-CoV-2 ORF6 and its shutdown of nucleocytoplasmic trafficking via nuclear pore interactions. We saw surprising differences between SARS-CoV and SARS-CoV-2 ORF6 in shutting down reporter protein production.
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@raphaelboffin,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@MassatoHirai,RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98. ùóîùòÇùòÅùóµùóºùóøùòÄ: Amin Addet‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@TheAbhijitDN,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98. ùóîùòÇùòÅùóµùóºùóøùòÄ: Amin Addetia, Nicole A.P. Lieberman, Quynh Phung, Hong Xie, Pavitra Roychoudhury, Michelle A Loprieno, Meeili... https://t.co/l7eBMUBphk https://"
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@LAsskoul,RT @DrRomainBrunel: Donde estaba este paper la semana pasada cuando dije en una reuni√≥n internacional que no sab√≠amos a qu√© serv√≠an la mayo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@vinayaka1prasad,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@HTLVnet,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@CharlotteFare,RT @schmidt_lab: SARS-Cov2 pitches in on the theme of large cargo transport through the NPC: How to get cellular mRNAs out of the way while‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@IgorUlitsky,RT @schmidt_lab: SARS-Cov2 pitches in on the theme of large cargo transport through the NPC: How to get cellular mRNAs out of the way while‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@ShorterLab,RT @schmidt_lab: SARS-Cov2 pitches in on the theme of large cargo transport through the NPC: How to get cellular mRNAs out of the way while‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@Ruben0628,RT @DrRomainBrunel: Donde estaba este paper la semana pasada cuando dije en una reuni√≥n internacional que no sab√≠amos a qu√© serv√≠an la mayo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@JayChance12,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and ..."" (https://t.co/AyAm7BI5ek). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.234559) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98 https://t.co/AyAm7BI5ek
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@RossollLab,RT @schmidt_lab: SARS-Cov2 pitches in on the theme of large cargo transport through the NPC: How to get cellular mRNAs out of the way while‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@schmidt_lab,SARS-Cov2 pitches in on the theme of large cargo transport through the NPC: How to get cellular mRNAs out of the way while making sure to maintain a steady supply of ribosomes? Easy: By reconfiguring the scaffold-client interactions of the FG hydrogel!
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@Ramona_Bio,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@DrRomainBrunel,Donde estaba este paper la semana pasada cuando dije en una reuni√≥n internacional que no sab√≠amos a qu√© serv√≠an la mayor√≠a de las proteinas accesorias del genoma?
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@xtalnzatter,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@COVID_Papers,üìù SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  medRxiv or bioRxiv https://t.co/MzAwONb9jm #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@TavoGLC,RT @biorxivpreprint: SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@biorxiv_micrbio,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/zHqSmpZXbU #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.03.234559,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98,@biorxivpreprint,SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98  https://t.co/0MOYww5A9I #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@outbreaksci,"Contribute a rapid review or request one for ""Functional immune mapping with deep-learning enabled phenomics applied to immunomodulato..."" (https://t.co/cStSc6IY34). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.233064) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@outbreaksci,Updated #SARSCoV preprint: Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery https://t.co/cStSc6IY34
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@e_petsalaki,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@zavaindar,Drug discovery with cat memes üêà
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@bertonearnshaw,"He promised a #tweetorial, and does he deliver.  @ImranSHaque uses jumping cats to describe @RecursionPharma‚Äôs method of visualizing high dimensional drug rescue. Stop what you are doing and read through this, it is worth your time."
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@RecursionChris,"Curious about how our @RecursionPharma machine works to help discover new drugs? In terms of Cat Gifs?  Oh yeah, check it out!"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@dgmacarthur,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@bungobot1,RT @Datascience__: Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@techtrendingnow,RT @Datascience__: Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery h‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Datascience__,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery https://t.co/fao853d6VQ  #DeepLearning
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@JaxToOnething,This should be trending by end of day Tuesday.
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@JaxToOnething,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@GeePawHill,"Imran, this is brilliant. That I almost get it is an astonishing feat of pedagogy. Keep up the great work."
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@bmabey,RT @i_draw_hexagons: It takes a little time to describe how 2D projections of high-dimensional drug rescues work @RecursionPharma. It takes‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@epuujee,RT @TinaMarrLarson: All science should be explained using cat gifs üòÇüêà https://t.co/d3hyDmrKPo
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@TinaMarrLarson,All science should be explained using cat gifs üòÇüêà
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Coryandar,RT @RecursionPharma: We are excited to announce our preprint on functional immune mapping with deep-learning enabled #phenomics. Read the p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@WesleyQian,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@jchodera,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Olu_GH,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@FishCsCells,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ElementoLab,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ThienVu91,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@qiutip1,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@NeedhiBhalla,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@RecursionPharma,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@rravi,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@LJIMicroCore,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@BioTurboNick,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@allmeasures,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@_JMeseguer,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@i_draw_hexagons,RT @DrAnneCarpenter: It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of imm‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@DrAnneCarpenter,"It's been tough keeping quiet; so happy I can now share this now!  Recursion made a beautiful systems-level map of immune pathways using cell morphology as input data. That alone would be a huge advance, but then they go & rapid-fire screen for TGFa/b,"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@gibson861,RT @RecursionPharma: Think these 200k images are cool? Check out the 430k+ images we‚Äôve already released at https://t.co/xQz5M08wOa. If tha‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@rajatdesikan,@PraneshPadmana1 This is a fantastic way to visualize drug-response üëáüèª
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Datascience__,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery https://t.co/fao853d6VQ  #DeepLearning
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@brieski,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@allmeasures,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@nathanlazar,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@alexras,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Arnaudkirsch,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@i_draw_hexagons,It takes a little time to describe how 2D projections of high-dimensional drug rescues work @RecursionPharma. It takes true inspiration to do it with cats. Well done @ImranSHaque
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Damkyan_Omega,RT @ImranSHaque: Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XA‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"Instead of measuring say, two parameters like viral titer and cell count, we measure 100s-1000s of parameters describing the morphology of cells in a plate. This information captures a lot of biology, as @i_draw_hexagons described in his tweetorial: https:"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"Happy Monday! In today's #tweetorial on our recent preprint  describing @RecursionPharma's platform (https://t.co/p1H7O7XAFP), I'll explain the unusual 2-D drug response plots we use there and in our COVID-19 screen data at https://t.co/MFMeW7YLtV..  in te"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@may_khanna,@Niloufar_mls
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@HarryHSolo,RT @i_draw_hexagons: @RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with exa‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@MogulAzam,RT @i_draw_hexagons: @RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with exa‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@BlkHwk0ps,RT @i_draw_hexagons: @RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with exa‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@MCAllenby,RT @i_draw_hexagons: @RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with exa‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ChrisRodell2,RT @i_draw_hexagons: @RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with exa‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@nathanlazar,"RT @allmeasures: It's not just disease states we can tell apart. We can identify drug mechanism-of-action from the images, too.   Within, s‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"RT @allmeasures: It's not just disease states we can tell apart. We can identify drug mechanism-of-action from the images, too.   Within, s‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"I got stuck in Zoom meetings like the rest of you, so I turned it over to @i_draw_hexagons to do the second #tweetorial about @RecursionPharma's preprint. He was the mastermind of this chunk of work, so you should read his masterful retelling!"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@zavaindar,RT @i_draw_hexagons: @RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with exa‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@allmeasures,"It's not just disease states we can tell apart. We can identify drug mechanism-of-action from the images, too.   Within, say, mTOR inhibitors, we can tell if they're rapalogs,  PI3K inhibitors, or mTORC1/2! https://t.co/LIf1wc5sGg"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@i_draw_hexagons,"@RecursionPharma‚Äôs recent preprint https://t.co/x178kdFtE4 on cell images and deep learning to hunt for drugs with examples in fibrosis, inflammation and COVID-19. It starts with a description of how we model the complexity of the immune system - and that"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@barneyp,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"@__ice9 @__philipn__ This is all wet lab data; ample details are provided in our preprint: https://t.co/p1H7O7XAFP. You're even welcome to download the ~860GB of primary screen images, image embeddings and metadata at https://t.co/ZLQXe7XsZM. The plots are"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@nathanlazar,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@jeremysayz,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@jchodera,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@thechadwick,"RT @i_draw_hexagons: One of my favorite figs from our preprint. Lines are high-dimensional similarity between stimulants, colored by the ce‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@bertonearnshaw,"The one and only @ImranSHaque gives us the first of 3(?) #tweetorial  on @RecursionPharma's COVID-19 work.  Don't forget, all the data in this preprint is yours at https://t.co/fhyImY81lP."
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@_RedFrog,RT @houndcl: https://t.co/c4sEdqcS9C endorse this dataset from @RecursionPharma. Whoever work on #COVID19 preclinical drug discovery should‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@AlexSamTG,RT @houndcl: https://t.co/c4sEdqcS9C endorse this dataset from @RecursionPharma. Whoever work on #COVID19 preclinical drug discovery should‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@KikiMatsumoto,"RT @ImranSHaque: We don't just talk about large interconnected immunology datasets, we bring receipts:  https://t.co/BFBb6h6YE7 https://t.c‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@houndcl,"https://t.co/c4sEdqcS9C endorse this dataset from @RecursionPharma. Whoever work on #COVID19 preclinical drug discovery should take a look. But I think it's also important to check #ACTT2 result (baricitinib), which will have result soon - it will help val"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@vandontweets,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@RecursionPharma,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,We've shown this in our @RecursionPharma preprints examining active SARS-CoV-2 infection in primary (not immortalized!) human cells: https://t.co/p1H7O7XAFP and https://t.co/eNFg4Pjh8r.
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@EllisJoel41,RT @RecursionPharma: We are excited to announce our preprint on functional immune mapping with deep-learning enabled #phenomics. Read the p‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@sameersoi,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Andrewdblevins,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@i_draw_hexagons,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@srikosuri,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@houndcl,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@just_whatever,RT @mattocko: Thread üëá
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@mattocko,Thread üëá
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@allmeasures,"RT @ImranSHaque: First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"First #tweetorial from @RecursionPharma's new preprint is on our COVID-19 research. I hear you: ""uh, didn't you talk about that 3 months ago?""  Only part of it.  TL;DR: if you liked our viral work, you'll love our cytokine storm work.  https://t.co/p1H7O7X"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@WonderMixTape,"RT @ImranSHaque: So much data released by the @RecursionPharma team today, I'll need 2-3 #tweetorial threads to do it justice...  Preprint:‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ron_alfa,RT @bertonearnshaw: Highlighting again the huge data and preprint release by @RecursionPharma yesterday.  You can now explore our covid dru‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@TinaMarrLarson,RT @bertonearnshaw: Highlighting again the huge data and preprint release by @RecursionPharma yesterday.  You can now explore our covid dru‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@wsbpress,"RT @ImranSHaque: We don't just talk about large interconnected immunology datasets, we bring receipts:  https://t.co/BFBb6h6YE7 https://t.c‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@mmsltn,"RT @ImranSHaque: So much data released by the @RecursionPharma team today, I'll need 2-3 #tweetorial threads to do it justice...  Preprint:‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@draparente,"RT @ImranSHaque: So much data released by the @RecursionPharma team today, I'll need 2-3 #tweetorial threads to do it justice...  Preprint:‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@cispt2,"RT @RecursionPharma: @edyong209 We 100% agree ‚Äî success in immunology drug discovery, COVID-19 and challenges ahead depend on a better unde‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@RecursionChris,"RT @RecursionPharma: @edyong209 We 100% agree ‚Äî success in immunology drug discovery, COVID-19 and challenges ahead depend on a better unde‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@ImranSHaque,"We don't just talk about large interconnected immunology datasets, we bring receipts:  https://t.co/BFBb6h6YE7 https://t.co/MTSYhYwE8K https://t.co/MFMeW7YLtV"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@bertonearnshaw,"RT @RecursionPharma: @edyong209 We 100% agree ‚Äî success in immunology drug discovery, COVID-19 and challenges ahead depend on a better unde‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@i_draw_hexagons,"RT @RecursionPharma: @edyong209 We 100% agree ‚Äî success in immunology drug discovery, COVID-19 and challenges ahead depend on a better unde‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@RecursionPharma,"@edyong209 We 100% agree ‚Äî success in immunology drug discovery, COVID-19 and challenges ahead depend on a better understanding of the system. Our take: evolve out of measurement of each factor in isolation and build large, interconnected datasets. Our fir"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@EduardoSuarez25,"RT @i_draw_hexagons: One of my favorite figs from our preprint. Lines are high-dimensional similarity between stimulants, colored by the ce‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@allmeasures,"RT @i_draw_hexagons: One of my favorite figs from our preprint. Lines are high-dimensional similarity between stimulants, colored by the ce‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@RecursionChris,LOVE that figure Mike!
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@machine_cuisine,I loved working on this with you @i_draw_hexagons! So proud of how it turned out!
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@i_draw_hexagons,"One of my favorite figs from our preprint. Lines are high-dimensional similarity between stimulants, colored by the cell type where the similarity was observed. Heatmaps in SI show they even sub-cluster by class. @machine_cuisine @RecursionPharma https://t"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@Aashiq_Kachroo,"RT @ImranSHaque: So much data released by the @RecursionPharma team today, I'll need 2-3 #tweetorial threads to do it justice...  Preprint:‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233064,Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery,@bertonearnshaw,"Highlighting again the huge data and preprint release by @RecursionPharma yesterday.  You can now explore our covid drug screen results here: https://t.co/fH8HjF8hIT  Preprint: https://t.co/2M634sFA5a Data releases: https://t.co/9IdVu0qjAe, https://t.co/Kt"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation..."" (https://t.co/bF0ZoJv6va). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.233866) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@outbreaksci,"Updated #SARSCoV preprint: SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein https://t.co/bF0ZoJv6va"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@christymaginn,@Zigmanfreud How do you know Sweden had the same strain of the virus that the US experienced? In any state??  Swedish researchers say their mapping leads to novel mutations.  https://t.co/vpyg6J3iwZ
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@didaclopez,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein. ùóîùòÇùòÅ‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein. ùóîùòÇùòÅùóµùóºùóøùòÄ: Tatiany Aparecida Teixeira Soratto, Hamid Darban, Annelie Bjerkner, Maarten Coorens, Jan Albe... https://t.co/K4pD9vypWM https://"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@ian_hoffecker,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein https://t.co/OGGym4Dmdr"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation..."" (https://t.co/bF0ZoJv6va). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.03.233866) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@outbreaksci,"New #SARSCoV preprint: SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein https://t.co/bF0ZoJv6va"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@cartalop,Very cool work from @bjpaan lab!
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@bjpaan,"RT @biorxivpreprint: SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein  https:/‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@bjpaan,https://t.co/8eeBiRTcS6 #bioRxiv #karolinskainst
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@helioRocha_,"#bioRxiv   SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein    #bioinfo https://t.co/jVbAucKfFV"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@COVID_Papers,"üìù SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein  medRxiv or bioRxiv https://t.co/ME3dJsv319 #COVID19 #COVID19Papers #SARSCoV2"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@brainsinacup,"RT @biorxiv_bioinfo: SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein  https:/‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@biorxiv_bioinfo,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein  https://t.co/bMhEWIkvOD #biorxiv_bioinfo"
http://biorxiv.org/cgi/content/short/2020.08.03.233866,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein",@biorxivpreprint,"SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein  https://t.co/cyrpLl01sM #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@alhamalhu,ÿ™ŸÖ ÿßÿÆÿ™ÿ®ÿßÿ± ÿπŸÑÿßÿ¨ ÿßŸÑÿßÿ¨ÿ≥ÿßŸÖ ÿßŸÑŸÖÿ∂ÿßÿØÿ© ÿ®ÿßŸÑÿ™ÿπÿßŸàŸÜ ŸÖÿπ Ÿàÿ≤ÿßÿ±ÿ© ÿßŸÑÿØŸÅÿßÿπ ÿßŸÑÿßŸÖÿ±ŸäŸÉŸäÿ© ÿ®ÿ≠ŸÇŸÜ ŸÖÿ¨ŸÖŸàÿπÿ© ŸÖŸÜ ÿßŸÑŸáÿßŸÖÿ≥ÿ™ÿ± ÿ®ÿßŸÑÿßÿ¨ÿ≥ÿßŸÖ Ÿàÿ™ŸÖ ÿ™ÿπÿ±Ÿäÿ∂Ÿáÿß ŸÑŸÑŸÅŸäÿ±Ÿàÿ≥   ÿßŸÑŸÜÿ™Ÿäÿ¨ÿ© ŸÉÿßŸÜÿ™ ÿ±ÿßÿ¶ÿπÿ© ŸàÿßŸÜŸáÿß ŸÑŸÖ ÿ™ÿµÿßÿ® ÿ®ÿßŸÑŸÖÿ±ÿ∂  https://t.co/oFS6pp1Btw
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@houndcl,@LucreSnooker https://t.co/d4vqFqMZwp Cell-to-cell direct spread may explain the much worse performance of REGN-COV2 in early treatment (d1) compared to prophylaxis?
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@engelbio,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/E2TKmz1BY2
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@keithwms,"RT @engr1624: In the fight against #SARSCoV2, there is a short-term alternative to vaccination: direct introduction of pr√™t-√†-porter antibo‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@engr1624,"In the fight against #SARSCoV2, there is a short-term alternative to vaccination: direct introduction of pr√™t-√†-porter antibodies. Here, @regeneron scientists & primate research colleagues describe results of REGN-COV2 tests in macaques and hamsters."
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@keithwms,"@Regeneron's #REGNCOV2 approach is showing promise vs. #SARSCoV2, as an ~alternative~ to vaccination. This preprint offered by Regeneron + primate research collaborators describes immunity raised in macaques & hamsters dosed w/ antibodies REGN10987/109"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@bpdbonkers,RT @thelonevirologi: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@2mstephane,RT @twhitfill: Exciting preclinical data with Regeneron's antibody cocktail REGN-COV-2 (REGN10987+REGN10933) as a prophylaxis and therapeut‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@ian_silber,"RT @SwiftBioSci: A Huge Step Forward toward a CoV-2 Therapeutic Vaccine from Regereron - Very proud of Swift Biosciences, Inc for developin‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@virology_chitra,RT @thelonevirologi: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@louvetou,RT @thelonevirologi: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@JoseffKaddash,RT @thelonevirologi: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@WFrancisEsq,RT @thelonevirologi: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@NaphiSoc,RT @thelonevirologi: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jC‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@thelonevirologi,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/08jCpgmMf5
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@HappyChicks4,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/89cd3YvYgl https://t.co/dJOomXruVT
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@behaviorben,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@safiume,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Noahpinion,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@VicusVd,"RT @SwiftBioSci: A Huge Step Forward toward a CoV-2 Therapeutic Vaccine from Regereron - Very proud of Swift Biosciences, Inc for developin‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@COSseaton,RT @CristinaDragani: A cocktail of two #antibodies targeting the spike protein of #SARSCoV2 significantly reduced the #viral load in the lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@SwiftBioSci,"A Huge Step Forward toward a CoV-2 Therapeutic Vaccine from Regereron - Very proud of Swift Biosciences, Inc for developing and deploying the sequencing technology supporting this program. https://t.co/z65r0Ka1BH"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Buzzczbumble,RT @CristinaDragani: A cocktail of two #antibodies targeting the spike protein of #SARSCoV2 significantly reduced the #viral load in the lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@waywardlad1,RT @CristinaDragani: A cocktail of two #antibodies targeting the spike protein of #SARSCoV2 significantly reduced the #viral load in the lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@RonThornton,RT @CristinaDragani: A cocktail of two #antibodies targeting the spike protein of #SARSCoV2 significantly reduced the #viral load in the lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Occhisquieti,RT @CristinaDragani: A cocktail of two #antibodies targeting the spike protein of #SARSCoV2 significantly reduced the #viral load in the lo‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@CristinaDragani,A cocktail of two #antibodies targeting the spike protein of #SARSCoV2 significantly reduced the #viral load in the lower and upper airways and decreased virus-induced pathological sequelae when administered to Rhesus macaques or golden hamsters. https://t
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@noR_libY,ÿßŸÑŸÄ◊ë◊ù◊ë ŸÑŸÑŸÄ◊ù https://t.co/IJSASasUW9
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Sahar70129769,ÿÆÿ®ÿ± ŸáÿßŸÖ ÿ¨ÿØÿß   ÿ¥ÿ±ŸÉÿ© Regeneron   ÿ™ŸÜÿ¥ÿ± ŸÜÿ™ÿßÿ¶ÿ¨ ÿØÿ±ÿßÿ≥ÿ™Ÿáÿß ÿßŸÑŸÖŸÉŸàŸÜ ŸÖŸÜ Ÿ¢ ŸÖŸÜ ÿßŸÑÿßÿ¨ÿ≥ÿßŸÖ ÿßŸÑŸÖÿ∂ÿßÿØÿ© ÿßŸÑŸÖÿµŸÜÿπÿ© ŸÅŸä ÿßŸÑŸÖÿπŸÖŸÑ ÿ™ŸÖÿ™ ÿ™ÿ¨ÿ±ÿ®ÿ™ÿ© ŸÅŸä ŸÖÿ¨ŸÖŸàÿπÿ™ŸäŸÜ ŸÖŸÜ ÿßŸÑŸÇÿ±ŸàÿØ ŸàŸÇÿßŸÖ ÿßŸÑŸÑŸÇÿßÿ≠ ÿ®ÿßŸÑŸÇÿ∂ÿßÿ° ÿπŸÑŸâ ÿßŸÑŸÅŸäÿ±Ÿàÿ≥ Ÿàÿ™ÿ≠ŸäŸäÿØŸá ŸàÿπŸÑÿßÿ¨ ÿßŸÑŸÖÿ±ÿ∂ ÿßŸÑŸÜÿßÿ¨ŸÖ ÿπŸÜŸá.  https://t.co/siL9kXUYrw
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Rosenchild,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@KoenigSangiran,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@FabierD,https://t.co/1AdWnowbYc REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@FabierD,@MOSSIALOS @Makis_Tr @telloglou @J_Panaretos @AdonisGeorgiadi https://t.co/1AdWnowbYc Œ£œÑŒπœÇ 7 ŒôŒøœÖŒªŒØŒøœÖ Œ±ŒΩŒ≠œÄœÑœÖŒæŒ± œÑŒøœÖœÇ œÄŒ±œÅŒ±Œ∫Œ¨œÑœâ œÄœÅŒøŒ≤ŒªŒ∑ŒºŒ±œÑŒπœÉŒºŒøœçœÇ https://t.co/vZnnPatx4h
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Links_Medicus,[Preprint] REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters ‚Äì via @biorxivpreprint https://t.co/liUXTOTCO0  Commentary: https://t.co/unvqDosJM6
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@FourWinns298,Monoclonal pre-print.   REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/Y9Rz9JAGre
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Khloe38735856,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@AlmadaSabate,RT @AndyBiotech: #COVID19 Here comes some very encouraging data in non-human primate models for $REGN's keenly-watched antibody cocktail‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@murillo12345,RT @KMonkemuller: Antibody Cocktails against SARS-CoV-2 are showing promise to prevent and treat infection in animal studies.
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@viralvideovlogs,RT @majidruq: ÿØÿ±ÿßÿ≥ÿ© ŸÖÿ®ÿ¥ÿ±ÿ© ŸÑÿπŸÑÿßÿ¨ #COVID19   REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hams‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@majidruq,ÿØÿ±ÿßÿ≥ÿ© ŸÖÿ®ÿ¥ÿ±ÿ© ŸÑÿπŸÑÿßÿ¨ #COVID19   REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters ŸÉŸàŸÉÿ™ŸäŸÑ ŸÖŸÜ ÿßŸÑŸÖÿ∂ÿßÿØ ÿßŸÑÿ≠ŸäŸàŸä ŸÜÿ¨ÿ≠ ŸÅŸä ÿßŸÑŸàŸÇÿßŸäÿ© ŸàÿπŸÑÿßÿ¨ ŸÖÿ±ÿ≠ŸÑÿ© ÿßŸÑÿ≠ŸäŸàÿßŸÜ ÿßŸÑŸÇÿ±ŸàÿØ ŸàÿßŸÑŸÅŸäÿ±ÿßŸÜÿåŸàŸÅŸêŸä ÿßŸÜÿ™ÿ∏ÿßÿ± ÿßŸÑŸÖÿ±ÿ≠ŸÑÿ© ÿßŸÑŸÇÿßÿØŸÖÿ© ÿ®ÿ≥ ÿ™ÿπÿØ ÿØÿ±ÿßÿ≥ÿ© ŸÖÿ®ÿ¥ÿ±ÿ© ÿ¨ÿØÿßŸã
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Briggsly,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@TomorrowScale,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@ProfBMT,RT @AliNouriPhD: 2) Regeneron's antibodies bind the Spike of the virus - the part that sticks out and lets the virus grab and enter the hos‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Winser_NBueno,"Aqu√≠ tenemos algunos resultados de ensayos pre - cl√≠nicos prometedores, pero hay que tomarlo con cautela. El c√≥ctel de anticuerpos REGN-COV2 previene y trata la infecci√≥n por #SARSCoV2 en macacos rhesus y h√°msters. Demuestra un potencial terap√©utico. https"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@SteveClarkAdept,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@zoheirrah,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/gIVbXB0Px1
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@stevenmosher,RT @AliNouriPhD: 2) Regeneron's antibodies bind the Spike of the virus - the part that sticks out and lets the virus grab and enter the hos‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@HaroldKski,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@vipintukur,"REGN-COV2, a cocktail of two potent nAbs can greatly reduce virus load in lower & upper airway & decrease virus induced pathological sequalae when administered prophylactically or therapeutically in both rhesus macaques & hamsters   https://t.c"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@SabinaWalker18,This MUST be read with joy!
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@ptolts,"RT @R_H_Ebright: Regeneron: ""[W]e evaluate..efficacy of..[REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@ScientistMasked,"RT @R_H_Ebright: Regeneron: ""[W]e evaluate..efficacy of..[REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@SudarRajagopal,"RT @R_H_Ebright: Regeneron: ""[W]e evaluate..efficacy of..[REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@deepvard,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Biotchinvestor,"RT @R_H_Ebright: Regeneron: ""[W]e evaluate..efficacy of..[REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Cosmicpixle,"RT @R_H_Ebright: Regeneron: ""[W]e evaluate..efficacy of..[REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@R_H_Ebright,"Regeneron: ""[W]e evaluate..efficacy of..[REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load..and decrease..pathological sequalae when administered prophylactically or therapeutically.""  htt"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@R_H_Ebright,"""[W]e evaluate..in vivo efficacy of.. [REGN-OV2w] antibody cocktail in..macaques and..hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load..and decrease..pathological sequalae when administered prophylactically or therapeutically.`  https"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Bust40960533,RT @AndyBiotech: #COVID19 Here comes some very encouraging data in non-human primate models for $REGN's keenly-watched antibody cocktail‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@milospm1206,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@xilu0306,Non peer reviewed data from Regeneron antibody cocktail in Rhesus and hamsters. Tl:dr - we have tested a highly anticipated treatment and prophylaxis/pretreatment for covid-19 in animals. Very positive data in animals. Moving to human clinical trials. http
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@erwinloh,"REGN-COV2EGN-COV2, a #cocktail of two potent #neutralizing #antibodies, prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters, finds a new study (3 August 2020). #COVID19 #coronavirus   Source: https://t.co/lAQhZBNJ61 https://t.co/LRXQxu"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Adam_D_Norris,Nice! üëåüëå  REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/syhnUHfXzW
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@gracehwang1970,RT @AndyBiotech: #COVID19 Here comes some very encouraging data in non-human primate models for $REGN's keenly-watched antibody cocktail‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@NovateurBio,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@UCastellotti,This looks very promising.
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@sdearth,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@StrepGal,Excellent indeed!!!
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@davemcveyr,RT @AndyBiotech: #COVID19 Here comes some very encouraging data in non-human primate models for $REGN's keenly-watched antibody cocktail‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@SaraNayeem,RT @AndyBiotech: #COVID19 Here comes some very encouraging data in non-human primate models for $REGN's keenly-watched antibody cocktail‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@slew_foot19,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Kaelynisamazing,@__ice9
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Aesculapius1898,"RT @RNAiAnalyst: $REGN Giving whopping amounts of monoclonal antibodies just 1 day after viral challenge in monkeys+hamsters, not very impr‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Rickcopin,Breaking news:  REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. https://t.co/uDnxs04Fqe
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Sredna8,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@cantika17024242,"RT @rmchavin: 8-2-2020:  Regeneron's 3-antibody cocktail, REGN-EB3, did much better against Ebola than remdesivir (and might have even outp‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@cantika17024242,RT @PromPreprint: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/h7KEG4N‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@avtansh,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. ùóîùòÇùòÅùóµùóºùóøùòÄ: Alina Baum, Richard Copin, Dharani Ajithdoss, Anbo Zhou, Kathryn Lanza, Nicole Negron, Min Ni, Yi Wei,... https://t.co/boSlN89Cht https://"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@seeker98747,RT @euanashley: Impressive results from @Regeneron antibody cocktail vs SARS-CoV-2 in vivo https://t.co/pztqdBUjd2 https://t.co/Ge5zpdSgOX
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@BormidaLiliana,RT @ernestorr: @paulyn1979_ La mejor esperanza antes de la vacuna. Otro parecido funcion√≥ en pruebas preliminares https://t.co/I0vLsTJXjN
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@latucura,RT @ernestorr: @paulyn1979_ La mejor esperanza antes de la vacuna. Otro parecido funcion√≥ en pruebas preliminares https://t.co/I0vLsTJXjN
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@RomainM45081967,@LussiD @Antagoniste_net https://t.co/YArvcadrKb
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Gambiste1,"RT @RNAiAnalyst: $REGN Giving whopping amounts of monoclonal antibodies just 1 day after viral challenge in monkeys+hamsters, not very impr‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@legalterrier,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@RNAiAnalyst,"$REGN Giving whopping amounts of monoclonal antibodies just 1 day after viral challenge in monkeys+hamsters, not very impressed to see this effect:  https://t.co/dRZTclv6nM https://t.co/d3S3hz8t0g"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@AskDrShashank,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@neurosheed,Actual article: https://t.co/asKO8xn2Zs
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@BPSBioScience,RT @PaulTitchenell: Data starting to trickle out for @Regeneron REGN-COV2 mAbs. Exciting and robust prophylactic and treatment responses in‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Hbba1Steels,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@mgmglobal,RT @AliNouriPhD: 2) Regeneron's antibodies bind the Spike of the virus - the part that sticks out and lets the virus grab and enter the hos‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@BiotechFischer,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@glckty,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@SJR78354712,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@CherrieHomes,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@fprael,RT @AndyBiotech: #COVID19 Here comes some very encouraging data in non-human primate models for $REGN's keenly-watched antibody cocktail‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@Watchdogsniffer,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@UTDuhon,"RT @AndyBiotech: #COVID19 REGN-COV2 shows efficacy as measured by reduced viral load in both upper and lower airways, reduced virus induced‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@HelloTeamTrump,RT @nkourtis: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters https://t.co/s0bQXojJbH
http://biorxiv.org/cgi/content/short/2020.08.02.233320,REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters,@robertdolci,RT @EricTopol: More news on neutralizing antibodies Preventive and therapeutic efficacy in non-human primates for a cocktail https://t.co/g‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Its effector cells: https://t.co/2hW8TKMBlv  Protocol: https://t.co/Z9pyXg1Onl  https:"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@SciscoreReports,"The paper ‚ÄúNatural Killer cell activation, reduced ACE2, TMPR...‚Äù (https://t.co/jvAy4TYyoP) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/8RBfQrRD60. We detected 2 of 6 rigor criteria and 22 key resource"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@weldeiry,"RT @weldeiry: Happy to share preprint  #BEACON #eldeirylab ‚Å¶@BrownMedicine‚Å© incredible team: Natural Killer cell activation, reduced ACE2,‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Rhizome333,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@MONEYEMPIRE,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@biscuitparty,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@AedinCulhane,"RT @biorxivpreprint: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. ùóîùòÇùòÅùóµùóºùóøùòÄ: Lanlan Zhou, Kelsey Huntington, Shengliang... https://t.co/kipin89Tpo https://"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@aseyhan,bioRxiv viewer https://t.co/boWKJuICvL
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@StockDisick,@boyw0nkers It was a study that came out that shows MEKi was a possible treatment for COVID  MEKi is a VSTM product.   https://t.co/0HdEMGP0hd
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@scorpions200,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells https://t.co/M2fHWQpUFz"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@music_caribbean,RT @MarkSizzle: $VSTM small position waiting on imminent PR. New study says their drug may attenuate coronavirus infection to allow immune‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@viralvideovlogs,RT @MarkSizzle: $VSTM small position waiting on imminent PR. New study says their drug may attenuate coronavirus infection to allow immune‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@HbkSwims,RT @MarkSizzle: $VSTM small position waiting on imminent PR. New study says their drug may attenuate coronavirus infection to allow immune‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@SmartrickGCT,RT @MarkSizzle: $VSTM small position waiting on imminent PR. New study says their drug may attenuate coronavirus infection to allow immune‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@cailieburns,"RT @weldeiry: Happy to share preprint  #BEACON #eldeirylab ‚Å¶@BrownMedicine‚Å© incredible team: Natural Killer cell activation, reduced ACE2,‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Sandman7591,@PLHstock @TrendSpider this is also out there Peter and it hasn't been  PRed yet   https://t.co/bANnwOJ1Ua  info from  @Flashtrading
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@outbreaksci,"New #SARSCoV preprint: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells https://t.co/McqNZkEkKS"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@outbreaksci,"Contribute a rapid review or request one for ""Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-C..."" (https://t.co/McqNZkEkKS). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.230839) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@outbreaksci,"New #COVID19 preprint: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells https://t.co/McqNZkEkKS"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@jsolberg7,$VSTM is my morning play! ü§ë
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@MarkSizzle,$VSTM small position waiting on imminent PR. New study says their drug may attenuate coronavirus infection to allow immune responses and antiviral agents to control #COVID19 disease progression and severity.  Thanks to @Ultra_Calls for pointing this 1 out
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@tahatangut07,"RT @yalcindedeoglu: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@CrossStocks,"$VSTM Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells  Link: https://t.co/ekFBG7LLEr"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@PromPreprint,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells https://t.co/EEcrksDcp9"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@NesrinOzoren,"RT @yalcindedeoglu: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@shankar_my,RT @avidresearch: Fascinating read. MEk inhibitors potential in COVID not evaluated so far and this paper surely makes a compelling case to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@yalcindedeoglu,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells https://t.co/USLe7wHFDh"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@LL379349775,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Hot_sOWce,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@NewGenStocks,RT @avidresearch: Fascinating read. MEk inhibitors potential in COVID not evaluated so far and this paper surely makes a compelling case to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@hun_funny,@TerpNation5688 @HulkCapitalPro https://t.co/72t75kTXLN
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@CrozrX,@VerastemOncolog @dremileyoussef @danwpaterson @NIHDirector @CDCgov @NCIDirector @theNCI @NIH @myESMO @OncoAlert @SteveFDA @DrWoodcockFDA @US_FDA @AneeshMehtaMD @WinshipAtEmory @EmoryUniversity @ekwaller @FranciscoMarty_ @VirusesImmunity @AndyBiotech @brad
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@sales_js,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@ilyassahin61,"RT @weldeiry: Happy to share preprint  #BEACON #eldeirylab ‚Å¶@BrownMedicine‚Å© incredible team: Natural Killer cell activation, reduced ACE2,‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@We_Love_Trading,RT @KillerStockCall: $VSTM NEWS: New study just posted shows Verastem's MEKi may attenuate coronavirus infection to allow immune responses‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@YuZhu4,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@GODZILLASLAYS65,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells | bioRxiv https://t.co/4SIRu1X7Pf"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@samstocksam,link to $VSTM study https://t.co/N7KkRt5oTg
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@NIck_Agr5,@QB_Hitman this the stock I was talking about months ago
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@StockSwingAlert,"RT @Kevin_W81: $VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the inf‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Leon_6_,RT @MarcJacksonLA: $VSTM Up over 20% AH https://t.co/KapTUELx3E
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@wiseheart48,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells https://t.co/5hEkTV7Fyd re VSTM shareholders and employees are part of authors team"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@DieOnMyFeet,RT @KillerStockCall: $VSTM NEWS: New study just posted shows Verastem's MEKi may attenuate coronavirus infection to allow immune responses‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@TChad704,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@BruceLeefromTT,RT @avidresearch: Fascinating read. MEk inhibitors potential in COVID not evaluated so far and this paper surely makes a compelling case to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@BioStocks,RT @avidresearch: Fascinating read. MEk inhibitors potential in COVID not evaluated so far and this paper surely makes a compelling case to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@avidresearch,Fascinating read. MEk inhibitors potential in COVID not evaluated so far and this paper surely makes a compelling case to at least try. $VSTM
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@MarcJacksonLA,$VSTM Up over 20% AH https://t.co/KapTUELx3E
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@PRSBiotech,@Pharmdca @ripster47 https://t.co/Fc4jXRwkhN VS-6766 is from $VSTM
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Kevin_W81,"$VSTM üöÄ after hours   VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). ""lessen the infection spread"", ""showed the greatest reduction in  ACE2""    Remdesivir + VS-6766 combo for Covid-19 treatment. P value < 0.01  ht"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@EllleDe,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@jorgemcepeda,RT @KillerStockCall: $VSTM NEWS: New study just posted shows Verastem's MEKi may attenuate coronavirus infection to allow immune responses‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@KillerStockCall,$VSTM NEWS: New study just posted shows Verastem's MEKi may attenuate coronavirus infection to allow immune responses and antiviral agents to control COVID-19 disease progression and severity.  https://t.co/noKqh24qaJ
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@adamwnsx,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@nick82gh,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@justinburkhard1,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@BrownUCancer,RT @KelseyHuntingt3: Check out my first co-first author preprint of grad school üéâ
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@BrownUCancer,RT @YLeyfman: Thank you for sharing your important work Dr. @weldeiry. It is great to see the potential of MEKi improve outcomes. Looking f‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@READY_2_PROFIT,https://t.co/pbDrF1DX6F https://t.co/hBfUtTheeb
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@KelseyHuntingt3,Check out my first co-first author preprint of grad school üéâ
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@jsolberg7,@Ultra_Calls with that snipe of an amazing stock!
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@READY_2_PROFIT,VSTM https://t.co/pbDrF1DX6F  $VSTM https://t.co/RU2qaTaWNR
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@BarbarianTrades,RT @Ultra_Calls: $VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@theswissfrank,$VSTM here‚Äôs the study for those interested. https://t.co/mddmWBCTud
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Ultra_Calls,$VSTM Full post didn‚Äôt fit on twitter. Here you go   https://t.co/U72UGR5DSB https://t.co/5f0iX5eyWS
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@Sal_2020_Sal,$VSTM +++ New study just posted shows Verastem's MEKi may attenuate coronavirus infection to allow immune responses and antiviral agents to control COVID-19 disease progression and severity.  https://t.co/i3vNiGLrF2
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@YLeyfman,Thank you for sharing your important work Dr. @weldeiry. It is great to see the potential of MEKi improve outcomes. Looking forward to the follow-up to this study. #SARSCoV2 #COVID19 #Covid_19
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@weldeiry,"Happy to share preprint  #BEACON #eldeirylab ‚Å¶@BrownMedicine‚Å© incredible team: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells | bioRxiv https:"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@maureviv,"RT @biorxivpreprint: Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@COVID_Papers,"üìù Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells  medRxiv or bioRxiv https://t.co/zoxBXqqTTE #COVID19 #COVID19Papers #SARSCoV2"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@biorxiv_cellbio,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK ...  https://t.co/fKyar6LVBH #biorxiv_cellbio"
http://biorxiv.org/cgi/content/short/2020.08.02.230839,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells",@biorxivpreprint,"Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells  https://t.co/GR8kzq0nDe #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@BlackPhysicists,Mechanism of duplex unwinding by coronavirus nsp13 helicases https://t.co/3jGPzsicWk #biophysics https://t.co/1kEmlCUIbB
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Mechanism of duplex unwinding by coronavirus nsp13 helicases. ùóîùòÇùòÅùóµùóºùóøùòÄ: Xiao Hu, Wei Hao, Bo Qin, Zhiqi Tian, Ziheng Li, Pengjiao Hou, Rong Zhao, Sheng Cui, Jiajie Diao https://t.co/Frv4V1ryCL https://t.co/0pZ1JbcWI1"
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@ian_hoffecker,Mechanism of duplex unwinding by coronavirus nsp13 helicases https://t.co/hKFFV8MVTO
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@outbreaksci,New #SARSCoV preprint: Mechanism of duplex unwinding by coronavirus nsp13 helicases https://t.co/kQ08YQuHML
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@outbreaksci,"Contribute a rapid review or request one for ""Mechanism of duplex unwinding by coronavirus nsp13 helicases"" (https://t.co/kQ08YQuHML). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.233510) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@outbreaksci,New #COVID19 preprint: Mechanism of duplex unwinding by coronavirus nsp13 helicases https://t.co/kQ08YQuHML
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@BarnabaCarlo,RT @bxv_biophys: Mechanism of duplex unwinding by coronavirus nsp13 helicases https://t.co/4CmTuggIQb
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@bxv_biophys,Mechanism of duplex unwinding by coronavirus nsp13 helicases https://t.co/4CmTuggIQb
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@COVID_Papers,üìù Mechanism of duplex unwinding by coronavirus nsp13 helicases  medRxiv or bioRxiv https://t.co/qrgsaOIPhh #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@biorxiv_biophys,Mechanism of duplex unwinding by coronavirus nsp13 helicases  https://t.co/V4hWjWb23L #biorxiv_biophys
http://biorxiv.org/cgi/content/short/2020.08.02.233510,Mechanism of duplex unwinding by coronavirus nsp13 helicases,@biorxivpreprint,Mechanism of duplex unwinding by coronavirus nsp13 helicases  https://t.co/4fm9XqI2wV #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165035,"Modified SIR-model applied to covid-19, similarity solutions and projections to further development",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Modified SIR-model applied to covid-19, similarity solutions and projections to further development. ùóîùòÇùòÅùóµùóºùóøùòÄ: Eckhard Rebhan https://t.co/4bN0MV5xYI https://t.co/OOJVEJoVgo"
http://medrxiv.org/cgi/content/short/2020.07.30.20165035,"Modified SIR-model applied to covid-19, similarity solutions and projections to further development",@COVID_Papers,"üìù Modified SIR-model applied to covid-19, similarity solutions and projections to further development  medRxiv or bioRxiv https://t.co/Htywt6UxVc #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.30.20165035,"Modified SIR-model applied to covid-19, similarity solutions and projections to further development",@medrxivpreprint,"Modified SIR-model applied to covid-19, similarity solutions and projections to further development  https://t.co/PU30kcmOE0 #medRxiv"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@limbovinny,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@outbreaksci,"Contribute a rapid review or request one for ""A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity"" (https://t.co/gnGSdBW6a1). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.232892) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@outbreaksci,New #SARSCoV preprint: A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity https://t.co/gnGSdBW6a1
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Herval68461744,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@LonkyMD,A new model of #SARSCoV2 infection theorizes the #virus enters host cell mitochondria and uses its protons for genome release. #HCQ could prevent viral infection and/or slow its replication by sequestering these protons. @biorxivpreprint #MedTwitter  https
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@jelavelechat,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@TX_4_EVER,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@kira82628387,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@beth7_b,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@infovestigacion,An√°lisis autom√°tico de art√≠culos cient√≠ficosüí°  üë©‚ÄçüíªEjemplo para ver en clase ‚§µÔ∏è
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@TheNoteGuy,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@SciscoreReports,The paper ‚ÄúA New Model of SARS-CoV-2 Infection Based on (Hydr...‚Äù (https://t.co/fnSlPaZqTF) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/2upT0lTTXn. We detected 0 of 6 rigor criteria and 2 key resources
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@PhillipUptain,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@lindasc48,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@GuilloryTracey,RT @CardallAdam: #Hydroxychloroquine #HydroxychloroquineIsTheCure #CrimesAgainstHumanity for withholding it to use their expensive drug #Re‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@AlamZarga,RT @zikrejaana: A new model of SARS-CoV-2 infection postulates virus enters host cell mitochondria and uses its protons for genome release.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@bballisgr8,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@_2020TRUMP2020_,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@yvete76,RT @CardallAdam: #Hydroxychloroquine #HydroxychloroquineIsTheCure #CrimesAgainstHumanity for withholding it to use their expensive drug #Re‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@LouiseH3142,RT @CardallAdam: #Hydroxychloroquine #HydroxychloroquineIsTheCure #CrimesAgainstHumanity for withholding it to use their expensive drug #Re‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@CardallAdam,#Hydroxychloroquine #HydroxychloroquineIsTheCure #CrimesAgainstHumanity for withholding it to use their expensive drug #Remdesivir that #Fauci others have stock in!! #hydroxychloriquineworks #FauciLiedPeopleDied
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@terriblewis1,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@singnb,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@mHKP3IROC2a0wdB,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Hermes23,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@MathesVamer,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@LittleMissCleo,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@alisipl,RT @zikrejaana: A new model of SARS-CoV-2 infection postulates virus enters host cell mitochondria and uses its protons for genome release.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@grawoig,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@NJP1964,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Ashrafpalpori,RT @zikrejaana: A new model of SARS-CoV-2 infection postulates virus enters host cell mitochondria and uses its protons for genome release.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@ShahhUsmaan,RT @zikrejaana: A new model of SARS-CoV-2 infection postulates virus enters host cell mitochondria and uses its protons for genome release.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@_iamnasir,@FaheemYounus sir your views on this please.
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@zikrejaana,A new model of SARS-CoV-2 infection postulates virus enters host cell mitochondria and uses its protons for genome release. (H)CQ could prevent viral infection and/or slow its replication by sequestering these protons.  Preprint. #hcqtrial #COVID19   https
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Ann_one_human,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@lisanke,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity | bioRxiv https://t.co/7VtsQG6gSD
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@MarcioA12851627,@Lisatuccio1 @PortalLearning @drsimonegold https://t.co/d3Yk3ABZS9
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@tarrimarkel,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@sanford_riley,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@BaskettRalph,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@ozwenya,#CCP ‚Äòs evil game of #CCPCoronavirus should be over with #Hydroxychloroquine SOON ! @ScottMorrisonMP @ausgov @VicGovAu @DanielAndrewsMP @NSWgov @NSWGovAU @GladysB @QldGov @QldGovernor @fanniebay @NTGovHealth @MarkMcGowanMP   @WAGovern
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Uglyduckping,"RT @AfterbirthDerf: @DeeJayRobA @WhiteHouse First of all, this just can out.  Seems #HCQWORKS.  And worked all along.  But since Trump took‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@AfterbirthDerf,"@DeeJayRobA @WhiteHouse First of all, this just can out.  Seems #HCQWORKS.  And worked all along.  But since Trump took it, it was bad.. https://t.co/2FOeLdK7Zl"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@SuzeSieb,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@joaoarthur1705,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Kathie1718,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@AfterbirthDerf,"More covid, what's going on, and why #HCQWORKS https://t.co/2FOeLdK7Zl"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@q_brcarlos,"@arrobarrobabb @VazThata Comprova√ß√£o cient√≠fica √© o que mais tem, posso ficar o dia todo transcrevendo, como este recente: https://t.co/JApzRFzi4D"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@PsilvaSidnei,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@JohnQPublic_2,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Rob42119369,This is old news that the media continues to hide from you because it doesn't suit their narrative. They are responsible for perpetuating thousands of deaths.
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@sheilal43605454,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@dtom74,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@MaryFab06205125,@GovWhitmer for the love of all that is good in this world today educate yourself and quit holding #Michigan citizens #hostage to #COVID19 ! #earlyHydroxychloroquinezincworks #HCQWorks #hydroxychloroquineworks
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@medicinewoman42,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@MaryMenopausal,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@cliffsiders,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Sparkman19571,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@janesmi41542442,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@life_benefit,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@yolandaelizabet,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@HD283271,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@RubenRa00274314,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@RoniVilar,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Gasparlimaoliv,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@icaro_pi,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@_JulietJohnson,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Ok_kev,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@dustylady62,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Dormieclubmemb1,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@sickQfsatan,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@LeviMarques9,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Yuri95879214,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@CarlosRios2013,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Mhstrayme,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Danielg93648110,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@rZnAruan,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Ricarda99340809,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Marinho4675,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@SueSensus,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@mbrasilsilva,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@charivarii1,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@sandral2335,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@tronderman,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@pantokawa,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@EUGNIODANTAS3,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Bob36783646,@jangajentaan @superjan https://t.co/6WSOPbPycK
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@truthpirate4Rt,@earl_leonard @bjam76 @JulianBurnside https://t.co/9PB1phT3QD
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@mikeCoxLonger,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@ngelo_guilherme,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@At100thMeridian,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@ragnarokkrr,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@kte06kte,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@LookingatLyme,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@julien0686,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@AnnLemieux2,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@Pax2Sofie,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@KathrynKemm,"RT @LukeMor19529310: üí•New research explains the mechanism of Hydroxychloroquine / Chloroquine, that could cause the prevention or slowing o‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@celoramon1972,"RT @_Leitadas_Loen: Novas pesquisas explicam o mecanismo da hidroxicloroquina / cloroquina, que pode causar a preven√ß√£o ou lentid√£o da repl‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.08.02.232892,A New Model of SARS-CoV-2 Infection Based on (Hydroxy) Chloroquine Activity,@robertodiaspoa,A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity  Um novo modelo de infec√ß√£o por SARS-CoV-2 baseado na atividade da (Hidroxi)Cloroquina  https://t.co/2v4xhF01sx
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@zzz_as_zzz,RT @love_nihonsyu: SARS-CoV-2„Çø„É≥„Éë„ÇØË≥™„ÅÆÊ©üËÉΩËß£Êòé„Çí„Åô„ÇãÂâçÊÆµÈöéÁöÑ„Å™Á†îÁ©∂ ‚Üì („Éó„É¨„Éó„É™„É≥„Éà)SARS-CoV-2„Çø„É≥„Éë„ÇØË≥™„ÅÆÁ¥∞ËÉûÂÜÖÂ±ÄÂú®„ÅÆÁ†îÁ©∂ https://t.co/2hsNBtdMLJ 29„Çø„É≥„Éë„ÇØË≥™„ÅÆ„ÅÜ„Å°28„Çø„É≥„Éë„ÇØË≥™„ÅÆ„Éí„ÉàÁ¥∞ËÉûÂÜÖ„Åß„ÅÆÁô∫Áèæ„Å´ÊàêÂäü‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@outbreaksci,"Contribute a rapid review or request one for ""A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins"" (https://t.co/KVx9tTkqc3). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.233023) at https://t.co/RnurTL3DyM @outbreaksci @PRErev"
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@outbreaksci,Updated #SARSCoV preprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins https://t.co/KVx9tTkqc3
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@dapeng225,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@vonklein300,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@bujaj49,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@outbreaksci,"Contribute a rapid review or request one for ""A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins"" (https://t.co/KVx9tTC13B). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.02.233023) at https://t.co/RnurTKM2ac @outbreaksci @PRErev"
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@outbreaksci,New #SARSCoV preprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins https://t.co/KVx9tTC13B
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@BashEya,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@love_nihonsyu,SARS-CoV-2„Çø„É≥„Éë„ÇØË≥™„ÅÆÊ©üËÉΩËß£Êòé„Çí„Åô„ÇãÂâçÊÆµÈöéÁöÑ„Å™Á†îÁ©∂ ‚Üì („Éó„É¨„Éó„É™„É≥„Éà)SARS-CoV-2„Çø„É≥„Éë„ÇØË≥™„ÅÆÁ¥∞ËÉûÂÜÖÂ±ÄÂú®„ÅÆÁ†îÁ©∂ https://t.co/2hsNBtdMLJ 29„Çø„É≥„Éë„ÇØË≥™„ÅÆ„ÅÜ„Å°28„Çø„É≥„Éë„ÇØË≥™„ÅÆ„Éí„ÉàÁ¥∞ËÉûÂÜÖ„Åß„ÅÆÁô∫Áèæ„Å´ÊàêÂäü„Åó„ÄÅÂêÑ„Çø„É≥„Éë„ÇØË≥™„Åå„Éí„ÉàÁ¥∞ËÉûÂÜÖ„ÅÆ„Å©„Åì„Å´Â±ÄÂú®„Åô„Çã„Åã„ÇíË™ø„Åπ„Åü„ÄÇ (SARS-CoV-2ÊÑüÊüì‰∏ã„ÅßÂêåÊßò„ÅÆÁ†îÁ©∂„ÅåÂøÖË¶Å)
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@Tariqbiotech27,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@10_blue,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@enerphyschem,RT @biorxivpreprint: A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@COVID_Papers,üìù A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  medRxiv or bioRxiv https://t.co/4ZjsRsL0NH #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@biorxiv_micrbio,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/ocmlaCCozc #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.08.02.233023,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins,@biorxivpreprint,A Systemic and Molecular Study of Subcellular Localization of SARS-CoV-2 Proteins  https://t.co/69N5KrZUEJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@GroupZirigoza,"‚úÖ Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay üëå üëâ https://t.co/qUc2eL0H7X üö© #Medical #GroupZirigoza"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@outbreaksci,"New #SARSCoV preprint: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay https://t.co/INSylWR7rn"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@outbreaksci,"Contribute a rapid review or request one for ""Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mA..."" (https://t.co/INSylWR7rn). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.231282) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@outbreaksci,"New #COVID19 preprint: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay https://t.co/INSylWR7rn"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@enerphyschem,"RT @biorxivpreprint: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay  https‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@pooledseq,"bioArXiv_ Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay https://t.co/3QEF554WTB"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@MitochondriaNe1,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay https://t.co/x5BWr8cSDb"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay. ùóîùòÇùòÅùóµùóºùóøùòÄ: Kang Lan Tee, Philip J Jackson, Joseph M Scarrott, Stephen RP Jaffe, Abayomi O Johnson, Yus... https://t.co/yRlgDSNTnZ https://"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@bxv_biochem,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay https://t.co/ycXZjs93KH"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@JayChance12,"RT @biorxivpreprint: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay  https‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@Astro_Erik,"RT @biorxivpreprint: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay  https‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@COVID_Papers,"üìù Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay  medRxiv or bioRxiv https://t.co/hjBGCegtcE #COVID19 #COVID19Papers #SARSCoV2"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@AlfredoBenni,"RT @biorxivpreprint: Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay  https‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231282,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay",@biorxivpreprint,"Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay  https://t.co/rXuAUE0gmo #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@AlfredoBenni,RT @GODZILLASLAYS65: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Ph‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@GODZILLASLAYS65,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis | bioRxiv https://t.co/0HvscHNG1Q
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@GroupZirigoza,‚úÖ Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis üëå üëâ https://t.co/VJgQISImkq üö© #Medical #GroupZirigoza
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@outbreaksci,New #SARSCoV preprint: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis https://t.co/sl7b6oqMrL
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@outbreaksci,"Contribute a rapid review or request one for ""Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tu..."" (https://t.co/sl7b6oqMrL). ""Add"" or ""Request"" w/DOI (10.1101/2020.08.01.232199) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@outbreaksci,New #COVID19 preprint: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis https://t.co/sl7b6oqMrL
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@msep0003,RT @biorxiv_micrbio: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Ph‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@JayChance12,RT @biorxivpreprint: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Ph‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis. ùóîùòÇùòÅùóµùóºùóøùòÄ: Silvia Ghezzi, Isabel Pagani, Guido Poli, Stefano Perboni, Elisa Vicenzi https://t.co/fHBJp1GzBu https://t.c"
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@Astro_Erik,RT @biorxivpreprint: Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Ph‚Ä¶
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@COVID_Papers,üìù Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis  medRxiv or bioRxiv https://t.co/sMek77JXrh #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.08.01.232199,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis,@biorxivpreprint,Rapid Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Tungsten Trioxide-Based (WO3) Photocatalysis  https://t.co/PNzET5sQpb #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@ElmerEdward1,RT @PandemicCovid20: Impact of tocilizumab administration on mortality in severe #COVID19 - https://t.co/7iY9blRnIz
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@PandemicCovid20,Impact of tocilizumab administration on mortality in severe #COVID19 - https://t.co/7iY9blRnIz
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@boticaria_la,Interesante
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@alfonso_casi,Impacto de la administraci√≥n de tocilizumab sobre la mortalidad en COVID-19 grave: El an√°lisis no respalda el uso de tocilizumab para el tratamiento de la tormenta de citoquinas en pacientes COVID-19. Su uso debe limitarse al contexto de un ensayo cl√≠nico.
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@WesKufel,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@ABsteward,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@outbreaksci,"Contribute a rapid review or request one for ""Impact of tocilizumab administration on mortality in severe COVID-19"" (https://t.co/HxyBG4CaLB). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20114959) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@outbreaksci,New #COVID19 preprint: Impact of tocilizumab administration on mortality in severe COVID-19 https://t.co/HxyBG4CaLB
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@ABarVent,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@Anil_Prasad1234,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@Cho08422014,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Impact of tocilizumab administration on mortality in severe COVID-19. ùóîùòÇùòÅùóµùóºùóøùòÄ: Andrew Tsai, Oumou Diawara, Ronald G Nahass, Luigi Brunetti https://t.co/QyKLVrQqas https://t.co/iGnefxYA9g"
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@KNRXRX,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@xxxichiroxxx041,Impact of tocilizumab administration on mortality in severe COVID-19 https://t.co/QG20pfyIWz  preprint„Åß„Åô„Åå„ÄÅUS„Åã„Çâ„Éà„Ç∑„É™„Ç∫„Éû„Éñ„ÅÆ‰ΩøÁî®„ÅØÊ≠ª‰∫°Áéá„Å®Áõ∏Èñ¢„Åó„Å™„ÅÑ„Å®„ÅÑ„ÅÜÂ†±Âëä„ÄÇ „Éí„Éâ„É≠„Ç≠„Ç∑„ÇØ„É≠„É≠„Ç≠„É≥„ÇíÂ§ö„Åè„ÅÆÁóá‰æã„Åß‰ΩøÁî®„Åï„Çå„Å¶„ÅÑ„ÅüÊôÇÊúü„ÅÆÊ§úË®é„ÅÆ„Çà„ÅÜ
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@UTDuhon,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@atselur,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@RoxanaBerenguer,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@AB_IDPharmD,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@Gremile,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@germageddoncom,RT @ABsteward: ‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@ABsteward,‚õîPreprint and sorry A single-center propensity-score matched cohort study:133 pts ‚õî Treatment with tocilizumab in patients with severe #COVID19  was not significantly associated with a difference in in-hospital mortality. #IDTwitter https://t.co/kpcZ3qVjdG
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@chitguppi,RT @medrxivpreprint: Impact of tocilizumab administration on mortality in severe COVID-19  https://t.co/k9iFSOoB3d #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@COVID_Papers,üìù Impact of tocilizumab administration on mortality in severe COVID-19  medRxiv or bioRxiv https://t.co/C1bbHTntFd #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20114959,Impact of tocilizumab administration on mortality in severe COVID-19,@medrxivpreprint,Impact of tocilizumab administration on mortality in severe COVID-19  https://t.co/k9iFSOoB3d #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@adamsfisch,"RT @MGHPathology: Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection  ‚úèÔ∏è Angela R Shih, Ivan Chebib, Rob‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@MLisaZhang,"RT @MGHPathology: Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection  ‚úèÔ∏è Angela R Shih, Ivan Chebib, Rob‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@pvanhouts,RT @nanostringtech: Learn about the first spatial and temporal RNA analysis of SARS-CoV-2 infected lung tissues run on the GeoMx Digital Sp‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@angelpanizo1,#pulmpath #COVID19
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@PathDocBoston,Congratulations to my friends & colleagues @MGHPathology for this great contribution to our understanding of SARS-CoV-2
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@MGHPathology,"Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection  ‚úèÔ∏è Angela R Shih, Ivan Chebib, Robert B Colvin, James R Stone, @Vik_deshpandeMD üóìÔ∏è 2020 Aug 2 üåê https://t.co/wmAW25r60K #MGHPathPublication #COVID19 https://t.co/71gWE0"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@nanostringtech,Learn about the first spatial and temporal RNA analysis of SARS-CoV-2 infected lung tissues run on the GeoMx Digital Spatial Profiler. What is the spatial relationship of infected cells with immune and non-immune cells in the microenvironment? Read more! h
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@LucasMassoth,"RT @Vik_deshpandeMD: SARS-Cov-2 viral load, interferon response and viral heterogeneity @MGHPathology @BrighamWomens @MGHCancerCenter @Colu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@eeeejjjaaaa,Wow... beautiful work
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@MGHPathology,"RT @Vik_deshpandeMD: SARS-Cov-2 viral load, interferon response and viral heterogeneity @MGHPathology @BrighamWomens @MGHCancerCenter @Colu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@ColumbiaPath,"RT @Vik_deshpandeMD: SARS-Cov-2 viral load, interferon response and viral heterogeneity @MGHPathology @BrighamWomens @MGHCancerCenter @Colu‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@scrowda,"With a newly released preprint at https://t.co/YnX6qyLOpu using GeoMxDSP, it is the first of several studies to come. To see more please consider attending our Spatial Biology Conference next month:"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@outbreaksci,"Contribute a rapid review or request one for ""Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection"" (https://t.co/fDOQDmMMtf). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165241) at https://t.co/RnurTKM2ac @outbreaksci @"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@outbreaksci,New #SARSCoV preprint: Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection https://t.co/fDOQDmvbBH
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection. ùóîùòÇùòÅùóµùóºùóøùòÄ: Niyati Desai, Azfar Neyaz, Annamaria Szabolcs, Angela R Shih, Jonathan H Chen, Vishal Thapar, Linda T Nieman, Alexand... https://t.co/DS0jAnWyRb https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@Vik_deshpandeMD,"SARS-Cov-2 viral load, interferon response and viral heterogeneity @MGHPathology @BrighamWomens @MGHCancerCenter @ColumbiaPath @broadinstitute @sloan_kettering https://t.co/bpYaHVKLir"
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@COVID_Papers,üìù Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection  medRxiv or bioRxiv https://t.co/BkA2Na3ZIC #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165241,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection,@medrxivpreprint,Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection  https://t.co/fnwVQWTHjT #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@CambridgeBiosci,New study from Denmark ranks our new suppliers Wantai's SARS-CoV-2 Ab ELISA as the top serology assay among 15 commercially available tests including automated immunoassays.  #sars_cov_2 #coronavirus #assays #biopharma   Read the article here ‚¨áÔ∏è https://t.
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@CABSACSB,RT @CoronavirusDk: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: htt‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@SciscoreReports,The paper ‚ÄúComparison of sixteen serological SARS-CoV-2 immun...‚Äù (https://t.co/WcxiWlQhHx) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/WnXnipBuug. We detected 0 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@VirologyConsult,Comparison of 15 Serological SARS-CoV-2 Immunoassays Commercially Available | @scoopit via @RetroVirox https://t.co/copxglaYyo
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@alfonso_casi,Estudio en Dinamarca: Comparaci√≥n de diecis√©is test de inmunoensayos serol√≥gicos de SARS-CoV-2 en diecis√©is laboratorios cl√≠nicos. https://t.co/5xic1yNhoG https://t.co/nW1sQZxXXY
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@PathologyPower,A COVID Antibody test Head to Head. Loving the direct competition between the diagnostics companies and Ortho on automated side (Total and IgG options) are top performers; https://t.co/rucH7LG9BQ
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@JHillingsoe,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@rikkepedersen74,Super with an ‚Äúapple to apple‚Äù comparison üëç
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@DonorHealthBTRU,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@DelemirDelev,New study from Denmark ranks @WantaiBio SARS-CoV-2 Ab ELISA as the top serology assay among 15 commercially available tests including automated immunoassays.  https://t.co/S9rJU2XGoM
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@WantaiBio,New study from Denmark ranks @WantaiBio SARS-CoV-2 Ab ELISA as the top serology assay among 15 commercially available tests including automated immunoassays.  https://t.co/Y4OTjSqjqa
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@SigneLoentoft,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@ProfHajeer,https://t.co/r9dPJP6IV0
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@mgybel,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@RocheDiaDK,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@outbreaksci,"Contribute a rapid review or request one for ""Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laborato..."" (https://t.co/rxNOM2DcCW). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165373) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@outbreaksci,New #SARSCoV preprint: Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories https://t.co/rxNOM2DcCW
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@hcpommergaard,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@a_husby,RT @henrik_ullum: We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@CoronavirusDk,We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: https://t.co/sOzJh5w0sZ via @henrik_ullum
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@henrik_ullum,We need good diagnostic tools to track #COVID19. Read our comparison of sixteen serological SARS-CoV-2 immunoassays: https://t.co/bICp7WUyXp
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories. ùóîùòÇùòÅùóµùóºùóøùòÄ: Lene Holm Harritshoej, Mikkel Gybel-Brask, Shoaib Afzal, Pia R. Kamstrup, Charlotte Svaerke Joergensen, Marianne... https://t.co/bWdz0idobM https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@CHOMES102,RT @medrxivpreprint: Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories  https://t.co/sPQwTccj3E #m‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@COVID_Papers,üìù Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories  medRxiv or bioRxiv https://t.co/hDdQSvYg96 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165373,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories,@medrxivpreprint,Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories  https://t.co/sPQwTccj3E #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@roux_group,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@ridu_nhsl,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@SarahFinn70,RT @RD_Catherine: Predicting mortality risk from #COVID19 in üá¨üáß#ICU patients: the '4C mortality score' risk stratification derived from age‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@gail_carson,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@JTSglobalhealth,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@RD_Catherine,"Predicting mortality risk from #COVID19 in üá¨üáß#ICU patients: the '4C mortality score' risk stratification derived from age, sex, comorbidities, RR, peripheral oxygen saturation, LOC, urea, and CRP on admission. #preprint #ISARIC #WHO https://t.co/a1IQC0Yyu"
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@CCPUKstudy,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@louise_sigfrid,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@Mojomiddleton83,Great to see some more of the fantastic work using ISARIC @CCPUKstudy and this is my first official acknowledgement after volunteering to help with the study!! Exciting!!!  @LivuniILCaMS
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@TweedieChap,RT @arosemaryt: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@arosemaryt,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score https://t.co/HBiSrnNrZ2  Excellent work. I have performed a review on publons h
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@outbreaksci,"Contribute a rapid review or request one for ""Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WH..."" (https://t.co/irEDkeYT75). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165464) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@outbreaksci,New #COVID19 preprint: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score https://t.co/irEDkfguvF
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@DrRaulvillar,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. ùóîùòÇùòÅùóµùóºùóøùòÄ: Stephen R Knight, Antonia ... https://t.co/kcyErGTTbm https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@Mojomiddleton83,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@RohamMakki,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@arosemaryt,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score https://t.co/HBiSrnNrZ2 Excellent work. I have performed a review on publons ht
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@endojmf,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@AbdTahrani,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@PerseusPotter1,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@AmarPut,RT @kamleshkhunti: ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@kamleshkhunti,ISARIC 4C (Coronavirus Clinical Characterisation Consortium) score: an easy-to-use & valid prediction tool for inpatient mortality  Developed by @CCPUKstudy @TweedieChap https://t.co/OPunhcRHYO @AbdTahrani @PHE_uk @AmarPut @Paddy_English @amibanerje
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@COVID_Papers,üìù Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score  medRxiv or bioRxiv https://t.co/6jwNWRMQqI #COVID19 #COVID19Papers #SARSCoV
http://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,@medrxivpreprint,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score  https://t.co/BifvuvpTzg #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165555,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making,@ElmerEdward1,RT @PandemicCovid20: Data-driven modeling and forecasting of #COVID19 outbreak for public policy making - https://t.co/CWav02xLKY
http://medrxiv.org/cgi/content/short/2020.07.30.20165555,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making,@PandemicCovid20,Data-driven modeling and forecasting of #COVID19 outbreak for public policy making - https://t.co/CWav02xLKY
http://medrxiv.org/cgi/content/short/2020.07.30.20165555,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Data-driven modeling and forecasting of COVID-19 outbreak for public policy making. ùóîùòÇùòÅùóµùóºùóøùòÄ: Agus Hasan, Endah Putri, Hadi Susanto, Nuning Nuraini https://t.co/uuHLCCInCw https://t.co/RWNz2xDjlu"
http://medrxiv.org/cgi/content/short/2020.07.30.20165555,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making,@GlobalPHObserv,RT @medrxivpreprint: Data-driven modeling and forecasting of COVID-19 outbreak for public policy making  https://t.co/Hw7htHnH8i #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165555,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making,@medrxivpreprint,Data-driven modeling and forecasting of COVID-19 outbreak for public policy making  https://t.co/Hw7htHnH8i #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@Chocolateemboli,RT @BSUHgas: Our first Covid-19 PPE related studies has been published (awaiting peer review). #COVID19papers #SARSCoV2 #medRxiv #properPPE‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@GODZILLASLAYS65,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study | medRxiv https://t.co/F1jNZpYOfL
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@BSUHgas,Our first Covid-19 PPE related studies has been published (awaiting peer review). #COVID19papers #SARSCoV2 #medRxiv #properPPE https://t.co/fwfV7quaqQ
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@outbreaksci,New #SARSCoV preprint: Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study https://t.co/eSl7ePJJWV
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@outbreaksci,"Contribute a rapid review or request one for ""Microbial contamination of powered air purifying respirators (PAPR) used during the CO..."" (https://t.co/eSl7ePJJWV). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165423) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@outbreaksci,New #COVID19 preprint: Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study https://t.co/eSl7eQ1llv
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study. ùóîùòÇùòÅùóµùóºùóøùòÄ: Abhijoy Chakladar, Claire Gabrielle Jones, Jimmy Siu, Mohammed Osma... https://t.co/KOnzMnDrIR https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@bfitzinAR,RT @blogdiva: JFC  ‚ùù PAPR hoods have the potential to cross-infect wearers and patients and are used primarily by clinicians who fail to fi‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@blogdiva,JFC  ‚ùù PAPR hoods have the potential to cross-infect wearers and patients and are used primarily by clinicians who fail to fit disposable FFP3 respirators; the female sex and non-Caucasian people are less likely to fit FFP3 respirators.‚ùû  https://t.co/EaZl
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@COVID_Papers,üìù Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study  medRxiv or bioRxiv https://t.co/5Q5pnxtso4 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165423,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study,@medrxivpreprint,Microbial contamination of powered air purifying respirators (PAPR) used during the COVID-19 pandemic: an in situ microbiological study  https://t.co/vUKQkxlGbO #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@RonThornton,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@jantamaja,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@SoulVersified,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@paschamo,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@RebelEkonomist,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@SaludHEALTHinfo,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@iRajMakhija,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@Mikeska,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@Lupo1960,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@bayrak1938,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@MarkusAberle_,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@CreightonJK,i got a sweat from just sitting...
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@COSseaton,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@BaartRalph,"RT @CristinaDragani: A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, we‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@CristinaDragani,"A study of 3281 people showed that loneliness and decreased physical activity, which occurred during the #pandemic, were risk factors for worsening #mentalhealth. https://t.co/V1MVys0B69 #exercises #COVID19 #coronavirus #healthy https://t.co/bril62icJ5"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.. ùóîùòÇùòÅùóµùóºùóøùòÄ: Byron Creese, Zunera Khan, William Henley, Anne Corbett, Miguel V... https://t.co/scerPULgFS https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@CovidWellbeing,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020. https://t.co/T6XAZzsgWZ #mentalhealth"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@drcameronjones,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020. https://t.co/Ukp4ezGSEg"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@phochsian,"RT @leoniedelt: Locking everyone in makes them sad, lonely, and lack of exercise is bad.  QED, sheesh! No brainer!!! https://t.co/F4CkgBwUA0"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@thartman2u,"RT @medrxivpreprint: Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety bet‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@COVID_Papers,"üìù Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.  medRxiv or bioRxiv https://t.co/EbPtcC10UH #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@leoniedelt,"Locking everyone in makes them sad, lonely, and lack of exercise is bad.  QED, sheesh! No brainer!!!"
http://medrxiv.org/cgi/content/short/2020.07.30.20165415,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.",@medrxivpreprint,"Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety between 2015 and 2020.  https://t.co/zqixOIT6tQ #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.30.20165399,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,@outbreaksci,"Contribute a rapid review or request one for ""Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and ..."" (https://t.co/DX9cG2b70R). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165399) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165399,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,@outbreaksci,New #SARSCoV preprint: Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread https://t.co/DX9cG2b70R
http://medrxiv.org/cgi/content/short/2020.07.30.20165399,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread. ùóîùòÇùòÅùóµùóºùóøùòÄ: Nick Petford, Jackie Campbell https://t.co/Fs5KN6e6ML https://t.co/ZnRomxvi3w"
http://medrxiv.org/cgi/content/short/2020.07.30.20165399,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,@nick_petford,RT @medrxivpreprint: Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of diseas‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165399,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,@COVID_Papers,üìù Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread  medRxiv or bioRxiv https://t.co/OnDvIJSMiP #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165399,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread,@medrxivpreprint,Covid-19 mortality rates in Northamptonshire UK: initial sub-regional comparisons and provisional SEIR model of disease spread  https://t.co/KZG8KEUi3k #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20158790,Real-Time Monitoring of COVID-19 in Scotland,@PhyloGiles,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: Real-Time Monitoring of COVID-19 in Scotland. ùóîùòÇùòÅùóµùóºùóøùòÄ: Giles David Calder-Gerver, Stella Mazeri, Samuel Haynes, Ca‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20158790,Real-Time Monitoring of COVID-19 in Scotland,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Real-Time Monitoring of COVID-19 in Scotland. ùóîùòÇùòÅùóµùóºùóøùòÄ: Giles David Calder-Gerver, Stella Mazeri, Samuel Haynes, Camille Anna Simonet, Mark EJ Woolhouse, Helen K Brown https://t.co/IAms4OQzUO https://t.co/yYNlJqNNo5"
http://medrxiv.org/cgi/content/short/2020.07.30.20158790,Real-Time Monitoring of COVID-19 in Scotland,@thartman2u,RT @medrxivpreprint: Real-Time Monitoring of COVID-19 in Scotland  https://t.co/tqChwBqxiX #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20158790,Real-Time Monitoring of COVID-19 in Scotland,@COVID_Papers,üìù Real-Time Monitoring of COVID-19 in Scotland  medRxiv or bioRxiv https://t.co/iS0Vfyk4m8 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20158790,Real-Time Monitoring of COVID-19 in Scotland,@medrxivpreprint,Real-Time Monitoring of COVID-19 in Scotland  https://t.co/tqChwBqxiX #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165282,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity. ùóîùòÇùòÅùóµùóºùóøùòÄ: Agus Hasan, Yuki Nasution https://t.co/724x3kRhk6 https://t.co/SiO4IoeNm6"
http://medrxiv.org/cgi/content/short/2020.07.30.20165282,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity,@CHOMES102,RT @medrxivpreprint: A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165282,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity,@crazygrape,RT @medrxivpreprint: A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165282,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity,@thartman2u,RT @medrxivpreprint: A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165282,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity,@medrxivpreprint,A Compartmental Epidemic Model Incorporating Probable Cases to Model COVID-19 Outbreak in Regions with Limited Testing Capacity  https://t.co/wEYHYBr0Kz #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@SciscoreReports,The paper ‚ÄúOutpatient screening of health status and lifestyl...‚Äù (https://t.co/QKvJ3P3fXM) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/KQwxdKeYvg. We detected 2 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@andrea_avilab,RT @GoesslerKarla: My preprint is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/mJKDhVavo0
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@Dihaugust,RT @Appl_Phys_Nutr: My preprint is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/Mi6EgJQQRN
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@GoesslerKarla,My preprint is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/mJKDhVavo0
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@RafaGenario,"Our recent scientific contribution, in pre-print version üî¨üí°"
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@Appl_Phys_Nutr,My preprint is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/Mi6EgJQQRN
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.. ùóîùòÇùòÅùóµùóºùóøùòÄ: Karla Fabiana Goessler, Carolina Ferreira Nicoletti, Diego Augusto Nun... https://t.co/XqKEtoUuDP https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165068,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.",@medrxivpreprint,"Outpatient screening of health status and lifestyle among post-bariatric patients during the Covid-19 pandemic in Sao Paulo, Brazil.  https://t.co/mnld2UKPEk #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@MassatoHirai,RT @outbreaksci: Updated #SARSCoV preprint: Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@outbreaksci,Updated #SARSCoV preprint: Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity https://t.co/Axa1M9NyXR
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@outbreaksci,"Contribute a rapid review or request one for ""Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity"" (https://t.co/Axa1M9NyXR). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165522) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@outbreaksci,Updated #COVID19 preprint: Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity https://t.co/Axa1M9NyXR
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@outbreaksci,Updated #SARSCoV preprint: Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity https://t.co/Axa1M9NyXR
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@outbreaksci,"Contribute a rapid review or request one for ""Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity"" (https://t.co/Axa1M9NyXR). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165522) at https://t.co/RnurTL3DyM @outbreaksc"
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@outbreaksci,Updated #COVID19 preprint: Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity https://t.co/Axa1M9vXzh
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity. ùóîùòÇùòÅùóµùóºùóøùòÄ: Yiqi Ruben Luo, Indrani Chakraborty, Cassandra Yun, Alan H.B. Wu, Kara Lake Lynch https://t.co/NxUkbkd8xa https://t.co/HKnRxXna2v"
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@COVID_Papers,üìù Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity  medRxiv or bioRxiv https://t.co/9CXBsk8AC3 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165522,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity,@medrxivpreprint,Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity  https://t.co/QZiAWa0zXb #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164475,Projecting hospital resource utilization during a surge using parametric bootstrapping,@ScubaSafari,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: Projecting hospital resource utilization during a surge using parametric bootstrapping. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jeffrey N Chiang,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20164475,Projecting hospital resource utilization during a surge using parametric bootstrapping,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Projecting hospital resource utilization during a surge using parametric bootstrapping. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jeffrey N Chiang, Ulzee An, Misagh Kordi, Brandon Jew, Clifford Kravit, William J Dunne, Ronald Perez, Neil R Parikh... https://t.co/ljjCZRJvf7 https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20164475,Projecting hospital resource utilization during a surge using parametric bootstrapping,@COVID_Papers,üìù Projecting hospital resource utilization during a surge using parametric bootstrapping  medRxiv or bioRxiv https://t.co/XfVqnNAldl #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20164475,Projecting hospital resource utilization during a surge using parametric bootstrapping,@medrxivpreprint,Projecting hospital resource utilization during a surge using parametric bootstrapping  https://t.co/ZvlOTtRIgq #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@CarlosQuiteno,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries https://t.co/0Hw1RBH62B"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@outbreaksci,"Contribute a rapid review or request one for ""COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Co..."" (https://t.co/m2KW86ciO1). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165290) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@outbreaksci,"New #COVID19 preprint: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries https://t.co/m2KW86ciO1"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@Auriandra,"MedRxiv Preprint, Md Mokhlesur Rahman et al [UNC]: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries https://t.co/3h4KGQ8h07 Data were collected from Google, UNDP, UN, BBC, Oxford University, Worldometer, etc htt"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries. ùóîùòÇùòÅùóµùóºùóøùòÄ: Md Mokhlesur Rahman, Jean-Claude Thill, Kamal Chandra Paul https://t.co/DoPEqtHdl7 https://t.co/v1Hpbw7Bxh"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@MdMokhl79843585,"RT @medrxivpreprint: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  https://t.co/UI4FnMqu6m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@kcpaul34,"Countries with a higher number of elderly people, employment in the service sector, and higher globalization trends are the worst victims of the coronavirus pandemic.  #Covid_19 #Covid_research https://t.co/Md5mYkbrKs"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@PandemicCovid20,"#COVID19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries - https://t.co/JM6joxQXLm"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@MdMokhl79843585,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries https://t.co/AXGWi7RAOj"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@ajv67,"RT @medrxivpreprint: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  https://t.co/UI4FnMqu6m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@CHOMES102,"RT @medrxivpreprint: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  https://t.co/UI4FnMqu6m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@CaronaUpdates,"RT @medrxivpreprint: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  https://t.co/UI4FnMqu6m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@COVID_Papers,"üìù COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  medRxiv or bioRxiv https://t.co/LPibXhhSEK #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@akkaufman,"RT @medrxivpreprint: COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  https://t.co/UI4FnMqu6m‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165290,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries",@medrxivpreprint,"COVID-19 Pandemic Severity, Lockdown Regimes, and People Mobility: Evidence from 88 Countries  https://t.co/UI4FnMqu6m #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,"Contribute a rapid review or request one for ""Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attendin..."" (https://t.co/S2OAILko0J). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165100) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,Updated #SARSCoV preprint: Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh https://t.co/S2OAILko0J
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,"Contribute a rapid review or request one for ""Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attendin..."" (https://t.co/S2OAILko0J). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165100) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,Updated #COVID19 preprint: Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh https://t.co/S2OAILko0J
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@phil_w888,707a/  Notes:  71.8% of patients were male  not specified if current or ever  smokeless tobacco use (not reported) could complicate results  https://t.co/jIDvQaVt7V
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,New #SARSCoV preprint: Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh https://t.co/wBG01AZnoo
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,"Contribute a rapid review or request one for ""Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attendin..."" (https://t.co/wBG01AZnoo). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165100) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@outbreaksci,New #COVID19 preprint: Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh https://t.co/wBG01AZnoo
http://medrxiv.org/cgi/content/short/2020.07.30.20165100,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh,@medrxivpreprint,Clinical manifestations of patients with Coronavirus Disease 2019 (COVID- 19) attending at hospitals in Bangladesh  https://t.co/A0GRERkLQv #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@alexabel09,RT @GregoireMillet1: Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@degache,RT @GregoireMillet1: Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@sora_shin_,RT @GregoireMillet1: Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@rouecool,RT @GregoireMillet1: Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@7rajashree,RT @GregoireMillet1: Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@unilsport,RT @GregoireMillet1: Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@GregoireMillet1,Effects of COVID-19 lockdown on heart rate variability https://t.co/Yztcg6nKAp
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@GregoireMillet1,RT @StephenSeiler: A different kind of 80:20 distribution.........  This preprint is featured on the @ResearchGate #COVID19 community page.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@AndBastosCoelho,RT @StephenSeiler: A different kind of 80:20 distribution.........  This preprint is featured on the @ResearchGate #COVID19 community page.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@RonGeorge_Dubai,RT @StephenSeiler: A different kind of 80:20 distribution.........  This preprint is featured on the @ResearchGate #COVID19 community page.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@StephenSeiler,A different kind of 80:20 distribution.........  This preprint is featured on the @ResearchGate #COVID19 community page. Read it here: https://t.co/zRepA42B3z
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@anaksmithcain,@SusanaDeLeonMD #heartmath  Los efectos de la cuarentena en un estudio en Francia resulta en que el 80% de los participantes se vio afectado negativamente su HRV (variabilidad del ritmo card√≠aco). Tambi√©n sugiere que HRV biofeedback como alternativa https
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@DhruvSeshadri,Effects of COVID-19 lockdown on heart rate variability | medRxiv https://t.co/kFZ5JdsMIK
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Effects of COVID-19 lockdown on heart rate variability. ùóîùòÇùòÅùóµùóºùóøùòÄ: Nicolas Bourdillon, Sasan Yazdani, Laurent Schmitt, Gregoire P Millet https://t.co/hrMop5dlsz https://t.co/EAC8SWNBVC"
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@ReinaMo20250164,RT @medrxivpreprint: Effects of COVID-19 lockdown on heart rate variability  https://t.co/AXrLbcoxqs #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@COVID_Papers,üìù Effects of COVID-19 lockdown on heart rate variability  medRxiv or bioRxiv https://t.co/T7NchVyQT9 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165118,Effects of COVID-19 lockdown on heart rate variability,@medrxivpreprint,Effects of COVID-19 lockdown on heart rate variability  https://t.co/AXrLbcoxqs #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@NHSWYRD,RT @midyorkslibrary: The relative infectiousness of #asymptomatic #SARSCoV2 infected persons compared with symptomatic individuals: A rapid‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@midyorkslibrary,"The relative infectiousness of #asymptomatic #SARSCoV2 infected persons compared with symptomatic individuals: A rapid scoping review https://t.co/zNcn1ODLsD. Pre-print, available open accessüîì #COVID19 https://t.co/sPBNX8L1vM"
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@aula531,RT @ma_press: ÁÑ°ÁóáÁä∂ÊÑüÊüìËÄÖ„ÅÆÊÑüÊüìÊÄß„ÇíË™ø„Åπ„Åü„É¨„Éì„É•„ÉºË´ñÊñá(ÊüªË™≠Ââç)„ÄÇ„Ç®„Éì„Éá„É≥„Çπ„Åå‰∏çË∂≥„Åó„Å¶„ÅÑ„Çã„Åå„ÄÅÊó¢Â≠ò„ÅÆ„Éá„Éº„Çø„Åã„Çâ„ÅØÊúâÁóáËÄÖ„ÅÆ40%-70%„ÅÆÊÑüÊüìÊÄß„ÅåÁ§∫ÂîÜ„Åï„Çå„Çã„Å®„ÅÆ„Åì„Å®„ÄÇ https://t.co/uv09zDHqeT
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@ma_press,ÁÑ°ÁóáÁä∂ÊÑüÊüìËÄÖ„ÅÆÊÑüÊüìÊÄß„ÇíË™ø„Åπ„Åü„É¨„Éì„É•„ÉºË´ñÊñá(ÊüªË™≠Ââç)„ÄÇ„Ç®„Éì„Éá„É≥„Çπ„Åå‰∏çË∂≥„Åó„Å¶„ÅÑ„Çã„Åå„ÄÅÊó¢Â≠ò„ÅÆ„Éá„Éº„Çø„Åã„Çâ„ÅØÊúâÁóáËÄÖ„ÅÆ40%-70%„ÅÆÊÑüÊüìÊÄß„ÅåÁ§∫ÂîÜ„Åï„Çå„Çã„Å®„ÅÆ„Åì„Å®„ÄÇ https://t.co/uv09zDHqeT
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@outbreaksci,"Contribute a rapid review or request one for ""The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with ..."" (https://t.co/xFCkntu7Zq). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165084) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@outbreaksci,New #SARSCoV preprint: The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review. https://t.co/xFCkntcwAQ
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@ElmerEdward1,RT @PandemicCovid20: The relative infectiousness of asymptomatic #SARSCoV2 infected persons compared with symptomatic individuals: A rapid‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@Janjean15,@AgnesWold @bills_n_thrills Vet inte om den h√§r kan vara relevant? https://t.co/itQDP48f76
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@rmchavin,"7-30-2020:  In a study released today, Irish researchers suggest that people with reduced COVID-19 symptoms (young people, asymptomatic adults, fish/seafood eaters, whole plant eaters, favipiravir swallowers) are only 0.4 to 0.7 as contagious as coughers:"
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@PandemicCovid20,The relative infectiousness of asymptomatic #SARSCoV2 infected persons compared with symptomatic individuals: A rapid scoping review. - https://t.co/aiUWB6sXD4
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.. ùóîùòÇùòÅùóµùóºùóøùòÄ: David Mc Evoy, Conor G McAloon, Aine B Collins, Kevin Hunt, Francis ... https://t.co/CyP50y3zq8 https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@StevenYHong,RT @medrxivpreprint: The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@ajv67,RT @medrxivpreprint: The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@CHOMES102,RT @medrxivpreprint: The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@Davyanonymous,My first time being first author. #covid19 #relativeinfectiousness #relativetransmissibilty #iemag
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@PMCC,RT @medrxivpreprint: The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@COVID_Papers,üìù The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.  medRxiv or bioRxiv https://t.co/7yijyZRCSI #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165084,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.,@medrxivpreprint,The relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: A rapid scoping review.  https://t.co/UXhAkxYSH6 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@outbreaksci,"Contribute a rapid review or request one for ""A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower ..."" (https://t.co/GKD9EVJj6A). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165043) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@outbreaksci,New #SARSCoV preprint: A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery https://t.co/GKD9EVJj6A
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@drvsivalingam,RT @rajmathur7: Reassuring study showing no SARS CoV-2 RNA in peritoneal and vaginal swabs from presumed negative women undergoing surgery‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@maureen_busby,RT @rajmathur7: Reassuring study showing no SARS CoV-2 RNA in peritoneal and vaginal swabs from presumed negative women undergoing surgery‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery. ùóîùòÇùòÅùóµùóºùóøùòÄ: Dominique Jones, David Faluyi, Sarah Hamilton, Nicholas Stylianides, Kenneth... https://t.co/2VEoqjEN0l https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@rajmathur7,Reassuring study showing no SARS CoV-2 RNA in peritoneal and vaginal swabs from presumed negative women undergoing surgery https://t.co/Ik3NCI0SIL
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@COVID_Papers,üìù A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery  medRxiv or bioRxiv https://t.co/wJtl8kqXxG #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@akkaufman,RT @medrxivpreprint: A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165043,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery,@medrxivpreprint,A prospective study to identify rates of SARS-CoV-2 virus in the peritoneum and lower genital tract of patients having surgery  https://t.co/lEjFwVP6gn #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@outbreaksci,New #SARSCoV preprint: Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19 https://t.co/twGeNR1rW0
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@outbreaksci,"Contribute a rapid review or request one for ""Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of iso..."" (https://t.co/twGeNR1rW0). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165191) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@outbreaksci,New #COVID19 preprint: Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19 https://t.co/twGeNR1rW0
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@COVID19arXiv,ùóßùó∂ùòÅùóπùó≤: Mathematical modeling of the transmission of SARS-CoV-2 '' Evaluating the impact of isolation in Sao Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19. ùóîùòÇùòÅùóµ... https://t.co/Q8bEDD6tiC https://
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@outbreaksci,New #SARSCoV preprint: Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19 https://t.co/twGeNQJQxq
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@outbreaksci,"Contribute a rapid review or request one for ""Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of iso..."" (https://t.co/twGeNQJQxq). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165191) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@outbreaksci,New #COVID19 preprint: Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19 https://t.co/twGeNR1rW0
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@akkaufman,RT @medrxivpreprint: Mathematical modeling of the transmission of SARS-CoV-2 '' Evaluating the impact of isolation in Sao Paulo State (Braz‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165191,Mathematical modeling of the transmission of SARS-CoV-2 ‚Ä≥ Evaluating the impact of isolation in S√£o Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19,@medrxivpreprint,Mathematical modeling of the transmission of SARS-CoV-2 '' Evaluating the impact of isolation in Sao Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of covid-19  https://t.co/aWJULnLWXp #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@bmpf21,RT @DrNESTORSOSA2: Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de ot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@outbreaksci,"Contribute a rapid review or request one for ""Five approaches to the suppression of SARS-CoV-2 without intensive social distancing"" (https://t.co/80nr9V5odx). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165159) at https://t.co/RnurTL3DyM @outbreaksci @P"
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@outbreaksci,New #SARSCoV preprint: Five approaches to the suppression of SARS-CoV-2 without intensive social distancing https://t.co/80nr9UNMOX
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@PedsICU_tweets,RT @PIPSQC: Five approaches to suppression of SARS-CoV-2 without intensive social distancing https://t.co/YqbIUmJcKm #covid19 #coronavirus‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@JBEcology,RT @drake_lab: New preprint on five approaches for suppressing transmission of SARS-CoV-2 without lockdowns https://t.co/dYlBjxa9tT A web s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@queerdesigrrrl,RT @drake_lab: New preprint on five approaches for suppressing transmission of SARS-CoV-2 without lockdowns https://t.co/dYlBjxa9tT A web s‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@EnriqueGomezDu1,RT @DrNESTORSOSA2: Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de ot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@drake_lab,New preprint on five approaches for suppressing transmission of SARS-CoV-2 without lockdowns https://t.co/dYlBjxa9tT A web summary is available on the CEID COVID-19 portal at  https://t.co/UHAe4mujiG
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@SaiedMaudy,RT @DrNESTORSOSA2: Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de ot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@yparsons13,RT @DrNESTORSOSA2: Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de ot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@waittwoweeks,3/  @WhereIsYanLing   Fast tests = gamechanger  https://t.co/QZHRFYjVKz
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@ElmerEdward1,RT @PandemicCovid20: Five approaches to the suppression of #SARSCoV2 without intensive social distancing - https://t.co/c4cYW5XQWT
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@dragiseller,RT @DrNESTORSOSA2: Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de ot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@sepnesto,RT @DrNESTORSOSA2: Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de ot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@DrNESTORSOSA2,Medidas a medias no son suficientes. Hay diversas publicaciones cient√≠ficas con modelos matem√°ticos y experiencias de otros pa√≠ses que lo demuestran.  https://t.co/7auh2ITXkt
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@AntifaDisabled,RT @PandemicCovid20: Five approaches to the suppression of #SARSCoV2 without intensive social distancing - https://t.co/c4cYW5XQWT
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@j_ashwani,RT @PandemicCovid20: Five approaches to the suppression of #SARSCoV2 without intensive social distancing - https://t.co/c4cYW5XQWT
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@PandemicCovid20,Five approaches to the suppression of #SARSCoV2 without intensive social distancing - https://t.co/c4cYW5XQWT
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Five approaches to the suppression of SARS-CoV-2 without intensive social distancing. ùóîùòÇùòÅùóµùóºùóøùòÄ: John Drake, Pejman Rohani, Kyle Dahlin, Andreas Handel https://t.co/tnMGJCxlp3 https://t.co/zdaK1n6Njc"
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@outbreaksci,"Contribute a rapid review or request one for ""Five approaches to the suppression of SARS-CoV-2 without intensive social distancing"" (https://t.co/80nr9UNMOX). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165159) at https://t.co/RnurTKM2ac @outbreaksci @P"
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@outbreaksci,New #SARSCoV preprint: Five approaches to the suppression of SARS-CoV-2 without intensive social distancing https://t.co/80nr9UNMOX
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@CHOMES102,RT @medrxivpreprint: Five approaches to the suppression of SARS-CoV-2 without intensive social distancing  https://t.co/kFYarU7P6l #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@Maibokkrub1,RT @medrxivpreprint: Five approaches to the suppression of SARS-CoV-2 without intensive social distancing  https://t.co/kFYarU7P6l #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@akkaufman,RT @medrxivpreprint: Five approaches to the suppression of SARS-CoV-2 without intensive social distancing  https://t.co/kFYarU7P6l #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165159,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing,@medrxivpreprint,Five approaches to the suppression of SARS-CoV-2 without intensive social distancing  https://t.co/kFYarU7P6l #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@germageddoncom,RT @PandemicCovid20: Visualizing and Assessing US County-Level #COVID19 Vulnerability - https://t.co/kdn4dijwvi
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@PandemicCovid20,Visualizing and Assessing US County-Level #COVID19 Vulnerability - https://t.co/kdn4dijwvi
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Visualizing and Assessing US County-Level COVID19 Vulnerability. ùóîùòÇùòÅùóµùóºùóøùòÄ: Gina Cahill, Carleigh Kutac, Nicholas L Rider https://t.co/tv30FnmLEl https://t.co/B6H9gQ4me0"
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@e_nterdiscipl,RT @NRider70: Appreciative of the NYT providing data and maintaining their awesome COVID19 GitHub repository! Enabling science with publicl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@datasciencebot_,RT @NRider70: Appreciative of the NYT providing data and maintaining their awesome COVID19 GitHub repository! Enabling science with publicl‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@NRider70,Appreciative of the NYT providing data and maintaining their awesome COVID19 GitHub repository! Enabling science with publicly available datasets and open source tools.  #COVID19 #DataVisualization #DataScience
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@akkaufman,RT @medrxivpreprint: Visualizing and Assessing US County-Level COVID19 Vulnerability  https://t.co/m1KzuAQZow #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164608,Visualizing and Assessing US County-Level COVID19 Vulnerability,@medrxivpreprint,Visualizing and Assessing US County-Level COVID19 Vulnerability  https://t.co/m1KzuAQZow #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165050,"Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and ... https://t.co/zlkBOXSoD8 https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165050,"Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis",@akkaufman,"RT @medrxivpreprint: Quantification of the association between predisposing health conditions, demographic, and behavioural factors with ho‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165050,"Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis",@medrxivpreprint,"Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis  https://t.co/UfUk1Ddski #med"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@masha_niv,@OdedRechavi Pay attention to your sense of smell..https://t.co/kY5pRNxwGI
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@FPFischmeister,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@HUJIAgri,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@ElmerEdward1,RT @PandemicCovid20: Self-rated smell ability enables highly specific predictors of #COVID19 status: a case control study in Israel - https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@KleinHadar,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@masha_niv,"RT @H_Rossman: Time to change the ineffective fever measurements to something more discriminative?  ""Self-rated smell ability enables highl‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@tomer1812,"RT @H_Rossman: Time to change the ineffective fever measurements to something more discriminative?  ""Self-rated smell ability enables highl‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@rannirpaz1,RT @NadavEyalDesk: ◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î.
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@germageddoncom,RT @PandemicCovid20: Self-rated smell ability enables highly specific predictors of #COVID19 status: a case control study in Israel - https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@j_ashwani,RT @PandemicCovid20: Self-rated smell ability enables highly specific predictors of #COVID19 status: a case control study in Israel - https‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@PandemicCovid20,Self-rated smell ability enables highly specific predictors of #COVID19 status: a case control study in Israel - https://t.co/jDgS0y5siI
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@Nilya25820952,RT @NadavEyalDesk: ◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î. https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@effiken,RT @yuvalbenj: Very happy to share this work... smell and taste loss highly specific indicators of Covid-19
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@masha_niv,RT @NadavEyalDesk: ◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î.
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@Oshrat7,RT @NadavEyalDesk: ◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î. https://t.c‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@dentelski,RT @NadavEyalDesk: ◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î.
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@RackMada,RT @NadavEyalDesk: ◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î.
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@NadavEyalDesk,◊û◊ó◊ß◊® ◊û◊ê◊ï◊ì ◊û◊¢◊†◊ô◊ô◊ü ◊©◊ú ◊ó◊ï◊ß◊®◊ô◊ù ◊§◊î ◊ë◊ô◊©◊®◊ê◊ú ◊©◊û◊®◊ê◊î ◊õ◊ô◊¶◊ì ◊î◊¢◊®◊õ◊î ◊¢◊¶◊û◊ô◊™ ◊©◊ú ◊ê◊ë◊ì◊ü ◊ó◊ï◊© ◊®◊ô◊ó ◊ï◊ò◊¢◊ù ◊û◊†◊ë◊ê◊™ ◊û◊¶◊ï◊ô◊ü ◊™◊ó◊ú◊ï◊ê◊î ◊ë◊ß◊ï◊®◊ï◊†◊î.
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@EitanMargulis,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel. ùóîùòÇùòÅùóµùóºùóøùòÄ: Noam Karni, Hadar Klein, Kim Asseo, Yuval Benjamini, Sarah Israel, Musa Nimri, Keren Olstein... https://t.co/tHFU3QX9E7 https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@grnfluoresceblg,RT @medrxivpreprint: Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@scientist_iam,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@rannirpaz1,"Nice work! Well done Noam, Marsha and the rest of the team!"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@H_Rossman,"Time to change the ineffective fever measurements to something more discriminative?  ""Self-rated smell ability enables highly specific predictors of COVID-19 status"" - Interesting work by @masha_niv  and others"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@masha_niv,RT @yuvalbenj: Very happy to share this work... smell and taste loss highly specific indicators of Covid-19 https://t.co/cjrJzBFfdU
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@masha_niv,RT @medrxivpreprint: Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@grnfluoresceblg,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@TasteProf,RT @masha_niv: Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-P‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@yuvalbenj,Very happy to share this work... smell and taste loss highly specific indicators of Covid-19
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@masha_niv,Equally proud of https://t.co/kY5pRNfVi8 with Noam Karni @KleinHadar Kim Asseo @yuvalbenj S Israel M Nimri K Olstein R Nir-Paz A Hershko M Muszkat  similar result: #Self #rated #smell ability enables highly specific predictors of #COVID19 status https://t.
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@Ghosteen2,RT @medrxivpreprint: Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel  https:‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@rmchavin,"7-30-2020:  In a double-blind Israeli clinical study released today, compared to those who tested negative (but not told of the results), those who tested positive (but not told of the results) had a statistically significant loss in both smell and taste:"
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@COVID_Papers,üìù Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel  medRxiv or bioRxiv https://t.co/xUB2dIjjMC #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20164327,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel,@medrxivpreprint,Self-rated smell ability enables highly specific predictors of COVID-19 status: a case control study in Israel  https://t.co/YFEDDd7UUD #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@outbreaksci,"Contribute a rapid review or request one for ""Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infe..."" (https://t.co/kqoGCAgk9M). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165175) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@outbreaksci,New #SARSCoV preprint: Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection https://t.co/kqoGCAgk9M
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@GaitondeSharada,RT @chitguppi: Direct T cell measurements are difficult. Measuring the level of T cell activation/ exhaustion markers can help.  Frequencie‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@chitguppi,"Direct T cell measurements are difficult. Measuring the level of T cell activation/ exhaustion markers can help.  Frequencies of T-cell activation markers (CD69, Ox40, HLA-DR & CD154) & T-cell activation/exhaustion markers (CD25, PD-L1 & TIGIT)"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@GaitondeSharada,RT @chitguppi: @ThePrintScience @abantika77 .Direct T cell measurements are difficult. Measuring the level of T cell activation/ exhaustion‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@Mundra08,RT @chitguppi: @ThePrintScience @abantika77 .Direct T cell measurements are difficult. Measuring the level of T cell activation/ exhaustion‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@chitguppi,"@ThePrintScience @abantika77 .Direct T cell measurements are difficult. Measuring the level of T cell activation/ exhaustion markers can help.  Frequencies of T-cell activation markers (CD69, Ox40, HLA-DR & CD154) & T-cell activation/exhaustion mar"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@JakeFiles93,Really excited to be performing cutting-edge COVID-19 research. Peer-reviewed article hopefully coming soon. ü§û
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@JakeFiles93,"RT @apoorva_nyc: This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@sangmotiani,"RT @apoorva_nyc: This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@waittwoweeks,"4/   @RafaelOsswald   ""Interestingly, many of these changes were found to increase over time in non-hospitalized longitudinal samples, suggesting a prolonged period of immune dysregulation following SARS-CoV-2 infection.""  https://t.co/6IWoovRuzC"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@Frugal_Saver,"RT @apoorva_nyc: This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@Frugal_Saver,"RT @apoorva_nyc: Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@FactsMon,"RT @apoorva_nyc: This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@passmeaneggroll,"RT @apoorva_nyc: Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@CovidLabs,"RT @apoorva_nyc: Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@ginnyfromgtx,"RT @apoorva_nyc: Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@gmukunda,"RT @apoorva_nyc: Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@KennethBodin,"RT @apoorva_nyc: Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@apoorva_nyc,"Goes well with this preprint, which also suggests that T cell exhaustion (among other things) is a marker for severity in Covid19  https://t.co/YroMIr1aSq"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@brookvillebandb,"RT @apoorva_nyc: This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@katimorris_h,"RT @apoorva_nyc: This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@apoorva_nyc,"This preprint adds to increasing evidence of immune dysregulation, including T & B cell exhaustion, in people with Covid  https://t.co/qs4UCof5z9"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jacob K Files, Sushma Boppana, Mildred D Perez, Sanghita Sarkar, Kelsey E Lowman, Kai Qin, Sarah Sterrett, Eric... https://t.co/AYE9z7GBzs https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@drcameronjones,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection https://t.co/MfdLKlkG4s
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@outbreaksci,"Contribute a rapid review or request one for ""Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infe..."" (https://t.co/kqoGCzYILc). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165175) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@outbreaksci,New #SARSCoV preprint: Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection https://t.co/kqoGCzYILc
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@COVID_Papers,üìù Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection  medRxiv or bioRxiv https://t.co/o3elupq8M6 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20165175,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection,@medrxivpreprint,Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection  https://t.co/Z8GppPcT65 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@outbreaksci,New #SARSCoV preprint: High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://t.co/1NNKZu8izp
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@outbreaksci,"Contribute a rapid review or request one for ""High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment"" (https://t.co/1NNKZu8izp). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165027) at https://t.co/RnurTL3DyM @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@outbreaksci,New #COVID19 preprint: High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://t.co/1NNKZu8izp
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@safh_info,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment. ùóîùòÇùòÅùóµùóºùóøùòÄ: Juan Macias, Ana‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment. ùóîùòÇùòÅùóµùóºùóøùòÄ: Juan Macias, Ana Pinilla, Francisco A Lao-Dominguez, Anais Corma, Enrique Contreras-Macias, Alejandro Gonzalez-Sern... https://t.co/WmMo6M9ubb https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@outbreaksci,New #SARSCoV preprint: High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://t.co/1NNKZupTqX
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@outbreaksci,"Contribute a rapid review or request one for ""High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment"" (https://t.co/1NNKZupTqX). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20165027) at https://t.co/RnurTKM2ac @outbreaksci"
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@outbreaksci,New #COVID19 preprint: High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://t.co/1NNKZupTqX
http://medrxiv.org/cgi/content/short/2020.07.30.20165027,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment,@medrxivpreprint,High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment  https://t.co/VLcmk9agLt #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@outbreaksci,"Contribute a rapid review or request one for ""Comparative effects of viral transport medium heat inactivation upon downstream SARS-C..."" (https://t.co/iVU5iTPezt). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164988) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@outbreaksci,New #SARSCoV preprint: Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples https://t.co/iVU5iTPezt
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@UoNCancerCentre,RT @CardallAlice: Great news to see our #COVID19 preprint is out! https://t.co/nQhsIFZU5h
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@JaineetaRichar1,Amazing team. Feeling honoured.
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@OrdonezMoranLab,RT @andyogenesis: Delighted to announce my COVID work is now on preprint.  A truly team science approach! @claireseedhouse @chrisdenning42‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@Hebdomadian,RT @andyogenesis: Delighted to announce my COVID work is now on preprint.  A truly team science approach! @claireseedhouse @chrisdenning42‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@angeladownie,"I did a useful thing this quarantine..and here is the pre-print to prove it! But seriously, it was a privilege to be part of this effort, be able to contribute, meet some great people and take part in an exercise in true scientific collaboration!"
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@jamthompson1,Wooo üí´
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@CardallAlice,Great news to see our #COVID19 preprint is out!
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jamie L Thompson, Angela Downie Ruiz Velasco, Alice Cardall, Rebecca Tarbox, Jainee... https://t.co/IWToMobTB2 https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@outbreaksci,"Contribute a rapid review or request one for ""Comparative effects of viral transport medium heat inactivation upon downstream SARS-C..."" (https://t.co/iVU5iTxDaT). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164988) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@outbreaksci,New #SARSCoV preprint: Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples https://t.co/iVU5iTxDaT
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@MSwift94,RT @andyogenesis: Delighted to announce my COVID work is now on preprint.  A truly team science approach! @claireseedhouse @chrisdenning42‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@claireseedhouse,Great!! Well done team!!
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@pomares_luisa,RT @andyogenesis: Delighted to announce my COVID work is now on preprint.  A truly team science approach! @claireseedhouse @chrisdenning42‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@MerryLabNotts,Well done @jamthompson1 and well done team! Really great to see this out after all your hard work.
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@chrisdenning42,"Nicely done, team..! Great to see preprint out for improved heat inactivation qPCR #COVID19 testing. Good luck with the main publication @JessicaCorner @JohnAth69240605 @AlextoFavier @UoNPressOffice @UoNresearch @UniofNottingham #WeAreUoN @NottinghamVets"
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@andyogenesis,Delighted to announce my COVID work is now on preprint.  A truly team science approach! @claireseedhouse @chrisdenning42 @PostdocPat @angeladownie @CardallAlice @jamthompson1 @JaineetaRichar1 and many more! https://t.co/5deICw6M5k
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@COVID_Papers,üìù Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples  medRxiv or bioRxiv https://t.co/p6LJALAAZI #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20164988,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples,@medrxivpreprint,Comparative effects of viral transport medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples  https://t.co/xvxXFFETeF #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@NROK1227,@SepsisUK Very interesting. Here is another one which demonstrates a reduction in mortality in ICU even after adjustment.  https://t.co/Yreyd54dgK
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@ElmerEdward1,"RT @PandemicCovid20: Improving #COVID19 critical care mortality over time in England: A national cohort study, March to June 2020 - https:/‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@Victori93908916,This trend remains after adjustment for patient demographics & comorbidities suggesting this improvement is not due to changing patient characteristics. Possible causes include the introduction of effective treatments as part of clinical trials and a f
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@Miti_Vigliero,"RT @PandemicCovid20: Improving #COVID19 critical care mortality over time in England: A national cohort study, March to June 2020 - https:/‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@PandemicCovid20,"Improving #COVID19 critical care mortality over time in England: A national cohort study, March to June 2020 - https://t.co/5GSGhCWDTA"
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@SciscoreReports,The paper ‚ÄúImproving COVID-19 critical care mortality over ti...‚Äù (https://t.co/ykcELqQN8V) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/3s7U8CLTOP. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@NROK1227,@renegadeangel01 @ganeshran This is an interesting UK study (pre print) highlighting falling icu mortality rates even after adjusting for comorbidities.  https://t.co/Yreyd54dgK
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@NROK1227,@cricketwyvern This is an interesting study highlighting improved mortality in England since April. https://t.co/Yreyd54dgK
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020. ùóîùòÇùòÅùóµùóºùóøùòÄ: John Dennis, Andrew McGovern, Sebastian Vollmer, Bilal A Mateen https://t.co/UWvm4BdqEV https://t.co/eQJTnqhB7W"
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@LucreSnooker,"looks like the COVID critical-care mortality rate in England is down quite a bit from the peak (adjusted for age, sex, ethnicity, co-mordities, and region, apparently) https://t.co/2jmg2G17Kd https://t.co/ySySeLHGow"
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@NROK1227,@ProfKarolSikora https://t.co/Yreyd54dgK this seems good news
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@NROK1227,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020 https://t.co/Yreyd54dgK"
http://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",@medrxivpreprint,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020  https://t.co/tZdX13vvXP #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@GEGENCovidioten,RT @GEGENCovidioten: @Karl_Lauterbach √ñstrogen und #COVID19Symptome:  Assoziationen bei Frauen aus der COVID-Symptomstudie   Ergebnisse st√º‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@GEGENCovidioten,"√ñstrogen und #COVID19Symptome:  Assoziationen bei Frauen aus der COVID-Symptomstudie   Ergebnisse st√ºtzen eine sch√ºtzende Wirkung von √ñstrogen auf COVID-19, basierend auf einer positiven Assoziation zwischen vorhergesagtem #COVID19 und dem Menopausenstatus"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@GEGENCovidioten,"@Karl_Lauterbach √ñstrogen und #COVID19Symptome:  Assoziationen bei Frauen aus der COVID-Symptomstudie   Ergebnisse st√ºtzen eine sch√ºtzende Wirkung von √ñstrogen auf COVID-19, basierend auf einer positiven Assoziation zwischen vorhergesagtem #COVID19 und dem"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@Andkr23038644,RT @GEGENCovidioten: √ñstrogen und #COVID19Symptome:  Assoziationen bei Frauen aus der COVID-Symptomstudie   Ergebnisse st√ºtzen eine sch√ºtze‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@GEGENCovidioten,"√ñstrogen und #COVID19Symptome:  Assoziationen bei Frauen aus der COVID-Symptomstudie   Ergebnisse st√ºtzen eine sch√ºtzende Wirkung von √ñstrogen auf COVID-19, basierend auf einer positiven Assoziation zwischen vorhergesagtem #COVID19 und dem Menopausenstatus"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@outbreaksci,"Contribute a rapid review or request one for ""Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study"" (https://t.co/GnLC9kxQpf). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164921) at https://t.co/RnurTL3DyM @outbreaksci @PRE"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@outbreaksci,Updated #SARSCoV preprint: Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study https://t.co/GnLC9kxQpf
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@ladyiolanthe,@genevrael It's from a pre-print article (meaning it hasn't yet been peer-reviewed) but seems legit? https://t.co/rauWkstwfb
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@koozers,"At last ,a good side affect ."
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@ElmerEdward1,RT @PandemicCovid20: Estrogen and #COVID19 symptoms: associations in women from the COVID Symptom Study - https://t.co/JdoAL95aeT
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@DaveraG,"‚Äù... findings support a protective effect of estrogen on COVID-19, based on positive association between predicted COVID-19 and menopausal status, and a negative association with COCP use. ‚Äú   https://t.co/MgDQ4sStTR"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@DavidJohnson_27,RT @WeTheWomenAsia: The study further observed that women in the age range of 45-50 who were post-menopausal had higher occurrences of COVI‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@WeTheWomenAsia,The study further observed that women in the age range of 45-50 who were post-menopausal had higher occurrences of COVID-19 than other women. Read the full report here: https://t.co/FPQDUkVEzg https://t.co/6yjbVhFBMi
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@shelly_rowe,@PaulGroves82 @jennyeclair https://t.co/X0s8k24KhP
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@waggytailkobe,@CCriadoPerez üëáüëáüëáüëáüëá  https://t.co/ChHJfvxhXA
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@Miti_Vigliero,RT @PandemicCovid20: Estrogen and #COVID19 symptoms: associations in women from the COVID Symptom Study - https://t.co/JdoAL95aeT
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@PandemicCovid20,Estrogen and #COVID19 symptoms: associations in women from the COVID Symptom Study - https://t.co/JdoAL95aeT
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@1AGMorgan,RT @AlfredaRAdams: Always full of incredible information HFC @hotflushclub2 @BLKMenopause @ITV @thismorning
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@riskyscientists,"Why are men and older women particularly vulnerable to severe symptoms of #Covid19? One answer may be oestrogen levels, which according to a study may help protect against the negative effects of the virus https://t.co/MFN5tMNLQH"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@biancalaino,"RT @filipemosca: Tem um preprint associando estrog√™nio e prote√ß√£o √† covid-19, achei bem interessante.  Mulheres em menopausa teriam mais ri‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@filipemosca,"Tem um preprint associando estrog√™nio e prote√ß√£o √† covid-19, achei bem interessante.  Mulheres em menopausa teriam mais risco e aquelas tomando anticoncepcional combinado, menor risco.   https://t.co/5RdT52MP9c"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@AlfredaRAdams,Always full of incredible information HFC @hotflushclub2 @BLKMenopause @ITV @thismorning
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@hotflushclub2,Are post menopausal women at risk ?  These are big findings . Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study | medRxiv https://t.co/2xusSspUj9
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@BlackLight01,"@sheenan12 @semartin @faithoverfearmn @sheeraf Estrogen (https://t.co/eP19pscAMW), progesterone (https://t.co/HRFWFW2Qv8) and other cheap hormones have also shown promising results. If all scientists were paid by big pharma then how come such research on d"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@snchez_manu,RT @emas_online: Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study: Preprint of Female users of the COVID‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@emas_online,"Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study: Preprint of Female users of the COVID Symptom Tracker Application in the UK, including 152,637 women for menopause status, 295,689 for COCP use, and 151,193 for HRT use.htt"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@lacks22,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study | medRxiv https://t.co/nGatUjVoo4
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@sangmotiani,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@JPThermoz,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@BabsGibson,RT @MicrobiomeMedic: Our pre-print examining the effect of oestrogen in COVID-19 is now live! @TwinsUKres @Join_ZOE @jordanatbell   medrxiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@luvenice_h,RT @MicrobiomeMedic: Our pre-print examining the effect of oestrogen in COVID-19 is now live! @TwinsUKres @Join_ZOE @jordanatbell   medrxiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@LwtEmmaBird,"@TheSun Or actually, this research shows the opposite: https://t.co/knSiJl6jtC"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@LwtEmmaBird,"@bpas1968 @EndoSocJournals @TheSun @WRISK_project @HeatherTrickey @d_spiegel @RCObsGyn In fact, this research suggests the opposite: https://t.co/knSiJl6jtC"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@aifbw,@FDrenos @drmdhaa95
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@timspector,RT @MicrobiomeMedic: Our pre-print examining the effect of oestrogen in COVID-19 is now live! @TwinsUKres @Join_ZOE @jordanatbell   medrxiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@mimfinds,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@DrLBoominathan,https://t.co/Zu6zG5iJkR
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@WarrenEducators,@apoorva_nyc As if this wasn't enough on a Sunday night for men everywhere!  https://t.co/ZbkK5JuBEN
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@TwinsUKres,RT @MicrobiomeMedic: Our pre-print examining the effect of oestrogen in COVID-19 is now live! @TwinsUKres @Join_ZOE @jordanatbell   medrxiv‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@kat_gris,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@MicrobiomeMedic,Our pre-print examining the effect of oestrogen in COVID-19 is now live! @TwinsUKres @Join_ZOE @jordanatbell   medrxiv viewer https://t.co/U51pROLUG8
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@sherkohmazari,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@SiccoVanHoegee,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@soniyaagrawal21,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@hnarasim23,Definitely warrants more investigation!
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@NARAYANRAO12,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@oommen,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@CovidLabs,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@cabcbg,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@AmyMillerPhD,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@Furious_mico,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@leavealighton42,ü§î
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@IsabelValin,RT @apoorva_nyc: A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@apoorva_nyc,A preliminary but somewhat intriguing link suggesting estrogen is protective against Covid:   https://t.co/aQvEGDoXXG
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study. ùóîùòÇùòÅùóµùóºùóøùòÄ: Ricardo Costerira, Karla A Lee, Benjamin Murray, Colette Christiansen, Juan Castillo-Fernandez, Mary Ni Lochlainn, Joan ... https://t.co/FXoNbbJrsW https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@outbreaksci,"Contribute a rapid review or request one for ""Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study"" (https://t.co/GnLC9kxQpf). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164921) at https://t.co/RnurTL3DyM @outbreaksci @PRE"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@outbreaksci,New #SARSCoV preprint: Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study https://t.co/GnLC9kgf0F
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@naomiattar,"Consistent pattern of modest protective effect of oestrogen against Covid-19 in age- and BMI-matched women using the @Join_ZOE symptom app   The app team had previously blogged about top line findings, but here provide the numbers"
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@akkaufman,RT @medrxivpreprint: Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study  https://t.co/E6ErTiHWge #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@COVID_Papers,üìù Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study  medRxiv or bioRxiv https://t.co/gbCxAlgExp #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,@medrxivpreprint,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study  https://t.co/E6ErTiHWge #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@outbreaksci,Updated #SARSCoV preprint: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/Et6msR1PS5
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@outbreaksci,"Contribute a rapid review or request one for ""High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of de..."" (https://t.co/Et6msR1PS5). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164970) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@outbreaksci,Updated #COVID19 preprint: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/Et6msR1PS5
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Meteo_NoelBanda,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/qPrZ1Kbl4D https://t.co/kKldx3tKso
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@shonajanelee,RT @LizDivala: Great work! local data on COVID-19 in Malawi coming up üëè https://t.co/8eSdQVylKu
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Zwa29,RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. ùóîùòÇùòÅùóµùóºùóø‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@kundayyi,RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. ùóîùòÇùòÅùóµùóºùóø‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@AnganileNgwira,There is still hope!
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@CapitalFMMw,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@CapitalFMMw,RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. ùóîùòÇùòÅùóµùóºùóø‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@JTSglobalhealth,RT @DrToniHo: Congrats to @kjambo & @MlwTrust  team for this important work. Adjusted #SARSCoV2 seroprevalence 12.3% (95% CI 9.0-15.7) amon‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MozyBeatz,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@_wanangwa,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MissChisomo,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MlwTrust,RT @DrToniHo: Congrats to @kjambo & @MlwTrust  team for this important work. Adjusted #SARSCoV2 seroprevalence 12.3% (95% CI 9.0-15.7) amon‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@AttipaC,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@kondwanimsofi,RT @LizDivala: Great work! local data on COVID-19 in Malawi coming up üëè
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@DrToniHo,Congrats to @kjambo & @MlwTrust  team for this important work. Adjusted #SARSCoV2 seroprevalence 12.3% (95% CI 9.0-15.7) among 500 asymptomatic healthcare workers in Blantyre #Malawi. 1/3
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@IfedayoTiffy,RT @medrxivpreprint: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@IfedayoTiffy,Interesting bit of work by @kjambo and other colleagues in Malawi.
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@AbenaPhD,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Nanyingih,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@AndrewAMataya,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Ice_Queen_402,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@NIHR_MPRU,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@ksbakes,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@m_heys,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@KatharineStott,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@GlobalHealthNut,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@HannekePot,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@ankurgw,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@HugoMlewa,RT @dremmacbw: Important data on which to base better mathematical models to estimate the #COVID19 epidemic in urban southern African count‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MelitaGordon5,Great to see these extremely interesting and important Malawi data from @kjambo
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Schulbz,A good read:  High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban #Malawi by @kjambo et al  https://t.co/61fAkzDTxm #Covid_19 #SARSCoV2 #coronavirus
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@TumaCMalenga,RT @dremmacbw: Important data on which to base better mathematical models to estimate the #COVID19 epidemic in urban southern African count‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@donal_bisanzio,RT @RLB_1: ‚ö†Ô∏èPREPRINT ALERT ‚ö†Ô∏è Fascinating data from #Malawi with high levels of COVID immunity found in healthcare workers despite relativ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@jay_salsa,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@iruka_okeke,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@HelenaFeasey,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@rashida_abbferr,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@dremmacbw,Important data on which to base better mathematical models to estimate the #COVID19 epidemic in urban southern African countries. Reported deaths 8x lower than predicted from European models. Excellent work from @MlwTrust @kjambo @Stephengordon14 and team
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Tamarafkamanga,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@virusmonologues,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MaccormickIan,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@GalloHeath,Really interesting results from Malawi regarding seroprevalence of SARS-CoV-2.
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Christinek712,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@rachaelburke,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@kjambo,RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. ùóîùòÇùòÅùóµùóºùóø‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. ùóîùòÇùòÅùóµùóºùóøùòÄ: Marah Grace Chibwana, Khuzwayo Chidiwa Jere, Jonathan Mandolo, Vincent Katunga-Phiri, Dumizulu T... https://t.co/ljfJGQtBVe https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@DavidLissauer,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Alyc_89,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@estariade,"RT @esamjones: One more study in (urban) East Africa, pointing to fairly high Covid-19 rates of infection, but seemingly low mortality."
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Thomasena_,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@TDivala,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Chiko_peno,Amazon work and congratulations @kjambo @khuzwayojere @MarahChibwana  and the  team
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MalawiMedHums,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@outbreaksci,New #SARSCoV preprint: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/Et6msR1PS5
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@outbreaksci,"Contribute a rapid review or request one for ""High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of de..."" (https://t.co/Et6msQKetv). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164970) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@outbreaksci,New #COVID19 preprint: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/Et6msQKetv
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Chris_Bunn,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@max_namanjasi,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@TDivala,RT @LizDivala: Great work! local data on COVID-19 in Malawi coming up üëè https://t.co/8eSdQVylKu
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@mseigna,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@ZilanieGondwe,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MrTwalib,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Chingango_M,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@TomMwamadi,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@GamaBee,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@glassmanamanda,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@esamjones,"One more study in (urban) East Africa, pointing to fairly high Covid-19 rates of infection, but seemingly low mortality."
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@WezzieLora,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@helleringer143,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@ElizaMbamba,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@SaraE_Fischer,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@LizDivala,Great work! local data on COVID-19 in Malawi coming up üëè
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Lusako20,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@YankhoKaimila,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@WCIPGLASGOW,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MarahChibwana,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@S_Amani,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@RLB_1,‚ö†Ô∏èPREPRINT ALERT ‚ö†Ô∏è Fascinating data from #Malawi with high levels of COVID immunity found in healthcare workers despite relatively low cases and deaths (at the time of writing).  Data like this is vital for us to improve the models used to predict SARS-Co
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@benjamesmorton,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@Xetanix,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@SepSaleh,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@YGadama,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@RebeccaSear,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@kanjalac,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@ChrispinChaguza,Congratulations @kjambo and the team @MlwTrust
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@DrChrisPaton,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@JosephFitchett,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@petermacp,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@leesmith2310,RT @medrxivpreprint: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi  https://t.‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@MlwTrust,RT @kjambo: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@kjambo,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi https://t.co/SW1eYs8gxG @MarahChibwana @MlwTrust @LSTMnews @MalawiGovt @MalawiHealth @HonKandodo @TDivala @SKChilima @LAZARUSCHAKWERA  @wellcometrust
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@COVID_Papers,üìù High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi  medRxiv or bioRxiv https://t.co/ufnBVvvxA3 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.30.20164970,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi,@medrxivpreprint,High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi  https://t.co/lcToal2Vt3 #medRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@outbreaksci,"Contribute a rapid review or request one for ""Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from feca..."" (https://t.co/NBjb2PCVlU). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.230102) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@outbreaksci,Updated #SARSCoV preprint: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants https://t.co/NBjb2PCVlU
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@Rosenchild,RT @biorxiv_genomic: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@Astro_Erik,RT @biorxivpreprint: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants. ùóîùòÇùòÅùóµùóºùóøùòÄ: Mingkun Li, Yi Xu, Lu Kang, Zijie Shen, Xufan... https://t.co/LgF1ZZJYOT https://"
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@outbreaksci,"Contribute a rapid review or request one for ""Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from feca..."" (https://t.co/NBjb2PljXk). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.230102) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@outbreaksci,New #SARSCoV preprint: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants https://t.co/NBjb2PljXk
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@Jun_Sky_0610,RT @biorxivpreprint: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@MicrobiomeBot,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants https://t.co/xKXTOehrJL
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@Xenobiom,RT @biorxivpreprint: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@TJesse62,RT @biorxiv_genomic: Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@COVID_Papers,üìù Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants  medRxiv or bioRxiv https://t.co/JbO8Fx6r0L #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.230102,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants,@biorxivpreprint,Hybrid capture-based sequencing enables unbiased recovery of SAR-CoV-2 genomes from fecal samples and characterization of the dynamics of intra-host variants  https://t.co/hLvBC4r9tk #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@VICB_Vanderbilt,"The @jonathanirishlab just dropped this preprint Covid article titled, ""Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy."" Check it out here: https://t.co/lmxkbmNzrk @scbiolab @biorxivprep"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@outbreaksci,"Contribute a rapid review or request one for ""Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus in..."" (https://t.co/MqHEcGGE5R). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.190454) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@outbreaksci,"Updated #SARSCoV preprint: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy https://t.co/MqHEcGGE5R"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@bexxmodd,"RT @saqibali_ca: Unsupervised machine learning reveals key immune cell subsets in COVID-19 , rhinovirus infection , and cancer therapy - Pu‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@saqibali_ca,"Unsupervised machine learning reveals key immune cell subsets in COVID-19 , rhinovirus infection , and cancer therapy - PubMed  https://t.co/1hWQ7D5IJl"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@UvaScience_Pubs,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy. https://t.co/gy5oZY8pPE https://t.co/T0MMsutxtd"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@PaperbirdsO,"New article: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy. https://t.co/Sj0QT4eqxo #melanoma #oncology https://t.co/kA1xtYmHbr"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@MlOncology,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy https://t.co/8YE623AK3L"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@FourZeroFourbot,"RT @ManchesterCytof: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy #c‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@ManchesterCytof,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy #cytofpub https://t.co/HHB8rjn0IZ"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@Doctor_JAW,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy https://t.co/uaxcPpswD0"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@TomAsh_1,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@LiesbethCelebi,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@bexxmodd,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@VICB_Vanderbilt,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@VUMC_VCI,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@bexxmodd,"RT @COVID19arXiv: ùóßùó∂ùòÅùóπùó≤: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therap‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy. ùóîùòÇùòÅùóµùóºùóøùòÄ: Sierra M. Barone, Alberta G.A. Paul, Lyndsey M. Muehling, Joanne A. Lannigan, William W... https://t.co/evBGrwYVhZ https://"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@BonamiRachel,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@bexxmodd,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@jonathanirish,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@scbiolab,RT @jonathanirish: @VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell sub‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@bexxmodd,"RT @outbreaksci: New #SARSCoV preprint: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@sanketmraut,"RT @outbreaksci: New #SARSCoV preprint: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, an‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@outbreaksci,"Contribute a rapid review or request one for ""Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus in..."" (https://t.co/MqHEcGYeXp). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.190454) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@outbreaksci,"New #SARSCoV preprint: Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy https://t.co/MqHEcGGE5R"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@jonathanirish,"@VanderbiltU T-REX machine learning algorithm now on bioRxiv:  Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy  https://t.co/dGGWy1Tum8   Tracking Responders Expanding (T-REX) code on Gith"
http://biorxiv.org/cgi/content/short/2020.07.31.190454,"Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy",@COVID_Papers,"üìù Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy  medRxiv or bioRxiv https://t.co/66QpHdsMBh #COVID19 #COVID19Papers #SARSCoV2"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@JieZhou55370495,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@MassatoHirai,RT @outbreaksci: Updated #SARSCoV preprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/9YIse9xsfV
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Engineered ACE2 receptor traps potently neutralize SARS-CoV-2"" (https://t.co/9YIse9xsfV). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.231746) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@outbreaksci,Updated #SARSCoV preprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/9YIse9xsfV
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@UZs_Scinippets,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@mo64ss,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@platypus_tech,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@RuthStone6,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@zibilith,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@twistopherrobin,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@twistopherrobin,RT @DocDellaire: Seems like a similar approach to the soluble ACE2 drug APN01 developed by Penninger and colleagues over 10 years ago and i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@DTELab,Proud of DTE lab alumna @helloanum for this awesome work in her postdoc @KortemmeLab! I am optimistic with all these great scientists and engineers working on this problem!
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@alfobioq,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@AdairLBorges,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@PhdBon,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@mil_moj,RT @rjerala: Proteinsko in≈æenirstvo za virusne inhibitorje: z mutagenezo so >100x izbolj≈°ali vezavo ACE2 mutant za virus ter uƒçinkovito inh‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@MThompsonLab,Really interesting and important work from my friend @helloanum. Always cooking up something cool with protein engineering!
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@tmfiesta,Retweeting some recent anti-COVID strategy work on Biorxiv from a brilliant scientist I feel lucky to call my friend
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Kannan9900,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@SavageCatsOnly,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@cole_bracken,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Anniemdg,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@NoamPrywes,Why make an antibody when the spike protein already has a favorite human receptor? Congrats to the whole team!
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@susanna_elledge,Check out this awesome ACE2 engineeeing work to make potent SARS-CoV-2 therapeutics! Great collaboration between many labs and great scientists!
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@vandontweets,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@mctucsf,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@pharmercologist,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@krena19639208,RT @rjerala: Proteinsko in≈æenirstvo za virusne inhibitorje: z mutagenezo so >100x izbolj≈°ali vezavo ACE2 mutant za virus ter uƒçinkovito inh‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@jrbyrnes8,Some very hard work by a group of dedicated scientists I work with led to an exciting potential therapeutic for SARS-CoV-2. Happy to see this up on @biorxivpreprint! https://t.co/riYdgdRru7
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@rdrighetto,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ayanosatoh,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ShorterLab,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@drjohnmorley,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/FzA6GEQqn6
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@prof_brunt,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@JayChance12,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@DocDellaire,"Seems like a similar approach to the soluble ACE2 drug APN01 developed by Penninger and colleagues over 10 years ago and in phase 2 clinical trials for COVID19, except the blocking proteins are not enzymatically active https://t.co/UlutQrqLqm"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@TalesOfDNA,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ClaireHills21,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@hladnikp,RT @rjerala: Proteinsko in≈æenirstvo za virusne inhibitorje: z mutagenezo so >100x izbolj≈°ali vezavo ACE2 mutant za virus ter uƒçinkovito inh‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@BojankaStern,RT @rjerala: Proteinsko in≈æenirstvo za virusne inhibitorje: z mutagenezo so >100x izbolj≈°ali vezavo ACE2 mutant za virus ter uƒçinkovito inh‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@rjerala,"Proteinsko in≈æenirstvo za virusne inhibitorje: z mutagenezo so >100x izbolj≈°ali vezavo ACE2 mutant za virus ter uƒçinkovito inhibirali virusno oku≈æbo celic. Ta protein je uporaben za vse viruse, ki uporabljajo isti receptor. @realJimWells @KortemmeLab  h"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ojh_compchem,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@brock_lab,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@FrankNoeBerlin,This is an interesting idea.
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@folding_covid19,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@handbrake101,"Cool therapeutic strategy using designed SARS-CoV2 ""receptor traps"" that bind the virus up to 170x more efficiently than our native receptors. They also mention that this approach could be used to design therapeutics for other viruses where the receptor is"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ToubiMohammed,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@kabirhbiswas,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ovais_epilogue,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@weinberz,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@glukozica,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@StacyMalaker,"Promising potential therapeutic agent from @helloanum, @KortemmeLab, and @RealJamesWells, wherein they engineered an ACE2 receptor trap to neutralize SARS-CoV2. Brilliant! Hope to see this in animal models soon."
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@DrAmberPaasch,Cool new research engineering a protein that binds up SARS-Cov-2 from @helloanum!
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@mykfish,Great work describing the design of a protein that neutralizes the #coronavirus in cell culture released as a preprint from Team Glasgow / @KortemmeLab / @realJimWells.  Looking forward to this project‚Äôs next steps. ü•Ω
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@robalberstein,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@amyguo1997,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ShawnMCostello,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@scientistamy,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@toutselonmoi,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@fraser_lab,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@elsanchez09,"RT @helloanum: We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the vi‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@helloanum,"We used a simple but powerful strategy to build a SARS-CoV-2 therapeutic, now on bioRxiv. It is great at neutralizing the virus in cell culture and we are optimistic that it could work in something with lungs. https://t.co/5uDfw6IM8s"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@QuirkySquark,https://t.co/3SwnfC5d08
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@celiacdisease,"2/ Instead of breaking into cells via the ACE2 receptor, the coronavirus that causes #COVID19 can be lured away and trapped by a new decoy version of ACE2, as shown in test tube experiments with human lung cells. (https://t.co/GCBWIMSinW) https://t.co/CVyG"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@twistopherrobin,"Apparently improving upon the #JosefPenninger #rhACE2 approach: ""Engineered ACE2 receptor traps potently neutralize SARS-CoV-2"" by Anum Glasgow, Jeff Glasgow, Daniel Limonta, University of California, August 1, 2020: https://t.co/iJtJ9U2Gr2"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Radio88mx,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@AMidnightBaker,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@network_motif,coronavirus honeypot
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@pi_and_power,RT @Astro_Erik: @pi_and_power @janelle_purple @multisensebrain
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@RXRollins,RT @PromPreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/m8aWVS5Fa7
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@TonyBurnetti,RT @PromPreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/m8aWVS5Fa7
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@PromPreprint,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/m8aWVS5Fa7
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Astro_Erik,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@megsmclaugh,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@davidtroponin,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@theywoulddo,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Sam7Rockstar,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ZakLockman,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ahramkim1128,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/sWtmQHLiCc
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. ùóîùòÇùòÅùóµùóºùóøùòÄ: Anum Glasgow, Jeff Edward Glasgow, Daniel Limonta, Paige Solomon, Irene Lui, Yang Zhang, Matthew A Nix, Nicholas J Rettko, Shion A Lim, Shosh... https://t.co/IGa2lec6K8 https://"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@mimasaji1,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@a_1_0_2,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@jawjahpeach,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@ajileigh,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@tipirneni,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@AutonomicAus,"Engineered ACE2 receptor traps potently neutralize SARS-CoV-2, by researchers at @UCSF_BioE, @ucsfpharmacy, @LKSIoV, @UAlberta_FoMD & @RockefellerUniv https://t.co/2aSnGkwJHb #proteinengineering #bioengineering #SARSCoV2 #ACE2 #receptors #ACE2recepto"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@AamirZakariaMD,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@KevohRipper,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@pat_shanks,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@epidatum,Engineered #ACE2 receptor traps potently neutralize #SARSCoV2  These optimized receptor traps tightly bind the receptor binding domain (RBD) of the viral spike protein and prevent entry into host cells.  https://t.co/kU7rgyxYWM https://t.co/vSZcSSrKtw
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Engineered ACE2 receptor traps potently neutralize SARS-CoV-2"" (https://t.co/9YIse9fQRl). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.231746) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/9YIse9fQRl
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@mushjet,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@bonnieorduz,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@MsWZ,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@inotof1,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Jun_Sky_0610,@pychiatrist1972 ‰ª•Ââç„Å´„ÄÅ„Åì„Çå„ÅÆ„Çà„ÅÜ„Å™„Åì„Å®„ÇíÂëü„ÅÑ„Å¶„ÅÑ„Åü„Çà„ÅÜ„Å™Ê∞ó„Åå„ÄÇ„ÄÇ„ÄÇ  https://t.co/zJAuP4htcT
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Jun_Sky_0610,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@Auriandra,"BioRxiv preprint, Anum Glasgow et al [UCSF]: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 https://t.co/IY3v3f9WZU ‚Äú[O]ptimized receptor traps tightly bind the receptor binding domain (RBD) of the viral spike protein and prevent entry into"
http://biorxiv.org/cgi/content/short/2020.07.31.231746,Engineered ACE2 receptor traps potently neutralize SARS-CoV-2,@JoyatiDas1,RT @biorxivpreprint: Engineered ACE2 receptor traps potently neutralize SARS-CoV-2  https://t.co/d2nT22KGKz #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@InciSioNUK,"RT @NANSIG1: *Another publication!*   ""Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early respons‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@medic_cd,"RT @NANSIG1: *Another publication!*   ""Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early respons‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@NANSIG1,"*Another publication!*   ""Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19""  Congratulations to everyone involved! The pre-print of the ADAPT study can be found here: ht"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@jas_a_medic,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19. ùóîùòÇùòÅùóµùóºùóøùòÄ: Anmol Arora, Georgios Solomou, Soham Bandyopadhyay, Julia Simons, A... https://t.co/IxqBKG6zub https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@alexrosborne,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@AnmolArora_98,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@RobinBorchert,Pre-print snapshot of what happened to UK medical schools during #COVID19 (ADAPT study). Great being involved   https://t.co/7bq4Yhtul2
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@inshal,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@RyanCla60282460,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@Harmani89532100,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@shumailm34,"Pre-print of the ADAPT study, looking at how COVID-19 initially affected medical student teaching! Well worth a read."
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@SohamBGlobal,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@esmefg,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@_mgoble,"Snapshot of what happened in UK med schools during Covid, have a looküëÅÔ∏èüëÅÔ∏è"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@jessicayxie,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@Coreybriffa,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@oliverdevine,RT @InciSioNUK: Want to know how #MedEd has been affected by #COVID19? Take a look at the preprint first report of ADAPT ‚¨áÔ∏è #MedTwitter #Me‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@medic_cd,RT @InciSioNUK: Want to know how #MedEd has been affected by #COVID19? Take a look at the preprint first report of ADAPT ‚¨áÔ∏è #MedTwitter #Me‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@medic_cd,"RT @NEDouglas_: COVID19 has disrupted #MedicalEducation- assessments, placements & teaching. The ADAPT Consortium looks at the impact on tr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@medic_cd,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@InciSioNUK,Want to know how #MedEd has been affected by #COVID19? Take a look at the preprint first report of ADAPT ‚¨áÔ∏è #MedTwitter #MedStudentTwitter #medicalstudent #medicaleducation
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@DrKarponis,A great initiative during challenging times. Very grateful for the opportunity to be a part of the team.
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@jcollm1,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@trydyrjabs,"RT @oliverdevine: COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@abbey_boyle,"The pre-print of this is now live, check it out! #MedEd #medicalstudent #MedTwitter"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@MedEdBot,RT @emmajanenorton1: More lockdown productivity #meded #Covid19UK #ADAPT https://t.co/dkAJAuQfTb
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@emmajanenorton1,More lockdown productivity #meded #Covid19UK #ADAPT
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@NEDouglas_,"COVID19 has disrupted #MedicalEducation- assessments, placements & teaching. The ADAPT Consortium looks at the impact on training. Read our preprint, looking at the initial response of schools up to April 2020: https://t.co/87qDozQs2b   #MedStudentTwit"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@ShreyaBn,What a privilege to work on this project. Our pre-print is now live. Do check it out!
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@oliverdevine,"COVID-19 has disrupted assessment, placements and teaching. @fmlm @NANSIG1 @rsm @TheDA_UK students have set up the ADAPT Consortium to study the impact on training. Preprint of first report, looking at the initial response of schools up to April 2020: http"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@COVID_Papers,"üìù Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19  medRxiv or bioRxiv https://t.co/jMW0aiBcMU #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.29.20163907,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19",@medrxivpreprint,"Adjusting to Disrupted Assessments, Placements and Teaching (ADAPT): a snapshot of the early response by UK medical schools to COVID-19  https://t.co/9w2bOtjRHH #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.29.20164566,Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity. ùóîùòÇùòÅùóµùóºùóøùòÄ: Eduard Campillo-Funollet, James Van Yperen, Phil Allman, Michael Bell, Warren Beresford, Jacqueline Clay, Grah... https://t.co/3ho6F2cLn2 https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20164566,Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity,@outbreaksci,"Contribute a rapid review or request one for ""Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and ca..."" (https://t.co/yiJf1nxvZk). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164566) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164566,Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity,@outbreaksci,New #COVID19 preprint: Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity https://t.co/yiJf1nxvZk
http://medrxiv.org/cgi/content/short/2020.07.29.20164566,Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity,@medrxivpreprint,Forecasting COVID-19: Using SEIR-D quantitative modelling for healthcare demand and capacity  https://t.co/vUd8aS3UxT #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164509,Estimating the total size of coronavirus epidemic in Algeria via different approaches,@COVID19arXiv,ùóßùó∂ùòÅùóπùó≤: Estimating the total size of coronavirus epidemic in Algeria via different approaches. ùóîùòÇùòÅùóµùóºùóøùòÄ: Mohamed REZKI https://t.co/IYGGsNmRSF https://t.co/E2M5ju32px
http://medrxiv.org/cgi/content/short/2020.07.29.20164509,Estimating the total size of coronavirus epidemic in Algeria via different approaches,@outbreaksci,"Contribute a rapid review or request one for ""Estimating the total size of coronavirus epidemic in Algeria via different approaches"" (https://t.co/B0L7xsDIpV). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164509) at https://t.co/RnurTKM2ac @outbreaksci @"
http://medrxiv.org/cgi/content/short/2020.07.29.20164509,Estimating the total size of coronavirus epidemic in Algeria via different approaches,@outbreaksci,New #COVID19 preprint: Estimating the total size of coronavirus epidemic in Algeria via different approaches https://t.co/B0L7xsDIpV
http://medrxiv.org/cgi/content/short/2020.07.29.20164509,Estimating the total size of coronavirus epidemic in Algeria via different approaches,@medrxivpreprint,Estimating the total size of coronavirus epidemic in Algeria via different approaches  https://t.co/9CsB1wZwBa #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164491,Modeling latent infection transmissions through biosocial stochastic dynamics,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Modeling latent infection transmissions through biosocial stochastic dynamics. ùóîùòÇùòÅùóµùóºùóøùòÄ: Bosiljka Tadic, Roderick Melnik https://t.co/SbuLqRtuYh https://t.co/lIDEFvpNn0"
http://medrxiv.org/cgi/content/short/2020.07.30.20164491,Modeling latent infection transmissions through biosocial stochastic dynamics,@outbreaksci,"Contribute a rapid review or request one for ""Modeling latent infection transmissions through biosocial stochastic dynamics"" (https://t.co/3DE84qGhoS). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164491) at https://t.co/RnurTKM2ac @outbreaksci @PRErevie"
http://medrxiv.org/cgi/content/short/2020.07.30.20164491,Modeling latent infection transmissions through biosocial stochastic dynamics,@outbreaksci,New #SARSCoV preprint: Modeling latent infection transmissions through biosocial stochastic dynamics https://t.co/3DE84qGhoS
http://medrxiv.org/cgi/content/short/2020.07.30.20164491,Modeling latent infection transmissions through biosocial stochastic dynamics,@medrxivpreprint,Modeling latent infection transmissions through biosocial stochastic dynamics  https://t.co/tvLlHgBxOD #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@plays4power,"RT @rmchavin: 7-29-2020:  In a South Korean clinical trial released today, ACE inhibitors and ARBs were the healthiest anti-hypertensive dr‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@MassatoHirai,RT @chriskc_Lee: Preprint on the clinical outcome of COVID-19 pts on ACEI/ARBs (S Korea).  Conclusion: no increase in adverse clinical outc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@gracehwang1970,RT @chriskc_Lee: Preprint on the clinical outcome of COVID-19 pts on ACEI/ARBs (S Korea).  Conclusion: no increase in adverse clinical outc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@GB_ruleofgame,RT @chriskc_Lee: Preprint on the clinical outcome of COVID-19 pts on ACEI/ARBs (S Korea).  Conclusion: no increase in adverse clinical outc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@chriskc_Lee,Preprint on the clinical outcome of COVID-19 pts on ACEI/ARBs (S Korea).  Conclusion: no increase in adverse clinical outcome.  https://t.co/QEEJbngr0b
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@gracehwang1970,RT @outbreaksci: New #COVID19 preprint: Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiot‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study. ùóîùòÇùòÅùóµùóºùóøùòÄ: Ju Hwan Kim,... https://t.co/Cbtg3JlVEn https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@outbreaksci,"Contribute a rapid review or request one for ""Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibit..."" (https://t.co/lsXTsKXDoq). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164822) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@outbreaksci,New #COVID19 preprint: Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study https://t.co/lsXTsKXDoq
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@rmchavin,"7-29-2020:  In a South Korean clinical trial released today, ACE inhibitors and ARBs were the healthiest anti-hypertensive drugs, not only for lowering blood pressure, but also for surviving COVID-19. This confirms identical results from China and the U.S."
http://medrxiv.org/cgi/content/short/2020.07.29.20164822,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study,@medrxivpreprint,Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study  https://t.co/gIrGFCr8BA #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,"Contribute a rapid review or request one for ""Rapid real-time tracking of non-pharmaceutical interventions and their association wit..."" (https://t.co/LFhbj0pGWW). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164665) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,Updated #SARSCoV preprint: Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study https://t.co/LFhbj0pGWW
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,"Contribute a rapid review or request one for ""Rapid real-time tracking of non-pharmaceutical interventions and their association wit..."" (https://t.co/LFhbj0pGWW). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164665) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,Updated #COVID19 preprint: Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study https://t.co/LFhbj0pGWW
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@waittwoweeks,"5/  @WhereIsYanLing   ""the only travel associated with higher likelihood of SARS-CoV-2 infection was use of public transport (aOR for 7 or more times vs. never: 4.29)""  https://t.co/NK7IsBQExc"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Rapid real-time tracking of non-pharmaceutical interventions and their association SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study. ùóîùòÇùòÅùóµùóºùóøùòÄ: Steven J. Clipman, Amy P. Wesolowski, Dustin G. Gibson, Smisha ... https://t.co/5rVQuv5OQB https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@MOCOElephant,"RT @waittwoweeks: @JamesOKeefeIII ""the only travel associated with higher likelihood of SARS-CoV-2 infection was use of public transport (a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@youroldestfan,"RT @waittwoweeks: @JamesOKeefeIII ""the only travel associated with higher likelihood of SARS-CoV-2 infection was use of public transport (a‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@waittwoweeks,"@JamesOKeefeIII ""the only travel associated with higher likelihood of SARS-CoV-2 infection was use of public transport (aOR for 7 or more times vs. never: 4.29)""  https://t.co/NK7IsC8foK"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,New #SARSCoV preprint: Rapid real-time tracking of non-pharmaceutical interventions and their association SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study https://t.co/LFhbj085ym
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,"Contribute a rapid review or request one for ""Rapid real-time tracking of non-pharmaceutical interventions and their association SAR..."" (https://t.co/LFhbj085ym). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164665) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@outbreaksci,New #COVID19 preprint: Rapid real-time tracking of non-pharmaceutical interventions and their association SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study https://t.co/LFhbj085ym
http://medrxiv.org/cgi/content/short/2020.07.29.20164665,Rapid real-time tracking of non-pharmaceutical interventions and their association with SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study,@medrxivpreprint,Rapid real-time tracking of non-pharmaceutical interventions and their association SARS-CoV-2 positivity: The COVID-19 Pandemic Pulse Study  https://t.co/TjhDLhbWGG #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20164855,SABCoM: A Spatial Agent-Based Covid-19 Model,@TracyPoelzer,RT @IneNoben: Yes please! Models that simulate policy regulations to control the #Covid_19 pandemic can help explain to the public why inte‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164855,SABCoM: A Spatial Agent-Based Covid-19 Model,@Peter__Courtney,The team I've been working with. (My name is at the bottom of the PDF even :)
http://medrxiv.org/cgi/content/short/2020.07.30.20164855,SABCoM: A Spatial Agent-Based Covid-19 Model,@IneNoben,Yes please! Models that simulate policy regulations to control the #Covid_19 pandemic can help explain to the public why interventions are being implemented. #coronamaatregelen @JoeriSchasfoort
http://medrxiv.org/cgi/content/short/2020.07.30.20164855,SABCoM: A Spatial Agent-Based Covid-19 Model,@SABCOM5,Our Spatial Agent-Based Covid-19 Model for the City of Cape Town is now available as a preprint: https://t.co/gOEHgUYEkw
http://medrxiv.org/cgi/content/short/2020.07.30.20164855,SABCoM: A Spatial Agent-Based Covid-19 Model,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: SABCoM: A Spatial Agent-Based Covid-19 Model. ùóîùòÇùòÅùóµùóºùóøùòÄ: Allan Davids, Gideon Du Rand, Co-Pierre Georg, Tina Koziol, Joeri Anton Schasfoort https://t.co/C44QL1cr4F https://t.co/tLeG3Z4j3T"
http://medrxiv.org/cgi/content/short/2020.07.30.20164855,SABCoM: A Spatial Agent-Based Covid-19 Model,@medrxivpreprint,SABCoM: A Spatial Agent-Based Covid-19 Model  https://t.co/GvbgjgEDRm #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@SciscoreReports,The paper ‚ÄúWhether the Weather Will Help Us Weather the COVID...‚Äù (https://t.co/fp66HfeQzA) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/tHE8Af9d2a. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@outbreaksci,"Contribute a rapid review or request one for ""Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning..."" (https://t.co/C71OiGeOlp). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164814) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@outbreaksci,New #SARSCoV preprint: Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions https://t.co/C71OiGeOlp
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@jmcrookston,https://t.co/btvEAHHxbE  Useless.
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions. ùóîùòÇùòÅùóµùóºùóøùòÄ: Marichi Gupta, Adity Bansal, Bhav Jain, Jillian Rochelle, Atharv Oak, Mohammad... https://t.co/z2oOUowknC https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@outbreaksci,"Contribute a rapid review or request one for ""Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning..."" (https://t.co/C71OiGwpcX). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164814) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@outbreaksci,New #influenza preprint: Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions https://t.co/C71OiGwpcX
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@MuinJKhoury,Using machine learning to assess whether the weather will help us weather the #COVID19 pandemic! Via @medrxivpreprint https://t.co/kfbmDRT41N https://t.co/RD7nFPMIhZ
http://medrxiv.org/cgi/content/short/2020.07.29.20164814,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions,@medrxivpreprint,Whether the Weather Will Help Us Weather the COVID-19 Pandemic: Using Machine Learning to Measure Twitter Users' Perceptions  https://t.co/eC77eutnEK #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164640,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study. ùóîùòÇùòÅùóµùóºùóøùòÄ: Tomi Jun, Sharon Nirenberg, Patricia Kovatch, Kuan-lin Huang https://t.co/tjVkkrY0Ou https://t.co/JkzKWwjuPS"
http://medrxiv.org/cgi/content/short/2020.07.29.20164640,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,@phil_w888,98/  https://t.co/c7mpq2oxg9
http://medrxiv.org/cgi/content/short/2020.07.29.20164640,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,@phil_w888,"689/  New York City, USA (adult smoking rate was 13.4% in 2017)  Of 2,400 hospitalized patients, 4.7% were current smokers (CS) & 21.3% were former smokers (FS)  1,371 male: CS=6.3% & FS=31.3%  1,029 female: CS=2.6% & FS=22.3%  https://t.co/3pK"
http://medrxiv.org/cgi/content/short/2020.07.29.20164640,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,@IDinBeirut,RT @medrxivpreprint: Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort st‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164640,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,@akkaufman,RT @medrxivpreprint: Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort st‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164640,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study,@medrxivpreprint,Sex-specificity of mortality risk factors among hospitalized COVID-19 patients in New York City: prospective cohort study  https://t.co/6vuEz3Yqf6 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@SciscoreReports,The paper ‚ÄúLoss expansion of SARS-CoV-2 specific immunity is...‚Äù (https://t.co/FZJ46BVaOn) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Pq3XIv1vAt. We detected 0 key resources.
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19. ùóîùòÇùòÅùóµùóºùóøùòÄ: Qiang Zeng, Gang Huang, Yong-zhe Li, Guoqiang Xu, Sheng-yong Dong, Tian-yu Zhong, Zong-tao Chen, Yang Xu https://t.co/6mFGzQITIk https://t."
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@CcNieukirk,"RT @outbreaksci: Contribute a rapid review or request one for ""Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@outbreaksci,"Contribute a rapid review or request one for ""Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients ..."" (https://t.co/bnaecQEbkM). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164681) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@outbreaksci,New #SARSCoV preprint: Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19 https://t.co/bnaecQVMJm
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@akkaufman,RT @medrxivpreprint: Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19  https://t.co/Yo9d‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164681,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19,@medrxivpreprint,Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19  https://t.co/Yo9d5p8I3U #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20163998,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.. ùóîùòÇùòÅùóµùóºùóøùòÄ: Giselle Ibette Silva Lopez-Lopes, Cintia Mayumi Ahagon, Margarete Aparecida Bonega, Fabiana Pereira dos Santos, Katia Co... https://t.co/kDp6pZO0fU https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20163998,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,@outbreaksci,"Contribute a rapid review or request one for ""Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19."" (https://t.co/01dkPazI6g). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20163998) at https://t.co/RnurTKM2ac @outbreaksci @PRE"
http://medrxiv.org/cgi/content/short/2020.07.29.20163998,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,@outbreaksci,New #SARSCoV preprint: Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19. https://t.co/01dkPazI6g
http://medrxiv.org/cgi/content/short/2020.07.29.20163998,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,@SciArt3D,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19. | medRxiv https://t.co/M5n96m86qX
http://medrxiv.org/cgi/content/short/2020.07.29.20163998,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,@akkaufman,RT @medrxivpreprint: Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.  https://t.co/XytEmyQ1cg #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20163998,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.,@medrxivpreprint,Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19.  https://t.co/XytEmyQ1cg #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Cwildoc2,RT @GilbertDeray: En √©tudiant les messages laiss√©s sur Twitter par les personnes se disant atteintes depuis plus de 60 jours par SARS-CoV-2‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@moreauchevrolet,RT @GilbertDeray: En √©tudiant les messages laiss√©s sur Twitter par les personnes se disant atteintes depuis plus de 60 jours par SARS-CoV-2‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@GilbertDeray,"En √©tudiant les messages laiss√©s sur Twitter par les personnes se disant atteintes depuis plus de 60 jours par SARS-CoV-2, une √©quipe a identifi√© des sympt√¥mes qui ne sont pas seulement ceux que connaissent les malades habituels.  https://t.co/BlButHnZ7o h"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@luna431168,"RT @Fraslin: Syndrome du ""long Covid"": une √©tude de l'universit√© d'Oxford. En plus des manifestations classiques secondaires √† l'infection‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@nausicaa_ulysse,"RT @Fraslin: Syndrome du ""long Covid"": une √©tude de l'universit√© d'Oxford. En plus des manifestations classiques secondaires √† l'infection‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@TheoLeChat,"RT @Fraslin: Syndrome du ""long Covid"": une √©tude de l'universit√© d'Oxford. En plus des manifestations classiques secondaires √† l'infection‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Eldo_Off,@TatianaVentose
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Fraslin,"Syndrome du ""long Covid"": une √©tude de l'universit√© d'Oxford. En plus des manifestations classiques secondaires √† l'infection par #SARSCoV2 comme l‚Äôanosmie, les maux de t√™te ou la douleur thoracique, de nombreux patients souffre d'insomnies, de tachycardie"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@JMBoiron,Alors ici d√©j√† ‚¨áÔ∏è
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@CSMOxford,"RT @OHDSI: New #MedRxiv #preprint led by @drjmbanda & @prieto_alhambra: ""Long-term patient-reported symptoms of #COVID19: an analysis of so‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@rosaalberola70,üìÑS√≠ntomas de #COVID19 a largo plazo informados por los pacientes: un an√°lisis de los datos de las redes sociales https://t.co/2vYtzaKx3R  S√≠ndrome #PostCOVID/#CovidPersistente/#LongCovid
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@rosaalberola70,RT @prieto_alhambra: A new preprint awaiting your feedback ‚Å¶@medrxivpreprint‚Å©: a first of hopefully many collaborations w another of the gr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@OsaidalserMD,RT @drjmbanda: Over the weekend at the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@drddawoud,Very interesting work üëçüëç
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,"RT @OHDSI: New #MedRxiv #preprint led by @drjmbanda & @prieto_alhambra: ""Long-term patient-reported symptoms of #COVID19: an analysis of so‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@epuujee,"RT @OHDSI: New #MedRxiv #preprint led by @drjmbanda & @prieto_alhambra: ""Long-term patient-reported symptoms of #COVID19: an analysis of so‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@OHDSI,"New #MedRxiv #preprint led by @drjmbanda & @prieto_alhambra: ""Long-term patient-reported symptoms of #COVID19: an analysis of social media data."" Characterizing #LongCovid on social media data w/ NLP & manual review by clinicians. üëèüëè #JoinTheJourne"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,RT @drjmbanda: Over the weekend at the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Gurdas2209,RT @drjmbanda: Over the weekend at the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@epuujee,RT @drjmbanda: Over the weekend at the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@drjmbanda,"Over the weekend at the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by clinicians. Exciting collaboration with  @prieto_alhambra, @Gurdas2209, and @OsaidalserMD https://t.co/kojZcleObJ"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@waittwoweeks,"6/  @RafaelOsswald   ""Long-term sequelae are therefore expected to include chronic kidney disease, heart failure and chronic obstructive pulmonary disease.""  https://t.co/b7hPtsJZ9h"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@rfrsarmiento,RT @prieto_alhambra: A new preprint awaiting your feedback ‚Å¶@medrxivpreprint‚Å©: a first of hopefully many collaborations w another of the gr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Long-term patient-reported symptoms of COVID-19: an analysis of social media data. ùóîùòÇùòÅùóµùóºùóøùòÄ: Juan M. Banda, Gurdas Viguruji Singh, Osaid Alser, DANIEL PRIETO-ALHAMBRA https://t.co/4KUKYmKTzE https://t.co/0Se3Fsdlx2"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@OHDSI,RT @kricketchirps: Very cool work! I look forward to seeing more collaborations between @drjmbanda @prieto_alhambra and others to bring the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@OsaidalserMD,"RT @Gurdas2209: Long-term COVID-19 has become very topical lately, with many patients failing to fully recover. Our preprint looks at the s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@OsaidalserMD,RT @prieto_alhambra: A new preprint awaiting your feedback ‚Å¶@medrxivpreprint‚Å©: a first of hopefully many collaborations w another of the gr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,RT @medrxivpreprint: Long-term patient-reported symptoms of COVID-19: an analysis of social media data  https://t.co/JMr2E2MYC8 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Tedsmithphd,RT @drjmbanda: Hot off the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@RebeccaMGoodwin,RT @drjmbanda: Hot off the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@ManeeshJuneja,RT @drjmbanda: Hot off the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Tribe_of_Khawla,@MMufwoko @aproko_doctor
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,RT @drjmbanda: Hot off the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Gurdas2209,RT @prieto_alhambra: A new preprint awaiting your feedback ‚Å¶@medrxivpreprint‚Å©: a first of hopefully many collaborations w another of the gr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@AmarPut,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,"RT @Gurdas2209: Long-term COVID-19 has become very topical lately, with many patients failing to fully recover. Our preprint looks at the s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,RT @kricketchirps: Very cool work! I look forward to seeing more collaborations between @drjmbanda @prieto_alhambra and others to bring the‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@NarcisoYu,RT @drjmbanda: Hot off the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@OHDSI,RT @prieto_alhambra: A new preprint awaiting your feedback ‚Å¶@medrxivpreprint‚Å©: a first of hopefully many collaborations w another of the gr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@kricketchirps,Very cool work! I look forward to seeing more collaborations between @drjmbanda @prieto_alhambra and others to bring the power of @OHDSI  OMOP vocabularies to unstructured text! #JoinTheJourney
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@ScottinOxford,"RT @Gurdas2209: Long-term COVID-19 has become very topical lately, with many patients failing to fully recover. Our preprint looks at the s‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@Gurdas2209,"Long-term COVID-19 has become very topical lately, with many patients failing to fully recover. Our preprint looks at the symptoms that patients have reported over social media to characterise what could be more than a short term disease- an international"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@prieto_alhambra,A new preprint awaiting your feedback ‚Å¶@medrxivpreprint‚Å©: a first of hopefully many collaborations w another of the great talents in @ohdsi: ‚Å¶@drjmbanda‚Å©   ‚ÄúLong-term patient-reported symptoms of COVID-19: an analysis of social media data‚Äù   https://t.co/8
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@drjmbanda,"Hot off the preprint press: Our work characterizing #LongCovid on social media data (#Twitter) with NLP and manual review by clinicians. Exciting collaboration with  @prieto_alhambra, @Gurdas2209, and @OsaidalserMD https://t.co/kojZcleObJ"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@UAcb4,"That‚Äôs true, but which is the best way to treat these symptoms?!? Wait and see?!? NDAIDs?!? Steroids?!? Hope we will find a solution üòâ"
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@LGARCIALSM,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@AbdTahrani,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@RamFernando1,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@AliRacaniere,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@DrAnneMurphy,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@AgnesAyton,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@drpatrickholmes,RT @kamleshkhunti: #LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 http‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@kamleshkhunti,#LongCovid Self-reported symptoms of Twitter users-malaise & fatigue the commonest symptom  https://t.co/kdsQ5g7pr9 https://t.co/t32wjSh6GI
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@COVID_Papers,üìù Long-term patient-reported symptoms of COVID-19: an analysis of social media data  medRxiv or bioRxiv https://t.co/ZsUh9Mka58 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@akkaufman,RT @medrxivpreprint: Long-term patient-reported symptoms of COVID-19: an analysis of social media data  https://t.co/JMr2E2MYC8 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164418,Long-term patient-reported symptoms of COVID-19: an analysis of social media data,@medrxivpreprint,Long-term patient-reported symptoms of COVID-19: an analysis of social media data  https://t.co/JMr2E2MYC8 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@MassatoHirai,RT @outbreaksci: Updated #SARSCoV preprint: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for ne‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@outbreaksci,"Contribute a rapid review or request one for ""Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-..."" (https://t.co/QF5F7jYveP). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164251) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@outbreaksci,Updated #SARSCoV preprint: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. https://t.co/QF5F7jYveP
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@KenVaughanSoc,Cuban study: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. | medRxiv https://t.co/Gaglp46t8P
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@Auriandra,"MedRxiv preprint, Esquivel-Moyelno Idelsis et al [Cuba]: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. htt"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@dianariveras,RT @caremuerto123: @DrAJRodriguezM @dianariveras @acinnacional @josemillanonate @acincentral @acincaribe @acinantioquia @AlvarezMorenoC @pe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@caremuerto123,@DrAJRodriguezM @dianariveras @acinnacional @josemillanonate @acincentral @acincaribe @acinantioquia @AlvarezMorenoC @pediatraencasa @ivanrodriguezmd @camachomgerman @MesaConS @RonnySuarez_ https://t.co/ROiDcpchuK
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@COVID19arXiv,ùóßùó∂ùòÅùóπùó≤: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.. ùóîùòÇùòÅùóµùóºùóøùòÄ: Esquive... https://t.co/Th8yLZxim7 https://
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@outbreaksci,"Contribute a rapid review or request one for ""Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-..."" (https://t.co/QF5F7jGTQf). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164251) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@outbreaksci,New #SARSCoV preprint: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. https://t.co/QF5F7jGTQf
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@rmchavin,"7-29-2020:  In a clinical trial released today, good news from Cuba for HeberFERON (interferon alfa-2b plus interferon gamma) vs. Heberon Alpha R (interferon alfa-2b alone) for treating early COVID-19.  Must now face the champ, Japan's Avigan (favipiravir)"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@DrLBoominathan,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. https://t.co/AfOiRN0UTA
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@a_1_0_2,"@joex92_ @lebon80 @AnalysonsC Alors comparons √† un traitement efficace ! No üì∏  ""Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized control"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@a_1_0_2,"@LaurentP83 @sambrewski_1 @QtScience @ben2_sam @saraart4 @P_Mater_ @MartineWonner @Stalec_ @75867966_Quinoa @rognologue @sonjoachim @AssoCovid @moon_bio @medicalfollower A lire absolument ! On a trouv√© le rem√®de ! üëá ""Effect and safety of combination of int"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@a_1_0_2,"@StevePhillipsMD @JamesTodaroMD @threadreaderapp Let see the difference with an effective medication  üëá ""Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary result"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@phil_w888,"690/  Cuba (adult current smoking rate was 35.2% in 2016)  Of 63 hospitalized patients, eight were current smokers (12.7%)  Note: median age was 38  https://t.co/vJOt5r6YGI"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@soltysik_rob,Cuban research team finds positive results for Covid-19 with the combination interferon-alpha & gamma.  This is the same treatment Dr. Chia (an actual ME doctor) prescribes for ME patients.  Cuba also officially prescribes chloroquine.  https://t.co/EG
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@7Robertinho,RT @DanielJDrucker: More glimmers of interferon efficacy in PPL with SARS-CoV-2 infection #VOVID19 https://t.co/VvzVLFhQyj
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@JamesonVoss,RT @medrxivpreprint: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@a_1_0_2,"In a cohort of 63 hospitalized patients with positive SARS-CoV-2, #HeberFERON significantly negativized the virus on day 4 of treatment  ""Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b CRT trials""  https://t.co/quw"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@a_1_0_2,"""Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.""  https://t.co/quw5DYjOrY"
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@MassatoHirai,RT @medrxivpreprint: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@DanielJDrucker,More glimmers of interferon efficacy in PPL with SARS-CoV-2 infection #VOVID19 https://t.co/VvzVLFhQyj
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@COVID_Papers,üìù Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.  medRxiv or bioRxiv https://t.co/UNMH1QKVtC #COVID19 #COV
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@akkaufman,RT @medrxivpreprint: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-Co‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164251,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.,@medrxivpreprint,Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.  https://t.co/QWozYuDzJ6 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@MassatoHirai,"RT @outbreaksci: Contribute a rapid review or request one for ""Analysis of the correlation between anti-MDA5 antibody and the severity of C‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,"Contribute a rapid review or request one for ""Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a..."" (https://t.co/WqeJgaXnXu). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164780) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,Updated #SARSCoV preprint: Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study https://t.co/WqeJgaXnXu
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@CoronaBot20,"RT @outbreaksci: Contribute a rapid review or request one for ""Analysis of the correlation between anti-MDA5 antibody and the severity of C‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,"Contribute a rapid review or request one for ""Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a..."" (https://t.co/WqeJgaXnXu). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164780) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,Updated #COVID19 preprint: Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study https://t.co/WqeJgaXnXu
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients. ùóîùòÇùòÅùóµùóºùóøùòÄ: Changzheng Liu, Qian Wang, Yeming Wang, Geng Wang, Linghang Wang, Hong Chen, Tao Jiao, Chaojun Hu, Xiaobo Lei, Li Guo, Lili ... https://t.co/U6VQO0lspZ https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,New #SARSCoV preprint: Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients https://t.co/WqeJgbeYP2
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,"Contribute a rapid review or request one for ""Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients"" (https://t.co/WqeJgbeYP2). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164780) at https://t.co/RnurTKM2ac @outbreaksci @PRErevi"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@outbreaksci,New #COVID19 preprint: Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients https://t.co/WqeJgaXnXu
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@phil_w888,"691/  China (adult smoking rate was 26.6% in 2018)  Of 188 hospitalized patients, 16 were current smokers (8.5%)  Of 39 of them who died, 5 were current smokers (12.8%)  https://t.co/CNplZrgIG9"
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@akkaufman,RT @medrxivpreprint: Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients  https://t.co/KFlTmWo2Tn #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164780,Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study,@medrxivpreprint,Augmentation of anti-MDA5 antibody implies severe disease in COVID-19 patients  https://t.co/KFlTmWo2Tn #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164699,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,@SciscoreReports,The paper ‚ÄúCOVID-19 Recurrent Varies with Different Combinato...‚Äù (https://t.co/DNPcgP16zy) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/5Y6ld5qj2b. We detected 2 of 5 rigor criteria and 1 key resource.
http://medrxiv.org/cgi/content/short/2020.07.29.20164699,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches. ùóîùòÇùòÅùóµùóºùóøùòÄ: Jia Huang, Song Zhai, Fangfan Ye, Song Wang, Manfei Zeng, George Way, Vipul Madarha, Te... https://t.co/etGVCVKMXw https://"
http://medrxiv.org/cgi/content/short/2020.07.29.20164699,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,@outbreaksci,"Contribute a rapid review or request one for ""COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined b..."" (https://t.co/L3FV3djc1B). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164699) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164699,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,@outbreaksci,New #SARSCoV preprint: COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches https://t.co/L3FV3djc1B
http://medrxiv.org/cgi/content/short/2020.07.29.20164699,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,@akkaufman,RT @medrxivpreprint: COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches  h‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164699,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches,@medrxivpreprint,COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches  https://t.co/K4JIBorhl2 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@jhaskinscabrera,"RT @aginnt: ""We observed that households were significantly higher from symptomatic index cases than asymptomatic index cases, to adult con‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@aginnt,"""We observed that households were significantly higher from symptomatic index cases than asymptomatic index cases, to adult contacts than children contacts... and in households with one contact than households with three or more contacts."" https://t.co/ayI"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@dirittok,RT @carpe_diem0820: ÂÆ∂Â∫≠ÂÜÖ„ÅÆ‰∫åÊ¨°ÊÑüÊüìÁéá(SAR)„Å´Èñ¢„Åô„ÇãÁ≥ªÁµ±„É¨„Éì„É•„Éº ‰∏ñÂ∏ØÂÖ®‰Ωì„ÅÆÊé®ÂÆöSAR„ÅØ18-8ÔºÖ(95ÔºÖCI 15.4ÔºÖ-22.2ÔºÖ) ‰∏ñÂ∏ØSAR„ÅØ„ÄÅÊúâÁóáÁä∂>ÁÑ°ÁóáÂÄô„ÄÅÊàê‰∫∫>Â≠ê‰æõ„Å®„ÅÆÊé•Ëß¶„ÄÅÈÖçÂÅ∂ËÄÖ>‰ªñ„ÅÆÂÆ∂Êóè„Å®„ÅÆÊé•Ëß¶„ÄÅ1‰∫∫„Å®„ÅÆÊé•Ëß¶>3‰∫∫‰ª•‰∏ä„Å®„ÅÆÊé•Ëß¶„ÅßÊúâÊÑè„Å´È´ò‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@lizditz,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@ketaminh,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@aivelsson,"@hezeveli @PirtaHotulainen @senjalarsen @tuomas_lehto @liisatlaine Ei taudin levi√§misvauhdin n√§k√∂kulmasta v√§est√∂tason immuniteetti ole on/off-valinta.  Jos patogeeni levi√§√§ saman huushollin sis√§ll√§ vain keskim. 19% tapauksista indexpotilaalta seuraavalle,"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@chanze47802655,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Tomblvd,"RT @BallouxFrancois: @apsmunro @paul_ucl @WesPegden There is also strong evidence for high rates of asymptomatic infections in children, an‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@BangoBilly,"RT @BallouxFrancois: @apsmunro @paul_ucl @WesPegden There is also strong evidence for high rates of asymptomatic infections in children, an‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@RS_Eng_Brain,"RT @BallouxFrancois: @apsmunro @paul_ucl @WesPegden There is also strong evidence for high rates of asymptomatic infections in children, an‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@dayyanl,"RT @BallouxFrancois: @apsmunro @paul_ucl @WesPegden There is also strong evidence for high rates of asymptomatic infections in children, an‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@BallouxFrancois,"@apsmunro @paul_ucl @WesPegden There is also strong evidence for high rates of asymptomatic infections in children, and asymptomatic carriers (not necessarily pre-symptomatic) being less infectious (review below) ... That said, yes, better studies are need"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@aivelsson,"@thlbr Kummallisesti k√§ytt√§ytyv√§ eksponentiaalisen kasvun patogeeni, kun huushollienkin sis√§ll√§ Secondary Attack Rate vain noin ~19%. Joko se on jostain syyst√§ korkeampi muualla kuin ruokakunnan sis√§ll√§ (?!) tai sitten joku ei muutoin t√§sm√§√§.  https://t.co"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@broedsel,RT @CarstenLincke: @Annevannis @HansKoppies 1) het blijkt dat kinderen een ondergschikte rol spelen in transmissie binnen households 2) hoe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@largitio,RT @HansKoppies: Veel onrust in het onderwijs is gebaseerd op onwetendheid. https://t.co/GWjZJWeTrz
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@BuroBloei,RT @HansKoppies: Veel onrust in het onderwijs is gebaseerd op onwetendheid.
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PandemicCovid20,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate https://t.co/73xhcvzt3Z
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@HansKoppies,Veel onrust in het onderwijs is gebaseerd op onwetendheid.
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@CarstenLincke,@Annevannis @HansKoppies 1) het blijkt dat kinderen een ondergschikte rol spelen in transmissie binnen households 2) hoewel asymptomatische dragers het virus kunnen verspreiden is het risico toch echt veel lager dan bij symptomatische dragers https://t.co/
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@mjcreid,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@covid19_experts,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@ElleMandell,RT @Babak_Javid_Lab: Fantastic review of household Covid transmission.    Important take home: average 'attack' rates for pre/symptomatic w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@lmmkelley,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@AMcardiosurgeon,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@politicalgale,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@pamelabell64,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PabloRichly,@marina3G Pareceria que contagian menos https://t.co/ELVXBCbQlb
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PabloRichly,@FloraYFauda Pareciera que si https://t.co/ELVXBCbQlb
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@jschneider,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@BenJMcFarland,"In looking at scattered studies, I kept seeing the number for household transmission being around 15% and it‚Äôs nice to see that approx. holds up when assessed systematically. Looks like something to hang your hat on."
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@carpe_diem0820,ÂÆ∂Â∫≠ÂÜÖ„ÅÆ‰∫åÊ¨°ÊÑüÊüìÁéá(SAR)„Å´Èñ¢„Åô„ÇãÁ≥ªÁµ±„É¨„Éì„É•„Éº ‰∏ñÂ∏ØÂÖ®‰Ωì„ÅÆÊé®ÂÆöSAR„ÅØ18-8ÔºÖ(95ÔºÖCI 15.4ÔºÖ-22.2ÔºÖ) ‰∏ñÂ∏ØSAR„ÅØ„ÄÅÊúâÁóáÁä∂>ÁÑ°ÁóáÂÄô„ÄÅÊàê‰∫∫>Â≠ê‰æõ„Å®„ÅÆÊé•Ëß¶„ÄÅÈÖçÂÅ∂ËÄÖ>‰ªñ„ÅÆÂÆ∂Êóè„Å®„ÅÆÊé•Ëß¶„ÄÅ1‰∫∫„Å®„ÅÆÊé•Ëß¶>3‰∫∫‰ª•‰∏ä„Å®„ÅÆÊé•Ëß¶„ÅßÊúâÊÑè„Å´È´ò„ÅÑ  Household transmission of SARS-CoV-2 (pre-print) https://t.co/htycJ6e7Pi
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@MoreeSpinne,Household SAR preprint paper from Univ of Florida.
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@covidpath,2. Analyzing household Covid transmission https://t.co/gnzOoTEuQ0
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@CollignonPeter,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@BelsizeVillage,RT @Babak_Javid_Lab: Fantastic review of household Covid transmission.    Important take home: average 'attack' rates for pre/symptomatic w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@drrajivb,Hugely valuable contribution. Was it possible to stratify by asymptomatic testing? Are you working on the same for non-household transmission? Any idea why there are so few US based studies?
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@mrc7cam,RT @Babak_Javid_Lab: Fantastic review of household Covid transmission.    Important take home: average 'attack' rates for pre/symptomatic w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Babak_Javid_Lab,RT @Babak_Javid_Lab: Fantastic review of household Covid transmission.    Important take home: average 'attack' rates for pre/symptomatic w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Neuro24de,"Metaanalyse von 40 Studien √ºber die Sekund√§r√ºbertragung im Haushalt gesamt 18,8% .  symptomatische Indexf√§llen >  asymptomatische Indexf√§lle,  Erwachsene > Kinderkontakte,  Ehepartnern> als andere Familienkontakte 2 Personenhaushalt >als gr√∂√üer"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@drklausner,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@kevinpurcell,"‚ÄúThe estimated overall household SAR was 18¬∑8% (95% confidence interval [CI]: 15¬∑4%‚Äì22¬∑2%), which is higher than previously observed SARs for SARS-CoV and MERS-CoV.‚Äù  But still less than 1 in 5."
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@JaredWestMD,Household SAR 19%. Household crowding is an important predictor of transmission. Symptomatics ~3x more likely to transmit than asymptomatics.
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@RapidCovidLabs,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Unni_Gopinathan,"RT @andersskyrud: Ny, systematisk oversikt over hvor mange i husholdningen til covid-19-pasienter som blir smitta. Dette virker solid fra d‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@cantika17024242,RT @Babak_Javid_Lab: Fantastic review of household Covid transmission.    Important take home: average 'attack' rates for pre/symptomatic w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@LAsskoul,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@pulmonology101,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@thlbr,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@MedMedIvan,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@vSoutherner,"Primary driver in China was household transmission. That would have been before the understanding of disease severity. I wouldn't attribute low secondary attack here to specific transmission type, outcome just as easily ascribed to behavioral changes that"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@ovais_epilogue,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@NMoqueet,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@MicrobLog_me_uk,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@zpyarom,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@KeenWallflower,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@raven58008,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@CovidLabs,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@JordanTzvetkov,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@DanHugo,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@TimTravis2,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@andersskyrud,"Ny, systematisk oversikt over hvor mange i husholdningen til covid-19-pasienter som blir smitta. Dette virker solid fra dyktige folk. Funnene oppsummert her. https://t.co/JmdS1V9BkO https://t.co/VxNC1CHZOO"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@apastorepiontti,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@jaibri1,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@mvianin,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@d_s_thakur,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PolicyCandy,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@JesseJames19861,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@KateYandell,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@KirkMartyn,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@nikkicolumbus,"RT @apsmunro: @nikkicolumbus @DrZoeHyde @MackayIM There are many, the most blatant being citing a single contact tracing study showing equa‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@KatyLonghorn_JC,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@EladSharonMD,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@AndyfromTucson,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@apsmunro,"@nikkicolumbus @DrZoeHyde @MackayIM There are many, the most blatant being citing a single contact tracing study showing equal SAR in children to adults, when almost every study since shows significantly lower in children *covered in 2 separate systematic"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@ajv67,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@EliudResearch,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Furious_mico,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@revolution_fr,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@dave_andersen,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@DidierPittet,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@chaplinscourage,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@DonaldWelsh16,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@boats2019,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@black_cat46,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PSummers1986,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@dwallacewells,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@cdmw3,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@jmstearns67,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@oakroots10,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@cantika17024242,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@MikroSundq,"RT @GermHunterMD: In a meta-analysis of 40 studies, overall SARS-CoV2 household secondary attack rate was 18¬∑8% (95% CI: 15¬∑4%‚Äì22¬∑2%)  This‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PleaseDoTheMath,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@northofcam,RT @Babak_Javid_Lab: Fantastic review of household Covid transmission.    Important take home: average 'attack' rates for pre/symptomatic w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@JamesonVoss,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Thomas67M,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@bdphill22,RT @stevebrown2856: This is a really interesting pre-print of a meta study of infection rates. Headlines:  1) Secondary Attack Rate (SAR) w‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@Esteban09090,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@PabloRichly,En la convivencia los adultos podrian contagiar mas que los ni√±os. https://t.co/ELVXBCbQlb https://t.co/P2KGG9uDv1
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@ChicagoScience,"RT @nataliexdean: Sharing our systematic review of SARS-CoV-2 household secondary attack rate, led by my excellent postdoc Zach Madewell. H‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164590,Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate,@CarlosdelRio7,RT @ShohamTxID: when we estimated the household attack rate for the post exposure prophylaxis power analysis all those months ago we guesse‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@Skandaya,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@sminaev2015,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@Peter_Voshol,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@DrPalmquist,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@spencer68,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@MarkReady47,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@Eva3034385615,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@immunity_co,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@SergeCampeau,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@sjacobm321,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@afashionfan,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@robinmonotti,RT @gerdosi: ‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general po‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@gerdosi,"‚ÄúThese results suggest caution in use serological testing to estimate the prevalence of SARS-CoV-2 infection in the general population.‚Äù  NB, dropping Ab levels are not necessarily reason to worry about lack of lasting immunity. https://t.co/87ZQSaWSC2"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@lconejosm,RT @alfonso_casi: Persistencia de anticuerpos anti-SARS-CoV-2 en trabajadores sanitarios convalecientes COVID-19 no hospitalizados: La redu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@PauChaoEscuer,RT @alfonso_casi: Persistencia de anticuerpos anti-SARS-CoV-2 en trabajadores sanitarios convalecientes COVID-19 no hospitalizados: La redu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@ajv67,RT @alfonso_casi: Persistencia de anticuerpos anti-SARS-CoV-2 en trabajadores sanitarios convalecientes COVID-19 no hospitalizados: La redu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@whlwest,RT @SamFazeli8: This is why we have to be very careful with all those human convalescent serum comparisons in vaccine trials. $PFE and $BNT‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@spasqualato,"RT @LoungeTcell: Take a look to our most recent work on antibody and cytokine responses in #COVID19 patients, and how these change over tim‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@epiangie,"RT @LoungeTcell: Take a look to our most recent work on antibody and cytokine responses in #COVID19 patients, and how these change over tim‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@LoungeTcell,"Take a look to our most recent work on antibody and cytokine responses in #COVID19 patients, and how these change over time in non-severe patients.  Congrats to all the team + @LabMapelli @spasqualato @IEOufficiale https://t.co/NKTJ3Nqa7f"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@alfonso_casi,Persistencia de anticuerpos anti-SARS-CoV-2 en trabajadores sanitarios convalecientes COVID-19 no hospitalizados: La reducci√≥n r√°pida de los t√≠tulos de anticuerpos y citocinas proinflamatorias puede ser una caracter√≠stica com√∫n de la infecci√≥n no grave...
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@emaspero1,RT @spasqualato: Our work on the effects of #COVID19:  - severe cases show higher antibody titers wrt less severe cases - antibody titers a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@PredatorDiaries,"I would go further, if all hopes are pinned on a single antibody, or even a single protein, then either you trade on Robinhood, are an academic playing at vaccine development, and you're both likely to be disappointed."
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@SamFazeli8,This is why we have to be very careful with all those human convalescent serum comparisons in vaccine trials. $PFE and $BNTX used asymptomatic patients and their neutralising antibody levels looked great. https://t.co/yHGM8rCRfi
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@LabMapelli,RT @spasqualato: Our work on the effects of #COVID19:  - severe cases show higher antibody titers wrt less severe cases - antibody titers a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@lab_colombo,RT @spasqualato: Our work on the effects of #COVID19:  - severe cases show higher antibody titers wrt less severe cases - antibody titers a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@MapelliMarina,RT @spasqualato: Our work on the effects of #COVID19:  - severe cases show higher antibody titers wrt less severe cases - antibody titers a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@fornerislab,RT @spasqualato: Our work on the effects of #COVID19:  - severe cases show higher antibody titers wrt less severe cases - antibody titers a‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@spasqualato,Our work on the effects of #COVID19:  - severe cases show higher antibody titers wrt less severe cases - antibody titers and pro-inflammatory cytokines levels drop over time in non-severe SARS-CoV-2 infections https://t.co/ZtaKPM8xZY with @MapelliMarina @L
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@kat_gris,RT @PRussW1: Given the continuing controversy surrounding humoral responses to #SARSCoV2 it is still necessary to discuss antibody response‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers. ùóîùòÇùòÅùóµùóºùóøùòÄ: Margherita Bruni, Valentina Cecatiello, Angelica Diaz-Basabe, Georgia Lattanzi, Erika Mileti, Silvi... https://t.co/qz74Fr5iRy https://"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@filipowi,RT @PRussW1: Given the continuing controversy surrounding humoral responses to #SARSCoV2 it is still necessary to discuss antibody response‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@outbreaksci,New #SARSCoV preprint: Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers https://t.co/B3Rh0b5o7K
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@outbreaksci,"Contribute a rapid review or request one for ""Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent he..."" (https://t.co/B3Rh0aNMJa). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.20164368) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@outbreaksci,New #COVID19 preprint: Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers https://t.co/B3Rh0aNMJa
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@anonymouscaper,RT @PRussW1: Given the continuing controversy surrounding humoral responses to #SARSCoV2 it is still necessary to discuss antibody response‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@hannahumming,RT @PRussW1: Given the continuing controversy surrounding humoral responses to #SARSCoV2 it is still necessary to discuss antibody response‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@wordsinusername,"‚ÄúRapid decline in antibody titers and in pro-inflammatory cytokines may be a common feature of non-severe SARS-CoV-2 infection, suggesting that antibody-mediated protection against re-infection with SARS-CoV-2 is of short duration.‚Äù https://t.co/IOaFB63Gfp"
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@nanogenomic,RT @PRussW1: Given the continuing controversy surrounding humoral responses to #SARSCoV2 it is still necessary to discuss antibody response‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@PRussW1,Given the continuing controversy surrounding humoral responses to #SARSCoV2 it is still necessary to discuss antibody responses. Here is a recent study discussing possible rapid declines in antibody levels.   https://t.co/TyK5DL9ZES
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@fornerislab,RT @medrxivpreprint: Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers  https://t.co/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@akkaufman,RT @medrxivpreprint: Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers  https://t.co/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.30.20164368,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers,@medrxivpreprint,Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers  https://t.co/Fq6I5KnnuD #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@PandemicCovid20,Comparative experimental evidence on compliance with social distancing during the #COVID19 pandemic https://t.co/nSz38XJHIc
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@ReinholdSchrde1,"@Sahakibrahimkhi Es gibt immer zwei Seiten einer Medaille. https://t.co/EWg8iVGOso Im Juni haben in #Berlin die gr√ºnlinken Berufsemp√∂rten, ohne R√ºcksicht auf #Corona-Regeln, noch einem Kriminellen begeistert gehuldigt.  https://t.co/zREc5XeFw0 #Berlin0108"
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@ReinholdSchrde1,"@mario78_erfurt @Ralf_Stegner Sie sollten ihre Zeit sinnvoll nutzen,hiermit k√∂nnen Sie anfangen... https://t.co/EWg8iVGOso Es gibt auch Informationen au√üerhalb der #Twitter und #Medien-Blase"
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@ReinholdSchrde1,"RT @ReinholdSchrde1: @Ralf_Stegner #Stegner, Sie sind wieder einmal uninformiert... https://t.co/3G8A9zwX4f Ein gro√üer Teil der Bev√∂lkerung‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@0BrainLess,"@Kieran790150950 @Karl_Lauterbach Nimm das, Schwachkopp!  https://t.co/1jHuM81cgE"
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@ReinholdSchrde1,"@Ralf_Stegner #Stegner, Sie sind wieder einmal uninformiert... https://t.co/3G8A9zwX4f Ein gro√üer Teil der Bev√∂lkerung zeigt ihnen und ihren mithaftenden Politikerdarstellern sozusagen den ausgestreckten Mittelfinger. #Covid_19 #Berlin0108"
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@COVID19arXiv,"ùóßùó∂ùòÅùóπùó≤: Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic. ùóîùòÇùòÅùóµùóºùóøùòÄ: Michael Becher, Daniel Stegmueller, Sylvain Brouard, Eric Kerrouche https://t.co/vshtgdbSeA https://t.co/rTPU3xin1S"
http://medrxiv.org/cgi/content/short/2020.07.29.20164806,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic,@medrxivpreprint,Comparative experimental evidence on compliance with social distancing during the COVID-19 pandemic  https://t.co/z60uh6aw8h #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164459,Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management,@SciscoreReports,The paper ‚ÄúMultisystem Inflammatory Syndrome in Children: Sur...‚Äù (https://t.co/sJVbUW8EAV) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/sBqDMYFg7g. We detected 1 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.29.20164459,Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management,@COVID_Papers,üìù Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management  medRxiv or bioRxiv https://t.co/qDm8repJwf #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.29.20164459,Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management,@medrxivpreprint,Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management  https://t.co/c2mEi1EXkZ #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165910,"Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support",@CovidWellbeing,"Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support https://t.co/cJCdaHMeKQ #mentalhealth"
http://medrxiv.org/cgi/content/short/2020.07.31.20165910,"Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support",@COVID_Papers,"üìù Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support  medRxiv or bioRxiv https://t.co/qQMEE3BBlT #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.31.20165910,"Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support",@medrxivpreprint,"Job insecurity, financial threat and mental health in the COVID-19 context: The buffer role of perceived social support  https://t.co/Q6wnlZPRY6 #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.31.20165829,"Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan",@motoakiutamura,A novel mathematical model was proposed and examined using COVID19 data for Tokyo. Results suggest that the rapid isolation of infectious cases has a large potential to effectively mitigate the spread of infection.  https://t.co/7Oi36tXLNd
http://medrxiv.org/cgi/content/short/2020.07.31.20165829,"Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan",@outbreaksci,"Contribute a rapid review or request one for ""Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tok..."" (https://t.co/irdObUmEcL). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.20165829) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.31.20165829,"Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan",@outbreaksci,"New #COVID19 preprint: Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan https://t.co/irdObUmEcL"
http://medrxiv.org/cgi/content/short/2020.07.31.20165829,"Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan",@medrxivpreprint,"Isolation Considered Epidemiological Model for the Prediction of COVID-19 Trend in Tokyo, Japan  https://t.co/HxrluLUWq6 #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.31.20165936,High effectiveness of multimodal infection control interventions in preventing SARS‚àíCoV‚àí2 infections in healthcare professionals: a prospective longitudinal seroconversion study,@robilad,‚ÄûConclusion: Multimodal infection control and prevention interventions are highly effective in mitigating SARS‚àíCoV‚àí2 infections of healthcare professionals.‚Äú üëçüèª
http://medrxiv.org/cgi/content/short/2020.07.31.20165936,High effectiveness of multimodal infection control interventions in preventing SARS‚àíCoV‚àí2 infections in healthcare professionals: a prospective longitudinal seroconversion study,@ProfGoeke,Wie gut konnte am UKE Das Personal vor COVID-19 gesch√ºtzt werden? https://t.co/9379iI5HJW #coronahh #UKEHamburg #COVID„Éº19 #CoronaVirusDE
http://medrxiv.org/cgi/content/short/2020.07.31.20165936,High effectiveness of multimodal infection control interventions in preventing SARS‚àíCoV‚àí2 infections in healthcare professionals: a prospective longitudinal seroconversion study,@akkaufman,RT @medrxivpreprint: High effectiveness of multimodal infection control interventions in preventing SARS-CoV-2 infections in healthcare pro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165936,High effectiveness of multimodal infection control interventions in preventing SARS‚àíCoV‚àí2 infections in healthcare professionals: a prospective longitudinal seroconversion study,@medrxivpreprint,High effectiveness of multimodal infection control interventions in preventing SARS-CoV-2 infections in healthcare professionals: a prospective longitudinal seroconversion study  https://t.co/OKK9mKoyx9 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@DonaldWelsh16,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@NewNormality20,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@Icutitup67,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@AsadLonePhD,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@JSteinbachsND,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@CFMorais65,"‚ÄúQuando o teste √© garantido e os recursos de sa√∫de s√£o suficientes, quarentena estrita e / ou medidas de bloqueio podem resultar em mortes excessivas em popula√ß√µes desprivilegiadas.‚Äù"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@gddamnbatmn,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@Peter_Voshol,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@robinmonotti,"RT @gerdosi: ‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@gerdosi,"‚ÄúWhen testing is warranted and healthcare resources are sufficient, strict quarantine and/or lockdown measures might result in excess deaths in underprivileged populations.‚Äù üßêü§î https://t.co/cM1GWMtEbC"
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@Mark_Coughlan,RT @medrxivpreprint: COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis bas‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@COVID_Papers,üìù COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data  medRxiv or bioRxiv https://t.co/egFHAKoD2R #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.31.20165811,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data,@medrxivpreprint,COVID-19 case-fatality rate and demographic and socioeconomic influencers: a worldwide spatial regression analysis based on country-level data  https://t.co/FjwXNyuoKR #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.28.20163915,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators,@GostaForsum,Awesome!  https://t.co/GD4GhCLusa
http://medrxiv.org/cgi/content/short/2020.07.28.20163915,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators,@waittwoweeks,"7/  ""Microwave ovens have been used to make plasmas. There are numerous how-to videos using grapes on the internet.""  https://t.co/lmInbjVM36"
http://medrxiv.org/cgi/content/short/2020.07.28.20163915,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators,@u0421793,RT @medrxivpreprint: Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators  https://t.co/HIJtXQ55wr‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20163915,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators,@COVID_Papers,üìù Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators  medRxiv or bioRxiv https://t.co/cZK5yCAlkC #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.28.20163915,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators,@medrxivpreprint,Converting Microwave Ovens into Plasma-Generating Decontamination Units for N-95 Respirators  https://t.co/HIJtXQ55wr #medRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@outbreaksci,"Contribute a rapid review or request one for ""A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia ..."" (https://t.co/NY2akTIO58). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230870) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@outbreaksci,Updated #SARSCoV preprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/NY2akTIO58
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@RudoMxMx,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@TonyBurnetti,RT @PromPreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@Eomesodermin,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/C6s3Dfg7OH #immunobot https://t.co/BO9Un6eoOR
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ToobaQuidwai,RT @ProfJWHolloway: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@PromPreprint,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/nzjbdDfLCw
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@theevanslab,RT @ProfJWHolloway: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@UoS_Medicine,RT @ProfJWHolloway: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@JaneSLucas1,RT @ProfJWHolloway: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@JaneSLucas1,RT @BIUSoton: BIU is delighted to have been involved in this paper finding a novel isoform in the airway @_Claire_Jackson @JaneSLucas1 @jam‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@_Claire_Jackson,RT @BIUSoton: BIU is delighted to have been involved in this paper finding a novel isoform in the airway @_Claire_Jackson @JaneSLucas1 @jam‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ProfJWHolloway,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/eQlWLsNMRf  Great work from my colleagues @UoS_Medicine @GabrielleWheway @MennellaVito @J
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@PublicPolicyUoS,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@UoS_Medicine,RT @BIUSoton: BIU is delighted to have been involved in this paper finding a novel isoform in the airway @_Claire_Jackson @JaneSLucas1 @jam‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@BIUSoton,BIU is delighted to have been involved in this paper finding a novel isoform in the airway @_Claire_Jackson @JaneSLucas1 @jamesjt89 @UoS_Medicine
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@EvolvingEpitope,"RT @prokuninaolsson: Everything you wanted to know about ACE2 expression! Epic presentations based on 3 preprints. Monday, August 3, 11 am‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@DrLindskog,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ElisabethMaure2,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@priya_luthra,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@GabrielleWheway,"RT @prokuninaolsson: Everything you wanted to know about ACE2 expression! Epic presentations based on 3 preprints. Monday, August 3, 11 am‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@KevinWNg,Looking forward to this - join in to find out more about our and others‚Äô latest findings on ACE2!
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@KevinWNg,"RT @prokuninaolsson: Everything you wanted to know about ACE2 expression! Epic presentations based on 3 preprints. Monday, August 3, 11 am‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@SGriffin_Lab,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ImmunoLatinXs,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@sudu87,RT @drdeannasanter: Here is the 3rd report of the novel #ACE2 isoform that is regulated by #IFNs üëá looking forward to all groups discussing‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@SJR78354712,RT @drdeannasanter: Here is the 3rd report of the novel #ACE2 isoform that is regulated by #IFNs üëá looking forward to all groups discussing‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@prokuninaolsson,"Everything you wanted to know about ACE2 expression! Epic presentations based on 3 preprints. Monday, August 3, 11 am EST Zoom ID:8021875343. @RoufDr @SegunOnabajo https://t.co/t5FU8p5PAU; @GabrielleWheway https://t.co/FGnNzniiO2; @KevinWNg https://t.co/HN"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@nata_zamorano,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ImmunoFever,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ImmunoFever,RT @drdeannasanter: Here is the 3rd report of the novel #ACE2 isoform that is regulated by #IFNs üëá looking forward to all groups discussing‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@jeremyhirota,RT @drdeannasanter: Here is the 3rd report of the novel #ACE2 isoform that is regulated by #IFNs üëá looking forward to all groups discussing‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@jeremyhirota,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@KevinWNg,RT @drdeannasanter: Here is the 3rd report of the novel #ACE2 isoform that is regulated by #IFNs üëá looking forward to all groups discussing‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@drdeannasanter,Here is the 3rd report of the novel #ACE2 isoform that is regulated by #IFNs üëá looking forward to all groups discussing their findings on Zoom tomorrow üòÄ
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@KevinWNg,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@_Claire_Jackson,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@UoS_Medicine,RT @ProfDBaralle: @GabrielleWheway @JelmerLegebeke @JaneSLucas1 novel ace2 isoform in airway upregulated with IF  but not SARS- CoV-2 proud‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ProfDBaralle,@GabrielleWheway @JelmerLegebeke @JaneSLucas1 novel ace2 isoform in airway upregulated with IF  but not SARS- CoV-2 proud to be part of this work. @unisouthampton @UoS_Medicine
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@jane19gibson,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@JanSVidal,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@DrLouisAlbanese,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@SenyoBotchie,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@glycopreprint,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/Z7SroDMxeJ #glycotime
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@mandalea98,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@Mhurz_,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@Neene_Solomon,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@Bacterioskeptic,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@GabrielleWheway,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@UoS_Medicine,RT @JaneSLucas1: Proud to be part of the fantastic #ACE2 team finding a novel isoform in the airways. @GabrielleWheway @MennellaVito @_Clai‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ProfDBaralle,RT @JaneSLucas1: Proud to be part of the fantastic #ACE2 team finding a novel isoform in the airways. @GabrielleWheway @MennellaVito @_Clai‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@HelenHelgriff,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@lucklepper,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@triciagoggin,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@triciagoggin,"RT @_Claire_Jackson: Proud to work alongside Dr Cornelia Blume, Professor Donna Davies, Professor @JaneSLucas1, Dr @GabrielleWheway and Dr‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@_Claire_Jackson,RT @JaneSLucas1: Proud to be part of the fantastic #ACE2 team finding a novel isoform in the airways. @GabrielleWheway @MennellaVito @_Clai‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@JaneSLucas1,"Proud to be part of the fantastic #ACE2 team finding a novel isoform in the airways. @GabrielleWheway @MennellaVito @_Claire_Jackson @jamesjt89 @BIUSoton @UoS_Medicine @UoS_WISHlab @ProfDBaralle Cornelia Blume, Donna Davies, & many other amazing scient"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@JelmerLegebeke,Thankful and grateful for being part of this exciting research on a novel short ACE2 isoform
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@UoS_Medicine,RT @GabrielleWheway: Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@_Claire_Jackson,"Proud to work alongside Dr Cornelia Blume, Professor Donna Davies, Professor @JaneSLucas1, Dr @GabrielleWheway and Dr @MennellaVito  on an amazing @unisouthampton collaboration ‚ù§ Epic 4 months #COVID19"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@GabrielleWheway,"Delighted to share our data describing a novel short ACE2 isoform in airway epithelia. Lacks SARS-CoV-2 binding sites. Upregulated in response to IFN & RV, not SARS-CoV-2. Differentially regulated in asthma. https://t.co/nms4JNyhmG @unisouthampton @Uo"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@outbreaksci,"Contribute a rapid review or request one for ""A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia ..."" (https://t.co/NY2akTrcGy). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230870) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@outbreaksci,New #SARSCoV preprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/NY2akTrcGy
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@thparietallobe,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@MLitbot,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection https://t.co/eCy0wG7KBr
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@emulenews,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@BabyBoomerWritr,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@suhail_ns8,ü§ôüèª
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@BenNavarrete,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@COVID_Papers,üìù A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection  medRxiv or bioRxiv https://t.co/1CiKrJP92T #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@Casey_Scientist,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@ImmunoLatinXs,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@MassatoHirai,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@guatauva_,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@TrevorSutcliffe,RT @biorxivpreprint: A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230870,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection,@biorxivpreprint,A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection  https://t.co/GWc9RFwqIk #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@BlackPhysicists,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction https://t.co/QONwBKbJu7 #biophysics
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@BorisVauzeilles,"RT @ElisaTelisa: N-glycans contribute to the binding, increasing the lifetime of the interaction between the ACE and SARS-CoV2 S RBD from S‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@glycodynamics,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction https://t.co/HfTVk8CgVZ
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@glycopreprint,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction https://t.co/gQntox6Gea #glycotime
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@dunckerUAEM,"RT @ElisaTelisa: N-glycans contribute to the binding, increasing the lifetime of the interaction between the ACE and SARS-CoV2 S RBD from S‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@AhmadRezaMehdi1,RT @biorxiv_biophys: Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction  https://t.co/Mpq6qN‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@ElisaTelisa,"N-glycans contribute to the binding, increasing the lifetime of the interaction between the ACE and SARS-CoV2 S RBD from SMD and experimental force spectroscopy #glycotime #gotglycans"
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@outbreaksci,"Contribute a rapid review or request one for ""Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein In..."" (https://t.co/9R968ljpxu). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230730) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@outbreaksci,New #SARSCoV preprint: Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction https://t.co/9R968ljpxu
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@RommieAmaro,RT @biorxiv_biophys: Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction  https://t.co/Mpq6qN‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@cristobalvega,RT @biorxivpreprint: Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction  https://t.co/TZfIaF‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@COVID_Papers,üìù Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction  medRxiv or bioRxiv https://t.co/HXzLDTERS1 #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@biorxiv_biophys,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction  https://t.co/Mpq6qNGaCK #biorxiv_biophys
http://biorxiv.org/cgi/content/short/2020.07.31.230730,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction,@biorxivpreprint,Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction  https://t.co/TZfIaFKRIt #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@outbreaksci,"Contribute a rapid review or request one for ""New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic D..."" (https://t.co/YSkHS2OJm9). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.231472) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@outbreaksci,Updated #SARSCoV preprint: New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release https://t.co/YSkHS2OJm9
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@outbreaksci,"Contribute a rapid review or request one for ""New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic D..."" (https://t.co/YSkHS2x7Xz). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.231472) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@outbreaksci,New #SARSCoV preprint: New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release https://t.co/YSkHS2x7Xz
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@helioRocha_,#bioRxiv   New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release    #bioinfo https://t.co/ak0zeyQtaK
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@MLitbot,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release https://t.co/Wb3ohEqhOS
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@COVID_Papers,üìù New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release  medRxiv or bioRxiv https://t.co/8XMWDYMDX7 #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.231472,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release,@biorxivpreprint,New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release  https://t.co/dkFT6yzjAJ #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@LeoHanke2,RT @DannySheward: #COVID19  It's good to know that an established vaccine platform - protein subunit in adjuvant -  elicits potent neutrali‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@jonatcoquet,Nothin like a good protein subunit vaccine!
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@mcinerney_gerry,RT @DannySheward: #COVID19  It's good to know that an established vaccine platform - protein subunit in adjuvant -  elicits potent neutrali‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@DannySheward,#COVID19  It's good to know that an established vaccine platform - protein subunit in adjuvant -  elicits potent neutralizing antibody responses in animals. We find that titers after 2 doses were 100x higher than those in seropositive humans. 1/2  https://
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@Genemedi1,Genemedi @Genemedi1 offers SARS-CoV-2 WT and Spike Mutation Pseudotyped virus.  https://t.co/za5w6U7ROk https://t.co/anFX2n35oL
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@glycopreprint,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses https://t.co/0GWVMtyHsQ #glycotime
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@NGR69575822,RT @biorxivpreprint: SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses  https://t.co/wWEPImJBng #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses https://t.co/1DcS0x28kv
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses"" (https://t.co/1DcS0xjJJ5). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.228486) at https://t.co/RnurTL3DyM @outbreaksci @PR"
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@outbreaksci,New #COVID19 preprint: SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses https://t.co/1DcS0xjJJ5
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@SteveRees16,Another shot on goal for the scientific community as we work to create a vaccine for COVID19.  Unbelievable progress and lots of hope for a vaccine in the near future
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@emulenews,RT @biorxivpreprint: SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses  https://t.co/wWEPImJBng #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@bxv_imm,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses https://t.co/tj23DdGplu
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@biolocousb,RT @biorxivpreprint: SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses  https://t.co/wWEPImJBng #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@biorxiv_immuno,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses  https://t.co/5IGmYU64H4 #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.07.31.228486,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses,@biorxivpreprint,SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses  https://t.co/wWEPImJBng #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@DN_Frick,https://t.co/Yh1votWCBf
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@BlackPhysicists,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase https://t.co/UZYe1vBIgo #biophysics
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@JeffTiLab,RT @KJMbio: Grateful to have the opportunity to do COVID-related research recently.   Force-dependent stimulation of RNA unwinding by SARS-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@mgrass81,RT @KJMbio: Grateful to have the opportunity to do COVID-related research recently.   Force-dependent stimulation of RNA unwinding by SARS-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@outbreaksci,"Contribute a rapid review or request one for ""Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase"" (https://t.co/nUvkuJnTkh). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.231274) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@outbreaksci,New #SARSCoV preprint: Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase https://t.co/nUvkuJFuIR
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@MikeVVieczorek,RT @KJMbio: Grateful to have the opportunity to do COVID-related research recently.   Force-dependent stimulation of RNA unwinding by SARS-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@hancock_lab,RT @KJMbio: Grateful to have the opportunity to do COVID-related research recently.   Force-dependent stimulation of RNA unwinding by SARS-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@bxv_biophys,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase https://t.co/wh1XMuQ0Mr
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@aaheramol,RT @KJMbio: Grateful to have the opportunity to do COVID-related research recently.   Force-dependent stimulation of RNA unwinding by SARS-‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@KJMbio,Grateful to have the opportunity to do COVID-related research recently.   Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase https://t.co/XBnEscWwgq
http://biorxiv.org/cgi/content/short/2020.07.31.231274,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase,@biorxivpreprint,Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase  https://t.co/typHWUUQfH #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@9Gesla,https://t.co/AqKwdYuwT6
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@VickyRaboso,Un nivel adecuado de Selenio en sangre protege frente a covid. Comer marisco salvaje ayuda a aumentar nuestros niveles as√≠ que hagamos el sacrificio üòÜüòÜüòÜüòÖüòÖüòÖhttps://t.co/pVXP5528pL
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Scrambu11,@Cara_TXZEAL eat a Brazil nut a day to keep the virus away https://t.co/W5GpDS9Dlr
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@GKeferstein,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@KamathGurudutt,The multi-vitamin I was taking was called A-Z!  We need vitamins and minerals from A to Z!  My own little discovery has been that Mg gives you good sleep. Have been taking a multi-vitamin with 50 mg of Mg nightly -- gives me sound sleep. (100 mg or more wo
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Tweet_Nutrition,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@KetofiedTammy,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@gingerdays,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Peter_Voshol,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@CryptoTeeVee,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@biorganico,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@PC65049955,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@SteveKe61657969,https://t.co/LMSUvGlb5x
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@theemilou,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@minto_keith,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@mikewill17,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Eva3034385615,thank you! I am now looking at what hurts & helps coronary artery disease....
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@PlumRemson,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Cat25Mom,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@HollyLarsson1,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Nollyblue,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@JatinJhala,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@moisuave,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@Frederic_Danel,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@FredNurf,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@lauracarter_dr,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@BChinatti,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@DogGuruji,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@NovoArgumente,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@JSteinbachsND,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@wasmittechnik,"RT @gerdosi: A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@gerdosi,"A Brazil nut a day keeps the virus at bay‚Ä¶ (OK, fish and red meat are also good sources.) https://t.co/QcivKx473Q"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, end..."" (https://t.co/VUFo5F3P5P). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230243) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@outbreaksci,"Updated #SARSCoV preprint: SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis https://t.co/VUFo5F3P5P"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@wberghe1,"RT @AngeliFriedmann: and here it is... SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and D‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@TomVBerghe,"RT @AngeliFriedmann: and here it is... SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and D‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@AngeliFriedmann,"and here it is... SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and DNA synthesis https://t.co/YBspxUfvKB"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER ..."" (https://t.co/VUFo5EMdHf). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230243) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@outbreaksci,"New #SARSCoV preprint: SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and DNA synthesis https://t.co/VUFo5EMdHf"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@biorxiv_micrbio,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and DNA synthesis  https://t.co/mbOuPsu9qG #biorxiv_micrbio"
http://biorxiv.org/cgi/content/short/2020.07.31.230243,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis",@biorxivpreprint,"SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, ER stress and DNA synthesis  https://t.co/SZdjxDDwHh #bioRxiv"
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@outbreaksci,"Contribute a rapid review or request one for ""Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2"" (https://t.co/HLAHwprmPH). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.229781) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@outbreaksci,Updated #SARSCoV preprint: Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2 https://t.co/HLAHwprmPH
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@SciscoreReports,The paper ‚ÄúStudy on Œ≤-Chitosan against the binding of SARS-Co...‚Äù (https://t.co/6pnzsTugr2) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/kioJFl4hea. We detected 2 of 6 rigor criteria and 21 key resource
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@outbreaksci,"Contribute a rapid review or request one for ""Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2"" (https://t.co/HLAHwp9Lr7). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.229781) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@outbreaksci,New #SARSCoV preprint: Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2 https://t.co/HLAHwprmPH
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@COVID_Papers,üìù Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2  medRxiv or bioRxiv https://t.co/W96PpvCb8R #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@biorxiv_cellbio,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2  https://t.co/Wl1mdxX3k2 #biorxiv_cellbio
http://biorxiv.org/cgi/content/short/2020.07.31.229781,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2,@biorxivpreprint,Study on Œ≤-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2  https://t.co/dDOY90MtaR #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@BlackPhysicists,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/3tgqGQZLjE #biophysics https://t.co/rCQqfNpjTo
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@cienciabrujula,RT @emulenews: #bioRxiv Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/b‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@gonchi_quevedo,RT @emulenews: #bioRxiv Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/b‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@emulenews,"#bioRxiv Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/bnxcagsbMB Initially, the spike adsorbs to both surfaces through essentially the same residues belonging to the receptor binding subu"
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@CESGA_,RT @Jordi_Faraudo: Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/UebdXU‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@glycopreprint,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/VG1MkKycis #glycotime
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@outbreaksci,"Contribute a rapid review or request one for ""Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and differ..."" (https://t.co/2vNGMBjvr7). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230888) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@outbreaksci,New #SARSCoV preprint: Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/2vNGMBjvr7
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@Jordi_Faraudo,RT @COVID_Papers: üìù Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces  medRxiv or bioRxi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@Jordi_Faraudo,RT @biorxivpreprint: Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces  https://t.co/HD5‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@Jordi_Faraudo,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/UebdXUXVWe our work @icmabCSIC about how the SARS-CoV-2 virus interacts with materials. It has been possible by special access provided by @CE
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@bxv_biophys,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces https://t.co/pd90bk1dAD
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@COVID_Papers,üìù Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces  medRxiv or bioRxiv https://t.co/4TmlyMq3ZL #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@FriendsOfPipe,RT @biorxivpreprint: Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces  https://t.co/HD5‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@biorxiv_biophys,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces  https://t.co/9gRd0aofMc #biorxiv_biophys
http://biorxiv.org/cgi/content/short/2020.07.31.230888,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces,@biorxivpreprint,Computer Simulations of the interaction between SARS-CoV-2 spike glycoprotein and different surfaces  https://t.co/HD5MF5id0g #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@amaury_upmc,RT @PhyDyn_Papers: Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare Nicol‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@jdzucker,RT @snoria: #nonhomothetic growth and #SARS-CoV-2 at  https://t.co/s5W7Xwv4c0
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@outbreaksci,"Contribute a rapid review or request one for ""Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths f..."" (https://t.co/02r3NwUFwl). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230607) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@outbreaksci,New #SARSCoV preprint: Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare https://t.co/02r3NxcgUV
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@PhyDyn_Papers,"Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare Nicolas Cluzel @nicocluzel, Amaury Lambert @amaury_upmc, Yvon Maday @MadayYvon, Gabriel Turinici @gabrielturinici, Antoine Danchin https://t."
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@snoria,#nonhomothetic growth and #SARS-CoV-2 at  https://t.co/s5W7Xwv4c0
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@COVID_Papers,üìù Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare  medRxiv or bioRxiv https://t.co/8ieK5bTk3m #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@biorxiv_micrbio,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare  https://t.co/JZl1vL69oY #biorxiv_micrbio
http://biorxiv.org/cgi/content/short/2020.07.31.230607,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare,@biorxivpreprint,Biochemical and mathematical lessons from the evolution of the SARS-CoV-2 virus: paths for novel antiviral warfare  https://t.co/XyGNFaG1F5 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@KhromykhAlex,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@jorjalark,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@apanasenko,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Wardog3624,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Luis_Science,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@NJdoc,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@NJdoc,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@BortzGroup,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@lisabuffalo,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@snw555,"""A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine"" https://t.co/NlfpUwbobA"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Benonisim,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@noawitheringly,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@noawitheringly,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@cantika17024242,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@glyn_dk,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@glyn_dk,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@covid19_experts,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@yjhifo,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@yjhifo,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@F_lean91,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@hughbarnard,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@DkOkenia,Cool for this reason üëáüëá
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@DkOkenia,This is cool
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@JenniferChelley,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@dottidal,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@StanStulak,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@nCoV2019Geoff,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@EuphoricEuler,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@EuphoricEuler,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@operationoxygen,ÎåÄÎ∞ïÏù¥ÎÑ§.
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@operationoxygen,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@sureshbabukm,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@sureshbabukm,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@ayirpelle,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Sci_j_my,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@JosephPepper,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@JosephPepper,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Natgcoh,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@PaulineSkarrott,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@malabtaiwan,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@PognandDestrier,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@iskander,"I'm very enamored with this vaccine, Twitter summary thread on their 1st paper: https://t.co/2oZNHQ07XV  This followup looks at the best NDV SARS-CoV-2 vaccine variant from the 1st paper, inactivates it, and tests in mice and hamsters +/- adjuvants"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@DuckSwabber,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@nancyoreally,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@AllamanSeb,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@akkaufman,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@nailbomb3,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@edwardcholmes,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Edward_Holloran,"RT @jkoers: This a great scientific COVID feed.   No politics, just actual data"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@kevinpurcell,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@DeeJayRobA,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Serrano_theham,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@KennethBodin,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@clafrisa,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@somsuj,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@onelovebabii7,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@the_sugars,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@ElementoLab,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Zusehrverkuerzt,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@m7m5ea,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@sangmotiani,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@jkoers,"This a great scientific COVID feed.   No politics, just actual data"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@gmopundit,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@K2thebizA,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@martafilizola,"And another major accomplishment by @GradSchoolSinai students and trainees. In alphabetical order: Fatima Amanat (student w/ FK), Yonghong (Alex) Liu (postdoc w/ PP), Wen-Chun (Claire) Liu (postdoc w/ RA), Justine Oliva (postdoc w/ PP), Weina Sun (postdoc"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@FOXTROT716,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@MeteYuksel14,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Shade_9SQ,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@TCondellone,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Erth53,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@KlausRiede,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@JPThermoz,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@postdienst41,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@postdienst41,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@paakoo92,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Glockinfora,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Bo759111Ne,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@louvetou,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@HICologne,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@jeffdecoursey,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@ImmunoFever,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@ImmunoFever,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@lsaiz,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@lsaiz,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Ciencia_2017,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@MenendezPepe,"RT @florian_krammer: 2) The huge advantage: It could be cheaply produced using existing flu vaccine production facilities, including in low‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@LeaoDeAlkmaar,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@TheWarMonitor,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@LFischer224103,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@mgmglobal,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@CeriFielding,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@bobblakley,Early result and not peer-reviewed yet but another piece of positive news.
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@WilliamDLees,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@kennywblog1,"the [low-cost] inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections/significantly attenuated #COVID19  induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which lowers cost  https://t.co/w6Id4pO4Mh"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@atufain,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Crof,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@GeorgeHagstrom,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@benadida,If we can build a SARS-CoV-2 vaccine on existing flu vaccine production infrastructure... Holy moly that feels like the best news in a while.
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@TetsuKaba,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.229120,A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine,@Tariqbiotech27,"RT @florian_krammer: 1) A follow up to Peter Palese's NDV SARS-CoV-2 vaccine: When produced as inactivated vaccine in eggs, just like flu v‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@outbreaksci,"Contribute a rapid review or request one for ""Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mut..."" (https://t.co/K6YW4Q2sq8). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228460) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@outbreaksci,Updated #SARSCoV preprint: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations https://t.co/K6YW4Q2sq8
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@romiwahengbam,RT @biorxivpreprint: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/0Oe8BuV1l‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@Rosenchild,RT @biorxiv_genomic: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/XXiFlTZbf‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@shrankhlab,RT @DBT_NCCS_Pune: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/wUAhEoUNXM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@sicb_dpcb,RT @kunaljaani: My frist preprint on #SARS_CoV_2 is out.  Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique lin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@AnushaRohit,"RT @DeepakNModi: A spectrum of variations in genome of #SARSCoV2 in patients from maharashtra, India.  Kudos @kunaljaani @theysslab @YShouc‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@evol_genomics,RT @kunaljaani: My frist preprint on #SARS_CoV_2 is out.  Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique lin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@durbignon,"RT @DeepakNModi: A spectrum of variations in genome of #SARSCoV2 in patients from maharashtra, India.  Kudos @kunaljaani @theysslab @YShouc‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@staffnccs,The background or this paper https://t.co/wBoNH8fBpR
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@kunaljaani,"RT @DeepakNModi: A spectrum of variations in genome of #SARSCoV2 in patients from maharashtra, India.  Kudos @kunaljaani @theysslab @YShouc‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@swapnilckajale,RT @kunaljaani: My frist preprint on #SARS_CoV_2 is out.  Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique lin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@r_karyakarte,"Sequencing of Covid-19, SARS-CoV-2... https://t.co/lDQ4S80ap1"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@DeepakNModi,"A spectrum of variations in genome of #SARSCoV2 in patients from maharashtra, India.  Kudos @kunaljaani @theysslab @YShouche  and team  @NCMR_Pune @DBTIndia https://t.co/U8DELb2Qx9"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@khemrajthakur,RT @theysslab: Big congratulations to all team members at @DBT_NCCS_Pune @NCMR_Pune #AFMC Pune and BJ Medical college Pune #BJMC for this e‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@SciCatalyst,RT @biorxivpreprint: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/0Oe8BuV1l‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@outbreaksci,"Contribute a rapid review or request one for ""Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mut..."" (https://t.co/K6YW4Qk3hG). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228460) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@outbreaksci,New #SARSCoV preprint: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations https://t.co/K6YW4Qk3hG
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@qunalyadav,RT @kunaljaani: My frist preprint on #SARS_CoV_2 is out.  Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique lin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@Gayatree_K,RT @kunaljaani: My frist preprint on #SARS_CoV_2 is out.  Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique lin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@ImAniketSaraf,Phylogenomic analysis of 98 SARS-CoV-2 genomes from western India  #AcademicTwitter #AcademicChatter
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@kunaljaani,My frist preprint on #SARS_CoV_2 is out.  Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations https://t.co/W47IZXHLWq #AcademicChatter @DBT_NCCS_Pune @NCMR_Pune
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@sharmaG30,RT @DBT_NCCS_Pune: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/wUAhEoUNXM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@kunaljaani,RT @theysslab: Big congratulations to all team members at @DBT_NCCS_Pune @NCMR_Pune #AFMC Pune and BJ Medical college Pune #BJMC for this e‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@kumarjan,RT @DBT_NCCS_Pune: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/wUAhEoUNXM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@PhyDyn_Papers,"Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations Dhiraj Paul, Jani, Kumar, Chauhan, Seshadri, Lal, Karyakarte, Joshi, Tambe, Sen, Karade, Bala Anand, Singh Shergill, Gupta, Bhat, Sahu, Yogesh S Shouche https://"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@NCMR_Pune,RT @DBT_NCCS_Pune: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/wUAhEoUNXM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@gutmicrobe,RT @theysslab: Big congratulations to all team members at @DBT_NCCS_Pune @NCMR_Pune #AFMC Pune and BJ Medical college Pune #BJMC for this e‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@gutmicrobe,RT @DBT_NCCS_Pune: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/wUAhEoUNXM‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@DBT_NCCS_Pune,"Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/wUAhEoUNXM  A collaborative effort between @DBT_NCCS_Pune @NCMR_Pune #AFMC Pune, #BJMC highlighting the distinct pattern of mutations in virus from"
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@theysslab,Big congratulations to all team members at @DBT_NCCS_Pune @NCMR_Pune #AFMC Pune and BJ Medical college Pune #BJMC for this effort !  @DBTIndia
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@PraveenRahi,New findings at @DBT_NCCS_Pune @NCMR_Pune portray the prevalence of unique linked mutations in SARS-CoV-2 in western India and their prevalence in symptomatic patients.
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@DBT_NCCS_Pune,RT @kumarjan: @DBT_NCCS_Pune @DBTIndia @NCMR_Pune @theysslab @r_karyakarte
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@kumarjan,@DBT_NCCS_Pune @DBTIndia @NCMR_Pune @theysslab @r_karyakarte
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@TakAcd1217,RT @biorxiv_genomic: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/XXiFlTZbf‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@aglucaci,RT @biorxivpreprint: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/0Oe8BuV1l‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@bxv_genomics,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations https://t.co/walEJMmxq8
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@prashbio,RT @biorxivpreprint: Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/0Oe8BuV1l‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@COVID_Papers,üìù Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  medRxiv or bioRxiv https://t.co/GcFwGhICob #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@biorxiv_genomic,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/XXiFlTZbfO #biorxiv_genomic
http://biorxiv.org/cgi/content/short/2020.07.30.228460,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations,@biorxivpreprint,Phylogenomic analysis of SARS-CoV-2 genomes from western India reveals unique linked mutations  https://t.co/0Oe8BuV1la #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@outbreaksci,"Contribute a rapid review or request one for ""Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug ..."" (https://t.co/cN5PJrb3oK). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230987) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@outbreaksci,Updated #SARSCoV preprint: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://t.co/cN5PJrb3oK
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@nareNKolimi,RT @ponoop_: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://t.co/eL‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@u_pranita,RT @ponoop_: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://t.co/eL‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@ponoop_,RT @SathyaseelanC5: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@ponoop_,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://t.co/eLD5GKF9bx #COVID__19 #research #SARS_CoV_2 #biomarkers
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@AGuleren,RT @biorxivpreprint: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@outbreaksci,"Contribute a rapid review or request one for ""Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug ..."" (https://t.co/cN5PJrb3oK). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.31.230987) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@outbreaksci,New #SARSCoV preprint: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://t.co/cN5PJrb3oK
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@helioRocha_,#bioRxiv   Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates    #bioinfo https://t.co/5ewE1xbqqm
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@SathyaseelanC5,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates https://t.co/edudfSxPCe
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@aglucaci,RT @biorxivpreprint: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@Theo_BrainC_lab,RT @biorxiv_bioinfo: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@ImmunoLatinXs,RT @biorxivpreprint: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@COVID_Papers,üìù Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  medRxiv or bioRxiv https://t.co/AmFyvvWG9V #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@akkaufman,RT @biorxivpreprint: Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  https:‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.31.230987,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates,@biorxivpreprint,Global variation in the SARS-CoV-2 proteome reveals the mutational hotspots in the drug and vaccine candidates  https://t.co/EmfcwrZxZ9 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@motbevron,"Lu et al. found SARS-CoV-2 N-protein undergoes phase separation with the M-protein and RNA, likely critical in viral RNA packaging during virion development.  #DeltaVision #COVID19 https://t.co/Y2uNVbcpBO"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@ray_berkeley,"RT @_KevinCorbett: Thrilled to see the excellent work of Shan Lu, Qiaozhen Ye, and Digvijay Singh out on bioRxiv! Phase separation underlie‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@outbreaksci,"Contribute a rapid review or request one for ""The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA..."" (https://t.co/g3z1zc2VnO). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228023) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@outbreaksci,New #SARSCoV preprint: The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein https://t.co/g3z1zbLjZe
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@RommieAmaro,"RT @_KevinCorbett: Thrilled to see the excellent work of Shan Lu, Qiaozhen Ye, and Digvijay Singh out on bioRxiv! Phase separation underlie‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@emulenews,RT @biorxivpreprint: The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@dgvjayS,"RT @_KevinCorbett: Thrilled to see the excellent work of Shan Lu, Qiaozhen Ye, and Digvijay Singh out on bioRxiv! Phase separation underlie‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@chris_carlson_,"RT @_KevinCorbett: Thrilled to see the excellent work of Shan Lu, Qiaozhen Ye, and Digvijay Singh out on bioRxiv! Phase separation underlie‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@TheVillaLab,"RT @_KevinCorbett: Thrilled to see the excellent work of Shan Lu, Qiaozhen Ye, and Digvijay Singh out on bioRxiv! Phase separation underlie‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@_KevinCorbett,"Thrilled to see the excellent work of Shan Lu, Qiaozhen Ye, and Digvijay Singh out on bioRxiv! Phase separation underlies interactions of SARS-CoV-2 Nucleocapsid with both RNA and the Membrane protein!"
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@ShorterLab,RT @biorxivpreprint: The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@bxv_biochem,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein https://t.co/Se0d2F53yn
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@COVID_Papers,üìù The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein  medRxiv or bioRxiv https://t.co/98OGEoBO7G #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@hitenmadhani,RT @biorxivpreprint: The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@ShorterLabGroup,RT @biorxivpreprint: The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228023,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein,@biorxivpreprint,The SARS-CoV-2 Nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein  https://t.co/ht013cwcXU #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@genperisi,"Diyor ki gozlemlerimize gore diyabet hastlarinda metformin kullanimi #covid19 sebepli olum oranlarini dusuruyor olabilir. Sonra diyor ki preprintimiz ekte, hakemlere gitmeden once elestiri ve katkilarinizi bekliyoruz. 9 saattir kimse adama laf sokmadi. Nel"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@eperlste,RT @mattmight: Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@stolidobranch,RT @mattmight: Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@sarahdcady,RT @mattmight: Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@ClementYChow,RT @mattmight: Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@documi,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@andrewsu,RT @mattmight: Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@LabcatPhd,RT @mattmight: Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patient‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@mattmight,Our observations allow us to hypothesize that metformin reduces (and possibly even normalizes) mortality in diabetic patients with COVID-19: https://t.co/drVNQgO7C6  Criticism on the pre-print welcomed and encouraged before we submit for peer review.
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@SciscoreReports,The paper ‚ÄúMETFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY...‚Äù (https://t.co/8PcevdZaP2) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Kpb2LVANOI. We detected 2 of 5 rigor criteria and 0 key resources
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@tatana2007,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@endojmf,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@ANNIEWI18240275,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@real_drshruti,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@drmohanv,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@EASDelearning,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@JamesRi81958925,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@Aaisha_Saqib,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@HellenaHH2020,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@LuisEscurra8,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@keddy_moise,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@DrMohgah,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@DrAnneMurphy,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@kamleshkhunti,RT @docmaltese: #Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@docmaltese,#Metformin use prior to the diagnosis of #COVID19 associated with a ~3-fold ‚¨áÔ∏è mortality in #diabetes  Potential mechanisms? ‚úÖ anti- inflammatory effects  ‚úÖanti-thrombotic effects   ‚úÖinhibition TNF-alpha & IL6 @Aemmedi @ESEndocrinology @DRG_Kings @Rcms
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@RDNSMathur,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@AmarPut,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@EURADIAnews,"RT @xaviercos: Crucial to phenotype and identify those risk factors, medications that can inform us how to treat and be proactive in a more‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@AliRacaniere,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@muffmuff5,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@alsheik_g,RT @OGMustafa: METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES https://t.co/ntFZS7xwcT
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@drleethegppmb,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@lareng19,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@plvrmap,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@outbreaksci,"Contribute a rapid review or request one for ""METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-..."" (https://t.co/vkbO3lOjxF). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20164020) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@outbreaksci,New #COVID19 preprint: METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES https://t.co/vkbO3lwIG7
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@Maria_3575,"RT @EverestT8: El VIH del virus es lo que produce tanto el aumento de las diabetes en los infectados, como el empeoramiento de los previame‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@RohamMakki,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@naomiattar,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@Dwijaraj8,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@hormone_doc,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@AbdTahrani,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@wschr63,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@ProfHschneider,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@DrMohgah,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@AnatolianLyceum,"Ucuz eski ≈üeker ilacƒ± glukofen, glukofaj vs bir s√ºr√º marka altƒ±nda neredeyse b√ºt√ºn firmalar √ºretiyor. https://t.co/23qjY3hVHK"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@EASDelearning,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@Annakoutroufini,"RT @xaviercos: Crucial to phenotype and identify those risk factors, medications that can inform us how to treat and be proactive in a more‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@Tribe_of_Khawla,Guys please take your Metformin and your blood pressure medication.
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@drpatrickholmes,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@xaviercos,"Crucial to phenotype and identify those risk factors, medications that can inform us how to treat and be proactive in a more #personalized approach od #SARS_CoV_2 new outbreaks #BigDataAnalytics @icscat @IDIAPJGol @AQuAScat @CAMFiC @apicsbcn"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@singhak_endo,RT @kamleshkhunti: Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZ‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@kamleshkhunti,Metformin associated with  ‚¨áÔ∏è mortality in people with diabetes & #COVID-19 https://t.co/1H32dmCnd2 https://t.co/axNXZIAwMH
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@AllergyNet,RT @medrxivpreprint: METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES  https://t.co/13‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@OGMustafa,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES https://t.co/ntFZS7xwcT
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@rmchavin,"7-29-2020:  The only 2 diabetes drugs that will increase life expectancy among diabetics & among COVID-19 victims are Glucophage (metformin) & Actos (pioglitazone).  All other diabetes drugs, especially insulin & sulfonylureas, cause heart dise"
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@Yahveth,"METFORMINA agotada en 3,2,1... Recuerden que para poder llegar a una conclusi√≥n de esa magnitud se necesitan estudios mucho m√°s grandes. Por lo mientras es una ASOCIACI√ìN o un hallazgo, SOLO ESO."
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@ivanphysician,"Uy pens√© que la estaban olvidando. Ya tengo listo el titular de la noticia en cualquier peri√≥dico: ""Medicamento para perder peso reduce las muertes de COVID-19"""
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@AdriMarquezE,Preprint: ‚ÄúEL USO DE METFORMINA EST√Å ASOCIADO CON MORTALIDAD REDUCIDA EN UNA POBLACI√ìN DIVERSA CON COVID-19 Y DIABETES‚Äú #COVID19 #MedRixv
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@COVID_Papers,üìù METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES  medRxiv or bioRxiv https://t.co/KDFrpKWmvr #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.29.20164020,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES,@medrxivpreprint,METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES  https://t.co/13cR2f3212 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@GTSciences,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@Choosy_Female,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@abbiemjohnson,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@AvalSara,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@brooke_JRM,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@invitro_veritas,I am so proud of my lab and school for the essential work they have done during this pandemic! https://t.co/sV3BGtwMj4
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@invitro_veritas,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@KhaledAKurdi,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@DavidFialho,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@francy_pants,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@RaquelLieberman,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@TyroChemist,RT @methanoJen: It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTS‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@methanoJen,It took a village! Here is the full team of 35 in the Covid-19 Test Kit Support Group. #WeCanDoThat üí™üëèüëèüëèüí™ @georgiatech @GTSciences @ibbgatech @GT_CHEM https://t.co/qPc84cTNIG
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@abovenyquist,RT @JanetMurray: My @GTSciences colleagues at @GeorgiaTech rock! They figured out a way academic Research labs can address a crucial COVID‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@benscitech,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@HSTSGeorgiaTech,RT @JanetMurray: My @GTSciences colleagues at @GeorgiaTech rock! They figured out a way academic Research labs can address a crucial COVID‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@methanoJen,RT @JanetMurray: My @GTSciences colleagues at @GeorgiaTech rock! They figured out a way academic Research labs can address a crucial COVID‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@JanetMurray,My @GTSciences colleagues at @GeorgiaTech rock! They figured out a way academic Research labs can address a crucial COVID test component gap  and are sharing it as a kit
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@outbreaksci,New #SARSCoV preprint: Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology https://t.co/nzvddxsqP0
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@outbreaksci,"Contribute a rapid review or request one for ""Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents pro..."" (https://t.co/nzvddxsqP0). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20163949) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@outbreaksci,New #COVID19 preprint: Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology https://t.co/nzvddxsqP0
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@mwillzzz411,RT @RaquelLieberman: üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@methanoJen,RT @RaquelLieberman: üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@jesshuntralston,April 2020: https://t.co/6iBWw8MQB4 July 2020:
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@Choosy_Female,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@AReddiLab,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@AReddiLab,RT @RaquelLieberman: üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@benscitech,RT @RaquelLieberman: üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@petaripenev,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@AvalSara,RT @RaquelLieberman: üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech https://t.co/Unc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@AndyHeckerling,RT @RaquelLieberman: üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech https://t.co/Unc‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@RaquelLieberman,üòÖ It‚Äôs out! Congrats to all (35!!) authors on this important project @GeorgiaTech @GT_CHEM @ibbgatech
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@AvalSara,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@methanoJen,Manuscript artwork is by @GT_CHEM PhD candidate Rebecca Guth-Metzler. üëèüëèüëèüëèüëè https://t.co/xGidOVIEU3
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@GTSciences,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@smestre28,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@saganorg,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@rebeccadonegan,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@RaquelLieberman,RT @methanoJen: Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLiebe‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@methanoJen,Our @GeorgiaTech @GTSciences @ibbgatech @GT_CHEM test kit formulation (35 authors!) is up on @medrxivpreprint! @RaquelLieberman deserves a special shout out for making this paper a reality. Hopefully it will be useful to many. https://t.co/aQY5CQ9RLv
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@NagissaM,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology https://t.co/uqZnkRVQSJ
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@COVID_Papers,üìù Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology  medRxiv or bioRxiv https://t.co/JSKwfZzcjV #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.29.20163949,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology,@medrxivpreprint,Buzz about RT-qPCR: An RT-qPCR formulation for SARS-CoV-2 detection using reagents produced at Georgia Institute of Technology  https://t.co/MM0rwv1nwD #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@SciscoreReports,The paper ‚ÄúRapid detection of SARS-CoV-2 by pulse-controlled...‚Äù (https://t.co/BTEzt1cyld) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/hKMZVHWzh4. We detected 0 of 6 rigor criteria and 2 key resources.
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@outbreaksci,"Contribute a rapid review or request one for ""Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)"" (https://t.co/PeIUZQmTKb). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20154104) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@outbreaksci,New #SARSCoV preprint: Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA) https://t.co/PeIUZQmTKb
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@Maria_Weyh,RT @medrxivpreprint: Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)  https://t.co/KHpOaijaCT #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@JamesonVoss,RT @medrxivpreprint: Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)  https://t.co/KHpOaijaCT #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@COVID_Papers,üìù Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)  medRxiv or bioRxiv https://t.co/Lu7sB6kq96 #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@jsteward2930,RT @medrxivpreprint: Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)  https://t.co/KHpOaijaCT #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.29.20154104,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA),@medrxivpreprint,Rapid detection of SARS-CoV-2 by pulse-controlled amplification (PCA)  https://t.co/KHpOaijaCT #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.30.20163790,"Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence",@PandemicCovid20,"Critical Mobility, a practical criterion and early indicator for regional #COVID19 resurgence https://t.co/AOWoWlwJUg"
http://medrxiv.org/cgi/content/short/2020.07.30.20163790,"Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence",@reef103,By knowing the current local number of cases and cell phone-based people‚Äôs motility we can predict how many cases we‚Äôll have in the next 15 days. #COVID__19 https://t.co/Q9VEY627mK
http://medrxiv.org/cgi/content/short/2020.07.30.20163790,"Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence",@COVID_Papers,"üìù Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence  medRxiv or bioRxiv https://t.co/FD5HbZLXFa #COVID19 #COVID19Papers #SARSCoV2"
http://medrxiv.org/cgi/content/short/2020.07.30.20163790,"Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence",@medrxivpreprint,"Critical Mobility, a practical criterion and early indicator for regional COVID-19 resurgence  https://t.co/FcglnK4zaG #medRxiv"
http://biorxiv.org/cgi/content/short/2020.07.30.228643,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison,@CovidWellbeing,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison https://t.co/ombs7M7oZ9 #mentalhealth
http://biorxiv.org/cgi/content/short/2020.07.30.228643,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison,@SciscoreReports,The paper ‚ÄúPerception of and anxiety about COVID-19 infection...‚Äù (https://t.co/efIPNnZJNk) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Mp8cxXNHSv. We detected 1 of 5 rigor criteria and 1 key resource.
http://biorxiv.org/cgi/content/short/2020.07.30.228643,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison,@COVID_Papers,üìù Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison  medRxiv or bioRxiv https://t.co/DEdlRkD5iL #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228643,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison,@Science_comedu,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison   https://t.co/JJpCqRtdQg
http://biorxiv.org/cgi/content/short/2020.07.30.228643,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison,@biorxivpreprint,Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: An international comparison  https://t.co/yi6WsjSvNZ #bioRxiv
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Gert_van_Dijk,@cor4office @hapelensrob Zoiets? https://t.co/QCjqhIcsxT
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Gert_van_Dijk,@Yorinvonder @cor4office @hapelensrob Uiteraard. Hier een meta-review. https://t.co/QCjqhIcsxT
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@zbysfedo,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection https://t.co/uy8PivSKpa
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@TaheriShahrad,"@methodsmanmd Conclusion There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19 or its exacerbation."
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@TaheriShahrad,@MiriamETucker https://t.co/jAVBV6YeIh
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@ndakaripa,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@JumaLazzati,https://t.co/oj4Em3kIfC
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@SciscoreReports,The paper ‚ÄúA meta-review of systematic reviews and an updated...‚Äù (https://t.co/W3zp41MpyR) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/GgeobDnpPb. We detected 2 of 5 rigor criteria and 9 key resources
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Cienciamundana,RT @emulenews: #medRxiv A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroqu‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@emulenews,#medRxiv A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection https://t.co/8bQFCezJtb CQ and HCQ with or without Azithromycin are not effective in treating COVI
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@allngulube1,RT @JMatizanadzo: https://t.co/08r2p8qrzk Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and #chloro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@6ck5uck,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Doc_R_C,RT @bhebheanele: Great work @TChivese üëèüèæ
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Sweetness___K,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@bhebheanele,Great work @TChivese üëèüèæ
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@CMitala,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@chidodc,RT @JMatizanadzo: https://t.co/08r2p8qrzk Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and #chloro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tandie_j,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@iAmKudaMaynard,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@teahobvu,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Nmakunika,RT @JMatizanadzo: https://t.co/08r2p8qrzk Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and #chloro‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@JMatizanadzo,https://t.co/08r2p8qrzk Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and #chloroquine (#CQ) in the treatment of #COVID19. With @TChivese and #Colleagues
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@AlekeMukunga,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tenkatreats,Bookmarked to read.. ‚ò∫.. I'm not even taking a dig at @TChivese smarts today because he might disappear again.
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tatemars,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tryemurwira,There has been a lot of talking on the use of the anti malaria drug in treating COVID19. This paper by @TChivese analyses the scientific research done so far on the use of the drug. The conclusion after the analysis is that chloroquine is not effective in
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tryemurwira,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@RuvimboNyamaku1,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@viralvideovlogs,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@joecharema,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@MsNShongwe,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@sindivanzyl,RT @TChivese: My article is featured on the @ResearchGate #COVID19 community page. Read it here:  https://t.co/20cr008zwt
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@DegrafH,@TRACEYBTHIERRY Tiens..une autre etude   https://t.co/AN5Cfaps0D
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@gnmusuka,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@TinofaMutevedzi,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@udnore,"RT @chidodc: Conclusion: There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@COVID_Papers,üìù A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection  medRxiv or bioRxiv https://t.co/Ls3qv31SkM #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@MiriraiKudiwa,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@PinkyManyau,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@rashida_abbferr,"RT @chidodc: Conclusion: There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@rashida_abbferr,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@CMitala,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@chidodc,"Conclusion: There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19 or its exacerbation."
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@zcphp,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tatemars,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tfambirai,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@ProsperZW,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@RatioScientiae,"""There is conclusive evidence that CQ and #Hydroxychloroquine , with or without Azithromycin are not effective in treating COVID-19 or its exacerbation."" https://t.co/SYHFD6kt3S"
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@tenkatreats,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@StevenYHong,RT @medrxivpreprint: A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@helloSVODAI,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@nYaShAmkz,@EniaMiss
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@nabo_26,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Mutape88,Proud Zimbabwean munetipasa manyemwe
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Mutape88,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@Admryr,RT @TChivese: Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@TChivese,Here is the preprint of our meta-review on the efficacy of #hydroxychloroquine (#HCQ) and chloroquine (#CQ) in the treatment of #COVID19  On medRxiv: https://t.co/xFAHdnbakG  A portable graphical link to the paper (QR code) can be obtained here: https://t.
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@CHOMES102,RT @medrxivpreprint: A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.28.20164012,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection,@medrxivpreprint,A meta-review of systematic reviews and an updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection  https://t.co/FdSrTN3DQH #medRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2"" (https://t.co/C60l9UKdkZ). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.229377) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@outbreaksci,Updated #SARSCoV preprint: Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2 https://t.co/C60l9UKdkZ
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@kobus5,RT @apoorva_nyc: Interesting preprint showing cross-reactivity of 10 antibodies to SARS classic to proteins from SARSCoV2. Goes well with t‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@avtansh,RT @apoorva_nyc: Interesting preprint showing cross-reactivity of 10 antibodies to SARS classic to proteins from SARSCoV2. Goes well with t‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@apoorva_nyc,Interesting preprint showing cross-reactivity of 10 antibodies to SARS classic to proteins from SARSCoV2. Goes well with the cross-reactive T cell data we've been seeing.  https://t.co/vkdI9zy4bH
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@NGR69575822,RT @biorxivpreprint: Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2  https://t.co/i9zp9YNR6j #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@outbreaksci,"Contribute a rapid review or request one for ""Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2"" (https://t.co/C60l9UsBWp). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.229377) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@outbreaksci,New #SARSCoV preprint: Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2 https://t.co/C60l9UKdkZ
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@COVID_Papers,üìù Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2  medRxiv or bioRxiv https://t.co/WenGMcx8Bw #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@biorxiv_immuno,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2  https://t.co/rezKkri90s #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.07.30.229377,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2,@biorxivpreprint,Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2  https://t.co/i9zp9YNR6j #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@cfDNA_papers,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19. https://t.co/6k62ZTcHDV https://t.co/Toorc8Fj1O
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@SciscoreReports,The paper ‚ÄúCirculating Mitochondrial DNA is an Early Indicato...‚Äù (https://t.co/zBGok7RepZ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/3MXL63M2je. We detected 2 of 5 rigor criteria and 2 key resources
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@SciscoreReports,The paper ‚ÄúCirculating Mitochondrial DNA is an Early Indicato...‚Äù (https://t.co/zBGok7RepZ) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/kUfS1vf283. We detected 2 of 6 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@RaviTharakan,RT @apoorva_nyc: Intriguing preprint on an association between high circulating DNA and severity of outcome in Covid19 patients  https://t.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@kobus5,RT @apoorva_nyc: Intriguing preprint on an association between high circulating DNA and severity of outcome in Covid19 patients  https://t.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@SavvyCindyB,RT @apoorva_nyc: Intriguing preprint on an association between high circulating DNA and severity of outcome in Covid19 patients  https://t.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@SJR78354712,RT @apoorva_nyc: Intriguing preprint on an association between high circulating DNA and severity of outcome in Covid19 patients  https://t.‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@apoorva_nyc,Intriguing preprint on an association between high circulating DNA and severity of outcome in Covid19 patients  https://t.co/v47UDUVJKI
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@inotof1,#COVID #mitochondria #DNA #mcas
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@LabCflores,RT @biorxivpreprint: Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@Ryan_Cupo,RT @biorxivpreprint: Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@enerphyschem,RT @biorxivpreprint: Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@a_1_0_2,"""Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19""  https://t.co/qv00kXR7P9"
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@phil_w888,"682/  Missouri*, USA (adult current smoking rate was 19.4% in 2019)  Of 97 hospitalized patients, 46.4% had a smoking history (SH)  Of 55 in ICU, SH=54.5%  Of 25 who died, SH=64%  Notes:  *probably  77.3% were African-American  reporting error in table 3"
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@paulcarald,RT @biorxivpreprint: Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@Arktist,RT @biorxivpreprint: Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@COVID_Papers,üìù Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  medRxiv or bioRxiv https://t.co/YHNGcjq2Qc #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@nictaylorbio,It always about mitochondria ! Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19 https://t.co/qPIkl2KJoo
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@t2438,RT @biorxivpreprint: Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@biorxiv_immuno,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/tGp4tjiL47 #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.07.30.227553,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19,@biorxivpreprint,Circulating Mitochondrial DNA is an Early Indicator of Severe Illness and Mortality from COVID-19  https://t.co/CMxtYuKgZu #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@Genemedi1,"Genemedi offers SARS-CoV-2 WT and Spike Mutation Pseudovirus(D614G,S943P,V367F,G476S,V483A,H49Y,Q239K,A831V,P1263L,D839Y/N/E,D839Y,D839N,D839E)  https://t.co/eJeLsfNk6Y  Pseudovirus neutralization assay protocol download: https://t.co/Z9pyXg1Onl https://t"
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@outbreaksci,Updated #SARSCoV preprint: Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses https://t.co/9gog0ymUKR
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@outbreaksci,"Contribute a rapid review or request one for ""Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immu..."" (https://t.co/9gog0ymUKR). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.227470) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@outbreaksci,Updated #COVID19 preprint: Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses https://t.co/9gog0ymUKR
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@SciscoreReports,The paper ‚ÄúAd26-vector based COVID-19 vaccine encoding a pref...‚Äù (https://t.co/6t3addAGSq) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/mCD8vH4K60. We detected 0 of 6 rigor criteria and 21 key resource
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@waittwoweeks,@R_H_Ebright https://t.co/uv8tjmx4Ot
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@outbreaksci,New #SARSCoV preprint: Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses https://t.co/9gog0yEvCp
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@outbreaksci,"Contribute a rapid review or request one for ""Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immu..."" (https://t.co/9gog0ymUKR). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.227470) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@outbreaksci,New #COVID19 preprint: Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses https://t.co/9gog0ymUKR
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@COVID_Papers,üìù Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses  medRxiv or bioRxiv https://t.co/KZ7Qfp4qtm #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@biorxiv_immuno,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular ...  https://t.co/a3LwMDfi1Z #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.07.30.227470,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses,@biorxivpreprint,Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses  https://t.co/4DOXdJRWoW #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@outbreaksci,"Contribute a rapid review or request one for ""A dynamic regulatory interface on SARS-CoV-2 RNA polymerase"" (https://t.co/byaOvBslKk). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.229187) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@outbreaksci,Updated #SARSCoV preprint: A dynamic regulatory interface on SARS-CoV-2 RNA polymerase https://t.co/byaOvBslKk
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@Bokayvir,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase https://t.co/UqWixBLxV9
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@SciscoreReports,The paper ‚ÄúA dynamic regulatory interface on SARS-CoV-2 RNA p...‚Äù (https://t.co/7DOMXo0sjh) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/iJAJGAIg66. We detected 0 of 5 rigor criteria and 5 key resources
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@outbreaksci,"Contribute a rapid review or request one for ""A dynamic regulatory interface on SARS-CoV-2 RNA polymerase"" (https://t.co/byaOvBJWBS). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.229187) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@outbreaksci,Updated #COVID19 preprint: A dynamic regulatory interface on SARS-CoV-2 RNA polymerase https://t.co/byaOvBJWBS
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@vnzloy,"""A dynamic regulatory interface on SARS-CoV-2 RNA polymerase Wei Shi, Ming Chen, Yang Yang, Wei Zhou, Shiyun Chen, Yangbo Hu and Bin Liu bioRxiv. posted 30 July 2020, 10.1101/2020.07.30.229187 https://t.co/tRSrCGSwdH"" https://t.co/Se5bhW1j66"
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@outbreaksci,"Contribute a rapid review or request one for ""A dynamic regulatory interface on SARS-CoV-2 RNA polymerase"" (https://t.co/byaOvBJWBS). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.229187) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@outbreaksci,New #SARSCoV preprint: A dynamic regulatory interface on SARS-CoV-2 RNA polymerase https://t.co/byaOvBslKk
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@dkumar02,RT @cryoEM_Papers: A dynamic regulatory interface on SARS-CoV-2 RNA polymerase https://t.co/A3KVR4v6IA
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@cryoEM_Papers,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase https://t.co/A3KVR4v6IA
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@COVID_Papers,üìù A dynamic regulatory interface on SARS-CoV-2 RNA polymerase  medRxiv or bioRxiv https://t.co/41n5TWEKeV #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.229187,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase,@biorxivpreprint,A dynamic regulatory interface on SARS-CoV-2 RNA polymerase  https://t.co/7gEM4sFxHN #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@SciscoreReports,The paper ‚ÄúSubstrate specificity of SARS-CoV-2 nsp10-nsp16 me...‚Äù (https://t.co/GTLOSbrvRr) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/34KAtibhte. We detected 0 of 5 rigor criteria and 2 key resources
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@outbreaksci,New #SARSCoV preprint: Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase https://t.co/NKQikSyBN4
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@outbreaksci,"Contribute a rapid review or request one for ""Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase"" (https://t.co/NKQikSyBN4). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228478) at https://t.co/RnurTKM2ac @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@outbreaksci,New #COVID19 preprint: Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase https://t.co/NKQikSyBN4
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@COVID_Papers,üìù Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase  medRxiv or bioRxiv https://t.co/dqqkvbTBxN #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@sackloo,RT
http://biorxiv.org/cgi/content/short/2020.07.30.228478,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase,@biorxivpreprint,Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase  https://t.co/7ZZQ6cDavA #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@maheshneralkar,RT @glycopreprint: Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein https://‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@glycopreprint,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein https://t.co/Xxo73Bsmgd #glycotime
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@outbreaksci,"Contribute a rapid review or request one for ""Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-C..."" (https://t.co/HWuWe9KCBy). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228221) at https://t.co/RnurTL3DyM @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@outbreaksci,New #SARSCoV preprint: Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein https://t.co/HWuWe9KCBy
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@bxv_imm,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein https://t.co/yW6bLlv4Ri
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@COVID_Papers,üìù Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein  medRxiv or bioRxiv https://t.co/jdObrgV3mo #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@biorxivpreprint,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein  https://t.co/sqWGhpnSiP #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.228221,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein,@biorxiv_immuno,Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein  https://t.co/tO4WKObvbu #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@tarekalaydi,EUAdb: a resource for COVID-19 test development [NEW RESULTS] https://t.co/ABkbohdJeg
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@outbreaksci,Updated #SARSCoV preprint: EUAdb: a resource for COVID-19 test development https://t.co/IO7Lvpr6or
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@outbreaksci,"Contribute a rapid review or request one for ""EUAdb: a resource for COVID-19 test development"" (https://t.co/IO7Lvpr6or). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228890) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@outbreaksci,Updated #COVID19 preprint: EUAdb: a resource for COVID-19 test development https://t.co/IO7Lvpr6or
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@outbreaksci,New #SARSCoV preprint: EUAdb: a resource for COVID-19 test development https://t.co/IO7Lvpr6or
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@outbreaksci,"Contribute a rapid review or request one for ""EUAdb: a resource for COVID-19 test development"" (https://t.co/IO7Lvpr6or). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228890) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@outbreaksci,New #COVID19 preprint: EUAdb: a resource for COVID-19 test development https://t.co/IO7Lvpr6or
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@helioRocha_,#bioRxiv   EUAdb: a resource for COVID-19 test development    #bioinfo https://t.co/bI1RcKFCRY
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@afifpj,RT @biorxiv_bioinfo: EUAdb: a resource for COVID-19 test development  https://t.co/ezy3e67NjV #biorxiv_bioinfo
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@ian_hoffecker,EUAdb: a resource for COVID-19 test development https://t.co/lToMTFPYwi
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@COVID_Papers,üìù EUAdb: a resource for COVID-19 test development  medRxiv or bioRxiv https://t.co/vDmWsEwUhp #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@biorxiv_bioinfo,EUAdb: a resource for COVID-19 test development  https://t.co/ezy3e67NjV #biorxiv_bioinfo
http://biorxiv.org/cgi/content/short/2020.07.30.228890,EUAdb: a resource for COVID-19 test development,@biorxivpreprint,EUAdb: a resource for COVID-19 test development  https://t.co/z66QrUnAXh #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@SciscoreReports,The paper ‚ÄúMucin-type O-glycosylation Landscapes of SARS-CoV-...‚Äù (https://t.co/leenV3ogIh) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/Om65Qs7Lvu. We detected 0 of 6 rigor criteria and 3 key resources
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@Tariqbiotech27,RT @glycopreprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/bGnmqcjmlw #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@dunckerUAEM,RT @glycopreprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/bGnmqcjmlw #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@JDon_chembio,RT @glycopreprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/bGnmqcjmlw #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@Jose98JV,RT @glycopreprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/bGnmqcjmlw #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@maheshneralkar,RT @glycopreprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/bGnmqcjmlw #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@aula531,RT @zzz_as_zzz: Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ„Çπ„Éë„Ç§„ÇØ„Å´„Åä„Åë„ÇãNÂûã„ÅÆÁ≥ñÈéñ‰øÆÈ£æ„ÅØÂπæ„Å§„ÅãË´ñÊñá„ÅåÂá∫„Å¶„Åæ„Åó„Åü„Åå„ÄÅ„Åì„Çå„ÅØOÂûã„ÅÆÁ≥ñÈéñ‰øÆÈ£æ„Å´„Å§„ÅÑ„Å¶„ÅÆË´ñÊñá„ÄÇ  ÂÆø‰∏ªÁ¥∞ËÉû„Å´„Çà„Çä„ÄÅÁ≥ñÈéñ„ÅÆÁ®ÆÈ°û„ÅåÁï∞„Å™„Å£„Å¶„ÅÑ„Åü„Åù„ÅÜ„Åß„Åô„ÄÇ  O„É™„É≥„ÇØ„ÅÆ„Ç∞„É™„Ç≥„Ç∑„É´Âåñ„ÅåÂ•Ω„Åç„Å™‰∫∫„ÅÆÂæÖ„Å£„Å¶„ÅÑ„ÅüË´ñÊñáÔºü https://t.c‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@zzz_as_zzz,Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ„Çπ„Éë„Ç§„ÇØ„Å´„Åä„Åë„ÇãNÂûã„ÅÆÁ≥ñÈéñ‰øÆÈ£æ„ÅØÂπæ„Å§„ÅãË´ñÊñá„ÅåÂá∫„Å¶„Åæ„Åó„Åü„Åå„ÄÅ„Åì„Çå„ÅØOÂûã„ÅÆÁ≥ñÈéñ‰øÆÈ£æ„Å´„Å§„ÅÑ„Å¶„ÅÆË´ñÊñá„ÄÇ  ÂÆø‰∏ªÁ¥∞ËÉû„Å´„Çà„Çä„ÄÅÁ≥ñÈéñ„ÅÆÁ®ÆÈ°û„ÅåÁï∞„Å™„Å£„Å¶„ÅÑ„Åü„Åù„ÅÜ„Åß„Åô„ÄÇ  O„É™„É≥„ÇØ„ÅÆ„Ç∞„É™„Ç≥„Ç∑„É´Âåñ„ÅåÂ•Ω„Åç„Å™‰∫∫„ÅÆÂæÖ„Å£„Å¶„ÅÑ„ÅüË´ñÊñáÔºü https://t.co/6ZIarVrQhn
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@glycopreprint,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/bGnmqcjmlw #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@outbreaksci,"Contribute a rapid review or request one for ""Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins"" (https://t.co/0xXc0c6eJD). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.227785) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@outbreaksci,New #SARSCoV preprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins https://t.co/0xXc0bODl3
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@COVID_Papers,üìù Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins  medRxiv or bioRxiv https://t.co/ZwMuGGjDbv #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@Sarumite,RT @biorxivpreprint: Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins  https://t.co/U7Rzwti1n8 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227785,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins,@biorxivpreprint,Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins  https://t.co/U7Rzwti1n8 #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ChaoGlycoGao,"How many ways can SARS-CoV-2 interact with our cells and tissues? A recent work led by @fieschif and @derafaeldelgado confirmed CLRs may play a role in viral infection! This work, ours https://t.co/QODaUKyO1n and many others give an alternative innate immu"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@FabrizioChiodo,@joshpowellphd Here the links to the pre-prints: https://t.co/6YXEWtsUG1 and https://t.co/nCaEiWbsAB
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@sc_papers,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors. https://t.co/lbNKcmRrc8 https://t.co/kydaiUsJcu
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@SciscoreReports,The paper ‚ÄúSARS-CoV-2 Spike Protein Interacts with Multiple I...‚Äù (https://t.co/jWakF2RqAF) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/EQCmC8Ne6V. We detected 0 of 6 rigor criteria and 2 key resources
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@emulenews,"#bioRxiv SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/4Niv3TjvzP S is recognized in a glycan-dependent manner by multiple innate immune receptors including the mannose receptor MR/CD206, DC-SIGN/CD209, L-SIGN/CD209L"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@JamieHMolinaro,RT @glycopreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/GwUjCdgzhs #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@Tariqbiotech27,RT @glycopreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/GwUjCdgzhs #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@dunckerUAEM,RT @glycopreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/GwUjCdgzhs #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@els_shanina,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@Ozlem__Dmr,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@zzz_as_zzz,"""The spike (S) glycoprotein in the envelope of SARS-CoV-2 is densely glycosylated  S is recognized in a glycan-dependent manner by multiple innate immune receptors including the mannose receptor MR/CD206, DC-SIGN/CD209, L-SIGN/CD209L, and MGL/CLEC10A/CD301"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@zzz_as_zzz,„Åï„Å£„ÅçOÂûã„ÅÆÁ≥ñÈéñ„ÅÆË´ñÊñá„Åå„ÅÇ„Çä„Åæ„Åó„Åü„Åå„ÄÅ„Åì„Çå„ÅØÊñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„Çπ„ÅÆ„Çπ„Éë„Ç§„ÇØ„Å´‰ªò„ÅèN„Å®O„ÅÆÁ≥ñÈéñ„Åå„ÄÅÂçòÁêÉ„ÄÅ„Éû„ÇØ„É≠„Éï„Ç°„Éº„Ç∏„ÄÅÊ®πÁä∂Á¥∞ËÉû„Å™„Å©„ÅÆËá™ÁÑ∂ÂÖçÁñ´Á¥∞ËÉû„ÅÆËÜú„Å´Â≠òÂú®„Åô„ÇãC„Çø„Ç§„Éó„É¨„ÇØ„ÉÅ„É≥ÂèóÂÆπ‰Ωì„Å´„Åè„Å£‰ªò„Åç„ÄÅÊÑüÊüì„Åô„ÇãÂèØËÉΩÊÄß„Åå„ÅÇ„Çã„Å®„Åô„ÇãË´ñÊñá„ÄÇ ÁêÜË´ñ‰∏ä„ÅÆ‰ªÆË™¨„Åß„Åô„Åå„ÄÇ
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@SetyantoWahyudi,RT @glycopreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/GwUjCdgzhs #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@glycopreprint,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/GwUjCdgzhs #glycotime
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@PromPreprint,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/GCH9Ta9ozL
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@yu_yonghao,RT @pengwuTSRI: Spike protein is recognized by innate immune receptors in a glycan-dependent way
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@song_kk,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@song_kk,RT @pengwuTSRI: Spike protein is recognized by innate immune receptors in a glycan-dependent way
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@pengwuTSRI,Spike protein is recognized by innate immune receptors in a glycan-dependent way
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@kakilake,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@glycocode,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@grawoig,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ahmedab44726388,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@HMSCfG,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@bidmcpda,Recent SARS-CoV-2 work done by BIDMC Postdoc @ChaoGlycoGao in pre-print.
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@RommieAmaro,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@micahstubbs,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@RommieAmaro,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@AbragamJoseph,https://t.co/QnVh09tu8E
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@AlessandraCambi,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@kakusan_RT,RT @love_nihonsyu: SARS-CoV-2„ÅåËá™ÁÑ∂ÂÖçÁñ´Á¥∞ËÉû„ÅÆ‰∏≠„Å´ÂÖ•„ÇäËæº„Çì„ÅßËÇ∫Â§ñÁµÑÁπî„Å´Êã°Êï£„Åó„Å¶„ÅÑ„Çã„ÅÆ„Å†„Å®„Åó„Åü„Çâ„ÄÅ ‚Üì „ÅÆ„É°„Ç´„Éã„Ç∫„É†„Å™„ÅÆ„Åã„ÇÇ„Åó„Çå„Å™„ÅÑ  („Éó„É¨„Éó„É™„É≥„Éà)SARS-CoV-2„ÅÆ„Çπ„Éë„Ç§„ÇØ„Çø„É≥„Éë„ÇØË≥™„ÅØSARS-CoV„Å®ÂêåÊßò„ÄÅÈ´òÂØÜÂ∫¶„Å´„Ç∞„É™„Ç≥„Ç∑„É´Âåñ„Åï„Çå„Å¶„Åä„Çä„ÄÅ„Ç∞‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@love_nihonsyu,SARS-CoV-2„ÅåËá™ÁÑ∂ÂÖçÁñ´Á¥∞ËÉû„ÅÆ‰∏≠„Å´ÂÖ•„ÇäËæº„Çì„ÅßËÇ∫Â§ñÁµÑÁπî„Å´Êã°Êï£„Åó„Å¶„ÅÑ„Çã„ÅÆ„Å†„Å®„Åó„Åü„Çâ„ÄÅ ‚Üì „ÅÆ„É°„Ç´„Éã„Ç∫„É†„Å™„ÅÆ„Åã„ÇÇ„Åó„Çå„Å™„ÅÑ  („Éó„É¨„Éó„É™„É≥„Éà)SARS-CoV-2„ÅÆ„Çπ„Éë„Ç§„ÇØ„Çø„É≥„Éë„ÇØË≥™„ÅØSARS-CoV„Å®ÂêåÊßò„ÄÅÈ´òÂØÜÂ∫¶„Å´„Ç∞„É™„Ç≥„Ç∑„É´Âåñ„Åï„Çå„Å¶„Åä„Çä„ÄÅ„Ç∞„É™„Ç´„É≥‰æùÂ≠òÁöÑ„Å´Ëá™ÁÑ∂ÂÖçÁñ´Á¥∞ËÉû„ÅÆÂèóÂÆπ‰Ωì„Å®Áõ∏‰∫í‰ΩúÁî®„Åô„Çã„ÄÇ https://t.co/vKPxEamwsj
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@outbreaksci,"Contribute a rapid review or request one for ""SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors"" (https://t.co/eJrs4k25Kg). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.227462) at https://t.co/RnurTL3DyM @outbreaksci @PREreview_"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@outbreaksci,New #SARSCoV preprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/eJrs4jKulG
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@delarivier,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ElisaTelisa,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@akulmehta,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@Mije_Science,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@DvsBlack,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@sunrainmakerain,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@KevinWNg,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@mstfozt,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@CarolynBertozzi,More #glycotime for #COVID19
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ch_zimmer,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@enerphyschem,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@CzerwinsMarcin,"RT @FabrizioChiodo: Fantastic work from R. Cummings, extending and supporting our previous findings with SARS-CoV-2 RBD and Human Lectins..‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@StephenGrove19,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@Real_Adam_B,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@FabrizioChiodo,"Fantastic work from R. Cummings, extending and supporting our previous findings with SARS-CoV-2 RBD and Human Lectins... #glycotime"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ToddEBear,RT @flavinkins: https://t.co/BtGEoemrsp https://t.co/Wz89u8ZInh
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@kathiralagesan,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@NightHowl11,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@flavinkins,https://t.co/BtGEoemrsp
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@emulenews,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@yolandapereznmr,RT @bxv_biochem: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/UVqqzwVrTL
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@_hoeman,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@samuelservinv,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@liljurist,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ToddEBear,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@caruan_eyes,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@dunckerUAEM,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@BrettGarabedian,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@a___noah,RT @ChaoGlycoGao: We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@JamieHMolinaro,RT @theNCFG: #glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein i‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@theNCFG,#glycotime #covid19 Our latest preprint demonstrates that innate immune receptors can recognize the SARS-CoV-2 Spike protein in a glycan-dependent manner. Great work by @ChaoGlycoGao and others @theNCFG #glycopreprint
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@ChaoGlycoGao,"We are humbly sharing our work in the SARS-CoV-2 glycobiology. Innate immune receptors can recognize the SARS-CoV-2 Spike Protein in a glycan-dependent manner, suggesting potential additional routes for viral infection and new anti-viral strategies. https:"
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@sciencesalesrep,Help a non-immunologist out. üôÇ Thoughts on this? üëá
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@CFSciences,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@scell_papers,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/r5X8a5Axq9
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@NGR69575822,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@simplycavero,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@bxv_biochem,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors https://t.co/UVqqzwVrTL
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@johanvawe,RT @biorxivpreprint: SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@COVID_Papers,üìù SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  medRxiv or bioRxiv https://t.co/387BEU1UIi #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.29.227462,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors,@biorxivpreprint,SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors  https://t.co/glPBlBjjsb #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@SciscoreReports,The paper ‚ÄúNo SARS-CoV-2 cross-neutralization by intravenous...‚Äù (https://t.co/T3mnRPlS5P) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/7Zd9X5V4Qe. We detected 0 of 6 rigor criteria and 5 key resources.
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@PAMJ84,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Abdulnasser__,@DrHowardLiu @VirusesImmunity @DeleDaviesMD https://t.co/nrrTenQo0w  üëÄ https://t.co/xzGvPwQSsC
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@siegnant,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@ep89870799,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@baroofakiris,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@mridulkthomas,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@swapneilparikh,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Eomesodermin,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic https://t.co/XxH5VtQMv1 #immunobot
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@SciscoreReports,The paper ‚ÄúNo SARS-CoV-2 cross-neutralization by intravenous...‚Äù (https://t.co/T3mnRPlS5P) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/TfvNGHwuf7. We detected 0 of 6 rigor criteria and 6 key resources.
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@CrohamLord,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@mqdicer,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@afashionfan,"RT @gerdosi: Donated plasma from before the pandemic is reactive to hCoVs, but doesn‚Äôt provide cross-neutralization for SARS-CoV-2. hCoV Ab‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@seeker98747,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@gerdosi,"Donated plasma from before the pandemic is reactive to hCoVs, but doesn‚Äôt provide cross-neutralization for SARS-CoV-2. hCoV Ab higher in older donors. How does hCoV exposure protect small kids? Could it be via secretory IgA? https://t.co/QQ8tosMj4U"
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Tony247F,RT @PromPreprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@PromPreprint,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic https://t.co/JiINbpVNP7
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@donkamion78,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@smp0312,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@outbreaksci,"Contribute a rapid review or request one for ""No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma c..."" (https://t.co/F8AO3yzBDV). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.30.228213) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@outbreaksci,New #SARSCoV preprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic https://t.co/F8AO3yRd2v
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Equateall,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@tugsandtost,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@CSchwiening,Unlikely that many people had pre-existing immunity from other coronaviruses. This is a 'new' one.
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@serenelyjoyful,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@ganbhag,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@DvsBlack,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@hcpommergaard,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@mammuthus,"@bnlawrence @Kit_Yates_Maths @jamesannan ......this. In isolation, some of the stuff they argue is worth thinking about and understanding, but fails to grasp the whole picture/evidence in my opinion. https://t.co/MPPGlWFHmO"
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@KevinWNg,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@mjknight0380,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@MsPacNWer,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@AGCT_team,RT @biorxiv_immuno: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandem‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@paulpetertak,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@alonzi_anthony,RT @biorxivpreprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pande‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@WBreymeyer,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@EvaSiu21,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@MarkPlackett1,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@wildwestpie,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@DavidDPreiss,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@GOBARMINT,"""No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic""  https://t.co/b8HzIoBSYN  Common cold coronavirus Ig don't work against SARS-CoV-2. Wonder if they will look at t cell responses too"
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@yemanouspeak,RT @biorxivpreprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pande‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@CFSciences,RT @biorxivpreprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pande‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@marypgkeating,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@MassatoHirai,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@JamesonVoss,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@PKanagaratnam,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@litomd,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Abdulnasser__,https://t.co/1FR9b5DAU9
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Heather03807097,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@JacksonWharf,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@COVID19digest1,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@NIptamenos,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@ilhamabuljadaye,ÿ®ŸÑÿßÿ≤ŸÖÿß ÿßŸÑŸÖÿ™ÿ®ÿ±ÿπŸäŸÜ ŸÖŸÜ ŸÇÿ®ŸÑ ÿ¨ÿßÿ¶ÿ≠ÿ© #ŸÅŸäÿ±Ÿàÿ≥_ŸÉŸàÿ±ŸàŸÜÿß_ÿßŸÑŸÖÿ≥ÿ™ÿ¨ÿØŸë ŸÑÿß ÿ™ÿ≠ÿ™ŸàŸä ÿπŸÑŸä ÿßÿ¨ÿ≥ÿßŸÖ ŸÖÿ∂ÿßÿØŸá ÿ™ÿ≠ŸäÿØ ÿßŸÑŸÅŸäÿ±Ÿàÿ≥ .. ŸÖÿπÿ±ŸàŸÅ ÿØÿß ÿßŸÑŸÉŸÑÿßŸÖ. ÿ®ÿ≥ ŸÜŸÉÿ±ÿ± ŸÑÿ™ÿ∞ŸÉŸäÿ±  #ŸÉŸàŸÅŸäÿØ_19
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@AntifaDisabled,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Clonamery13,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@MGuru2020,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@conazole,RT @NAChristakis: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@jeremyphoward,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@NAChristakis,"No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins in 54 samples of plasma collected in the USA and Europe (from a few hundred donors overall) before the 2020 pandemic. Hence, in this population, cross-immunity from cold virus may be rare. h"
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@bicidiario,RT @biorxivpreprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pande‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@bicidiario,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@Fradbius,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@jacmbrd,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@BallouxFrancois,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@aDNA_papers,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic https://t.co/MOzUSu5OEQ
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@johnmcclean_ie,RT @bealelab: In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adu‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@bealelab,In agreement with data from George Kassiotis‚Äô lab (@KevinWNg et al) that pre-existing neutralising antibodies are rare in adults.
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@benjamin_n_bell,RT @biorxivpreprint: No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pande‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@COVID_Papers,üìù No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic  medRxiv or bioRxiv https://t.co/TDnG4JQw9w #COVID19 #COVID19Papers #SARSCoV2
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@biorxiv_immuno,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic  https://t.co/A4rugZZcnN #biorxiv_immuno
http://biorxiv.org/cgi/content/short/2020.07.30.228213,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic,@biorxivpreprint,No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic  https://t.co/Y3EyaQom7C #bioRxiv
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Bubblechuck,RT @estergeama: @Bubblechuck @stuartjdneil Saw it here: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nuc‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@estergeama,"@Bubblechuck @stuartjdneil Saw it here: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses  https://t.co/AoeONZzjaA"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@mariojoseh555,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@TonyBurnetti,RT @PromPreprint: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominan‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@PromPreprint,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses https://t.co/2ppGlCfSDS"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@MitchJones00,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@uberrimaefidei1,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Eomesodermin,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses https://t.co/iFj8r34FES #immunobot https://t.co/N4NPQcSnpE"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Gambiste1,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@namatu555,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@dhovekamp42,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@shimmyyah79,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@godsmack4ever,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@DonnaYoungDC,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@dutchtcapital,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@SaltCreekGBR,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@without416,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@FatLenny12,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@MSollender,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@BIOTECH888,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Roveees1,"RT @AndyBiotech: For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice gen‚Ä¶"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@AndyBiotech,"For all those $NK trolls, this is the key sentence in today's PR that confirms what I tweeted on Friday: only 2/5 mice generated decent neutralizing antibodies.  Good luck with a vaccine candidate that can't even consistently elicit neutralizing antibody r"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@mejia_bf,RT @HoekstraTweets: Further very promising evidence that #RaDVaC‚Äôs Gen. 7 formula (with both S and N epitopes) is on the right track: both‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@OpenSciTalk,RT @HoekstraTweets: Further very promising evidence that #RaDVaC‚Äôs Gen. 7 formula (with both S and N epitopes) is on the right track: both‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@HoekstraTweets,Further very promising evidence that #RaDVaC‚Äôs Gen. 7 formula (with both S and N epitopes) is on the right track: both neutralizing #antibodies + #Tcell response (w/ Th2 bias).  https://t.co/iDLoSZUxXl #COVID19 #vaccine #openscience @RADVACproject
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Alveolus1023,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses https://t.co/IeJN9dCVaa"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@SciscoreReports,The paper ‚ÄúA Next Generation Bivalent Human Ad5 COVID-19 Vacc...‚Äù (https://t.co/9KsVB9FpnU) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/LGUyspTyvS. We detected 1 of 6 rigor criteria and 44 key resource
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,@BARDA Fund ImmunityBio's vaccine! https://t.co/7wrO70qI9l
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Digihealthy1,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,$NK @AndyBiotech is a short selling shill. These are the impressive pre-clinical vaccine results from @DrPatSoonShiong : https://t.co/7wrO70qI9l https://t.co/qIoDMbrWh9
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@AGCT_team,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@mariojoseh555,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@len_unofficial,"""Further studies are ongoing to explore utilizing this vaccine construct in oral, intranasal, and sublingual formulations to induce mucosal immunity in addition to cell-mediated and humoral immunity.""  delivery mechanisms are important!  https://t.co/cw3eP"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,RT @biorxivpreprint: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Domi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,RT @outbreaksci: New #SARSCoV preprint: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antige‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,RT @COVID_Papers: üìù A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Domin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,RT @biorxiv_immuno: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Domin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@DotknightWang,RT @RNorris02: $NK https://t.co/7wrO70qI9l
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@KkFontaine23,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@LindaGalliher,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@MassatoHirai,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Gambiste1,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@RNorris02,$NK https://t.co/7wrO70qI9l
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@hardy_bm,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Dereklowe,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@portefeuillefun,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@earningsurprise,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@SaltCreekGBR,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Jalen_Birch_X,RT @AndyBiotech: $NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 o‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@AndyBiotech,$NK preprint out for its adenovirus 5 vaccine data in mice https://t.co/jVvBOwunne  Good luck with human trials when 3/5 of your animals don't even generate much neutralizing antibodies even in mice? https://t.co/FUWHdGPTAj
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@outbreaksci,"Contribute a rapid review or request one for ""A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleoca..."" (https://t.co/iiDArHqbaJ). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.227595) at https://t.co/RnurTKM2ac @outbreaks"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@outbreaksci,"New #SARSCoV preprint: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses https://t.co/iiDArH8Ajb"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@LucreSnooker,lol even the one & only Patrick Soon-Shiong is getting on the intranasal bandwagon https://t.co/sjesGMBoVs https://t.co/tkC3rnaoY1
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@AntifaDisabled,RT @COVID_Papers: üìù A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Domin‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@benjamin_n_bell,RT @biorxivpreprint: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Domi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@Daria_Neca,RT @biorxivpreprint: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Domi‚Ä¶
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@COVID_Papers,"üìù A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses  medRxiv or bioRxiv https://t.co/W3upBnwuqU #COVID19 #COVID19Papers #SARSCoV"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@biorxiv_immuno,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ ...  https://t.co/84vAjHENOC #biorxiv_immuno"
http://biorxiv.org/cgi/content/short/2020.07.29.227595,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses",@biorxivpreprint,"A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses  https://t.co/p4DS1hHk9M #bioRxiv"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@highkingofnoldo,Kaynaklƒ± konu≈üuyorum: https://t.co/1psSmlex7d
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@solution_covid,#itolizumab works #COVID__19 #coronavirus
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@Rajkish11254347,Humanized anti-CD6 monoclonal antibody Itolizumab in combination with other antivirals and anticoagulants  assoc with reduction COVID-19 disease worsening and mortality;  https://t.co/ldbS1fAWwo
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@rocatanho,Humanized anti-CD6 monoclonal antibody Itolizumab in combination with other antivirals and anticoagulants  assoc with reduction COVID-19 disease worsening and mortality;  https://t.co/0im8oNmf48
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@holi_matos,"Es otra noticia prometedora; la verdad es qu√© sin una vacuna,  tendremos que imponernos a guardar la distancia y las mascarillas para todos y el fin de los eventos multitudinarios. @urenacard @raquelpenavice"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@MARILLIZARDO,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@DrHuascar,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@yayomatias,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@EdwinMaria1,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@RoaAnne2,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@DorisHesni,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@Nicky0139835180,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@FranklinMinyet2,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@jorgeciprian,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@BCiprian,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@lcamachoramos,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@jinmicruz,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@agrodejesus,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@RubiDuval,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@gaiatonos,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@154128bcce3b428,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@kitana3777,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@AlexBV05_,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@Soniaavargas,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@arielgonzalez04,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@EduardoJCoats,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@Cecy_Bautista,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@miahichez,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@nelson_morillo,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@pedro_regil,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@ryhp0608,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@miguelo6312,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@avila_olimpia,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@JoseSan92927197,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@joelrodriguez05,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@karolinarosat,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@Elmy_Pina,"RT @vicatallah: itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19,‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@vicatallah,"itolizumab f√°rmaco anticuerpos que se usa contra coronavirus en Cuba reduce riesgo muerte pacientes edad avanzada COVID-19, disminuy√≥ riesgo ingreso cuidados intensivos y muerte residentes hogares ancianos con COVID-19 moderado, seg√∫n peque√±o estudio #VEA"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@das_seed,"@giridar100 @kiranshaw @BioCentury @Bioconlimited @AaishwaryaM @pash22 @malini_aisola @d_s_thakur Yes, I think they are providing this for media hype and some predatory journal with acceptable impact factor. They did what DCGI SEC did for exemption of Phas"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@das_seed,"@WakeArtisan @GorwayGlobal @pash22 @prat1112001 @dawalelo @malini_aisola @d_s_thakur Pre-print of a Cuban #Itolizumab #COVID19 trial out. Ethics approval on April 4. Claims mortality reduction as well.    Data part of  clinical trial IIC RD-EC 179, #VICTOR"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@das_seed,@malini_aisola @GorwayGlobal @prat1112001 @ItsPankajGupta @giridar100 @SeemaAhuja1 @Bioconlimited @kiranshaw @d_s_thakur @drcheruvarun @sundarramanan Mortality reduction and effectivity confirming claims of #VICTORIA are HOAX. Trial design isn't FIT to mak
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@das_seed,"https://t.co/pFpm84V6Rp part of #VICTORIA trial, IIC RD-EC 179 (Cuba) on #Itolizumab #COVID19. It's not RCT, claim of mortality reduction is HOAX. Initial protocol was for severe cases, later included moderate cases. Nothing conclusive, just observational."
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@GorwayGlobal,"@WakeArtisan, Have you seen this? does it pass muster to enter the Living Network Meta-analysis project?"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@MassatoHirai,RT @outbreaksci: New #COVID19 preprint: Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVI‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@das_seed,@malini_aisola @GorwayGlobal @prat1112001 @ItsPankajGupta @giridar100 @SeemaAhuja1 @Bioconlimited @kiranshaw @d_s_thakur @drcheruvarun Pre-print from Cuba on a #Itolizumab clinical trial is out within a week of EUA from Cuban regulatory board. What about I
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@das_seed,"Pre-print of a Cuban #Itolizumab #COVID19 trial out. Ethics approval on April 4. Claims mortality reduction as well.    Different trial or data part of IIC RD-EC 179,  https://t.co/fZlpGd8cv7 https://t.co/pFpm85cHIX https://t.co/EOvCaOFlqy @pash22 @prat"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@outbreaksci,New #SARSCoV preprint: Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 https://t.co/9QOpJDVnnZ
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@outbreaksci,New #COVID19 preprint: Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 https://t.co/9QOpJDVnnZ
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@rmchavin,"7-24-2020:  In the 19-participant Alzumab (itolizumab) clinical trial released today, Cuban MDs said that for ""every 3 moderately ill patients treated with itolizumab, 1 admission into the ICU was prevented:"" https://t.co/zy3IM3zhMb https://t.co/gFs9mRLRro"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@phil_w888,"677/  Cuba (adult current smoking rate was 35.2% in 2016)  Of 19 patients hospitalized after being infected in one nursing home, two were reported as smokers (10.5%)  Notes:  median age was 79 (64 to 100 years old)  63.2% of patients were female  https://t"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@SciscoreReports,The paper ‚ÄúUse of a humanized anti-CD6 monoclonal antibody (i...‚Äù (https://t.co/M29HlVJ6hF) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/XWgtAS5nBz. We detected 2 of 5 rigor criteria and 3 key resources
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@a_1_0_2,"""Use of a humanized anti-CD6 monoclonal antibody (#itolizumab) in elderly patients with moderate COVID-19""  https://t.co/yMRAM01yCh"
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@COVID_Papers,üìù Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19  medRxiv or bioRxiv https://t.co/qIc6IqmL7S #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@villagerhans,RT @medrxivpreprint: Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19  https://t.co/‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.24.20153833,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19,@medrxivpreprint,Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19  https://t.co/Q6rAboSqxZ #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.27.20163212,Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization,@outbreaksci,"Contribute a rapid review or request one for ""Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian random..."" (https://t.co/cnELu7tIeX). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.27.20163212) at https://t.co/RnurTKM2ac @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.27.20163212,Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization,@outbreaksci,New #COVID19 preprint: Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization https://t.co/cnELu7LjDx
http://medrxiv.org/cgi/content/short/2020.07.27.20163212,Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization,@COVID_Papers,üìù Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization  medRxiv or bioRxiv https://t.co/Y8XKoqcd3l #COVID19 #COVID19Papers #SARSCoV2
http://medrxiv.org/cgi/content/short/2020.07.27.20163212,Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization,@medrxivpreprint,Association between Alzheimer's disease and COVID-19: A bidirectional Mendelian randomization  https://t.co/8xgizWer11 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.26.20157040,Minimizing Population Health Loss in Times of Scarce Surgical Capacity,@BGravesteijn,Wij hebben een vergelijkbare aanpak voor triage voor OK's bedacht. Wij benoemen dit ook in onze discussie.  Wij maakten een tool om op groepsniveau verlies van gezondheid (QALY) te kwantificeren. Daardoor blijft er ruimte voor individuele voorkeuren.  http
http://medrxiv.org/cgi/content/short/2020.07.26.20157040,Minimizing Population Health Loss in Times of Scarce Surgical Capacity,@IRetelHelmrich,RT @BGravesteijn: Our preprint is out! How to prioritize surgery during periods with scarce recources?  Using a decision model we tried to‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.26.20157040,Minimizing Population Health Loss in Times of Scarce Surgical Capacity,@BGravesteijn,Our preprint is out! How to prioritize surgery during periods with scarce recources?  Using a decision model we tried to quantify urgency as the loss in health per month delay of frequently performed procedures at @ErasmusMC.  For more details: https://t.c
http://medrxiv.org/cgi/content/short/2020.07.26.20157040,Minimizing Population Health Loss in Times of Scarce Surgical Capacity,@BGravesteijn,RT @medrxivpreprint: Minimizing Population Health Loss in Times of Scarce Surgical Capacity  https://t.co/1AqVOznx79 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.26.20157040,Minimizing Population Health Loss in Times of Scarce Surgical Capacity,@medrxivpreprint,Minimizing Population Health Loss in Times of Scarce Surgical Capacity  https://t.co/1AqVOznx79 #medRxiv
http://medrxiv.org/cgi/content/short/2020.07.28.20163626,"Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing.",@outbreaksci,"Contribute a rapid review or request one for ""Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-..."" (https://t.co/maioKwBH6h). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.28.20163626) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.28.20163626,"Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing.",@outbreaksci,"New #SARSCoV preprint: Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing. https://t.co/maioKwk5HH"
http://medrxiv.org/cgi/content/short/2020.07.28.20163626,"Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing.",@MedicalScitech,"üíØClinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based #COVID19 #TestTestTest ¬ª https://t.co/YiVgACYL9Q The protocol presented for this assay employs limited reagents and yields results with high sensitivity. https"
http://medrxiv.org/cgi/content/short/2020.07.28.20163626,"Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing.",@medrxivpreprint,"Clinical validation of innovative, low cost, kit-free, RNA processing protocol for RT-PCR based COVID-19 testing.  https://t.co/9VsGCQ4O2N #medRxiv"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@RoelandRuijsch,RT @OlifaNT: De Campbell van 7 aug (ik loop achter) is interessant. Hij bespreekt deze https://t.co/YZahNPIhVt deze https://t.co/WLPs9nerf6‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@OlifaNT,De Campbell van 7 aug (ik loop achter) is interessant. Hij bespreekt deze https://t.co/YZahNPIhVt deze https://t.co/WLPs9nerf6 deze https://t.co/VHTRxLXYNN  en deze https://t.co/uWlbiAnhhs studies.   https://t.co/4MWC62oGQw
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@ColdProofUK,RT @DRTomlinsonEP: Wonderful data @timspector and team. üëè @PHE_uk @DHSCgovuk please take note. @IndependentSage @ColdProofUK @katylindemann‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@FinnPadmore,RT @felicitycallard: Wells et al preprint (using KCL/Zoe app) shows fully asymptomatic rate of 19% ‚Äî much lower than other studies looking‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@covid19testgrp,RT @alvie_barr: Estimates of the Rate of Infection & Asymptomatic #COVID19 Disease in a Population Sample from SE England  üëâ Seroprevalence‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@AbScentUK,"In a recent study in SE England, a seroprevalence of 12% demonstrated and specificity of anosmia for sero+ was 95% https://t.co/QI2Y4MHGcF"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@BagaiDr,"20%-COVID without https://t.co/wHNjQKKW0F Abs testing(King's College London)analyzed data=431(19-89yrs):London.12%+viral Abs,19% of + Abs asymptomatic.25% didn‚Äôt have core signs:(cough,fever,Anosmia-strongest indicator):seropositivity.seroprevalence% vital"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@onnmin,RT @lizWWyld: Preprint! And relatively small numbers 20% asymptomatic and anosmia very specific. #covid19 Estimates of the rate of infectio‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@ValerieJStorm,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Sleepisthenews1,RT @felicitycallard: Wells et al preprint (using KCL/Zoe app) shows fully asymptomatic rate of 19% ‚Äî much lower than other studies looking‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@glyn_dk,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Melly_Pan,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@MrSandy_P,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@GarethDEdwards,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@mat8iou,"RT @amy_tisi: This is really interesting. Anecdotally, friends in London and SE were suspecting Covid in March with a wide range of symptom‚Ä¶"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@MarioFalchi,RT @PhilippaWells1: Our preprint on covid antibodies out today
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DrWinTadd,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@KkeatsR,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DAHatfield_,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@TheFirstNuomics,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@LibbyJe62787208,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@kmmurray97,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@MaguireTJA,RT @felicitycallard: Wells et al preprint (using KCL/Zoe app) shows fully asymptomatic rate of 19% ‚Äî much lower than other studies looking‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@MaguireTJA,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@preshitorian,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Alsxia,RT @alvie_barr: Estimates of the Rate of Infection & Asymptomatic #COVID19 Disease in a Population Sample from SE England  üëâ Seroprevalence‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@leni_lava,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@outbreaksci,"Contribute a rapid review or request one for ""Estimates of the rate of infection and asymptomatic COVID-19 disease in a population s..."" (https://t.co/PGwuVMJ1UO). ""Add"" or ""Request"" w/DOI (10.1101/2020.07.29.20162701) at https://t.co/RnurTL3DyM @outbreaks"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@outbreaksci,New #SARSCoV preprint: Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England https://t.co/PGwuVMJ1UO
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@RafaelOsswald,RT @felicitycallard: Wells et al preprint (using KCL/Zoe app) shows fully asymptomatic rate of 19% ‚Äî much lower than other studies looking‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@GreveJanice,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@jadenozzz,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@suesearle,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@snowleopardess,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@philippefroguel,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Hookawoolly,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@RedBee23,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DRTomlinsonEP,Wonderful data @timspector and team. üëè @PHE_uk @DHSCgovuk please take note. @IndependentSage @ColdProofUK @katylindemann   Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England https://t.co/WxWEtYMmlS
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@nitamarq,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DRTomlinsonEP,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@LaurenceBettle,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@CTrentham88,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@AnnesMien,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DrRMHRumney,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@ruairidhm,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@andycarmich,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@stuartjdneil,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@HongKongAnnie59,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DogLady2020,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@markbishopuk,"RT @Daltmann10: More than a quarter of exposed, antibody-positive recorded none of the core #COVID19 symptoms: https://t.co/hybY3kcMlb"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@basho87,RT @felicitycallard: Wells et al preprint (using KCL/Zoe app) shows fully asymptomatic rate of 19% ‚Äî much lower than other studies looking‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@felicitycallard,Wells et al preprint (using KCL/Zoe app) shows fully asymptomatic rate of 19% ‚Äî much lower than other studies looking for more restricted range of symptoms. This is what many of us predicted wd happen as awareness of heterogeneity of symptoms grew #Covid19
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@rosespenfold,"Latest from @CovidSymptom Study Seroprevalence of 12% in a London and SE England population - 19% of seropositive individuals ""asymptomatic"" @PhilippaWells1 @timspector @DrClaireSteves https://t.co/KTA3RVHlsC"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@lizWWyld,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@lizWWyld,Preprint! And relatively small numbers 20% asymptomatic and anosmia very specific. #covid19 Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England | medRxiv https://t.co/HNrcXb2eCu
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@mgh0406,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@markbishopuk,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Gardensafari,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@michael_malim,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@sophsweet,"Can't help thinking how much better off the UK would be if governments allowed scientists and medical people to handle responses to new coronaviruses each time they reach the UK, not industry-interests as trace and track from the start to eliminate transmi"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@KathrinJThomas,"Watch out for mild symptoms, especially anaemia. Many people may recognise they may have had COVID retrospectively, because so mild, but that's a challenge for active intervention with isolation"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Clink67,"RT @Daltmann10: More than a quarter of exposed, antibody-positive recorded none of the core #COVID19 symptoms:"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@naomiattar,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@SallyAnMatthews,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@HelenRSalisbury,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Clink67,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@FrezzaLab,"Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals were fully asymptomatic  Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England https://t.co/"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@RebsyG,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@SimonBornschein,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@gailtpilates,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@TraceyMaylor,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@rachnachowla,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@urologyal,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@amy_tisi,"This is really interesting. Anecdotally, friends in London and SE were suspecting Covid in March with a wide range of symptoms even though official symptoms might not have been present."
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Doobeye,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Winniness,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@tentative52,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@mindfulmoogs,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@AgnesAyton,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@SFuentes_Micro,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@GillJThompson,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@ProfTomEllis,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@VikiLovesFACS,"#COVID19 seroprevalence among 431 ppl in London and SE was 12%. Of these, 19% fully asymptomatic, but you can pick up a further 27% if you look out for atypical symptoms.  https://t.co/wHdKnRxsK8"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@caringcapitalis,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@riversampler,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@KeeneRoz,Very important results from @timspector group at Kings. Good to see that good old reliable 1980s ELISA technology is still going strong and being put to excellent use. I was the original 1980s ELISA diva circa 1984!
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@fflamglas,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@SusannaHowe,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@MalcolmHarland,"RT @Daltmann10: More than a quarter of exposed, antibody-positive recorded none of the core #COVID19 symptoms:"
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@nazarello1,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Triumphmark1215,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@ksuhre,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@chrislambwell,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@robfitz585,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@johnfinnes,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@BBCTomFeilden,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@TatjanaBilich,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@DaveoftheR,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@Variola3,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,@BerniePalmer2,RT @timspector: One in eight Londoners and those in South-East have antibodies to Covid-19 . Our survey in preprint also found asymptomatic‚Ä¶
http://medrxiv.org/cgi/content/short/2020.07.27.20163287,"The relationship between demographic, psychosocial and health-related parameters and the impact of COVID-19: a study of twenty-four Indian regions",@SciscoreReports,"The paper ‚ÄúThe relationship between demographic, psychosocial...‚Äù (https://t.co/gc6d0dIFiL) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/BGpGVTrAUU. We detected 1 of 5 rigor criteria and 1 key resource."
http://medrxiv.org/cgi/content/short/2020.07.27.20163287,"The relationship between demographic, psychosocial and health-related parameters and the impact of COVID-19: a study of twenty-four Indian regions",@SciscoreReports,"The paper ‚ÄúThe relationship between demographic, psychosocial...‚Äù (https://t.co/gc6d0dIFiL) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/1o7TBTmZ3Y. We detected 1 of 5 rigor criteria and 1 key resource."
http://medrxiv.org/cgi/content/short/2020.07.27.20163287,"The relationship between demographic, psychosocial and health-related parameters and the impact of COVID-19: a study of twenty-four Indian regions",@medrxivpreprint,"The relationship between demographic, psychosocial and health-related parameters and the impact of COVID-19: a study of twenty-four Indian regions  https://t.co/okgJgAgb98 #medRxiv"
